PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	LANGE, LG; SCHREINER, GF				LANGE, LG; SCHREINER, GF			MECHANISMS OF DISEASE - IMMUNE-MECHANISMS OF CARDIAC DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TUMOR-NECROSIS-FACTOR; IDIOPATHIC DILATED CARDIOMYOPATHY; POLYMERASE CHAIN-REACTION; COXSACKIE B3 MYOCARDITIS; CHRONIC HEART-FAILURE; SUPPRESSOR T-CELLS; ALLOGRAFT-REJECTION; LYMPHOCYTIC MYOCARDITIS; VENTRICULAR ARRHYTHMIAS; ENDOMYOCARDIAL BIOPSY				LANGE, LG (corresponding author), CV THERAPEUT, 1615 PLYMOUTH ST, Mountain View, CA 94043 USA.							ALVAREZ FL, 1987, CLIN IMMUNOL IMMUNOP, V43, P129, DOI 10.1016/0090-1229(87)90164-4; BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BENDER JR, 1991, CIRCULATION, V83, P704, DOI 10.1161/01.CIR.83.2.704; BINAH O, 1991, TRANSPLANTATION, V52, P508, DOI 10.1097/00007890-199109000-00024; BOHM M, 1990, CIRCULATION, V82, P1249, DOI 10.1161/01.CIR.82.4.1249; BOHM M, 1988, EUR HEART J, V9, P844; Bradley J, 1992, TRANSPLANT REV, V6, P115; BRISTOW MR, 1985, J MOL CELL CARDIOL, V17, P41, DOI 10.1016/0022-2828(85)90007-0; CHUNG MK, 1990, CIRC RES, V67, P753, DOI 10.1161/01.RES.67.3.753; DALLMAN MJ, 1991, J EXP MED, V174, P493, DOI 10.1084/jem.174.2.493; DAVIDOFF R, 1991, CIRCULATION, V83, P953, DOI 10.1161/01.CIR.83.3.953; DEMELLO DE, 1990, NEW ENGL J MED, V323, P1542, DOI 10.1056/NEJM199011293232207; DISESA VJ, 1991, J THORAC CARDIOV SUR, V101, P446; ENTMAN ML, 1991, FASEB J, V5, P2529, DOI 10.1096/fasebj.5.11.1868978; ESTRIN M, 1986, AM J PATHOL, V125, P578; Fallon J T, 1988, Cardiovasc Clin, V18, P155; FELDMAN AM, 1988, J CLIN INVEST, V82, P189, DOI 10.1172/JCI113569; FORBES RDC, 1984, IMMUNOL REV, V77, P5, DOI 10.1111/j.1600-065X.1984.tb00716.x; GAJEWSKI TF, 1989, IMMUNOL REV, V111, P79, DOI 10.1111/j.1600-065X.1989.tb00543.x; GODENY EK, 1987, J IMMUNOL, V139, P913; GODENY EK, 1987, AM J PATHOL, V129, P267; GULICK T, 1989, P NATL ACAD SCI USA, V86, P6753, DOI 10.1073/pnas.86.17.6753; GULICK T, 1988, BIOCHEM BIOPH RES CO, V150, P1, DOI 10.1016/0006-291X(88)90478-0; GULICK T, 1991, CIRCULATION, V84, P313, DOI 10.1161/01.CIR.84.1.313; HALL BM, 1987, TRANSPLANT P, V19, P50; HAN RO, 1991, BIOCHEM BIOPH RES CO, V181, P520, DOI 10.1016/0006-291X(91)91219-3; HASSIN D, 1987, AM J PHYSIOL, V252, pC10, DOI 10.1152/ajpcell.1987.252.1.C10; HEGEWISCH S, 1990, LANCET, V335, P294, DOI 10.1016/0140-6736(90)90115-L; HOSENPUD JD, 1989, J HEART TRANSPLANT, V8, P460; HOSENPUD JD, 1985, J AM COLL CARDIOL, V6, P797, DOI 10.1016/S0735-1097(85)80485-X; HUBER SA, 1984, AM J PATHOL, V116, P21; HUBER SA, 1980, AM J PATHOL, V98, P681; HUNT S, 1991, ANNU REV MED, V42, P437, DOI 10.1146/annurev.me.42.020191.002253; KAWAI C, 1987, ANNU REV MED, V38, P221, DOI 10.1146/annurev.med.38.1.221; KEMNITZ J, 1987, AM J SURG PATHOL, V11, P503, DOI 10.1097/00000478-198707000-00002; KUPIECWEGLINSKI JW, 1986, P NATL ACAD SCI USA, V83, P2624, DOI 10.1073/pnas.83.8.2624; KURNICH J, 1989, LYMPHOKINES IMMUNE R, P1; LESLIE KO, 1990, AM J PATHOL, V136, P683; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; LIEBERMAN EB, 1991, J AM COLL CARDIOL, V18, P1617, DOI 10.1016/0735-1097(91)90493-S; LIMAS CJ, 1989, CIRC RES, V64, P97, DOI 10.1161/01.RES.64.1.97; MAISCH B, 1983, AM J CARDIOL, V52, P1072, DOI 10.1016/0002-9149(83)90535-0; MASON JW, 1980, AM J CARDIOL, V45, P1037, DOI 10.1016/0002-9149(80)90174-5; McManus B M, 1988, Cardiovasc Clin, V18, P163; MIDEI MG, 1990, CIRCULATION, V81, P922, DOI 10.1161/01.CIR.81.3.922; MILLER LW, 1991, PROG CARDIOVASC DIS, V33, P229, DOI 10.1016/0033-0620(91)90028-K; MORRIS SA, 1990, CIRCULATION, V82, P1900, DOI 10.1161/01.CIR.82.6.1900; MYLES JL, 1987, ARCH PATHOL LAB MED, V111, P947; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NEU N, 1987, J IMMUNOL, V139, P3630; OCONNELL JB, 1986, CIRCULATION, V73, P353, DOI 10.1161/01.CIR.73.2.353; OLSEN EGJ, 1985, PROG CARDIOVASC DIS, V27, P241, DOI 10.1016/0033-0620(85)90008-8; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PAGANI FD, 1992, J CLIN INVEST, V90, P389, DOI 10.1172/JCI115873; PAQUE RE, 1979, J IMMUNOL, V123, P358; PARRILLO JE, 1989, NEW ENGL J MED, V321, P1061, DOI 10.1056/NEJM198910193211601; ROBERTS AB, 1992, J CLIN INVEST, V90, P2056, DOI 10.1172/JCI116087; ROBINSON JA, 1981, P SOC EXP BIOL MED, V166, P80; ROSE N, 1988, IMMUNOL TODAY, V9, P277; ROSE NR, 1988, IMMUNOL TODAY, V9, P117, DOI 10.1016/0167-5699(88)91282-0; SCHROEDER JS, 1974, AM J CARDIOL, V33, P604, DOI 10.1016/0002-9149(74)90249-5; SCHULZE K, 1990, CIRCULATION, V81, P959, DOI 10.1161/01.CIR.81.3.959; SEKO Y, 1991, CIRCULATION, V84, P788, DOI 10.1161/01.CIR.84.2.788; SMITH SC, 1992, CIRC RES, V70, P856, DOI 10.1161/01.RES.70.4.856; SMITH SC, 1991, J IMMUNOL, V147, P2141; STANEK G, 1990, NEW ENGL J MED, V322, P249, DOI 10.1056/NEJM199001253220407; STROM TB, 1988, TRANSPL P, V20, P143; SUGRUE DD, 1984, J AM COLL CARDIOL, V4, P952, DOI 10.1016/S0735-1097(84)80056-X; TAZELAAR HD, 1986, AM J SURG PATHOL, V10, P405, DOI 10.1097/00000478-198606000-00005; TOMINAGA M, 1991, CIRCULATION, V83, P2021, DOI 10.1161/01.CIR.83.6.2021; VALANTINE HA, 1987, CIRCULATION, V76, P86; VIGNOLA PA, 1984, J AM COLL CARDIOL, V4, P812, DOI 10.1016/S0735-1097(84)80411-8; WEBER KT, 1989, J AM COLL CARDIOL, V13, P1637, DOI 10.1016/0735-1097(89)90360-4; WIECHMANN R J, 1991, Journal of the American College of Cardiology, V17, p57A; WOODRUFF JF, 1980, AM J PATHOL, V101, P425; WYNNE J, 1992, HEART DISEASE TXB CA, V2, P1394; YOUNG JDE, 1988, IMMUNOL REV, V103, P161, DOI 10.1111/j.1600-065X.1988.tb00755.x	77	98	100	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 21	1994	330	16					1129	1135						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF699	8133856				2022-12-28	WOS:A1994NF69900007
J	PAPADOPOULOS, N; NICOLAIDES, NC; WEI, YF; RUBEN, SM; CARTER, KC; ROSEN, CA; HASELTINE, WA; FLEISCHMANN, RD; FRASER, CM; ADAMS, MD; VENTER, JC; HAMILTON, SR; PETERSEN, GM; WATSON, P; LYNCH, HT; PELTOMAKI, P; MECKLIN, JP; DELACHAPELLE, A; KINZLER, KW; VOGELSTEIN, B				PAPADOPOULOS, N; NICOLAIDES, NC; WEI, YF; RUBEN, SM; CARTER, KC; ROSEN, CA; HASELTINE, WA; FLEISCHMANN, RD; FRASER, CM; ADAMS, MD; VENTER, JC; HAMILTON, SR; PETERSEN, GM; WATSON, P; LYNCH, HT; PELTOMAKI, P; MECKLIN, JP; DELACHAPELLE, A; KINZLER, KW; VOGELSTEIN, B			MUTATION OF A MUTL HOMOLOG IN HEREDITARY COLON-CANCER	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; SALMONELLA-TYPHIMURIUM; NUCLEOTIDE-SEQUENCE; COLORECTAL-CANCER; MISMATCH REPAIR; CLONING; K-12; PMS1; HEXB	Some cases of hereditary nonpolyposis colorectal cancer (HNPCC) are due to alterations in a mutS-related mismatch repair gene. A search of a large database of expressed sequence tags derived from random complementary DNA clones revealed three additional human mismatch repair genes, all related to the bacterial mutL gene. One of these genes (hMLH1) resides on chromosome 3p21, within 1 centimorgan of markers previously linked to cancer susceptibility in HNPCC kindreds. Mutations of hMLH1 that would disrupt the gene product were identified in such kindreds, demonstrating that this gene is responsible for the disease. These results suggest that defects in any of several mismatch repair genes can cause HNPCC.	JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850; INST GENOM RES,GAITHERSBURG,MD 20878; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH PUBL HLTH & HYG,DEPT EPIDEMIOL,BALTIMORE,MD 21205; CREIGHTON UNIV,SCH MED,DEPT PREVENT MED,OMAHA,NE 68178; CREIGHTON UNIV,SCH MED,DEPT PUBL HLTH,OMAHA,NE 68178; UNIV HELSINKI,DEPT MED GENET,SF-00290 HELSINKI,FINLAND	Johns Hopkins University; Johns Hopkins Medicine; GlaxoSmithKline; Human Genome Sciences Inc; J. Craig Venter Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Creighton University; Creighton University; University of Helsinki			Papadopoulos, Nickolas/K-7272-2012; Mecklin, Jukka-Pekka/AAC-9650-2019	Fraser, Claire/0000-0003-1462-2428; Peltomaki, Paivi/0000-0001-8819-2980	NATIONAL CANCER INSTITUTE [R37CA035494, R01CA035494, R01CA047527] Funding Source: NIH RePORTER; NCI NIH HHS [CA35494, CA47527] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JASS JR, 1992, GUT, V33, P783, DOI 10.1136/gut.33.6.783; JASS JR, UNPUB; JOHNSON CV, 1991, GENET ANAL-BIOMOL E, V8, P75, DOI 10.1016/1050-3862(91)90052-S; JOHNSON CV, 1991, METHOD CELL BIOL, V35, P73; KNUDSON AG, 1985, CANCER RES, V45, P1437; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; Maniatis T., 1982, MOL CLONING; MANKOVICH JA, 1989, J BACTERIOL, V171, P5325, DOI 10.1128/jb.171.10.5325-5331.1989; NYSTROMLAHTI M, IN PRESS P NATL ACAD; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PARSONS R, UNPUB; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; PRUDHOMME M, 1989, J BACTERIOL, V171, P7196; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TSUI HCT, 1992, NUCLEIC ACIDS RES, V20, P2379, DOI 10.1093/nar/20.9.2379; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; VERMA R, 1989, HUMAN CHROMOSOMES MA, P115; WEI Y, UNPUB	35	1727	1793	0	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 18	1994	263	5153					1625	1629		10.1126/science.8128251	http://dx.doi.org/10.1126/science.8128251			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	8128251				2022-12-28	WOS:A1994NB67300036
J	JANSSON, A; GILLIN, F; KAGARDT, U; HAGBLOM, P				JANSSON, A; GILLIN, F; KAGARDT, U; HAGBLOM, P			CODING OF HEMOLYSINS WITHIN THE RIBOSOMAL-RNA REPEAT ON A PLASMID IN ENTAMOEBA-HISTOLYTICA	SCIENCE			English	Article							CIRCULAR DNA; PATHOGENESIS; DIFFERENTIATION; TROPHOZOITES; MECHANISMS; AMEBIASIS; PROTEIN; PROBES; ACIDS; GENES	The pathogenesis of amoebic dysentery is a result of cytolysis of the colonic mucosa by the parasitic protozoan Entamoeba histolytica. The cytolysis results in extensive local ulceration and allows the amoeba to penetrate and metastasize to distant sites. Factors involved in this process were defined with three clones that express hemolytic activities in Escherichia coli. These potential amoebic virulence determinants were also toxic to human colonic epithelial cells, the primary cellular targets in amoebal invasion of the large intestine. The coding sequences for the hemolysins were close to each other on a 2.6-kilobase segment of a 25-kilobase extrachromosomal DNA element. The structural genes for the hemolysins were within inverted repeats that encode ribosomal RNAs.	UPPSALA UNIV,CTR BIOMED,DEPT MICROBIOL,S-75123 UPPSALA,SWEDEN; UNIV CALIF SAN DIEGO,DEPT PATHOL,SAN DIEGO,CA 92103	Uppsala University; University of California System; University of California San Diego								AGRAWAL A, 1990, B SOC FRANCAISE PARA; ANDERBERG EK, 1992, J PHARM SCI, V81, P879, DOI 10.1002/jps.2600810908; AVILA EE, 1985, J PROTOZOOL, V32, P163; BHATTACHARYA S, 1989, J PROTOZOOL, V36, P455, DOI 10.1111/j.1550-7408.1989.tb01080.x; BOER PH, 1988, CELL, V55, P399, DOI 10.1016/0092-8674(88)90026-8; BRACHA R, 1990, J CLIN MICROBIOL, V28, P680, DOI 10.1128/JCM.28.4.680-684.1990; CAVALLOS MA, 1993, NUCLEIC ACIDS RES, V21, P355; CLARK CG, 1991, MOL BIOCHEM PARASIT, V49, P297, DOI 10.1016/0166-6851(91)90073-F; GARFINKEL LI, 1989, INFECT IMMUN, V57, P926, DOI 10.1128/IAI.57.3.926-931.1989; GRUZREYES JA, 1992, PARASITOLOGY, V104, P239; HAGBLOM P, UNPUB; HUBER M, 1989, MOL BIOCHEM PARASIT, V32, P285, DOI 10.1016/0166-6851(89)90077-7; Jarumilinta R., 1960, Transactions of the Royal Society of Tropical Medicine and Hygiene, V54, P5; LEIPPE M, 1992, EMBO J, V11, P3501, DOI 10.1002/j.1460-2075.1992.tb05432.x; LOHIA A, 1993, GENE, V127, P203, DOI 10.1016/0378-1119(93)90720-N; LONGKRUG SA, 1985, J INFECT DIS, V152, P536, DOI 10.1093/infdis/152.3.536; LOPEZREVILLA R, 1980, AM J TROP MED HYG, V29, P209, DOI 10.4269/ajtmh.1980.29.209; MARTINEZPALOMO A, 1987, PARASITOL TODAY, V3, P111, DOI 10.1016/0169-4758(87)90048-2; MUNOZ MD, 1982, J EXP MED, V155, P42, DOI 10.1084/jem.155.1.42; QUE X, 1991, NUCLEIC ACIDS RES, V19, P5438, DOI 10.1093/nar/19.19.5438; RAMACHANDRAN S, 1993, NUCLEIC ACIDS RES, V21, P2011, DOI 10.1093/nar/21.8.2011; RAVDIN JI, 1986, REV INFECT DIS, V8, P247; RAVDIN JI, 1982, REV INFECT DIS, V4, P1185; REED S, 1993, J CLIN INVEST, V91, P1532, DOI 10.1172/JCI116359; REED SL, 1989, J IMMUNOL, V143, P189; Rosales-Encina J L, 1992, Arch Med Res, V23, P243; ROSALESENCINA JL, 1987, J INFECT DIS, V156, P790, DOI 10.1093/infdis/156.5.790; ROSENBERG I, 1989, MOL BIOCHEM PARASIT, V33, P237, DOI 10.1016/0166-6851(89)90085-6; SAIDFERNANDEZ S, 1988, INFECT IMMUN, V56, P874; SAMBROCK J, 1989, MOL CLONING LABORATO; TANNICH E, 1989, P NATL ACAD SCI USA, V86, P5118, DOI 10.1073/pnas.86.13.5118; UDEZULU IA, 1987, INFECT IMMUN, V55, P181, DOI 10.1128/IAI.55.1.181-186.1987; UPCROFT JA, 1990, NUCLEIC ACIDS RES, V18, P7077, DOI 10.1093/nar/18.23.7077; YOUNG JDE, 1985, J CELL BIOCHEM, V29, P299, DOI 10.1002/jcb.240290404	34	30	30	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1440	1443		10.1126/science.8128227	http://dx.doi.org/10.1126/science.8128227			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128227				2022-12-28	WOS:A1994MZ92700033
J	ORR, WC; SOHAL, RS				ORR, WC; SOHAL, RS			EXTENSION OF LIFE-SPAN BY OVEREXPRESSION OF SUPEROXIDE-DISMUTASE AND CATALASE IN DROSOPHILA-MELANOGASTER	SCIENCE			English	Article							OXYGEN RADICALS; AGE	The hypothesis that oxygen free radicals are causally involved in the aging process was tested by a study of the effects of simultaneous overexpression of copper-zinc superoxide dismutase and catalase. As compared to diploid controls, transgenic flies carrying three copies of each of these genes exhibited as much as a one-third extension of life-span, a longer mortality rate doubling time, a lower amount of protein oxidative damage, and a delayed loss in physical performance. Results provide direct support for the free radical hypothesis of aging.			ORR, WC (corresponding author), SO METHODIST UNIV,DEPT BIOL SCI,DALLAS,TX 75275, USA.				NIA NIH HHS [R01AG8459] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG008459] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMES BN, 1987, SCIENCE, V236, P271, DOI 10.1126/science.3563506; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Finch C. E., 1990, SENESCENCE GENOME; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LEFFELAAR D, 1984, DEV GENET, V4, P211; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Luck H., 1974, ESTIMATION CATALASE, V885; MCARTHUR MC, 1982, J GERONTOL, V37, P268, DOI 10.1093/geronj/37.3.268; MIQUEL J, 1976, MECH AGEING DEV, V5, P347, DOI 10.1016/0047-6374(76)90034-8; MISRA HP, 1977, ANAL BIOCHEM, V79, P553, DOI 10.1016/0003-2697(77)90429-8; ORR WC, 1992, ARCH BIOCHEM BIOPHYS, V297, P35, DOI 10.1016/0003-9861(92)90637-C; ORR WC, 1993, ARCH BIOCHEM BIOPHYS, V301, P34, DOI 10.1006/abbi.1993.1111; PAGE EB, 1963, J AM STAT ASSOC, V58, P216, DOI 10.2307/2282965; Pryor W. A., 1987, MODERN BIOL THEORIES, P89; ROBERTSON HM, 1988, GENETICS, V118, P461; SACHER GA, 1977, HDB BIOL AGING, P582; SMITH J, 1979, COMP BIOCHEM PHYS B, V63, P39, DOI 10.1016/0305-0491(79)90231-1; SOHAL RS, 1982, AGE, V5, P21, DOI 10.1007/BF02431719; SOHAL RS, 1990, MECH AGEING DEV, V56, P223, DOI 10.1016/0047-6374(90)90084-S; SOHAL RS, 1993, P NATL ACAD SCI USA, V90, P7255, DOI 10.1073/pnas.90.15.7255; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616	26	1207	1254	0	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 25	1994	263	5150					1128	1130		10.1126/science.8108730	http://dx.doi.org/10.1126/science.8108730			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	8108730				2022-12-28	WOS:A1994MX75900029
J	PERRAUDEAU, M; WALPORT, M; OAKLEY, C; BLOOM, S; BROOKS, D				PERRAUDEAU, M; WALPORT, M; OAKLEY, C; BLOOM, S; BROOKS, D			GRAND ROUNDS - HAMMERSMITH-HOSPITAL - LATE PRESENTATION OF KARTAGENERS-SYNDROME	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMMOTILE-CILIA				PERRAUDEAU, M (corresponding author), HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, LONDON W12 0NN, ENGLAND.			Brooks, David/0000-0003-2602-2518; Walport, Mark/0000-0001-7220-5273				AFZELIUS B A, 1976, Science (Washington D C), V193, P317; BROWN NA, 1991, CIBA F SYMP, V162, P182; CLARKE SW, 1989, EUROPEAN J RESPIR S7, V2, P588; ELIASSON R, 1977, NEW ENGL J MED, V297, P1, DOI 10.1056/NEJM197707072970101; ESCUDIER E, 1990, AM REV RESPIR DIS, V142, P674, DOI 10.1164/ajrccm/142.3.674; GIBBONS IR, 1965, SCIENCE, V149, P424, DOI 10.1126/science.149.3682.424; Kartagener M., 1933, BEITR KLIN ERFORSCH, V83, P489, DOI DOI 10.1007/BF02141468; MAGM SJ, 1982, NEW ENGL J MED, V307, P113; ROTT HD, 1983, EUR J RESPIR DIS, V64, P1; Siewart A, 1904, KLIN WOCHENSCHR, V41, P139; SLEIGH MA, 1981, LANCET, V2, P476	11	6	8	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 19	1994	308	6927					519	521		10.1136/bmj.308.6927.519	http://dx.doi.org/10.1136/bmj.308.6927.519			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX814	8136672	Green Published			2022-12-28	WOS:A1994MX81400027
J	RAO, VR; COHEN, GB; OPRIAN, DD				RAO, VR; COHEN, GB; OPRIAN, DD			RHODOPSIN MUTATION G90D AND A MOLECULAR MECHANISM FOR CONGENITAL NIGHT BLINDNESS	NATURE			English	Article							DOMINANT RETINITIS-PIGMENTOSA; BOVINE RHODOPSIN; GENE	MUTATIONS in the gene for the visual pigment rhodopsin cause retinitis pigmentosa (RP) and congenital night blindness(1-7). Inheritance of the diseases is generally autosomal dominant and about 40 different rhodopsin mutations have been documented. Although the cell death and retinal degeneration associated with RP have been suggested to result from improper folding and accumulation of the mutant proteins in rod photoreceptor cells(8), this may not account for the disease in all cases. For example, RP mutations at Lys 296, site of Schiff base linkage to the retinal chromophore, result in constitutive;activation of the protein in vitro(9-11); that is, the mutants can catalytically activate the G protein transducin in the absence of chromophore and in the absence of light. Similarly, mutation of Ala 292 --> Glu activates opsin in vitro and causes night blindness(7). We show here that the mutation Gly 90 --> Asp (G90D) in the second transmembrane segment of rhodopsin, which causes congenital night blindness(12), also constitutively activates opsin. Furthermore, we show that Asp 90 can substitute for the Schiff base counterion, Glu 113, which is located in the third transmembrane segment of the protein. This demonstrates the proximity of Asp 90 and Lys 296 in the three-dimensional structure of rhodopsin and suggests that the constitutively activating mutations operate by a common molecular mechanism, disrupting a salt bridge between Lys 296 and the Schiff base counterion, Glu 113.			RAO, VR (corresponding author), BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254, USA.				NATIONAL EYE INSTITUTE [R01EY007965] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY007965] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; DRYJA TP, 1993, NAT GENET, V4, P280, DOI 10.1038/ng0793-280; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; FAIN GL, 1993, EXP EYE RES, V57, P335, DOI 10.1006/exer.1993.1132; FARRAR GJ, 1990, AM J HUM GENET, V47, P941; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; HUMPHRIES P, 1992, SCIENCE, V256, P804, DOI 10.1126/science.1589761; KEEN TJ, 1991, GENOMICS, V11, P199, DOI 10.1016/0888-7543(91)90119-Y; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; MORTON RA, 1955, BIOCHEM J, V59, P128, DOI 10.1042/bj0590128; NOELL WK, 1980, VISION RES, V20, P1163, DOI 10.1016/0042-6989(80)90055-3; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; RANDO RR, 1990, ANGEW CHEM INT EDIT, V29, P461, DOI 10.1002/anie.199004611; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SIEVING PA, 1992, INVEST OPHTH VIS SCI, V33, P1397; SULLIVAN JM, 1993, INVEST OPHTH VIS SCI, V34, P1149; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	31	318	323	2	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 17	1994	367	6464					639	642		10.1038/367639a0	http://dx.doi.org/10.1038/367639a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	8107847				2022-12-28	WOS:A1994MW68800052
J	ROMEO, G; RONCHETTO, P; LUO, Y; BARONE, V; SERI, M; CECCHERINI, I; PASINI, B; BOCCIARDI, R; LERONE, M; KAARIAINEN, H; MARTUCCIELLO, G				ROMEO, G; RONCHETTO, P; LUO, Y; BARONE, V; SERI, M; CECCHERINI, I; PASINI, B; BOCCIARDI, R; LERONE, M; KAARIAINEN, H; MARTUCCIELLO, G			POINT MUTATIONS AFFECTING THE TYROSINE KINASE DOMAIN OF THE RET PROTOONCOGENE IN HIRSCHPRUNGS DISEASE	NATURE			English	Article							ACTIVATION; RECEPTOR	HIRSCHSPRUNG'S disease is a genetic disorder of neural crest development affecting 1 in 5,000 births. It is characterized by the absence of intramural ganglion cells in the hindgut, which often results in partial to complete intestinal obstruction during the first years of life. An autosomal dominant gene causing this disease was recently mapped to chromosome 10q11.2 (refs 1, 2), using an interstitial deletion of this region isolated in a cell hybrid3,4. It was subsequently localized to a 250-kilobase interval which contains the RET proto-oncogene5. Using flanking intronic sequences as primers6 to amplify 12 of the 20 exons of RET from genomic DNA of 27 Hirschsprung's disease patients, we have now identified four mutations (one frameshift and three missense) that totally disrupt or partially change the structure of the tyrosine kinase domain of the RET protein (Ret). Mutations in the extracellular cysteine-rich domain of Ret have been identified previously7,8 in patients with multiple endocrine neoplasia type 2A, and a targeted mutation in the tyrosine kinase domain of the same gene produces intestinal aganglionosis and kidney agenesis in homozygous transgenic mice9. Our results support the hypothesis that RET, in addition to its potential role in tumorigenesis, plays a critical role in the embryogenesis of the mammalian enteric nervous system.	UNIV HELSINKI,DEPT MED GENET,SF-00014 HELSINKI,FINLAND	University of Helsinki	ROMEO, G (corresponding author), IST GIANNINA GASLINI,I-16148 GENOA,ITALY.		Barone, Virginia/K-8782-2015; Pasini, Barbara/AHI-2004-2022; Ronchetto, Patrizia/AAA-7742-2020; Bocciardi, Renata/J-8577-2016; Ceccherini, Isabella/P-8195-2014; Martucciello, Giuseppe/J-6543-2018; lerone, margherita/AAC-1583-2021; Seri, Marco/A-4339-2014	Barone, Virginia/0000-0001-8794-9291; Pasini, Barbara/0000-0002-4373-1212; Bocciardi, Renata/0000-0001-8415-3802; Ceccherini, Isabella/0000-0001-8732-1955; Martucciello, Giuseppe/0000-0002-7709-8937; lerone, margherita/0000-0003-0666-4740; Seri, Marco/0000-0003-2425-2176; Ronchetto, Patrizia/0000-0002-2606-3398				ANGRIST M, 1993, NAT GENET, V4, P351, DOI 10.1038/ng0893-351; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P1085; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; IWAMOTO T, 1993, ONCOGENE, V8, P1087; KWOK JBJ, 1993, ONCOGENE, V8, P2575; LYONNET S, 1993, NAT GENET, V4, P346, DOI 10.1038/ng0893-346; MARTUCCIELLO G, 1992, PEDIATR SURG INT, V7, P308; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PULITI A, 1993, CYTOGENET CELL GENET, V63, P102, DOI 10.1159/000133510; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; YIN L, 1993, HUM MOL GENET, V2, P1803	25	621	636	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					377	378		10.1038/367377a0	http://dx.doi.org/10.1038/367377a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	8114938				2022-12-28	WOS:A1994MT54000070
J	HAWKEN, MJ; GEGENFURTNER, KR; TANG, C				HAWKEN, MJ; GEGENFURTNER, KR; TANG, C			CONTRAST DEPENDENCE OF COLOR AND LUMINANCE MOTION MECHANISMS IN HUMAN VISION	NATURE			English	Article							PERCEPTION; DETECTORS; MOVEMENT; MODEL	CONVENTIONAL VieWS Of visual perception propose a colour-blind pathway conveying motion information and a motion-blind pathway carrying colour information1,2. Recent studies show that motion perception is not always colour blind, is partially depen dent on attention5,6, can show considerable perceptual slowing around isoluminance7-9 and is contrast-dependent10,11. If there is a single motion pathway, receiving luminance and chromatic input, then the dependence of relative perceived velocity on relative stimulus contrast should be the same for both luminance and chromatic targets. Here we provide a distinctive characterization of the motion mechanisms using a robust velocity-matching task. A relative contrast scale allows direct comparison of the performance with luminance and chromatic targets. The results show that the perceived speed of slowly moving coloured targets at isoluminance has a steep contrast dependence. The perceived speed of slowly moving luminance tar-ets shows a much lower contrast dependence. At high speeds the contrast dependence is low for both luminance and isoluminant stimuli, although the behaviour is unlike either of the slow mechanisms. The results suggest two independent pathways that perceive slowly moving targets: one is luminance-sensitive and the other is colour-sensitive. Fast movement is signalled via a single motion pathway that is contrast-invariant and not colour blind.	NYU,HOWARD HUGHES MED INST,NEW YORK,NY 10003	Howard Hughes Medical Institute; New York University	HAWKEN, MJ (corresponding author), NYU,CTR NEURAL SCI,4 WASHINGTON PL,NEW YORK,NY 10003, USA.			Gegenfurtner, Karl/0000-0001-5390-0684				ADELSON EH, 1985, J OPT SOC AM A, V2, P284, DOI 10.1364/JOSAA.2.000284; CAVANAGH P, 1984, J OPT SOC AM A, V1, P893, DOI 10.1364/JOSAA.1.000893; CAVANAGH P, 1992, SCIENCE, V257, P1563, DOI 10.1126/science.1523411; CAVANAGH P, 1991, VISION RES, V31, P2109, DOI 10.1016/0042-6989(91)90169-6; CAVANAGH P, 1985, VISION RES, V25, P1593; DERRINGTON AM, 1993, VISION RES, V33, P799, DOI 10.1016/0042-6989(93)90199-7; GEGENFURTNER KR, 1992, J OPT SOC AM A, V9, P1880, DOI 10.1364/JOSAA.9.001880; HEEGER DJ, 1987, J OPT SOC AM A, V4, P1455, DOI 10.1364/JOSAA.4.001455; KULIKOWSKI JJ, 1973, J PHYSIOL-LONDON, V232, P149, DOI 10.1113/jphysiol.1973.sp010261; LIVINGSTONE MS, 1987, J NEUROSCI, V7, P3416; MERIGAN WH, 1991, J NEUROSCI, V11, P3422; MULLEN KT, 1992, VISION RES, V32, P483, DOI 10.1016/0042-6989(92)90240-J; RAMACHANDRAN VS, 1978, NATURE, V275, P55, DOI 10.1038/275055a0; STONE LS, 1992, VISION RES, V32, P1535, DOI 10.1016/0042-6989(92)90209-2; STROMEYER CF, 1985, VISION RES, V25, P219, DOI 10.1016/0042-6989(85)90116-6; THOMPSON P, 1982, VISION RES, V22, P377, DOI 10.1016/0042-6989(82)90153-5; VANSANTEN JPH, 1985, J OPT SOC AM A, V2, P300, DOI 10.1364/JOSAA.2.000300; WATSON AB, 1985, J OPT SOC AM A, V2, P322, DOI 10.1364/JOSAA.2.000322; WATSON AB, 1981, VISION RES, V21, P1115, DOI 10.1016/0042-6989(81)90014-6; ZEKI SM, 1978, NATURE, V274, P423, DOI 10.1038/274423a0	20	117	118	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 20	1994	367	6460					268	270		10.1038/367268a0	http://dx.doi.org/10.1038/367268a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	8121491				2022-12-28	WOS:A1994MR49400055
J	KADOWAKI, T; KADOWAKI, H; MORI, Y; TOBE, K; SAKUTA, R; SUZUKI, Y; TANABE, Y; SAKURA, H; AWATA, T; GOTO, Y; HAYAKAWA, T; MATSUOKA, K; KAWAMORI, R; KAMADA, T; HORAI, S; NONAKA, I; HAGURA, R; AKANUMA, Y; YAZAKI, Y				KADOWAKI, T; KADOWAKI, H; MORI, Y; TOBE, K; SAKUTA, R; SUZUKI, Y; TANABE, Y; SAKURA, H; AWATA, T; GOTO, Y; HAYAKAWA, T; MATSUOKA, K; KAWAMORI, R; KAMADA, T; HORAI, S; NONAKA, I; HAGURA, R; AKANUMA, Y; YAZAKI, Y			A SUBTYPE OF DIABETES-MELLITUS ASSOCIATED WITH A MUTATION OF MITOCHONDRIAL-DNA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INSULIN-RECEPTOR GENE; RESISTANCE; DEAFNESS	Background. Several families have been described in which a mutation of mitochondrial DNA, the substitution of guanine for adenine (A --> G) at position 3243 of leucine transfer RNA, is associated with diabetes mellitus and deafness. The prevalence, clinical features, and pathophysiology of diabetes with this mutation are largely undefined. Methods. We studied 55 patients with insulin-dependent diabetes mellitus (IDDM) and a family history of diabetes (group 1), 85 patients with IDDM and no family history of diabetes (group 2), 100 patients with non-insulin-dependent diabetes mellitus (NIDDM) and a family history of diabetes (group 3), and 5 patients with diabetes and deafness (group 4) for the mutation. We also studied the prevalence and characteristics of diabetes in 39 patients with a syndrome consisting of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes who were known to have the mutation and 127 of their relatives (group 5). Results. We identified 16 unrelated patients with diabetes associated with the A --> G mutation: 3 patients from group 1 (6 percent), 2 patients from group 3 (2 percent), 3 patients from group 4 (60 percent), and 8 patients from group 5 (21 percent). We also identified 16 additional subjects who had diabetes and the mutation among 42 relatives of the patients with diabetes and the mutation in groups 1, 2, 3, and 4 and 20 affected subjects among the 127 relatives of the patients in group 5. Diabetes cosegregated with the mutation in a fashion consistent with maternal transmission, was frequently (in 61 percent of cases) associated with sensory hearing loss, and was generally accompanied by impaired insulin secretion. Conclusions. Diabetes mellitus associated with the A --> G mutation at position 3243 of mitochondrial leucine transfer RNA represents a subtype of diabetes found in both patients with IDDM and patients with NIDDM in Japan.	ASAHI LIFE FDN,INST DIABET CARE & RES,TOKYO,JAPAN; NATL INST NEUROSCI,DIV ULTRASTRUCT RES,KODAIRA,JAPAN; CHIBA CHILDRENS HOSP,CHIBA,JAPAN; JICHI MED SCH,DEPT ENDOCRINOL & METAB,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; SAISEIKAI CENT HOSP,TOKYO,JAPAN; OSAKA UNIV,SCH MED,DEPT INTERNAL MED 1,OSAKA,JAPAN; NATL INST GENET,MISHIMA,JAPAN	Asahi Life Foundation; National Center for Neurology & Psychiatry - Japan; Chiba Children's Hospital; Jichi Medical University; Tokyo Saiseikai Central Hospital; Osaka University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	KADOWAKI, T (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN.			Awata, Takuya/0000-0003-2622-8129				[Anonymous], 1985, WHO TECH REP SER, V727, P1; ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; ETO K, 1993, DIABETES, V42, P1133, DOI 10.2337/diabetes.42.8.1133; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FROGUEL P, 1992, NATURE, V357, P607, DOI 10.1038/357607c0; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; KADOWAKI H, 1993, LANCET, V341, P893, DOI 10.1016/0140-6736(93)93101-6; KADOWAKI T, 1984, DIABETOLOGIA, V26, P44, DOI 10.1007/BF00252262; KADOWAKI T, 1990, P NATL ACAD SCI USA, V87, P658, DOI 10.1073/pnas.87.2.658; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KAWAMORI R, 1991, J NUTR SCI VITAMINOL, V37, pS35, DOI 10.3177/jnsv.37.Supplement_S35; KOBAYASHI T, 1987, DIABETES, V36, P510, DOI 10.2337/diabetes.36.4.510; REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953	21	487	497	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 7	1994	330	14					962	968		10.1056/NEJM199404073301403	http://dx.doi.org/10.1056/NEJM199404073301403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND793	8121460	Bronze			2022-12-28	WOS:A1994ND79300003
J	TORRES, CF; REBSAMEN, S; SILBER, JH; SUTTON, LN; BILANIUK, LT; ZIMMERMAN, RA; GOLDWEIN, JW; PHILLIPS, PC; LANGE, BJ				TORRES, CF; REBSAMEN, S; SILBER, JH; SUTTON, LN; BILANIUK, LT; ZIMMERMAN, RA; GOLDWEIN, JW; PHILLIPS, PC; LANGE, BJ			SURVEILLANCE SCANNING OF CHILDREN WITH MEDULLOBLASTOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHILDHOOD BRAIN-TUMORS; RECURRENT MEDULLOBLASTOMA; NEUROECTODERMAL TUMORS; ADJUVANT CHEMOTHERAPY; VINCRISTINE; MYELOGRAPHY; EFFICACY; DISEASE; THERAPY; CCNU	Background. The standard follow-up care for children with medulloblastoma includes regular clinical evaluations and surveillance scanning of the central nervous system with computed tomography or magnetic resonance imaging. The evaluations and scanning assess the response of the tumor to treatment, detect any recurrence of disease, and monitor any complications of treatment. We compared the effectiveness of a periodic history taking and physical examination with that of surveillance scanning in detecting recurrent tumors. Methods. We reviewed the medical records, including 794 scanning reports or scans, of 86 children with posterior fossa medulloblastoma who were followed regularly between 1980 and 1991. Recurrent tumors were classified as symptomatic if neuroimaging studies had been prompted by clinical symptoms or signs and as radiographic if the tumor had been detected by imaging in an asymptomatic patient. Results. Twenty-three of the 86 children (27 percent) had a recurrence of tumor. Four recurrences (17 percent) were detected on scanning only, and 19 (83 percent) were associated with symptoms arising a median of four months after the previous scan. The median and range of survival after a recurrence of the tumor were 5 months and <1 to 38 months, respectively, for a symptomatic recurrence and 20 months and 10 to 32 months, respectively, for a radiographic recurrence (P = 0.03). No patient survived after a recurrence. The longer survival of patients with recurrent tumors detected by scanning most likely reflects the small number of patients and lead-time and length biases associated with screening. Conclusions. Among children with medulloblastoma, surveillance scanning is of little clinical value. Scanning detected a minority of recurrences, and no patient who had a recurrence survived.	UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT PEDIAT,DIV ONCOL,PHILADELPHIA,PA 19104; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT NEUROL,PHILADELPHIA,PA; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT NEUROSURG,PHILADELPHIA,PA; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT RADIOL,PHILADELPHIA,PA; HOSP UNIV PENN,SCH MED,LEONARD DAVIS INST HLTH ECON,PHILADELPHIA,PA; HOSP UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA; HOSP UNIV PENN,SCH MED,DEPT RADIAT THERAPY,PHILADELPHIA,PA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine					NATIONAL CANCER INSTITUTE [K04CA001480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS031102] Funding Source: NIH RePORTER; NCI NIH HHS [KO4 CA01480] Funding Source: Medline; NINDS NIH HHS [NS31102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHMSON TG, 1992, MED PEDIATR ONCOL, V20, P381; ALLEN JC, 1987, J CLIN ONCOL, V5, P459, DOI 10.1200/JCO.1987.5.3.459; ALLEN JC, 1982, J NEUROSURG, V57, P446, DOI 10.3171/jns.1982.57.4.0446; BAILAR JC, 1976, ANN INTERN MED, V84, P77, DOI 10.7326/0003-4819-84-1-77; CAIRNCROSS JG, 1985, ANN NEUROL, V17, P570; COHEN BH, 1989, NEUROLOGY, V39, P1178, DOI 10.1212/WNL.39.9.1178; Conover W. J., 1980, PRACTICAL NONPARAMET, P278; CRAFTS DC, 1978, J NEUROSURG, V49, P589, DOI 10.3171/jns.1978.49.4.0589; DEUTSCH M, 1985, CANCER, V56, P1763, DOI 10.1002/1097-0142(19851001)56:7+<1763::AID-CNCR2820561306>3.0.CO;2-6; Elterman R. D., 1993, Pediatric Neurosurgery, V19, P322; EVANS AE, 1990, J NEUROSURG, V72, P572, DOI 10.3171/jns.1990.72.4.0572; FRIEDMAN HS, 1986, NEUROSURGERY, V18, P335, DOI 10.1227/00006123-198603000-00014; FRIEDMAN HS, 1987, J NEURO-ONCOL, V5, P217, DOI 10.1007/BF00151225; GEYER JR, 1988, J CLIN ONCOL, V6, P996, DOI 10.1200/JCO.1988.6.6.996; GOLDWEIN JW, 1993, CANCER, V71, P2647, DOI 10.1002/1097-0142(19930415)71:8<2647::AID-CNCR2820710833>3.0.CO;2-S; KRAMER ED, 1991, NEUROLOGY, V41, P46, DOI 10.1212/WNL.41.1.46; KUN LE, 1985, CANCER-AM CANCER SOC, V56, P1818, DOI 10.1002/1097-0142(19851001)56:7+<1818::AID-CNCR2820561320>3.0.CO;2-9; LEFKOWITZ IB, 1990, CANCER-AM CANCER SOC, V65, P412, DOI 10.1002/1097-0142(19900201)65:3<412::AID-CNCR2820650306>3.0.CO;2-4; MISER J, 1989, P AN M AM SOC CLIN, V8, P84; MOERTEL CG, 1993, JAMA-J AM MED ASSOC, V270, P943, DOI 10.1001/jama.270.8.943; PACKER RJ, 1991, J NEUROSURG, V74, P433, DOI 10.3171/jns.1991.74.3.0433; PACKER RJ, 1988, ANN NEUROL, V24, P503, DOI 10.1002/ana.410240405; ROGERS PCJ, 1984, LANCET, V1, P1320; RORKE LB, 1985, CANCER-AM CANCER SOC, V56, P1869, DOI 10.1002/1097-0142(19851001)56:7+<1869::AID-CNCR2820561330>3.0.CO;2-0; SNEDECOR GW, 1980, STATISTICAL METHODS, P96; VANEYS J, 1988, J PEDIATR-US, V113, P601, DOI 10.1016/S0022-3476(88)80662-0; YACHNIS AT, 1992, AM J SURG PATHOL, V16, P998, DOI 10.1097/00000478-199210000-00011; ZELEN M, 1969, BIOMETRIKA, V56, P601, DOI 10.2307/2334668; ZIMMERMAN RA, 1987, PROG EXP TUMOR RES, V30, P61	29	147	147	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	1994	330	13					892	895		10.1056/NEJM199403313301303	http://dx.doi.org/10.1056/NEJM199403313301303			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC608	8114859				2022-12-28	WOS:A1994NC60800003
J	NOUEIRY, AO; LUCAS, WJ; GILBERTSON, RL				NOUEIRY, AO; LUCAS, WJ; GILBERTSON, RL			2 PROTEINS OF A PLANT DNA VIRUS COORDINATE NUCLEAR AND PLASMODESMAL TRANSPORT	CELL			English	Article							GOLDEN MOSAIC-VIRUS; BEAN-INFECTING GEMINIVIRUSES; NICOTIANA-BENTHAMIANA; SYSTEMIC INFECTION; MOVEMENT PROTEIN; COAT PROTEIN; RIBONUCLEOPROTEINS; EXPORT	Plant viruses establish a systemic infection by moving through plasmodesmata, but little is known of the mechanism(s) involved. The roles of two movement-associated proteins of a single-stranded DNA virus were investigated in vivo, using functional proteins expressed in E. coli and microinjection into plant cells. We report here that the all protein of bean dwarf mosaic geminivirus moves extensively from cell to cell, increases mesophyll plasmodesmal size exclusion limit, and potentiates the movement of double-stranded DNA from cell to cell. Movement of single and double-stranded DNA out of the nucleus is mediated by the BR1 protein. These results provide direct experimental evidence for intercellular macromolecular transport in plants, and suggest that the BR1 and BL1 proteins coordinate the movement of viral DNA across both nuclear and plasmodesmal boundaries.	UNIV CALIF DAVIS,DIV BIOL SCI,PLANT BIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis	NOUEIRY, AO (corresponding author), UNIV CALIF DAVIS,DEPT PLANT PATHOL,DAVIS,CA 95616, USA.							AMABILECUEVAS CF, 1993, AM SCI, V81, P332; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BROUGH CL, 1988, J GEN VIROL, V69, P503, DOI 10.1099/0022-1317-69-3-503; DEOM CM, 1992, CELL, V69, P221, DOI 10.1016/0092-8674(92)90403-Y; ELMER S, 1990, NUCLEIC ACIDS RES, V18, P2001, DOI 10.1093/nar/18.8.2001; ETESSAMI P, 1988, NUCLEIC ACIDS RES, V16, P4811, DOI 10.1093/nar/16.11.4811; ETESSAMI P, 1989, J GEN VIROL, V70, P277, DOI 10.1099/0022-1317-70-2-277; GARDINER WE, 1988, EMBO J, V7, P899, DOI 10.1002/j.1460-2075.1988.tb02894.x; GILBERTSON RL, 1991, PLANT DIS, V75, P336, DOI 10.1094/PD-75-0336; GILBERTSON RL, 1993, J GEN VIROL, V74, P23, DOI 10.1099/0022-1317-74-1-23; GILBERTSON RL, 1991, PHYTOPATHOLOGY, V81, P980, DOI 10.1094/Phyto-81-980; GLAZER AN, 1992, NATURE, V359, P859, DOI 10.1038/359859a0; HARRISON BD, 1985, ANNU REV PHYTOPATHOL, V23, P55, DOI 10.1146/annurev.py.23.090185.000415; HIDAYAT SH, 1993, PHYTOPATHOLOGY, V83, P181, DOI 10.1094/Phyto-83-181; HULL R, 1989, ANNU REV PHYTOPATHOL, V27, P213; LAZAROWITZ SG, 1992, CRIT REV PLANT SCI, V11, P327, DOI [10.1080/07352689209382350, 10.1080/713608038]; Lucas William J., 1993, Trends in Cell Biology, V3, P308, DOI 10.1016/0962-8924(93)90013-Q; MALYSHENKO SI, 1993, J GEN VIROL, V74, P1149, DOI 10.1099/0022-1317-74-6-1149; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; MORALES F, 1990, PHYTOPATHOLOGY, V80, P96, DOI 10.1094/Phyto-80-96; Oparka K J, 1993, Semin Cell Biol, V4, P131, DOI 10.1006/scel.1993.1016; PASCAL E, 1993, PLANT CELL, V5, P795, DOI 10.1105/tpc.5.7.795; PATEL VP, 1993, NUCLEIC ACIDS RES, V21, P1325, DOI 10.1093/nar/21.5.1325; REY O, 1992, J VIROL, V66, P5815, DOI 10.1128/JVI.66.10.5815-5824.1992; ROBARDS AW, 1990, ANNU REV PLANT PHYS, V41, P369, DOI 10.1146/annurev.pp.41.060190.002101; Stanley J., 1991, Seminars in Virology, V2, P139; VANLENT J, 1991, J GEN VIROL, V72, P2615, DOI 10.1099/0022-1317-72-11-2615; VONARNIM A, 1993, VIROLOGY, V192, P264, DOI 10.1006/viro.1993.1029; VONARNIM A, 1992, VIROLOGY, V187, P555, DOI 10.1016/0042-6822(92)90458-2; WICK RA, 1989, BIOTECHNIQUES, V7, P262; WOLF S, 1989, SCIENCE, V246, P377, DOI 10.1126/science.246.4928.377; XIONG Z, 1993, VIROLOGY, V193, P213, DOI 10.1006/viro.1993.1117	32	310	327	1	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 11	1994	76	5					925	932		10.1016/0092-8674(94)90366-2	http://dx.doi.org/10.1016/0092-8674(94)90366-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124726				2022-12-28	WOS:A1994NA89000017
J	SANSONETTI, PJ; MOUNIER, J; PREVOST, MC; MEGE, RM				SANSONETTI, PJ; MOUNIER, J; PREVOST, MC; MEGE, RM			CADHERIN EXPRESSION IS REQUIRED FOR THE SPREAD OF SHIGELLA-FLEXNERI BETWEEN EPITHELIAL-CELLS	CELL			English	Article							ADHESION MOLECULES; LISTERIA-MONOCYTOGENES; INTERCELLULAR SPREAD; ACTIN-FILAMENTS; HELA-CELLS; F-ACTIN; MOVEMENT; POLYMERIZATION; PROTEIN; CACO-2	Shigella flexneri, a gram-negative pathogen, invades the human colonic epithelium. After entering epithelial cells, bacteria escape into the cytoplasm, move intracellularly, and pass from cell to cell. The bacterium diverts actin and associated actin-binding proteins to generate a cytoskeleton-based motor that pushes forward the bacterium. As the moving bacterium reaches the inner face of the host-cell cytoplasmic membrane, a protrusion forms that allows passage of this bacterium into a neighboring cell. We show here that components of the intermediate junction are used by the bacterium to allow this passage. Using S180, a mouse fibroblastic sarcoma cell line that does not produce cell adhesion molecules (CAM), and S180L and S180cadN, the same cell line transfected with L-CAM and N-cadherin cDNA, respectively, we demonstrate that expression of a cadherin is required for cell-to-cell spread to occur.	INST PASTEUR,CENT MICROSCOPIE ELECTR STN,F-75724 PARIS 15,FRANCE; INSERM,U153,F-75005 PARIS,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)	SANSONETTI, PJ (corresponding author), INST PASTEUR,INSERM,U389,UNITE PATHOGENIE MICROBIENNE MOLEC,28 RUE DR ROUX,PARIS,FRANCE.		Mege, Rene Marc/M-9569-2013	Mege, Rene-Marc/0000-0001-8128-5543				ALLAOUI A, 1992, MOL MICROBIOL, V6, P1605, DOI 10.1111/j.1365-2958.1992.tb00885.x; BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; BOLLER K, 1985, J CELL BIOL, V100, P327, DOI 10.1083/jcb.100.1.327; BOYER B, 1989, J MEMBRANE BIOL, V112, P97, DOI 10.1007/BF01871271; CLERC P, 1987, INFECT IMMUN, V55, P2681, DOI 10.1128/IAI.55.11.2681-2688.1987; DHAUTEVILLE H, 1992, MOL MICROBIOL, V6, P833, DOI 10.1111/j.1365-2958.1992.tb01534.x; DOMMAN E, 1992, EMBO J, V11, P1981; DUNHAM LJ, 1953, JNCI-J NATL CANCER I, V13, P1299; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EDELMAN GM, 1987, P NATL ACAD SCI USA, V84, P8502, DOI 10.1073/pnas.84.23.8502; GALLIN WJ, 1983, P NATL ACAD SCI-BIOL, V80, P1038, DOI 10.1073/pnas.80.4.1038; GEIGER B, 1991, Current Biology, V1, P237, DOI 10.1016/0960-9822(91)90068-8; GOLDBERG M, 1993, IN PRESS J BACTERIOL; HALE TL, 1979, INFECT IMMUN, V24, P879, DOI 10.1128/IAI.24.3.879-886.1979; HALE TL, 1979, INFECT IMMUN, V24, P887, DOI 10.1128/IAI.24.3.887-894.1979; HATTA K, 1987, DEV BIOL, V120, P215, DOI 10.1016/0012-1606(87)90119-9; KADURUGAMUWA JL, 1991, INFECT IMMUN, V59, P3663; KEMLER R, 1989, BIOESSAYS, V11, P88, DOI 10.1002/bies.950110403; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; LABREC EH, 1964, J BACTERIOL, V88, P1503, DOI 10.1128/JB.88.5.1503-1518.1964; Magee AI, 1991, CURR OPIN CELL BIOL, V3, P854, DOI 10.1016/0955-0674(91)90060-C; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MOUNIER J, 1990, INFECT IMMUN, V58, P1048, DOI 10.1128/IAI.58.4.1048-1058.1990; MOUNIER J, 1992, INFECT IMMUN, V60, P237, DOI 10.1128/IAI.60.1.237-248.1992; OAKS EV, 1985, INFECT IMMUN, V48, P124, DOI 10.1128/IAI.48.1.124-129.1985; OGAWA H, 1968, JPN J MED SCI BIOL, V21, P259, DOI 10.7883/yoken1952.21.259; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PAL T, 1989, INFECT IMMUN, V57, P477; PREVOST MC, 1992, INFECT IMMUN, V60, P4088; SANGER JM, 1992, INFECT IMMUN, V60, P3509; SANSONETTI PJ, 1991, VACCINE, V9, P416, DOI 10.1016/0264-410X(91)90128-S; SANSONETTI PJ, 1986, INFECT IMMUN, V51, P461, DOI 10.1128/IAI.51.2.461-469.1986; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; Theriot Julie A., 1992, Current Biology, V2, P649, DOI 10.1016/0960-9822(92)90115-Q; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; VASSELON T, 1992, INFECT IMMUN, V60, P1031, DOI 10.1128/IAI.60.3.1031-1040.1992; VASSELON T, 1991, INFECT IMMUN, V59, P1723, DOI 10.1128/IAI.59.5.1723-1732.1991; VOLK T, 1986, J CELL BIOL, V103, P1441, DOI 10.1083/jcb.103.4.1441	42	129	130	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 11	1994	76	5					829	839		10.1016/0092-8674(94)90358-1	http://dx.doi.org/10.1016/0092-8674(94)90358-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124719				2022-12-28	WOS:A1994NA89000009
J	DACEY, DM; LEE, BB				DACEY, DM; LEE, BB			THE BLUE-ON OPPONENT PATHWAY IN PRIMATE RETINA ORIGINATES FROM A DISTINCT BISTRATIFIED GANGLION-CELL TYPE	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; MACAQUE RETINA; BIPOLAR CELLS; MONKEY RETINA; RHESUS-MONKEY; COLOR-VISION; CONE INPUTS; SENSITIVITY; MORPHOLOGY; NEURONS	COLOUR vision in humans and Old World monkeys begins with the differential activation of three types of cone photoreceptor which are maximally sensitive to short (S), medium (M) and long (L) wavelengths. Signals from the three cone types are relayed to the retinal ganglion cells via cone-specific bipolar cell types1-4. Colour-coding ganglion cells fall into two major physiological classes: the red-green opponent cells, which receive antagonistic input from M- and L-sensitive cones, and the blue-yellow opponent cells, which receive input from S-sensitive cones, opposed by combined M- and L-cone input. The neural mechanisms producing colour opponency are not understood. It has been assumed that both kinds of opponent signals are transmitted to the lateral geniculate nucleus by one type of ganglion cell, the midget cell5,6. We now report that a distinct non-midget ganglion cell type, the small bistratified cell, corresponds to the physiological type that receives excitatory input from S cones, the 'blue-on' cell. Our results thus demonstrate an anatomically distinct pathway that conveys S-cone signals to the brain. The morphology of the blue-on cell also suggest a novel hypothesis for the retinal circuitry underlying the blue-yellow opponent response.	MAX PLANCK INST BIOPHYS CHEM, D-37077 GOTTINGEN, GERMANY	Max Planck Society	DACEY, DM (corresponding author), UNIV WASHINGTON, DEPT BIOL STRUCT, SEATTLE, WA 98195 USA.			Dacey, Dennis/0000-0001-8476-5585				BOYCOTT BB, 1991, EUR J NEUROSCI, V3, P1069, DOI 10.1111/j.1460-9568.1991.tb00043.x; DACEY DM, 1988, SCIENCE, V240, P1196, DOI 10.1126/science.3375811; DACEY DM, 1993, VISUAL NEUROSCI, V10, P1081, DOI 10.1017/S0952523800010191; DACEY DM, 1992, VISUAL NEUROSCI, V9, P279, DOI 10.1017/S0952523800010695; DACEY DM, 1993, J NEUROSCI, V13, P5334, DOI 10.1523/JNEUROSCI.13-12-05334.1993; DACHEUX RF, 1990, PROC R SOC SER B-BIO, V239, P213, DOI 10.1098/rspb.1990.0014; DEMONASTERIO FM, 1979, BRAIN RES, V166, P39, DOI 10.1016/0006-8993(79)90647-4; DEMONASTERIO FM, 1975, J PHYSIOL-LONDON, V251, P167, DOI 10.1113/jphysiol.1975.sp011086; FAMIGLIETTI EV, 1976, SCIENCE, V194, P193, DOI 10.1126/science.959847; KOUYAMA N, 1992, J NEUROSCI, V12, P1233; LEE BB, 1988, J PHYSIOL-LONDON, V404, P323, DOI 10.1113/jphysiol.1988.sp017292; LEVENTHAL AG, 1981, SCIENCE, V213, P1139, DOI 10.1126/science.7268423; MARIANI AP, 1984, NATURE, V308, P184, DOI 10.1038/308184a0; Mollon J.D., 1990, P119; MOLLON JD, 1989, J EXP BIOL, V146, P21; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; PERRY VH, 1984, NEUROSCIENCE, V12, P1101, DOI 10.1016/0306-4522(84)90006-X; REID RC, 1992, NATURE, V356, P716, DOI 10.1038/356716a0; RODIECK RW, 1991, NATO ADV SCI I A-LIF, V203, P83; SCHILLER PH, 1978, J NEUROPHYSIOL, V41, P788, DOI 10.1152/jn.1978.41.3.788; SMITH VC, 1975, VISION RES, V15, P161, DOI 10.1016/0042-6989(75)90203-5; SWANSON WH, 1987, J OPT SOC AM A, V4, P1992, DOI 10.1364/JOSAA.4.001992; TSO DY, 1988, J NEUROSCI, V8, P1712; VALBERG A, 1986, VISION RES, V26, P1061, DOI 10.1016/0042-6989(86)90040-4; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P1115, DOI 10.1152/jn.1966.29.6.1115; Wyszecki G., 1982, COLOR SCI, V8; ZRENNER E, 1981, VISION RES, V21, P1605, DOI 10.1016/0042-6989(81)90042-0; ZRENNER E, 1983, BRAIN RES, V262, P181, DOI 10.1016/0006-8993(83)91007-7	28	516	530	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					731	735		10.1038/367731a0	http://dx.doi.org/10.1038/367731a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	8107868				2022-12-28	WOS:A1994MX63100057
J	RODRIGUEZ, LAG; JICK, H				RODRIGUEZ, LAG; JICK, H			RISK OF GYNECOMASTIA ASSOCIATED WITH CIMETIDINE, OMEPRAZOLE, AND OTHER ANTIULCER	BRITISH MEDICAL JOURNAL			English	Article							GYNECOMASTIA; THERAPY	Objective-To study the risk of gynaecomastia associated with cimetidine, misoprostol, omeprazole and ranitidine. Design-Open cohort study with nested case-control analysis. Setting-General practices in United Kingdom that had computerised offices, 1989-92. Subjects-81 535 men aged 25-84 years who received at least one prescription for cimetidine, misoprostol, omeprazole, or ranitidine during the study period. Main outcome measures-New occurrences of idiopathic gynaecomastia diagnosed by general practitioner. Results-The relative risk of gynaecomastia for current users of cimetidine compared with non-users was 7.2 (95% confidence interval 1.5 to 11.3). Relative risks for misoprostol, omeprazole, and ranitidine were 2.0 (0.1 to 10.7), 0.6 (0.1 to 3.3), and 1.5 (0.8 to 2.6), respectively. Current users of cimetidine on a daily dose greater than or equal to 1000 mg had more than 40 times the risk of developing gynaecomastia than non-users. The period of highest risk was seven to 12 months after starting cimetidine treatment. Spironolactone (relative risk 9.3 (3.3 to 26.1)) and verapamil (9.7 (2.6 to 36.0)) were associated with a relative risk of gynaecomastia comparable to one for cimetidine. Conclusions-Use of cimetidine, but not the three other antiulcer drugs, is associated with a substantially greater risk of gynaecomastia in men. A strong dose-response relation was present among cimetidine users.			RODRIGUEZ, LAG (corresponding author), BOSTON UNIV,MED CTR,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,LEXINGTON,MA 02173, USA.		rodriguez, luis a garcia/B-1980-2010	Jick, Hershel/0000-0003-4270-5992				BRAUNSTEIN GD, 1993, NEW ENGL J MED, V328, P490; CARLSON HE, 1980, NEW ENGL J MED, V303, P795, DOI 10.1056/NEJM198010023031405; CONVENS C, 1991, LANCET, V338, P1153, DOI 10.1016/0140-6736(91)92018-W; DELLEFAVE GF, 1977, LANCET, V1, P1319; GALBRAITH RA, 1989, NEW ENGL J MED, V321, P269, DOI 10.1056/NEJM198908033210501; GALBRAITH RA, 1993, PHARMACOLOGY, V47, P8, DOI 10.1159/000139072; HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012; JENSEN RT, 1983, NEW ENGL J MED, V308, P883, DOI 10.1056/NEJM198304143081508; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; LINDQUIST M, 1992, BRIT MED J, V305, P451, DOI 10.1136/bmj.305.6851.451; MIGNON M, 1982, LANCET, V2, P499; NUTTALL FQ, 1979, J CLIN ENDOCR METAB, V48, P338, DOI 10.1210/jcem-48-2-338; PAYNE CD, 1986, GENERALIZED LINEAR I; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P311; SANTUCCI L, 1991, NEW ENGL J MED, V324, P635; SPENCE RW, 1979, GUT, V20, P154, DOI 10.1136/gut.20.2.154; TOSTI S, 1982, LANCET, V2, P160; Walker AM, 1991, OBSERVATION INFERENC	19	57	58	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	1994	308	6927					503	506		10.1136/bmj.308.6927.503	http://dx.doi.org/10.1136/bmj.308.6927.503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX814	8136667	Green Published			2022-12-28	WOS:A1994MX81400020
J	HALLAM, L				HALLAM, L			PRIMARY MEDICAL-CARE OUTSIDE NORMAL WORKING HOURS - REVIEW OF PUBLISHED WORK	BRITISH MEDICAL JOURNAL			English	Review							GENERAL-PRACTICE; HOURS CALLS; DEPUTIZING SERVICES; EMERGENCY DEPARTMENTS; TELEPHONE ADVICE; MENTAL-HEALTH; 24-HOUR CARE; INNER CITIES; JOB STRESS; EAST-END	Fundamental changes in the delivery of primary medical care outside normal surgery hours are under consideration in Great Britain. Published research into the provision and utilisation of out of hours services shows long term trends towards decreasing personal committment among general practitioners and rising demand from patients for primary and hospital accident and emergency department care. Wide variations exist regionally, locally, and between practices. Previous studies, however, have been limited in scope and provide an inadequate basis for assessing the potential impact of change. The overall demand for care across all sources of provision cannot be measured: there is a lack of data on costs, and evaluative studies comparing alternative patterns of service delivery have rarely been undertaken. A period of experimentation and evaluation of a range of options should precede the wider adoption of any particular models.			HALLAM, L (corresponding author), UNIV MANCHESTER,RUSHOLME HLTH CTR,DEPT GEN PRACTICE,CTR PRIMARY CARE,MANCHESTER M14 5NP,ENGLAND.							BAIN DJG, 1984, BRIT MED J, V289, P471, DOI 10.1136/bmj.289.6443.471; BARLEY SL, 1979, J R COLL GEN PRACT, V29, P752; BLAIR JSG, 1986, J ROY COLL GEN PRACT, V36, P359; BOLLAM MJ, 1988, BRIT MED J, V296, P829, DOI 10.1136/bmj.296.6625.829; BOWLING A, 1987, FAM PRACT, V4, P85, DOI 10.1093/fampra/4.2.85; BRACKENBURY PH, 1985, HLTH TRENDS, V17, P31; BUXTON MJ, 1977, BRIT MED J, V1, P827, DOI 10.1136/bmj.1.6064.827; CALNAN M, 1982, J SOC POLICY, V11, P483, DOI 10.1017/S0047279400022546; CALNAN M, 1984, Journal of Emergency Medicine, V2, P57, DOI 10.1016/0736-4679(84)90049-0; CALNAN M, 1985, SOCIAL HLTH ILLNESS, V5, P149; CARLISLE RD, 1993, BRIT MED J, V306, P1383, DOI 10.1136/bmj.306.6889.1383; CARTWRIGHT A, 1981, GENERAL PRACTICE REV; CAVANAGH AUJM, 1978, BRIT MED J, V2, P34; COHEN J, 1987, FAM PRACT, V4, P81, DOI 10.1093/fampra/4.2.81; COOPER CL, 1989, BRIT MED J, V298, P366, DOI 10.1136/bmj.298.6670.366; CREIGHTON PA, 1982, BRIT MED J, V284, P1090, DOI 10.1136/bmj.284.6322.1090; CROWE MGF, 1976, BRIT MED J, V1, P1582, DOI 10.1136/bmj.1.6025.1582; CUBITT T, 1983, BRIT MED J, V287, P28, DOI 10.1136/bmj.287.6384.28; Cunningham R J, 1980, J R Coll Gen Pract, V30, P745; DAVIES T, 1986, BRIT MED J, V292, P241, DOI 10.1136/bmj.292.6515.241; DAVISON AG, 1983, J ROY SOC MED, V76, P37, DOI 10.1177/014107688307600109; DEER B, 1983, SUNDAY TIMES, V8; DIXON RA, 1988, BRIT MED J, V297, P1519, DOI 10.1136/bmj.297.6662.1519; DIXON RA, 1977, BRIT MED J, V1, P560, DOI 10.1136/bmj.1.6060.560; DRISCOLL PA, 1987, ARCH EMERG MED, V4, P77; FARMER RDT, 1982, RELATIONSHIP USES AC; FEARN R, 1987, SOC SCI MED, V24, P263, DOI 10.1016/0277-9536(87)90053-0; FEGER H, 1992, PULSE           0516, P3; FEGER H, 1992, PULSE           0704, P1; FOROUGHI D, 1989, PRACTITIONER, V233, P657; Fry J, 1984, NHS DATA BOOK; Gabriel R, 1976, J R Coll Gen Pract, V26, P74; GADSBY R, 1987, J ROY COLL GEN PRACT, V37, P462; GILBERT JR, 1978, PRACTITIONER, V220, P21; GRANT JA, 1984, BMJ-BRIT MED J, V288, P1366, DOI 10.1136/bmj.288.6427.1366; GRAVELLE HSE, 1980, DEPUTISING SERVICES; GREEN J, 1992, SOC SCI MED, V35, P987, DOI 10.1016/0277-9536(92)90238-L; Green J, 1991, Health Serv J, V101, P25; HALLAM L, 1992, OUT HOURS CARE GENER; HARRIS A, 1969, BRIT MED J, V298, P63; HOBBS FDR, 1991, BRIT MED J, V302, P329, DOI 10.1136/bmj.302.6772.329; HOBDAY PJ, 1984, BRIT MED J, V289, P663, DOI 10.1136/bmj.289.6446.663; HOBDAY PJ, 1988, J ROY COLL GEN PRACT, V38, P35; Jackson J, 1980, J R Coll Gen Pract, V30, P520; Jeffery R, 1979, Sociol Health Illn, V1, P90, DOI 10.1111/1467-9566.ep11006793; JONES H, 1992, PULSE           0704, P7; KNOX JDE, 1989, PRACTICAL GUIDES GEN, P9; LEWIS B, HLTH SOC SERVICES J, P1139; LINDEN M, 1993, PULSE           0925, P3; LIVINGSTONE AE, 1989, BRIT MED J, V299, P368, DOI 10.1136/bmj.299.6695.368; Lockstone D R, 1976, J R Coll Gen Pract, V26, P68; MAIN JA, 1989, BRIT MED J, V299, P627, DOI 10.1136/bmj.299.6699.627-b; MARSH GN, 1987, J ROY COLL GEN PRACT, V37, P301; MARSH GN, 1987, ARCH DIS CHILD, V62, P392, DOI 10.1136/adc.62.4.392; MAWHINNEY B, 1993, PULSE           1127, P15; MCCARTHY M, 1990, BRIT J GEN PRACT, V40, P19; MILNER PC, 1988, J EPIDEMIOL COMMUN H, V42, P274, DOI 10.1136/jech.42.3.274; MORRISON JM, 1991, BRIT MED J, V303, P1111, DOI 10.1136/bmj.303.6810.1111; MORRISON WG, 1991, BRIT J CLIN PRACT, V45, P95; MORTON DJ, 1979, J R COLL GEN PRACT, V29, P205; MUCKLE DS, 1973, BRIT MED J, V3, P699, DOI 10.1136/bmj.3.5882.699-c; Murray T S, 1977, J R Coll Gen Pract, V27, P209; MYERS P, 1982, J ROY SOC MED, V75, P879; MYERSON S, 1990, FAM PRACT, V7, P91, DOI 10.1093/fampra/7.2.91; MYERSON S, 1991, Medical Science Research, V19, P267; Naidoo A S, 1982, J R Coll Gen Pract, V32, P564; NGUYENVANTAM JS, 1992, BRIT MED J, V305, P157, DOI 10.1136/bmj.305.6846.157; ODWYER F, 1991, ARCH EMERG MED, V8, P196; OLIVER DJ, 1982, BRIT MED J, V284, P1195, DOI 10.1136/bmj.284.6323.1195; PEPIATT R, 1980, PRACTITIONER, V224, P11; PERRY JR, 1990, BRIT J GEN PRACT, V40, P190; PITTS J, 1988, J ROY COLL GEN PRACT, V38, P2; PITTS J, 1990, BRIT MED J, V300, P113; PRINCE A, J PUBLIC HLTH MED, V14, P177; PRUDHOE RH, 1984, BRIT MED J, V288, P718, DOI 10.1136/bmj.288.6418.718-a; Reilly P M, 1981, J R Coll Gen Pract, V31, P223; RIDDELL JA, 1980, BRIT MED J, V280, P1518, DOI 10.1136/bmj.280.6230.1518; RIDSDILLSMITH RM, 1983, UPDATE, V26, P274; ROLAND M, 1984, BRIT MED J, V289, P451, DOI 10.1136/bmj.289.6443.451; ROTH JA, 1972, AM J SOCIOL, V77, P839, DOI 10.1086/225227; SAWYER L, 1982, BRIT MED J, V284, P1531, DOI 10.1136/bmj.284.6328.1531; SHELDON MG, 1984, BRIT MED J, V289, P474, DOI 10.1136/bmj.289.6443.474; SIMPSON R, 1979, 6 ROYAL COMM NAT HLT; SINGH S, 1988, BRIT MED J, V297, P1179, DOI 10.1136/bmj.297.6657.1179; STEVENSON JSK, 1982, BRIT MED J, V284, P947, DOI 10.1136/bmj.284.6320.947; STYLES WM, 1983, J ROY COLL GEN PRACT, V33, P395; SUTHERLAND VJ, 1992, BMJ-BRIT MED J, V304, P1545, DOI 10.1136/bmj.304.6841.1545; TULLOCH AJ, 1984, PRACTITIONER, V228, P663; USHERWOOD TP, 1985, J ROY COLL GEN PRACT, V35, P395; WAKEFORD R, 1984, WORLD MED       0307, P17; WARRY R, 1993, GENERAL PRACTIT 1001, P11; WHITBY M, 1989, PRACTITIONER, V223, P493; WILKIN D, 1987, ANATOMY URGAN GENERA; WILLIAMS BT, 1985, BRIT MED J, V291, P1689, DOI 10.1136/bmj.291.6510.1689; WILLIAMS DJ, 1988, BRIT MED J, V296, P1197, DOI 10.1136/bmj.296.6630.1197; WOOD TCA, 1986, PUBLIC HEALTH, V100, P15; YATES DW, 1987, J ROYAL SOC HLTH, V4, P153; 1992, YOUR CHOICES SPECIAL; 1989, GENERAL PRACTICE NAT; 1976, J R COLL GEN PRACT, V26, P3; 1991, GENERAL MED PRACTITI; 1987, GENERAL MED PRACTITI; 1990, COMMUNITY HOSPITALS; 1993, SOCIAL TRENDS, V23; 1991, HLTH PERSONAL SOCIAL; HLTH CIRCULAR, V84; 1992, BR J GEN PRACT, V42, P90; 1992, PULSE           0404, P1; 1993, GENERAL PRACTIT 0730, P32; 1992, YOUR CHOICES FUTURE; 1984, BRIT MED J, V288, P1627; 1989, JR COLL GEN PRACT, V34, P362; 1984, OUT HOURS PATIENT CA	113	102	102	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 22	1994	308	6923					249	253		10.1136/bmj.308.6923.249	http://dx.doi.org/10.1136/bmj.308.6923.249			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT539	8111262	Green Published			2022-12-28	WOS:A1994MT53900024
J	HE, ZJJ; NAKAYAMA, K				HE, ZJJ; NAKAYAMA, K			APPARENT MOTION DETERMINED BY SURFACE LAYOUT NOT BY DISPARITY OR 3-DIMENSIONAL DISTANCE	NATURE			English	Article							REPRESENTATION; PATHS	THE most meaningful events ecologically, including the motion of objects, occur in relation to or on surfaces1. We run along the ground, cars travel on roads, balls roll across lawns, and so on. Even though there are other motions, such as flying of birds, it is likely that motion along surfaces is more frequent and more significant biologically. To examine whether events occurring in relation to surfaces have a preferred status in terms of visual representation, we asked whether the phenomenon of apparent motion would show a preference for motion attached to surfaces. We used a competitive three-dimensional motion paradigm2 and found that there is a preference to see motion between tokens placed within the same disparity as opposed to different planes. Supporting our surface-layout hypothesis, the effect of disparity was eliminated either by slanting the tokens so that they were all seen within the same surface plane or by inserting a single slanted background surface upon which the tokens could rest. Additionally, a highly curved stereoscopic surface led to the perception of a more circuitous motion path defined by that surface, instead of the shortest path in three-dimensional space.			HE, ZJJ (corresponding author), HARVARD UNIV,DEPT PSYCHOL,VIS SCI LAB,33 KIRKLAND ST,CAMBRIDGE,MA 02138, USA.							ATTNEAVE F, 1973, PERCEPT PSYCHOPHYS, V13, P301, DOI 10.3758/BF03214143; BURT P, 1981, PSYCHOL REV, V88, P171, DOI 10.1037/0033-295X.88.2.171; CARLTON EH, 1990, J MATH PSYCHOL, V34, P127, DOI 10.1016/0022-2496(90)90001-P; Finney D.J., 1971, PROBIT ANAL; FOSTER DH, 1975, BIOL CYBERN, V18, P81; Gibson J.J., 1986, ECOLOGICAL APPROACH; GREEN M, 1986, SCIENCE, V233, P1427, DOI 10.1126/science.3749887; HARRIS JP, 1973, PERCEPTION, V2, P235, DOI 10.1068/p020235; Marr D., 1982, VISION; MUTCH K, 1983, PERCEPTION, V12, P305, DOI 10.1068/p120305; RAMACHANDRAN VS, 1983, NATURE, V304, P529, DOI 10.1038/304529a0; SHIMOJO S, 1990, PERCEPTION, V19, P285, DOI 10.1068/p190285; Ullman S., 1979, PROC R SOC SER B-BIO, DOI 10.7551/mitpress/3877.003.0009	13	47	47	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 13	1994	367	6459					173	175		10.1038/367173a0	http://dx.doi.org/10.1038/367173a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MQ780	8114913				2022-12-28	WOS:A1994MQ78000061
J	LOPEZ, GA; JAN, YN; JAN, LY				LOPEZ, GA; JAN, YN; JAN, LY			EVIDENCE THAT THE S6 SEGMENT OF THE SHAKER VOLTAGE-GATED K+ CHANNEL COMPRISES PART OF THE PORE	NATURE			English	Article							POTASSIUM CHANNELS; SODIUM-CHANNELS; GIANT-AXONS; BARIUM IONS; INACTIVATION; BLOCK; DROSOPHILA; MUTATIONS; RECEPTOR; REGION	POTASSIUM channels are highly selective and allow the rapid flux of potassium ions through their pore1. Several studies have implicated the H5 (P or SS1-SS2) segment2,3 as part of the pore in voltage-gated ion channels4-10. The proposal that H5 spans at least 80% of the electric potential drop across the K+ channel pore5,11 is based on altered internal tetraethylammonium sensitivity arising from mutations of H5 residues that are 100% conserved among K+ channels having differing sensitivity to tetraethylammonium5-7,12,13. Here we report that the S6 segment is also involved in K+ ion permeation and in governing the sensitivity to internal tetraethylammonium and barium. Transplanting the S6 segment of NGK2 into Shaker causes this S6 chimaera to adopt the single-channel conductance and sensitivity to internal tetraethylammonium and barium ions from the NGK2 channel. The differences between NGK2 and Shaker in external tetraethylammonium sensitivity, but not single-channel conductance, can be attributed to the differences in their H5 sequences. Three non-conserved S6 residues have been found to affect either single-channel conductance or internal tetraethylammonium sensitivity.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	LOPEZ, GA (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,PARNASSUS & 3RD AVE,U-426,SAN FRANCISCO,CA 94143, USA.		lopez, george/W-4435-2019	Jan, Lily/0000-0003-3938-8498				ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1980, BIOPHYS J, V30, P473, DOI 10.1016/S0006-3495(80)85108-3; ARMSTRONG CM, 1982, J GEN PHYSIOL, V80, P663, DOI 10.1085/jgp.80.5.663; ARMSTRONG CM, 1965, J GEN PHYSIOL, V48, P859, DOI 10.1085/jgp.48.5.859; ARMSTRONG CM, 1966, J GEN PHYSIOL, V50, P491, DOI 10.1085/jgp.50.2.491; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; ARMSTRONG CM, 1972, J GEN PHYSIOL, V59, P388, DOI 10.1085/jgp.59.4.388; BACKX PH, 1992, SCIENCE, V257, P248, DOI 10.1126/science.1321496; BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; CHOI KL, 1993, NEURON, V10, P553; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hille B., 1991, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; KIRSCH GE, 1991, AM J PHYSIOL, V261, pC583, DOI 10.1152/ajpcell.1991.261.4.C583; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; TAGLIALATELA M, 1991, MOL PHARMACOL, V40, P299; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	30	162	163	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 13	1994	367	6459					179	182		10.1038/367179a0	http://dx.doi.org/10.1038/367179a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ780	8114915				2022-12-28	WOS:A1994MQ78000063
J	GRINDON, AJ				GRINDON, AJ			BLOOD DONATION FROM PATIENTS WITH HEMOCHROMATOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											GRINDON, AJ (corresponding author), AMER RED CROSS,BLOOD SERV,ATLANTA,GA, USA.							ALTER HJ, 1972, ANN INTERN MED, V77, P691, DOI 10.7326/0003-4819-77-5-691	1	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					880	880						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	8133632				2022-12-28	WOS:A1993LR61200042
J	PRODHOM, G; LEUENBERGER, P; KOERFER, J; BLUM, A; CHIOLERO, R; SCHALLER, MD; PERRET, C; SPINNLER, O; BLONDEL, J; SIEGRIST, H; SAGHAFI, L; BLANC, D; FRANCIOLI, P				PRODHOM, G; LEUENBERGER, P; KOERFER, J; BLUM, A; CHIOLERO, R; SCHALLER, MD; PERRET, C; SPINNLER, O; BLONDEL, J; SIEGRIST, H; SAGHAFI, L; BLANC, D; FRANCIOLI, P			NOSOCOMIAL PNEUMONIA IN MECHANICALLY VENTILATED PATIENTS RECEIVING ANTACID, RANITIDINE, OR SUCRALFATE AS PROPHYLAXIS FOR STRESS-ULCER - A RANDOMIZED CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						GROSS INFECTION; PEPTIC ULCER; PNEUMONIA; SUCRALFATE; VENTILATORS, MECHANICAL	INTENSIVE-CARE UNIT; CRITICALLY ILL PATIENTS; PROTECTED SPECIMEN BRUSH; MULTIPLE TRAUMA PATIENTS; SELECTIVE DECONTAMINATION; GASTRIC COLONIZATION; INTUBATED PATIENTS; DIGESTIVE-TRACT; BRONCHOALVEOLAR LAVAGE; ANTIBACTERIAL ACTIVITY	Objective: To assess three anti-stress ulcer prophylaxis regimens in mechanically ventilated patients for bacterial colonization, early- and late-onset nosocomial pneumonia, and gastrointestinal bleeding. Design: Randomized controlled trial. Patients: Consecutive eligible patients with mechanical ventilation and a nasogastric tube. Of 258 eligible patients, 244 were assessable. Setting: Medical and surgical intensive care units. Intervention: At intubation, patients were randomly assigned to receive one of the following: antacid (a suspension of aluminum hydroxide and magnesium hydroxide), 20 mL every 2 hours; ranitidine, 150 mg as a continuous intravenous infusion; or sucralfate, 1 g every 4 hours. Measurements: Using predetermined criteria, the incidence of gastric bleeding, gastric colonization, early-onset pneumonia, and late-onset pneumonia was assessed in patients intubated for more than 24 hours. Results: Of 244 assessable patients, macroscopic gastric bleeding was observed in 10%, 4%, and 6% of patients assigned to receive sucralfate, antacid, and ranitidine, respectively (P > 0.2). The incidence of early-onset pneumonia was not statistically different among the three treatment groups (P > 0.2). Among the 213 patients observed for more than 4 days, late-onset pneumonia was observed in 5% of the patients who received sucralfate compared with 16% and 21% of the patients who received antacid or ranitidine, respectively (P = 0.022). Mortality was not statistically different among the three treatment groups. Patients who received sucralfate had a lower median gastric pH (P < 0.001) and less frequent gastric colonization compared with the other groups (P = 0.015). Using molecular typing, 84% of the patients with late-onset gramnegative bacillary pneumonia were found to have gastric colonization with the same bacteria before pneumonia developed. Conclusion: Stress ulcer prophylaxis with sucralfate reduces the risk for late-onset pneumonia in ventilated patients compared with antacid or ranitidine.	CHU VAUDOIS, DIV AUTONOME MED PREVENT HOSP, CH-1011 LAUSANNE, SWITZERLAND; CHU VAUDOIS, DIV PNEUMOL, CH-1011 LAUSANNE, SWITZERLAND; CHU VAUDOIS, DIV GASTROENTEROL, CH-1011 LAUSANNE, SWITZERLAND; CHU VAUDOIS, ANESTHESIOL SERV, CH-1011 LAUSANNE, SWITZERLAND; CHU VAUDOIS, SERV SOINS INTENS MED, CH-1011 LAUSANNE, SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)				Blanc, Dominique/0000-0002-0324-8437				ATHERTON ST, 1978, LANCET, V2, P968; BLANC DS, 1993, J CLIN MICROBIOL, V31, P71, DOI 10.1128/JCM.31.1.71-77.1993; BRANDL M, 1984, ANESTHESIA, V34, P257; CHASTRE J, 1988, AM J MED, V85, P499; COLARDYN F, 1990, INTENS CARE MED, V16, pS18; COOK DJ, 1991, AM J MED, V91, P519, DOI 10.1016/0002-9343(91)90189-5; CROSS AS, 1981, AM J MED, V70, P681, DOI 10.1016/0002-9343(81)90596-9; DASCHNER F, 1988, INFECT CONT HOSP EP, V9, P59, DOI 10.1086/645786; DONOWITZ LG, 1986, INFECT CONT HOSP EP, V7, P23, DOI 10.1017/S0195941700063748; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; DUMOULIN GC, 1982, LANCET, V1, P242; EDDLESTON JM, 1991, CRIT CARE MED, V19, P1491, DOI 10.1097/00003246-199112000-00009; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FLAHERTY J, 1990, J INFECT DIS, V162, P1393, DOI 10.1093/infdis/162.6.1393; FORSTER A, 1982, NOUV PRESSE MED, V11, P2281; GARCIALABATTUT A, 1990, CRIT CARE MED S1, V16, pS19; GARVEY BM, 1989, CRIT CARE MED, V17, P211, DOI 10.1097/00003246-198903000-00002; GOULARTE TA, 1986, AM J INFECT CONTROL, V14, P88; HILLMAN KM, 1982, CRIT CARE MED, V10, P444, DOI 10.1097/00003246-198207000-00005; INGLIS TJJ, 1993, LANCET, V341, P911, DOI 10.1016/0140-6736(93)91208-4; JACOBS S, 1990, JPEN-PARENTER ENTER, V14, P353, DOI 10.1177/0148607190014004353; JEHLE EC, 1990, Z GASTROENTEROL, V28, P315; KAHN RJ, 1982, CRIT CARE MED, V10, P229, DOI 10.1097/00003246-198203000-00109; KAPPSTEIN I, 1991, AM J MED, V91, pS125, DOI 10.1016/0002-9343(91)90464-9; KAPPSTEIN I, 1987, EUR J CLIN MICROBIOL, V6, P216, DOI 10.1007/BF02018225; Karlstadt R, 1989, AM J GASTROENTEROL, V84, P1162; KERVER AJH, 1988, CRIT CARE MED, V16, P1087, DOI 10.1097/00003246-198811000-00001; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LACROIX J, 1989, CRIT CARE MED, V17, P862, DOI 10.1097/00003246-198909000-00003; LANGER M, 1989, AM REV RESPIR DIS, V140, P302, DOI 10.1164/ajrccm/140.2.302; LANGER M, 1987, INTENS CARE MED, V13, P342; LEDINGHAM IM, 1988, LANCET, V1, P785; LOWY FD, 1987, INFECT CONT HOSP EP, V8, P245, DOI 10.1017/S0195941700066121; MAHUL P, 1992, INTENS CARE MED, V18, P20, DOI 10.1007/BF01706421; MARTINETTI G, 1990, RES MICROBIOL, V141, P1151, DOI 10.1016/0923-2508(90)90088-8; MCCARTHY DM, 1991, NEW ENGL J MED, V325, P1017; Peura D A, 1987, Am J Med, V83, P3, DOI 10.1016/0002-9343(87)90804-7; PINGLETON SK, 1986, AM J MED, V80, P827, DOI 10.1016/0002-9343(86)90623-6; PUGIN J, 1991, JAMA-J AM MED ASSOC, V265, P2704, DOI 10.1001/jama.265.20.2704; PUGIN J, 1991, AM REV RESPIR DIS, V143, P1121, DOI 10.1164/ajrccm/143.5_Pt_1.1121; REUSSER P, 1989, J INFECT DIS, V160, P414, DOI 10.1093/infdis/160.3.414; RUDDELL WSJ, 1980, LANCET, V1, P672; RYAN P, 1990, Critical Care Medicine, V18, pS253, DOI 10.1097/00003246-199012001-00148; SALATA RA, 1987, AM REV RESPIR DIS, V135, P426; SCHUSTER DP, 1984, AM J MED, V76, P623, DOI 10.1016/0002-9343(84)90286-9; SIMMS HH, 1991, J TRAUMA, V31, P531, DOI 10.1097/00005373-199104000-00013; SIMON RH, 1986, CARDIOPULMONARY CRIT, P1; STANNARD VA, 1988, BRIT MED J, V296, P155, DOI 10.1136/bmj.296.6616.155; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; STOUTENBEEK CP, 1984, J ANTIMICROB CHEMOTH, V14, P203, DOI 10.1093/jac/14.suppl_B.203; TETTEROO GWM, 1990, LANCET, V335, P704, DOI 10.1016/0140-6736(90)90813-K; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; TRYBA M, 1991, CRIT CARE MED, V19, P942, DOI 10.1097/00003246-199107000-00020; TRYBA M, 1991, AM J MED, V91, pS135, DOI 10.1016/0002-9343(91)90466-B; TRYBA M, 1987, AM J MED, V83, P117, DOI 10.1016/0002-9343(87)90840-0; TRYBA M, 1987, AM J MED, V83, P125, DOI 10.1016/0002-9343(87)90841-2; ULRICH C, 1989, INTENS CARE MED, V15, P424, DOI 10.1007/BF00255597; UNERTL K, 1987, INTENS CARE MED, V13, P106; WILCOX CM, 1988, AM J GASTROENTEROL, V83, P1199; WINTER R, 1989, INTENS CARE MED, V15, P479, DOI 10.1007/BF00255609	60	245	249	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1994	120	8					653	662		10.7326/0003-4819-120-8-199404150-00005	http://dx.doi.org/10.7326/0003-4819-120-8-199404150-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE850	8135449				2022-12-28	WOS:A1994NE85000005
J	MARENBERG, ME; RISCH, N; BERKMAN, LF; FLODERUS, B; DEFAIRE, U				MARENBERG, ME; RISCH, N; BERKMAN, LF; FLODERUS, B; DEFAIRE, U			GENETIC SUSCEPTIBILITY TO DEATH FROM CORONARY HEART-DISEASE IN A STUDY OF TWINS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INDEPENDENT RISK FACTOR; MYOCARDIAL-INFARCTION; FAMILY HISTORY; PARENTAL HISTORY; ARTERY DISEASE; AGGREGATION; ONSET; AGE; RELATIVES; MORTALITY	Background. A family history of premature coronary heart disease has long been thought to be a risk factor for coronary heart disease. Using data from 26 years of follow-up of 21,004 Swedish twins born between 1886 and 1925, we investigated this issue further by assessing the risk of death from coronary heart disease in pairs of monozygotic and dizygotic twins. Methods. The study population consisted of 3298 monozygotic and 5964 dizygotic male twins and 4012 monozygotic and 7730 dizygotic female twins. The age at which one twin died of coronary heart disease was used as the primary independent variable to predict the risk of death from coronary heart disease in the other twin. Information about other risk factors was obtained from questionnaires administered in 1961 and 1963. Actuarial life-table analysis was used to estimate the cumulative probability of death from coronary heart disease. Relative-hazard estimates were obtained from a multivariate survival analysis. Results. Among the men, the relative hazard of death from coronary heart disease when one's twin died of coronary heart disease before the age of 55 years, as compared with the hazard when one's twin did not die before 55, was 8.1 (95 percent confidence interval, 2.7 to 24.5) for monozygotic twins and 3.8 (1.4 to 10.5) for dizygotic twins. Among the women, when one's twin died of coronary heart disease before the age of 65 years, the relative hazard was 15.0 (95 percent confidence interval, 7.1 to 31.9) for monozygotic twins and 2.6 (1.0 to 7.1) for dizygotic twins. Among both the men and the women, whether monozygotic or dizygotic twins, the magnitude of the relative hazard decreased as the age at which one's twin died of coronary heart disease increased. The ratio of the relative-hazard estimate for the monozygotic twins to the estimate for the dizygotic twins approached 1 with increasing age. These relative hazards were little influenced by other risk factors for coronary heart disease. Conclusions. Our findings suggest that at younger ages, death from coronary heart disease is influenced by genetic factors in both women and men. The results also imply that the genetic effect decreases at older ages.	KAROLINSKA INST, DEPT ENVIRONM HYG, S-10401 STOCKHOLM, SWEDEN; KAROLINSKA HOSP, DEPT INTERNAL MED, DIV CARDIOVASC MED, S-10401 STOCKHOLM, SWEDEN; KAROLINSKA INST, INST ENVIRONM MED, DIV EPIDEMIOL, S-10401 STOCKHOLM, SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	MARENBERG, ME (corresponding author), YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, 60 COLL ST, NEW HAVEN, CT 06510 USA.		Girelli, Domenico/B-1183-2008	Girelli, Domenico/0000-0001-9684-1899	NHGRI NIH HHS [HG-00348] Funding Source: Medline; NIMH NIH HHS [2-T32-MH-14235] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH014235] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON AJ, 1979, PREV MED, V8, P419, DOI 10.1016/0091-7435(79)90019-7; AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; BARRETTCONNOR E, 1984, CIRCULATION, V69, P1065, DOI 10.1161/01.CIR.69.6.1065; BLOTH B, 1976, ACTA MED SCAND, V200, P281; BONNEY GE, 1987, BIOMETRICS, V43, P951, DOI 10.2307/2531548; BRESLOW JL, 1991, ANNU REV MED, V42, P357, DOI 10.1146/annurev.me.42.020191.002041; BRITTON M, 1974, ACTA MED SCAND, V196, P203; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; Cederlof R, 1977, Acta Med Scand Suppl, V612, P1; CEDERLOF R, 1967, ARCH ENVIRON HEALTH, V14, P397, DOI 10.1080/00039896.1967.10664761; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P48, DOI 10.1093/oxfordjournals.aje.a114223; DEFAIRE U, 1975, PREV MED, V4, P509, DOI 10.1016/0091-7435(75)90036-5; DEUTSCHER S, 1970, AM J EPIDEMIOL, V91, P233, DOI 10.1093/oxfordjournals.aje.a121133; FRIEDLANDER Y, 1985, BRIT HEART J, V53, P382; GOLDBOURT U, 1986, ARTERIOSCLEROSIS, V6, P357, DOI 10.1161/01.ATV.6.4.357; HAMSTEN A, 1987, AM J CARDIOL, V59, P14, DOI 10.1016/S0002-9149(87)80061-9; HARVALD B, 1970, ACTA GENET MED GEMEL, V19, P248, DOI 10.1017/S1120962300025609; HELLER DA, 1993, NEW ENGL J MED, V328, P1150, DOI 10.1056/NEJM199304223281603; HOPKINS PN, 1989, ANNU REV NUTR, V9, P303; Hosmer DW, 1989, APPL LOGISTIC REGRES, P238; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; NEALE MC, 1989, AM J HUM GENET, V45, P226; NERBRAND C, 1991, SCAND J SOC MED, V19, P154, DOI 10.1177/140349489101900303; NORA JJ, 1980, CIRCULATION, V61, P503, DOI 10.1161/01.CIR.61.3.503; PHILLIPS RL, 1974, AM J EPIDEMIOL, V100, P87, DOI 10.1093/oxfordjournals.aje.a112021; RISCH N, 1990, AM J HUM GENET, V46, P222; RISSANEN AM, 1979, BRIT HEART J, V42, P294, DOI 10.1136/hrt.42.3.294; ROSE G, 1964, BRIT J PREV SOC MED, V18, P75; SCHILDKRAUT JM, 1989, AM J CARDIOL, V64, P555, DOI 10.1016/0002-9149(89)90477-3; SHEA S, 1984, J AM COLL CARDIOL, V4, P793, DOI 10.1016/S0735-1097(84)80408-8; SHOLTZ RI, 1975, AM J EPIDEMIOL, V102, P350, DOI 10.1093/oxfordjournals.aje.a112171; SING CF, 1990, ANNU REV GENET, V24, P171; SING CF, 1989, INT J EPIDEMIOL, V18, pS183; SLACK J., 1966, J MED GENET, V3, P239, DOI 10.1136/jmg.3.4.239; SNOWDEN CB, 1982, AM J EPIDEMIOL, V115, P217, DOI 10.1093/oxfordjournals.aje.a113293; SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202; TENKATE LP, 1982, AM J CARDIOL, V50, P945, DOI 10.1016/0002-9149(82)90400-3; THORDARSON O, 1979, ACTA MED SCAND, V205, P493; TSAI WY, 1987, BIOMETRIKA, V74, P883; 1991, OFFICIAL STATISTICS	41	958	992	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 14	1994	330	15					1041	1046		10.1056/NEJM199404143301503	http://dx.doi.org/10.1056/NEJM199404143301503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF022	8127331				2022-12-28	WOS:A1994NF02200003
J	COSTA, M; WILSON, ET; WIESCHAUS, E				COSTA, M; WILSON, ET; WIESCHAUS, E			A PUTATIVE CELL SIGNAL ENCODED BY THE FOLDED GASTRULATION GENE COORDINATES CELL-SHAPE CHANGES DURING DROSOPHILA GASTRULATION	CELL			English	Article							LARVAL CUTICLE; ZYGOTIC LOCI; 3RD CHROMOSOME; X-CHROMOSOME; MELANOGASTER; EMBRYOS; PATTERN; PROTEIN; MUTATIONS; REQUIREMENTS	The folded gastrulation (fog) gene is required during Drosophila gastrulation for two morphogenetic movements, formation of the ventral furrow and invagination of the posterior midgut primordium. fog coordinates cell shape changes during these invaginations by inducing apical constriction of cells in spatially and temporally defined manners. fog is expressed in the invagination primordia in a pattern that precisely precedes the pattern of constrictions. Overexpression of fog in the dorsoanterior region of the embryo induces ectopic constrictions, indicating localization of fog transcripts may define domains of cell shape changes. fog encodes a novel protein with a putative signal sequence but no potential transmembrane domains. We suggest fog functions as a secreted signal that activates the G protein alpha subunit encoded by concertina in neighboring cells. Our analyses indicate that cell-cell communication ensures the rapid, orderly progression of constriction initiations from the middle of invagination primordia out toward the margins.	UNIV UTAH,SCH MED,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah	COSTA, M (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM012480, T32GM007388] Funding Source: NIH RePORTER; NICHD NIH HHS [5RO1HD22780] Funding Source: Medline; NIGMS NIH HHS [1F32GM12480-01, 5T32GM07388-14] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CASANOVA J, 1990, DEVELOPMENT, V110, P621; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; COSTA M, 1992, DEV DROSOPHILA MELAN; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ERDELYI M, 1989, GENETICS, V122, P111; ETTENSOHN CA, 1985, Q REV BIOL, V60, P289, DOI 10.1086/414426; FOE VE, 1989, DEVELOPMENT, V107, P1; FRISTROM D, 1988, TISSUE CELL, V20, P645, DOI 10.1016/0040-8166(88)90015-8; GARZA D, 1989, SCIENCE, V246, P641, DOI 10.1126/science.2510296; GONZALEZCRESPO S, 1993, GENE DEV, V7, P1703, DOI 10.1101/gad.7.9.1703; GOVIND S, 1993, DEVELOPMENT, V117, P135; HARDIN J, 1988, DEVELOPMENT, V103, P211; HINTON CW, 1959, GENETICS, V44, P923; HORTSCH M, 1990, DEVELOPMENT, V110, P1327; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KAM Z, 1991, DEVELOPMENT, V112, P365; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANE MC, 1993, DEVELOPMENT, V117, P1049; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LEPTIN M, 1990, DEVELOPMENT, V110, P73; LEPTIN M, 1991, GASTRULATION MOVEMEN, P198; MANOUKIAN AS, 1992, GENE DEV, V6, P1740, DOI 10.1101/gad.6.9.1740; MERRILL PT, 1988, DEVELOPMENT, V104, P495; MIKLOS GLG, 1988, P NATL ACAD SCI USA, V85, P2051, DOI 10.1073/pnas.85.7.2051; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; NUSSLEINVOLHARD C, 1979, S SOC DEV BIOL, V37, P185; ODELL GM, 1981, DEV BIOL, V85, P446, DOI 10.1016/0012-1606(81)90276-1; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PERRIMON N, 1989, GENETICS, V121, P313; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J, 1989, MOL CLONING LABORATO; SCHEJTER ED, 1993, CELL, V75, P373, DOI 10.1016/0092-8674(93)80078-S; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SIMPSON L, 1990, DEVELOPMENT, V110, P851; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; Sturtevant AH, 1936, GENETICS, V21, P554; SWEETON D, 1991, DEVELOPMENT, V112, P775; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WIESCHAUS E, 1988, DEVELOPMENT, V104, P483; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; YOUNG PE, 1990, DEVELOPMENT, V111, P1; ZUSMAN SB, 1987, GENETICS, V115, P725; ZUSMAN SB, 1985, DEV BIOL, V111, P359, DOI 10.1016/0012-1606(85)90490-7	52	232	233	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1075	1089		10.1016/0092-8674(94)90384-0	http://dx.doi.org/10.1016/0092-8674(94)90384-0			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137424				2022-12-28	WOS:A1994ND24600013
J	FRIEDMAN, E				FRIEDMAN, E			GETTING A HEAD-START - THE STATES AND HEALTH-CARE REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		BUTLER PA, 1992, TAXING CHOICES ERISA; FIRSHEIN J, 1993, MED HLTH        0719, V47, P3; IGLEHART JK, 1994, NEW ENGL J MED, V330, P75, DOI 10.1056/NEJM199401063300128; KRONICK R, 1993, NEW ENGL J MED, V328, P148, DOI 10.1056/NEJM199301143280225; LIPSON D, 1992, 924 FAULKN GRAY RES; NELSON H, 1993, STATES THAT COULD NO; WHITE J, 1993, HLTH PROG        OCT, V74, P47; WHITE J, 1993, HLTH PROG        OCT, V74, P10; YAWN BP, 1993, JAMA-J AM MED ASSOC, V269, P511, DOI 10.1001/jama.269.4.511; 1993, PROFILES STATES HLTH; 1993, STATE INITIATIVES HL; 1992, GAOHRD9270 US GEN AC; 1992, EBRI27 EMPL BEN RES; 1993, INTERSTUDY COMPETITI, V3, P15	14	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					875	878						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ498	8114245				2022-12-28	WOS:A1994MZ49800037
J	GOODMAN, RA; THACKER, SB; SOLOMON, SL; OSTERHOLM, MT; HUGHES, JM				GOODMAN, RA; THACKER, SB; SOLOMON, SL; OSTERHOLM, MT; HUGHES, JM			INFECTIOUS-DISEASES IN COMPETITIVE SPORTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HERPES-GLADIATORUM; ASEPTIC-MENINGITIS; FOOTBALL PLAYERS; HIV-INFECTION; OUTBREAK; TRANSMISSION; WRESTLERS; EPIDEMIC; MEASLES; TEAM	Objective.-Participation in competitive sports is popular and widely encouraged throughout the United States. Reports of infectious disease outbreaks among competitive athletes and recent publicity regarding infectious disease concerns in sports underscore the need to better characterize the occurrence of these problems. Data Sources.-To identify reports of infectious diseases in sports, we performed a comprehensive search of the medical literature (MEDLINE) and newspaper databases in two on-line services (NEXIS and DIALOG PAPERS). Study Selection.-Articles selected from the literature review included those describing cases or outbreaks of disease in which exposure to an infectious agent was likely to have occurred during training for competitive sports or during actual competition. Articles from the newspaper review included reports of outbreaks, exposures, or preventive measures that directly or indirectly involved teams or spectators. Data Synthesis.-The literature review identified 38 reports of infectious disease outbreaks or other instances of transmission through person-to-person (24 reports), common-source (nine reports), or airborne (five reports) routes; the newspaper search identified 28 reports. Infectious agents included predominantly viruses but also a variety of fungi and gram-positive and gram-negative bacteria. Conclusions.-Our findings indicate that strategies to prevent transmission of infectious diseases in sports must recognize risks at three levels: the individual athlete, the team, and spectators or others who may become exposed to infectious diseases as a result of sports-related activities. Team physicians and others who are responsible for the health of athletes should be especially familiar with the features of infectious diseases that occur in sports and measures for the prevention of these problems.	CTR DIS CONTROL,NATL CTR INFECT DIS,ATLANTA,GA 30333; MINNESOTA DEPT HLTH,MINNEAPOLIS,MN	Centers for Disease Control & Prevention - USA; Minnesota Department of Health (MHD)	GOODMAN, RA (corresponding author), CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30333, USA.							ALEXANDER JP, 1993, J INFECT DIS, V167, P1201, DOI 10.1093/infdis/167.5.1201; ALFANO P, 1989, NY TIMES, pD17; AREY N, 1992, ATLANTA CONSTIT 0409, V1, P6; Atkinson William L., 1992, Morbidity and Mortality Weekly Report, V41, P1; BARON RC, 1982, JAMA-J AM MED ASSOC, V248, P1724, DOI 10.1001/jama.248.14.1724; BARTLETT PC, 1982, AM J SPORT MED, V10, P371, DOI 10.1177/036354658201000611; BASLER RSW, 1983, PRIMARY CARE, V10, P479; BECKER TM, 1988, AM J SPORT MED, V16, P665, DOI 10.1177/036354658801600620; BELONGIA EA, 1991, NEW ENGL J MED, V325, P906, DOI 10.1056/NEJM199109263251302; BONDY F, 1992, NY TIMES        1117, pA1; BONDY F, 1992, NY TIMES        1117, pB11; BROWN LS, IN PRESS MED SCI SPO; BROWN LS, 1993, 9TH INT C AIDS BERL; CALABRESE LH, 1993, SPORTS MED, V15, P6, DOI 10.2165/00007256-199315010-00002; COHEN BA, 1992, NEW ENGL J MED, V327, P820, DOI 10.1056/NEJM199209103271121; COMMENS CA, 1987, MED J AUSTRALIA, V146, P117, DOI 10.5694/j.1326-5377.1987.tb136293.x; DAVIS RM, 1987, AM J EPIDEMIOL, V126, P438, DOI 10.1093/oxfordjournals.aje.a114675; DECKER MD, 1986, AM J EPIDEMIOL, V124, P969, DOI 10.1093/oxfordjournals.aje.a114486; DORMAN JM, 1981, NEW ENGL J MED, V305, P467; DYKE LM, 1965, JAMA-J AM MED ASSOC, V194, P153; EHRESMANN KR, 1992, 32ND INT C ANT AG CH; FREEMAN MJ, 1977, CUTIS, V20, P333; FRISK A, 1966, ACTA DERM-VENEREOL, V46, P453; GLEZEN WP, 1972, LANCET, V1, P301; GOLD A, 1992, NY TIMES        0204, pB11; GOLDSMITH MF, 1992, JAMA-J AM MED ASSOC, V267, P1311, DOI 10.1001/jama.267.10.1311; GRAY C, 1992, CAN MED ASSOC J, V146, P1437; GRAY C, 1992, CAN MED ASSOC J, V146, P1440; HEDBERG CW, 1992, JAMA-J AM MED ASSOC, V268, P3208, DOI 10.1001/jama.268.22.3208; IKEDA RM, 1993, JAMA-J AM MED ASSOC, V270, P2205, DOI 10.1001/jama.270.18.2205; JOHNSON F, 1992, Morbidity and Mortality Weekly Report, V41, P109; JOHNSON M, 1991, SPORTS ILLUSTRAT NOV, V18, P16; KASHIWAGI S, 1982, JAMA-J AM MED ASSOC, V248, P213, DOI 10.1001/jama.248.2.213; LAYMAN C, 1993, STATE ALASKA EPIDEMI, V9, P1; LEVINE N, 1980, J AM ACAD DERMATOL, V3, P415, DOI 10.1016/S0190-9622(80)80337-9; LUDLAM H, 1986, LANCET, V2, P331; MARE JB, 1978, S AFR MED J, V54, P752; MOORE M, 1983, JAMA-J AM MED ASSOC, V249, P2039, DOI 10.1001/jama.249.15.2039; MORSE LJ, 1972, J AMER MED ASSOC, V219, P706, DOI 10.1001/jama.219.6.706; NEMECHEK PM, 1991, NEW ENGL J MED, V325, P357; OSTERBACK L, 1987, ACTA PAEDIATR SCAND, V76, P944, DOI 10.1111/j.1651-2227.1987.tb17269.x; PETERS EM, 1983, S AFR MED J, V64, P582; POLLARD JG, 1967, J AMER COLL HEALTH A, V15, P234; PORTER PS, 1965, JAMA-J AM MED ASSOC, V194, P150; REID TMS, 1981, J HYG-CAMBRIDGE, V86, P357, DOI 10.1017/S0022172400069114; RISSER WL, 1992, PHYSICIAN SPORTSMED, V20, P190; ROBERTSON SE, 1992, PUBLIC HEALTH REP, V107, P24; ROSENBAUM GS, 1990, INT J DERMATOL, V29, P141, DOI 10.1111/j.1365-4362.1990.tb04088.x; SCOTT MJ, 1989, JAMA-J AM MED ASSOC, V262, P207, DOI 10.1001/jama.1989.03430020049017; SELLING B, 1964, NEW ENGL J MED, V270, P979, DOI 10.1056/NEJM196405072701903; SHUTE P, 1979, LANCET, V2, P1629; SNOOK GA, 1980, AM J SPORT MED, V8, P450, DOI 10.1177/036354658000800616; SOSIN DM, 1989, AM J SPORT MED, V17, P828, DOI 10.1177/036354658901700618; STILLER MJ, 1992, J AM ACAD DERMATOL, V27, P632, DOI 10.1016/S0190-9622(08)80205-8; STRAUSS RH, 1989, NEW ENGL J MED, V320, P598; SUDMAN JH, 1988, 8809 CDC, P1; THOMAS JC, 1990, J SCHOOL HEALTH, V60, P11; TORRE D, 1990, LANCET, V335, P1105, DOI 10.1016/0140-6736(90)92684-A; VERBOV J, 1974, LANCET, V2, P1523; WHEELER CE, 1965, JAMA-J AM MED ASSOC, V194, P145; WHITE WB, 1984, JAMA-J AM MED ASSOC, V252, P533; 1992, NATIONAL FEDERATION; 1987, NY TIMES        0506, pD32; 1989, NY TIMES        0319, P4; 1982, NY TIMES        0531, pC2; 1989, WORLD HEALTH FORUM, V10, P287; 1981, MMWR MORB MORTAL WKL, V29, P631; 1991, PEDIATRICS, V88, P640; 1991, DHHS PHS9150212 PUBL, P93; 1993, NCAA SPORTS MED HDB, P24; 1981, MMWR MORB MORTAL WKL, V29, P637	71	52	54	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					862	867		10.1001/jama.271.11.862	http://dx.doi.org/10.1001/jama.271.11.862			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ498	8114242				2022-12-28	WOS:A1994MZ49800034
J	DAWE, RK; SEDAT, JW; AGARD, DA; CANDE, WZ				DAWE, RK; SEDAT, JW; AGARD, DA; CANDE, WZ			MEIOTIC CHROMOSOME PAIRING IN MAIZE IS ASSOCIATED WITH A NOVEL CHROMATIN ORGANIZATION	CELL			English	Article							SYNAPTONEMAL COMPLEX; SACCHAROMYCES-CEREVISIAE; LILIUM-LONGIFLORUM; MEIOSIS; CONDENSATION; PROPHASE; STAGE; GENE	Three-dimensional light microscopy and the excellent cytological features of maize meiotic chromosomes are used to analyze the early events of chromosome synapsis. We demonstrate that the chromosomes undergo a dramatic structural reorganization prior to synapsis in zygotene. The unique features of prezygotene chromosomes are a partial separation of sister chromatids, an elongation of knob heterochromatin, an increase in surface complexity, a 50% increase in total chromosome volume, and a peripheral localization and alignment of telomeric, but not proximal, loci. At zygotene, chromosome volume decreases and chromosomes appear as single fibers. The specialized prezygotene chromosome morphology may facilitate homology recognition once the homologs have been brought together.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	DAWE, RK (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.				NIGMS NIH HHS [GM23238] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023238] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARD DA, 1989, METHOD CELL BIOL, V30, P353; BELMONT A, 1984, J CELL SCI, V65, P123; BELMONT AS, 1987, J CELL BIOL, V105, P77, DOI 10.1083/jcb.105.1.77; BOJKO M, 1983, CARLSBERG RES COMMUN, V48, P457, DOI 10.1007/BF02911920; BURNHAM CR, 1972, GENETICS, V71, P111; Carlson W. R., 1988, Corn and corn improvement. Third edition., P259; CHANG MT, 1989, GENOME, V32, P232, DOI 10.1139/g89-434; CHEN H, 1989, HDB BIOL CONFOCAL MI, P153; Chughtai S. R., 1989, Sabrao Journal, V21, P21; Creighton HB, 1931, P NATL ACAD SCI USA, V17, P492, DOI 10.1073/pnas.17.8.492; CRONENWETT C, 1967, MAIZE GENET COOP NEW, V41, P179; DAWE RK, 1992, MAIZE GENET COOP NEW, V66, P23; GILLIES CB, 1975, CR TRAV LAB CARLSB, V40, P135; GOLUBOVSKAYA IN, 1989, ADV GENET, V26, P149; GOYON C, 1993, MOL CELL BIOL, V13, P373, DOI 10.1128/MCB.13.1.373; HAN CD, 1992, EMBO J, V11, P4037, DOI 10.1002/j.1460-2075.1992.tb05497.x; HAWLEY RS, 1993, CELL, V72, P301, DOI 10.1016/0092-8674(93)90108-3; Hiraoka Y, 1991, Semin Cell Biol, V2, P153; HOLM PB, 1977, CARLSBERG RES COMMUN, V42, P249, DOI 10.1007/BF02910453; HOLM PB, 1977, CARLSBERG RES COMMUN, V42, P103, DOI 10.1007/BF02906489; HSU S-Y, 1981, Iowa State Journal of Research, V55, P351; Huskins CL, 1934, J GENET, V28, P397, DOI 10.1007/BF02981762; JENKINS G, 1983, CARLSBERG RES COMMUN, V48, P255, DOI 10.1007/BF02907772; JOHN B, 1974, CHROMOSOMA, V46, P181, DOI 10.1007/BF00332516; John B., 1990, MEIOSIS; KLECKNER N, 1991, COLD SH Q B, V56, P729; LOIDL J, 1990, GENOME, V33, P759, DOI 10.1139/g90-115; LU BC, 1970, CHROMOSOMA, V29, P305, DOI 10.1007/BF00325945; MAGUIRE MP, 1984, J THEOR BIOL, V106, P605, DOI 10.1016/0022-5193(84)90010-9; MAGUIRE MP, 1983, CYTOLOGIA, V48, P811, DOI 10.1508/cytologia.48.811; MAGUIRE MP, 1985, GENET RES, V46, P273, DOI 10.1017/S0016672300022771; MAGUIRE MP, 1988, CHROMOSOME STRUCTURE, P117; McClintock B., 1978, Maize breeding and genetics. Section 2. Evolution., P159; MOENS PB, 1969, CHROMOSOMA, V28, P1, DOI 10.1007/BF00325986; OEHLKERS F, 1957, CHROMOSOMA, V8, P351; PADDY MR, 1990, CELL, V62, P89, DOI 10.1016/0092-8674(90)90243-8; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PARVINEN M, 1976, NATURE, V260, P534, DOI 10.1038/260534a0; PEACOCK WJ, 1981, P NATL ACAD SCI-BIOL, V78, P4490, DOI 10.1073/pnas.78.7.4490; PEII T, 1982, OPT ENG, V21, P108; RHOADES MM, 1950, J HERED, V41, P58, DOI 10.1093/oxfordjournals.jhered.a106089; Rhoades MM, 1961, CELL, VIII, P1; Robertson WRB, 1931, J MORPHOL PHYSIOL, V51, P119, DOI 10.1002/jmor.1050510103; RUSS CJ, 1992, IMAGE PROCESSING HDB; SALONEN K, 1982, CHROMOSOMA, V85, P611, DOI 10.1007/BF00330775; SCHERTHAN H, 1992, CHROMOSOMA, V101, P590, DOI 10.1007/BF00360535; SMITHIES O, 1986, PHILOS T ROY SOC B, V312, P291, DOI 10.1098/rstb.1986.0008; STAIGER CJ, 1990, DEV BIOL, V138, P231, DOI 10.1016/0012-1606(90)90193-M; STERN H, 1975, P NATL ACAD SCI USA, V72, P961, DOI 10.1073/pnas.72.3.961; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; THOMAS JB, 1976, HEREDITY, V36, P155, DOI 10.1038/hdy.1976.19; VINCENT JE, 1993, CHROMOSOMA, V102, P195, DOI 10.1007/BF00387734; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WESTERGA.M, 1970, CR TRAV LAB CARLSB, V37, P239	54	140	144	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 11	1994	76	5					901	912		10.1016/0092-8674(94)90364-6	http://dx.doi.org/10.1016/0092-8674(94)90364-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124724				2022-12-28	WOS:A1994NA89000015
J	VAUX, DL; HAECKER, G; STRASSER, A				VAUX, DL; HAECKER, G; STRASSER, A			AN EVOLUTIONARY PERSPECTIVE ON APOPTOSIS	CELL			English	Review							CELL-DEATH; BCL-2; ENZYME				VAUX, DL (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA.		Strasser, Andreas/C-7581-2013; Vaux, David L/C-7249-2013	Strasser, Andreas/0000-0002-5020-4891; Vaux, David L/0000-0003-2703-1651				CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HENGATNER HO, 1994, CELL, V76, P665; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KAMITA SG, 1993, J VIROL, V67, P455, DOI 10.1128/JVI.67.1.455-463.1993; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VAUX DL, 1992, INT IMMUNOL, V4, P821, DOI 10.1093/intimm/4.7.821; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	21	708	734	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 11	1994	76	5					777	779		10.1016/0092-8674(94)90350-6	http://dx.doi.org/10.1016/0092-8674(94)90350-6			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124715				2022-12-28	WOS:A1994NA89000001
J	BENJACOB, E; SCHOCHET, O; TENENBAUM, A; COHEN, I; CZIROK, A; VICSEK, T				BENJACOB, E; SCHOCHET, O; TENENBAUM, A; COHEN, I; CZIROK, A; VICSEK, T			GENERIC MODELING OF COOPERATIVE GROWTH-PATTERNS IN BACTERIAL COLONIES	NATURE			English	Article							FRACTAL GROWTH	BACTERIAL colonies must often cope with unfavourable environmental conditions(1,2). To do so, they have developed sophisticated modes of cooperative behaviour(3-10). It has been found that such behaviour can cause bacterial colonies to exhibit complex growth patterns similar to those observed during non-equilibrium growth processes in non-living systems(11) some of the qualitative features of the latter may be invoked to account for the complex patterns of bacterial growth(12-18). Here we show that a simple model of bacterial growth can reproduce the salient features of the observed growth patterns. The model incorporates random walkers, representing aggregates of bacteria, which move in response to gradients in nutrient concentration and communicate with each other by means of chemotactic 'feedback'. These simple features allow the colony to respond efficiently to adverse growth conditions, and generate self-organization over a wide range of length scales.	EOTVOS LORAND UNIV, DEPT ATOM PHYS, H-1088 BUDAPEST, HUNGARY	Eotvos Lorand University	BENJACOB, E (corresponding author), TEL AVIV UNIV, RAYMOND & BEVERLY SACKLER FAC EXACT SCI, SCH PHYS & ASTRON, IL-69978 TEL AVIV, ISRAEL.		Czirok, Andras/E-4253-2014; Vicsek, Tamas/A-3305-2009	Czirok, Andras/0000-0002-2694-5163; 				ADLER J, 1969, SCIENCE, V166, P1588, DOI 10.1126/science.166.3913.1588; ALLISON C, 1991, SCI PROG, V75, P403; BENJACOB E, 1994, PHYSICA A, V202, P1, DOI 10.1016/0378-4371(94)90165-1; BENJACOB E, 1992, PHYSICA A, V187, P378, DOI 10.1016/0378-4371(92)90002-8; BENJACOB E, 1990, NATURE, V343, P523, DOI 10.1038/343523a0; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; BUDRENE EO, 1991, NATURE, V349, P630, DOI 10.1038/349630a0; COOPER AL, 1968, PROC R SOC SER B-BIO, V171, P175, DOI 10.1098/rspb.1968.0063; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; FUJIKAWA H, 1989, J PHYS SOC JPN, V58, P3875, DOI 10.1143/JPSJ.58.3875; HENRICHSEN J, 1972, BACTERIOL REV, V36, P478, DOI 10.1128/MMBR.36.4.478-503.1972; HENRICI TH, 1948, BIOL BACTERIA; KESSLER D, IN PRESS PHYS REV E; KESSLER JO, 1985, CONTEMP PHYS, V26, P147, DOI 10.1080/00107518508210745; LACKIIE JM, 1981, BIOL CHEMOTACTIC RES; MATSUYAMA T, 1993, CRIT REV MICROBIOL, V19, P117, DOI 10.3109/10408419309113526; NOSSAL R, 1972, EXP CELL RES, V75, P138, DOI 10.1016/0014-4827(72)90529-0; SANDER LM, 1986, NATURE, V322, P789, DOI 10.1038/322789a0; SCHINDLER J, 1992, Binary Computing in Microbiology, V4, P66; Shapiro J. A., 1988, SCI AM, V258, P62; SHAPIRO JA, 1991, PHYSICA D, V49, P214, DOI 10.1016/0167-2789(91)90209-R; STANIER RY, 1957, MICROBIAL WORLD	22	443	451	2	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					46	49		10.1038/368046a0	http://dx.doi.org/10.1038/368046a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	8107881				2022-12-28	WOS:A1994MY56900047
J	STEARNS, T; KIRSCHNER, M				STEARNS, T; KIRSCHNER, M			IN-VITRO RECONSTITUTION OF CENTROSOME ASSEMBLY AND FUNCTION - THE CENTRAL ROLE OF GAMMA-TUBULIN	CELL			English	Article							MICROTUBULE-ORGANIZING CENTERS; CELL-FREE-EXTRACTS; SPISULA-SOLIDISSIMA OOCYTES; HAMSTER OVARY CELLS; ASPERGILLUS-NIDULANS; NUCLEATING ACTIVITY; CYTOPLASMIC EXTRACTS; DROSOPHILA EMBRYO; MITOTIC SPINDLE; PROTEIN-KINASE	The centrosome nucleates microtubule polymerization, affecting microtubule number, polarity, and structure. We use an in vitro system based on extracts of Xenopus eggs to examine the role of gamma-tubulin in centrosome assembly and function. gamma-Tubulin is present in the cytoplasm of frog eggs and vertebrate somatic cells in a large similar to 25S complex. The egg extracts assemble centrosomes around sperm centrioles. Formation of a centrosome in the extract requires both the gamma-tubulin complex and ATP and can take place in the absence of microtubules. gamma-Tubulin is not present on the sperm prior to incubation in extract, but is recruited from the cytoplasm during centrosome assembly. The gamma-tubulin complex also binds to microtubules, likely the minus end, independent of the centrosome. These results suggest that gamma-tubulin is an essential component of the link between the centrosome and the microtubule, probably playing a direct role in microtubule nucleation.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco				Stearns, Tim/0000-0002-0671-6582				BARON AT, 1988, J CELL BIOL, V107, P2669, DOI 10.1083/jcb.107.6.2669; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; BUENDIA B, 1992, J CELL BIOL, V116, P1431, DOI 10.1083/jcb.116.6.1431; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CENTONZE VE, 1990, J CELL SCI, V95, P405; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; EVANS L, 1985, J CELL BIOL, V100, P1185, DOI 10.1083/jcb.100.4.1185; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; GARD DL, 1987, J CELL BIOL, V105, P2191, DOI 10.1083/jcb.105.5.2191; GOULD RR, 1977, J CELL BIOL, V73, P601, DOI 10.1083/jcb.73.3.601; HEIDEMANN SR, 1975, J CELL BIOL, V57, P105; HELDEMANN SR, 1980, NATURE, V286, P517; HILLER G, 1978, CELL, V14, P795, DOI 10.1016/0092-8674(78)90335-5; HORIO T, 1991, J CELL SCI, V99, P693; HUANG B, 1988, J CELL BIOL, V107, P133, DOI 10.1083/jcb.107.1.133; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; Kalt Astrid, 1993, Trends in Cell Biology, V3, P118, DOI 10.1016/0962-8924(93)90174-Y; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; KELLOGG DR, 1992, MOL BIOL CELL, V3, P1, DOI 10.1091/mbc.3.1.1; KERYER G, 1990, J CELL SCI, V97, P553; KURIYAMA R, 1981, J CELL BIOL, V91, P822, DOI 10.1083/jcb.91.3.822; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MANIOTIS A, 1991, CELL, V67, P495, DOI 10.1016/0092-8674(91)90524-3; MASUDA H, 1992, J CELL BIOL, V117, P1055, DOI 10.1083/jcb.117.5.1055; MCDONALD KL, 1992, J CELL BIOL, V118, P369, DOI 10.1083/jcb.118.2.369; MCNIVEN MA, 1988, J CELL BIOL, V106, P1593, DOI 10.1083/jcb.106.5.1593; MELKI R, 1993, J CELL BIOL, V122, P1301, DOI 10.1083/jcb.122.6.1301; MIAKELYE R, 1985, CELL, V41, P165, DOI 10.1016/0092-8674(85)90071-6; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; NUMATA O, 1983, EXP CELL RES, V148, P207, DOI 10.1016/0014-4827(83)90200-8; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; OHTA K, 1993, J CELL SCI, V104, P125; PALAZZO RE, 1992, SCIENCE, V256, P219, DOI 10.1126/science.1566068; RAFF JW, 1993, J CELL BIOL, V121, P823, DOI 10.1083/jcb.121.4.823; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; SUPRENANT KA, 1991, CELL MOTIL CYTOSKEL, V19, P207, DOI 10.1002/cm.970190308; TAO W, 1988, J CELL BIOL, V107, P1025, DOI 10.1083/jcb.107.3.1025; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; WEIL CF, 1986, MOL CELL BIOL, V6, P2963, DOI 10.1128/MCB.6.8.2963; Wilson E.B., 1906, CELL DEV INHERITANCE; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZABALA JC, 1992, CELL MOTIL CYTOSKEL, V23, P222, DOI 10.1002/cm.970230306; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	56	414	420	3	16	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	1994	76	4					623	637		10.1016/0092-8674(94)90503-7	http://dx.doi.org/10.1016/0092-8674(94)90503-7			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124706				2022-12-28	WOS:A1994MZ28500006
J	KATZ, PS; GETTING, PA; FROST, WN				KATZ, PS; GETTING, PA; FROST, WN			DYNAMIC NEUROMODULATION OF SYNAPTIC STRENGTH INTRINSIC TO A CENTRAL PATTERN GENERATOR CIRCUIT	NATURE			English	Article							CENTRAL NERVOUS-SYSTEM; MOTOR ORGANIZATION; NEURAL NETWORKS; TRITONIA; NEURONS; BEHAVIOR; APLYSIA; MODULATION; INTERNEURONS; MECHANISMS	MOTOR circuits are often thought to be physically separate from their neuromodulatory systems1,2. We report here a counter example, where neurons within a circuit appear to modulate synaptic properties of that same circuit during its normal operation. The dorsal swim interneurons (DSIs) are members of the central pattern generator circuit for escape swimming in the mollusc Tritonia diomedea3. However, DSI stimulation also rapidly enhances the synaptic potentials evoked by another neuron in the same circuit onto its follower cells. This modulatory action appears to be mediated by serotonin (5-hydroxytryptamine); the DSIs are serotonin-immunoreactive4, and bath-application of serotonin mimics and occludes the effect of DSIs. These results indicate that during the escape swim, circuit connection strengths are dynamically controlled by the activity of neurons within the circuit itself. This 'intrinsic neuromodulation' may be important for the animal's initial decision to swim, the generation of the swim motor programme itself, and certain types of learning.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa	KATZ, PS (corresponding author), UNIV TEXAS, SCH MED, DEPT NEUROBIOL & ANAT, HOUSTON, TX 77225 USA.							ABRAHAM F D, 1971, Communications in Behavioral Biology Part A Original Articles, V6, P271; BISHOP CA, 1987, J NEUROSCI, V7, P1769; BROWN G D, 1991, Society for Neuroscience Abstracts, V17, P549; CHIEL HJ, 1990, TRENDS NEUROSCI, V13, P223, DOI 10.1016/0166-2236(90)90164-6; CROLL RP, 1989, J COMP NEUROL, V280, P122, DOI 10.1002/cne.902800109; CROPPER EC, 1987, P NATL ACAD SCI USA, V84, P3486, DOI 10.1073/pnas.84.10.3486; FROST W N, 1989, Society for Neuroscience Abstracts, V15, P1118; FROST W N, 1988, Society for Neuroscience Abstracts, V14, P607; Getting P.A., 1985, P3; GETTING P A, 1985, Society for Neuroscience Abstracts, V11, P1023; GETTING PA, 1989, ANNU REV NEUROSCI, V12, P185, DOI 10.1146/annurev.neuro.12.1.185; GETTING PA, 1985, J NEUROPHYSIOL, V53, P466, DOI 10.1152/jn.1985.53.2.466; GETTING PA, 1980, J NEUROPHYSIOL, V44, P151, DOI 10.1152/jn.1980.44.1.151; GETTING PA, 1981, J NEUROPHYSIOL, V46, P65, DOI 10.1152/jn.1981.46.1.65; GETTING PA, 1983, SYM SOC EXP BIOL, P89; HARRISWARRICK RM, 1991, ANNU REV NEUROSCI, V14, P39, DOI 10.1146/annurev.ne.14.030191.000351; HAWKINS RD, 1981, J NEUROPHYSIOL, V45, P315, DOI 10.1152/jn.1981.45.2.315; HUME RI, 1982, J NEUROPHYSIOL, V47, P60, DOI 10.1152/jn.1982.47.1.60; HUME RI, 1982, J NEUROPHYSIOL, V47, P75, DOI 10.1152/jn.1982.47.1.75; Jordan L M, 1992, Curr Opin Neurobiol, V2, P794, DOI 10.1016/0959-4388(92)90136-9; Kaczmarek LK, 1987, NEUROMODULATION BIOC; Katz P. S., 1993, Society for Neuroscience Abstracts, V19, P1700; KATZ PS, 1990, TRENDS NEUROSCI, V13, P367, DOI 10.1016/0166-2236(90)90021-2; KATZ PS, 1989, J NEUROPHYSIOL, V62, P571, DOI 10.1152/jn.1989.62.2.571; NUSBAUM MP, 1992, J NEUROSCI, V12, P2706; TAGHERT PH, 1978, J COMP PHYSIOL, V123, P253, DOI 10.1007/BF00656878; WEINREICH D, 1973, J NEUROCHEM, V20, P969, DOI 10.1111/j.1471-4159.1973.tb00067.x; WHIM MD, 1990, J NEUROSCI, V10, P3313; WILLOWS AOD, 1973, J NEUROBIOL, V4, P207, DOI 10.1002/neu.480040306; [No title captured]	30	119	120	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	1994	367	6465					729	731		10.1038/367729a0	http://dx.doi.org/10.1038/367729a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	8107867				2022-12-28	WOS:A1994MX63100056
J	WILLIAMS, RW; HOGAN, D; GARRAGHTY, PE				WILLIAMS, RW; HOGAN, D; GARRAGHTY, PE			TARGET RECOGNITION AND VISUAL MAPS IN THE THALAMUS OF ACHIASMATIC DOGS	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; BINOCULAR COMPETITION; SIAMESE CAT; PROJECTIONS; ORGANIZATION; PATHWAYS; FIELD	VISION is dependent on ordered neuronal representations or maps of visual space. These maps depend on precise connections between retinal axons and their targets cells. In mammals, nerve fibres from right and left eyes produce congruent maps of contralateral visual space in adjacent layers of the lateral geniculate nucleus (LGN)(1). We have identified an autosomal recessive mutation in Belgian sheepdogs(2,3) that eliminates the optic chiasm. In these mutants, all retinal axons project into the ipsilateral optic tract, including those originating in the nasal hemiretina that normally cross midline. These animals exhibit a pronounced horizontal nystagmus(4,5). The abnormal ipsilaterally directed nasal fibres innervate the LGN as if they had successfully crossed the midline, terminating in the appropriate layer of the nucleus. As a consequence, the LGN contains non-congruent, mirror-image maps of visual space in adjacent layers. These results show that there is a robust affinity between nasal and temporal retinal axons and,specific LGN layers even when all retinal axons originate from a single eye.	INDIANA UNIV, DEPT PSYCHOL, PROGRAM NEURAL SCI, BLOOMINGTON, IN 47405 USA	Indiana University System; Indiana University Bloomington	WILLIAMS, RW (corresponding author), UNIV TENNESSEE, SCH MED, DEPT ANAT & NEUROBIOL, 855 MONROE AVE, MEMPHIS, TN 38163 USA.		Williams, Robert W./H-8789-2016	Williams, Robert W./0000-0001-8924-4447				APKARIAN P, IN PRESS EUR J NEURO; BALKEMA GW, 1990, VISUAL NEUROSCI, V4, P595, DOI 10.1017/S0952523800005794; BERMAN N, 1972, J PHYSIOL-LONDON, V224, P363, DOI 10.1113/jphysiol.1972.sp009900; BONHOEFFER F, 1985, NATURE, V315, P408, DOI 10.1038/315409a0; CHALUPA LM, 1984, HUM NEUROBIOL, V3, P103; COOPER ML, 1979, J COMP NEUROL, V187, P313, DOI 10.1002/cne.901870205; DELLOSSO LF, 1988, CURR NEURO OPHTHALMO, V1, P139; GARRAGHTY PE, 1988, VISUAL NEUROSCI, V1, P93, DOI 10.1017/S0952523800001048; GUILLERY RW, 1971, J COMP NEUROL, V143, P73, DOI 10.1002/cne.901430106; GUILLERY RW, 1986, TRENDS NEUROSCI, V9, P364, DOI 10.1016/0166-2236(86)90115-3; GUILLERY RW, 1985, J NEUROSCI, V5, P1370; Hogan D., 1993, Society for Neuroscience Abstracts, V19, P524; HUANG K, 1985, DEV BRAIN RES, V20, P213, DOI 10.1016/0165-3806(85)90108-7; HUBEL DH, 1971, J PHYSIOL-LONDON, V218, P33, DOI 10.1113/jphysiol.1971.sp009603; KAAS JH, 1973, BRAIN BEHAV EVOLUT, V6, P253; LEVENTHAL AG, 1985, J NEUROSCI, V5, P795; RAKIC P, 1981, SCIENCE, V214, P928, DOI 10.1126/science.7302569; Rioch DM, 1929, J COMP NEUROL, V49, P1, DOI 10.1002/cne.900490102; SANDERSON KJ, 1971, J COMP NEUROL, V143, P101, DOI 10.1002/cne.901430107; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STONE J, 1978, J COMP NEUROL, V180, P783, DOI 10.1002/cne.901800409; WALSH C, 1983, NATURE, V302, P611, DOI 10.1038/302611a0; WILLIAMS R W, 1991, Society for Neuroscience Abstracts, V17, P187; WILLIAMS RW, 1993, INVEST OPHTH VIS SCI, V34, P1125	24	68	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	1994	367	6464					637	639		10.1038/367637a0	http://dx.doi.org/10.1038/367637a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	8107846				2022-12-28	WOS:A1994MW68800051
J	HONG, KS; DRISCOLL, M				HONG, KS; DRISCOLL, M			A TRANSMEMBRANE DOMAIN OF THE PUTATIVE CHANNEL SUBUNIT MEC-4 INFLUENCES MECHANOTRANSDUCTION AND NEURODEGENERATION IN C-ELEGANS	NATURE			English	Article							TOUCH RECEPTOR NEURONS; CAENORHABDITIS-ELEGANS; GENE	ABERRANT ion channel activity plays a causative role in several human disorders1-3. Inappropriately regulated channel activity also appears to be the basis for neurodegeneration induced by dominant mutations of Caenorhabditis elegans mec-4 (mec-4(d)), a member of the degenerin gene family postulated to encode a subunit of a mechanosensory channel4. The degenerin gene family has been defined by two C. elegans genes, mec-4 and deg-1 (ref. 5), which can mutate to gain-of-function alleles that induce degeneration of specific groups of neurons. A related mammalian gene, rat alpha-rENaC, induces an amiloride-sensitive Na+ current when introduced to Xenopus oocytes6, strongly suggesting that degenerin genes encode ion channel proteins. Deduced amino-acid sequences of the degenerins include two predicted membrane-spanning domains6,7. Here we show that conserved amino acids within the second membrane-spanning domain (MSDII) are critical for MEC-4 activity and that specific substitutions within MSDII, whether encoded in cis or in trans to a mec-4(d) mutation, block or delay the onset of degeneration. Remarkably, MSDII from two other family members, C. elegans deg-1 (ref. 5) and rat alpha-rENaC (ref. 6), can functionally substitute for MEC-4 MSDII in chimaeric proteins. Our results support a structural model for a mechanosensory channel in which multiple MEC-4 subunits are oriented such that MSDII lines the channel pore, and a neurodegeneration model in which aberrant ion flow through this channel is a key event.	RUTGERS UNIV,CTR ADV BIOTECHNOL & MED,DEPT MOLEC BIOL & BIOCHEM,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick								BETZ H, 1990, BIOCHEMISTRY-US, V29, P3591, DOI 10.1021/bi00467a001; BRENNER S, 1974, GENETICS, V77, P71; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; CHALFIE M, 1993, NATURE, V361, P504, DOI 10.1038/361504a0; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; DRISCOLL M, 1992, J NEUROBIOL, V23, P1327, DOI 10.1002/neu.480230919; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FRENCH AS, 1992, ANNU REV PHYSIOL, V54, P135, DOI 10.1146/annurev.physiol.54.1.135; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; PTACEK LJ, 1993, ANN NEUROL, V33, P300, DOI 10.1002/ana.410330312; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1; 1991, GENETICS COMPUTER GR	23	183	193	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					470	473		10.1038/367470a0	http://dx.doi.org/10.1038/367470a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	8107806				2022-12-28	WOS:A1994MU67900057
J	NAGY, LM; CARROLL, S				NAGY, LM; CARROLL, S			CONSERVATION OF WINGLESS PATTERNING FUNCTIONS IN THE SHORT-GERM EMBRYOS OF TRIBOLIUM-CASTANEUM	NATURE			English	Article							SEGMENT-POLARITY GENE; WHOLE DROSOPHILA EMBRYOS; LOCALIZATION; EXPRESSION	DURING embryogenesis, all insects reach a conserved, or phylotypic, stage at which all future segments are present1,2. Different insects, however, arrive at this stage by overtly different pathways. In the long-germ insect Drosophila melanogaster, segmentation of the entire embryo occurs nearly simultaneosly and results from the action of a cascade of transcriptional regulatory factors that operate in the acellular environment of the syncytial blastoderm3,4. In short-germ insects, segmentation occurs in an anterior-to-posterior sequence, within a cellular environment1, and might then be dependent on intercellular signalling5,6. To compare the molecular mechanisms of segmentation, we have isolated a homologue of the Drosophila wingless gene, a mediator of cell-cell communications7-9, from the short-germ beetle Tribolium castaneum. The principal features of wingless expression patterns in Drosophila are conserved in Tribolium, including its early deployment in rostral and caudal domains in the blastoderm, its segmental iteration in cells immediately anterior to cells expressing the engrailed gene, and its later restriction to a ventral sector of the developing appendages.			NAGY, LM (corresponding author), UNIV WISCONSIN, HOWARD HUGHES MED INST, MOLEC BIOL LAB, MADISON, WI 53706 USA.							AKAM M, 1992, Current Biology, V2, P395, DOI 10.1016/0960-9822(92)90313-Y; AKAM M, 1987, DEVELOPMENT, V101, P1; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEVELOPMENT, V103, P289; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; INGHAM PW, 1988, NATURE, V331, P73, DOI 10.1038/331073a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGHAM PW, 1993, DEVELOPMENT, V117, P283; KNIPPLE DC, 1985, NATURE, V317, P40, DOI 10.1038/317040a0; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PATEL NH, 1994, NATURE, V367, P429, DOI 10.1038/367429a0; PATEL NH, 1989, DEVELOPMENT, V107, P201; PATEL NH, 1993, EVOLUTIONARY CONSERVATION OF DEVELOPMENTAL MECHANISMS, P85; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Sander K., 1976, Advances in insect physiology. Volume 12., P125, DOI 10.1016/S0065-2806(08)60255-6; SANDERK, 1983, DEV EVOLUTION, P137; SIMCOX AA, 1989, DEVELOPMENT, V107, P715; SOMMER RJ, 1993, NATURE, V361, P448, DOI 10.1038/361448a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STUART JJ, 1993, DEVELOPMENT, V117, P233; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2	29	131	132	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	1994	367	6462					460	463		10.1038/367460a0	http://dx.doi.org/10.1038/367460a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	8107804				2022-12-28	WOS:A1994MU67900054
J	RICHARDS, T				RICHARDS, T			THE WORLD-MEDICAL-ASSOCIATION - CAN HOPE TRIUMPH OVER EXPERIENCE	BRITISH MEDICAL JOURNAL			English	Article								The World Medical Association was set up in 1947 in the wake of outrage about war crimes committed by doctors in Hider's Germany. For nearly 50 years it has lurched from one controversy to another, arguing within itself about its funding, its voting system, and the representativeness and political affiliation of some of its member medical associations The BMA withdrew from the association in 1984, supporting a breakaway ''Toronto'' group including Canada, the Scandinavian countries, the Netherlands, Ireland, and jamaica. All but Britain and jamaica have now rejoined and membership is growing, but the association is still struggling to gain credibility and clout. After 20 years of part time stewardship the recent appointment of a new full time secretary general has fuelled expectations that internal reforms will be implemented, and the WMA's standing and profile improved.										GRODIN MA, 1993, HASTINGS CTR REPORT; MACPHERSON G, 1982, BRIT MED J, V285, P1681, DOI 10.1136/bmj.285.6356.1681; Tuffs Annette, 1993, Lancet, V341, P297, DOI 10.1016/0140-6736(93)92635-7; 1985, BRIT MED J, V290, P802; 1947, BRIT MED J, V2, P498; 1977, BRIT MED J, V1, P1610	6	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 22	1994	308	6923					262	266		10.1136/bmj.308.6923.262	http://dx.doi.org/10.1136/bmj.308.6923.262			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT539	8111265	Green Published			2022-12-28	WOS:A1994MT53900028
J	PEKAREK, KJ; JACOB, JS; MATHIOWITZ, E				PEKAREK, KJ; JACOB, JS; MATHIOWITZ, E			DOUBLE-WALLED POLYMER MICROSPHERES FOR CONTROLLED DRUG-RELEASE	NATURE			English	Article							POLYANHYDRIDE MICROSPHERES; SOLVENT REMOVAL; MICROENCAPSULATION; MORPHOLOGY; SYSTEMS; COACERVATION	ONE approach to the controlled release of drugs involves incorporation of the drug molecules into the matrix of microscopic polymer spheres or capsules1-10. Existing methods for preparing such microparticles do not, however, always guarantee a constant release rate, for example because drug molecules may be trapped preferentially at the surface, because they have to diffuse through an increasing thickness of polymer when the particles are non-eroding or because the surface area changes for eroding particles. In other situations pulsed release may be required-an application to which simple polymer microspheres do not readily lend themselves. Multi-walled microspheres might solve some of these problems. Here we describe a one-step process for preparing double-walled polymer microspheres with diameters ranging from about 20 to 1,000 micrometres. Our technique11 involves the phase separation of a polymer mixture owing to solvent evaporation: with an appropriate choice of interfacial tensions and evaporation rate, a spherical droplet of one polymer becomes coated with a highly uniform layer of the other. This process, which might be adapted to yield multi-walled microspheres, should make possible the engineering of highly specific drug-release properties.	BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912	Brown University								Green B. K., 1957, US, Patent No. [US 2800458 A, 2800458, 2800458A]; Green B.K., 1957, Patent Brevet, Patent No. [2,800,457, 2800457, US 2800457]; HARKIN WD, 1952, PYSICAL CHEM SURFACE; HEISTAND EN, 1836, Patent No. 24899; HELLER J, 1985, J CONTROL RELEASE, V1, P87; MADAN PL, 1978, DRUG DEV IND PHARM, V4, P95, DOI 10.3109/03639047809055641; MADAN PL, 1972, J PHARM SCI, V61, P1586, DOI 10.1002/jps.2600611008; MATHIOWITZ E, 1990, POLYMER, V31, P547, DOI 10.1016/0032-3861(90)90401-J; MATHIOWITZ E, 1988, J APPL POLYM SCI, V35, P755, DOI 10.1002/app.1988.070350316; MATHIOWITZ E, 1992, J APPL POLYM SCI, V45, P125, DOI 10.1002/app.1992.070450115; MATHIOWITZ E, 1990, SCANNING MICROSCOPY, V4, P329; Mathiowitz E, 1989, US Patent, Patent No. 4861627; MISSELBROOK J, 1976, Patent No. 3960757; PARROTT EL, 1970, PHARM TECHNOLOGY, P86; TORZA S, 1970, J COLLOID INTERF SCI, V33, P67, DOI 10.1016/0021-9797(70)90073-1; Vrancken MN., 1970, U.S. Patent, Patent No. [3523906, 3,523,906]	16	231	268	2	101	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 20	1994	367	6460					258	260		10.1038/367258a0	http://dx.doi.org/10.1038/367258a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	8121490				2022-12-28	WOS:A1994MR49400051
J	GUZDER, SN; QIU, HF; SOMMERS, CH; SUNG, P; PRAKASH, L; PRAKASH, S				GUZDER, SN; QIU, HF; SOMMERS, CH; SUNG, P; PRAKASH, L; PRAKASH, S			DNA-REPAIR GENE RAD3 OF SACCHAROMYCES-CEREVISIAE IS ESSENTIAL FOR TRANSCRIPTION BY RNA POLYMERASE-II	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; XERODERMA-PIGMENTOSUM; NUCLEOTIDE-SEQUENCE; DEPENDENT ATPASE; YEAST HOMOLOG; INITIATION; REQUIREMENT; HELICASE; PROTEIN; ENCODES	THE RAD3 gene of Saccharomyces cerevisiae is required for excision repair of ultraviolet-damaged DNA and is essential for cell viability1. The RAD3-encoded protein shares a high degree of homology with the human ERCC2(XPD) gene product2. Mutations in XPD, besides causing the cancer-prone syndrome xeroderma pigmentosum, can also result in Cockayne's syndrome and trichothiodystrophy3. To investigate the role of RAD3 in viability, we examine here the effect of a recessive, temperature-sensitive (ts) conditional lethal mutation of the gene on transcription by RNA polymerase II. Upon transfer to the restrictive temperature, the rad3-ts mutant rapidly ceases growth and poly(A)+ RNA synthesis is inhibited drastically. Messenger RNA levels of all the genes examined, HIS3, TRP3, STE2, MET19, RAD23, CDC7, CDC9 and ACT1, decline rapidly upon loss of RAD3 activity. The synthesis of heat-shock-inducible HSP26 mRNA and galactose-inducible GAL7 and GAL10 mRNAs is also drastically inhibited in the rad3-ts mutant at the restrictive temperature. The RNA polymerase II transcriptional activity in extract from the rad3-ts14 strain is thermolabile, and this in vitro transcriptional defect can be fully corrected by the addition of homogeneous RAD3 protein. These findings indicate that RAD3 protein has a direct and essential role in RNA polymerase II transcription.	UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT BIOPHYS,ROCHESTER,NY 14642; UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Rochester; University of Rochester; University of Texas System; University of Texas Medical Branch Galveston			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261				BAILLY V, 1991, P NATL ACAD SCI USA, V88, P9712, DOI 10.1073/pnas.88.21.9712; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; JOHNSON RT, 1992, MUTAT RES, V273, P97, DOI 10.1016/0921-8777(92)90072-B; KNAPP G, 1978, CELL, V14, P221, DOI 10.1016/0092-8674(78)90109-5; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; LEHMANN A R, 1987, Cancer Reviews, V7, P82; MADURA K, 1986, J BACTERIOL, V166, P914, DOI 10.1128/jb.166.3.914-923.1986; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; OGDEN RC, 1984, NUCLEIC ACIDS RES, V12, P9367, DOI 10.1093/nar/12.24.9367; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; REYNOLDS P, 1985, NUCLEIC ACIDS RES, V13, P2357, DOI 10.1093/nar/13.7.2357; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; VENEMA J, 1991, THESIS STATE U LEIDE; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	30	135	137	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 6	1994	367	6458					91	94		10.1038/367091a0	http://dx.doi.org/10.1038/367091a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	8107780				2022-12-28	WOS:A1994MP86500067
J	GOLDHABER, SZ; SIMONS, GR; ELLIOTT, CG; HAIRE, WD; TOLTZIS, R; BLACKLOW, SC; DOOLITTLE, MH; WEINBERG, DS				GOLDHABER, SZ; SIMONS, GR; ELLIOTT, CG; HAIRE, WD; TOLTZIS, R; BLACKLOW, SC; DOOLITTLE, MH; WEINBERG, DS			QUANTITATIVE PLASMA D-DIMER LEVELS AMONG PATIENTS UNDERGOING PULMONARY ANGIOGRAPHY FOR SUSPECTED PULMONARY-EMBOLISM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FIBRIN DEGRADATION PRODUCTS; MONOCLONAL-ANTIBODIES; FDP	Objective.-To test the hypothesis that a low D-dimer level has a high negative predictive value for acute pulmonary embolism (PE) among patients undergoing diagnostic pulmonary angiography. Design.-Blinded comparison of quantitative plasma D-dimer levels, measured using a monoclonal antibody assay, with pulmonary angiographic results from 173 patients with suspected acute PE. Setting.-Tertiary care setting at four participating institutions. Patients.-Plasma samples were analyzed in 173 patients who underwent diagnostic pulmonary arteriography for suspected acute PE. Main Outcome Measures.-Sensitivity, specificity, and predictive values of quantitative plasma D-dimer levels for the diagnosis of PE, using pulmonary angiographic data as the criterion standard test. Results.-Of 35 patients with D-dimer values less than 500 ng/mL, only three had abnormal pulmonary angiograms. The negative predictive value of a plasma D-dimer level less than 500 ng/mL for acute PE was 91.4% (95% confidence interval [CI], 76.9% to 98.2%). D-dimer levels were greater than 500 ng/mL in 42 of 45 patients with PE and in 96 of 128 patients without PE (P=.016). Sensitivity, specificity, and positive predictive value of a plasma D-dimer level greater than 500 ng/mL for acute PE were 93.3% (95% CI, 81.7% to 98.6%), 25.0% (95% CI, 17.5% to 32.5%), and 30.4% (95% CI, 22.8% to 38.1%), respectively. Conclusions.-The results of our study indicate that quantitative plasma D-dimer levels can be useful in screening patients with suspected PE who require. pulmonary angiography. Plasma D-dimer values less than 500 ng/mL may obviate the need for pulmonary angiography, particularly among medical patients for whom the clinical suspicion of PE is low. The plasma D-dimer value, assayed using a commercially available enzyme-linked immunosorbent assay kit, is a sensitive but nonspecific test for the presence of acute PE.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115; LATTER DAY ST HOSP,SALT LAKE CITY,UT 84143; UNIV NEBRASKA,MED CTR,OMAHA,NE 68105; CHRIST HOSP,CINCINNATI,OH 45219	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Nebraska System; University of Nebraska Medical Center; Christ Hospital - Ohio	GOLDHABER, SZ (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.				NCRR NIH HHS [M01 RR02635] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BOUNAMEAUX H, 1991, LANCET, V337, P196, DOI 10.1016/0140-6736(91)92158-X; Bounameaux H, 1990, Blood Coagul Fibrinolysis, V1, P577, DOI 10.1097/00001721-199010000-00045; BOUNAMEAUX H, 1988, LANCET, V2, P628; BOUNAMEAUX H, 1992, SANG THROMBOSE VAISS, V4, P255; ELMS MJ, 1983, THROMB HAEMOSTASIS, V50, P591; GAFFNEY PJ, 1988, BRIT J HAEMATOL, V68, P91, DOI 10.1111/j.1365-2141.1988.tb04184.x; GARDNER MJ, 1989, BRIT MED J; GOLDHABER SZ, 1988, AM HEART J, V116, P505, DOI 10.1016/0002-8703(88)90625-4; HUNT FA, 1985, BRIT J HAEMATOL, V60, P715, DOI 10.1111/j.1365-2141.1985.tb07476.x; LEITHA T, 1991, CHEST, V100, P1536, DOI 10.1378/chest.100.6.1536; PERRIER A, IN PRESS AM HEART J; ROWBOTHAM BJ, 1990, THORAX, V45, P684, DOI 10.1136/thx.45.9.684; WHITAKER AN, 1984, J CLIN PATHOL, V37, P882, DOI 10.1136/jcp.37.8.882; 1990, JAMA-J AM MED ASSOC, V263, P2753; 1991, EPI INFO VERSION 501	15	115	118	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1993	270	23					2819	2822		10.1001/jama.270.23.2819	http://dx.doi.org/10.1001/jama.270.23.2819			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK941	8133620				2022-12-28	WOS:A1993MK94100030
J	BREO, DL				BREO, DL			THE DENTAL AIDS CASES - MURDER OR AN UNSOLVABLE MYSTERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1990, MORBIDITY MORTA 0727	1	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2732	2734		10.1001/jama.270.22.2732	http://dx.doi.org/10.1001/jama.270.22.2732			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MJ821	8133594				2022-12-28	WOS:A1993MJ82100036
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND FOR NON-INSULIN-DEPENDENT DIABETES-MELLITUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2669	2669						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	8133573				2022-12-28	WOS:A1993MJ82100005
J	RICHELDI, L; SORRENTINO, R; SALTINI, C				RICHELDI, L; SORRENTINO, R; SALTINI, C			HLA-DPB1 GLUTAMATE-69 - A GENETIC-MARKER OF BERYLLIUM DISEASE	SCIENCE			English	Article							JUVENILE RHEUMATOID-ARTHRITIS; DP-BETA ALLELE; LUNG-DISEASE; HLA-DQ; CELIAC-DISEASE; CLASS-II; T-CELLS; ANTIGEN; DNA; AMPLIFICATION	Chronic beryllium disease (CBD) is a lung disorder related to beryllium exposure and is characterized by the accumulation in the lung of beryllium-specific CD4+ major histocompatibility complex (MHC) class II-restricted T lymphocytes. Evaluation of MHC class II genes in 33 CBD cases and 44 controls has shown a negative association with HLA-DPB1*0401 (P < 0.001) and a positive association with HLA-DPB1*0201 (P < 0.05) alleles, which differ at residues 36, 55 to 56, and 69 of the beta1 chain. Among CBD cases, 97 percent expressed the HLA-DPB1*0201-associated glutamic acid (unaffected population, 30 percent; P < 0.001) at residue 69, a position involved in susceptibility to autoimmune disorders. This suggests that HLA-DP has a role in conferring susceptibility and that residue 69 of HLA-DPB1 could be used in risk assessment for CBD.	UNIV ROME, POSTGRAD SCH CARDIORESP PHYSIOPATHOL, I-00100 ROME, ITALY; UNIV MODENA, INST TB & RESP DIS, USL 16, I-41100 MODENA, ITALY; UNIV LAQUILA, DEPT EXPTL MED, I-67100 LAQUILA, ITALY; UNIV ROMA LA SAPIENZA, DEPT CELLULAR & DEV BIOL, I-00185 ROME, ITALY	Sapienza University Rome; Universita di Modena e Reggio Emilia; University of L'Aquila; Sapienza University Rome			Sorrentino, Rosa/G-5472-2012; Richeldi, Luca/B-6243-2019; Richeldi, Luca/ABF-2486-2020	Sorrentino, Rosa/0000-0002-9632-2383; Richeldi, Luca/0000-0001-8594-1448				ALDACCAK R, 1991, HUM IMMUNOL, V31, P277, DOI 10.1016/0198-8859(91)90100-N; ANGELINI G, 1989, HUM IMMUNOL, V26, P169, DOI 10.1016/0198-8859(89)90036-0; BARNA BP, 1984, INT ARCH ALLER A IMM, V73, P42, DOI 10.1159/000233436; BARTTER T, 1991, ARCH INTERN MED, V151, P1197, DOI 10.1001/archinte.151.6.1197; BEGOVICH AB, 1989, P NATL ACAD SCI USA, V86, P9489, DOI 10.1073/pnas.86.23.9489; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BUGAWAN TL, 1989, NATURE, V339, P470, DOI 10.1038/339470a0; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; COLONNA M, 1990, HUM IMMUNOL, V29, P263, DOI 10.1016/0198-8859(90)90040-V; CULLEN MR, 1987, AM REV RESPIR DIS, V135, P201; DAVISON AG, 1983, THORAX, V38, P119, DOI 10.1136/thx.38.2.119; DEODHAR SD, 1973, CHEST, V63, P309, DOI 10.1378/chest.63.3.309; DEVUYST P, 1987, AM REV RESPIR DIS, V135, P493; DOHERTY DG, 1992, HUM IMMUNOL, V34, P53, DOI 10.1016/0198-8859(92)90085-2; EISENBUD M, 1983, J OCCUP ENVIRON MED, V25, P196, DOI 10.1097/00043764-198303000-00012; FUGGER L, 1990, IMMUNOGENETICS, V32, P150, DOI 10.1007/BF02114968; GOLDMAN M, 1991, IMMUNOL TODAY, V12, P223, DOI 10.1016/0167-5699(91)90034-Q; GUIDOTTI TL, 1988, J OCCUP ENVIRON MED, V30, P570; HIRAYAMA K, 1987, NATURE, V327, P426, DOI 10.1038/327426a0; HUA H, 1992, LAB INVEST, V67, P138; KARL M, 1993, J CLIN ENDOCR METAB, V76, P683, DOI 10.1210/jc.76.3.683; KREISS K, 1989, J OCCUP ENVIRON MED, V31, P603, DOI 10.1097/00043764-198907000-00011; KREISS K, 1993, J OCCUP ENVIRON MED, V35, P267; KRIEBEL D, 1988, AM REV RESPIR DIS, V137, P464, DOI 10.1164/ajrccm/137.2.464; MESSER G, 1991, J EXP MED, V173, P209, DOI 10.1084/jem.173.1.209; NEMERY B, 1990, EUR RESPIR J, V3, P202; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; REDLINE S, 1986, BRIT J IND MED, V43, P652; ROMAGNOLI P, 1992, J CLIN INVEST, V89, P254, DOI 10.1172/JCI115569; ROSSMAN MD, 1988, ANN INTERN MED, V108, P687, DOI 10.7326/0003-4819-108-5-687; SALTINI C, 1989, NEW ENGL J MED, V320, P1103, DOI 10.1056/NEJM198904273201702; SALTINI C, 1990, J EXP MED, V171, P1123, DOI 10.1084/jem.171.4.1123; SINIGAGLIA F, 1985, J IMMUNOL, V135, P3929; SMILEK DE, 1990, IMMUNOL REV, V118, P37, DOI 10.1111/j.1600-065X.1990.tb00813.x; SORRENTINO R, 1992, IMMUNOGENETICS, V36, P248, DOI 10.1007/BF00215055; STASTNY P, 1991, Recenti Progressi in Medicina, V82, P409; STERNER JH, 1951, AMA ARCH IND HYG OCC, V4, P123; STROMINGER JL, 1986, J CLIN INVEST, V77, P1411, DOI 10.1172/JCI112451; TEPPER LB, 1961, TOXICITY BERYLLIUM C; Tiwari JL, 1985, HLA DISEASE ASS, P32; Tiwari JL, 1985, HLA DISEASE ASS, P18; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; WILLIAMS WJ, 1983, THORAX, V38, P41, DOI 10.1136/thx.38.1.41	45	361	366	2	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1993	262	5131					242	244		10.1126/science.8105536	http://dx.doi.org/10.1126/science.8105536			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA665	8105536				2022-12-28	WOS:A1993MA66500035
J	MEYER, KS; URBAN, C; EAGAN, JA; BERGER, BJ; RAHAL, JJ				MEYER, KS; URBAN, C; EAGAN, JA; BERGER, BJ; RAHAL, JJ			NOSOCOMIAL OUTBREAK OF KLEBSIELLA INFECTION RESISTANT TO LATE-GENERATION CEPHALOSPORINS	ANNALS OF INTERNAL MEDICINE			English	Article						CROSS INFECTION; KLEBSIELLA PNEUMONIAE; CEPHALOSPORINS; DRUG RESISTANCE, MICROBIAL; CEFTAZIDIME	MEDIATED BETA-LACTAMASE; BROAD-SPECTRUM CEPHALOSPORINS; TRANSFERABLE ENZYMATIC RESISTANCE; 3RD-GENERATION CEPHALOSPORINS; CEFTAZIDIME RESISTANCE; ESCHERICHIA-COLI; PNEUMONIAE STRAINS; ENTEROBACTERIACEAE; DISSEMINATION; COLONIZATION	Objective: To describe the epidemiology, antimicrobial susceptibility, and control of widespread ceftazidime-resistant Klebsiella pneumoniae infections in a North American hospital and circumstances that led to delayed detection. Design: A 2-year epidemiologic, microbiologic, and clinical cohort study. Setting: A 487-bed general hospital in New York City. Patients and Clinical Isolates: Patient records were reviewed retrospectively and prospectively. Isolates were obtained from the Clinical Microbiology Laboratory. Results: Four hundred thirty-two isolates of ceftazidime-resistant Klebsiella pneumoniae were recovered during a 19-month study period. The peak incidence reached 17.3% of all Klebsiella isolates. One hundred fifty-five patients were colonized or infected, representing more than 70 per 1000 average daily census. Infections occurred in 39% of patients from whom ceftazidime-resistant Klebsiella was isolated. These included 14 bacteremias and 17 pulmonary infections among 52 infected patients. The outbreak coincided with increasing use of ceftazidime therapy for multiresistant Acinetobacter infections. Reduction in ceftazidime use and barrier precautions markedly reduced the incidence of colonization and infection. Ceftriaxone, ceftizoxime, cefotaxime, and cephamycins were inhibitory, but not bactericidal, against ceftazidime-resistant Klebsiella and appeared effective by routine disc diffusion tests. In contrast, imipenem provided consistent bactericidal activity. Preliminary studies indicated that the outbreak was caused by one or more plasmid-mediated beta lactamases. Conclusions. Nosocomial ceftazidime-resistant Klebsiella pneumoniae may be resistant to the bactericidal activity of all cephalosporins and cephamycins. Such isolates appear susceptible to cephalosporins other than ceftazidime by routine disc diffusion testing. Ineffective therapy, delayed detection of resistance, and epidemic spread are potential consequences. Imipenem provides consistent bactericidal activity. Ceftazidime restriction and barrier precautions for colonized and infected patients are effective control measures.	NEW YORK HOSP, MED CTR QUEENS, 56-45 MAIN ST, FLUSHING, NY 11355 USA; NYU, SCH MED, NEW YORK, NY 10003 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, BRONX, NY 10461 USA	NewYork-Presbyterian Hospital; New York University; Yeshiva University; Albert Einstein College of Medicine								ADLER JL, 1970, J PEDIATR-US, V77, P376, DOI 10.1016/S0022-3476(70)80004-X; BENREDJEB S, 1988, J ANTIMICROB CHEMOTH, V21, P263; BRUNBUISSON C, 1987, LANCET, V2, P302; BULGER RJ, 1967, ANN INTERN MED, V67, P523, DOI 10.7326/0003-4819-67-3-523; BURE A, 1988, EUR J CLIN MICROBIOL, V7, P780, DOI 10.1007/BF01975048; CHANAL C, 1988, J ANTIMICROB CHEMOTH, V22, P81, DOI 10.1093/jac/22.1.81; CHANAL CM, 1989, ANTIMICROB AGENTS CH, V33, P1915, DOI 10.1128/AAC.33.11.1915; DECHAMPS C, 1989, J CLIN MICROBIOL, V27, P2887, DOI 10.1128/JCM.27.12.2887-2890.1989; DONOWITZ GR, 1990, PRINCIPLES PRACTICE, P246; GARDNER P, 1969, ANN INTERN MED, V71, P1, DOI 10.7326/0003-4819-71-1-1; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GUTMANN L, 1989, ANTIMICROB AGENTS CH, V33, P951, DOI 10.1128/AAC.33.6.951; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; JARLIER V, 1988, REV INFECT DIS, V10, P867; KITZIS MD, 1988, ANTIMICROB AGENTS CH, V32, P9, DOI 10.1128/AAC.32.1.9; KNOTHE H, 1983, INFECTION, V11, P315, DOI 10.1007/BF01641355; MARTIN CM, 1971, J INFECT DIS, V124, pS24, DOI 10.1093/infdis/124.Supplement_1.S24; MATTHEW M, 1979, J BACTERIOL, V138, P657, DOI 10.1128/JB.138.3.657-662.1979; NAUMOVSKI L, 1992, ANTIMICROB AGENTS CH, V36, P1991, DOI 10.1128/AAC.36.9.1991; NOREIGA ER, 1975, J INFECT DIS S, V131, pS45; PANGON B, 1989, J INFECT DIS, V159, P1005, DOI 10.1093/infdis/159.5.1005; PAPANICOLAOU GA, 1990, ANTIMICROB AGENTS CH, V34, P2200, DOI 10.1128/AAC.34.11.2200; PETIT A, 1988, ANTIMICROB AGENTS CH, V32, P626, DOI 10.1128/AAC.32.5.626; QUINN JP, 1989, ANTIMICROB AGENTS CH, V33, P1451, DOI 10.1128/AAC.33.9.1451; RICE LB, 1990, ANTIMICROB AGENTS CH, V34, P2193, DOI 10.1128/AAC.34.11.2193; SANDERS CC, 1984, ANTIMICROB AGENTS CH, V26, P797, DOI 10.1128/AAC.26.6.797; SCHABERG DR, 1976, J INFECT DIS, V133, P363, DOI 10.1093/infdis/133.3.363; SCHABERG DR, 1981, AM J MED, V70, P445, DOI 10.1016/0002-9343(81)90786-5; SHAH PM, 1983, J ANTIMICROB CHEMOTH, V11, P597, DOI 10.1093/jac/11.6.597; SIROT D, 1987, J ANTIMICROB CHEMOTH, V20, P323, DOI 10.1093/jac/20.3.323; SIROT J, 1988, REV INFECT DIS, V10, P850; SMITH CE, 1990, ANTIMICROB AGENTS CH, V34, P1290, DOI 10.1128/AAC.34.6.1290; SPENCER RC, 1987, J ANTIMICROB CHEMOTH, V20, P919, DOI 10.1093/jac/20.6.919; TERMAN JW, 1972, AM J MED SCI, V264, P191; THOMAS FE, 1977, ARCH INTERN MED, V137, P581, DOI 10.1001/archinte.137.5.581; URBAN C, 1993, J INFECT DIS, V167, P448, DOI 10.1093/infdis/167.2.448; URBAN CM, 1991, 31ST P INT C ANT AG; VERSCHRAEGEN G, 1988, ACTA CLIN BELG, V43, P356; WEBER DA, 1990, J INFECT DIS, V162, P460, DOI 10.1093/infdis/162.2.460; 1987, ANTIMICROBIAL SUSCEP, V5, P589	40	477	497	2	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1993	119	5					353	358		10.7326/0003-4819-119-5-199309010-00001	http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ476	8135915				2022-12-28	WOS:A1993LZ47600001
J	CRAWSHAW, R				CRAWSHAW, R			GRASS-ROOTS PARTICIPATION IN HEALTH-CARE REFORM	ANNALS OF INTERNAL MEDICINE			English	Article							OREGON	Concerned citizens have responded to the health care crisis by developing the health decisions movement. American Health Decisions, a national consortium of 21 state organizations, leads a grass roots discussion network of community meetings committed to education and consensus on the ethical, technologic, legal, and economic issues (the tough issues) of health policy. The movement (with its stages of development, structure, process, and accomplishments) is described, and potential roles for physician cooperation and participation in forging functional, community-based health policy are delineated.										BARBER B, 1984, STRONG DEMOCRACY PAR; BLAKESLEE S, 1990, NY TIMES        0614, pB7; BROWN LD, 1993, HEALTH AFFAIR, V12, P8, DOI 10.1377/hlthaff.12.2.7; CRAWSHAW R, 1989, WESTERN J MED, V150, P361; CRAWSHAW R, 1985, JAMA-J AM MED ASSOC, V254, P3213, DOI 10.1001/jama.254.22.3213; CRAWSHAW R, 1983, JAMA-J AM MED ASSOC, V250, P1857, DOI 10.1001/jama.250.14.1857; DANS PE, 1993, ANN INTERN MED, V118, P227, DOI 10.7326/0003-4819-118-3-199302010-00015; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; Jennings B, 1988, Hastings Cent Rep, V18, P1; LEICHTER HM, 1993, HEALTH AFFAIR, V12, P48, DOI 10.1377/hlthaff.12.2.48; NEUBAUER D, 1993, HEALTH AFFAIR, V12, P31, DOI 10.1377/hlthaff.12.2.31; 1982, REPORT ETHICAL LEGAL, V1, P34; 1993, STATE COULD NOT WAIT	13	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1994	120	8					677	681		10.7326/0003-4819-120-8-199404150-00009	http://dx.doi.org/10.7326/0003-4819-120-8-199404150-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE850	8135453				2022-12-28	WOS:A1994NE85000009
J	STEELE, RM; SCHUNA, AA; SCHREIBER, RT				STEELE, RM; SCHUNA, AA; SCHREIBER, RT			CALCIUM ANTAGONIST-INDUCED GINGIVAL HYPERPLASIA	ANNALS OF INTERNAL MEDICINE			English	Note							NIFEDIPINE; OVERGROWTH		WILLIAM S MIDDLETON MEM VET ADM MED CTR, MADISON, WI 53705 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital	STEELE, RM (corresponding author), COOK CTY HOSP, DEPT PHARM, 1900 W POLK, SUITE 552, CHICAGO, IL 60612 USA.							ANGELOPO.AP, 1972, ORAL SURG ORAL MED O, V34, P898, DOI 10.1016/0030-4220(72)90228-9; Fattore L, 1991, Spec Care Dentist, V11, P107, DOI 10.1111/j.1754-4505.1991.tb00828.x; HANCOCK RH, 1992, J CLIN PERIODONTOL, V19, P12, DOI 10.1111/j.1600-051X.1992.tb01141.x; HEIJL L, 1989, J PERIODONTOL, V60, P104, DOI 10.1902/jop.1989.60.2.104; MILLER CS, 1992, J PERIODONTOL, V63, P453, DOI 10.1902/jop.1992.63.5.453; RAMON Y, 1984, INT J CARDIOL, V5, P195, DOI 10.1016/0167-5273(84)90145-1; SEYMOUR RA, 1991, BRIT DENT J, V170, P376, DOI 10.1038/sj.bdj.4807564; SHAFTIC AA, 1986, DRUG INTEL CLIN PHAR, V20, P602, DOI 10.1177/106002808602000724; SLAVIN J, 1987, LANCET, V2, P739; 1992, PHYSICIANS DESK REFE, P1781	10	35	37	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1994	120	8					663	664		10.7326/0003-4819-120-8-199404150-00006	http://dx.doi.org/10.7326/0003-4819-120-8-199404150-00006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE850	8135450				2022-12-28	WOS:A1994NE85000006
J	OUSLANDER, JG; OSTENWEIL, D				OUSLANDER, JG; OSTENWEIL, D			PHYSICIAN EVALUATION AND MANAGEMENT OF NURSING-HOME RESIDENTS	ANNALS OF INTERNAL MEDICINE			English	Review							GERIATRIC DEPRESSION SCALE; PROSTATE-SPECIFIC ANTIGEN; ELDERLY PATIENTS; PREVENTIVE TREATMENT; HEARING IMPAIRMENT; SCREENING-TESTS; OLDER ADULTS; CARE; CANCER; TUBERCULOSIS	The diverse goals of nursing home care, the heterogeneity of nursing home residents, and the varied circumstances under which physicians care for them make their evaluation and care complex and challenging. When evaluating and caring for nursing home residents, physicians must address many issues besides treatment of multiple chronic diseases (including impairments in cognitive and physical functioning, sensory deficits, depression, and behavioral disorders associated with dementia) and concerns of family members. The physician should be integrated with an interdisciplinary team composed of nurses, rehabilitation therapists, social workers, and others. Recently implemented federal rules for nursing home care, which include the Minimum Data Set and Resident Assessment Protocols, provide a useful framework for interdisciplinary assessment and care planning and should improve the care nursing home residents receive. Better data are needed on the most cost-effective strategies for evaluating and caring for nursing home residents. Reimbursement for physician services, availability of nurse practitioners and physician assistants, and overall quality of nursing home care must be improved so physicians can better achieve the recommendations outlined.	UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ALEXOPOULOS GS, 1988, J AM GERIATR SOC, V36, P230, DOI 10.1111/j.1532-5415.1988.tb01806.x; APPLEGATE WB, 1990, NEW ENGL J MED, V322, P1207; BALDUCCI L, 1991, J AM GERIATR SOC, V39, P1113, DOI 10.1111/j.1532-5415.1991.tb02879.x; BRAWER MK, 1992, J UROLOGY, V147, P841, DOI 10.1016/S0022-5347(17)37401-3; BURKE WJ, 1992, J AM GERIATR SOC, V40, P1227, DOI 10.1111/j.1532-5415.1992.tb03647.x; BURKE WJ, 1989, J AM GERIATR SOC, V37, P856, DOI 10.1111/j.1532-5415.1989.tb02266.x; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CEBUL RD, 1987, ANN INTERN MED, V106, P403, DOI 10.7326/0003-4819-106-3-403; COOPER JK, 1986, J AM GERIATR SOC, V34, P814, DOI 10.1111/j.1532-5415.1986.tb03988.x; DOMOTO K, 1985, AM J PUBLIC HEALTH, V75, P243, DOI 10.2105/AJPH.75.3.243; ELON R, 1992, J AM GERIATR SOC, V40, P958, DOI 10.1111/j.1532-5415.1992.tb01996.x; FAHS MC, 1992, ANN INTERN MED, V117, P520, DOI 10.7326/0003-4819-117-6-520; FINUCANE TE, 1988, J AM GERIATR SOC, V36, P77, DOI 10.1111/j.1532-5415.1988.tb03438.x; GAMBERT SR, 1982, J CHRON DIS, V35, P65, DOI 10.1016/0021-9681(82)90031-5; GARNICK MB, 1993, ANN INTERN MED, V118, P804, DOI 10.7326/0003-4819-118-10-199305150-00008; GARRARD J, 1990, MED CARE, V28, P271, DOI 10.1097/00005650-199003000-00007; GORDON WZ, 1985, J AM GERIATR SOC, V33, P519, DOI 10.1111/j.1532-5415.1985.tb04614.x; Institute of Medicine report, 1986, IMPROVING QUALITY CA; IRVINE PW, 1984, J AM GERIATR SOC, V32, P103, DOI 10.1111/j.1532-5415.1984.tb05848.x; IRVINE PW, 1984, J AM GERIATR SOC, V32, P540, DOI 10.1111/j.1532-5415.1984.tb02243.x; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; JOSEPH C, 1992, J AM GERIATR SOC, V40, P98, DOI 10.1111/j.1532-5415.1992.tb01837.x; KAFONEK S, 1989, J AM GERIATR SOC, V37, P29, DOI 10.1111/j.1532-5415.1989.tb01565.x; Kane RA, 1987, LONG TERM CARE PRINC; KANE RL, 1989, AM J PUBLIC HEALTH, V79, P1271, DOI 10.2105/AJPH.79.9.1271; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KAYSERJONES JS, 1989, GERONTOLOGIST, V29, P502, DOI 10.1093/geront/29.4.502; KRAMER BS, 1993, ANN INTERN MED, V119, P914, DOI 10.7326/0003-4819-119-9-199311010-00009; LACHS MS, 1990, ANN INTERN MED, V112, P699, DOI 10.7326/0003-4819-112-9-699; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LEVINSTEIN MR, 1987, JAMA-J AM MED ASSOC, V258, P1909, DOI 10.1001/jama.258.14.1909; MARTIN SE, 1990, PRINCIPLES PRACTICE; MOON TD, 1992, J AM GERIATR SOC, V40, P622, DOI 10.1111/j.1532-5415.1992.tb02116.x; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; MULROW CD, 1990, ANN INTERN MED, V113, P188, DOI 10.7326/0003-4819-113-3-188; MULROW CD, 1991, J GEN INTERN MED, V6, P249, DOI 10.1007/BF02598971; OBOLER SK, 1989, ANN INTERN MED, V110, P214, DOI 10.7326/0003-4819-110-3-214; OUSLANDER J, 1990, J AM GERIATR SOC, V38, P490, DOI 10.1111/j.1532-5415.1990.tb03556.x; OUSLANDER J, 1991, MED CARE NURSING HOM; OUSLANDER JG, 1989, JAMA-J AM MED ASSOC, V262, P2582, DOI 10.1001/jama.262.18.2582; PARMELEE PA, 1992, J GERONTOL, V47, pP3, DOI 10.1093/geronj/47.1.P3; PARMELEE PA, 1992, J GERONTOL, V47, pM189, DOI 10.1093/geronj/47.6.M189; PARMELEE PA, 1989, J GERONTOL, V44, pM22, DOI 10.1093/geronj/44.1.M22; Rovner B W, 1990, Int Psychogeriatr, V2, P13, DOI 10.1017/S1041610290000266; ROVNER BW, 1991, JAMA-J AM MED ASSOC, V265, P993, DOI 10.1001/jama.265.8.993; RUBENSTEIN LZ, 1990, ANN INTERN MED, V113, P308, DOI 10.7326/0003-4819-113-4-308; SIU AL, 1991, ANN INTERN MED, V115, P122, DOI 10.7326/0003-4819-115-2-122; SOX HC, 1993, JAMA-J AM MED ASSOC, V269, P2678, DOI 10.1001/jama.269.20.2678; STEAD WW, 1987, ANN INTERN MED, V107, P837, DOI 10.7326/0003-4819-107-6-837; STEAD WW, 1985, NEW ENGL J MED, V312, P1483, DOI 10.1056/NEJM198506063122304; STEAD WW, 1987, ANN INTERN MED, V107, P843, DOI 10.7326/0003-4819-107-6-843; TANGALOS EG, 1990, JAMA-J AM MED ASSOC, V264, P693, DOI 10.1001/jama.264.6.693; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; TINETTI ME, 1988, JAMA-J AM MED ASSOC, V259, P1190, DOI 10.1001/jama.259.8.1190; TINETTI ME, 1986, J AM GERIATR SOC, V34, P119, DOI 10.1111/j.1532-5415.1986.tb05480.x; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; UHLMANN RF, 1989, J GEN INTERN MED, V4, P90, DOI 10.1007/BF02602346; WIELAND D, 1986, JAMA-J AM MED ASSOC, V255, P2622, DOI 10.1001/jama.255.19.2622; WOLFKLEIN GP, 1985, J AM GERIATR SOC, V33, P325, DOI 10.1111/j.1532-5415.1985.tb07131.x; WOOLF SH, 1990, J AM GERIATR SOC, V38, P933, DOI 10.1111/j.1532-5415.1990.tb05712.x; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; YOSHIKAWA TT, 1992, J AM GERIATR SOC, V40, P178, DOI 10.1111/j.1532-5415.1992.tb01941.x; ZIEMBA SE, 1991, AM J MED, V91, P576, DOI 10.1016/0002-9343(91)90209-G; 1993, POSITION STATEMENT S; 1991, RESIDENT ASSESSMENT; 1992, DRUG REGIMEN REV PRO; FED REGISTER, V56, P48865; 1993, MED4TH SYSTEMS	69	28	27	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					584	592		10.7326/0003-4819-120-7-199404010-00010	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8116998				2022-12-28	WOS:A1994NC76400010
J	WOOD, MJ; JOHNSON, RW; MCKENDRICK, MW; TAYLOR, J; MANDAL, BK; CROOKS, J				WOOD, MJ; JOHNSON, RW; MCKENDRICK, MW; TAYLOR, J; MANDAL, BK; CROOKS, J			A RANDOMIZED TRIAL OF ACYCLOVIR FOR 7 DAYS OR 21 DAYS WITH AND WITHOUT PREDNISOLONE FOR TREATMENT OF ACUTE HERPES-ZOSTER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORAL ACYCLOVIR; POSTHERPETIC NEURALGIA; THERAPY	Background. Acyclovir given for 7 to 10 days is of proved benefit in acute herpes tester, but studies of its effectiveness in preventing postherpetic neuralgia have had conflicting results. The role of corticosteroids in the treatment of herpes tester is also controversial. Methods. We conducted a double-blind, controlled trial in patients with acute herpes tester to determine whether either 21 days of acyclovir therapy or the addition of prednisolone offered any improvement over 7 days of acyclovir therapy. Patients with a rash of less than 72 hours' duration were assigned to receive acyclovir (800 mg orally, five times daily) for 7 days with either prednisolone or placebo, or acyclovir for 21 days with either prednisolone or placebo. Prednisolone therapy was initiated at a dose of 40 mg per day and tapered over a three-week period. Patients were assessed frequently through day 28 and then monthly through month 6 to assess postherpetic neuralgia. Results. Of 400 patients recruited, 349 completed the study. No significant differences were detected between the four groups in the progression of the rash (P>0.1). With steroid therapy, a significantly higher proportion of the rash area had healed on days 7 and 14 (P = 0.02). Pain reduction was greater during the acute phase of disease in patients treated with steroids or 21 days of acyclovir(P<0.01 and P = 0.02, respectively, on day 7; P<0.01 for steroid therapy on day 14). However, on follow-up there were no significant differences between any of the groups in the time to a first or a complete cessation of pain. The steroid recipients reported more adverse events. Conclusions. In acute herpes tester, treatment with acyclovir for 21 days or the addition of prednisolone to acyclovir therapy confers only slight benefits over standard 7-day treatment with acyclovir. Neither additional treatment reduces the frequency of postherpetic neuralgia.	BRISTOL ROYAL INFIRM & GEN HOSP,SIR HUMPHRY DAVY DEPT ANAESTHESIA,BRISTOL,AVON,ENGLAND; ROYAL HALLAMSHIRE HOSP,DEPT INFECT DIS & MED,SHEFFIELD,S YORKSHIRE,ENGLAND; WELLCOME RES LABS,BECKENHAM,KENT,ENGLAND; MONSALL HOSP,DEPT INFECT DIS & TROP MED,MANCHESTER,LANCS,ENGLAND	Bristol Royal Infirmary; University of Sheffield; GlaxoSmithKline; Wellcome Research Laboratories	WOOD, MJ (corresponding author), BIRMINGHAM HEARTLANDS HOSP,DEPT INFECT & TROP MED,BORDESLEY GREEN E,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND.		Wood, Malissa/ABI-4543-2020	Wood, Malissa/0000-0003-0482-1116				BEAN B, 1982, LANCET, V2, P118; BURGOON CF, 1957, JAMA-J AM MED ASSOC, V164, P265, DOI 10.1001/jama.1957.02980030041010; CLEMMENSEN OJ, 1984, CLIN EXP DERMATOL, V9, P557, DOI 10.1111/j.1365-2230.1984.tb00859.x; DEMORAGAS JM, 1957, ARCH DERMATOL, V75, P193, DOI 10.1001/archderm.1957.01550140037006; EAGLSTEIN WH, 1970, J AMER MED ASSOC, V211, P1681, DOI 10.1001/jama.211.10.1681; ESMANN V, 1987, LANCET, V2, P126; HARDING SP, 1991, CURR EYE RES, V10, P177, DOI 10.3109/02713689109020376; HUFF JC, 1988, AM J MED, V85, P84; KECZKES K, 1980, BRIT J DERMATOL, V102, P551, DOI 10.1111/j.1365-2133.1980.tb07654.x; MORTON P, 1989, NEW ZEAL MED J, V102, P93; SCHMADER KE, 1989, J GEN INTERN MED, V4, P83, DOI 10.1007/BF02602345; WATSON PN, 1986, ARCH NEUROL-CHICAGO, V43, P836, DOI 10.1001/archneur.1986.00520080074027; WOOD MJ, 1988, AM J MED, V85, P79; WOOD MJ, 1986, RES CLIN FORUMS, V8, P61; WOOD MJ, 1991, SCAND J INFECT DIS S, V80, P53	15	306	319	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	1994	330	13					896	900		10.1056/NEJM199403313301304	http://dx.doi.org/10.1056/NEJM199403313301304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC608	8114860				2022-12-28	WOS:A1994NC60800004
J	JONES, KR; FARINAS, I; BACKUS, C; REICHARDT, LF				JONES, KR; FARINAS, I; BACKUS, C; REICHARDT, LF			TARGETED DISRUPTION OF THE BDNF GENE PERTURBS BRAIN AND SENSORY NEURON DEVELOPMENT BUT NOT MOTOR-NEURON DEVELOPMENT	CELL			English	Article							NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; MOLECULAR-CLONING; MESSENGER-RNAS; SYSTEM; NGF; DIFFERENTIATION; EXPRESSION; RECEPTORS; BINDING	Brain-derived neurotrophic factor (BDNF), a neurotrophin, enhances the survival and differentiation of several classes of neurons in vitro. To determine its essential functions, we have mutated the BDNF gene. Most homozygote mutants die within 2 days after birth, but a fraction live for 2-4 weeks. These develop symptoms of nervous system dysfunction, including ataxia. The BDNF mutant homozygotes have substantially reduced numbers of cranial and spinal sensory neurons. Although their central nervous systems show no gross structural abnormalities, expression of neuropeptide Y and calcium-binding proteins is altered in many neurons, suggesting they do not function normally. In contrast with mice lacking the BDNF receptor TrkB, motor neurons appear normal in the BDNF mutant.	UNIV CALIF SAN FRANCISCO,SCH MED,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	JONES, KR (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.		Farinas, Isabel/L-7118-2014	Farinas, Isabel/0000-0003-2903-4960; JONES, KEVIN/0000-0002-3802-7562	NIMH NIH HHS [MH48200] Funding Source: Medline; NINDS NIH HHS [P01 NS016033-17A10014, P01 NS016033] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016033] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; CELIO MR, 1990, NEUROSCIENCE, V35, P375, DOI 10.1016/0306-4522(90)90091-H; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IP NY, 1993, J NEUROSCI, V13, P3394; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; Joyner AL, 1993, GENE TARGETING PRACT; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KORSCHING S, 1993, J NEUROSCI, V13, P2739; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; NAMBA T, 1967, AM J CLIN PATHOL, V47, P74; NAWA H, 1993, J NEUROCHEM, V60, P772, DOI 10.1111/j.1471-4159.1993.tb03216.x; PIRVOLA U, 1992, P NATL ACAD SCI USA, V89, P9915, DOI 10.1073/pnas.89.20.9915; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; Scott SA, 1992, SENSORY NEURONS DIVE; SUTER U, 1991, EMBO J, V10, P2395, DOI 10.1002/j.1460-2075.1991.tb07778.x; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; ZIAI MR, 1988, J NEUROCHEM, V51, P1771, DOI 10.1111/j.1471-4159.1988.tb01158.x	23	907	916	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					989	999		10.1016/0092-8674(94)90377-8	http://dx.doi.org/10.1016/0092-8674(94)90377-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137432	Green Accepted			2022-12-28	WOS:A1994ND24600006
J	PEPPAS, NA; LANGER, R				PEPPAS, NA; LANGER, R			NEW CHALLENGES IN BIOMATERIALS	SCIENCE			English	Article							BIOPROSTHETIC HEART-VALVES; POLYMERIC MATERIALS; CONTROLLED-RELEASE; PLASMA DEPOSITION; HYDROGELS; INVIVO; BIOCOMPATIBILITY; POLYURETHANES; CALCIFICATION; BIOMOLECULES	Significant opportunities and challenges exist in the creation and characterization of biomaterials. Materials have been designed for contact with blood, as replacements for soft and hard tissues, as adhesives, and as dental materials. Current methods of synthesis and characterization of these materials are outlined. Approaches for controlling the interface between tissue and biomaterials and ways in which the engineered materials may contribute to medicine are considered.	MIT,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	PEPPAS, NA (corresponding author), PURDUE UNIV,SCH CHEM ENGN,W LAFAYETTE,IN 47907, USA.				NIGMS NIH HHS [GM45027, GM43337, GM25810] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025810, R01GM045027, R01GM043337] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLCOCK HR, 1992, SCIENCE, V255, P1106, DOI 10.1126/science.255.5048.1106; ALPER M, 1991, MATERIALS SYNTHESIS; ANSETH KS, IN PRESS ADV POLYM S; AUTIAN J, 1977, ARTIF ORGANS, V1, P53; BARRERA DA, 1993, J AM CHEM SOC, V115, P11010, DOI 10.1021/ja00076a077; BOSTMAN OM, 1991, J BONE JOINT SURG AM, V73A, P148, DOI 10.2106/00004623-199173010-00022; BOWMAN CN, 1991, MACROMOLECULES, V24, P1914, DOI 10.1021/ma00008a032; BOWMAN CN, 1992, CHEM ENG SCI, V47, P1411, DOI 10.1016/0009-2509(92)80286-L; BRANNONPEPPAS L, 1991, J CONTROL RELEASE, V16, P319, DOI 10.1016/0168-3659(91)90009-3; BREM H, 1991, J NEUROSURG, V74, P441, DOI 10.3171/jns.1991.74.3.0441; BRUCK SD, 1989, MED PROG TECHNOL, V15, P5; BRUCK SD, 1985, INT J ARTIF ORGANS, V8, P65, DOI 10.1177/039139888500800201; CIMA LG, 1990, ADV MATER, V2, P405; COHEN S, 1990, J AM CHEM SOC, V112, P7832, DOI 10.1021/ja00177a074; CONTARD P, 1993, J INVEST DERMATOL, V100, P35, DOI 10.1111/1523-1747.ep12349952; COURY AJ, 1987, LIFE SUPPORT SYST, V5, P25; DOMB AJ, 1993, ADV POLYM SCI, V107, P143; EBERT CD, 1982, J BIOMED MATER RES, V16, P629, DOI 10.1002/jbm.820160510; EISENTHAL KB, 1992, ANNU REV PHYS CHEM, V43, P627, DOI 10.1146/annurev.physchem.43.1.627; ERTEL SI, 1990, J BIOMED MATER RES, V24, P1637, DOI 10.1002/jbm.820241207; FICEK BJ, 1993, J CONTROL RELEASE, V27, P259, DOI 10.1016/0168-3659(93)90156-Y; FINE EG, 1991, BIOMATERIALS, V12, P775, DOI 10.1016/0142-9612(91)90029-A; GURNY R, 1993, PULSATILE DRUG DELIV, P41; HARKER L, 1993, CARDIOVASCULAR PAT S, V2; HELLER A, 1992, J PHYS CHEM-US, V96, P3579, DOI 10.1021/j100188a007; HELLER J, 1993, ADV POLYM SCI, V107, P41; Heller J., 1988, J BIOACT COMPAT POLY, V3, P97; HENCH LL, 1991, J AM CERAM SOC, V74, P1487, DOI 10.1111/j.1151-2916.1991.tb07132.x; HEYMAN P, 1985, MAKROMOL CHEM S, V9, P119; HILLWEST JL, 1994, OBSTET GYNECOL, V83, P59; HOFFMAN AS, 1991, POLYMER GELS, P289; HOFFMAN AS, 1972, T AM SOC ART INT ORG, V18, P10; JABBARI E, 1993, J CONTROL RELEASE, V26, P99, DOI 10.1016/0168-3659(93)90109-I; KAMATH KR, 1993, ADV DRUG DELIVER REV, V11, P59, DOI 10.1016/0169-409X(93)90027-2; KIM D, 1994, J APPL POLYM SCI, V51, P661, DOI 10.1002/app.1994.070510410; KIM DJ, 1993, POLYMER, V34, P3638, DOI 10.1016/0032-3861(93)90048-F; KIM SW, 1985, CRITICAL REV BIOCOMP, P221; KO TM, 1993, J COLLOID INTERF SCI, V156, P207, DOI 10.1006/jcis.1993.1101; KOHN J, 1986, J IMMUNOL METHODS, V95, P31, DOI 10.1016/0022-1759(86)90314-5; KOHN J, 1987, J AM CHEM SOC, V109, P817, DOI 10.1021/ja00237a030; KOHN J, 1993, TRENDS POLYM SCI, V0001, P00206; LANGER R, 1983, J MACROMOL SCI R M C, VC23, P61, DOI 10.1080/07366578308079439; LANGER R, 1981, J BIOMED MATER RES, V15, P267, DOI 10.1002/jbm.820150212; LENZ RW, 1993, ADV POLYM SCI, V107, P1; LEONG KW, 1986, J BIOMED MATER RES, V20, P51, DOI 10.1002/jbm.820200106; LEVY RJ, 1985, SCIENCE, V228, P190, DOI 10.1126/science.3919445; MASSIA SP, 1992, CYTOTECHNOLOGY, V10, P189, DOI 10.1007/BF00146670; MATHIOWITZ E, 1993, MACROMOLECULES, V26, P6756, DOI 10.1021/ma00077a010; MAYNARD J, 1984, BIOMATERIALS, V5, P135; MCGRATH KP, 1992, J AM CHEM SOC, V114, P727, DOI 10.1021/ja00028a048; MERRILL EW, 1993, J BIOMAT SCI-POLYM E, V5, P1; MILLER LL, 1988, MOL CRYST LIQ CRYST, V160, P297, DOI 10.1080/15421408808083024; OHSHIRO T, 1980, INT J ARTIF ORGANS, V4, P58; OKANO T, 1981, J BIOMED MATER RES, V15, P393, DOI 10.1002/jbm.820150310; OKANO T, 1993, ADV POLYM SCI, V110, P179; Palapura S., 1992, J BIOMATER APPL, V6, P216; Park K., 1987, HYDROGELS MED PHARM, P151; PATHAK CP, 1992, J AM CHEM SOC, V114, P8311, DOI 10.1021/ja00047a065; PEPPAS N A, 1985, Journal of Controlled Release, V2, P257, DOI 10.1016/0168-3659(85)90050-1; PEPPAS NA, 1991, J BIOACT COMPAT POL, V6, P241, DOI 10.1177/088391159100600303; PEPPAS NA, 1991, J CONTROL RELEASE, V16, P305, DOI 10.1016/0168-3659(91)90007-Z; PEPPAS NA, IN PRESS PHARM TECHN; PORTER J, 1977, JAMA-J AM MED ASSOC, V237, P879, DOI 10.1001/jama.237.9.879; PULAPURA S, 1990, BIOMATERIALS, V11, P666, DOI 10.1016/0142-9612(90)90025-L; RATNER BD, 1990, J VAC SCI TECHNOL A, V8, P2306, DOI 10.1116/1.576755; RATNER BD, 1992, J BIOMAT SCI-POLYM E, V4, P3; RATNER BD, 1993, J BIOMED MATER RES, V27, P837, DOI 10.1002/jbm.820270702; RAY JA, 1981, SURG GYNECOL OBSTET, V153, P497; RUYTER IE, 1988, CRIT REV BIOCOMPAT, V4, P247; SCHOEN FJ, 1992, J THORAC CARDIOV SUR, V104, P1285; SEFTON MV, 1993, BIOMATERIALS, V14, P1127; SHEELA MS, 1991, J APPL POLYM SCI, V42, P561, DOI 10.1002/app.1991.070420301; SILVER JH, 1992, BIOMATERIALS, V13, P339, DOI 10.1016/0142-9612(92)90037-O; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; STAUBLI A, 1990, J AM CHEM SOC, V112, P4419, DOI 10.1021/ja00167a045; Szycher Michael, 1994, P233; TAMADA JA, 1993, P NATL ACAD SCI USA, V90, P552, DOI 10.1073/pnas.90.2.552; TANZAWA H, 1993, BIOMEDICAL APPLICATI, P1; TOMALIA DA, 1990, ANGEW CHEM INT EDIT, V29, P138, DOI 10.1002/anie.199001381; TORMALA P, 1991, J BIOMED MATER RES, V25, P1, DOI 10.1002/jbm.820250102; URRY DW, 1992, PROG BIOPHYS MOL BIO, V57, P27; WINTERMANTEL E, 1990, ADV MATER PROCESS, V2, P737; WONG JY, 1994, P NATL ACAD SCI USA, V91, P3201, DOI 10.1073/pnas.91.8.3201; WU J, IN PRESS MACROMOLECU; WU S, 1990, BIOMATERIALS, V11, P481; YAMAUCHI Y, 1990, ORGANIC POLYM GELS; ZHAO QH, 1993, J BIOMED MATER RES, V27, P379, DOI 10.1002/jbm.820270311; ZHAO QH, 1992, J BIOMED MATER RES, V26, P1019, DOI 10.1002/jbm.820260805	88	867	935	6	352	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 25	1994	263	5154					1715	1720		10.1126/science.8134835	http://dx.doi.org/10.1126/science.8134835			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC040	8134835				2022-12-28	WOS:A1994NC04000025
J	BALDING, DJ; DONNELLY, P				BALDING, DJ; DONNELLY, P			HOW CONVINCING IS DNA EVIDENCE	NATURE			English	Editorial Material											BALDING, DJ (corresponding author), QUEEN MARY & WESTFIELD COLL,SCH MATH SCI,MILE END RD,LONDON E1 4NS,ENGLAND.		Balding, David/G-9898-2011	Balding, David/0000-0002-1480-6115; Donnelly, Peter/0000-0001-9495-3408				ANDERSON C, 1992, NATURE, V359, P349, DOI 10.1038/359349a0; ANDERSON C, 1992, NATURE, V355, P753; [Anonymous], 1992, DNA TECHNOLOGY FOREN; Koehler J.J., 1993, JURIMETRICS J, V34, P21; LANDER ES, 1989, NATURE, V339, P501, DOI 10.1038/339501a0; LEWONTIN RC, 1991, SCIENCE, V254, P1745, DOI 10.1126/science.1845040; MACILWAIN C, 1994, NATURE, V367, P101, DOI 10.1038/367101a0; ROBERTS L, 1991, SCIENCE, V254, P1721, DOI 10.1126/science.1763321; ROBERTS L, 1992, CHANCE, V5, P60; THOMPSON WC, 1993, JUDICATURE, V77, P57	10	21	21	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					285	286		10.1038/368285a0	http://dx.doi.org/10.1038/368285a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127359				2022-12-28	WOS:A1994NB98500023
J	BOWDEN, CL; BRUGGER, AM; SWANN, AC; CALABRESE, JR; JANICAK, PG; PETTY, F; DILSAVER, SC; DAVIS, JM; RUSH, AJ; SMALL, JG; GARZATREVINO, ES; RISCH, SC; GOODNICK, PJ; MORRIS, DD				BOWDEN, CL; BRUGGER, AM; SWANN, AC; CALABRESE, JR; JANICAK, PG; PETTY, F; DILSAVER, SC; DAVIS, JM; RUSH, AJ; SMALL, JG; GARZATREVINO, ES; RISCH, SC; GOODNICK, PJ; MORRIS, DD			EFFICACY OF DIVALPROEX VS LITHIUM AND PLACEBO IN THE TREATMENT OF MANIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AFFECTIVE-DISORDERS; BIPOLAR DISORDER; DOUBLE-BLIND; FOLLOW-UP; VALPROATE; ILLNESS; CARBAMAZEPINE; ALCOHOL; STATES; SODIUM	Objective.-To compare the effectiveness of divalproex sodium with that of lithium and placebo in patients with acute mania. Design.-Randomized, double-blind, parallel-group study of treatment outcomes in patients with manic-depressive illness. Patients.-A total of 179 hospitalized, acutely manic patients meeting the Research Diagnostic Criteria for manic disorder, approximately half of whom had been nonresponsive to lithium previously, were studied at nine university-affiliate hospitals. Interventions.-After a minimum 3-day washout period, random assignment for 21 days to divalproex, lithium, or placebo in a 2:1:2 ratio. Dosage of divalproex and lithium was increased if tolerated to a target concentration of 1041 mu mol/L (150 mu g/ mL) or 1.5 mmol/L (conventionally expressed as milliequivalents per liter), respectively. Main Outcome Measures.-Primary outcome measures were changes in the Mania Rating scale derived from the Schedule for Affective Disorders and Schizophrenia. Results.-lntent-to-treat analysis for efficacy was based on data from 68, 35, and 73 patients in the divalproex, lithium, and placebo groups, respectively. Groups were initially comparable except that all eight patients with four or more manic episodes in the previous year were in the divalproex group. In 30%, 33%, and 51% of the above groups, treatment was prematurely terminated due to lack of efficacy, with fewer premature terminations from divalproex than placebo (P=.017). The proportions of patients improving at least 50% were higher for divalproex and lithium groups than for the placebo group: 48% for divalproex (P=.004) and 49% for lithium (P=.025) vs 25% for placebo. Divalproex was as effective in rapid-cycling manic patients as in other patients. Conclusions.-Both divalproex and lithium were significantly more effective than placebo in reducing the symptoms of acute mania. The efficacy of divalproex appears to be independent of prior responsiveness to lithium.	AUDIE L MURPHY MEM VET ADM MED CTR, SAN ANTONIO, TX USA; ABBOTT LABS, CLIN RES SECT, N CHICAGO, IL USA; UNIV TEXAS, SCH MED, DEPT PSYCHIAT, HOUSTON, TX USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT PSYCHIAT, CLEVELAND, OH 44106 USA; ILLINOIS STATE PSYCHIAT INST, CHICAGO, IL USA; UNIV ILLINOIS, DEPT PSYCHIAT, CHICAGO, IL 60612 USA; VET AFFAIRS MED CTR, DALLAS, TX USA; UNIV TEXAS, SW MED CTR, DEPT PSYCHIAT, DALLAS, TX USA; INDIANA UNIV, SCH MED, DEPT PSYCHIAT, INDIANAPOLIS, IN 46202 USA; EMORY UNIV, SCH MED, DEPT PSYCHIAT, ATLANTA, GA 30322 USA; UNIV MIAMI, DEPT PSYCHIAT, CORAL GABLES, FL USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Abbott Laboratories; University of Texas System; Case Western Reserve University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Indiana University System; Indiana University-Purdue University Indianapolis; Emory University; University of Miami	BOWDEN, CL (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT PSYCHIAT, DIV BIOL PSYCHIAT, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA.			Rush, Augustus/0000-0003-2004-2382				ALTMAN EG, 1989, MODERN PERSPECTIVES, P292; BOWDEN CL, 1980, COMPR PSYCHIAT, V21, P263, DOI 10.1016/0010-440X(80)90029-2; CALABRESE JR, 1990, AM J PSYCHIAT, V147, P431; COPPEN A, 1990, LANCET, V335, P1347, DOI 10.1016/0140-6736(90)91232-Y; EGELAND JA, 1983, COMPR PSYCHIAT, V24, P337, DOI 10.1016/0010-440X(83)90062-7; EMRICH HM, 1980, ARCH PSYCHIAT NERVEN, V229, P1, DOI 10.1007/BF00343800; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; Fleiss JL, 1981, STAT METHODS RATES P; FREEMAN TW, 1992, AM J PSYCHIAT, V149, P108; GELENBERG AJ, 1989, NEW ENGL J MED, V321, P1489, DOI 10.1056/NEJM198911303212201; GERSHON ES, 1990, MANIC DEPRESSIVE ILL, P369; GOODWIN FK, 1969, ARCH GEN PSYCHIAT, V21, P486; GOODWIN FK, 1990, MANIC DEPRESSIVE ILL, P22; HARROW M, 1990, ARCH GEN PSYCHIAT, V47, P665; HIMMELHOCH JM, 1986, PSYCHOPHARMACOL BULL, V22, P613; JANICAK PG, 1989, PSYCHOPHARMACOL BULL, V25, P243; KELLER MB, 1986, JAMA-J AM MED ASSOC, V255, P3138, DOI 10.1001/jama.255.22.3138; KRAUTHAMMER C, 1978, ARCH GEN PSYCHIAT, V35, P1333; KUKOPULOS A, 1980, NEUROPSYCHOPHARMAKOL, V13, P156; LERER B, 1987, J CLIN PSYCHIAT, V48, P89; MAGGS R, 1963, BRIT J PSYCHIAT, V109, P56, DOI 10.1192/bjp.109.458.56; MAJ M, 1989, PSYCHOPHARMACOLOGY, V98, P535, DOI 10.1007/BF00441955; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MIRIN SM, 1991, COMPR PSYCHIAT, V32, P36, DOI 10.1016/0010-440X(91)90068-N; POPE HG, 1991, ARCH GEN PSYCHIAT, V48, P62; POST RM, 1989, J CLIN PSYCHIAT, V50, P3; PRIEN RF, 1984, HOSP COMMUNITY PSYCH, V35, P1097; PRIEN RF, 1990, PSYCHOPHARMACOL BULL, V26, P409; REGIER D A, 1990, Journal of the American Medical Association, V264, P2511, DOI 10.1001/jama.264.19.2511; ROSS HE, 1988, ARCH GEN PSYCHIAT, V45, P1023; RYAN ND, 1986, AM PSYCHIATRIC ASS A, V5, P420; SCHOU M, 1954, J NEUROL NEUROSUR PS, V17, P250, DOI 10.1136/jnnp.17.4.250; SECUNDA SK, 1985, J AFFECT DISORDERS, V8, P113, DOI 10.1016/0165-0327(85)90033-3; SMALL JG, 1988, ARCH GEN PSYCHIAT, V45, P727; SMALL JG, 1991, ARCH GEN PSYCHIAT, V48, P915; Spitzer RL, 1975, RES DIAGNOSTIC CRITE; STOKES PE, 1971, LANCET, V1, P1319; SWANN AC, 1986, PSYCHIAT RES, V18, P127, DOI 10.1016/0165-1781(86)90025-9; TOHEN M, 1990, J AFFECT DISORDERS, V19, P79, DOI 10.1016/0165-0327(90)90012-W; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; Weissman M. M., 1991, PSYCHIAT DISORDERS A, P53; WEISSMAN MM, 1988, PSYCHOL MED, V18, P141, DOI 10.1017/S0033291700001975; WILDER BJ, 1983, NEUROLOGY, V33, P808, DOI 10.1212/WNL.33.6.808; 1989, COSTART CODING SYMBO; 1991, SAS USERS GUIDE STAT	45	796	808	1	45	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	1994	271	12					918	924		10.1001/jama.271.12.918	http://dx.doi.org/10.1001/jama.271.12.918			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA743	8120960				2022-12-28	WOS:A1994NA74300027
J	LENFANT, C				LENFANT, C			SPEED URGED FOR THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL-INFARCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LENFANT, C (corresponding author), NHLBI,BETHESDA,MD 20892, USA.							1994, ANN EMERG MED, V23, P311; 1993, JAMA-J AM MED ASSOC, V270, P1211	2	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					738	738						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY288	8114202				2022-12-28	WOS:A1994MY28800007
J	FEELISCH, M; POEL, MT; ZAMORA, R; DEUSSEN, A; MONCADA, S				FEELISCH, M; POEL, MT; ZAMORA, R; DEUSSEN, A; MONCADA, S			UNDERSTANDING THE CONTROVERSY OVER THE IDENTITY OF EDRF	NATURE			English	Article							NITRIC-OXIDE; RELAXING FACTOR; BIOLOGICAL-ACTIVITY; ENDOTHELIAL-CELLS; S-NITROSOCYSTEINE; MECHANISM; VASODILATOR; RELAXATION; NITROXYL	THIRTEEN years after its discovery(1), there is still controversy over the chemical identity of endothelium-derived relaxing factor (EDRF). Although pharmacological and chemical evidence indicates that EDRF is nitric oxide(2), other candidates, including S-nitrosocysteine(3,4), complex(5), nitroxyl(6) and hydroxylamine(7), have been proposed to account for the vasorelaxant properties of EDRF. Such diverse compounds should differ in their stability and in reactivity with oxyhaemoglobin and with redox-active nucleophiles such as thiols. Here we use a bioassay to compare the pharmacodynamic profiles of these and other compounds with those of nitric oxide and EDRF. We find that some S-nitrosothiols, dinitrosyl-iron-cysteine complex, sodium nitroxyl and hydroxylamine can be eliminated as candidates as they are more stable than EDRF and less susceptible to inhibition by oxyhaemoglobin. Co-infusion of cysteine revealed major differences between the remaining candidates because it reduced the effect of authentic nitric oxide and EDRF on the bioassay tissues but enhanced the survival of S-nitrosocysteine and S-nitroso-cysteamine. Our results further support the evidence that EDRF, the pharmacological entity described by Furchgott and Zawadzki(1), is nitric oxide.	HEINRICH HEINE UNIV, CTR PHYSIOL, D-40225 DUSSELDORF, GERMANY; WELLCOME RES LABS, BECKENHAM BR3 3BS, KENT, ENGLAND	Heinrich Heine University Dusseldorf; GlaxoSmithKline; Wellcome Research Laboratories	FEELISCH, M (corresponding author), SCHWARZ PHARMA AG, DEPT PHARMACOL, D-40789 MONHEIM, GERMANY.		Feelisch, Martin/C-3042-2008; Zamora, Renato/ABE-6898-2020	Feelisch, Martin/0000-0003-2320-1158; Zamora, Renato/0000-0002-2223-3361				FELLISCH M, 1991, J CARDIOVASC PHARM, V17, pS25; FLITNEY FW, 1992, BRIT J PHARMACOL, V107, P842, DOI 10.1111/j.1476-5381.1992.tb14534.x; FUKUTO JM, 1992, J PHARMACOL EXP THER, V263, P546; FUKUTO JM, 1992, FASEB J, V6, pA972; FURCHGOTT RF, 1992, JPN J PHARMACOL, V58, pP185; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; JOCELYN PC, 1972, BIOCH SH GROUP; KELM M, 1988, BIOCHEM BIOPH RES CO, V154, P236, DOI 10.1016/0006-291X(88)90675-4; LEWIS SJ, 1992, FASEB J, V6, pA1165; MCANINLY J, 1993, J CHEM SOC CHEM COMM, P1758, DOI 10.1039/c39930001758; MISRA HP, 1974, J BIOL CHEM, V249, P2151; MONCADA S, 1986, P NATL ACAD SCI USA, V83, P9164, DOI 10.1073/pnas.83.23.9164; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PINO RZ, 1993, ENDOTHELIUM, V1, pS69; RUBANYI GM, 1988, CIRCULATION S, V80, P281; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; THOMAS G, 1989, BIOCHEM BIOPH RES CO, V164, P889, DOI 10.1016/0006-291X(89)91542-8; VANIN AF, 1991, FEBS LETT, V289, P1, DOI 10.1016/0014-5793(91)80894-9; VEDERNIKOV YP, 1992, EUR J PHARMACOL, V211, P313, DOI 10.1016/0014-2999(92)90386-I; ZINTL E, 1933, CHEM BER, V66, P760	21	228	232	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					62	65		10.1038/368062a0	http://dx.doi.org/10.1038/368062a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	8107883	Green Accepted			2022-12-28	WOS:A1994MY56900053
J	ROELINK, H; AUGSBURGER, A; HEEMSKERK, J; KORZH, V; NORLIN, S; ALTABA, ARI; TANABE, Y; PLACZEK, M; EDLUND, T; JESSELL, TM; DODD, J				ROELINK, H; AUGSBURGER, A; HEEMSKERK, J; KORZH, V; NORLIN, S; ALTABA, ARI; TANABE, Y; PLACZEK, M; EDLUND, T; JESSELL, TM; DODD, J			FLOOR PLATE AND MOTOR-NEURON INDUCTION BY VHH-1, A VERTEBRATE HOMOLOG OF HEDGEHOG EXPRESSED BY THE NOTOCHORD	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; CHICK LIMB BUD; FORK-HEAD; XENOPUS-LAEVIS; POLARITY GENE; SPINAL-CORD; INT-1 PROTOONCOGENE; DROSOPHILA; PROTEIN; EMBRYO	The differentiation of distinct cell types in the ventral neural tube depends on local inductive signals from the notochord. We have isolated a vertebrate homolog of the Drosophila segment polarity gene hedgehog (hh) from zebrafish and rat, termed vhh-1. vhh-1 is expressed in the node, notochord, floor plate, and posterior limb bud mesenchyme. Each of these cell groups has floor plate inducing activity, suggesting that the vhh-1 gene may encode a floor plate-inducing molecule. Widespread expression of rat vhh-1 in frog embryos leads to ectopic floor plate differentiation in the neural tube. In vitro tests for the signaling functions of vhh-1 demonstrate that COS cells expressing the rat vhh-1 gene induce floor plate and motor neuron differentiation in neural plate explants. vhh-1 may, therefore, contribute to the floor plate and motor neuron inducing activities of the notochord.	COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, DEPT PHYSIOL & CELLULAR BIOPHYS, NEW YORK, NY 10032 USA; UMEA UNIV, DEPT MICROBIOL, S-90187 UMEA, SWEDEN; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	Columbia University; Howard Hughes Medical Institute; Columbia University; Umea University; MRC National Institute for Medical Research			Korzh, Vladimir P/H-1596-2011; Placzek, Marysia/E-6172-2010	Korzh, Vladimir P/0000-0002-6580-7986; Ruiz i Altaba, Ariel/0000-0003-2292-3933; Placzek, Marysia/0000-0002-4106-9229	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS030532] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-30532] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTABA ARI, 1992, DEVELOPMENT, V116, P81; ALTABA ARI, 1992, DEVELOPMENT, V116, P67; ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ALTABA ARI, 1993, CURR OPIN GENET DEV, V3, P633, DOI 10.1016/0959-437X(93)90100-4; ALTABA ARI, 1993, ESSENTIAL DEV BIOL P, P39; ANDERSON R, 1993, DEVELOPMENT, V117, P1421; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEVELOPMENT, V102, P489; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BASLER K, 1994, IN PRESS NATURE; BOLCE ME, 1993, DEV BIOL, V160, P413, DOI 10.1006/dbio.1993.1317; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CLARKE JDW, 1991, DEVELOPMENT, V112, P499; DALE L, 1987, DEVELOPMENT, V99, P527; DENT JA, 1989, DEVELOPMENT, V105, P61; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EIFFERT H, 1992, INFECT IMMUN, V60, P1864, DOI 10.1128/IAI.60.5.1864-1868.1992; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; HOLLYDAY M, 1977, BRAIN RES, V132, P197, DOI 10.1016/0006-8993(77)90416-4; HONIG LS, 1985, J EMBRYOL EXP MORPH, V87, P163; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V94, P257; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JESSELL TM, 1992, HARVEY LECT, V86, P87; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KNOCHEL S, 1992, MECH DEVELOP, V38, P157, DOI 10.1016/0925-4773(92)90007-7; KORZH V, 1993, DEVELOPMENT, V118, P417; KRAUSS S, 1991, NATURE, V353, P267, DOI 10.1038/353267a0; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PARR BA, 1993, DEVELOPMENT, V119, P247; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1991, DEVELOPMENT, P105; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STOCKER KM, 1990, ROUX ARCH DEV BIOL, V198, P371, DOI 10.1007/BF00376155; STRAHLE U, 1993, GENE DEV, V7, P1436, DOI 10.1101/gad.7.7b.1436; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; TASHIRO S, 1993, GENE, V124, P183; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; VANSTRAATEN HWM, 1991, ANAT EMBRYOL, V184, P55; VOGEL A, 1993, DEVELOPMENT, V119, P199; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WAGNER M, 1992, DEVELOPMENT, V116, P55; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	91	769	811	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	1994	76	4					761	775		10.1016/0092-8674(94)90514-2	http://dx.doi.org/10.1016/0092-8674(94)90514-2			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124714				2022-12-28	WOS:A1994MZ28500017
J	STRUHL, K				STRUHL, K			DUALITY OF TBP, THE UNIVERSAL TRANSCRIPTION FACTOR	SCIENCE			English	Editorial Material							TATA-BINDING PROTEIN; RNA POLYMERASE-II; DNA-SEQUENCES; PROMOTER; YEAST; ACTIVATION; INITIATION; COMPONENTS; INVITRO; TFIIIB				STRUHL, K (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.							AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; BURATOWSKI S, 1992, TRANSCRIPTIONAL REGU, P227; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Geiduschek E.P., 1992, TRANSCRIPTIONAL REGU, P247; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INOSTROZA JA, 1992, CELL, V70, P477; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLUG A, 1979, J MOL BIOL, V131, P669, DOI 10.1016/0022-2836(79)90196-7; LEE WS, 1991, CELL, V67, P367; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LOBO SM, 1992, CELL, V71, P1041; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; REEDER RH, 1992, TRANSCRIPTIONAL REGU, P315; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9	34	70	72	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 25	1994	263	5150					1103	1104		10.1126/science.8108728	http://dx.doi.org/10.1126/science.8108728			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	8108728				2022-12-28	WOS:A1994MX75900021
J	HARTMANN, E; SOMMER, T; PREHN, S; GORLICH, D; JENTSCH, S; RAPOPORT, TA				HARTMANN, E; SOMMER, T; PREHN, S; GORLICH, D; JENTSCH, S; RAPOPORT, TA			EVOLUTIONARY CONSERVATION OF COMPONENTS OF THE PROTEIN TRANSLOCATION COMPLEX	NATURE			English	Article							SIGNAL RECOGNITION PARTICLE; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; 4.5S RNA; YEAST; RIBONUCLEOPROTEIN; RECONSTITUTION; SUFFICIENT; INSERTION	PROTEIN translocation into the mammalian endoplasmic reticulum requires the Sec61p complex, which consists of three membrane proteins(1). The alpha-subunit, the homologue of Sec61p of yeast(2-4), shows some similarity to SecYp(5), a key component of the protein export apparatus of bacteria(6,7). In Escherichia coli, SecYp is also associated with two other proteins (SecEp and band-1 protein)(8,9). We have now determined the sequences of the beta- and gamma-subunits of the mammalian Sec61p complex. Sec61-gamma is homologous to SSS1p, a suppressor of sec61 mutants in Saccharomyces cerevisiae, and can functionally replace it in yeast cells. Moreover, Sec61-gamma and SSSIp are structurally related to SecEp of E. coli and to putative homologues in various other bacteria. At least two subunits of the Sec61/SecYp complex therefore seem to be keg components of the protein translocation apparatus in all classes of organisms.	MAX DELBRUCK CTR MOLEC MED, D-12135 BERLIN, GERMANY; HUMBOLDT UNIV BERLIN, INST BIOCHEM, D-10115 BERLIN, GERMANY; UNIV HEIDELBERG, CTR MOLEC BIOL, ZMBH, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Ruprecht Karls University Heidelberg			Görlich, Dirk/B-8296-2017; Hartmann, Enno/C-5687-2013	Görlich, Dirk/0000-0002-4343-5210; 				AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Guthrie C, 1991, GUIDE YEAST GENETICS; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; ITO K, 1983, CELL, V32, P789, DOI 10.1016/0092-8674(83)90065-X; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SCHATZ PJ, 1991, EMBO J, V10, P1749, DOI 10.1002/j.1460-2075.1991.tb07699.x; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	26	226	232	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	1994	367	6464					654	657		10.1038/367654a0	http://dx.doi.org/10.1038/367654a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	8107851				2022-12-28	WOS:A1994MW68800057
J	KUJALA, UM; KAPRIO, J; SARNA, S				KUJALA, UM; KAPRIO, J; SARNA, S			OSTEOARTHRITIS OF WEIGHT-BEARING JOINTS OF LOWER-LIMBS IN FORMER ELITE MALE-ATHLETES	BRITISH MEDICAL JOURNAL			English	Article							OSTEO-ARTHRITIS; HIP; DISEASE; KNEE	Objective-To compare the cumulative 21 year incidence of admission to hospital for osteoarthritis of the hip, knee, and ankle in former elite athletes and control subjects. Design-National population based study. Setting-Finland. Subjects-2049 male athletes who had represented Finland in international events during 1920-65 and 1403 controls who had been classified healthy at the age of 20. Main outcome measures-Hospital admissions for osteoarthritis of the hip, knee, and ankle joints identified from the national hospital discharge registry between 1970 and 1990. Results-Athletes doing endurance sports, mixed sports, and power sports all had higher incidences of admission to hospital for osteoarthritis than controls. Age adjusted odds ratios compared with controls were 1.3 (95% confidence interval 0.99 to 3.01, P=0.063) in endurance, 1.90 (1.24 to 2.92, P=0.003) in mixed sports athletes, and 2.17 (1.41 to 3.32, P=0.0003) in power sports athletes. The mean age at first admission to hospital was higher in endurance athletes (70.6) than in other groups (58.2 in mixed sports, 61.9 in power sports, and 61.2 in controls). Among the 2046 respondents to a questionnaire in 1985, the odds ratios for admission to hospital were similar in all three groups after adjusting for age, occupation, and body mass index at 20 (2.37, 2.42, 2.68). Conclusions-Athletes from all types of competitive sports are at slightly increased risk of requiring hospital care because of osteoarthritis of the hip, knee, or ankle. Mixed sports and power sports lead to increased admissions for premature osteoarthritis, but in endurance athletes the admissions are at an older age.	UNIV HELSINKI,DEPT PUBL HLTH,SF-00290 HELSINKI 29,FINLAND	University of Helsinki	KUJALA, UM (corresponding author), HELSINKI RES INST SPORTS & EXERCISE MED,TOOLO SPORTS HALL,MANNERHEIMINTIE 17,SF-00250 HELSINKI,FINLAND.		Kujala, Urho/AAP-2547-2020; Kaprio, Jaakko/A-1820-2008	Kaprio, Jaakko/0000-0002-3716-2455; Kujala, Urho/0000-0002-9262-1992; Sarna, Seppo/0000-0003-3458-1627				ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; Aro S, 1990, Duodecim, V106, P1443; CROFT P, 1992, BRIT MED J, V304, P1269, DOI 10.1136/bmj.304.6837.1269; DEHAVEN KE, 1985, CLIN SPORT MED, V4, P267; FAIRBANK TJ, 1948, J BONE JOINT SURG BR, V30, P664, DOI 10.1302/0301-620X.30B4.664; FELSON DT, 1988, ANN INTERN MED, V109, P18, DOI 10.7326/0003-4819-109-1-18; JOHNSON RJ, 1984, CLIN ORTHOP RELAT R, V183, P122; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KANNUS P, 1987, J BONE JOINT SURG AM, V69A, P1007, DOI 10.2106/00004623-198769070-00008; KLUNDER KB, 1980, ACTA ORTHOP SCAND, V51, P925, DOI 10.3109/17453678008990896; KONRADSEN L, 1990, AM J SPORT MED, V18, P379, DOI 10.1177/036354659001800408; LANE NE, 1986, JAMA-J AM MED ASSOC, V255, P1147; LINDBERG H, 1993, ACTA ORTHOP SCAND, V64, P165, DOI 10.3109/17453679308994561; MARTI B, 1989, BRIT MED J, V299, P91, DOI 10.1136/bmj.299.6691.91; PANUSH RS, 1986, JAMA-J AM MED ASSOC, V255, P1152, DOI 10.1001/jama.255.9.1152; PURANEN J, 1975, BRIT MED J, V2, P424, DOI 10.1136/bmj.2.5968.424-a; SARNA S, 1993, MED SCI SPORT EXER, V25, P237; Solonen K A, 1966, Ann Chir Gynaecol Fenn, V55, P176; VINGARD E, 1993, AM J SPORT MED, V21, P195, DOI 10.1177/036354659302100206; VINGARD E, 1991, ARBETE HALSA, V25, P1; 1972, TILASTOKESKUS AAKOSE	21	201	204	0	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 22	1994	308	6923					231	234		10.1136/bmj.308.6923.231	http://dx.doi.org/10.1136/bmj.308.6923.231			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT539	8111258	Green Published			2022-12-28	WOS:A1994MT53900018
J	IWASHITA, Y; KAWAGUCHI, S; MURATA, M				IWASHITA, Y; KAWAGUCHI, S; MURATA, M			RESTORATION OF FUNCTION BY REPLACEMENT OF SPINAL-CORD SEGMENTS IN THE RAT	NATURE			English	Article							CENTRAL NERVOUS-SYSTEM; AXONAL REGENERATION; CORTICOSPINAL TRACT; PLASTICITY; TRANSPLANTATION; TRANSECTION; MECHANISMS; PROJECTION; RECOVERY; GUIDANCE	RECONSTRUCTiON Of 2 Severed mammalian spinal cord with restoration of function has so far not been achieved1-12, although structural and functional restitution after spinal transection has been successful in some lower vertebrates12-14. In quail hick nd chick chick chimaeras, spinal cord segments were found to be functional after replacement by isotopic and isochronic grafting of the neural tube15,16. Here we achieve such a replacement in neonatal rats under less restricted topological and temporal conditions than were necessary for the avian chimaeras. The replaced segments united with the host spinal cord and promoted robust growth and regrowth of axons across the graft, enabling neural connections to be reconstructed that were hardly distinguishable from normal. The animals with replaced segments could walk, run and climb with almost normal hind-forelimb coordination. This functional restoration in these animals appeared to be permanent, raising the possibility of therapeutic application in humans.	KYOTO UNIV, FAC MED, DEPT ORTHOPAED SURG, KYOTO 606, JAPAN	Kyoto University	IWASHITA, Y (corresponding author), KYOTO UNIV, FAC MED, DEPT INTEGRAT BRAIN SCI, KYOTO 606, JAPAN.							AMASSIAN VE, 1964, ANN NY ACAD SCI, V112, P5, DOI 10.1111/j.1749-6632.1964.tb26740.x; [Anonymous], 1959, DEGENERATION REGENER; BERNSTEIN DR, 1983, J COMP NEUROL, V221, P382, DOI 10.1002/cne.902210403; BJORKLUND A, 1991, TRENDS NEUROSCI, V14, P319, DOI 10.1016/0166-2236(91)90154-M; BOLZ J, 1993, TRENDS NEUROSCI, V16, P310, DOI 10.1016/0166-2236(93)90107-W; BREGMAN BS, 1991, EXP NEUROL, V112, P49, DOI 10.1016/0014-4886(91)90113-Q; BREGMAN BS, 1989, J COMP NEUROL, V282, P355, DOI 10.1002/cne.902820304; DAS GD, 1986, NEURAL TRANSPLANTATI, P1; GIESLER GJ, 1981, J COMP NEUROL, V195, P243, DOI 10.1002/cne.901950205; GRILLNER S, 1975, PHYSIOL REV, V55, P247, DOI 10.1104/pp.55.2.247; GUTH L, 1983, TRENDS NEUROSCI, V6, P20, DOI 10.1016/0166-2236(83)90009-7; HARRIS WA, 1989, NATURE, V339, P218, DOI 10.1038/339218a0; ITASAKI N, 1992, NEURON, V8, P787, DOI 10.1016/0896-6273(92)90099-Y; KALIL K, 1979, SCIENCE, V205, P1158, DOI 10.1126/science.472734; KAO CC, 1977, EXP NEUROL, V54, P591, DOI 10.1016/0014-4886(77)90259-X; KAWAGUCHI S, 1986, J COMP NEUROL, V245, P258, DOI 10.1002/cne.902450208; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KINUTANI M, 1985, DEV BIOL, V111, P243, DOI 10.1016/0012-1606(85)90449-X; KUNKELBAGDEN E, 1990, EXP BRAIN RES, V81, P25; LEDOUARIN NM, 1993, TRENDS NEUROSCI, V16, P64, DOI 10.1016/0166-2236(93)90019-I; MATSUSHITA M, 1979, BRAIN RES, V173, P185, DOI 10.1016/0006-8993(79)90620-6; REIER PJ, 1986, J COMP NEUROL, V247, P275, DOI 10.1002/cne.902470302; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHREYER DJ, 1982, NEUROSCIENCE, V7, P1837, DOI 10.1016/0306-4522(82)90001-X; SELZER ME, 1978, J PHYSIOL-LONDON, V277, P395, DOI 10.1113/jphysiol.1978.sp012280; SENG KL, 1984, J COMP NEUROL, V228, P18, DOI 10.1002/cne.902280104; SIERADZAN K, 1989, NEUROSCIENCE, V31, P115, DOI 10.1016/0306-4522(89)90034-1; SINGER M, 1979, J COMP NEUROL, V185, P1, DOI 10.1002/cne.901850102; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0	30	197	203	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	1994	367	6459					167	170		10.1038/367167a0	http://dx.doi.org/10.1038/367167a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ780	8114911				2022-12-28	WOS:A1994MQ78000059
J	BLENDON, RJ; BENSON, JM; DONELAN, K				BLENDON, RJ; BENSON, JM; DONELAN, K			THE PUBLIC AND THE CONTROVERSY OVER ABORTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									HARVARD UNIV,SCH PUBL HLTH,HARVARD PROGRAM PUBL OPIN & HLTH CARE,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health	BLENDON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Donelan, Karen/R-6162-2019					DAVIS JA, 1993, GENERAL SOCIAL SURVE; HENSHAW SK, 1982, FAM PLANN PERSPECT, V14, P53, DOI 10.2307/2134813; SCOTT J, 1989, SOC PSYCHOL QUART, V52, P319, DOI 10.2307/2786995; 1962, GALLUP POLL     0823; 1992, ABS NEWS WASHIN 0701; 1991, HARRIS POLL     0531; 1993, GALLUP GNN US T 0226; 1992, HARRIS POLL     1030; 1993, HARRIS POLL     1001; 1993, NBS NEWS WALL S 0604; 1986, RES FORECASTS H 1020; 1984, CBS NEWS NEW YO 1106; 1993, MELLMAN LAZARUS 0514; 1989, LOS ANGELES TIM 0303; 1993, PRINCETON SURVE 0408; 1965, NATIONAL OPINIO 1201; 1984, ABS NEWS ELECTR 1106; 1992, PRINCETON SURVE 0430; 1991, ABS NEWS WASHIN 0530; 1988, ABS NEWS ELECTR 1108; 1992, NBC NEWS WALL S 0515; 1992, HARRIS POLL     0717; 1992, CBS NEWS NY TIM 0708; 1993, NBC NEWS WALL S 0417; 1989, CBS NEWS NY TIM 0917; 1991, TIME CNN YANKEL 0717; 1991, LOS ANGELES TIM 0628; 1993, GALLUP POLL     0312; 1993, NBS NEWS POLL   0922; 1992, AM VIEWPOINT PO 0708; 1988, GALLUP POLL     0909; 1992, ASS PRESS POLL  0529; 1988, CBS NEWS NEW YO 1108; 1992, VOTER RES SURVE 1103; 1993, LOS ANGELES TIM 0612; 1988, LOS ANGELES TIM 1108	36	18	18	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1993	270	23					2871	2875		10.1001/jama.270.23.2871	http://dx.doi.org/10.1001/jama.270.23.2871			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MK941	8133631				2022-12-28	WOS:A1993MK94100042
J	GIOVANNUCCI, E; TOSTESON, TD; SPEIZER, FE; ASCHERIO, A; VESSEY, MP; COLDITZ, GA				GIOVANNUCCI, E; TOSTESON, TD; SPEIZER, FE; ASCHERIO, A; VESSEY, MP; COLDITZ, GA			A RETROSPECTIVE COHORT STUDY OF VASECTOMY AND PROSTATE-CANCER IN UNITED-STATES MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN SEMINAL PLASMA; MYOCARDIAL-INFARCTION; SPERM ANTIGENS; RISK; ETIOLOGY; DISEASE; EPIDEMIOLOGY; HEALTH; MOUSE; AGE	Objective.-To examine the relationship between vasectomy and prostate cancer. Design.-Retrospective cohort study. Setting.-Husbands of nurses in 11 large states in the United States. Participants.-In questionnaires administered in 1976 and 1978, 14 607 married female participants of the Nurses' Health Study reported vasectomy as the couple's form of contraception. In 1989, we contacted these 14607 women and 14607 age-matched participants whose husbands had not had a vasectomy prior to 1978 to ascertain their husband's disease status between 1976 and 1989. Main Outcome Measure.-Diagnosis of prostate cancer. Results.-During the study period, from 1976 through 1989, 96 new cases of prostate cancer were diagnosed in the cohort. Vasectomy was associated with an increased risk of prostate cancer (age-adjusted relative risk, 1.56; 95% confidence interval, 1.03 to 2.37; P=.04). The relative risk of prostate cancer increased overtime since vasectomy. Among men who had their vasectomy 20 or more years in the past, the relative risk of prostate cancer was 1.89 (95% confidence interval, 1.14 to 3.14; P=.005), and after excluding stage A and B cases, the relative risk was 2.06 (95% confidence interval, 0.95 to 4.43; P=.07). This elevated risk of prostate cancer among vasectomized men persisted when we adjusted for smoking, alcohol consumption, educational level, body mass index, and geographical area of residence. Conclusions.-These results support evidence from other epidemiologic studies that vasectomy increases risk of prostate cancer. A biological mechanism whereby vasectomy influences the rate of prostate cancer may be related to a diminished secretory rate of prostatic fluid following vasectomy, or, alternatively, to the postvasectomy immune response to sperm antigens, which may cross-react with tumor-associated antigens and suppress tumor immunosurveillance mechanisms.	DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,BIOSTAT & EPIDEMIOL GRP,HANOVER,NH 03756; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,OXFORD,ENGLAND	Dartmouth College; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; University of Oxford	GIOVANNUCCI, E (corresponding author), HARVARD UNIV,SCH MED,CHANNING LAB,DEPT MED,180 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD092913] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA040935] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40935] Funding Source: Medline; NICHD NIH HHS [N01-HD-09-2913] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adamopoulos D A, 1976, Acta Eur Fertil, V7, P219; ALEXANDER NJ, 1980, J ANDROL, V1, P40; ANDERSON DJ, 1982, J NATL CANCER I, V69, P551; ANDERSON DJ, 1983, AM J PATHOL, V111, P129; ANSBACHE.R, 1972, FERTIL STERIL, V23, P640; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; CASTRO JE, 1974, CANCER RES, V34, P2055; CHI IC, 1990, INT J EPIDEMIOL, V19, P1113, DOI 10.1093/ije/19.4.1113; CHISM SE, 1976, J IMMUNOL, V117, P1870; Coggin J H Jr, 1974, Adv Cancer Res, V19, P105, DOI 10.1016/S0065-230X(08)60053-6; Cox D. R., 1984, ANAL SURVIVAL DATA; DELATORRE B, 1983, INT J ANDROL, V6, P125; FREUND M, 1969, FERTIL STERIL, V20, P163; GACHELIN G, 1977, DEV BIOL, V57, P199, DOI 10.1016/0012-1606(77)90365-7; GIOVANNUCCI E, 1992, NEW ENGL J MED, V326, P1392, DOI 10.1056/NEJM199205213262104; GOLDACRE MJ, 1983, NEW ENGL J MED, V308, P805, DOI 10.1056/NEJM198304073081403; GOLDBERG EH, 1977, TRANSPLANT P, V9, P1363; GUANGHUA T, 1988, INT J EPIDEMIOL, V17, P608; HONDA GD, 1988, BRIT J CANCER, V57, P326, DOI 10.1038/bjc.1988.74; ISAACS JT, 1983, PROSTATE, V4, P351, DOI 10.1002/pros.2990040405; JAKOBSEN H, 1988, PROSTATE, V13, P57, DOI 10.1002/pros.2990130107; JAKOBSEN H, 1989, J REPROD FERTIL, V87, P39; JOHNSONBAUGH RE, 1975, FERTIL STERIL, V26, P329; JOSHI UM, 1981, ARCH ANDROLOGY, V7, P187, DOI 10.3109/01485018108999306; JOUANNET P, 1978, FERTIL STERIL, V29, P435; KINSON GA, 1977, RES COMMUN CHEM PATH, V18, P561; LAUSCH RN, 1974, PROG EXP TUMOR RES, V19, P48; LELANNOU D, 1980, INT J ANDROL, V3, P502; LINNET L, 1978, CLIN EXPT IMMUNOLOGY, V30, P413; LOHIYA N K, 1987, Acta Europaea Fertilitatis, V18, P207; MASSEY FJ, 1984, JAMA-J AM MED ASSOC, V252, P1023, DOI 10.1001/jama.252.8.1023; MENDIRATTA R, 1980, INDIAN J EXP BIOL, V18, P409; MENGE AC, 1978, DEV BIOL, V63, P111, DOI 10.1016/0012-1606(78)90117-3; METTLIN C, 1990, AM J EPIDEMIOL, V132, P1056, DOI 10.1093/oxfordjournals.aje.a115747; NAG DSK, 1984, ANDROLOGIA, V16, P451; NAIK VK, 1980, J REPROD FERTIL, V58, P289; NIENHUIS H, 1992, BRIT MED J, V304, P743, DOI 10.1136/bmj.304.6829.743; NOMURA A, 1988, CANCER RES, V48, P3515; PARMIANI G, 1974, INT J CANCER, V14, P555, DOI 10.1002/ijc.2910140416; PERLMAN JA, 1991, AM J EPIDEMIOL, V134, P107, DOI 10.1093/oxfordjournals.aje.a115985; PERRIN EB, 1984, AM J PUBLIC HEALTH, V74, P128, DOI 10.2105/AJPH.74.2.128; PETITTI DB, 1982, AM J PUBLIC HEALTH, V72, P476, DOI 10.2105/AJPH.72.5.476; PIERREPOINT CG, 1975, J REPROD FERTIL, V44, P395; PURVIS K, 1976, CLIN ENDOCRINOL, V5, P263, DOI 10.1111/j.1365-2265.1976.tb01952.x; ROSENBERG L, 1990, AM J EPIDEMIOL, V132, P1051, DOI 10.1093/oxfordjournals.aje.a115746; ROSENBERG L, 1986, AM J EPIDEMIOL, V123, P1049, DOI 10.1093/oxfordjournals.aje.a114333; ROSS RK, 1983, PROSTATE, V4, P333, DOI 10.1002/pros.2990040403; RUI H, 1986, J ANDROL, V7, P93; SAMUEL T, 1975, CLIN EXP IMMUNOL, V21, P65; SHETH AR, 1982, MED HYPOTHESES, V8, P237, DOI 10.1016/0306-9877(82)90118-9; SIDNEY S, 1991, CANCER CAUSE CONTROL, V2, P113, DOI 10.1007/BF00053130; SKEGG DCG, 1976, BRIT MED J, V1, P621, DOI 10.1136/bmj.1.6010.621; SKINNER JD, 1968, J ENDOCRINOL, V42, P355, DOI 10.1677/joe.0.0420355; SOLTER D, 1977, DEV BIOL, V57, P199; SPITZ MR, 1991, AM J EPIDEMIOL, V134, P108, DOI 10.1093/oxfordjournals.aje.a115986; SRIVASTAVA A, 1986, ACTA ENDOCRINOL-COP, V113, P440, DOI 10.1530/acta.0.1130440; VARMA MM, 1975, J CLIN ENDOCR METAB, V40, P868, DOI 10.1210/jcem-40-5-868; WALKER AM, 1981, LANCET, V1, P13; YING W, 1983, INT J ANDROL, V6, P116, DOI 10.1111/j.1365-2605.1983.tb00330.x; ZARIDZE DG, 1987, BRIT J UROL, V59, P493, DOI 10.1111/j.1464-410X.1987.tb04862.x	60	124	126	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1993	269	7					878	882		10.1001/jama.269.7.878	http://dx.doi.org/10.1001/jama.269.7.878			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL474	8123059				2022-12-28	WOS:A1993KL47400025
J	RIVIER, DH; PILLUS, L				RIVIER, DH; PILLUS, L			SILENCING SPEAKS UP	CELL			English	Review							SACCHAROMYCES-CEREVISIAE; REPLICATION ORIGIN; DNA-REPLICATION; YEAST; TRANSCRIPTION; SEGREGATION; REPRESSION; ACTIVATION; PLASMIDS; GENES		UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309; UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801	University of Colorado System; University of Colorado Boulder; University of Illinois System; University of Illinois Urbana-Champaign	RIVIER, DH (corresponding author), UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801, USA.							ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; APARICIO OM, 1991, CELL, V66, P1; AXELROD A, 1991, MOL CELL BIOL, V11, P1080, DOI 10.1128/MCB.11.2.1080; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; Depamphilis Melvin L., 1993, Trends in Cell Biology, V3, P161, DOI 10.1016/0962-8924(93)90137-P; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; KIMMERLY WJ, 1987, MOL CELL BIOL, V7, P4225, DOI 10.1128/MCB.7.12.4225; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LYON MF, 1992, ANNU REV GENET, V26, P17, DOI 10.1146/annurev.ge.26.120192.000313; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; Rivier DH, 1992, CURR OPIN GENET DEV, V2, P286, DOI 10.1016/S0959-437X(05)80286-2; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; SHAFFER CD, 1993, TRENDS GENET, V9, P35, DOI 10.1016/0168-9525(93)90171-D; WAKIMOTO BT, 1990, GENETICS, V125, P141	24	26	26	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					963	966		10.1016/0092-8674(94)90373-5	http://dx.doi.org/10.1016/0092-8674(94)90373-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137430				2022-12-28	WOS:A1994ND24600002
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA PROPOSES RULE TO PROTECT IDENTITIES OF REPORTERS OF ADVERSE EVENTS AND PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					812	812						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ498	8114223				2022-12-28	WOS:A1994MZ49800039
J	COX, TC; BOTTOMLEY, SS; WILEY, JS; BAWDEN, MJ; MATTHEWS, CS; MAY, BK				COX, TC; BOTTOMLEY, SS; WILEY, JS; BAWDEN, MJ; MATTHEWS, CS; MAY, BK			X-LINKED PYRIDOXINE-RESPONSIVE SIDEROBLASTIC ANEMIA DUE TO A THR(388)-TO-SER SUBSTITUTION IN ERYTHROID 5-AMINOLEVULINATE SYNTHASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DELTA-AMINOLEVULINATE SYNTHASE; BONE-MARROW; ESCHERICHIA-COLI; MESSENGER-RNA; GENE; CELLS; IDENTIFICATION; CHROMOSOME; ENZYME; LIGASE	Background. X-linked sideroblastic anemia is usually associated with reduced 5-aminolevulinate synthase activity in erythroid cells, and some cases are responsive to treatment with pyridoxine, the precursor to the cofactor of the enzyme. The recently identified gene for an erythroid-specific 5-aminolevulinate synthase isoenzyme and its localization to the X chromosome make it likely that one or more defects in this gene underlie the anemia. Methods. Using a polymorphic dinucleotide-repeat sequence in the erythroid 5-aminolevulinate synthase gene, we confirmed the linkage of this gene to the disorder in a family with X-linked pyridoxine-responsive sideroblastic anemia. We therefore sought evidence of a nucleotide-sequence abnormality in the erythroid 5-aminolevulinate synthase gene by analyzing enzymatically amplified DNA. Results. DNA-sequencing studies in two affected males and one carrier female in the kindred demonstrated a cytosine-to-guanine change at nucleotide 1215 (in exon 8). This change results in the substitution of serine for threonine at amino acid residue 388, near the lysine that binds the pyridoxal phosphate cofactor. In expression studies, the activity of the mutant enzyme was reduced relative to that of the wild type, and this reduction was comparable to that in erythroid cells of the proband during relapse of the anemia; the enzyme activity expressed in the presence of pyridoxine was comparable to that in the proband's marrow cells during remission. Although the affinity of the mutant enzyme for pyridoxal phosphate was not altered, the mutation appears to introduce a conformational change at the active site of the enzyme. Conclusions. We identified a point mutation resulting in an amino acid change near the pyridoxal phosphate-binding site of the erythroid 5-aminolevulinate synthase isoenzyme as the underlying defect in a kindred with X-linked pyridoxine-responsive sideroblastic anemia.	VET AFFAIRS MED CTR,HEMATOL ONCOL SECT,OKLAHOMA CITY,OK 73104; UNIV ADELAIDE,DEPT BIOCHEM,ADELAIDE,SA,AUSTRALIA; UNIV OKLAHOMA,COLL MED,DEPT MED,OKLAHOMA CITY,OK 73190; AUSTIN HOSP,DEPT HEMATOL,HEIDELBERG,VIC,AUSTRALIA	University of Oklahoma System; University of Oklahoma Health Sciences Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Adelaide; University of Oklahoma System; University of Oklahoma Health Sciences Center; Austin Research Institute; Florey Institute of Neuroscience & Mental Health				Wiley, James/0000-0001-9421-4154				ARONSON BD, 1988, NUCLEIC ACIDS RES, V16, P3586, DOI 10.1093/nar/16.8.3586; BISHOP DF, 1990, NUCLEIC ACIDS RES, V18, P7187, DOI 10.1093/nar/18.23.7187; BISHOP DF, 1990, GENOMICS, V7, P207, DOI 10.1016/0888-7543(90)90542-3; BOTTOMLEY SS, 1992, AM J HEMATOL, V41, P76, DOI 10.1002/ajh.2830410203; BOTTOMLEY SS, 1993, WINTROBES CLIN HEMAT, V1, P852; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONBOY JG, 1992, J BIOL CHEM, V267, P18753; COTTER PD, 1992, P NATL ACAD SCI USA, V89, P4028, DOI 10.1073/pnas.89.9.4028; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; COX TC, 1990, AM J HUM GENET, V46, P107; COX TC, 1992, HUM MOL GENET, V1, P639, DOI 10.1093/hmg/1.8.639; FERREIRA GC, 1993, PROTEIN SCI, V2, P1959, DOI 10.1002/pro.5560021117; FITZSIMONS EJ, 1986, ANAL BIOCHEM, V153, P9, DOI 10.1016/0003-2697(86)90053-9; HAMFELT A, 1988, CLIN PHYSL APPLICATI, P95; HARRIS JW, 1964, VITAM HORM, V22, P721, DOI 10.1016/S0083-6729(08)60362-3; JOHN SWM, 1991, NUCLEIC ACIDS RES, V19, P408, DOI 10.1093/nar/19.2.408; Jordan P.M., 1991, NEW COMPREHENSIVE BI, V19, P1, DOI DOI 10.1016/S0167-7306(08)60108-8; MAY BK, 1990, MOL BIOL MED, V7, P405; MUKHERJEE JJ, 1990, BIOCHIM BIOPHYS ACTA, V1037, P24, DOI 10.1016/0167-4838(90)90097-Y; RIDDLE RD, 1989, P NATL ACAD SCI USA, V86, P792, DOI 10.1073/pnas.86.3.792; ROSENBERG SJ, 1969, NEW YORK STATE J MED, V69, P1430; Sambrook J, 1989, MOL CLONING LABORATO; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRIEBEL F, 1979, LEUKEMIA RES, V3, P131, DOI 10.1016/0145-2126(79)90010-9	24	108	111	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 10	1994	330	10					675	679		10.1056/NEJM199403103301004	http://dx.doi.org/10.1056/NEJM199403103301004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY575	8107717	Bronze			2022-12-28	WOS:A1994MY57500004
J	WARNER, KE; FULTON, GA				WARNER, KE; FULTON, GA			THE ECONOMIC-IMPLICATIONS OF TOBACCO PRODUCT SALES IN A NONTOBACCO STATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-The tobacco industry claims that tobacco makes a significant economic contribution to each of the states in the United States. We sought to determine whether Michigan, a nontobacco state, would reap more economic benefits from the presence or absence of tobacco product sales. Design.-Computer simulation of the Michigan economy, with and without tobacco product sales, for the years 1992 through 2005. Intervention.-We simulated Michigan's economy with tobacco expenditures eliminated or reduced and the equivalent spending redistributed to other goods and services, according to consumers' normal spending patterns. We compare these results with baseline forecasts of the economy. Main Outcome Measures.-Numbers of jobs and tax revenues. Results.-Michigan would have had 5600 more jobs in 1992 had there been no expenditure on tobacco products, with equivalent spending redistributed to other goods and services (and to other taxes, to replace half of lost cigarette excise tax revenues). By the year 2005, a tobacco-free Michigan would still have almost 1500 more jobs than it will have if sales trends for tobacco products continue tie, gradually declining over time). If, instead of tobacco expenditures ceasing, the contemporary rate of decline in tobacco consumption had doubled, the state would have had over 300 more jobs in 1992 and would have nearly 800 more in 2005. With cigarette excise tax revenues not replaced, the elimination of spending on tobacco products would have decreased Michigan's tax revenues by $254 million in 1992. The more realistic doubling of the expected decline in smoking would have decreased revenues by $14 million that year. Conclusions.-Reducing or eliminating tobacco product spending in Michigan will increase employment in the state, as well as health.	UNIV MICHIGAN,DEPT ECON,ANN ARBOR,MI 48109; UNIV MICHIGAN,INST LABOR & IND RELAT,ANN ARBOR,MI	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	WARNER, KE (corresponding author), UNIV MICHIGAN,SCH PUBL HLTH,DEPT PUBL HLTH POLICY & ADM,1420 WASHINGTON HTS,ANN ARBOR,MI 48109, USA.			Warner, Kenneth/0000-0002-8214-1776				[Anonymous], 1992, EC REPORT PRESIDENT; HODGSON TA, 1992, MILBANK Q, V70, P81, DOI 10.2307/3350086; SCHELLING TC, 1986, PREV MED, V15, P549, DOI 10.1016/0091-7435(86)90030-7; Treyz G. I., 1993, REGIONAL EC MODELING; TREYZ GI, 1992, INT REGIONAL SCI REV, V14, P221, DOI 10.1177/016001769201400301; WARNER KE, 1987, JAMA-J AM MED ASSOC, V258, P2080, DOI 10.1001/jama.258.15.2080; 1993, MMWR MORB MORTAL WKL, V42, P645; 1993, EC LOSSES US EC SPEC; 1993, TAX BURDEN TOBACCO H; 1979, STUDY TOBACCO IND EC; 1993, SAVING LIVES RAISING; 1990, DHHS CDC878396 DEP H; 1992, MICHIGAN ASSIST PROJ; 1985, EC IMPACT TOBACCO IN, pCH5; 1990, EC IMPACT TOBACCO IN; 1992, EC IMPACT TOBACCO IN	16	34	34	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					771	776		10.1001/jama.271.10.771	http://dx.doi.org/10.1001/jama.271.10.771			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MY288	8114214				2022-12-28	WOS:A1994MY28800032
J	CHEN, JH; IYENGAR, R				CHEN, JH; IYENGAR, R			SUPPRESSION OF RAS-INDUCED TRANSFORMATION OF NIH 3T3 CELLS BY ACTIVATED G-ALPHA(S)	SCIENCE			English	Article							MAP KINASE; G-PROTEINS; PROLIFERATION; STIMULATION	Conversion of external signals into proliferative responses may be mediated by interactions between signaling pathways that control cell proliferation. Interactions between G alpha(s), the alpha subunit of the heterotrimeric guanine nucleotide binding protein that stimulates adenylyl cyclase, and Ras, an important element in growth factor signaling, were studied. Expression of activated G alpha(s), in NIH 3T3 cells increased intracellular concentrations of adenosine 3',5'-monophosphate (cAMP) and inhibited H-Ras-stimulated DNA synthesis and mitogen-activated protein kinase activity. Activated G alpha(s) and 8-Br-cAMP suppressed H-Ras-induced transformation of NIH 3T3 cells. Apparently, G alpha(s) inhibits proliferative signals from Ras by stimulating cAMP production and activating protein kinase A.	CUNY MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NCI NIH HHS [CA-44998] Funding Source: Medline; NIDDK NIH HHS [DK-38761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHEN J, 1994, THESIS CITY U NEW YO; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; KROLL SD, 1992, J BIOL CHEM, V267, P23183; LAMORTE VJ, 1993, J CELL BIOL, V245, P1146; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARX J, 1993, SCIENCE, V260, P1588, DOI 10.1126/science.8503004; MCCORMICK F, 1989, NATURE, V340, P678, DOI 10.1038/340678a0; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; RIGBY PWJ, 1982, NATURE, V297, P451, DOI 10.1038/297451a0; RUBIN H, 1989, P NATL ACAD SCI USA, V86, P1860, DOI 10.1073/pnas.86.6.1860; SPADA A, 1992, TRENDS ENDOCRIN MET, V3, P355, DOI 10.1016/1043-2760(92)90001-H; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WINITZ S, 1993, J BIOL CHEM, V268, P19196	24	113	114	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 4	1994	263	5151					1278	1281		10.1126/science.8122111	http://dx.doi.org/10.1126/science.8122111			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	8122111				2022-12-28	WOS:A1994MY57000036
J	MORRIS, SW; KIRSTEIN, MN; VALENTINE, MB; DITTMER, KG; SHAPIRO, DN; SALTMAN, DL; LOOK, AT				MORRIS, SW; KIRSTEIN, MN; VALENTINE, MB; DITTMER, KG; SHAPIRO, DN; SALTMAN, DL; LOOK, AT			FUSION OF A KINASE GENE, ALK, TO A NUCLEOLAR PROTEIN GENE, NPM, IN NON-HODGKINS-LYMPHOMA	SCIENCE			English	Article							LARGE-CELL LYMPHOMA; CLINICAL-FEATURES; GROWTH; HYBRIDIZATION; INTERPHASE; ACTIVATION; NUMATRIN; LEUKEMIA; CLONING; FAMILY	The 2;5 chromosomal translocation occurs in most anaplastic large-cell non-Hodgkin's lymphomas arising from activated T lymphocytes. This rearrangement was shown to fuse the NPM nucleolar phosphoprotein:gene on chromosome 5q35 to a previously unidentified protein tyrosine kinase gene, ALK, on chromosome 2p23. In the predicted hybrid protein, the amino terminus of nucleophosmin (NPM) is linked to the catalytic domain of anaplastic lymphoma kinase (ALK). Expressed in the small intestine, testis, and brain but not in normal lymphoid cells, ALK shows greatest sequence similarity to the insulin receptor subfamily of kinases. Unscheduled expression of the truncated ALK may contribute to malignant transformation in these lymphomas.	ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; GENELABS INC, REDWOOD CITY, CA 94063 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	MORRIS, SW (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38105 USA.				NCI NIH HHS [CA 21765, KO8 CA 01702, P01 CA 20180] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, P01CA020180, K08CA001702] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BITTER MA, 1990, AM J SURG PATHOL, V14, P305, DOI 10.1097/00000478-199004000-00001; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BRINKMAN A, 1988, EMBO J, V7, P2417, DOI 10.1002/j.1460-2075.1988.tb03087.x; BURNETT RC, 1991, GENE CHROMOSOME CANC, V3, P461, DOI 10.1002/gcc.2870030608; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; FEUERSTEIN N, 1991, EXP CELL RES, V194, P289, DOI 10.1016/0014-4827(91)90367-4; GREER JP, 1991, J CLIN ONCOL, V9, P539, DOI 10.1200/JCO.1991.9.4.539; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; KADIN ME, 1991, J CLIN ONCOL, V9, P533, DOI 10.1200/JCO.1991.9.4.533; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; MASON DY, 1990, BRIT J HAEMATOL, V74, P161; MORGAN R, 1989, BLOOD, V73, P2155; MORRIS SC, UNPUB; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; SALTMAN DL, 1992, NUCLEIC ACIDS RES, V20, P1401, DOI 10.1093/nar/20.6.1401; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STANSFELD AG, 1988, LANCET, V1, P292; STEIN H, 1992, NEOPLASTIC HEMATOPAT, P675; TRASK BJ, 1991, AM J HUM GENET, V48, P1; TYCKO B, 1991, J EXP MED, V174, P867, DOI 10.1084/jem.174.4.867	29	1754	1826	4	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 4	1994	263	5151					1281	1284		10.1126/science.8122112	http://dx.doi.org/10.1126/science.8122112			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	8122112				2022-12-28	WOS:A1994MY57000037
J	WANG, ZG; SVEJSTRUP, JQ; FEAVER, WJ; WU, XH; KORNBERG, RD; FRIEDBERG, EC				WANG, ZG; SVEJSTRUP, JQ; FEAVER, WJ; WU, XH; KORNBERG, RD; FRIEDBERG, EC			TRANSCRIPTION FACTOR-B (TFIIH) IS REQUIRED DURING NUCLEOTIDE-EXCISION REPAIR IN YEAST	NATURE			English	Article							HUMAN CELL-EXTRACTS; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; XERODERMA-PIGMENTOSUM; GENE; MUTAGENESIS; POLYMERASE; HELICASE; HOMOLOG; CLONING	NUCLEOTIDE-excision repair (NER)(1) is an important cellular defence mechanism against mutagenesis and carcinogenesis. The essential yeast genes RAD3 (ref 2) and SSL2 (RAD25)(3,4), homologues of the human xeroderma pigmentosum genes XPD(5,6) and XPB(7) respectively, have been implicated in NER in yeast. The products of these genes are also subunits of (Rad3 protein) or associate with (Ssl2 protein) purified yeast RNA polymerase II transcription initiation factor b, the counterpart of human TFIIH8. Rad3 and Ssl2 proteins may participate directly in NER. Alternatively, they may function exclusively as transcription factors that support NER by influencing the expression of other NER genes. Here we show that defective NER in rad3 mutant extracts can be specifically complemented by purified transcription factor b. Similarly, defective NER in ssl2 mutant extracts is corrected by purified factor b/Ssl2 complex. These results support a direct role of factor b during NER in yeast. Hence, factor b (TFlIH) has a dual role in transcription and NER.	STANFORD UNIV,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305	Stanford University	WANG, ZG (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PATHOL,MOLEC PATHOL LAB,DALLAS,TX 75235, USA.			Svejstrup, Jesper/0000-0003-4964-6147				[Anonymous], 1985, DNA REPAIR; BARDWELL L, IN PESS P NATN ACAD; DOWNES CS, 1993, BIOESSAYS, V15, P209, DOI 10.1002/bies.950150311; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FLEJTER WL, 1992, P NATL ACAD SCI USA, V89, P261, DOI 10.1073/pnas.89.1.261; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; FUCHS RPP, 1984, EMBO J, V3, P757, DOI 10.1002/j.1460-2075.1984.tb01880.x; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; HANSSON J, 1989, J BIOL CHEM, V264, P21788; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; NAEGELI H, 1992, J BIOL CHEM, V267, P392; NAUMOVSKI L, 1986, MOL CELL BIOL, V6, P1218, DOI 10.1128/MCB.6.4.1218; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; Qui H., 1993, GENE DEV, V7, P2161; SANCAR A, 1985, J MOL BIOL, V184, P725, DOI 10.1016/0022-2836(85)90316-X; SWEDER KS, 1994, J BIOL CHEM, V269, P1852; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; TERLETH C, 1991, MUTAGENESIS, V6, P103, DOI 10.1093/mutage/6.2.103; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; WANG ZG, 1993, P NATL ACAD SCI USA, V90, P4907, DOI 10.1073/pnas.90.11.4907; WANG ZG, 1991, J BIOL CHEM, V266, P22472; WANG ZG, 1992, BIOCHEMISTRY-US, V31, P3694, DOI 10.1021/bi00129a019; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463	27	155	156	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					74	76		10.1038/368074a0	http://dx.doi.org/10.1038/368074a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	8107888				2022-12-28	WOS:A1994MY56900057
J	BOGAN, JS; PAGE, DC				BOGAN, JS; PAGE, DC			OVARY - TESTIS - A MAMMALIAN DILEMMA	CELL			English	Review							DENYS-DRASH SYNDROME; SEX-DETERMINING REGION; TUMOR-SUPPRESSOR GENE; Y-CHROMOSOME; UROGENITAL DEVELOPMENT; XY-FEMALE; WT1 GENE; MOUSE; SRY; MICE		MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA; MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA	Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital	BOGAN, JS (corresponding author), MIT, WHITEHEAD INST BIOMED RES, HOWARD HUGHES RES LABS, CAMBRIDGE, MA 02142 USA.		Bogan, Jonathan S/A-1575-2010	Bogan, Jonathan S/0000-0001-6463-8466				ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; CLINE TW, 1993, TRENDS GENET, V9, P385, DOI 10.1016/0168-9525(93)90138-8; EICHER EM, 1986, ANNU REV GENET, V20, P327, DOI 10.1146/annurev.ge.20.120186.001551; FOSTER JW, 1992, NATURE, V359, P531, DOI 10.1038/359531a0; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GINSBURG M, 1990, DEVELOPMENT, V110, P521; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUBBAY J, 1992, P NATL ACAD SCI USA, V89, P7953, DOI 10.1073/pnas.89.17.7953; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; Hastie Nicholas D., 1992, Human Molecular Genetics, V1, P293; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; JOST A, 1953, RECENT PROG HORM RES, V8, P379; KING TR, 1991, GENOMICS, V11, P273, DOI 10.1016/0888-7543(91)90133-Y; KNEBELMANN B, 1991, P NATL ACAD SCI USA, V88, P3767, DOI 10.1073/pnas.88.9.3767; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LOVELLBADGE R, 1990, DEVELOPMENT, V109, P635; MCLAREN A, 1991, BIOESSAYS, V13, P151, DOI 10.1002/bies.950130402; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; O WS, 1988, NATURE, V331, P716; PAGE DC, 1986, COLD SPRING HARB SYM, V51, P229, DOI 10.1101/SQB.1986.051.01.028; PALMER MS, 1989, NATURE, V342, P937, DOI 10.1038/342937a0; PALMER SJ, 1991, DEVELOPMENT, V113, P709; PALMER SJ, 1991, DEVELOPMENT, V112, P265; PATEK CE, 1991, DEVELOPMENT, V113, P311; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; TOMMERUP N, 1993, NAT GENET, V4, P170, DOI 10.1038/ng0693-170; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; VIGIER B, 1989, P NATL ACAD SCI USA, V86, P3684, DOI 10.1073/pnas.86.10.3684; ZWINGMAN T, 1993, P NATL ACAD SCI USA, V90, P814, DOI 10.1073/pnas.90.3.814	39	45	46	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	1994	76	4					603	607		10.1016/0092-8674(94)90501-0	http://dx.doi.org/10.1016/0092-8674(94)90501-0			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124705				2022-12-28	WOS:A1994MZ28500004
J	NAKAYAMA, K; NAKAYAMA, K; NEGISHI, I; KUIDA, K; LOUIE, MC; KANAGAWA, O; NAKAUCHI, H; LOH, DY				NAKAYAMA, K; NAKAYAMA, K; NEGISHI, I; KUIDA, K; LOUIE, MC; KANAGAWA, O; NAKAUCHI, H; LOH, DY			REQUIREMENT FOR CD8 BETA-CHAIN IN POSITIVE SELECTION OF CD8-LINEAGE T-CELLS	SCIENCE			English	Article							CLASS-I MOLECULES; MHC CLASS; ALPHA-3 DOMAIN; MOUSE CD8; SURFACE EXPRESSION; LYMPHOCYTES-T; RECEPTOR; GENES; RECOGNITION; THYMOCYTES	CD8 is either an alphaalpha homodimer or an alphabeta heterodimer, although most peripheral CD8-lineage T cells express only the CD8alphabeta heterodimer. The physiological function of CD8beta was elucidated with mice that were chimeric for the homozygous disruption of the CD8beta gene. The CD8beta-/- T cells developed normally to CD4-CD8+ stage, but did not efficiently differentiate further, which resulted in few peripheral CD8+ T cells. The number of peripheral CD8+ T cells was restored by transfer of an exogenous CD8beta gene into CD8beta-deficient T cells. Thus, CD8beta is necessary for the maturation of CD8+ T cells.	WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; INST PHYS & CHEM RES, CELL GROWTH & DIFFERENTIAT LAB, TSUKUBA, IBARAKI 305, JAPAN; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); RIKEN; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NIAID NIH HHS [AI 34580] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034580, U01AI034580] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLANC D, 1988, EUR J IMMUNOL, V18, P613, DOI 10.1002/eji.1830180419; BLUE ML, 1988, CELL, V54, P413, DOI 10.1016/0092-8674(88)90204-8; CHAN IT, 1993, SCIENCE, V261, P1581, DOI 10.1126/science.8372352; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; DEMBIC Z, 1987, NATURE, V326, P510, DOI 10.1038/326510a0; FUNGLEUNG WP, 1993, EUR J IMMUNOL, V23, P2834, DOI 10.1002/eji.1830231117; FUNGLEUNG WP, 1993, EUR J IMMUNOL, V23, P212, DOI 10.1002/eji.1830230133; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; GORMAN SD, 1988, J IMMUNOL, V140, P3646; KARAKI S, 1992, J IMMUNOL, V149, P1613; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; LETOURNEUR F, 1990, P NATL ACAD SCI USA, V87, P2339, DOI 10.1073/pnas.87.6.2339; LIN T, 1993, EUR J IMMUNOL, V23, P1968, DOI 10.1002/eji.1830230836; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; LOH DY, 1991, NEW BIOL, V3, P924; NAKAUCHI H, 1987, P NATL ACAD SCI USA, V84, P4210, DOI 10.1073/pnas.84.12.4210; NAKAYAMA K, 1993, INT IMMUNOL, V5, P419, DOI 10.1093/intimm/5.4.419; NAKAYAMA K, 1992, SCIENCE, V257, P94, DOI 10.1126/science.1621101; NAKAYAMA K, 1989, J IMMUNOL, V142, P2540; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NAKAYAMA K, 1991, IMMUNOGENETICS, V33, P206, DOI 10.1007/BF01719243; NAKAYAMA K, UNPUB; NAKAYAMA KI, 1992, J IMMUNOL, V148, P1919; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; ROBEY EA, 1992, CELL, V69, P1089, DOI 10.1016/0092-8674(92)90631-L; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SHERMAN LA, 1992, SCIENCE, V258, P815, DOI 10.1126/science.1439792; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TORRESNAGEL N, 1992, EUR J IMMUNOL, V22, P2841, DOI 10.1002/eji.1830221113; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WHEELER CJ, 1992, NATURE, V357, P247, DOI 10.1038/357247a0	37	113	116	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 25	1994	263	5150					1131	1133		10.1126/science.8108731	http://dx.doi.org/10.1126/science.8108731			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	8108731				2022-12-28	WOS:A1994MX75900030
J	DECOCK, KM; ZADI, F; ADJORLOLO, G; DIALLO, MO; SASSANMOROKRO, M; EKPINI, E; SIBAILLY, T; DOORLY, R; BATTER, V; BRATTEGAARD, K; GAYLE, H				DECOCK, KM; ZADI, F; ADJORLOLO, G; DIALLO, MO; SASSANMOROKRO, M; EKPINI, E; SIBAILLY, T; DOORLY, R; BATTER, V; BRATTEGAARD, K; GAYLE, H			RETROSPECTIVE STUDY OF MATERNAL HIV-1 AND HIV-2 INFECTIONS AND CHILD SURVIVAL IN ABIDJAN, COTE-DIVOIRE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POLYMERASE CHAIN-REACTION; IVORY-COAST; VERTICAL TRANSMISSION; WEST-AFRICA; PREVALENCE; TYPE-2; AIDS; MORTALITY; INFANTS; BISSAU	Objectives-To compare the effects of maternal HIV-1 and HIV-2 infections on outcome of pregnancy, infant mortality, and child survival, and to measure serological concordance between mothers and children. Design-Retrospective cohort study with cross sectional study of concordance for HIV antibodies. Setting-Hospital, tuberculosis clinic, and maternal and child health centre in Abidjan, Cote d'Ivoire, west Africa. Subjects-986 women who had had a total of 2758 pregnancies since 1980, The last born children of 194 of these women. Main outcome measures-Pregnancy outcomes; mortality for all children born since 1980; and outcome for last born children. Serological concordance between mothers and last born children. Results-Women with HIV-1 and HIV-2 infections had higher rates of spontaneous abortion and stillbirth than uninfected women (86/769 in HIV-1 positive women, 48/421 in HIV-2 positive, 31/234 in dually reactive, and 96/1131 in uninfected). Compared with children born to uninfected mothers (mortality 10.3%), greater proportions of children of HIV-1 positive (20.6%) and dually reactive (20.3%) mothers had died; mortality in children of HIV-2 infected women (13.1%) was not significantly increased. Infant mortalities for the last born children of HIV-1 positive, dually reactive, HTV3 positive, and seronegative women were, respectively, 133, 82, 32, and 40 per 1000 live births. Nine of 77 last born children of HIV-1 positive mothers were concordantly seropositive compared with none of 21 children of HIV-2 infected mothers. Conclusions-Maternal HIV-2 infection has less influence on child survival than infection with HIV-1, probably because of a lower vertical transmission rate.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV HIV AIDS, ATLANTA, GA USA; PROJET RETRO CI, DATA MANAGEMENT SECT, ABIDJAN, COTE IVOIRE; PROJET RETRO CI, LAB SECT, ABIDJAN, COTE IVOIRE	Centers for Disease Control & Prevention - USA								ANDREASSON PA, 1993, AIDS, V7, P989, DOI 10.1097/00002030-199307000-00013; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DECOCK KM, 1991, AIDS, V5, pS21; DECOCK KM, 1990, AIDS, V4, P443, DOI 10.1097/00002030-199005000-00010; DECOCK KM, 1989, AIDS, V3, pS89, DOI 10.1097/00002030-198901001-00013; DECOCK KM, 1989, LANCET, V2, P408; DECOCKKM, 1993, JAMA-J AM MED ASSOC, V270, P2083; DELMISTRO A, 1992, J ACQ IMMUN DEF SYND, V5, P19; GAYLE HD, 1992, J ACQ IMMUN DEF SYND, V5, P513; GEORGE JR, 1992, LANCET, V340, P337, DOI 10.1016/0140-6736(92)91406-X; GNAORE E, 1989, LANCET, V2, P513; HALSEY NA, 1990, JAMA-J AM MED ASSOC, V264, P2088, DOI 10.1001/jama.264.16.2088; LALLEMANT M, 1989, AIDS, V3, P643, DOI 10.1097/00002030-198910000-00004; MATHERON S, 1990, LANCET, V335, P1103, DOI 10.1016/0140-6736(90)92682-8; MIOTTI PG, 1992, INT J EPIDEMIOL, V21, P792; MIOTTI PG, 1990, AIDS, V4, P733, DOI 10.1097/00002030-199008000-00003; MORGAN G, 1990, AIDS, V4, P879, DOI 10.1097/00002030-199009000-00008; PEETERS M, 1992, LANCET, V340, P339, DOI 10.1016/0140-6736(92)91407-Y; POULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25; RAYFIELD M, 1988, J INFECT DIS, V158, P1170, DOI 10.1093/infdis/158.6.1170; ROSSI P, 1992, J ACQ IMMUN DEF SYND, V5, P1019; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; TEMMERMAN M, 1990, AIDS, V4, P1087, DOI 10.1097/00002030-199011000-00006	25	41	42	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 12	1994	308	6926					441	443		10.1136/bmj.308.6926.441	http://dx.doi.org/10.1136/bmj.308.6926.441			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW976	8124173	Green Published			2022-12-28	WOS:A1994MW97600020
J	SEMPRINI, AE; RAVIZZA, M; MUGGIASCA, ML; GIUNTELLI, S; FIORE, S; PARDI, G				SEMPRINI, AE; RAVIZZA, M; MUGGIASCA, ML; GIUNTELLI, S; FIORE, S; PARDI, G			PATERNAL HIV-INFECTION AND TRANSFER OF HIV FROM MOTHER TO FETUS	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SEMEN						SEMPRINI, AUGUSTO ENRICO/S-6415-2017	SEMPRINI, AUGUSTO ENRICO/0000-0002-1113-2012				ANDERSON DJ, 1990, HETEROSEXUAL TRANSMI, P167; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; KRIEGER JN, 1991, J INFECT DIS, V163, P386, DOI 10.1093/infdis/163.2.386; SEMPRINI AE, 1992, LANCET, V340, P1317, DOI 10.1016/0140-6736(92)92495-2; 1992, LANCET, V339, P1007	5	8	8	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	1994	308	6926					453	453		10.1136/bmj.308.6926.453	http://dx.doi.org/10.1136/bmj.308.6926.453			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW976	8124177	Green Published			2022-12-28	WOS:A1994MW97600024
J	TASKER, RC; WILKINSON, K; SLATER, TJ; NOVELLI, V				TASKER, RC; WILKINSON, K; SLATER, TJ; NOVELLI, V			LESSON OF THE WEEK - UNSUSPECTED PNEUMOCYSTIS-CARINII PNEUMONIA AND VERTICALLY ACQUIRED HIV-INFECTION IN INFANTS REQUIRING INTENSIVE-CARE	BRITISH MEDICAL JOURNAL			English	Article									HOSP SICK CHILDREN,DEPT PAEDIAT INFECT DIS,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	TASKER, RC (corresponding author), HOSP SICK CHILDREN,PAEDIAT INTENS CARE UNIT,GREAT ORMOND ST,LONDON WC1N 3JH,ENGLAND.		Tasker, Robert C/R-5837-2019; Slater, Anthony/C-4372-2016	Slater, Anthony/0000-0002-3127-1060; Tasker, Robert/0000-0003-3647-8113				ADES AE, 1991, LANCET, V337, P1562, DOI 10.1016/0140-6736(91)93260-G; ALPERT BE, 1992, PEDIATR PULM, V13, P38, DOI 10.1002/ppul.1950130110; KOUMBOURLIS AC, 1993, PEDIATR PULM, V15, P257, DOI 10.1002/ppul.1950150413	3	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	1994	308	6926					462	463		10.1136/bmj.308.6926.462	http://dx.doi.org/10.1136/bmj.308.6926.462			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW976	8124183	Green Published			2022-12-28	WOS:A1994MW97600030
J	IGARASHI, K; KATAOKA, K; ITOH, K; HAYASHI, N; NISHIZAWA, M; YAMAMOTO, M				IGARASHI, K; KATAOKA, K; ITOH, K; HAYASHI, N; NISHIZAWA, M; YAMAMOTO, M			REGULATION OF TRANSCRIPTION BY DIMERIZATION OF ERYTHROID FACTOR NF-E2 P45 WITH SMALL MAF PROTEINS	NATURE			English	Article							LEUCINE ZIPPERS; MESSENGER-RNA; DNA-BINDING; DIFFERENTIATION; EXPRESSION; PROMOTER; SYNTHASE; CELLS; GENE; FOS	TRANSCRIPTION factor NF-E2 is crucial for regulating erythroid-specific gene expression1. Cloning of the NF-E2 p45 protein has revealed that it contains a basic region-leucine zipper (b-zip) domain which associates with another unidentified protein (of relative molecular mass 18,000) to form functional NF-E2 (ref. 2). We show here that products of the maf proto-oncogene family3-5, MafF, MafG and MafK (the small Maf proteins) which possess a b-zip DNA-binding domain but lack a canonical transactivation domain3, directly control the DNA-binding properties of p45 by heterodimeric association with p45. Whereas homodimers of the small Maf proteins act as negative regulators, heterodimers composed of Maf and p45 support active transcription in vivo. These results indicate that one (or all) of the small Maf proteins is the second constituent chain required for NF-E2 activity, and that negative as well as positive regulation can be achieved through an NF-E2 site, depending on the equilibrium concentrations of p45 and the Maf proteins inside erythroid cells.	TOHOKU UNIV,SCH MED,DEPT BIOCHEM,2-1 SEIRYOMACHI,AOBA KU,SENDAI,MIYAGI 980,JAPAN; JAPANESE FDN CANC RES,INST CANC,DEPT VIRAL ONCOL,TOSHIMA KU,TOKYO 170,JAPAN	Tohoku University; Japanese Foundation for Cancer Research			Yamamoto, Masayuki/A-4873-2010; Itoh, Ken/B-9506-2013	Yamamoto, Masayuki/0000-0002-9073-9436; Itoh, Ken/0000-0002-5518-0729; Igarashi, Kazuhiko/0000-0002-2470-2475				AKIYAMA Y, 1974, BIKEN J, V17, P195; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; FUJITA H, 1991, J BIOL CHEM, V266, P17494; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; Maniatis T, 1989, DECONTAMINATION DILU; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOON AM, 1990, P NATL ACAD SCI USA, V87, P7693, DOI 10.1073/pnas.87.19.7693; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; REITMAN M, 1988, P NATL ACAD SCI USA, V85, P6267, DOI 10.1073/pnas.85.17.6267; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	22	403	408	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					568	572		10.1038/367568a0	http://dx.doi.org/10.1038/367568a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	8107826				2022-12-28	WOS:A1994MV86300062
J	ALGAZI, M; ANCELLEPARK, R; ASJO, B; BARIN, F; BARME, M; BARRESINOUSSI, F; BAYLON, H; BENICHOU, J; BENICHOU, G; BEZEAUD, A; BLANCHER, A; BLATTNER, WA; BLOT, P; BOURROUILLOU, G; BOUTTIER, D; BOVEN, B; BRUNET, JB; CADROY, Y; CAEN, J; CAHAN, C; CALVAS, P; CARANOBE, C; CARRELL, RW; CHANZY, M; CHAOUAT, G; CHIODI, F; COLOMBIES, P; COUTINHO, A; DAUSSET, J; DEVINCENTI, I; DEBRE, P; DENIS, F; DESMYTER, J; DEUBEL, V; DEVERGIE, A; DODIN, A; DORE, JF; DREYFUS, JC; DREYFUSBRISAC, C; DUCOS, J; DURAND, H; FENYO, EM; FLEURY, H; FOURNEL, JJ; FROTTIER, J; GAILLARD, J; GALANAUD, P; GARCON, P; GAZZOLO, L; GEORGES, AJ; GEORGESCOURBOT, MC; GIRARD, M; GLUCKMAN, E; GLUCKMAN, JC; GOLDBERG, M; GOUBAU, P; GUILLIN, MC; HERRAULT, A; JENNINGS, M; JUHANVAGUE, I; KANKI, PJ; KAZATCHKINE, M; KIRN, A; KLATZMANN, D; KOHEN, JP; KREIS, H; KRUH, J; LEMINOR, L; LESOURD, G; LIDEREAU, R; LORTHOLARY, P; LOWENSTEIN, W; LOYGUE, J; MARCOVICH, H; MARTY, M; MATHIOT, C; MONODBROCA, P; ORTH, G; DASILVA, LP; PERES, G; PILLOT, J; POLICARD, C; REYNES, J; ROZENBAUM, W; SCARLATTI, G; SCHAISON, G; SCHUPBACH, J; SIE, P; SMILOVICI, W; SOURNIA, JC; TARANTOLA, D; TAVITIAN, A; TEDGUI, A; TESTAS, P; TIOLLAIS, P; ULLMAN, A; WOLLMAN, E; WOLLMAN, A				ALGAZI, M; ANCELLEPARK, R; ASJO, B; BARIN, F; BARME, M; BARRESINOUSSI, F; BAYLON, H; BENICHOU, J; BENICHOU, G; BEZEAUD, A; BLANCHER, A; BLATTNER, WA; BLOT, P; BOURROUILLOU, G; BOUTTIER, D; BOVEN, B; BRUNET, JB; CADROY, Y; CAEN, J; CAHAN, C; CALVAS, P; CARANOBE, C; CARRELL, RW; CHANZY, M; CHAOUAT, G; CHIODI, F; COLOMBIES, P; COUTINHO, A; DAUSSET, J; DEVINCENTI, I; DEBRE, P; DENIS, F; DESMYTER, J; DEUBEL, V; DEVERGIE, A; DODIN, A; DORE, JF; DREYFUS, JC; DREYFUSBRISAC, C; DUCOS, J; DURAND, H; FENYO, EM; FLEURY, H; FOURNEL, JJ; FROTTIER, J; GAILLARD, J; GALANAUD, P; GARCON, P; GAZZOLO, L; GEORGES, AJ; GEORGESCOURBOT, MC; GIRARD, M; GLUCKMAN, E; GLUCKMAN, JC; GOLDBERG, M; GOUBAU, P; GUILLIN, MC; HERRAULT, A; JENNINGS, M; JUHANVAGUE, I; KANKI, PJ; KAZATCHKINE, M; KIRN, A; KLATZMANN, D; KOHEN, JP; KREIS, H; KRUH, J; LEMINOR, L; LESOURD, G; LIDEREAU, R; LORTHOLARY, P; LOWENSTEIN, W; LOYGUE, J; MARCOVICH, H; MARTY, M; MATHIOT, C; MONODBROCA, P; ORTH, G; DASILVA, LP; PERES, G; PILLOT, J; POLICARD, C; REYNES, J; ROZENBAUM, W; SCARLATTI, G; SCHAISON, G; SCHUPBACH, J; SIE, P; SMILOVICI, W; SOURNIA, JC; TARANTOLA, D; TAVITIAN, A; TEDGUI, A; TESTAS, P; TIOLLAIS, P; ULLMAN, A; WOLLMAN, E; WOLLMAN, A			APPEAL TO MITTERRAND IN BLOOD SCANDAL	NATURE			English	Letter													Barre-Sinoussi, Françoise/G-8355-2011; ORTH, Gérard C/C-2518-2009; eliane, Gluckman/AAA-5024-2021; scarlatti, gabriella/H-1482-2018	scarlatti, gabriella/0000-0003-2316-2689					0	1	1	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					312	312						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	8114928				2022-12-28	WOS:A1994MT54000029
J	EDERY, P; LYONNET, S; MULLIGAN, LM; PELET, A; DOW, E; ABEL, L; HOLDER, S; NIHOULFEKETE, C; PONDER, BAJ; MUNNICH, A				EDERY, P; LYONNET, S; MULLIGAN, LM; PELET, A; DOW, E; ABEL, L; HOLDER, S; NIHOULFEKETE, C; PONDER, BAJ; MUNNICH, A			MUTATIONS OF THE RET PROTOONCOGENE IN HIRSCHSPRUNGS-DISEASE	NATURE			English	Article								HIRSCHSPRUNG'S disease (HSCR)1 is a common condition (1 in 5,000 live births) resulting in intestinal obstruction in neonates2 and megacolon in infants and adults3. This disease has been ascribed to the absence of autonomic ganglion cells, which are derived from the neural crest, in the terminal hindgut4. Segregation analyses have suggested incompletely penetrant dominant inheritance in familial HSCR5. Recently, a gene for HSCR has been mapped to chromosome 10q11.2 (refs 6, 7). No recombination was observed between the disease locus and the locus for the RET proto-oncogene8, a protein tyrosine kinase gene expressed in the cells derived from the neural crest9,10. Here we report nonsense and missense mutations in the extracellular domain of RET protein (exons, 2, 3, 5, and 6) in six unrelated probands and show that the mutant genotypes segregate with the disease in HSCR families. Mutations of RET have been previously reported in multiple endocrine neoplasia type 2A (MEN 2A)11,12. Thus, germ-line mutations of the RET gene may contribute either to developmental anomalies in HSCR or to inherited predisposition to cancer in MEN 2A.	HOP NECKER ENFANTS MALAD,CHIRURG INFANTILE CLIN,SERV GENET MED,149 RUE SEVRES,F-75743 PARIS 15,FRANCE; HOP NECKER ENFANTS MALAD,INSERM,U393,UNITE RECH HANDICAPS GENET ENFANT,F-75743 PARIS 15,FRANCE; UNIV CAMBRIDGE,DEPT PATHOL,CRC HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 1QP,ENGLAND; ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,LONDON W2 1PG,ENGLAND; HOP LA PITIE SALPETRIERE,INSERM,U194,F-75634 PARIS 13,FRANCE; INST CHILD HLTH,MOTHERCARE UNIT CLIN GENET,LONDON WC1N 1EH,ENGLAND	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Cambridge; Imperial College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of London; University College London			Dow, Eleanor/A-7927-2012; Lyonnet, Stanislas/H-5483-2017; Abel, Laurent/H-8888-2017	Lyonnet, Stanislas/0000-0001-5426-9417; PELET, Anastella/0000-0002-8353-1725; Abel, Laurent/0000-0001-7016-6493				ANGRIST M, 1993, NAT GENET, V4, P351, DOI 10.1038/ng0893-351; BADNER JA, 1990, AM J HUM GENET, V46, P568; BODIAN M, 1963, ANN HUM GENET, V26, P261, DOI 10.1111/j.1469-1809.1963.tb01983.x; BOTTANI A, 1991, HUM GENET, V87, P748; COOPER DN, 1990, HUM GENET, V85, P55; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1993, AM J HUM GEMET S, V53, pA996; EMANUEL B, 1965, J PEDIATR-US, V66, P437, DOI 10.1016/S0022-3476(65)80201-3; FEWTRELL MS, IN PRESS J MED GENET; HAYASHI K, 1993, HUM MUTAT, V2, P338, DOI 10.1002/humu.1380020503; Hirschsprung H., 1888, JAHRBUCHF RKINDERHEI, V27, P1; IWAMOTO T, 1993, ONCOGENE, V8, P1087; KWOK JBJ, 1993, ONCOGENE, V8, P2575; LANE PW, 1966, J HERED, V57, P29, DOI 10.1093/oxfordjournals.jhered.a107457; LEDOUARI.NM, 1973, J EMBRYOL EXP MORPH, V30, P31; LESSER PB, 1979, JAMA-J AM MED ASSOC, V242, P747, DOI 10.1001/jama.242.8.747; LIPSON AH, 1987, CLIN GENET, V32, P175; LYONNET S, 1993, NAT GENET, V4, P346, DOI 10.1038/ng0893-346; MARTUCCIELLO G, 1992, PEDIATR SURG INT, V7, P308; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, IN PRESS NATURE GENE; Okamoto E, 1967, J PEDIATR SURG, V2, P437; PASSARGE E, 1972, Birth Defects Original Article Series, V8, P63; PASSARGE E, 1987, NEW ENGL J MED, V276, P138; Polley, 1986, PEDIATR SURG INT, V1, P80, DOI 10.1007/BF00166865; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; WHITEHOUSE FR, 1948, ARCH INTERN MED, V82, P75, DOI 10.1001/archinte.1948.00220250085005	30	639	652	2	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					378	380		10.1038/367378a0	http://dx.doi.org/10.1038/367378a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	8114939				2022-12-28	WOS:A1994MT54000071
J	SCHUCHARDT, A; DAGATI, V; LARSSONBLOMBERG, L; COSTANTINI, F; PACHNIS, V				SCHUCHARDT, A; DAGATI, V; LARSSONBLOMBERG, L; COSTANTINI, F; PACHNIS, V			DEFECTS IN THE KIDNEY AND ENTERIC NERVOUS-SYSTEM OF MICE LACKING THE TYROSINE KINASE RECEPTOR RET	NATURE			English	Article							MOUSE EMBRYO; PROTEIN; CELLS; DIFFERENTIATION; GENES	RECEPTOR tyrosine kinases (RTKs) are cell-surface molecules that transduce signals for cell growth and differentiation1. The RTK encoded by the c-ret proto-oncogene2-5 is rearranged and constitutively activated in a large proportion of thyroid papillary carcinomas6, and germ-line point mutations in c-ret seem to be responsible for the dominantly inherited cancer syndromes multiple endocrine neoplasia (MEN) types 2A7,8 and B-9. The gene is expressed in the developing central and peripheral nervous systems (sensory, autonomic and enteric ganglia) and the excretory system (Wolffian duct and ureteric bud epithelium) of mice, indicating that it may play a role in normal development5. Here we show that mice homozygous for a targeted mutation in c-ret develop to term, but die soon after birth, showing renal agenesis or severe dysgenesis, and lacking enteric neurons throughout the digestive tract. Ret is thus an essential component of a signalling pathway required for renal organogenesis and enteric neurogenesis.	NATL INST MED RES,GENE STRUCT & EXPRESS LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND; COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	MRC National Institute for Medical Research; Columbia University; Columbia University				Pachnis, Vassilis/0000-0001-9733-7686				ANGRIST M, 1993, NAT GENET, V4, P351, DOI 10.1038/ng0893-351; Bernstein J, 1989, RENAL PATHOLOGY CLIN, P1278; BISHOP AE, 1985, HISTOCHEMISTRY, V82, P93, DOI 10.1007/BF00502095; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CARLSON KM, IN PRESS P NATN ACAD; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ERICKSON RA, 1968, J EXP ZOOL, V169, P33, DOI 10.1002/jez.1401690105; FONTAINEPERUS JC, 1982, CELL DIFFER DEV, V11, P183, DOI 10.1016/0045-6039(82)90065-3; GERSHON MD, 1993, J NEUROBIOL, V24, P199, DOI 10.1002/neu.480240207; GROBSTEIN C, 1953, SCIENCE, V118, P52, DOI 10.1126/science.118.3054.52; GROBSTEIN C, 1955, J EXP ZOOL, V130, P319, DOI 10.1002/jez.1401300207; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; IWAMOTO T, 1993, ONCOGENE, V8, P1087; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LEDOUARI.NM, 1973, J EMBRYOL EXP MORPH, V30, P31; LEDOUARIN NM, 1975, P NATL ACAD SCI USA, V72, P728; LYONNET S, 1993, NAT GENET, V4, P346, DOI 10.1038/ng0893-346; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROODHOOFT M, 1984, NEW ENGL J MED, V310, P1341, DOI 10.1056/NEJM198405243102101; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TROY CM, 1990, NEUROSCIENCE, V36, P217, DOI 10.1016/0306-4522(90)90364-A; WHITEHOUSE FR, 1948, ARCH INTERN MED, V82, P75, DOI 10.1001/archinte.1948.00220250085005; WILSON RD, 1985, AM J MED GENET, V21, P153, DOI 10.1002/ajmg.1320210123; YIN L, IN PRESS HUMAN MOL G; YNTEMA CL, 1954, J COMP NEUROL, V101, P515, DOI 10.1002/cne.901010212	34	1317	1354	6	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					380	383		10.1038/367380a0	http://dx.doi.org/10.1038/367380a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	8114940				2022-12-28	WOS:A1994MT54000072
J	BREO, DL				BREO, DL			FLOOD, SWEAT, AND TEARS - TRYING TO BUILD EMOTIONAL LEVEES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1993	270	23					2860	2862		10.1001/jama.270.23.2860	http://dx.doi.org/10.1001/jama.270.23.2860			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK941	8133630				2022-12-28	WOS:A1993MK94100040
J	HANKINSON, SE; HUNTER, DJ; COLDITZ, GA; WILLETT, WC; STAMPFER, MJ; ROSNER, B; HENNEKENS, CH; SPEIZER, FE				HANKINSON, SE; HUNTER, DJ; COLDITZ, GA; WILLETT, WC; STAMPFER, MJ; ROSNER, B; HENNEKENS, CH; SPEIZER, FE			TUBAL-LIGATION, HYSTERECTOMY, AND RISK OF OVARIAN-CANCER - A PROSPECTIVE-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STERILIZATION; TALC	Objective.-To assess whether tubal ligation and hysterectomy affect subsequent risk of ovarian cancer. Design.-Prospective cohort study with 12 years of follow-up. Setting.-United States, multistate. Participants.-A total of 121 700 female registered nurses who were 30 to 55 years of age in 1976; the follow-up rate was 90% as of 1988. Main Outcome Measure.-Ovarian cancer of epithelial origin confirmed by medical record review. Results.-We observed a strong inverse association between tubal ligation and ovarian cancer, which persisted after adjustment for age, oral contraceptive use, parity, and other ovarian cancer risk factors (multivariate relative risk [RR], 0.33; 95% confidence interval [CI], 0.16 to 0.64). The association was similar when we assessed tubal ligation status at the baseline questionnaire and excluded cases in the first 4 years to eliminate any possible short-term decrease in risk due to screening of the ovaries during ligation surgery. We noted a weaker inverse association between simple hysterectomy and ovarian cancer (RR, 0.67; 95% CI, 0.45 to 1.00). Neither vasectomy nor condom use by a partner was associated with risk of ovarian cancer. Conclusions.-These data indicate that tubal ligation, and perhaps hysterectomy, may substantially reduce risk of epithelial ovarian cancer.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	HANKINSON, SE (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, T32CA009001, R01CA040356] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356, 5T32CA09001] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZSANCHEZ F, 1981, FERTIL STERIL, V36, P606; ANNEGERS JF, 1979, CANCER, V43, P723, DOI 10.1002/1097-0142(197902)43:2<723::AID-CNCR2820430248>3.0.CO;2-1; BACHMANN GA, 1990, J REPROD MED, V35, P839; BOOTH M, 1989, BRIT J CANCER, V60, P592, DOI 10.1038/bjc.1989.320; CATTANACH J, 1985, LANCET, V1, P847; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; CORSON SL, 1981, J REPROD MED, V26, P333; COX DR, 1972, J R STAT SOC B, V34, P187; CRAMER DW, 1982, CANCER-AM CANCER SOC, V50, P372, DOI 10.1002/1097-0142(19820715)50:2<372::AID-CNCR2820500235>3.0.CO;2-S; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DESTEFANO F, 1983, OBSTET GYNECOL, V62, P673; DESTEFANO F, 1985, AM J OBSTET GYNECOL, V152, P835, DOI 10.1016/S0002-9378(85)80073-9; DONNEZ J, 1981, OBSTET GYNECOL, V57, P65; DOYLE LL, 1971, AM J OBSTET GYNECOL, V110, P92, DOI 10.1016/0002-9378(71)90221-3; EGLI GE, 1961, FERTIL STERIL, V12, P151; FATHALLA MF, 1971, LANCET, V2, P163; HANKINSON SE, 1992, OBSTET GYNECOL, V80, P708; HARTGE P, 1988, AM J EPIDEMIOL, V127, P990, DOI 10.1093/oxfordjournals.aje.a114902; HELM G, 1983, ACTA OBSTET GYN SCAN, V62, P63, DOI 10.3109/00016348309155761; HENDERSON WJ, 1979, LANCET, V1, P499; HUGGINS GR, 1984, FERTIL STERIL, V41, P337; IRWIN KL, 1991, AM J EPIDEMIOL, V134, P362, DOI 10.1093/oxfordjournals.aje.a116098; JANSON PO, 1977, AM J OBSTET GYNECOL, V127, P349; KOCH M, 1984, CANCER DETECT PREV, V7, P241; KOCH M, 1988, CANCER DETECT PREV, V13, P131; MCGOWAN L, 1979, GYNECOL ONCOL, V7, P325, DOI 10.1016/0090-8258(79)90111-2; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MORI M, 1988, AM J EPIDEMIOL, V128, P771, DOI 10.1093/oxfordjournals.aje.a115030; Moses V I, 1983, MMWR CDC Surveill Summ, V32, p9SS; RADWANSKA E, 1979, OBSTET GYNECOL, V54, P189; RADWANSKA E, 1982, J REPROD MED, V27, P376; RIVERA R, 1989, CONTRACEPTION, V40, P157, DOI 10.1016/0010-7824(89)90003-6; RULIN MC, 1989, OBSTET GYNECOL, V74, P149; SCOTTENFELD D, 1982, CANCER EPIDEMIOL, P871; SHU XO, 1989, CANCER RES, V49, P3670; SIMON WE, 1983, J NATL CANCER I, V70, P839; SORENSEN T, 1981, ACTA OBSTET GYN SCAN, V60, P559, DOI 10.3109/00016348109155486; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STEIN KF, 1949, ANAT REC, V82, P1; STONE SC, 1975, AM J OBSTET GYNECOL, V121, P193, DOI 10.1016/0002-9378(75)90638-9; WEISS NS, 1986, AM J EPIDEMIOL, V124, P856, DOI 10.1093/oxfordjournals.aje.a114463; WHITTEMORE AS, 1988, AM J EPIDEMIOL, V128, P1228, DOI 10.1093/oxfordjournals.aje.a115077; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; WYNDER EL, 1969, CANCER, V23, P352, DOI 10.1002/1097-0142(196902)23:2<352::AID-CNCR2820230212>3.0.CO;2-4; 1990, NIH902789 US DEP HLT, P128	47	235	247	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1993	270	23					2813	2818		10.1001/jama.270.23.2813	http://dx.doi.org/10.1001/jama.270.23.2813			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK941	8133619				2022-12-28	WOS:A1993MK94100029
J	KARLSTROM, E; ABEL, GG				KARLSTROM, E; ABEL, GG			BIOFEEDBACK FOR MUSCULOSKELETAL PAIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											KARLSTROM, E (corresponding author), BEHAV MED INST ATLANTA,ATLANTA,GA, USA.							FOGEL ER, 1987, BIOFEEDBACK PRACTITI, P390; SHERMAN PA, 1991, AM PAIN SOC B, V1, P11; SHERMAN RA, 1992, SPINAL MANIPULATIVE, P177	3	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2736	2736		10.1001/jama.270.22.2736	http://dx.doi.org/10.1001/jama.270.22.2736			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	8133597				2022-12-28	WOS:A1993MJ82100039
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW LABEL WOULD ADVISE CONSUMERS TO CONSULT PHYSICIAN BEFORE TAKING ASPIRIN FOR THE HEART	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1993, FED REGISTER, V58, P54224	1	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2669	2669						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MJ821	8133573				2022-12-28	WOS:A1993MJ82100004
J	COLE, FH				COLE, FH			THE NEED FOR CHAPERONES - CHAPERONES ARE EXPENSIVE AND TIME CONSUMING	BRITISH MEDICAL JOURNAL			English	Letter											COLE, FH (corresponding author), HLTH CTR,CASTLE VALE,BIRMINGHAM B35 7QX,ENGLAND.							JONES R, 1993, BRIT MED J, V307, P951, DOI 10.1136/bmj.307.6910.951; SPEELMAN A, 1993, BRIT MED J, V307, P986, DOI 10.1136/bmj.307.6910.986	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1993	307	6915					1353	1353		10.1136/bmj.307.6915.1353-b	http://dx.doi.org/10.1136/bmj.307.6915.1353-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH556	8130698	Green Published, Bronze			2022-12-28	WOS:A1993MH55600042
J	PROTHEROE, D				PROTHEROE, D			THE NEED FOR CHAPERONES - CHAPERONES VALUABLE IN DIFFICULT PSYCHIATRIC INTERVIEWS	BRITISH MEDICAL JOURNAL			English	Letter											PROTHEROE, D (corresponding author), ST JAMES UNIV HOSP,ACAD UNIT PSYCHIAT,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.							JONES R, 1993, BRIT MED J, V307, P951, DOI 10.1136/bmj.307.6910.951	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1993	307	6915					1353	1353		10.1136/bmj.307.6915.1353-c	http://dx.doi.org/10.1136/bmj.307.6915.1353-c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MH556	8130699	Green Published, Bronze			2022-12-28	WOS:A1993MH55600043
J	WELCH, KMA				WELCH, KMA			DRUG-THERAPY - DRUG-THERAPY OF MIGRAINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DOUBLE-BLIND TRIAL; PROPHYLACTIC TREATMENT; NAPROXEN SODIUM; INTRAVENOUS DIHYDROERGOTAMINE; SUBCUTANEOUS SUMATRIPTAN; PERCUTANEOUS ESTRADIOL; PREMENSTRUAL-SYNDROME; CORONARY VASOSPASM; MENSTRUAL MIGRAINE; CLASSIC MIGRAINE				WELCH, KMA (corresponding author), HENRY FORD HOSP & HLTH SCI CTR, DEPT NEUROL, K-1, 2799 W GRAND BLVD, DETROIT, MI 48202 USA.							Abrahamsen B, 1992, Ugeskr Laeger, V154, P3602; ALBERS GW, 1989, HEADACHE, V29, P215, DOI 10.1111/j.1526-4610.1989.hed22904215.x; ANDERSEN AN, 1977, BRIT J OBSTET GYNAEC, V84, P370, DOI 10.1111/j.1471-0528.1977.tb12601.x; ANDERSON BA, IN PRESS NEW ADV HEA, V3; [Anonymous], 1991, Eur Neurol, V31, P314; ANTHONY M, 1969, ARCH NEUROL-CHICAGO, V21, P263, DOI 10.1001/archneur.1969.00480150053007; AWIDI AS, 1982, CURR THER RES CLIN E, V32, P492; BARKLEY GL, 1990, CEPHALALGIA, V10, P171, DOI 10.1046/j.1468-2982.1990.1004171.x; BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BELGRADE MJ, 1989, NEUROLOGY, V39, P590, DOI 10.1212/WNL.39.4.590; BELL R, 1990, ANN EMERG MED, V19, P1079, DOI 10.1016/S0196-0644(05)81507-0; BENNETT A, 1986, CEPHALALGIA, V6, P17, DOI 10.1177/03331024860060S402; BURING JE, 1990, JAMA-J AM MED ASSOC, V264, P1711, DOI 10.1001/jama.264.13.1711; BUZZI MG, 1989, EUR J PHARMACOL, V165, P251; CADY RK, 1991, JAMA-J AM MED ASSOC, V265, P2831, DOI 10.1001/jama.265.21.2831; CALLAHAM M, 1986, HEADACHE, V26, P168, DOI 10.1111/j.1526-4610.1986.hed2604168.x; CARASSO RL, 1985, INT J NEUROSCI, V27, P67, DOI 10.3109/00207458509149135; CHESTER AH, 1990, CARDIOVASC RES, V24, P932, DOI 10.1093/cvr/24.11.932; CLEAL A, 1991, EUR NEUROL, V31, P323; COUCH JR, 1979, ARCH NEUROL-CHICAGO, V36, P695, DOI 10.1001/archneur.1979.00500470065013; COUCH JR, 1975, HEADACHE, V15, P41, DOI 10.1111/j.1526-4610.1975.hed1501041.x; CURTIN T, 1992, BRIT MED J, V305, P713, DOI 10.1136/bmj.305.6855.713-d; DECHANT KL, 1992, DRUGS, V43, P776, DOI 10.2165/00003495-199243050-00010; DELIGNIERES B, 1986, BMJ-BRIT MED J, V293, P1540, DOI 10.1136/bmj.293.6561.1540; DENNERSTEIN L, 1988, GYNECOL ENDOCRINOL, V2, P113, DOI 10.3109/09513598809023619; DRUMMOND PD, 1985, HEADACHE, V25, P145, DOI 10.1111/j.1526-4610.1985.hed2503145.x; GAUTHIER J, 1981, Journal of Behavioral Medicine, V4, P407, DOI 10.1007/BF00846150; GELMERS HJ, 1983, HEADACHE, V23, P106; GOADSBY PJ, 1991, CEPHALALGIA, V11, P3, DOI 10.1177/0333102491011S1102; GOADSBY PJ, 1988, ANN NEUROL, V23, P193, DOI 10.1002/ana.410230214; GREENBERG DA, 1986, CLIN NEUROPHARMACOL, V9, P311, DOI 10.1097/00002826-198608000-00001; HAKKARAINEN H, 1980, J CLIN PHARMACOL, V20, P590, DOI 10.1002/j.1552-4604.1980.tb01674.x; HAKKARAINEN H, 1982, HEADACHE, V22, P10, DOI 10.1111/j.1526-4610.1982.hed2201010.x; HAKKARAINEN H, 1978, HEADACHE, V18, P35, DOI 10.1111/j.1526-4610.1978.hed1801035.x; HAKKARAINEN H, 1982, 1981 P TIM INT S STO, P433; HAVANKAKANNIAINEN H, 1985, CEPHALALGIA, V5, P39, DOI 10.1046/j.1468-2982.1985.0501039.x; HERING R, 1992, CEPHALALGIA, V12, P81, DOI 10.1046/j.1468-2982.1992.1202081.x; JOHANNSSON V, 1987, HEADACHE, V27, P372, DOI 10.1111/j.1526-4610.1987.hed2707372.x; JOHNSON ES, 1985, CEPHALALGIA, V5, P5, DOI 10.1046/j.1468-2982.1985.0501005.x; JOHNSON RH, 1986, ACTA NEUROL SCAND, V73, P490, DOI 10.1111/j.1600-0404.1986.tb04591.x; JONES J, 1989, JAMA-J AM MED ASSOC, V261, P1174, DOI 10.1001/jama.261.8.1174; KANGASNIEMI P, 1987, CEPHALALGIA S6, V7, P464; KARACHALIOS GN, 1992, HEADACHE, V32, P98, DOI 10.1111/j.1526-4610.1992.hed3202098.x; KLAPPER JA, 1991, HEADACHE, V31, P523, DOI 10.1111/j.1526-4610.1991.hed3108523.x; KLOSTER R, 1992, CEPHALALGIA, V12, P169, DOI 10.1046/j.1468-2982.1992.1203169.x; Kuritzky A., 1987, CEPHALALGIA, V7, P457, DOI DOI 10.1177/03331024870070S6203; Lance J W, 1965, Med J Aust, V2, P909; LANE PL, 1989, ANN EMERG MED, V18, P360, DOI 10.1016/S0196-0644(89)80570-0; LARSEN BH, 1990, ACTA NEUROL SCAND, V81, P464; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; LLOYD DK, 1992, BRIT MED J, V305, P310, DOI 10.1136/bmj.305.6848.310-d; MACINTYRE PD, 1993, CIRCULATION, V87, P401, DOI 10.1161/01.CIR.87.2.401; MARKLEY HG, 1984, NEUROLOGY, V34, P973, DOI 10.1212/WNL.34.7.973; MARKLEY HG, 1991, AM J MED S5A, V90; MASEL BE, 1978, NEUROLOGY, V28, P371; MCARTHUR JC, 1989, NEUROLOGY, V39, P284, DOI 10.1212/WNL.39.2.284; MELLOR C, 1991, EUR NEUROL, V31, P306; MEYER JS, 1983, HEADACHE, V23, P266, DOI 10.1111/j.1526-4610.1983.hed2306266.x; MIKKELSEN BM, 1982, ACTA NEUROL SCAND, V66, P105; MOSKOWITZ MA, 1984, ANN NEUROL, V16, P157, DOI 10.1002/ana.410160202; MOSKOWITZ MA, 1991, J NEUROL, V238, pS18, DOI 10.1007/BF01642901; MYLECHARANE EJ, 1991, J NEUROL, V238, pS45, DOI 10.1007/BF01642906; NESTVOLD K, 1985, CEPHALALGIA, V5, P115, DOI 10.1046/j.1468-2982.1985.0502115.x; NODA S, 1984, NEUROL MED, V21, P333; OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406; OLSEN TS, 1987, ARCH NEUROL-CHICAGO, V44, P156, DOI 10.1001/archneur.1987.00520140028013; OTTERVANGER JP, 1993, LANCET, V341, P861, DOI 10.1016/0140-6736(93)93064-8; PEATFIELD RC, 1983, CEPHALALGIA, V3, P129, DOI 10.1046/j.1468-2982.1983.0302129.x; PEROUTKA SJ, 1990, NEUROL CLIN, V8, P829, DOI 10.1016/S0733-8619(18)30320-7; POWLES TJ, 1986, LANCET, V2, P1344; PRADALIER A, 1985, CEPHALALGIA, V5, P107, DOI 10.1046/j.1468-2982.1985.0502107.x; PRADALIER A, 1992, PATHOL BIOL, V40, P397; RAPOPORT AM, 1985, CEPHALALGIA S3, V5, P448; RASKIN NH, 1986, NEUROLOGY, V36, P995, DOI 10.1212/WNL.36.7.995; RYAN RE, 1983, HEADACHE, V23, P26; SAADAH HA, 1992, HEADACHE, V32, P143, DOI 10.1111/j.1526-4610.1992.hed3203143.x; SARGENT J, 1985, HEADACHE, V25, P320; SARNO AP, 1987, OBSTET GYNECOL, V70, P33; SAXENA PR, 1992, CEPHALALGIA, V12, P187, DOI 10.1046/j.1468-2982.1992.1204187.x; SCHMIDT R, 1974, EUR J CLIN PHARMACOL, V7, P213, DOI 10.1007/BF00560383; SCHOENEN J, 1986, CEPHALALGIA, V6, P229, DOI 10.1046/j.1468-2982.1986.0604229.x; Schoenen J, 1985, CEPHALALGIA S3, V5, P480; SELBY G, 1960, J NEUROL NEUROSUR PS, V23, P23, DOI 10.1136/jnnp.23.1.23; SHANKS RG, 1985, MIGRAINE BETABLOCKAD, P45; SOLOMON GD, 1983, JAMA-J AM MED ASSOC, V250, P2500, DOI 10.1001/jama.250.18.2500; SOMERVILLE BW, 1975, NEUROLOGY, V25, P239, DOI 10.1212/WNL.25.3.239; SOMERVILLE BW, 1976, MED J AUSTRALIA, V1, P865, DOI 10.5694/j.1326-5377.1976.tb141126.x; SORENSEN KV, 1988, ACTA NEUROL SCAND, V78, P346, DOI 10.1111/j.1600-0404.1988.tb03667.x; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; SPIERINGS ELH, 1980, NEUROLOGY, V30, P696; STENSRUD P, 1974, HEADACHE, V14, P96, DOI 10.1111/j.1526-4610.1974.hed1402096.x; STENSRUD P, 1980, HEADACHE, V20, P204, DOI 10.1111/j.1526-4610.1980.h2004006.x; STEWART DJ, 1988, HEADACHE, V28, P260, DOI 10.1111/j.1526-4610.1988.hed2804260.x; STRICKER BHC, 1992, BRIT MED J, V305, P118, DOI 10.1136/bmj.305.6845.118-a; TANSEY MJB, IN PRESS NEW ADV HEA, V3; TEK DS, 1990, ANN EMERG MED, V19, P1083, DOI 10.1016/S0196-0644(05)81508-2; TFELTHANSEN P, 1984, CEPHALALGIA, V4, P107, DOI 10.1046/j.1468-2982.1984.0402107.x; WEBER RB, 1972, NEUROLOGY, V22, P366, DOI 10.1212/WNL.22.4.366; WELCH K, 1984, CEPHALALGIA, V4, P227, DOI 10.1046/j.1468-2982.1984.0404227.x; WELCH KMA, 1985, NEUROLOGY, V35, P1304, DOI 10.1212/WNL.35.9.1304; WELCH KMA, 1990, NEUROL CLIN, V8, P817, DOI 10.1016/S0733-8619(18)30319-0; WELCH KMA, 1987, ARCH NEUROL-CHICAGO, V44, P323, DOI 10.1001/archneur.1987.00520150063024; WIDEROE TE, 1974, BRIT MED J, V2, P699, DOI 10.1136/bmj.2.5921.699; WILLETT F, 1992, BRIT MED J, V304, P1415, DOI 10.1136/bmj.304.6839.1415; 1991, CEPHALAGIA, V11, P1; 1991, N EGNL J MED, V325, P316; 1992, EUR EUROL, V32, P177	107	127	133	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1993	329	20					1476	1483						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF292	8105379				2022-12-28	WOS:A1993MF29200008
J	PELL, ACH; HUGHES, D; KEATING, J; CHRISTIE, J; BUSUTTIL, A; SUTHERLAND, GR				PELL, ACH; HUGHES, D; KEATING, J; CHRISTIE, J; BUSUTTIL, A; SUTHERLAND, GR			BRIEF REPORT - FULMINATING FAT-EMBOLISM SYNDROME CAUSED BY PARADOXICAL EMBOLISM THROUGH A PATENT FORAMEN OVALE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							TRANSESOPHAGEAL ECHOCARDIOGRAPHY; PULMONARY-HYPERTENSION; PRESSURE; LIFE		ROYAL EDINBURGH & ASSOCIATED HOSP, DEPT CARDIOL, EDINBURGH EH3 9HB, MIDLOTHIAN, SCOTLAND; ROYAL EDINBURGH & ASSOCIATED HOSP, DEPT PATHOL, EDINBURGH EH3 9HB, MIDLOTHIAN, SCOTLAND; ROYAL EDINBURGH & ASSOCIATED HOSP, DEPT ORTHOPAED SURG, EDINBURGH EH3 9HB, MIDLOTHIAN, SCOTLAND	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh								CURRIE PJ, 1985, J AM COLL CARDIOL, V6, P750, DOI 10.1016/S0735-1097(85)80477-0; EMSON HE, 1958, J CLIN PATHOL, V11, P28, DOI 10.1136/jcp.11.1.28; EVARTS CM, 1970, SURG CLIN N AM, V50, P493; FABIAN TC, 1990, CRIT CARE MED, V18, P42; FONTE DA, 1971, J TRAUM, V11, P668, DOI 10.1097/00005373-197108000-00004; Gurd A R, 1970, J Bone Joint Surg Br, V52, P732; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; HAGLEY SR, 1983, ANAESTH INTENS CARE, V11, P167, DOI 10.1177/0310057X8301100215; HULMAN G, 1988, LANCET, V1, P1366; KAMENAR E, 1980, STROKE, V11, P477, DOI 10.1161/01.STR.11.5.477; KONSTADT SN, 1991, ANESTHESIOLOGY, V74, P212, DOI 10.1097/00000542-199102000-00003; LANG I, 1988, EUR HEART J, V9, P678, DOI 10.1093/oxfordjournals.eurheartj.a062561; LANGHOLZ D, 1991, J AM COLL CARDIOL, V18, P1112, DOI 10.1016/0735-1097(91)90775-5; LEHMAN EP, 1972, ARCH SURG-CHICAGO, V14, P621; LEMAIRE F, 1982, ANESTHESIOLOGY, V57, P233, DOI 10.1097/00000542-198209000-00016; LEONARD RCF, 1982, EUR HEART J, V3, P362, DOI 10.1093/oxfordjournals.eurheartj.a061319; LEVY D, 1990, CLIN ORTHOP RELAT R, V261, P281; MANNING JB, 1983, J TRAUMA, V23, P322, DOI 10.1097/00005373-198304000-00009; NAGELHOUT DA, 1991, AM HEART J, V121, P1552, DOI 10.1016/0002-8703(91)90170-M; NIJSTEN MWN, 1989, LANCET, V1, P1271; Pell Alastair C. H., 1993, Journal of the American College of Cardiology, V21, p264A; PELTIER LF, 1956, SURGERY, V40, P665; PELTIER LF, 1988, CLIN ORTHOP RELAT R, V232, P263; RISKA EB, 1982, J TRAUMA, V22, P891, DOI 10.1097/00005373-198211000-00001; SEVITT S, 1977, ANN CLIN RES, V9, P173; Sevitt S, 1962, FAT EMBOLISM; Watson A J, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P132, DOI 10.1136/jcp.s3-4.1.132	27	133	138	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1993	329	13					926	929		10.1056/NEJM199309233291305	http://dx.doi.org/10.1056/NEJM199309233291305			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX751	8123102	Bronze			2022-12-28	WOS:A1993LX75100005
J	RAAD, II; LUNA, M; KHALIL, SAM; COSTERTON, JW; LAM, C; BODEY, GP				RAAD, II; LUNA, M; KHALIL, SAM; COSTERTON, JW; LAM, C; BODEY, GP			THE RELATIONSHIP BETWEEN THE THROMBOTIC AND INFECTIOUS COMPLICATIONS OF CENTRAL VENOUS CATHETERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SEPTIC THROMBOPHLEBITIS; FIBRONECTIN; FIBRINOGEN; ADHERENCE	Objective.-To assess the frequency of thrombotic and infectious complications of long-term use of vascular catheters in cancer patients and to determine whether the two types of complication are related. Design.-Case series. Setting.-A 500-bed tertiary cancer center. Patients.-Seventy-two cancer patients. Interventions.-During a 16-month Period, postmortem examinations of catheterized veins and contralateral uncatheterized veins were done on all patients with indwelling central venous catheters who met study criteria. Main Outcome Measures.-Catheter-related septicemia determined by clinical and microbiological data as well as postmortem pathology; venous pathological changes such as mural hemorrhage, thrombosis, calcification, ulceration, and inflammation. Results.-Premortem clinical and microbiological data were obtained retrospectively on all patients. Pathological changes were noted in 35 catheterized veins (49%) compared with five contralateral control veins (9.2%) (P<.001). Mural thrombi were noted in 27 catheterized veins (38%) compared with only one contralateral control vein (1.4%) (P<.001). Other pathological changes consisted of four central venous catheter-related mural thrombi (5.6%) in the right atrium and four instances (5.6%) of nonbacterial thrombotic endocarditis, three involving the tricuspid and one the mitral valves. Seven patients had catheter-related septicemia. Of the 31 patients with mural thrombosis of the catheterized vein or right atrium, seven developed catheter-related septicemia, whereas none of the 41 patients with normal catheterized veins and atria developed catheter-related septicemia (P<.01). Conclusions.-Thrombotic complications are common in catheterized veins and are often associated with catheter sepsis.	UNIV CALGARY, DEPT BIOL SCI, CALGARY T2N 1N4, ALBERTA, CANADA; AL-AZHAR UNIV, NASR CITY FAC MED, DEPT PUBL HLTH & EPIDEMIOL, CAIRO, EGYPT; UNIV TEXAS, HLTH SCI CTR, SCH MED, HOUSTON, TX 77225 USA	University of Calgary; Egyptian Knowledge Bank (EKB); Al Azhar University; University of Texas System; University of Texas Health Science Center Houston	RAAD, II (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MED SPECIAL, INFECT DIS SECT, HOUSTON, TX 77030 USA.							FRASCHINI G, 1991, MAY P ANN M AM SOC C; GARRISON RN, 1982, SOUTHERN MED J, V75, P917, DOI 10.1097/00007611-198208000-00004; HERRMANN M, 1988, J INFECT DIS, V158, P693, DOI 10.1093/infdis/158.4.693; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; ONEILL JA, 1968, J TRAUM, V8, P256, DOI 10.1097/00005373-196803000-00012; PETERS WR, 1973, SURG GYNECOL OBSTET, V137, P43; PRUITT BA, 1980, ANN SURG, V191, P546, DOI 10.1097/00000658-198005000-00005; RAAD II, 1992, EUR J CLIN MICROBIOL, V11, P1; RADD I, 1993, J INFECT DIS, V168, P400, DOI 10.1093/infdis/168.2.400; SCHUMAN ES, 1987, INFECT SURG      FEB, P103; SHERERTZ RJ, 1990, J CLIN MICROBIOL, V28, P76, DOI 10.1128/JCM.28.1.76-82.1990; STRINDEN WD, 1985, ANN SURG, V202, P653, DOI 10.1097/00000658-198511000-00019; TENNEY JH, 1986, ARCH INTERN MED, V146, P1949, DOI 10.1001/archinte.146.10.1949; VAUDAUX P, 1989, J INFECT DIS, V160, P865, DOI 10.1093/infdis/160.5.865; VERGHESE A, 1985, MEDICINE, V64, P394, DOI 10.1097/00005792-198511000-00004	15	339	353	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	1994	271	13					1014	1016		10.1001/jama.271.13.1014	http://dx.doi.org/10.1001/jama.271.13.1014			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND949	8139059				2022-12-28	WOS:A1994ND94900032
J	SHAW, LJ; MILLER, D; ROMEIS, JC; KARGL, D; YOUNIS, LT; CHAITMAN, BR				SHAW, LJ; MILLER, D; ROMEIS, JC; KARGL, D; YOUNIS, LT; CHAITMAN, BR			GENDER DIFFERENCES IN THE NONINVASIVE EVALUATION AND MANAGEMENT OF PATIENTS WITH SUSPECTED CORONARY-ARTERY DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY DISEASE; SEX FACTORS; EXERCISE TEST; RADIONUCLIDE ANGIOGRAPHY; MYOCARDIAL REVASCULARIZATION	MULTIVARIABLE MATHEMATICAL-METHODS; MYOCARDIAL-INFARCTION; PREDICTING SURVIVAL; PROGNOSTIC VARIABLES; ELDERLY PATIENTS; BYPASS-SURGERY; HEART-DISEASE; WOMEN; BIAS; MEN	Objective: To determine if gender-based differences exist in the post-test management and clinical outcome of patients with clinically suspected coronary artery disease who have stress electrocardiographic or myocardial perfusion imaging evaluation. Design: Retrospective cohort study. Setting: University medical center. Patients: From a cohort of 3975 middle-aged patients referred for outpatient stress testing, 840 (47% women) were evaluated noninvasively for clinically suspected coronary artery disease. Measurements: The rates of subsequent diagnostic procedures and the incidence of subsequent coronary revascularization, myocardial infarction, or cardiac death were determined for women and men. Results: Pretest cardiac risk profiles were similar, except hypertension and hypercholesterolemia were more frequent in women. Atypical angina was more common in women than in men (57.5% compared with 44.5%, respectively; P < 0.001). Rates of initial test positivity (defined as exercise-induced horizontal or downsloping ST-segment depression greater than or equal to 1.0 mm or greater than or equal to 1 reversible thallium-201 defect) were similar in women and men. Compared with men, most women with an initial positive test result had no additional coronary artery disease evaluation (62.3% compared with 38.0%; P = 0.002). Coronary revascularization procedures were done more frequently in men (4.9% [22 of 449] compared with 2.0% [8 of 391]; P = 0.03). Cardiac death or myocardial infarction occurred more often in women during 2 years of follow-up (6.9% [27 of 391] compared with 2.4% [11 of 449]; P = 0.002). Conclusions: Women with suspected coronary artery disease have fewer additional diagnostic tests than men after an initial abnormal noninvasive stress test result, even though the incidence of typical angina, cardiac risk factors, and initial diagnostic test positivity rates are similar.	ST LOUIS UNIV, MED CTR, SCH MED, DIV CARDIOL, ST LOUIS, MO 63110 USA; ST LOUIS UNIV, SCH MED, ST LOUIS, MO 63104 USA; HLTH SERV RES & DEV PROGRAM, DURHAM, NC USA	Saint Louis University; Saint Louis University								ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BASS EB, 1989, J CLIN EPIDEMIOL, V42, P385, DOI 10.1016/0895-4356(89)90126-1; BELLER GA, 1991, CIRCULATION, V84, pI1; BENEDETTI J, 1990, LIFE TABLES SURVIVOR, V2, P941; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; BRUCE RA, 1971, ANN CLIN RES, V3, P323; CALLAHAM PR, 1989, J AM COLL CARDIOL, V14, P1175, DOI 10.1016/0735-1097(89)90413-0; Cook RD, 1982, RESIDUALS INFLUENCE; CUNNINGHAM MA, 1989, J GEN INTERN MED, V4, P392, DOI 10.1007/BF02599688; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; Draper N.R., 1981, APPL REGRESSION ANAL, Vsecond, DOI DOI 10.1002/9781118625590; ENGELMAN L, 1990, STEPWISE LOGISTIC RE, P1017; EYSMANN SB, 1992, JAMA-J AM MED ASSOC, V268, P1903, DOI 10.1001/jama.268.14.1903; FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P339, DOI 10.1016/0895-4356(90)90120-E; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; ISKANDRIAN AS, 1988, AM J CARDIOL, V61, P269, DOI 10.1016/0002-9149(88)90929-0; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; POLISSAR L, 1982, MED CARE, V20, P959, DOI 10.1097/00005650-198209000-00008; RALEVIC V, 1991, CIRCULATION, V84, P1, DOI 10.1161/01.CIR.84.1.1; SHAW L, 1992, J AM COLL CARDIOL, V19, P1390, DOI 10.1016/0735-1097(92)90592-B; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TIERNEY WM, 1985, CRIT CARE MED, V13, P526, DOI 10.1097/00003246-198507000-00002; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; WALTER SD, 1990, J CLIN EPIDEMIOL, V43, P349, DOI 10.1016/0895-4356(90)90121-5; WEISBERG S, 1980, APPLIED LINEAR REGRE; WELLS CK, 1990, J CLIN EPIDEMIOL, V43, P361, DOI 10.1016/0895-4356(90)90122-6; YOUNIS LT, 1989, J AM COLL CARDIOL, V14, P1635, DOI 10.1016/0735-1097(89)90008-9; YOUNIS LT, 1989, AM J CARDIOL, V64, P161, DOI 10.1016/0002-9149(89)90450-5; 1990, DHHS HRSA HRSPDV901; 1990, BMDP STATISTICAL SOF, V1, P269	35	282	284	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					559	566		10.7326/0003-4819-120-7-199404010-00005	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8116993				2022-12-28	WOS:A1994NC76400005
J	ADAMS, MD; KERLAVAGE, AR; KELLEY, JM; GOCAYNE, JD; FIELDS, C; FRASER, CM; VENTER, JC				ADAMS, MD; KERLAVAGE, AR; KELLEY, JM; GOCAYNE, JD; FIELDS, C; FRASER, CM; VENTER, JC			A MODEL FOR HIGH-THROUGHPUT AUTOMATED DNA-SEQUENCING AND ANALYSIS CORE FACILITIES	NATURE			English	Article							GENES; TAGS				ADAMS, MD (corresponding author), INST GENOM RES,932 CLOPPER RD,GAITHERSBURG,MD 20878, USA.			Fields, Chris/0000-0002-4812-0744; Fraser, Claire/0000-0003-1462-2428; Kerlavage, Anthony/0000-0002-3954-9653				ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRUTLAG DL, 1993, COMPUT CHEM, V17, P203, DOI 10.1016/0097-8485(93)85011-Z; CATHCART R, 1990, NATURE, V347, P310, DOI 10.1038/347310a0; DURKIN AS, 1994, CYTOGENET CELL GENET, V65, P86, DOI 10.1159/000133606; GOCAYNE J, 1987, P NATL ACAD SCI USA, V84, P8296, DOI 10.1073/pnas.84.23.8296; KERLAVAGE A, 1993, 26TH P HAW INT C SYS, P585; KHAN AS, 1992, NAT GENET, V2, P180, DOI 10.1038/ng1192-180; MARTINGALLARDO A, 1992, NAT GENET, V1, P34, DOI 10.1038/ng0492-34; MASSUNG RF, 1993, NATURE, V366, P748, DOI 10.1038/366748a0; MCCOMBIE WR, 1992, NAT GENET, V1, P348, DOI 10.1038/ng0892-348; MCCOMBIE WR, 1992, NAT GENET, V1, P124, DOI 10.1038/ng0592-124; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; POLYMEROPOULOS MH, 1993, NAT GENET, V4, P381, DOI 10.1038/ng0893-381; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; WHITE O, 1993, NUCLEIC ACIDS RES, V21, P3829, DOI 10.1093/nar/21.16.3829	19	28	29	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 31	1994	368	6470					474	475		10.1038/368474a0	http://dx.doi.org/10.1038/368474a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	8133896				2022-12-28	WOS:A1994ND12000070
J	SALMELIN, R; HARI, R; LOUNASMAA, OV; SAMS, M				SALMELIN, R; HARI, R; LOUNASMAA, OV; SAMS, M			DYNAMICS OF BRAIN ACTIVATION DURING PICTURE NAMING	NATURE			English	Article								THE cerebral representation of language, deduced from observing patients with brain lesions and from stimulations and recordings performed during brain surgery1,2, has been further clarified by recent positron emission tomography3 and functional magnetic resonance imaging measurements4. We now expand this static view into the dynamics of cortical activation using the accurate spatiotemporal resolution of whole-head magnetoencephalography5. During picture naming, the conversion from visual to symbolic representation progressed bilaterally from the occipital visual cortex towards temporal and frontal lobes. Overt naming elicited the most widespread cortical activation. Some language-related sites also reacted, though more weakly or after a longer delay, during covert naming and even passive viewing.			SALMELIN, R (corresponding author), HELSINKI UNIV TECHNOL,LOW TEMP LAB,SF-02150 ESPOO,FINLAND.		Sams, Mikko E/G-7060-2012; Hari, Riitta K/J-1880-2012; Salmelin, Riitta H/I-7044-2012	Hari, Riitta K/0000-0002-3142-2703; Salmelin, Riitta H/0000-0003-2499-193X				AHONEN AI, 1992, 14TH P SAT S NEUR TE, P16; Geschwind N., 1967, CORTEX, V3, P97; HAMALAINEN M, 1993, REV MOD PHYS, V65, P413, DOI 10.1103/RevModPhys.65.413; HARI R, 1991, J CLIN NEUROPHYSIOL, V8, P157, DOI 10.1097/00004691-199104000-00004; HINKE RM, 1993, NEUROREPORT, V4, P675, DOI 10.1097/00001756-199306000-00018; Ojemann G. A., 1990, SEMINARS NEUROSCIENC, V2, P297; Penfield W., 1959, SPEECH BRAIN MECHANI; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; SALMELIN R, IN PRESS NEUROSCI	9	259	261	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 31	1994	368	6470					463	465		10.1038/368463a0	http://dx.doi.org/10.1038/368463a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	8133893				2022-12-28	WOS:A1994ND12000066
J	MASLOV, DA; AVILA, HA; LAKE, JA; SIMPSON, L				MASLOV, DA; AVILA, HA; LAKE, JA; SIMPSON, L			EVOLUTION OF RNA EDITING IN KINETOPLASTID PROTOZOA	NATURE			English	Article							TRYPANOSOMA-BRUCEI; GUIDE RNAS; CRITHIDIA-FASCICULATA; SUBUNIT; GENE; MITOCHONDRIA; TRANSCRIPT; DOMAINS; REGION; DNA	THE editing of RNA in trypanosomatid mitochondria involves the insertion and occasional deletion of uridine residues within coding regions of maxicircle messenger RNA transcripts. The extent to which the transcripts of homologous genes undergo editing differs in different species. In some, entire genes are edited (pan-editing), whereas in others, editing is limited to the 5' termini of editing domains (5' editing)(1,2). Here we investigate which type of editing is ancestral and which is derived, by analysing RNA editing in the different lineages, using a kinetoplastid phylogeny reconstructed from nuclear small subunit ribosomal RNA sequences. We conclude that the ancestral cryptogenes were pan-edited, and we hypothesize that the 5'-edited homologues were generated by several independent events from partially edited RNAs, in which case editing may be a more primitive mechanism than previously thought.	UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles								BARROIS M, 1981, P NATL ACAD SCI-BIOL, V78, P3323, DOI 10.1073/pnas.78.6.3323; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BRIONES MRS, 1992, MOL BIOCHEM PARASIT, V53, P121, DOI 10.1016/0166-6851(92)90014-B; CORELL RA, 1993, NUCLEIC ACIDS RES, V21, P4313, DOI 10.1093/nar/21.18.4313; COVELLO PS, 1993, TRENDS GENET, V9, P265, DOI 10.1016/0168-9525(93)90011-6; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; DERR LK, 1993, NATURE, V361, P170, DOI 10.1038/361170a0; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; Felsenstein J, 1991, PHYLIP PHYLOGENY INF; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; FRASCH ACC, 1980, BIOCHIM BIOPHYS ACTA, V607, P397, DOI 10.1016/0005-2787(80)90150-1; HERNANDEZ R, 1990, MOL BIOCHEM PARASIT, V41, P207, DOI 10.1016/0166-6851(90)90183-M; Hoare C, 1972, TRYPANOSOMES MAMMALS; KIVIC PA, 1984, ORIGINS LIFE EVOL B, V13, P269, DOI 10.1007/BF00927177; KOSLOWSKY DJ, 1992, MOL CELL BIOL, V12, P2043, DOI 10.1128/MCB.12.5.2043; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; LAKE JA, 1988, P NATL ACAD SCI USA, V85, P4779, DOI 10.1073/pnas.85.13.4779; LAKE JA, 1994, P NATL ACAD SCI USA, V91, P1455, DOI 10.1073/pnas.91.4.1455; LANDWEBER LF, 1993, NATURE, V363, P179, DOI 10.1038/363179a0; LANDWEBER LF, 1992, BIOSYSTEMS, V28, P41, DOI 10.1016/0303-2647(92)90006-K; LEE ST, 1993, MOL BIOCHEM PARASIT, V58, P187, DOI 10.1016/0166-6851(93)90041-U; LIM J, 1976, BIOL KINETIPLASTIDA, P267; MASLOV DA, 1992, CELL, V70, P459, DOI 10.1016/0092-8674(92)90170-H; OLSEN GJ, 1992, NUCLEIC ACIDS RES, V20, P2199, DOI 10.1093/nar/20.suppl.2199; OLSEN GJ, 1990, SEQUENCE EDITOR ANAL; PECKOVA H, 1990, PARASITOL RES, V76, P553, DOI 10.1007/BF00932559; SCHNARE MN, 1986, CURR GENET, V10, P405, DOI 10.1007/BF00418414; Simpson L, 1993, RNA EDITING ALTERATI, P53; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; STUART K, 1993, RNA EDITING ALTERATI, P25; STURM NR, 1992, CELL, V70, P469, DOI 10.1016/0092-8674(92)90171-8; STURM NR, 1991, NUCLEIC ACIDS RES, V19, P6277, DOI 10.1093/nar/19.22.6277; SWOFFORD DL, 1993, PAUP PHYLOGENETIC AN; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x; Vickerman K., 1976, P1	36	129	132	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					345	348		10.1038/368345a0	http://dx.doi.org/10.1038/368345a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127370				2022-12-28	WOS:A1994NB98500049
J	DONALDSON, SS				DONALDSON, SS			RADIATION PROCTITIS AFTER PROSTATE CARCINOMA-THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											DONALDSON, SS (corresponding author), STANFORD UNIV,MED CTR,STANFORD,CA 94305, USA.							DANGIO GJ, 1959, RADIOLOGY, V73, P175, DOI 10.1148/73.2.175; DONALDSON SS, 1974, ANN INTERN MED, V81, P407, DOI 10.7326/0003-4819-81-3-407; LAWTON CA, 1991, INT J RADIAT ONCOL, V21, P935, DOI 10.1016/0360-3016(91)90732-J	3	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					819	820		10.1001/jama.271.11.819	http://dx.doi.org/10.1001/jama.271.11.819			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ498	8114228				2022-12-28	WOS:A1994MZ49800011
J	BARON, JF; MUNDLER, O; BERTRAND, M; VICAUT, E; BARRE, E; GODET, G; SAMAMA, CM; CORIAT, P; KIEFFER, E; VIARS, P				BARON, JF; MUNDLER, O; BERTRAND, M; VICAUT, E; BARRE, E; GODET, G; SAMAMA, CM; CORIAT, P; KIEFFER, E; VIARS, P			DIPYRIDAMOLE-THALLIUM SCINTIGRAPHY AND GATED RADIONUCLIDE ANGIOGRAPHY TO ASSESS CARDIAC RISK BEFORE ABDOMINAL AORTIC-SURGERY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERIPHERAL VASCULAR-SURGERY; POSTOPERATIVE MYOCARDIAL-ISCHEMIA; CORONARY-ARTERY DISEASE; REGIONAL WALL MOTION; NONCARDIAC SURGERY; EJECTION FRACTION; SURGICAL-MANAGEMENT; MORTALITY; MORBIDITY; INDEX	Background. Because many patients with atherosclerotic disease of the abdominal aorta also have coronary artery disease, assessment of cardiac risk before abdominal aortic surgery has received much attention. Our prospective study was designed to identify predictors of cardiac risk in consecutive patients evaluated preoperatively with dipyridamole-thallium single-photon-emission computed tomography (SPECT) to assess myocardial perfusion and radionuclide angiography to measure left ventricular ejection fraction. Methods. Clinical and scintigraphic data were collected prospectively during hospitalization in 457 consecutive patients undergoing elective abdominal aortic surgery. Adverse cardiac outcomes were predicted with multivariate analyses. Results. Eighty-six patients (19 percent) had one or more of the following postoperative complications: prolonged myocardial ischemia (61 patients), myocardial infarction (22), congestive heart failure (20), and severe ventricular tachyarrhythmia (2). Twenty patients died postoperatively (4.4 percent), half of them from cardiac causes. Information about myocardial perfusion obtained from dipyridamole-thallium SPECT did not accurately predict adverse cardiac outcomes. The best correlates of cardiac complications were definite clinical evidence of coronary artery disease (odds ratio, 2.6; 95 percent confidence interval, 1.6 to 4.3) and age greater than 65 years (odds ratio, 2.3; 95 percent confidence interval, 1.4 to 3.6). Measurement of the ejection fraction was useful only in the prediction of left ventricular failure. Age greater than 65 years was the only predictor of death (odds ratio, 26.4; 95 percent confidence interval, 3.5 to 200.0). Conclusions. The presence of definite clinical evidence of coronary artery disease and older age were the most important preoperative predictors of an adverse cardiac outcome after abdominal aortic surgery; These results suggest that the routine use of dipyridamole-thallium SPECT and radionuclide angiography for screening before abdominal aortic surgery may not be justified.	HOP LA PITIE SALPETRIERE,DEPT ANESTHESIOL,PARIS,FRANCE; HOP LA PITIE SALPETRIERE,DEPT VASC SURG,PARIS,FRANCE; HOP LARIBOISIERE,NUCL MED LAB,PARIS,FRANCE; HOP FERNAND WIDAL,BIOPHYS LAB,PARIS,FRANCE; HOP FERNAND WIDAL,INSERM,U141,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite								ACINAPURA AJ, 1987, J CARDIOVASC SURG, V28, P552; BARON JF, 1991, ANESTHESIOLOGY, V75, P611, DOI 10.1097/00000542-199110000-00010; BERNARD M, 1989, CLIN CHEM ENZYM COMM, V2, P35; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; CARLINER NH, 1985, AM J CARDIOL, V56, P51, DOI 10.1016/0002-9149(85)90565-X; COOPERMAN M, 1978, SURGERY, V84, P505; CRAWFORD ES, 1981, SURGERY, V90, P1055; CUTLER BS, 1987, J VASC SURG, V5, P91; DEBAKEY ME, 1984, J VASC SURG, V1, P605, DOI 10.1067/mva.1984.avs0010605; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; DILSIZIAN V, 1990, NEW ENGL J MED, V323, P141, DOI 10.1056/NEJM199007193230301; DIXON WJ, 1985, BMDP STATISTICAL SOF; DRAPER N, 1967, REGRESSION ANAL; DRIPPS RD, 1961, JAMA-J AM MED ASSOC, V178, P261, DOI 10.1001/jama.1961.03040420001001; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; EAGLE KA, 1987, JAMA-J AM MED ASSOC, V257, P2185, DOI 10.1001/jama.257.16.2185; EISNER RL, 1986, J NUCL MED, V27, P1717; FISER WP, 1983, SURGERY, V94, P736; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GOULD KL, 1982, CIRCULATION, V66, P1141, DOI 10.1161/01.CIR.66.6.1141; Gouny P, 1989, Ann Vasc Surg, V3, P328, DOI 10.1016/S0890-5096(06)60155-6; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; HOLLENBERG M, 1992, JAMA-J AM MED ASSOC, V268, P205, DOI 10.1001/jama.268.2.205; JAMIESON WRE, 1982, CIRCULATION, V66, P92; KAZMERS A, 1988, J VASC SURG, V8, P307, DOI 10.1067/mva.1988.avs0080307; KAZMERS A, 1988, J VASC SURG, V8, P128, DOI 10.1067/mva.1988.avs0080128; LEPPO J, 1979, CIRCULATION, V59, P714, DOI 10.1161/01.CIR.59.4.714; LEPPO J, 1982, CIRCULATION, V66, P649, DOI 10.1161/01.CIR.66.3.649; LEPPO J, 1987, J AM COLL CARDIOL, V9, P269, DOI 10.1016/S0735-1097(87)80374-1; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1991, CIRCULATION, V84, P493, DOI 10.1161/01.CIR.84.2.493; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARSHALL RC, 1977, CIRCULATION, V56, P820, DOI 10.1161/01.CIR.56.5.820; PASTERNACK PF, 1984, J VASC SURG, V1, P320; RABY KE, 1992, JAMA-J AM MED ASSOC, V268, P222, DOI 10.1001/jama.268.2.222; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; THOMPSON JE, 1975, ANN SURG, V181, P654, DOI 10.1097/00000658-197505000-00020	37	250	254	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 10	1994	330	10					663	669		10.1056/NEJM199403103301002	http://dx.doi.org/10.1056/NEJM199403103301002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY575	8107716				2022-12-28	WOS:A1994MY57500002
J	CALAKOS, N; BENNETT, MK; PETERSON, KE; SCHELLER, RH				CALAKOS, N; BENNETT, MK; PETERSON, KE; SCHELLER, RH			PROTEIN-PROTEIN INTERACTIONS CONTRIBUTING TO THE SPECIFICITY OF INTRACELLULAR VESICULAR TRAFFICKING	SCIENCE			English	Article							BIOSPECIFIC INTERACTION ANALYSIS; INTEGRAL MEMBRANE-PROTEIN; SURFACE-PLASMON RESONANCE; SYNAPTIC VESICLES; RAT-BRAIN; PURIFICATION; EXPRESSION; TRANSPORT; COMPLEX; CLONING	Intracellular vesicles destined to fuse with the plasma membrane and secrete their contents must have a mechanism for specifically interacting with the appropriate target membrane. Such a mechanism is now suggested by the demonstration of specific interaction between vesicular proteins and plasma membrane proteins. The vesicle-associated membrane proteins (VAMPs) 1 and 2 specifically bind the acceptor membrane proteins syntaxin 1A and 4 but not syntaxin 2 or 3. The binding site is within amino acids 194 to 267 of syntaxin 1A, and the approximate equilibrium dissociation constant is 4.7 x 10(-6) molar. These data suggest a physical basis for the specificity of intracellular vesicular transport.			CALAKOS, N (corresponding author), STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305, USA.							AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BENNETT MK, 1993, J NEUROSCI, V13, P1701; BENNETT MK, 1991, SCIENCE, V252, P1162; CALAKOS N, UNPUB; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FERSHT A, 1985, ENZYME STRUCTURE MEC, P150; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HUTTNER WB, 1993, NATURE, V365, P104, DOI 10.1038/365104a0; INOUE A, 1992, J BIOL CHEM, V267, P10613; JAHN R, 1993, J NEUROCHEM, V61, P12, DOI 10.1111/j.1471-4159.1993.tb03533.x; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPRING J, 1993, TRENDS BIOCHEM SCI, V18, P124, DOI 10.1016/0968-0004(93)90018-I; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1990, J NEUROSCI, V10, P1380; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	38	376	379	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 25	1994	263	5150					1146	1149		10.1126/science.8108733	http://dx.doi.org/10.1126/science.8108733			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	8108733				2022-12-28	WOS:A1994MX75900035
J	OLSSON, R; LINDBERG, C; ANDERSEN, O				OLSSON, R; LINDBERG, C; ANDERSEN, O			CENTROLOBULAR LIVER-CELL NECROSIS, MYOCARDIAL-INFARCTION, AND HYPERAMYLASEMIA AFTER HIGH-DOSE CORTICOSTEROIDS	BRITISH MEDICAL JOURNAL			English	Note											OLSSON, R (corresponding author), SAHLGRENS UNIV HOSP,S-41345 GOTHENBURG,SWEDEN.							WALD JA, 1991, J ALLERGY CLIN IMMUN, V88, P277, DOI 10.1016/0091-6749(91)90340-T	1	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	1994	308	6926					454	454		10.1136/bmj.308.6926.454	http://dx.doi.org/10.1136/bmj.308.6926.454			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW976	8124178	Green Published			2022-12-28	WOS:A1994MW97600025
J	DEDHAR, S; RENNIE, PS; SHAGO, M; HAGESTEIJN, CYL; YANG, HL; FILMUS, J; HAWLEY, RG; BRUCHOVSKY, N; CHENG, H; MATUSIK, RJ; GIGUERE, V				DEDHAR, S; RENNIE, PS; SHAGO, M; HAGESTEIJN, CYL; YANG, HL; FILMUS, J; HAWLEY, RG; BRUCHOVSKY, N; CHENG, H; MATUSIK, RJ; GIGUERE, V			INHIBITION OF NUCLEAR HORMONE-RECEPTOR ACTIVITY BY CALRETICULIN	NATURE			English	Article							EMBRYONAL CARCINOMA-CELLS; RO/SS-A AUTOANTIGEN; GLUCOCORTICOID RECEPTOR; MOLECULAR-CLONING; BINDING PROTEIN; BETA-TUBULIN; EXPRESSION; INDUCTION; ANTIGEN; DOMAIN	WE have shown that a polypeptide of M(r) 60,000 (60K) that shares N-terminal homology with a calcium-binding protein, calreticulin, can bind to an amino-acid sequence motif, KXGFFKR, found in the cytoplasmic domains of all integrin alpha-subunits1. The homologous amino-acid sequence, KXFFKR (where X is either G, A or V), is also present in the DNA-binding domain of all known members of the steroid hormone receptor family2; amino acids in this sequence make direct contact with nucleotides in their DNA-responsive elements and are crucial for DNA binding3. Here we show that both the 60K protein (p60), purified on a KLGFFKR-Sepharose affinity matrix, and recombinant calreticulin can inhibit the binding of androgen receptor to its hormone-responsive DNA element in a KXFFKR-sequence-specific manner. Calreticulin can also inhibit androgen receptor and retinoic acid receptor transcriptional activities in vivo, as well as retinoic acid-induced neuronal differentiation. Our results indicate that calreticulin can act as an important modulator of the regulation of gene transcription by nuclear hormone receptors.	UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DEPT MED BIOPHYS,TORONTO M4N 3M5,ON,CANADA; BRITISH CANC CANC AGCY,DEPT CANC ENDOCRINOL,VANCOUVER V5Z 4E6,BC,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,DIV ENDOCRINE RES,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,DEPT MOLEC & MED GENET,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV MANITOBA,DEPT PHYSIOL,WINNIPEG R3E 0W3,MANITOBA,CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Manitoba	DEDHAR, S (corresponding author), UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DIV CANC RES,REICHMANN RES BLDG,2075 BAYVIEW AVE,TORONTO M4N 3M5,ON,CANADA.			Hawley, Robert/0000-0003-3512-5818; Giguere, Vincent/0000-0001-9567-3694; Dedhar, Shoukat/0000-0003-4355-1657; Matusik, Robert/0000-0003-2057-9892				ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; DEDHAR S, 1991, J BIOL CHEM, V266, P21846; DETHE H, 1990, NATURE, V343, P1771; FILMUS J, 1992, NUCLEIC ACIDS RES, V20, P2755, DOI 10.1093/nar/20.11.2755; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; FULLER PJ, 1991, FASEB J, V5, P3092, DOI 10.1096/fasebj.5.15.1743440; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LEE MK, 1990, CELL MOTIL CYTOSKEL, V17, P118, DOI 10.1002/cm.970170207; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARZLUFF WF, 1985, TRANSCRIPTION TRANSL, P89; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCCAULIFFE DP, 1990, J CLIN INVEST, V86, P332, DOI 10.1172/JCI114704; MCCAULIFFE DP, 1990, J CLIN INVEST, V85, P1379, DOI 10.1172/JCI114582; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295	25	329	335	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					480	483		10.1038/367480a0	http://dx.doi.org/10.1038/367480a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	8107809				2022-12-28	WOS:A1994MU67900060
J	STUART, GJ; SAKMANN, B				STUART, GJ; SAKMANN, B			ACTIVE PROPAGATION OF SOMATIC ACTION-POTENTIALS INTO NEOCORTICAL PYRAMIDAL CELL DENDRITES	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL-NEURONS; RAT HIPPOCAMPUS; VISUAL-CORTEX; THRESHOLDS; INITIATION; INDUCTION; CHANNELS; SYNAPSES; SLICES	THE dendrites of neurons in the mammalian central nervous system have been considered as electrically passive structures which funnel synaptic potentials to the soma and axon initial segment, the site of action potential initiation1,2.More recent studies, however, have shown that the dendrites of many neurons are not passive, but contain active conductances3,4. The role of these dendritic voltage-activated channels in the initiation of action potentials in neurons is largely unknown. To assess this directly, patch-clamp recordings were made from the dendrites of neocortical pyramidal cells in brain slices. Voltage-activated sodium currents were observed in dendritic outside-out patches, while action potentials could be evoked by depolarizing current pulses or by synaptic stimulation during dendritic whole-cell recordings. To determine the site of initiation of these action potentials, simultaneous whole-cell recordings were made from the soma and the apical dendrite or axon of the same cell. These experiments showed that action potentials are initiated first in the axon and then actively propagate back into the dendritic tree.			STUART, GJ (corresponding author), MAX PLANCK INST MED RES,ZELLPHYSIOL ABT,POSTFACH 103820,D-69028 HEIDELBERG,GERMANY.		stuart, greg j/F-7328-2011	stuart, greg/0000-0001-9395-2219				Adams Paul R., 1992, Current Biology, V2, P625, DOI 10.1016/0960-9822(92)90093-P; AMITAI Y, 1993, CEREB CORTEX, V3, P26, DOI 10.1093/cercor/3.1.26; ANDERSEN P, 1987, J PHYSIOL-LONDON, V383, P509; ANDERSEN P, 1966, EXP BRAIN RES, V2, P247; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; BENARDO LS, 1982, J NEUROSCI, V2, P1614; DESCHENES M, 1981, EXP BRAIN RES, V43, P304; DODT HU, 1990, BRAIN RES, V537, P333, DOI 10.1016/0006-8993(90)90380-T; Eccles, 2013, PHYSL SYNAPSES; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; HERRERAS O, 1990, J NEUROPHYSIOL, V64, P1429, DOI 10.1152/jn.1990.64.5.1429; HUGUENARD JR, 1989, P NATL ACAD SCI USA, V86, P2473, DOI 10.1073/pnas.86.7.2473; JAFFE D, 1990, J NEUROPHYSIOL, V64, P948, DOI 10.1152/jn.1990.64.3.948; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; kandel, 1977, NERVOUS SYSTEM, V1; KOMATSU Y, 1992, J NEUROPHYSIOL, V67, P401, DOI 10.1152/jn.1992.67.2.401; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; MIYAKAWA H, 1986, BRAIN RES, V399, P303, DOI 10.1016/0006-8993(86)91520-9; MOORE JW, 1983, J PHYSIOL-LONDON, V336, P301, DOI 10.1113/jphysiol.1983.sp014582; PEINADO A, 1993, NEURON, V10, P103, DOI 10.1016/0896-6273(93)90246-N; POCKBERGER H, 1991, BRAIN RES, V539, P181, DOI 10.1016/0006-8993(91)91619-C; Purpura DP., 1967, NEUROSCIENCES A STUD, P372; REGEHR W, 1993, NEURON, V11, P145, DOI 10.1016/0896-6273(93)90278-Y; Sakmann B, 1983, SINGLE CHANNEL RECOR, P37; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P272, DOI 10.1152/jn.1961.24.3.272; STRICHARTZ GR, 1973, J GEN PHYSIOL, V62, P37, DOI 10.1085/jgp.62.1.37; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; TURNER RW, 1989, J NEUROPHYSIOL, V62, P1375, DOI 10.1152/jn.1989.62.6.1375; TURNER RW, 1991, J NEUROSCI, V11, P2270; WONG RKS, 1979, P NATL ACAD SCI USA, V76, P986, DOI 10.1073/pnas.76.2.986	30	954	973	0	55	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 6	1994	367	6458					69	72		10.1038/367069a0	http://dx.doi.org/10.1038/367069a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	8107777				2022-12-28	WOS:A1994MP86500061
J	SATO, TT				SATO, TT			FRENZIED CALM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Sato, Thomas/0000-0001-6547-6403					0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1993	270	23					2794	2794		10.1001/jama.270.23.2794	http://dx.doi.org/10.1001/jama.270.23.2794			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK941	8133605				2022-12-28	WOS:A1993MK94100008
J	PAK, CYC; SAKHAEE, K; PIZIAK, V; PETERSON, RD; BRESLAU, NA; BOYD, P; POINDEXTER, JR; HERZOG, J; HEARDSAKHAEE, A; HAYNES, S; ADAMSHUET, B; REISCH, JS				PAK, CYC; SAKHAEE, K; PIZIAK, V; PETERSON, RD; BRESLAU, NA; BOYD, P; POINDEXTER, JR; HERZOG, J; HEARDSAKHAEE, A; HAYNES, S; ADAMSHUET, B; REISCH, JS			SLOW-RELEASE SODIUM-FLUORIDE IN THE MANAGEMENT OF POSTMENOPAUSAL OSTEOPOROSIS - A RANDOMIZED CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							CALCIUM CITRATE; BONE; CARBONATE; BIOAVAILABILITY	Objective: To test whether intermittent treatment with slow-release sodium fluoride and continuous calcium citrate supplementation inhibits vertebral fractures without causing fluoride complications. Design:A placebo-controlled, randomized trial. Setting: Outpatient setting of specialty clinics in Dallas and Temple, Texas. Interventions: Slow-release sodium fluoride (25 mg twice daily) in repeated 14-month cycles (12 months on treatment followed by 2 months off treatment) compared with placebo. Both groups took calcium citrate (400 mg calcium twice daily) continuously. P Patients: 110 patients with postmenopausal osteoporosis were randomly assigned to two groups. In the slow-release sodium fluoride group, 48 of 54 patients completed more than 1 cycle of treatment (mean, 2.44 cycles/patient), whereas 51 of 56 patients in the placebo group completed at least 1 cycle (mean, 2.14 cycles/patient) in this interim analysis. Measurements: Vertebral fracture rate and lumbar bone mineral content. Vertebral fractures were quantified from yearly radiographs. Bone mass was determined annually by densitometry. Results: In the sodium fluoride group, the mean L2 to L4 bone mineral content increased by 4% to 6% in each cycle and the mean femoral neck bone density increased by 4.1% and 2.1% during the first two cycles, but the radial bone density did not change, The placebo group showed no statistical change in bane mass at any site. Compared with the placebo group, the sodium fluoride group had, a lower individual new vertebral fracture rate (0.057/patient cycle compared with 0.204/ patient cycle, P = 0.017), a higher fracture-free rate (83.3% compared with 64.7%, P = 0.042), and a lower group fracture rate (0.085/patient cycle compared with 0.239/patient cycle, P = 0.006). The side-effect profile was similar for the two groups; no patient developed microfractures, hip fractures, or blood loss anemia. s Conclusions: Intermittent slow-release sodium fluoride plus continuous calcium citrate, administered for about 2.5 years, inhibits new vertebral fractures, increases the mean spinal bone mass without decreasing the radial shaft bone density, and is safe to use.	SCOTT & WHITE MEM HOSP & CLIN, TEMPLE, TX 76508 USA	Scott & White Medical Center	PAK, CYC (corresponding author), UNIV TEXAS, SOUTHWESTERN MED CTR, CTR MINERAL METAB & CLIN RES, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.				NCRR NIH HHS [M01-RR00633] Funding Source: Medline; NIAMS NIH HHS [R01AR-16061] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016061] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CONOVER W. J, 1980, PRACTICAL NONPARAMET; FACCINI JM, 1974, CALC TISS RES, V16, P45, DOI 10.1007/BF02008212; FARLEY JR, 1983, SCIENCE, V222, P330; GALLAGHER JC, 1992, J BONE MINER RES, V7, pS318; GELLER NL, 1987, BIOMETRICS, V43, P213, DOI 10.2307/2531962; HARVEY JA, 1990, J AM COLL NUTR, V9, P583; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KLEEREKOPER M, 1990, J BONE MINER RES S2, V5, pS140; KLEINBAUM DG, 1982, LIFETIME LEARNING PU, P283; NICAR MJ, 1985, J CLIN ENDOCR METAB, V61, P391, DOI 10.1210/jcem-61-2-391; Pak C Y, 1986, J Bone Miner Res, V1, P563; PAK CY, 1993, 4TH INT S OST, P122; PAK CYC, 1989, J CLIN ENDOCR METAB, V68, P150, DOI 10.1210/jcem-68-1-150; PAK CYC, 1975, LANCET, V2, P7; REED BY, 1993, J BONE MINER RES, V8, P19; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; SAKHAEE K, 1991, BONE MINER, V14, P131, DOI 10.1016/0169-6009(91)90090-M; TAVES DR, 1970, FED PROC, V29, P1185; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; ZERWEKH JE, 1991, J BONE MINER RES, V6, P239; ZERWEKH JE, 1992, BONE MINER, V18, P65, DOI 10.1016/0169-6009(92)90800-S	21	95	96	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1994	120	8					625	632		10.7326/0003-4819-120-8-199404150-00001	http://dx.doi.org/10.7326/0003-4819-120-8-199404150-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE850	8135445				2022-12-28	WOS:A1994NE85000001
J	ROSENCRANCE, G				ROSENCRANCE, G			HERPES-ZOSTER	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											ROSENCRANCE, G (corresponding author), W VIRGINIA UNIV,HLTH SCI CTR,CHARLESTON,WV 25304, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	1994	330	13					906	906						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC608	8114862				2022-12-28	WOS:A1994NC60800006
J	DAVIES, JF; ALMASSY, RJ; HOSTOMSKA, Z; FERRE, RA; HOSTOMSKY, Z				DAVIES, JF; ALMASSY, RJ; HOSTOMSKA, Z; FERRE, RA; HOSTOMSKY, Z			2.3-ANGSTROM CRYSTAL-STRUCTURE OF THE CATALYTIC DOMAIN OF DNA POLYMERASE-BETA	CELL			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; ESCHERICHIA-COLI; IDENTIFICATION; RESIDUES; REPAIR; REPLICATION; REFINEMENT; EXPRESSION; RESOLUTION; FRAGMENT	The crystal structure of the catalytic domain of rat DNA polymerase beta (pol beta) has been determined at 2.3 angstrom resolution and refined to an R factor of 0.22. The mixed alpha/beta protein has three subdomains arranged in an overall U shape reminiscent of other polymerase structures. The folding topology of pol beta, however, is unique. Two divalent metals bind near three aspartic acid residues implicated in the catalytic activity. In the presence of Mn2+ and dTTP, interpretable electron density is seen for two metals and the triphosphate, but not the deoxythymidine moiety. The principal interaction of the triphosphate moiety is with the bound divalent metals.			DAVIES, JF (corresponding author), AGOURON PHARMACEUT INC,3565 GEN ATOM COURT,SAN DIEGO,CA 92121, USA.							BAKER H, 1879, J CHEM SOC, V35, P7860; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARMICHAEL J, 1991, INT J RADIAT ONCOL, V20, P197, DOI 10.1016/0360-3016(91)90089-M; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; GILSON MK, 1987, J COMPUT CHEM, V9, P327; HAMMOND RA, 1990, BIOCHEMISTRY-US, V29, P286, DOI 10.1021/bi00453a039; HIROSE F, 1989, EXP CELL RES, V181, P169, DOI 10.1016/0014-4827(89)90191-2; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JAYARAM B, 1989, BIOPOLYMERS, V28, P975, DOI 10.1002/bip.360280506; JENKINS TM, 1992, SCIENCE, V258, P475, DOI 10.1126/science.1411545; JOHNSON CK, 1965, OAK RIDGE THERMAL EL; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; LINSKENS MHK, 1990, CELL, V62, P845, DOI 10.1016/0092-8674(90)90258-G; MATSUMOTO Y, 1989, MOL CELL BIOL, V9, P3750, DOI 10.1128/MCB.9.9.3750; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; NOWAK R, 1990, EXP CELL RES, V191, P51, DOI 10.1016/0014-4827(90)90034-8; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; READ RJ, 1990, ACTA CRYSTALLOGR A, V46, P900, DOI 10.1107/S0108767390005529; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; TANABE K, 1979, BIOCHEMISTRY-US, V18, P3401, DOI 10.1021/bi00582a029; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199	41	162	163	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1123	1133		10.1016/0092-8674(94)90388-3	http://dx.doi.org/10.1016/0092-8674(94)90388-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137427				2022-12-28	WOS:A1994ND24600017
J	VERSELIS, VK; GINTER, CS; BARGIELLO, TA				VERSELIS, VK; GINTER, CS; BARGIELLO, TA			OPPOSITE VOLTAGE GATING POLARITIES OF 2 CLOSELY-RELATED CONNEXINS	NATURE			English	Article							DEPENDENT JUNCTIONAL CONDUCTANCE; GAP JUNCTION; MOLECULAR-CLONING; XENOPUS OOCYTES; CELL CHANNELS; EXPRESSION; MEMBRANE	THE molecular mechanisms underlying the voltage dependence of intercellular channels formed by the family of vertebrate gap junction proteins (connexins) are unknown. All vertebrate gap junctions are sensitive to the voltage difference between the cells, defined as the transjunctional voltage, V-j (refs 1, 2), and most appear to gate by the separate actions of their component hemichannels(3-8). The heterotypic Cx32/Cx26 junction displays an unpredicted rectification that was reported to represent a novel V-j dependence created by hemichannel interactions, mediated in part by the first extracellular loop E1 (ref. 9). Here we show that aspects of the rectification of Cx32/Cx26 junctions are explained by opposite gating polarities of the component hemichannels, and that the opposite gating polarity of Cx32 and Cx26 results from a charge difference in a single amino-acid residue located at the second position in the N terminus. We also shea that charge substitutions at the border of the first transmembrane (M1) and E1 domains can reverse gating polarity and suppress the effects of a charge substitution at the N terminus. We conclude that the combined actions of residues at the N terminus and M1/E1 border form a charge complex that is probably an integral part of tbe connexin voltage sensor. A consistent correlation between charge substitution and gating polarity indicates that Cx26 and Cx32 voltage sensors are oppositely charged and that both move towards the cytoplasm upon hemichannel closure.			VERSELIS, VK (corresponding author), ALBERT EINSTEIN COLL MED,DEPT NEUROSCI,1300 MORRIS PK AVE,BRONX,NY 10461, USA.							BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; Bennett M V, 1992, Semin Cell Biol, V3, P29; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BENNETT MVL, 1988, GAP JUNCTIONS, P287; BRUZZONE R, 1993, MOL BIOL CELL, V4, P7, DOI 10.1091/mbc.4.1.7; DEVRIES SH, 1992, J PHYSIOL-LONDON, V445, P201, DOI 10.1113/jphysiol.1992.sp018920; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HARRIS AL, 1981, J GEN PHYSIOL, V77, P95, DOI 10.1085/jgp.77.1.95; HENNEMANN H, 1992, J CELL BIOL, V117, P1299, DOI 10.1083/jcb.117.6.1299; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; OBAID AL, 1983, J MEMBRANE BIOL, V73, P69, DOI 10.1007/BF01870342; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; RUBIN JB, 1992, P NATL ACAD SCI USA, V89, P3820, DOI 10.1073/pnas.89.9.3820; RUBIN JB, 1992, THESIS A EINSTEIN CO; RUBIN JB, 1992, BIOPHYS J, V62, P197; SILVER MR, 1990, J GEN PHYSIOL, V96, P109, DOI 10.1085/jgp.96.1.109; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; SUCHYNA TM, 1993, NATURE, V365, P847, DOI 10.1038/365847a0; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; THOMAS L, 1993, P NATL ACAD SCI USA, V90, P5446, DOI 10.1073/pnas.90.12.5446; VERSELIS VK, 1991, BIOPHYS J, V59, P114, DOI 10.1016/S0006-3495(91)82204-4; WERNER R, 1991, P ROY SOC B-BIOL SCI, V243, P5, DOI 10.1098/rspb.1991.0002; WILDERS R, 1992, BIOPHYS J, V63, P942, DOI 10.1016/S0006-3495(92)81664-8	27	298	304	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					348	351		10.1038/368348a0	http://dx.doi.org/10.1038/368348a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127371				2022-12-28	WOS:A1994NB98500050
J	XIE, X; HARRISON, DH; SCHLICHTLING, I; SWEET, RM; KALABOKIS, VN; SZENTGYORGYI, AG; COHEN, C				XIE, X; HARRISON, DH; SCHLICHTLING, I; SWEET, RM; KALABOKIS, VN; SZENTGYORGYI, AG; COHEN, C			STRUCTURE OF THE REGULATORY DOMAIN OF SCALLOP MYOSIN AT 2.8 ANGSTROM RESOLUTION	NATURE			English	Article							LIGHT-CHAINS; CALCIUM-BINDING; PEPTIDE COMPLEX; CALMODULIN; PROTEIN; DISSOCIATION; ACTIN	The regulatory domain of scallop myosin is a three-chain protein complex that switches on this major in response to Ca2+ binding. This domain has been crystallized and the structure solved to 2.8 Angstrom resolution. Side-chain interactions link the two light chains in tandem to adjacent segments of the heavy chain bearing the IQ-sequence motif. The Ca2+-binding site is a novel EF-hand motif on the essential light chain and is stabilized by linkages involving the heavy chain and both light chains, accounting for the requirement of all three chains for Ca2+ binding and regulation in the intact myosin molecule.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; MAX PLANCK INST MED RES,W-6900 HEIDELBERG,GERMANY; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254	Brandeis University; Max Planck Society; United States Department of Energy (DOE); Brookhaven National Laboratory; Brandeis University			Schlichting, Ilme/I-1339-2013					BENNETT AJ, 1986, BIOCHEM J, V233, P173, DOI 10.1042/bj2330173; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BRUNGER AT, 1992, X PLOR V 3 0 MANUAL; CHANTLER PD, 1980, J MOL BIOL, V138, P473, DOI 10.1016/S0022-2836(80)80013-1; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; DASILVA ACR, 1991, TRENDS BIOCHEM SCI, V16, P53, DOI 10.1016/0968-0004(91)90024-P; FROMHERZ S, 1993, BIOPHYS J A, V64, P7; FUNK MO, 1979, INT J PEPT PROT RES, V13, P296; HARDWICKE PMD, 1983, NATURE, V301, P478, DOI 10.1038/301478a0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KENDRICK-JONES J, 1970, Journal of Molecular Biology, V54, P313, DOI 10.1016/0022-2836(70)90432-8; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KWON H, 1990, P NATL ACAD SCI USA, V87, P4771, DOI 10.1073/pnas.87.12.4771; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROWE T, 1992, EMBO J, V11, P4715, DOI 10.1002/j.1460-2075.1992.tb05576.x; SEKHARUDU CY, 1993, PROTEIN SCI, V2, P620; SELLERS JR, 1980, J MOL BIOL, V144, P223, DOI 10.1016/0022-2836(80)90088-1; STAFFORD WF, 1979, BIOCHEMISTRY-US, V24, P5273; Strynadka NCJ, 1991, CURR OPIN STRUC BIOL, V1, P905, DOI 10.1016/0959-440X(91)90085-8; SZENTGYO.AG, 1973, J MOL BIOL, V74, P179, DOI 10.1016/0022-2836(73)90106-X; SZENTGYORGYI AG, 1994, MYOLOGY, V2, P506; SZENTKIRALYI EM, 1984, J MUSCLE RES CELL M, V5, P147, DOI 10.1007/BF00712153; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WELLS C, 1985, NATURE, V313, P696, DOI 10.1038/313696a0; WELLS JA, 1982, METHOD ENZYMOL, V85, P93; WILLIAMANN T, 1981, BIOCHEMISTRY-US, V20, P1176	37	285	294	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					306	312		10.1038/368306a0	http://dx.doi.org/10.1038/368306a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127365				2022-12-28	WOS:A1994NB98500037
J	AIKEN, C; KONNER, J; LANDAU, NR; LENBURG, ME; TRONO, D				AIKEN, C; KONNER, J; LANDAU, NR; LENBURG, ME; TRONO, D			NEF INDUCES CD4 ENDOCYTOSIS - REQUIREMENT FOR A CRITICAL DILEUCINE MOTIF IN THE MEMBRANE-PROXIMAL CD4 CYTOPLASMIC DOMAIN	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; EPIDERMAL GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; TYPE-1 GLYCOPROTEIN PRECURSOR; HUMAN LYMPHOCYTES-T; SIGNAL TRANSDUCTION; HTLV-III; ENDOPLASMIC-RETICULUM; ENVELOPE GLYCOPROTEIN; MUTATIONAL ANALYSIS	CD4 is crucial for antigen-driven helper T cell signaling and is used as receptor by the human immunodeficiency virus (HIV). The HIV early protein Nef causes a loss of CD4 from cell surfaces through a previously undefined posttranscriptional mechanism. Here, we demonstrate that Nef acts by inducing CD4 endocytosis, resulting in its degradation in lysosomes. CD4 down-regulation is strongly enhanced by the association of Nef with cell membranes through myristoylation. The study of chimeric molecules reveals that 20 membrane-proximal residues of the CD4 cytoplasmic domain are sufficient to confer Nef sensitivity. Within this region, a dileucine motif, reminiscent of an endocytosis and lysosamal targeting signal found in the CD3 gamma and delta chains, is crucial for CD4 response to Nef.	SALK INST BIOL STUDIES, INFECT DIS LAB, LA JOLLA, CA 92037 USA; AARON DIAMOND AIDS RES CTR, NEW YORK, NY 10016 USA; NYU, SCH MED, NEW YORK, NY 10016 USA	Salk Institute; New York University			Lenburg, Marc/B-8027-2008; Aiken, Christopher/Y-9252-2019	Lenburg, Marc/0000-0002-5760-4708; Konner, Jason/0000-0002-0720-2719				ACRES BR, 1986, J BIOL CHEM, V34, P16210; ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; AHMAD N, 1988, SCIENCE, V241, P1481, DOI 10.1126/science.3262235; ALLAN JS, 1985, SCIENCE, V230, P810, DOI 10.1126/science.2997921; Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; ANDERSON S, 1993, J VIROL, V67, P4923, DOI 10.1128/JVI.67.8.4923-4931.1993; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAENZIGER JW, 1991, NEW BIOL, V3, P1233; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BENSON RE, 1993, J EXP MED, V177, P1561, DOI 10.1084/jem.177.6.1561; BEYERS AD, 1991, EMBO J, V10, P377, DOI 10.1002/j.1460-2075.1991.tb07959.x; BLUE ML, 1987, J IMMUNOL, V139, P3949; BLUE ML, 1989, J IMMUNOL, V142, P374; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COCHET C, 1988, J BIOL CHEM, V263, P3290; CRISE B, 1990, J VIROL, V64, P5585, DOI 10.1128/JVI.64.11.5585-5593.1990; CRISE B, 1992, J VIROL, V66, P2296, DOI 10.1128/JVI.66.4.2296-2301.1992; CULLEN BR, 1991, J VIROL, V65, P1053, DOI 10.1128/JVI.65.3.1053-1056.1991; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DAS M, 1978, P NATL ACAD SCI USA, V75, P2644, DOI 10.1073/pnas.75.6.2644; DERONDE A, 1992, VIROLOGY, V188, P391, DOI 10.1016/0042-6822(92)90772-H; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; FANGER BO, 1989, FASEB J, V3, P71, DOI 10.1096/fasebj.3.1.2783412; FRANCHINI G, 1986, VIROLOGY, V155, P593, DOI 10.1016/0042-6822(86)90219-9; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GARCIA JV, 1993, J VIROL, V67, P1511, DOI 10.1128/JVI.67.3.1511-1516.1993; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HAUGHN L, 1992, NATURE, V358, P328, DOI 10.1038/358328a0; HOXIE JA, 1988, J IMMUNOL, V140, P786; HOXIE JA, 1986, J IMMUNOL, V137, P1194; JABBAR MA, 1990, J VIROL, V64, P6297, DOI 10.1128/JVI.64.12.6297-6304.1990; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIM SY, 1989, P NATL ACAD SCI USA, V86, P9544, DOI 10.1073/pnas.86.23.9544; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KLOTMAN ME, 1991, P NATL ACAD SCI USA, V88, P5011, DOI 10.1073/pnas.88.11.5011; LENBURG ME, 1993, J VIROL, V67, P7238, DOI 10.1128/JVI.67.12.7238-7245.1993; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LIN CR, 1984, SCIENCE, V224, P843, DOI 10.1126/science.6326261; LUCIW PA, 1987, P NATL ACAD SCI USA, V84, P1434, DOI 10.1073/pnas.84.5.1434; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MARIANI R, 1993, P NATL ACAD SCI USA, V90, P5549, DOI 10.1073/pnas.90.12.5549; Miceli M C, 1991, Semin Immunol, V3, P133; NIEDERMAN TMJ, 1989, P NATL ACAD SCI USA, V86, P1128, DOI 10.1073/pnas.86.4.1128; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; PELCHENMATTHEWS A, 1992, J CELL BIOL, V117, P279, DOI 10.1083/jcb.117.2.279; PELCHENMATTHEWS A, 1991, J EXP MED, V173, P575, DOI 10.1084/jem.173.3.575; PELCHENMATTHEWS A, 1993, J EXP MED, V178, P1209, DOI 10.1084/jem.178.4.1209; PELCHENMATTHEWS A, 1989, EMBO J, V8, P3641, DOI 10.1002/j.1460-2075.1989.tb08538.x; POMERANTZ RJ, 1992, J VIROL, V66, P1809, DOI 10.1128/JVI.66.3.1809-1813.1992; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; ROBEY E, 1990, CELL, V60, P697, DOI 10.1016/0092-8674(90)90082-P; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUEGG CL, 1992, J BIOL CHEM, V267, P18837; SCHLESSINGER J, 1978, P NATL ACAD SCI USA, V75, P2659, DOI 10.1073/pnas.75.6.2659; SCHWARTZ O, 1993, J VIROL, V67, P3274, DOI 10.1128/JVI.67.6.3274-3280.1993; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SLECKMAN BP, 1992, P NATL ACAD SCI USA, V89, P7566, DOI 10.1073/pnas.89.16.7566; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TERWILLIGER EF, 1991, P NATL ACAD SCI USA, V88, P10971, DOI 10.1073/pnas.88.23.10971; TRONO D, 1990, EMBO J, V9, P4155, DOI 10.1002/j.1460-2075.1990.tb07638.x; TROWBRIDGE IS, 1993, IN PRESS ANN REV CEL; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VINCENT MJ, 1993, J VIROL, V67, P5538, DOI 10.1128/JVI.67.9.5538-5549.1993; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WEYAND CM, 1987, J IMMUNOL, V138, P1351; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992; ZAZOPOULOS E, 1992, P NATL ACAD SCI USA, V89, P6634, DOI 10.1073/pnas.89.14.6634; Zuniga-Pflucker J C, 1991, Semin Immunol, V3, P167	83	622	636	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 11	1994	76	5					853	864		10.1016/0092-8674(94)90360-3	http://dx.doi.org/10.1016/0092-8674(94)90360-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124721				2022-12-28	WOS:A1994NA89000011
J	TORNALETTI, S; PFEIFER, GP				TORNALETTI, S; PFEIFER, GP			SLOW REPAIR OF PYRIMIDINE DIMERS AT P53 MUTATION HOTSPOTS IN SKIN-CANCER	SCIENCE			English	Article							TUMOR SUPPRESSOR GENE; LIGATION MEDIATED PCR; UV-INDUCED MUTATIONS; ESCHERICHIA-COLI; TRANSCRIBED STRAND; CELL CARCINOMAS; MAMMALIAN-CELLS; DHFR GENE; PHOTOPRODUCTS; MUTAGENESIS	Ultraviolet light has been linked with the development of human skin cancers. Such cancers often exhibit mutations in the p53 tumor suppressor gene. Ligation-mediated polymerase chain reaction was used to analyze at nucleotide resolution the repair of cyclobutane pyrimidine dimers along the p53 gene in ultraviolet-irradiated human fibroblasts. Repair rates at individual nucleotides were highly variable and sequence-dependent. Slow repair was seen at seven of eight positions frequently mutated in skin cancer, suggesting that repair efficiency may strongly contribute to the mutation spectrum in a cancer-associated gene.	BECKMAN RES INST CITY HOPE,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NIEHS NIH HHS [ES06070] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES006070, R01ES006070] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMSTRONG JD, 1990, P NATL ACAD SCI USA, V87, P9005, DOI 10.1073/pnas.87.22.9005; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; BRASH E, 1991, P NATL ACAD SCI USA, V88, P1014; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; EVANS MK, 1993, CANCER RES, V53, P5377; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; HSIA HC, 1989, J MOL BIOL, V205, P103, DOI 10.1016/0022-2836(89)90368-9; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGREGOR WG, 1991, MOL CELL BIOL, V11, P1927, DOI 10.1128/MCB.11.4.1927; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MILLER JH, 1985, J MOL BIOL, V182, P45, DOI 10.1016/0022-2836(85)90026-9; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MOLES JP, 1993, ONCOGENE, V8, P583; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PFEIFER GP, 1992, MOL CELL BIOL, V12, P1798, DOI 10.1128/MCB.12.4.1798; PFEIFER GP, 1993, METHOD ENZYMOL, V225, P567; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; RADY P, 1992, CANCER RES, V52, P3804; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; THOMAS DC, 1988, P NATL ACAD SCI USA, V85, P3723, DOI 10.1073/pnas.85.11.3723; TORNALETTI S, 1993, ONCOGENE, V8, P2051; TORNALETTI S, UNPUB; URBACH F, 1989, PHOTOCHEM PHOTOBIOL, V50, P507, DOI 10.1111/j.1751-1097.1989.tb05556.x; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	30	268	272	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1436	1438		10.1126/science.8128225	http://dx.doi.org/10.1126/science.8128225			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128225				2022-12-28	WOS:A1994MZ92700031
J	GILSON, MK; STRAATSMA, TP; MCCAMMON, JA; RIPOLL, DR; FAERMAN, CH; AXELSEN, PH; SILMAN, I; SUSSMAN, JL				GILSON, MK; STRAATSMA, TP; MCCAMMON, JA; RIPOLL, DR; FAERMAN, CH; AXELSEN, PH; SILMAN, I; SUSSMAN, JL			OPEN BACK DOOR IN A MOLECULAR-DYNAMICS SIMULATION OF ACETYLCHOLINESTERASE	SCIENCE			English	Article							TORPEDO-CALIFORNICA; PROTEIN; PROGRAM	The enzyme acetylcholinesterase generates a strong electrostatic field that can attract the cationic substrate acetylcholine to the active site. However, the long and narrow active site gorge seems inconsistent with the enzyme's high catalytic rate. A molecular dynamics simulation of acetylcholinesterase in water reveals the transient opening of a short channel, large enough to pass a water molecule, through a thin wall of the active site near tryptophan-84. This simulation suggests that substrate, products, or solvent could move through this ''back door,'' in addition to the entrance revealed by the crystallographic structure. Electrostatic calculations show a strong field at the back door, oriented to attract the substrate and the reaction product choline and to repel the other reaction product, acetate. Analysis of the open back door conformation suggests a mutation that could seal the back door and thus test the hypothesis that thermal motion of this enzyme may open multiple routes of access to its active site.	CORNELL UNIV,CORNELL THEORY CTR,ITHACA,NY 14853; CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT STRUCT BIOL,IL-76100 REHOVOT,ISRAEL	Cornell University; Cornell University; University of Pennsylvania; Weizmann Institute of Science; Weizmann Institute of Science	GILSON, MK (corresponding author), UNIV HOUSTON,DEPT CHEM,HOUSTON,TX 77204, USA.		McCammon, J. Andrew/AAG-1832-2021	Sussman, Joel/0000-0003-0306-3878				AXELSEN PH, IN PRESS PROTEIN SCI; BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; CYGLER M, 1993, PROTEIN SCI, V2, P366; DAVIS ME, 1991, COMPUT PHYS COMMUN, V62, P187, DOI 10.1016/0010-4655(91)90094-2; DEMCHENKO AP, 1986, ESSAYS BIOCHEM, V22, P120; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; KLAPPER I, 1986, Proteins Structure Function and Genetics, V1, P47, DOI 10.1002/prot.340010109; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; NICHOLLS A, GRASP VERS 1 04; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; RIPOLL DR, 1993, P NATL ACAD SCI USA, V90, P5128, DOI 10.1073/pnas.90.11.5128; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; STRAATSMA TP, 1990, J COMPUT CHEM, V11, P943, DOI 10.1002/jcc.540110806; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAN RC, 1993, BIOCHEMISTRY-US, V32, P401, DOI 10.1021/bi00053a003; van Gunsteren W. F., 1987, GRONINGEN MOL SIMULA; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; VIGNY M, 1978, EUR J BIOCHEM, V85, P317, DOI 10.1111/j.1432-1033.1978.tb12241.x; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; WEISE C, 1990, EMBO J, V9, P3885, DOI 10.1002/j.1460-2075.1990.tb07607.x	23	241	244	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 4	1994	263	5151					1276	1278		10.1126/science.8122110	http://dx.doi.org/10.1126/science.8122110			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	8122110				2022-12-28	WOS:A1994MY57000035
J	ARCHER, J; SOLOMON, F				ARCHER, J; SOLOMON, F			DECONSTRUCTING THE MICROTUBULE-ORGANIZING CENTER	CELL			English	Review							GAMMA-TUBULIN; CYTOPLASMIC MICROTUBULES; ASPERGILLUS-NIDULANS; CENTROSOME; COMPONENT; CELLS		MIT,CTR CANC RES,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	ARCHER, J (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.							BRINKLEY BR, 1981, J CELL BIOL, V90, P554, DOI 10.1083/jcb.90.3.554; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; FELIX MA, 1994, J CELL BIOL, V124, P19, DOI 10.1083/jcb.124.1.19; HORIO T, 1991, J CELL SCI, V99, P693; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; Kalt Astrid, 1993, Trends in Cell Biology, V3, P118, DOI 10.1016/0962-8924(93)90174-Y; KIRSCHNER MW, 1980, J CELL BIOL, V86, P338; MELKI R, 1993, J CELL BIOL, V122, P1301, DOI 10.1083/jcb.122.6.1301; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; OSBORN M, 1976, P NATL ACAD SCI USA, V73, P867, DOI 10.1073/pnas.73.3.867; PICKETTHEAPS J, 1975, ANN NY ACAD SCI, V2553, P352; RAFF JW, 1993, J CELL BIOL, V121, P823, DOI 10.1083/jcb.121.4.823; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	17	42	45	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 25	1994	76	4					589	591		10.1016/0092-8674(94)90496-0	http://dx.doi.org/10.1016/0092-8674(94)90496-0			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124702				2022-12-28	WOS:A1994MZ28500001
J	BARONDES, SH				BARONDES, SH			THINKING ABOUT PROZAC	SCIENCE			English	Editorial Material											BARONDES, SH (corresponding author), UNIV CALIF SAN FRANCISCO,CTR NEUROBIOL & PSYCHIAT,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143, USA.							BARONDES SH, 1993, MOL MENTAL ILLNESS, P3; Deniker P., 1970, DISCOVERIES BIOL PSY, P155; KLEIN DF, 1964, PSYCHOPHARMACOLOGIA, V5, P397, DOI 10.1007/BF02193476; Kramer P. D., 1989, MOMENTS ENGAGEMENT I; Kramer Peter D., 1993, LISTENING PROZAC PSY; Kuhn R, 1970, DISCOVERIES BIOL PSY, P205; MONSMA FJ, 1993, MOL PHARMACOL, V43, P320; Rapoport J.L., 1989, BOY WHO COULDNT STOP; SHEN Y, 1993, J BIOL CHEM, V268, P18200; STARK P, 1985, J CLIN PSYCHIAT, V46, P58; Tecott L H, 1993, Curr Opin Neurobiol, V3, P310, DOI 10.1016/0959-4388(93)90122-F	11	23	23	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 25	1994	263	5150					1102	1103		10.1126/science.8108727	http://dx.doi.org/10.1126/science.8108727			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	8108727				2022-12-28	WOS:A1994MX75900020
J	MARK, DB; SHAW, LK; DELONG, ER; CALIFF, RM; PRYOR, DB				MARK, DB; SHAW, LK; DELONG, ER; CALIFF, RM; PRYOR, DB			ABSENCE OF SEX BIAS IN THE REFERRAL OF PATIENTS FOR CARDIAC-CATHETERIZATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; ACUTE MYOCARDIAL-INFARCTION; GOOD CLINICAL JUDGMENT; GENDER DIFFERENCES; BYPASS-SURGERY; MANAGEMENT; LIKELIHOOD; WOMEN	Background. It has been suggested that women with clinical evidence of coronary artery disease are less often referred for cardiac catheterization than are men. To determine whether there is sex-related bias in referral for cardiac catheterization, we prospectively studied a cohort of 410 symptomatic outpatients (280 men and 130 women) who were being evaluated with exercise testing for possible coronary artery disease. Methods. Before the patients underwent exercise testing, 15 cardiologists from an academic medical center were asked to predict the probability that the patients they saw in the cardiology clinic would have angiographic evidence of any obstructive coronary disease (stenosis of 75 percent or more); the probability of severe coronary disease (three-vessel or left main coronary artery disease); the probability of left main coronary artery disease; and the probability of survival one, three, and five years after the evaluation. Similar predictions were generated by previously validated statistical models with use of data collected before exercise testing from the history, physical examination, and 12-lead electrocardiography with the patient at rest. Results. Overall, women were referred for cardiac catheterization significantly less often than men (18 percent vs. 27 percent, P = 0.03). As compared with men, women had a significantly lower pretest probability of coronary disease (as estimated by their physicians) and a lower rate of positive exercise-test results. After accounting for differences in these two factors, sex was not an independent predictor of referral for catheterization. Comparing physicians' estimates of outcome with those generated by the statistical models revealed no evidence that the physicians were underestimating the risk of coronary disease in women. Furthermore, physicians' predictions did not underestimate the probability of any obstructive coronary disease in men and women who subsequently underwent catheterization. Conclusions. Academic cardiologists made appropriately lower pretest predictions of categories of disease in women with possible coronary artery disease than in men, and these assessments, along with women's lower rate of positive exercise tests, rather than bias based on sex, accounted for the lower rate of catheterization among women.	DUKE UNIV,MED CTR,DEPT COMMUNITY & FAMILY MED,DIV BIOMETRY,DURHAM,NC 27710	Duke University	MARK, DB (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DIV CARDIOL,BOX 3485,DURHAM,NC 27710, USA.			Mark, Daniel/0000-0001-6340-8087	AHRQ HHS [HS-05635, HS-06503] Funding Source: Medline; NHLBI NIH HHS [HL-36587] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS005635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036587] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; CHAITMAN BR, 1981, CIRCULATION, V64, P360, DOI 10.1161/01.CIR.64.2.360; JOHNSON SH, 1991, AM J CARDIOL, V67, P919, DOI 10.1016/0002-9149(91)90161-D; KANNEL WB, 1972, AM J CARDIOL, V29, P154, DOI 10.1016/0002-9149(72)90624-8; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; LASKEY WK, 1992, ANN INTERN MED, V116, P869, DOI 10.7326/0003-4819-116-10-869; MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; MARK DB, 1986, TXB SURGERY BIOL BAS, V2, P2135; MARK DB, 1993, CARDIOVASCULAR HLTH, P81; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; PRYOR DB, 1991, AM J MED, V90, P553; PRYOR DB, 1983, AM J MED, V75, P771, DOI 10.1016/0002-9343(83)90406-0; PRYOR DB, 1991, STAT MED, V10, P617, DOI 10.1002/sim.4780100412; PRYOR DB, 1993, ANN INTERN MED, V118, P81, DOI 10.7326/0003-4819-118-2-199301150-00001; PRYOR DB, 1989, CIRCULATION S2, V80, P409; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530	20	150	149	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 21	1994	330	16					1101	1106		10.1056/NEJM199404213301601	http://dx.doi.org/10.1056/NEJM199404213301601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF699	8133852				2022-12-28	WOS:A1994NF69900001
J	ALBERINI, CM; GHIRARDI, M; METZ, R; KANDEL, ER				ALBERINI, CM; GHIRARDI, M; METZ, R; KANDEL, ER			C/EBP IS AN IMMEDIATE-EARLY GENE REQUIRED FOR THE CONSOLIDATION OF LONG-TERM FACILITATION IN APLYSIA	CELL			English	Article							ENHANCER-BINDING-PROTEIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; SPONTANEOUS TRANSMITTER RELEASE; SENSORY NEURONS; C-FOS; HETEROSYNAPTIC FACILITATION; BEHAVIORAL SENSITIZATION; STRUCTURAL-CHANGES; GILL-WITHDRAWAL; TRANSCRIPTIONAL REGULATION	The consolidation of long-term memory requires protein and mRNA synthesis. A similar requirement has been demonstrated for learning-related synaptic plasticity in the gill-withdrawal reflex of Aplysia. The monosynaptic component of this reflex can be reconstituted in vitro, where it undergoes both short- and long-term increases in synaptic strength in response to serotonin (5-HT), a neurotransmitter released during behavioral sensitization, a simple form of learning. As with sensitization, the long-term synaptic modification is characterized by a brief consolidation period during which gene expression is required. We f ind that during this phase, the transcription factor Aplysia CCAAT enhancer-binding protein (ApC/EBP) is induced rapidly by 5-HT and by cAMP, even in the presence of protein synthesis inhibitors. Blocking the function of ApC/EBP blocks long-term facilitation selectively without affecting the short-term process. These data indicate that cAMP-inducible immediate-early genes have an essential role in the consolidation of stable long-term synaptic plasticity in Aplysia.	BRISTOL MYERS SQUIBB,DEPT MOLEC BIOL,PRINCETON,NJ 08543	Bristol-Myers Squibb	ALBERINI, CM (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032, USA.		ghirardi, mirella/AEQ-0420-2022					AGRANOFF BW, 1972, CHEM MOOD MOTIVATION; ASHBURNER M, 1990, CELL, V61, P1, DOI 10.1016/0092-8674(90)90205-S; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BAILEY CH, 1992, NEURON, V9, P749, DOI 10.1016/0896-6273(92)90037-E; BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; BAILEY CH, 1989, J NEUROSCI, V9, P1774; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BARONDES SH, 1975, SHORT TERM MEMORY, P379; BARZILAI A, 1989, NEURON, V2, P1577, DOI 10.1016/0896-6273(89)90046-9; BERGOLD PJ, 1990, P NATL ACAD SCI USA, V87, P3788, DOI 10.1073/pnas.87.10.3788; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BYRNE JH, 1993, ADV SEC MESS PHOSPH, V27, P47; BYRNE JH, 1987, PHYSIOL REV, V67, P329, DOI 10.1152/physrev.1987.67.2.329; CAO Z, 1991, GENE DEV, V5, P1539; CAREW TJ, 1986, ANNU REV NEUROSCI, V9, P435, DOI 10.1146/annurev.ne.09.030186.002251; CASTELLUCCI V, 1976, SCIENCE, V194, P1176, DOI 10.1126/science.11560; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK GA, 1984, P NATL ACAD SCI-BIOL, V81, P2577, DOI 10.1073/pnas.81.8.2577; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; CROW T, 1990, P NATL ACAD SCI USA, V87, P4490, DOI 10.1073/pnas.87.12.4490; DALE N, 1993, P NATL ACAD SCI USA, V90, P7163, DOI 10.1073/pnas.90.15.7163; DALE N, 1990, J PHYSIOL-LONDON, V421, P203, DOI 10.1113/jphysiol.1990.sp017941; DALE N, 1988, SCIENCE, V239, P282, DOI 10.1126/science.2892269; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DRAGUNOW M, 1989, NEUROSCI BIOBEHAV R, V13, P301, DOI 10.1016/S0149-7634(89)80066-1; DUNCAN CP, 1949, J COMP PHYSIOL PSYCH, V42, P32, DOI 10.1037/h0058173; FLEXNER J, 1983, SCIENCE, V141, P57; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GLANZMAN DL, 1989, J NEUROSCI, V9, P4200; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; Hawkins RD, 1987, HDB PHYSL 1, VV, P25; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOCHNER B, 1992, P NATL ACAD SCI USA, V89, P11476, DOI 10.1073/pnas.89.23.11476; HU YH, 1993, NEURON, V10, P921, DOI 10.1016/0896-6273(93)90207-8; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KENNEDY TE, 1992, NEURON, V9, P1013, DOI 10.1016/0896-6273(92)90062-I; KLEIN M, 1980, P NATL ACAD SCI-BIOL, V77, P6912, DOI 10.1073/pnas.77.11.6912; KUHL D, 1992, J CELL BIOL, V119, P1069, DOI 10.1083/jcb.119.5.1069; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; LIU JS, 1991, J BIOL CHEM, V266, P19095; LO DC, 1993, P NATL ACAD SCI USA, V90, P7230, DOI 10.1073/pnas.90.15.7230; MCGAUGH JL, 1989, ANNU REV NEUROSCI, V12, P255, DOI 10.1146/annurev.neuro.12.1.255; METZ R, 1991, ONCOGENE, V6, P2165; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MULLER GE, 1990, Z PSYCHOL, V1, P1; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NATSUKA S, 1992, BLOOD, V79, P460; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; RAYPORT SG, 1986, J NEUROSCI, V6, P759; Russell WR, 1971, TRAUMATIC AMNESIAS; RUSSELL WR, 1946, BRAIN, V69, P183; SCHACHER S, 1988, SCIENCE, V240, P167; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SCHOLZ KP, 1988, SCIENCE, V240, P1664, DOI 10.1126/science.2837826; SIEGELBAUM SA, 1982, NATURE, V299, P413, DOI 10.1038/299413a0; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; THOMAS MS, 1987, J MOL BIOL, V196, P333, DOI 10.1016/0022-2836(87)90694-2; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; Zubin J, 1941, P SOC EXP BIOL MED, V48, P596	82	460	471	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1099	1114		10.1016/0092-8674(94)90386-7	http://dx.doi.org/10.1016/0092-8674(94)90386-7			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137425				2022-12-28	WOS:A1994ND24600015
J	GRAZIANO, V; GERCHMAN, SE; SCHNEIDER, DK; RAMAKRISHNAN, V				GRAZIANO, V; GERCHMAN, SE; SCHNEIDER, DK; RAMAKRISHNAN, V			HISTONE H1 IS LOCATED IN THE INTERIOR OF THE CHROMATIN 30-NM FILAMENT	NATURE			English	Article							HIGHER-ORDER STRUCTURE; GLOBULAR DOMAIN; RNA GENES; TRANSCRIPTION; ACCESSIBILITY; ORGANIZATION; ANTIBODIES; FRAGMENTS; EXCHANGE; FIBER	THE linker histone H1 binds to the nucleosome and is essential for the organization of nucleosomes into the 30-nm filament of chromatin(1). It has been implicated in the repression of transcription(2,5), and phosphorylation of H1 may be involved in cell-cycle-dependent chromatin condensation and decondensation(6). A long-standing issue concerns the location of H1 in the chromatin filament(7). The original solenoidal model(8) proposes that H1 is inside the 30-nm filament, but other models, also helical, suggest a variable(9) or more accessible(10) location for H1. Investigations to determine the location of the linker histone based on its accessibility to antibodies(11-15) or immobilized proteases(16) under various ionic conditions have yielded conflicting results. Here we use neutron scattering in a direct structural determination to show that H1 is located in the interior of the filament.	BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	United States Department of Energy (DOE); Brookhaven National Laboratory				Ramakrishnan, V/0000-0002-4699-2194				BANCHEV TB, 1990, MOL CELL BIOCHEM, V95, P167; CARON F, 1981, J MOL BIOL, V146, P513, DOI 10.1016/0022-2836(81)90045-0; CATTINI PA, 1988, J HISTOCHEM CYTOCHEM, V36, P425, DOI 10.1177/36.4.2450120; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DIMITROV SI, 1987, EMBO J, V6, P2387, DOI 10.1002/j.1460-2075.1987.tb02516.x; FELSENFELD G, 1986, CELL, V44, P375, DOI 10.1016/0092-8674(86)90456-3; FINCH JT, 1976, P NATL ACAD SCI USA, V73, P1897, DOI 10.1073/pnas.73.6.1897; GERCHMAN SE, 1987, P NATL ACAD SCI USA, V87, P7802; GRAZIANO V, 1990, J MOL BIOL, V214, P897, DOI 10.1016/0022-2836(90)90344-L; GRAZIANO V, 1988, J MOL BIOL, V203, P997, DOI 10.1016/0022-2836(88)90124-6; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; IBEL K, 1975, J MOL BIOL, V93, P255, DOI 10.1016/0022-2836(75)90131-X; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; LASTERS I, 1985, EUR J BIOCHEM, V151, P283, DOI 10.1111/j.1432-1033.1985.tb09098.x; LEUBA SH, 1993, J MOL BIOL, V229, P917, DOI 10.1006/jmbi.1993.1096; MCGHEE JD, 1983, CELL, V33, P831, DOI 10.1016/0092-8674(83)90025-9; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; RUSSANOVA VR, 1987, EUR J BIOCHEM, V167, P321, DOI 10.1111/j.1432-1033.1987.tb13339.x; SCHLISSEL MS, 1984, CELL, V37, P903, DOI 10.1016/0092-8674(84)90425-2; SERDYUK IN, 1975, BROOKHAVEN S BIOL, V27, P49; SHANNON MF, 1987, J BIOL CHEM, V262, P9664; STUDIER FW, 1990, METHOD ENZYMOL, V185, P61; SUAU P, 1979, EUR J BIOCHEM, V97, P593, DOI 10.1111/j.1432-1033.1979.tb13148.x; THIBODEAU A, 1988, J BIOL CHEM, V263, P16236; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS JO, 1983, EUR J BIOCHEM, V134, P109, DOI 10.1111/j.1432-1033.1983.tb07538.x; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; WOODCOCK CLF, 1984, J CELL BIOL, V99, P42, DOI 10.1083/jcb.99.1.42	29	100	100	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					351	354		10.1038/368351a0	http://dx.doi.org/10.1038/368351a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127372				2022-12-28	WOS:A1994NB98500051
J	WAISBREN, SJ; GEIBEL, JP; MODLIN, IM; BORON, WF				WAISBREN, SJ; GEIBEL, JP; MODLIN, IM; BORON, WF			UNUSUAL PERMEABILITY PROPERTIES OF GASTRIC GLAND-CELLS	NATURE			English	Article							NH3; PERMEATION; MEMBRANES	PHYSIOLOGISTS have long pondered the riddle of why the stomach is itself not digested by the very juice it secretes. One explanation is that a mucus-bicarbonate barrier, coating the stomach lumen as well as superficial portions of gastric glands, prevents autodigestion(1). However, this leaves unanswered the question of what protects cells deeper in the glands, which seem to lack a mucus barrier(2). These are the parietal and chief cells, which secrete acid and pepsin. Using perfused single gastric glands from rabbit, we recently found that intracellular pH is uniquely resistant to extreme degrees of luminal acidification(2), suggesting that the apical (luminal) barrier might also exclude ammonia and carbon dioxide, to which cell membranes are generally highly permeable(3,4). We now show that this is indeed the case. There are three reports of membranes with very low permeabilities to NH3 (refs 5-7), and none of membranes impermeable to CO2.	YALE UNIV,SCH MED,DEPT SURG,GASTROINTESTINAL SURG PATHOBIOL RES UNIT,NEW HAVEN,CT 06510	Yale University	WAISBREN, SJ (corresponding author), YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510, USA.		Boron, Walter/ABI-1564-2020	Boron, Walter/0000-0003-4741-7287				BORON WF, 1976, NATURE, V259, P240, DOI 10.1038/259240a0; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; BURCKHARDT BC, 1992, PFLUG ARCH EUR J PHY, V420, P83, DOI 10.1007/BF00378645; BURG MB, 1982, KIDNEY INT, V22, P417, DOI 10.1038/ki.1982.194; GARVIN J L, 1988, American Journal of Physiology, V255, pF57; GEIBEL J, 1993, GASTROENTEROLOGY, V104, pA86; GOLCHINI K, 1988, AM J PHYSIOL, V255, pF135, DOI 10.1152/ajprenal.1988.255.1.F135; GUTKNECHT J, 1977, J GEN PHYSIOL, V69, P779; HELANDER HF, 1972, GASTROENTEROLOGY, V63, P951; Jacobs MH, 1922, J GEN PHYSIOL, V5, P181, DOI 10.1085/jgp.5.2.181; Jacobs MH, 1920, AM J PHYSIOL, V51, P321, DOI 10.1152/ajplegacy.1920.51.2.321; KIKERI D, 1989, NATURE, V339, P478, DOI 10.1038/339478a0; LAPENNAS GN, 1977, J EXP BIOL, V67, P175; PRIVER NA, 1993, BIOCHEMISTRY-US, V32, P2459, DOI 10.1021/bi00061a002; SCHOFIELD GC, 1979, J ANAT, V128, P669; SILEN W, 1985, AM J MED, V79, P45, DOI 10.1016/0002-9343(85)90572-8; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TOWNSLEY MC, 1989, AM J PHYSIOL, V257, pG350, DOI 10.1152/ajpgi.1989.257.3.G350; WAISBREN SJ, IN PRESS AM J PHYSL	20	132	136	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					332	335		10.1038/368332a0	http://dx.doi.org/10.1038/368332a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127367				2022-12-28	WOS:A1994NB98500045
J	BIOU, V; YAREMCHUK, A; TUKALO, M; CUSACK, S				BIOU, V; YAREMCHUK, A; TUKALO, M; CUSACK, S			THE 2.9 ANGSTROM CRYSTAL-STRUCTURE OF THERMUS-THERMOPHILUS SERYL-TRANSFER-RNA SYNTHETASE COMPLEXED WITH TRNA(SER)	SCIENCE			English	Article							TRANSFER-RNA-SYNTHETASE; ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; TRANSFER RNA(SER); RESOLUTION; REFINEMENT; SEQUENCE; ERRORS; LOOP; MAPS	The crystal structure of Thermus thermophilus seryl-transfer RNA synthetase, a class 2 aminoacyl-tRNA synthetase, complexed with a single tRNA(Ser) molecule was solved at 2.9 Angstrom resolution. The structure revealed how insertion of conserved base G20b from the D loop into the core of the tRNA determines the orientation of the long variable arm, which is a characteristic feature of most serine specific tRNAs. On tRNA binding, the antiparallel coiled-coil domain of one subunit of the synthetase makes contacts with the variable arm and T Psi C loop of the tRNA and directs the acceptor stem of the tRNA into the active site of the other subunit. Specificity depends principally on recognition of the shape of tRNA(Ser) through backbone contacts and secondarily on sequence specific interactions.	EUROPEAN MOLEC BIOL LAB,F-38042 GRENOBLE,FRANCE	European Molecular Biology Laboratory (EMBL)				Cusack, Stephen/0000-0002-9324-0796; Tukalo, Michael/0000-0002-0982-2372				BELRHALI H, 1994, SCIENCE, V263, P1432, DOI 10.1126/science.8128224; BRENNAN T, 1976, NUCLEIC ACIDS RES, V3, P3235, DOI 10.1093/nar/3.11.3235; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; CAVERELLI J, 1993, NATURE, V362, P181; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DOCKBREGEON AC, 1989, J MOL BIOL, V206, P707, DOI 10.1016/0022-2836(89)90578-0; DOCKBREGEON AC, 1987, COLD SPRING HARB SYM, V52, P113, DOI 10.1101/SQB.1987.052.01.016; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FOURME R, 1992, REV SCI INSTRUM, V63, P982, DOI 10.1063/1.1143716; FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576; HIMENO H, 1990, NUCLEIC ACIDS RES, V18, P6815, DOI 10.1093/nar/18.23.6815; HOLBROOK SR, 1978, J MOL BIOL, V123, P631, DOI 10.1016/0022-2836(78)90210-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; LESLIE AGW, 1981, JOINT CCP4 ESF EACBM; MCCLAIN WH, 1993, J MOL BIOL, V234, P257, DOI 10.1006/jmbi.1993.1582; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; NASSAR N, 1992, THESISU GRENOBLE; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; NORMANLY J, 1992, P NATL ACAD SCI USA, V89, P5680, DOI 10.1073/pnas.89.12.5680; PETRUSHENKO Z, UNPUB; PRICE S, 1993, FEBS LETT, V324, P167, DOI 10.1016/0014-5793(93)81386-E; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAKS ME, 1991, PROG NUCLEIC ACID RE, V41, P23; SAMPSON JR, 1993, NUCLEIC ACIDS RES, V21, P4467, DOI 10.1093/nar/21.19.4467; SCHATZ D, 1991, P NATL ACAD SCI USA, V88, P6132, DOI 10.1073/pnas.88.14.6132; SUNDHARA.G, 1968, P NATL ACAD SCI USA, V61, P693, DOI 10.1073/pnas.61.2.693; THUNE T, 1993, THESIS TU MUNICH; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; WU XQ, 1993, NUCLEIC ACIDS RES, V21, P5589, DOI 10.1093/nar/21.24.5589; YAREMCHUK AD, 1992, FEBS LETT, V310, P157, DOI 10.1016/0014-5793(92)81319-H; YAREMCHUK AD, 1992, J MOL BIOL, V224, P519, DOI 10.1016/0022-2836(92)91014-G; YAREMCHUK AD, UNPUB	39	420	431	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1404	1410		10.1126/science.8128220	http://dx.doi.org/10.1126/science.8128220			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128220				2022-12-28	WOS:A1994MZ92700021
J	KONDO, M; TAKESHITA, T; HIGUCHI, M; NAKAMURA, M; SUDO, T; NISHIKAWA, SI; SUGAMURA, K				KONDO, M; TAKESHITA, T; HIGUCHI, M; NAKAMURA, M; SUDO, T; NISHIKAWA, SI; SUGAMURA, K			FUNCTIONAL PARTICIPATION OF THE IL-2 RECEPTOR-GAMMA CHAIN IN IL-7 RECEPTOR COMPLEXES	SCIENCE			English	Article							INTERLEUKIN-2; GENERATION; DEFICIENT; MOLECULE; CLONING; MICE; P64	The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect. Studies with monoclonal antibodies specific for the IL-2 receptor gamma chain showed that the gamma chain participates in the functional high-affinity receptor complexes for IL-7 that are involved in the differentiation of T and B cells. Participation of the gamma subunit in more than one receptor may enable the elucidation of the mechanisms of XSCID development and lymphocyte differentiation.	TOHOKU UNIV,SCH MED,DEPT MICROBIOL,SENDAI,MIYAGI 980,JAPAN; TORAY INDUSTRIES LTD,BASIC RES LABS,KAMAKURA,KANAGAWA 248,JAPAN; KYOTO UNIV,FAC MED,DEPT MOLEC GENET,KYOTO,KYOTO 606,JAPAN	Tohoku University; Toray Industries, Inc.; Kyoto University			Takeshita, Toshikazu/AAL-1382-2021					ARMITAGE RJ, 1992, BLOOD, V79, P1738; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; CARDING SR, 1991, IMMUNOL TODAY, V12, P239, DOI 10.1016/0167-5699(91)90037-T; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GRABSTEIN KH, 1993, J EXP MED, V178, P257, DOI 10.1084/jem.178.1.257; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KONDO M, UNPUB; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUMAKI S, 1993, BIOCHEM BIOPH RES CO, V193, P356, DOI 10.1006/bbrc.1993.1631; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PARK LS, 1990, J EXP MED, V171, P1073, DOI 10.1084/jem.171.4.1073; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAKESHITA T, 1990, INT IMMUNOL, V2, P477, DOI 10.1093/intimm/2.5.477; Takeshita T. Y., UNPUB; TANAKA Y, 1990, INT J CANCER, V46, P675, DOI 10.1002/ijc.2910460421; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G	24	361	372	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1453	1454		10.1126/science.8128231	http://dx.doi.org/10.1126/science.8128231			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128231				2022-12-28	WOS:A1994MZ92700037
J	SHI, L; NISHIOKA, WK; THNG, J; BRADBURY, EM; LITCHFIELD, DW; GREENBERG, AH				SHI, L; NISHIOKA, WK; THNG, J; BRADBURY, EM; LITCHFIELD, DW; GREENBERG, AH			PREMATURE P34(CDC2) ACTIVATION REQUIRED FOR APOPTOSIS	SCIENCE			English	Article							PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; NUCLEAR LAMINA; CDC2 KINASE; IDENTIFICATION; MITOSIS; P34CDC2; SITES; CELLS	Activation of the serine-threonine kinase p34cdc2 at an inappropriate time during the cell cycle leads to cell death that resembles apoptosis. Premature activation of p34cdc2 was shown to be required for apoptosis induced by a lymphocyte granule protease. The kinase was rapidly activated and tyrosine dephosphorylated at the initiation of apoptosis. DNA fragmentation and nuclear collapse could be prevented by blocking p34cdc2 activity with excess peptide substrate, or by inactivating p34cdc2 in a temperature-sensitive mutant. Premature p34cdc2 activation may be a general mechanism by which cells induced to undergo apoptosis initiate the disruption of the nucleus.	UNIV MANITOBA,MANITOBA INST CELL BIOL,100 OLIVIA ST,WINNIPEG R3E 0V9,MANITOBA,CANADA; LA JOLLA INST ALLERGY & IMMUNOL,LA JOLLA,CA 92037; UNIV CALIF DAVIS,DEPT BIOL CHEM,DAVIS,CA 95616	University of Manitoba; La Jolla Institute for Immunology; University of California System; University of California Davis			Litchfield, David/E-4636-2015	Litchfield, David/0000-0002-2425-6620				BISONETTE RP, 1992, NATURE, V359, P552; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LANGAN TA, 1989, MOL CELL BIOL, V9, P233; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; NISHIOKA WK, IN PRESS J EXP MED; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PASTERNACK MS, 1986, NATURE, V322, P740, DOI 10.1038/322740a0; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Shi L., UNPUB; SHI L, 1993, J EXP MED, V176, P1521; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHIVER JW, 1992, CELL, V71, P615; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; UCKER DS, 1992, MOL CELL BIOL, V12, P3030; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZYCHLINSHY A, 1985, J CELL SCI, V74, P169	25	617	640	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 25	1994	263	5150					1143	1145		10.1126/science.8108732	http://dx.doi.org/10.1126/science.8108732			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	8108732				2022-12-28	WOS:A1994MX75900034
J	MILLAUER, B; SHAWVER, LK; PLATE, KH; RISAU, W; ULLRICH, A				MILLAUER, B; SHAWVER, LK; PLATE, KH; RISAU, W; ULLRICH, A			GLIOBLASTOMA GROWTH INHIBITED IN-VIVO BY A DOMINANT-NEGATIVE FLK-1 MUTANT	NATURE			English	Article							RETROVIRAL VECTORS; ANGIOGENESIS; RECEPTOR; EXPRESSION	ANGIOGENESIS, the sprouting of capillaries from pre-existing blood vessels, is a fundamental process in the formation of the vascular system during embryonic development. In adulthood, angiogenesis takes place during corpus luteum formation and in pathological conditions such as wound healing, diabetic retinopathy, and tumorigenesis. Vascularization is essential for solid tumour growth and is thought to be regulated by tumour cell-produced factors, which have a chemotactic and mitogenic effect on endothelial cells1-4. Vascular endothelial growth factor (VEGF), a homodimeric glycoprotein of relative molecular mass 45,000, is the only mitogen, however, that specifically acts on endothelial cells, and it may be a major regulator of tumour angiogeness in vivo5,6. Its expression has been shown to be upregulated by hypoxia, and its cell-surface receptor, Flk-1, is exclusively expressed in endothelial cells7,8. Here we investigate the biological relevance of the VEGF/Flk-1 receptor/ligand system for angiogenesis using a retrovirus encoding a dominant-negative mutant of the Flk-1/VEGF receptor to infect endothelial target cells in vivo, and find that tumour growth is prevented in nude mice. Our results emphasize the central role of the Flk-1 /VEGF system in angiogenesis in general and in the development of solid tumours in particular.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY; SUGEN INC,REDWOOD CITY,CA 94063; MAX PLANCK INST PHYSIOL & CLIN RES,WG KERCKHOFF INST,DEPT MOLEC CELL BIOL,D-61231 BAD NAUHEIM,GERMANY	Max Planck Society; Max Planck Society								AMAYA E, 1991, CELL, V66, P287; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEWART CL, 1987, EMBO J, V6, P383, DOI 10.1002/j.1460-2075.1987.tb04766.x; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331	19	1121	1209	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					576	579		10.1038/367576a0	http://dx.doi.org/10.1038/367576a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	8107827				2022-12-28	WOS:A1994MV86300064
J	KUNDRA, V; ESCOBEDO, JA; KAZLAUSKAS, A; KIM, HK; RHEE, SG; WILLIAMS, LT; ZETTER, BR				KUNDRA, V; ESCOBEDO, JA; KAZLAUSKAS, A; KIM, HK; RHEE, SG; WILLIAMS, LT; ZETTER, BR			REGULATION OF CHEMOTAXIS BY THE PLATELET-DERIVED GROWTH-FACTOR RECEPTOR-BETA	NATURE			English	Article							PHOSPHOLIPASE-C-GAMMA; PDGF RECEPTOR; SIGNALING COMPLEX; ASSOCIATION; BINDING; SITES; GAP; PHOSPHORYLATION; KINASE	CHEMOTAXIS is an important component of wound healing, development, immunity and metastasis, yet the signalling pathways that mediate chemotaxis are poorly understood. Platelet-derived growth factor (PDGF) acts both as a mitogen and a chemoattractant1. Upon stimulation, the tyrosine kinase PDGF receptor-beta (PDGFR-beta) autophosphorylates2 and forms a complex that includes SH2(Src homology 2)-domain-containing proteins such as the phosphatidylinositol-specific phospholipase C-gamma (ref. 3), Ras-GTPase-activating protein (GAP)4, and phosphatidylinositol-3-OH kinase5. Specific tyrosine-to-phenylalanine substitutions in the PDGFR-beta can prevent binding of one SH2-domain-containing protein without affecting binding of other receptor-associated proteins6,7. Here we use phospholipase C-gamma (ref. 8) and PDGFR-beta mutants9-11 to map specific tyrosines involved in both positive and negative regulation of chemotaxis towards the PDGF-BB homodimer. Our results indicate that a delicate balance of migration-promoting (phospholipase C-gamma and phosphatidylinositol-3-OH kinase) and migration-suppressing (GAP) activities are recruited by the PDGFR-beta to drive chemotaxis towards PDGF-BB.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,300 LONGWOOD AVE,BOSTON,MA 02115; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143; NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206; NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; University of California System; University of California San Francisco; National Jewish Health; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; COUGHLIN SR, 1989, SCIENCE, V243, P1191; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KIM K, 1991, CELL, V6, P435; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; SHARIFF A, 1992, SCIENCE, V256, P245, DOI 10.1126/science.1373523; TURKER MS, 1988, CELL BIOL TOXICOL, V4, P211, DOI 10.1007/BF00119247; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	19	418	422	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					474	476		10.1038/367474a0	http://dx.doi.org/10.1038/367474a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	8107807				2022-12-28	WOS:A1994MU67900058
J	LEE, IM; MANSON, JE; HENNEKENS, CH; PAFFENBARGER, RS				LEE, IM; MANSON, JE; HENNEKENS, CH; PAFFENBARGER, RS			BODY-WEIGHT AND MORTALITY - A 27-YEAR FOLLOW-UP OF MIDDLE-AGED MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; RELATIVE WEIGHT; MASS INDEX; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; PHYSICAL-ACTIVITY; COLLEGE ALUMNI; RISK-FACTORS; SMOKING; POPULATION	Objective.-To investigate the nature of the relation between body weight and all-cause mortality. Design.-Prospective cohort study, following up men from 1962 or 1966 (1962/1966) through 1988. Setting/Participants.-Harvard University alumni with a mean age of 46.6 years in 1962/1966 and without self-reported, physician-diagnosed coronary heart disease, stroke, or cancer, who completed questionnaires on weight, height, cigarette smoking habit, and physical activity (n=19297). We calculated body mass index (weight in kilograms divided by the square of height in meters) using self-reported measures. Main Outcome Measure.-All-cause mortality (4370 deaths). Results.-In multivariate analysis adjusting for age, cigarette smoking habit, and physical activity, we found a J-shaped relation between body mass index and mortality. Relative risks of dying for men with a body mass index of less than 22.5, 22.5 to less than 23.5, 23.5 to less than 24.5, 24.5 to less than 26.0, and 26.0 or greater were 1.00 (referent), 0.99 (95% confidence interval, 0.89 to 1.20), 0.95 (0.87 to 1.05), 1.01 (0.91 to 1.10), and 1.18 (1.08 to 1.28), respectively (P for linear trend=.0008). Among current smokers, the relation between body mass index and mortality was U-shaped, with lowest risk of death at a body mass index of 23.5 to less than 24.5. During early follow-up (1962/1966 through 1974), we also observed a U-shaped curve, this time with lowest mortality risk at a body mass index of 24.5 to less than 26.0. To minimize confounding by cigarette smoking and bias from antecedent disease and early mortality, we conducted analysis only among never smokers and omitted the first 5 years of follow-up (51 0 deaths). The corresponding relative risks from this analysis, adjusted for age and physical activity, were 1.00, 1.23 (95% confidence interval, 0.90 to 1.67), 1.06 (0.80 to 1.42), 1.27 (0.96 to 1.68), and 1.67 (1.29 to 2.17), respectively (P for linear trend=.0001). Conclusions.-In these prospective data, body weight and mortality were directly related. After accounting for confounding by cigarette smoking and bias resulting from illness-related weight loss or inappropriate control for the biologic effects of obesity, we found no evidence of excess mortality among lean men. Indeed, lowest mortality was observed among men weighing, on average, 20% below the US average for men of comparable age and height.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA 02115 USA; STANFORD UNIV, MED CTR, SCH MED, DIV EPIDEMIOL, STANFORD, CA 94305 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Stanford University	LEE, IM (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Lee, I-Min/ABD-5409-2021		NCI NIH HHS [CA 44854] Funding Source: Medline; NHLBI NIH HHS [HL 34174] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044854] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034174] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; BORHANI NO, 1963, J CHRON DIS, V16, P1251, DOI 10.1016/0021-9681(63)90067-5; BOTTIGER LE, 1980, ATHEROSCLEROSIS, V36, P389, DOI 10.1016/0021-9150(80)90219-1; CAMPBELL AJ, 1990, AGE AGEING, V19, P131, DOI 10.1093/ageing/19.2.131; CHAPMAN JM, 1964, J CHRON DIS, V17, P933, DOI 10.1016/0021-9681(64)90163-8; COMSTOCK GW, 1966, AM J EPIDEMIOL, V83, P548, DOI 10.1093/oxfordjournals.aje.a120606; COX DR, 1972, J R STAT SOC B, V34, P187; DYER AR, 1975, J CHRON DIS, V28, P109, DOI 10.1016/0021-9681(75)90067-3; FITZGERALD AP, 1992, INT J OBESITY, V16, P119; FOLSOM AR, 1993, JAMA-J AM MED ASSOC, V269, P483, DOI 10.1001/jama.269.4.483; GARFINKEL L, 1988, CANCER, V62, P1844, DOI 10.1002/1097-0142(19881015)62:1+<1844::AID-CNCR2820621328>3.0.CO;2-O; GARN SM, 1983, AM J CLIN NUTR, V38, P313, DOI 10.1093/ajcn/38.2.313; GARRISON RJ, 1983, JAMA-J AM MED ASSOC, V249, P2199, DOI 10.1001/jama.249.16.2199; GORDON T, 1988, INT J EPIDEMIOL, V17, P77, DOI 10.1093/ije/17.1.77; HAMM P, 1989, AM J EPIDEMIOL, V129, P312, DOI 10.1093/oxfordjournals.aje.a115135; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; HOFFMANS MDAF, 1988, J CLIN EPIDEMIOL, V41, P749, DOI 10.1016/0895-4356(88)90161-8; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KEYS A, 1989, ANN MED, V21, P163, DOI 10.3109/07853898909149927; KEYS A, 1971, ARCH INTERN MED, V128, P201, DOI [10.1001/archinte.128.2.201, 10.1001/archinte.1971.00310200037002]; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KOZAREVIC D, 1976, AM J EPIDEMIOL, V104, P133, DOI 10.1093/oxfordjournals.aje.a112283; LEE IM, 1992, JAMA-J AM MED ASSOC, V268, P2045, DOI 10.1001/jama.268.15.2045; LEE IM, 1992, AM J EPIDEMIOL, V135, P915, DOI 10.1093/oxfordjournals.aje.a116387; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LINDSTED K, 1991, INT J OBESITY, V15, P397; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; Lissner L., 1989, Obesity in Europe 88. Proceedings of the 1st European Congress on Obesity, 5-6 June, 1988, Stockholm, Sweden., P55; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; NOPPA H, 1980, AM J EPIDEMIOL, V111, P682, DOI 10.1093/oxfordjournals.aje.a112946; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PALTA M, 1982, AM J EPIDEMIOL, V115, P223, DOI 10.1093/oxfordjournals.aje.a113294; PAUL O, 1963, CIRCULATION, V28, P20, DOI 10.1161/01.CIR.28.1.20; PYORALA K, 1979, J CHRON DIS, V32, P729, DOI 10.1016/0021-9681(79)90052-3; RABKIN SW, 1977, AM J CARDIOL, V39, P452, DOI 10.1016/S0002-9149(77)80104-5; RHOADS GG, 1983, LANCET, V1, P492; RISSANEN A, 1989, J CLIN EPIDEMIOL, V42, P781, DOI 10.1016/0895-4356(89)90076-0; SCHROLL M, 1981, DAN MED BULL, V28, P106; SIDNEY S, 1987, AM J PUBLIC HEALTH, V77, P317, DOI 10.2105/AJPH.77.3.317; STEVENS J, 1992, AM J EPIDEMIOL, V135, P1137, DOI 10.1093/oxfordjournals.aje.a116214; STEVENS J, 1992, ARCH INTERN MED, V152, P1257, DOI 10.1001/archinte.152.6.1257; STEWART AW, 1987, AM J EPIDEMIOL, V125, P122, DOI 10.1093/oxfordjournals.aje.a114494; STUNKARD AJ, 1981, AM J CLIN NUTR, V34, P1593, DOI 10.1093/ajcn/34.8.1593; TIBBLIN G, 1975, AM J CARDIOL, V35, P514, DOI 10.1016/0002-9149(75)90834-6; TUOMILEHTO J, 1987, BRIT MED J, V295, P623, DOI 10.1136/bmj.295.6599.623; VANDENBROUCKE JP, 1984, JAMA-J AM MED ASSOC, V252, P2859, DOI 10.1001/jama.252.20.2859; WAALER HT, 1984, ACTA MED SCAND, P1; WANNAMETHEE G, 1989, BRIT MED J, V299, P1497, DOI 10.1136/bmj.299.6714.1497; WESTLUND K, 1972, SCAND J CLIN LAB INV, V30, P1; WILCOSKY T, 1990, J CLIN EPIDEMIOL, V43, P743, DOI 10.1016/0895-4356(90)90232-E; WILLETT WC, 1991, AM J CLIN NUTR, V53, P1102, DOI 10.1093/ajcn/53.5.1102; WILLIAMSON DF, 1991, NEW ENGL J MED, V324, P739, DOI 10.1056/NEJM199103143241106; [No title captured]; 1990, NUTRITION YOUR HLTH; 1959, B METROPOLITAN LIFE, V40, P1; 1966, VITAL HLTH STAT, V11; 1980, BUILD STUDY 1979	59	334	335	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1993	270	23					2823	2828		10.1001/jama.270.23.2823	http://dx.doi.org/10.1001/jama.270.23.2823			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK941	8133621				2022-12-28	WOS:A1993MK94100031
J	SAUVE, JS; LAUPACIS, A; OSTBYE, T; FEAGAN, B; SACKETT, DL				SAUVE, JS; LAUPACIS, A; OSTBYE, T; FEAGAN, B; SACKETT, DL			DOES THIS PATIENT HAVE A CLINICALLY IMPORTANT CAROTID BRUIT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATURAL-HISTORY; HIGH-GRADE; STROKE; RISK; POPULATION; STENOSIS; SURGERY; TRIALS; NECK		MCMASTER UNIV, DEPT MED, HAMILTON L8S 4L8, ONTARIO, CANADA; MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON L8S 4L8, ONTARIO, CANADA; UNIV OTTAWA, DEPT MED, OTTAWA K1N 6N5, ONTARIO, CANADA; UNIV OTTAWA, DEPT EPIDEMIOL & COMMUNITY MED, OTTAWA K1N 6N5, ONTARIO, CANADA; UNIV WESTERN ONTARIO, DEPT EPIDEMIOL & BIOSTAT, LONDON N6A 3K7, ONTARIO, CANADA; UNIV WESTERN ONTARIO, DEPT FAMILY MED, LONDON N6A 3K7, ONTARIO, CANADA; UNIV WESTERN ONTARIO, DEPT MED, LONDON N6A 3K7, ONTARIO, CANADA	McMaster University; McMaster University; University of Ottawa; University of Ottawa; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)			Feagan, Brian G/M-4283-2015					BARNES RW, 1981, SURGERY, V90, P1075; CHAMBERS BR, 1985, NEUROLOGY, V35, P742, DOI 10.1212/WNL.35.5.742; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; EVANS WE, 1978, SURGERY, V83, P521; FOWLER NO, 1964, AM HEART J, V67, P135, DOI 10.1016/0002-8703(64)90409-0; HANKEY GJ, 1990, BMJ-BRIT MED J, V300, P1485, DOI 10.1136/bmj.300.6738.1485; HARRISON MJG, 1984, BRIT J HOSP MED, V32, P80; HAYNES RB, 1992, CLIN RES, V40, pA184; HEYMAN A, 1980, NEW ENGL J MED, V302, P838, DOI 10.1056/NEJM198004103021504; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; HURST JW, 1980, NEW ENGL J MED, V302, P862, DOI 10.1056/NEJM198004103021512; INGALL TJ, 1989, ARCH NEUROL-CHICAGO, V46, P418, DOI 10.1001/archneur.1989.00520400078023; IVEY TD, 1984, J THORAC CARDIOV SUR, V87, P183; JONES FL, 1962, NEW ENGL J MED, V267, P658, DOI 10.1056/NEJM196209272671307; MATTHEWS WB, 1961, J NEUROL NEUROSUR PS, V24, P161, DOI 10.1136/jnnp.24.2.161; MESSERT B, 1977, ANN NEUROL, V2, P535, DOI 10.1002/ana.410020616; RATCHESON RA, 1982, CLIN NEUR, V29, P464; ROPPER AH, 1982, NEW ENGL J MED, V307, P1388, DOI 10.1056/NEJM198211253072207; SAUVE S, 1992, CLIN RES, V40, pA304; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; VANRUISWYK J, 1990, ANN INTERN MED, V112, P340, DOI 10.7326/0003-4819-112-5-340; WADIA NH, 1957, BRAIN, V80, P492, DOI 10.1093/brain/80.4.492; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WIEBERS DO, 1990, STROKE, V21, P984, DOI 10.1161/01.STR.21.7.984; WOLF PA, 1981, JAMA-J AM MED ASSOC, V245, P1442, DOI 10.1001/jama.245.14.1442; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; ZIEGLER DK, 1971, NEUROLOGY, V21, P860, DOI 10.1212/WNL.21.8.860	27	22	22	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1993	270	23					2843	2845		10.1001/jama.270.23.2843	http://dx.doi.org/10.1001/jama.270.23.2843			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK941	8133624				2022-12-28	WOS:A1993MK94100035
J	WOOLF, SH				WOOLF, SH			ROUTINE IRON SUPPLEMENTATION DURING PREGNANCY - REVIEW ARTICLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							SERUM FERRITIN LEVELS; PAPUA-NEW-GUINEA; DEFICIENCY ANEMIA; MATERNAL ANEMIA; RANDOMIZED TRIAL; BIRTH-WEIGHT; ORAL IRON; STORES; INFANTS; RISK				WOOLF, SH (corresponding author), US PHS, OFF DIS PREVENT & HLTH PROMOT, 330 C ST SW, ROOM 2132, SWITZER BLDG, WASHINGTON, DC 20201 USA.							AGARWAL KN, 1991, INDIAN J MED RES-B, V94, P277; AGRAWAL RMD, 1983, ACTA PAEDIATR SCAND, V72, P545, DOI 10.1111/j.1651-2227.1983.tb09768.x; ANDELMAN MB, 1966, AM J DIS CHILD, V111, P45, DOI 10.1001/archpedi.1966.02090040081007; [Anonymous], BR J OBSTET GYNAECOL; BASTA SS, 1979, AM J CLIN NUTR, V32, P916, DOI 10.1093/ajcn/32.4.916; BENTLEY DP, 1985, CLIN HAEMATOL, V14, P613; BHARGAVA M, 1989, ACTA PAEDIATR SCAND, V78, P321, DOI 10.1111/j.1651-2227.1989.tb11080.x; BRABIN BJ, 1990, ANN TROP MED PARASIT, V84, P11, DOI 10.1080/00034983.1990.11812429; BRATLID D, 1980, EUR J PEDIATR, V134, P125, DOI 10.1007/BF01846030; CELADA A, 1982, HELV PAEDIATR ACTA, V37, P11; CELADA A, 1982, HELV PAEDIATR ACTA, V37, P239; CHANARIN I, 1971, BRIT MED J, V2, P81, DOI 10.1136/bmj.2.5753.81; Colomer J, 1990, Paediatr Perinat Epidemiol, V4, P196, DOI 10.1111/j.1365-3016.1990.tb00638.x; DALLMAN PR, 1987, AM J CLIN NUTR, V46, P329, DOI 10.1093/ajcn/46.2.329; DALLMAN PR, 1989, J INTERN MED, V226, P367, DOI 10.1111/j.1365-2796.1989.tb01410.x; DAMSDARAN M, 1979, INDIAN J MED RES, V69, P448; DAVIES CTM, 1973, CLIN SCI, V44, P555, DOI 10.1042/cs0440555; DAVIES CTM, 1973, BRIT J IND MED, V30, P335; DAWSON EB, 1987, J REPROD MED, V32, P478; ELWOOD PC, 1969, J CHRON DIS, V21, P615, DOI 10.1016/0021-9681(69)90034-4; ELWOOD PC, 1973, AM J CLIN NUTR, V26, P958, DOI 10.1093/ajcn/26.9.958; FLEMING AF, 1974, MED J AUSTRALIA, V2, P429, DOI 10.5694/j.1326-5377.1974.tb70897.x; GARN SM, 1981, SEMIN PERINATOL, V5, P155; GILMAN AG, 1990, PHARMACOL BASIS THER, P1282; GOPALDAS T, 1985, Indian Pediatrics, V22, P737; GRINDULIS H, 1986, ARCH DIS CHILD, V61, P843, DOI 10.1136/adc.61.9.843; GRONER JA, 1986, J ADOLESCENT HEALTH, V7, P44, DOI 10.1016/S0197-0070(86)80094-8; HARRISON KA, 1973, J OBSTET GYN BR COMM, V80, P798; HEMMINKI E, 1991, J AM COLL NUTR, V10, P3; HEMMINKI E, 1991, INT J VITAM NUTR RES, V61, P370; HEMMINKI E, 1989, CONTROL CLIN TRIALS, V10, P290, DOI 10.1016/0197-2456(89)90069-X; HORN E, 1988, BRIT MED J, V297, P1325, DOI 10.1136/bmj.297.6659.1325; HUSSAIN MAM, 1977, ARCH DIS CHILD, V52, P782, DOI 10.1136/adc.52.10.782; KLEBANOFF MA, 1991, AM J OBSTET GYNECOL, V164, P59, DOI 10.1016/0002-9378(91)90626-3; KLEIN L, 1962, AM J OBSTET GYNECOL, V83, P588, DOI 10.1016/S0002-9378(16)35887-2; KNOTTNERUS JA, 1990, J CLIN EPIDEMIOL, V43, P461, DOI 10.1016/0895-4356(90)90134-B; KULLANDER S, 1976, ACTA OBSTET GYN SCAN, V55, P287, DOI 10.3109/00016347609158500; LAO TT, 1991, BIOL NEONATE, V60, P303, DOI 10.1159/000243421; LENNARTSSON J, 1979, SCAND J HAEMATOL, V22, P17; LIEBERMAN E, 1988, AM J OBSTET GYNECOL, V159, P107, DOI 10.1016/0002-9378(88)90502-9; LITOVITZ TL, 1989, AM J EMERG MED, V7, P495, DOI 10.1016/0735-6757(89)90252-0; LOZOFF B, 1987, PEDIATRICS, V79, P981; LOZOFF B, 1982, J PEDIATR-US, V100, P351, DOI 10.1016/S0022-3476(82)80428-9; LOZOFF B, 1991, NEW ENGL J MED, V325, P687, DOI 10.1056/NEJM199109053251004; MACGREGOR MARGARET W., 1963, SCOTTISH MED JOUR, V8, P134; MESSER RD, 1980, AUST PAEDIATR J, V16, P185; MURPHY JF, 1986, LANCET, V1, P992; MURRAY MJ, 1978, BRIT J NUTR, V39, P627, DOI 10.1079/BJN19780077; OPPENHEIMER SJ, 1986, T ROY SOC TROP MED H, V80, P818, DOI 10.1016/0035-9203(86)90393-7; OSKI FA, 1978, J PEDIATR-US, V92, P21, DOI 10.1016/S0022-3476(78)80063-8; OSKI FA, 1985, PEDIATR CLIN N AM, V32, P493; PAINTIN D. B., 1966, Journal of Obstetrics and Gynaecology of the British Commonwealth, V73, P181, DOI 10.1111/j.1471-0528.1966.tb05144.x; Primbs K, 1973, Geburtshilfe Frauenheilkd, V33, P552; Puolakka J, 1980, Acta Obstet Gynecol Scand Suppl, V95, P57; REINHARDT MC, 1978, HELV PAEDIAT ACT S41, V33, P43; REYNOLDS JEF, 1989, MARTINDALE EXTRA PHA, P1189; RIOS E, 1975, PEDIATRICS, V55, P694; ROMSLO I, 1983, BRIT J OBSTET GYNAEC, V90, P101, DOI 10.1111/j.1471-0528.1983.tb08891.x; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SCHOLL TO, 1992, AM J CLIN NUTR, V55, P985, DOI 10.1093/ajcn/55.5.985; SCHULTINK W, 1993, AM J CLIN NUTR, V57, P135, DOI 10.1093/ajcn/57.2.135; SELBY JV, 1988, INT J CANCER, V41, P677, DOI 10.1002/ijc.2910410507; STEVENS RG, 1988, NEW ENGL J MED, V319, P1047, DOI 10.1056/NEJM198810203191603; SUITOR CW, 1990, J AM DIET ASSOC, V90, P268; Svanberg B, 1975, Acta Obstet Gynecol Scand Suppl, V48, P87; TAYLOR DJ, 1976, BRIT J OBSTET GYNAEC, V83, P760, DOI 10.1111/j.1471-0528.1976.tb00740.x; TAYLOR DJ, 1982, BRIT J OBSTET GYNAEC, V89, P1011, DOI 10.1111/j.1471-0528.1982.tb04656.x; VANEIJK HG, 1978, CLIN CHIM ACTA, V83, P81, DOI 10.1016/0009-8981(78)90210-3; VUORI E, 1980, AM J CLIN NUTR, V33, P227, DOI 10.1093/ajcn/33.2.227; WALTER T, 1983, J PEDIATR-US, V102, P519, DOI 10.1016/S0022-3476(83)80177-2; WALTER T, 1989, PEDIATRICS, V84, P7; WILLOUGHBY ML, 1967, BRIT J HAEMATOL, V13, P503, DOI 10.1111/j.1365-2141.1967.tb00760.x; WORTHINGTONROBERTS B, 1985, J ENVIRON PATHOL TOX, V5, P1; 1989, MMWR MORB MORTAL WKL, V38, P400; 1989, DRUG EVALUATIONS, P591; 1984, ASSESSMENT IRON NUTR; 1990, MMWR MORB MORTAL WKL, V39, P73; 1993, JAMA-J AM MED ASSOC, V270, P2846; 1968, TECHNICAL REPORT SER, V405; 1990, NUTRITION PREGNANC 2, P272	80	24	24	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1993	270	23					2848	2854						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK941	8133626				2022-12-28	WOS:A1993MK94100037
J	DUFFY, TP				DUFFY, TP			REMEMBERING THE ABCS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOWN-SYNDROME; VITAMIN				DUFFY, TP (corresponding author), YALE UNIV, SCH MED, 333 CEDAR ST, NEW HAVEN, CT 06510 USA.							BUTTERWORTH RF, 1991, LANCET, V338, P1086, DOI 10.1016/0140-6736(91)91948-T; CATALANO RA, 1990, SURV OPHTHALMOL, V34, P385, DOI 10.1016/0039-6257(90)90116-D; COOLEY WC, 1991, CLIN PEDIATR, V30, P233, DOI 10.1177/000992289103000407; FERNANDEZBANARES F, 1989, AM J GASTROENTEROL, V84, P744; FIEL SB, 1993, LANCET, V341, P1070, DOI 10.1016/0140-6736(93)92423-Q; IZUMI Y, 1989, J PERIODONTOL, V60, P238, DOI 10.1902/jop.1989.60.5.238; MARCUS CL, 1991, PEDIATRICS, V88, P132; PUESCHEL SM, 1990, J MENT DEFIC RES, V34, P269; PUESCHEL SM, 1992, J INTELL DISABIL RES, V36, P99; PUESCHEL SM, 1990, AM J MED GENET, P52; REULER JB, 1985, NEW ENGL J MED, V312, P1035, DOI 10.1056/NEJM198504183121606; RUDMAN D, 1985, NUTR REV, V43, P1, DOI 10.1111/j.1753-4887.1985.tb02383.x; SOMMER A, 1988, AUST NZ J OPHTHALMOL, V16, P31, DOI 10.1111/j.1442-9071.1988.tb01197.x; SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V99, P2014; SPIVAK JL, 1977, JOHNS HOPKINS MED J, V140, P295; WELLS TR, 1992, PEDIATR PATHOL, V12, P673, DOI 10.3109/15513819209024220; WITTPENN JR, 1986, ARCH OPHTHALMOL-CHIC, V104, P327; YATZIDIS H, 1975, BRIT MED J, V3, P352, DOI 10.1136/bmj.3.5979.352	19	8	8	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 7	1994	330	14					994	996		10.1056/NEJM199404073301408	http://dx.doi.org/10.1056/NEJM199404073301408			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND793	8121463				2022-12-28	WOS:A1994ND79300008
J	BURNS, R				BURNS, R			FROZEN IN TIME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	1994	271	13					965	965		10.1001/jama.271.13.965	http://dx.doi.org/10.1001/jama.271.13.965			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND949	8139066				2022-12-28	WOS:A1994ND94900002
J	KNAPP, MJ; KNOPMAN, DS; SOLOMON, PR; PENDLEBURY, WW; DAVIS, CS; GRACON, SI; APTER, JT; LAZARUS, CN; BAKER, KE; BARNETT, M; BAUMEL, B; EISNER, LS; CASTELLS, B; BOLOURI, R; BENNETT, D; FORCHETTI, C; LEVIN, A; BLASS, JP; NOLAN, KA; GAINES, ER; RELKIN, N; BORISON, RL; DIAMOND, B; CELESIA, GG; ROSS, AP; DEXTER, J; DOODY, R; LIPSCOMB, L; KREITER, K; DUBOFF, EA; BLOCK, P; MARSHALL, D; WESTERGAARD, N; EARL, NL; WYNE, SV; HINMANSMITH, E; FARLOW, M; HENDRIE, HC; CARESS, JA; FARMER, M; HARPER, JE; FERGUSON, J; FOSTER, NL; BARBAS, NR; BLUEMLEIN, LA; GELB, DJ; BERENT, S; GIORDANI, B; GREENWALD, M; BERGMAN, S; ROGER, LF; GROENENDYK, A; WOOD, M; JURKOWSKI, C; KATZ, I; DOYLE, S; SMITH, BD; KELLNER, C; BERNSTEIN, HJ; BACHMAN, DL; KNOPMAN, DS; DEINARD, S; LANGLEY, L; BRIDGES, S; MARGOLIN, RA; BURGER, MC; WISER, SL; CRENSHAW, C; MORRIS, JC; RUBIN, EH; COATS, MA; REYES, PF; BENTZ, C; DOYLE, LL; RYMER, MM; BETTINGER, IE; LAUBINGER, MP; SADOWSKY, CH; MARTINEZ, W; ZUNIGA, J; STONE, R; WINNER, P; MATE, L; LESSARD, C; SCHNEIDER, L; PAWLUCZYK, S; SMITH, WT; LOSK, SN; MARAMBE, L; SOLOMON, PR; PENDLEBURY, WW; GROCCIAELLISON, ME; EDWARDS, KR; TAYLOR, J; CALABRESE, VP; HARKINS, SW; THEIN, SG; DEWAR, JA; WILLIAMS, G; DRENNAN, C; TUTTLE, P; PRINCIPI, N; FORD, EM; TYNDALL, RJ; KELLEY, CK				KNAPP, MJ; KNOPMAN, DS; SOLOMON, PR; PENDLEBURY, WW; DAVIS, CS; GRACON, SI; APTER, JT; LAZARUS, CN; BAKER, KE; BARNETT, M; BAUMEL, B; EISNER, LS; CASTELLS, B; BOLOURI, R; BENNETT, D; FORCHETTI, C; LEVIN, A; BLASS, JP; NOLAN, KA; GAINES, ER; RELKIN, N; BORISON, RL; DIAMOND, B; CELESIA, GG; ROSS, AP; DEXTER, J; DOODY, R; LIPSCOMB, L; KREITER, K; DUBOFF, EA; BLOCK, P; MARSHALL, D; WESTERGAARD, N; EARL, NL; WYNE, SV; HINMANSMITH, E; FARLOW, M; HENDRIE, HC; CARESS, JA; FARMER, M; HARPER, JE; FERGUSON, J; FOSTER, NL; BARBAS, NR; BLUEMLEIN, LA; GELB, DJ; BERENT, S; GIORDANI, B; GREENWALD, M; BERGMAN, S; ROGER, LF; GROENENDYK, A; WOOD, M; JURKOWSKI, C; KATZ, I; DOYLE, S; SMITH, BD; KELLNER, C; BERNSTEIN, HJ; BACHMAN, DL; KNOPMAN, DS; DEINARD, S; LANGLEY, L; BRIDGES, S; MARGOLIN, RA; BURGER, MC; WISER, SL; CRENSHAW, C; MORRIS, JC; RUBIN, EH; COATS, MA; REYES, PF; BENTZ, C; DOYLE, LL; RYMER, MM; BETTINGER, IE; LAUBINGER, MP; SADOWSKY, CH; MARTINEZ, W; ZUNIGA, J; STONE, R; WINNER, P; MATE, L; LESSARD, C; SCHNEIDER, L; PAWLUCZYK, S; SMITH, WT; LOSK, SN; MARAMBE, L; SOLOMON, PR; PENDLEBURY, WW; GROCCIAELLISON, ME; EDWARDS, KR; TAYLOR, J; CALABRESE, VP; HARKINS, SW; THEIN, SG; DEWAR, JA; WILLIAMS, G; DRENNAN, C; TUTTLE, P; PRINCIPI, N; FORD, EM; TYNDALL, RJ; KELLEY, CK			A 30-WEEK RANDOMIZED CONTROLLED TRIAL OF HIGH-DOSE TACRINE IN PATIENTS WITH ALZHEIMERS-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SENILE DEMENTIA; CHOLINERGIC NEURONS; SELECTIVE LOSS; DOUBLE-BLIND; PROGRESSION; IMPAIRMENT; TETRAHYDROAMINOACRIDINE; MULTICENTER; SCALE	Objective.-To evaluate the efficacy and safety of high-dose tacrine hydrochloride over 30 weeks in patients with probable Alzheimer's disease. Design.-A 30-week randomized, double-blind, placebo-controlled, parallel-group trial. Setting.-Outpatients at 33 US centers. Patients.-Men and women at least 50 years of age with mild to moderate Alzheimer's disease and otherwise in good health. Interventions.-Group 1 received placebo; group 2 received 40 mg/d of tacrine for 6 weeks, then 80 mg/d for 24 weeks; groups 3 and 4 received 40 mg/d of tacrine for 6 weeks, 80 mg/d for 6 weeks, and 120 mg/d for 6 weeks. Group 3 remained on a dosage of 120 mg/d for a total of 18 weeks; after 6 weeks at 120 mg/d, group 4 titrated to 160 mg/d for the last 12 weeks. Primary Outcome Measures.-Clinician Interview-Based Impression (CIBI), Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog), and Final Comprehensive Consensus Assessment (FCCA). Results.-A total of 663 patients entered the study; 653 patients were included in an intent-to-treat (ITT) analysis; 263 had evaluable data at 30 weeks. The results of the ITT analysis revealed significant (P less-than-or-equal-to .05) dose-response trends and between-group comparisons on CIBI and ADAS-Cog. In evaluable patients, significant dose-response trends were observed for all three primary measures (P less-than-or-equal-to .001). Significant differences in favor of 160 mg/d of tacrine vs placebo were observed on the CIBI (P less-than-or-equal-to .002) and ADAS-Cog and FCCA (P less-than-or-equal-to .001), as well as caregiver-global and quality-of-life assessments (P less-than-or-equal-to .05). On the CIBI, 23% and 42% of tacrine-treated patients in the ITT and evaluable-patient populations, respectively, were rated improved compared with 17% and 18% of placebo patients, respectively. The primary reasons for withdrawal of tacrine-treated patients were asymptomatic liver transaminase elevations (28%) and gastrointestinal complaints (1 6%). These adverse events were reversible on discontinuation of treatment, and many patients were able to restart tacrine. Conclusions.-Tacrine produced statistically significant, dose-related improvements on objective performance-based tests, clinician- and caregiver-rated global evaluations, and measures of quality of life. There was no evidence that the large number of patient withdrawals biased the overall conclusions of the study.	UNIV MINNESOTA, DEPT NEUROL, MINNEAPOLIS, MN 55455 USA; WILLIAMS COLL, DEPT PSYCHOL, WILLIAMSTOWN, MA 01267 USA; UNIV VERMONT, DEPT PATHOL, BURLINGTON, VT 05405 USA; UNIV IOWA, COLL MED, DIV BIOSTAT, IOWA CITY, IA 52242 USA; PRINCETON BIOMED RES, PRINCETON, NJ USA; NEURO MED RES ASSOCIATES, MIAMI BEACH, FL USA; RUSH ALZHEIMERS DIS CTR, CHICAGO, IL USA; CORNELL UNIV, COLL MED, WHITE PLAINS, NY 10605 USA; DOWNTOWN VET AFFAIRS MED CTR, AUGUSTA, GA USA; LOYOLA UNIV, MED CTR, MAYWOOD, IL 60153 USA; UNIV MISSOURI, HLTH SCI CTR, COLUMBIA, MO 65201 USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; CTR BEHAV MED, WHEAT RIDGE, CO USA; MEMORY DISORDERS CLIN, DURHAM, NC USA; INDIANA UNIV, CTR ALZHEIMERS DIS & RELATED DISORDERS, INDIANAPOLIS, IN 46204 USA; CLIN STUDIES FLORIDA, ST PETERSBURG, FL USA; PHARMACOL RES CORP, SALT LAKE CITY, UT USA; UNIV MICHIGAN, MED CTR, ANN ARBOR, MI 48109 USA; SW INST CLIN RES, RANCHO MIRAGE, CA USA; MEM HOSP BURLINGTON CTY, MT HOLLY, NJ USA; MED COLL PENN, PHILADELPHIA, PA 19129 USA; MED UNIV S CAROLINA, CHARLESTON, SC 29425 USA; UNIV MINNESOTA, SCH MED, MINNEAPOLIS, MN 55455 USA; VANDERBILT UNIV, MED CTR, SCH MED, NASHVILLE, TN 37232 USA; WASHINGTON UNIV, SCH MED, ST LOUIS, MO 63110 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, PHILADELPHIA, PA 19107 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, RICHMOND, VA 23298 USA; PACIFIC RES NETWORK, SAN DIEGO, CA USA; CAROLINA NEUROL CLIN, CHARLOTTE, NC USA; CLIN TRIALS CTR, SPRINGFIELD, MO USA; CTR CLIN NEUROL STUDIES, KANSAS CITY, MO USA; W PALM BEACH NEUROL GRP, W PALM BEACH, FL USA; UNIV SO CALIF, LOS ANGELES, CA 90089 USA; PACIFIC NW RES CTR, PORTLAND, OR USA; SW VERMONT MED CTR, BENNINGTON, VT USA	University of Minnesota System; University of Minnesota Twin Cities; Williams College; University of Vermont; University of Iowa; Rush University; Cornell University; Loyola University Chicago; University of Missouri System; University of Missouri Columbia; Baylor College of Medicine; Indiana University System; Indiana University-Purdue University Indianapolis; University of Michigan System; University of Michigan; Drexel University; Medical University of South Carolina; University of Minnesota System; University of Minnesota Twin Cities; Vanderbilt University; Washington University (WUSTL); Jefferson University; Virginia Commonwealth University; University of Southern California	KNAPP, MJ (corresponding author), PARKE DAVIS & CO, PHARMACEUT RES, CLIN RES DEPT, 2800 PLYMOUTH RD, ANN ARBOR, MI 48106 USA.		Morris, John C/A-1686-2012; Giordani, Bruno/AAR-1910-2021; Kellner, Charles/ABC-3434-2020					BECKER JT, 1988, ARCH NEUROL-CHICAGO, V45, P263, DOI 10.1001/archneur.1988.00520270037018; BOWEN DM, 1982, J NEUROL SCI, V57, P191, DOI 10.1016/0022-510X(82)90026-0; BOWEN DM, 1976, BRAIN, V99, P459, DOI 10.1093/brain/99.3.459; BURNS A, 1991, J AM GERIATR SOC, V39, P39, DOI 10.1111/j.1532-5415.1991.tb05904.x; DAVIES P, 1976, LANCET, V2, P1403; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; DEJONG R, 1989, CLIN THER, V11, P545; FARLOW M, 1992, JAMA-J AM MED ASSOC, V268, P2523, DOI 10.1001/jama.268.18.2523; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GALASKO D, 1991, J AM GERIATR SOC, V39, P932, DOI 10.1111/j.1532-5415.1991.tb04463.x; GAUTHIER S, 1990, NEW ENGL J MED, V322, P1272, DOI 10.1056/NEJM199005033221804; KNOPMAN D, 1994, NEUROLOGY, V44, P260, DOI 10.1212/WNL.44.2.260; KRAMERGINSBERG E, 1988, PSYCHOPHARMACOL BULL, V24, P458; LANDIS JR, 1978, INT STAT REV, V46, P237, DOI 10.2307/1402373; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MOHS RC, 1985, AM J PSYCHIAT, V142, P28; ORTOF E, 1989, J AM GERIATR SOC, V37, P511, DOI 10.1111/j.1532-5415.1989.tb05681.x; PERRY EK, 1977, LANCET, V1, P189; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; SALMON DP, 1990, NEUROLOGY, V40, P1225, DOI 10.1212/WNL.40.8.1225; SCHNEIDER LS, 1992, J AM GERIATR SOC, V40, P537, DOI 10.1111/j.1532-5415.1992.tb02030.x; Snedecor G. W, 1989, STAT METHODS, V8th; SUMMERS WK, 1986, NEW ENGL J MED, V315, P1241, DOI 10.1056/NEJM198611133152001; UHLMANN RF, 1986, J AM GERIATR SOC, V34, P207, DOI 10.1111/j.1532-5415.1986.tb04204.x; WHITEHOUSE PJ, 1981, ANN NEUROL, V10, P122, DOI 10.1002/ana.410100203; 1989, SAS STAT USERS GUIDE	28	920	934	0	34	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	1994	271	13					985	991		10.1001/jama.271.13.985	http://dx.doi.org/10.1001/jama.271.13.985			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND949	8139083				2022-12-28	WOS:A1994ND94900027
J	SHAKKED, Z; GUZIKEVICHGUERSTEIN, G; FROLOW, F; RABINOVICH, D; JOACHIMIAK, A; SIGLER, PB				SHAKKED, Z; GUZIKEVICHGUERSTEIN, G; FROLOW, F; RABINOVICH, D; JOACHIMIAK, A; SIGLER, PB			DETERMINANTS OF REPRESSOR-OPERATOR RECOGNITION FROM THE STRUCTURE OF THE TRP OPERATOR BINDING-SITE	NATURE			English	Article							DNA DOUBLE HELIX; T-C-G; B-DNA; RESOLUTION; CRYSTAL; COMPLEX	ON the basis of the crystal structure of the trp repressor/operator complex1, it has been proposed that the specificity of the interaction can be explained not only by direct hydrogen bonding and non-polar contacts between the protein and the bases of its target DNA, but also by indirect structural effects and water-mediated interactions. To understand the contribution of DNA structure and hydration in this context, the structure of the free DNA must be compared with its structure when complexed with the protein. Here we present the high-resolution crystal structure of the trp operator region that is most important in the recognition process. By comparing the free and bound states of the DNA regulatory sequence, we show that the structure and hydration of the DNA target are important elements in its recognition by the repressor protein.	YALE UNIV,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University	SHAKKED, Z (corresponding author), WEIZMANN INST SCI,DEPT STRUCT BIOL,IL-76100 REHOVOT,ISRAEL.		Frolow, Felix/A-1760-2013					BAIKALOV I, 1993, J MOL BIOL, V231, P768, DOI 10.1006/jmbi.1993.1325; Brunger AT, 1992, X PLOR VERSION 3 0 S; Chandrasekaran R., 1989, LANDOLTBORNSTEIN B, V1/II, P31; Dickerson RE, 1989, EMBO J, V8, P1; GRZESKOWIAK K, 1991, J BIOL CHEM, V266, P8861; HEINEMANN U, 1989, J MOL BIOL, V210, P369, DOI 10.1016/0022-2836(89)90337-9; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; LIPANOV A, 1993, BIOCHEMISTRY-US, V32, P1373, DOI 10.1021/bi00056a024; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PRIVE GG, 1991, J MOL BIOL, V217, P177, DOI 10.1016/0022-2836(91)90619-H; QUINTANA J, 1991, J MOL BIOL, V225, P379; RABINOVICH D, 1984, ACTA CRYSTALLOGR A, V40, P195, DOI 10.1107/S010876738400043X; SCHNEIDER B, 1992, BIOPOLYMERS, V32, P725, DOI 10.1002/bip.360320703; SHAKKED Z, 1989, NATURE, V342, P456, DOI 10.1038/342456a0; SHAKKED Z, 1986, PROG BIOPHYS MOL BIO, V47, P159, DOI 10.1016/0079-6107(86)90013-1; Shakked Z, 1991, CURR OPIN STRUC BIOL, V1, P446, DOI 10.1016/0959-440X(91)90046-V; SIGLER PB, 1992, TRANSCRIPTIONAL REGU, V1, P475; TIMSIT Y, 1989, NATURE, V341, P459, DOI 10.1038/341459a0; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; YUAN H, 1992, BIOCHEMISTRY-US, V31, P8009, DOI 10.1021/bi00149a035	22	165	169	2	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 31	1994	368	6470					469	473		10.1038/368469a0	http://dx.doi.org/10.1038/368469a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	8133895				2022-12-28	WOS:A1994ND12000068
J	ALDHOUS, P				ALDHOUS, P			SWEDEN - LEVELING THE PLAYING FIELD IN STOCKHOLM	SCIENCE			English	Article																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1482	1482		10.1126/science.8128233	http://dx.doi.org/10.1126/science.8128233			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128233				2022-12-28	WOS:A1994MZ92700046
J	HEMMI, S; BOHNI, R; STARK, G; DIMARCO, F; AGUET, M				HEMMI, S; BOHNI, R; STARK, G; DIMARCO, F; AGUET, M			A NOVEL MEMBER OF THE INTERFERON RECEPTOR FAMILY COMPLEMENTS FUNCTIONALITY OF THE MURINE INTERFERON-GAMMA RECEPTOR IN HUMAN-CELLS	CELL			English	Article							SIGNAL TRANSDUCER GP130; MOLECULAR-CLONING; INTERLEUKIN-5 RECEPTOR; EXTRACELLULAR DOMAIN; EXPRESSION CLONING; ACCESSORY FACTOR; GENE PROMOTER; GM-CSF; CDNA; ALPHA	Expression of the human interferon gamma receptor (IFN-gamma R) in mouse cells is not sufficient to confer biological responsiveness to human IFN-gamma and vice versa. An additional species-specific component is required for signal transduction. We identified this cofactor by expression cloning in simian COS cells stably transfected with the nonfunctional murine IFN-gamma R and a IFN-gamma-inducible reporter construct encoding the human Tac antigen (interleukin-2 receptor alpha chain, CD25). A cDNA clone was obtained that, upon stable transfection, rendered human HEp-2 cells expressing the murine IFN-gamma R fully responsive to murine IFN-gamma. This cDNA encodes a novel 332 amino acid type I transmembrane protein that belongs to the IFN receptor family and that we designate IFN-gamma R beta chain.			HEMMI, S (corresponding author), UNIV ZURICH,INST MOLEC BIOL 1,HONGGERBERG,CH-8093 ZURICH,SWITZERLAND.							AGUET M, 1987, J EXP MED, V165, P988, DOI 10.1084/jem.165.4.988; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BASU M, 1989, J INTERFERON RES, V9, P551, DOI 10.1089/jir.1989.9.551; BAZAN JF, 1990, CELL, V61, P753, DOI 10.1016/0092-8674(90)90182-E; CALOS MP, 1983, P NATL ACAD SCI-BIOL, V80, P3015, DOI 10.1073/pnas.80.10.3015; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GAUTIER C, 1989, NUCLEIC ACIDS RES, V17, P8389, DOI 10.1093/nar/17.20.8389; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; HIBINO Y, 1991, J BIOL CHEM, V266, P6948; HO YAS, 1993, P NATL ACAD SCI USA, V90, P11267; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KALINA U, 1993, J VIROL, V67, P1702, DOI 10.1128/JVI.67.3.1702-1706.1993; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUHL D, 1987, CELL, V50, P1057, DOI 10.1016/0092-8674(87)90172-3; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; MACDONALD NJ, 1990, CELL, V60, P737; MCGEADY ML, 1986, DNA-J MOLEC CELL BIO, V5, P289, DOI 10.1089/dna.1986.5.289; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; SAILER A, 1992, NUCLEIC ACIDS RES, V20, P2374, DOI 10.1093/nar/20.9.2374; Sailer Andreas, 1992, Gene Expression, V2, P329; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHORLE H, 1991, NATURE, V352, P62162; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WATSON N, 1988, GENE, V70, P399, DOI 10.1016/0378-1119(88)90212-0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	59	191	197	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 11	1994	76	5					803	810		10.1016/0092-8674(94)90355-7	http://dx.doi.org/10.1016/0092-8674(94)90355-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124717				2022-12-28	WOS:A1994NA89000006
J	SCHALLREUTER, KU; WOOD, JM; PITTELKOW, MR; GUTLICH, M; LEMKE, KR; RODL, W; SWANSON, NN; HITZEMANN, K; ZIEGLER, I				SCHALLREUTER, KU; WOOD, JM; PITTELKOW, MR; GUTLICH, M; LEMKE, KR; RODL, W; SWANSON, NN; HITZEMANN, K; ZIEGLER, I			REGULATION OF MELANIN BIOSYNTHESIS IN THE HUMAN EPIDERMIS BY TETRAHYDROBIOPTERIN	SCIENCE			English	Article							PHENYLALANINE-HYDROXYLASE	The participation of (6R) 5,6,7,8-tetrahydrobiopterin (6-BH4) in regulating the tyrosine supply for melanin biosynthesis was investigated by the examination of human keratinocytes, melanocytes, and epidermal suction blisters from normal human skin and from patients with the depigmentation disorder vitiligo. Cells, as well as total epidermis, contained high phenylalanine hydroxylase activities and also displayed the capacity to synthesize and recycle 6-BH4, the essential cofactor for this enzyme. In vitiligo, 4a-hydroxy-BH4 dehydratase activity was extremely low or absent, yielding an accumulation of the nonenzymatic by-product 7-tetrahydrobiopterin (7-BH4) at concentrations up to 8 x 10(-6) M in the epidermis. This by-product is a potent competitive inhibitor in the phenylalanine hydroxylase reaction with an inhibition constant of 10(-6) M. Thus, 6-BH4 seems to control melanin biosynthesis in the human epidermis, whereas 7-BH4 may initiate depigmentation in patients with vitiligo.	UNIV BRADFORD, DEPT BIOMED SCI, BRADFORD BD7 1OP, W YORKSHIRE, ENGLAND; MAYO CLIN & MAYO FDN, DEPT DERMATOL, ROCHESTER, MN 55905 USA; GSF MUNICH, INST CLIN MOLEC BIOL & TUMOR GENET, D-81377 MUNICH, GERMANY	University of Bradford; Mayo Clinic; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	SCHALLREUTER, KU (corresponding author), UNIV HAMBURG, DEPT DERMATOL, MARTINISTR 52, D-20246 HAMBURG, GERMANY.							ABITA JP, 1987, METHOD ENZYMOL, V142, P27; BURG AW, 1968, J BIOL CHEM, V243, P2349; CURTIUS HC, 1990, J BIOL CHEM, V265, P3923; DAVIS MD, 1992, P NATL ACAD SCI USA, V89, P10109, DOI 10.1073/pnas.89.21.10109; DAVIS MD, 1991, P NATL ACAD SCI USA, V88, P385, DOI 10.1073/pnas.88.2.385; DAVIS MD, 1989, J BIOL CHEM, V264, P8585; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; IOZUMI K, 1993, J INVEST DERMATOL, V100, P806, DOI 10.1111/1523-1747.ep12476630; IWATA M, 1990, J INVEST DERMATOL, V95, P9, DOI 10.1111/1523-1747.ep12872677; KAUFMAN S, 1962, OXYGENASES, P285; KERLER F, 1990, J CELL PHYSIOL, V142, P268, DOI 10.1002/jcp.1041420208; LERNER AB, 1959, J INVEST DERMATOL, V32, P285, DOI 10.1038/jid.1959.49; Prota G., 1992, MELANINS MELANOGENES; SCHALLREUTER KU, 1992, BIOCHEM BIOPH RES CO, V189, P72, DOI 10.1016/0006-291X(92)91527-W; WILKE MS, 1988, AM J PATHOL, V131, P171; WOOD JM, 1991, BIOCHIM BIOPHYS ACTA, V1074, P378, DOI 10.1016/0304-4165(91)90088-X; ZIEGLER I, 1992, FEBS LETT, V307, P147, DOI 10.1016/0014-5793(92)80755-6	17	283	287	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 11	1994	263	5152					1444	1446		10.1126/science.8128228	http://dx.doi.org/10.1126/science.8128228			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128228				2022-12-28	WOS:A1994MZ92700034
J	PICOT, D; LOLL, PJ; GARAVITO, RM				PICOT, D; LOLL, PJ; GARAVITO, RM			THE X-RAY CRYSTAL-STRUCTURE OF THE MEMBRANE-PROTEIN PROSTAGLANDIN-H(2) SYNTHASE-1	NATURE			English	Article							HIGHER OXIDATION-STATES; CYTOCHROME-C PEROXIDASE; ENDOPEROXIDE SYNTHASE; H SYNTHASE; COMPLEMENTARY-DNA; CYCLOOXYGENASE; ENZYME; SPECTROSCOPY; RESOLUTION; CATALYSIS	The three-dimensional structure of prostaglandin H-2 synthase-1, an integral membrane Protein, has been determined at 3.5 angstrom resolution by X-ray crystallography. This bifunctional enzyme comprises three independent folding units: an epidermal growth factor domain, a membrane-binding motif and an enzymatic domain. Two adjacent but spatially distinct active sites were found for its haem-dependent peroxidase and cyclooxygenase activities. The cyclooxygenase active site is created by a long, hydrophobic channel that is the site of non-steroidal anti-inflammatory drug binding. The conformation of the membrane-binding motif strongly suggests that the enzyme integrates into only one leaflet of the lipid bilayer and is thus a monotopic membrane protein.	UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, 920 E 58TH ST, CHICAGO, IL 60637 USA	University of Chicago				Picot, Daniel/0000-0002-1375-1490				ABRAMSON S, 1991, Current Opinion in Rheumatology, V3, P336, DOI 10.1097/00002281-199106000-00002; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRUNGER AT, 1992, XPLOR MANUAL VERSION; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; ERMAN JE, 1992, J AM CHEM SOC, V114, P6592, DOI 10.1021/ja00042a068; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9; FLOWER RJ, 1974, PHARMACOL RES COMMUN, V26, P33; GARAVITO R M, 1990, Methods (Orlando), V1, P57, DOI 10.1016/S1046-2023(05)80147-1; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAISER ET, 1987, ANNU REV BIOPHYS BIO, V16, P561; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1989, J BIOL CHEM, V264, P14136; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LANDS WEM, 1984, FREE RADICAL BIO MED, V6, P34; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MAKHEJA AN, 1992, MOL CELL BIOCHEM, V111, P137; MARNETT L J, 1990, Environmental Health Perspectives, V88, P5, DOI 10.2307/3431044; Marnett L. J., 1991, PEROXIDASES CHEM BIO, V1, P293; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MONTELIONE GT, 1992, BIOCHEMISTRY-US, V31, P236, DOI 10.1021/bi00116a033; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OTTO JC, 1993, J BIOL CHEM, V268, P18234; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PASCHER I, 1987, BIOCHIM BIOPHYS ACTA, V896, P77, DOI 10.1016/0005-2736(87)90358-0; PICOT D, 1989, CYTOCHROME P, V450, P29; POULOS TL, 1993, J BIOL CHEM, V268, P4429; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; Smith W.L.B.P., 1991, BIOCH LIPIDS LIPOPRO, P297, DOI [10.1016/S0167-7306(08)60338-5, DOI 10.1016/S0167-7306(08)60338-5]; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; TOH H, 1989, FEBS LETT, V258, P317, DOI 10.1016/0014-5793(89)81683-7; VANE J, 1987, FASEB J, V1, P89, DOI 10.1096/fasebj.1.2.3111928; WILLARD JE, 1992, NEW ENGL J MED, V327, P175; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	49	1114	1139	0	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	1994	367	6460					243	249		10.1038/367243a0	http://dx.doi.org/10.1038/367243a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	8121489				2022-12-28	WOS:A1994MR49400046
J	JABS, EW; MULLER, U; LI, X; MA, L; LUO, W; HAWORTH, IS; KLISAK, I; SPARKES, R; WARMAN, ML; MULLIKEN, JB; SNEAD, ML; MAXSON, R				JABS, EW; MULLER, U; LI, X; MA, L; LUO, W; HAWORTH, IS; KLISAK, I; SPARKES, R; WARMAN, ML; MULLIKEN, JB; SNEAD, ML; MAXSON, R			A MUTATION IN THE HOMEODOMAIN OF THE HUMAN MSX2 GENE IN A FAMILY AFFECTED WITH AUTOSOMAL-DOMINANT CRANIOSYNOSTOSIS	CELL			English	Article							HOMEOBOX-CONTAINING GENE; INSITU HYBRIDIZATION; EXPRESSION; TOOTH; CHROMOSOMES; MESENCHYME; SEQUENCE; LINKAGE; ELEMENT; HOX-8	Craniosynostosis, the premature fusion of calvarial sutures, is a common developmental anomaly that causes abnormal skull shape. The locus for one autosomal dominant form of craniosynostosis has been mapped to chromosome 5qter. The human MSX2 gene localizes to chromosome 5, and a polymorphic marker in the MSX2 intron segregates in a kindred with the disorder with no recombination. Moreover, a histidine substitutes for a highly conserved proline at position 7 of the MSX2 homeodomain exclusively in affected members. In the mouse, transcripts of the Msx2 gene are localized to calvarial sutures. These results provide compelling evidence that the mutation causes this craniosynostosis syndrome.	JUSTUS LIEBIG UNIV,INST HUMANGENET,D-35392 GIESSEN,GERMANY; KENNETH R NORRIS CANC HOSP & INST,INST GENET MED,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033; CHILDRENS HOSP MED CTR,DIV PLAST SURG,CTR CRANIOFACIAL,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DIV GENET,BOSTON,MA 02115; JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,DEPT SURG,BALTIMORE,MD; UNIV SO CALIF,SCH DENT,CTR CRANIOFACIAL MOLEC BIOL,LOS ANGELES,CA 90089; UNIV SO CALIF,SCH PHARM,DEPT PHARMACEUT SCI,LOS ANGELES,CA 90089; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024	Justus Liebig University Giessen; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Johns Hopkins University; Johns Hopkins University; University of Southern California; University of Southern California; University of California System; University of California Los Angeles	JABS, EW (corresponding author), JOHNS HOPKINS UNIV,DEPT PEDIAT,CTR MED GENET,BALTIMORE,MD 21287, USA.			Jabs, Ethylin/0000-0001-8983-5466	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010180] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00052] Funding Source: Medline; NICHD NIH HHS [HD24061] Funding Source: Medline; NIDCR NIH HHS [DE10180] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANGERER RC, 1983, TIME SPACE PATTERN E, P101; BELL JR, 1993, HOX, V8, P123; BHATT B, 1988, NUCLEIC ACIDS RES, V16, P3951, DOI 10.1093/nar/16.9.3951; BRUETON LA, 1992, J MED GENET, V29, P681, DOI 10.1136/jmg.29.10.681; CANNIZZARO LA, 1984, CYTOGENET CELL GENET, V38, P308, DOI 10.1159/000132079; Christiansen RL, 1980, CURRENT RES TRENDS P, P47; COELHO CND, 1991, MECH DEVELOP, V34, P143, DOI 10.1016/0925-4773(91)90051-7; Cohen, 1986, CRANIOSYNOSTOSIS DIA; COHEN MM, 1993, IN PRESS AM J MED GE, V47; CONLON RA, 1992, DEVELOPMENT, V116, P357; DAVIDSON DR, 1991, NATURE, V352, P429, DOI 10.1038/352429a0; DECKER JD, 1985, ANAT RECORD, V212, P81, DOI 10.1002/ar.1092120112; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; FURTWANGLER JA, 1985, ACTA ANAT, V124, P74; Gorlin RJ, 1990, PLAST RECONSTR SURG; HEWITT JE, 1991, GENOMICS, V11, P670, DOI 10.1016/0888-7543(91)90074-O; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; JOHANSEN VA, 1982, ACTA ANT, V114, P8; JOWETT AK, 1993, DEVELOPMENT, V117, P461; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LAMMER EJ, 1987, P GREENWOOD GENET CT, V6, P126; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MACKENZIE A, 1992, DEVELOPMENT, V115, P403; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; MULLER U, 1993, MOL GENET, V2, P119; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; ROBERT B, 1991, GENE DEV, V5, P2363, DOI 10.1101/gad.5.12b.2363; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; SNEAD ML, 1988, DEVELOPMENT, V104, P77; SNEAD ML, 1989, DEV BIOL, V134, P420, DOI 10.1016/0012-1606(89)90114-0; SU MW, 1991, DEVELOPMENT, V111, P1179; TAKAHASHI Y, 1991, EMBO J, V10, P2387, DOI 10.1002/j.1460-2075.1991.tb07777.x; TAKAHASHI Y, 1990, P NATL ACAD SCI USA, V87, P7482, DOI 10.1073/pnas.87.19.7482; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; WARMAN ML, 1993, AM J MED GENET, V46, P444, DOI 10.1002/ajmg.1320460420	38	566	579	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 5	1993	75	3					443	450		10.1016/0092-8674(93)90379-5	http://dx.doi.org/10.1016/0092-8674(93)90379-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MF830	8106171				2022-12-28	WOS:A1993MF83000007
J	OSSWALD, S; TROUTON, TG				OSSWALD, S; TROUTON, TG			NEUROCARDIOGENIC (VASODEPRESSOR) SYNCOPE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											OSSWALD, S (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.		Osswald, Stefan/A-6904-2018	Osswald, Stefan/0000-0002-9240-6731					0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1993	329	1					30	30						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ338	8110215				2022-12-28	WOS:A1993LJ33800006
J	CANTWELL, MF; SHEHAB, ZM; COSTELLO, AM; SANDS, L; GREEN, WF; EWING, EP; VALWAY, SE; ONORATO, IM				CANTWELL, MF; SHEHAB, ZM; COSTELLO, AM; SANDS, L; GREEN, WF; EWING, EP; VALWAY, SE; ONORATO, IM			CONGENITAL TUBERCULOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							NEONATAL TUBERCULOSIS; MOTHER		CTR DIS CONTROL, CTR INFECT DIS, SCI RESOURCES PROGRAM, ATLANTA, GA 30333 USA; UNIV ARIZONA, STEELE MEM CHILDRENS RES CTR, TUCSON, AZ USA; UNIV ARIZONA, DEPT PEDIAT, TUCSON, AZ USA; UNIV ARIZONA, MED CTR, TUCSON, AZ USA; ARIZONA DEPT HLTH SERV, PHOENIX, AZ USA; PUBL HLTH SERV INDIAN HOSP, ALBUQUERQUE, NM USA	Centers for Disease Control & Prevention - USA; University of Arizona; University of Arizona; University of Arizona; Arizona Department of Health Services	CANTWELL, MF (corresponding author), CTR DIS CONTROL, DIV TB ELIMINAT, 1600 CLIFTON RD, E-10, ATLANTA, GA 30333 USA.							AIREDE KI, 1990, ANN TROP PAEDIATR, V10, P363, DOI 10.1080/02724936.1990.11747458; ASENSI F, 1990, PEDIATR INFECT DIS J, V9, P223, DOI 10.1097/00006454-199003000-00021; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BATE TWP, 1986, ARCH DIS CHILD, V61, P512, DOI 10.1136/adc.61.5.512; Beitzke H., 1935, ERGEB GES TUBERK FOR, V7, P1; BLACKALL PB, 1969, MED J AUSTRALIA, V2, P1055, DOI 10.5694/j.1326-5377.1969.tb107597.x; COOPER AR, 1985, PEDIATR INFECT DIS J, V4, P181, DOI 10.1097/00006454-198503000-00014; CORNER BERYL D., 1955, THORAX, V10, P99, DOI 10.1136/thx.10.2.99; FOO AL, 1993, TUBERCLE LUNG DIS, V74, P59, DOI 10.1016/0962-8479(93)90070-E; HAGEMAN J, 1980, PEDIATRICS, V66, P980; Haumann T J, 1988, Ned Tijdschr Geneeskd, V132, P1116; HUGHESDON MR, 1946, ARCH DIS CHILD, V21, P121, DOI 10.1136/adc.21.107.121; KANG G H, 1990, Journal of Korean Medical Science, V5, P59; LI CK, 1989, AUST PAEDIATR J, V25, P366; MACHIN GA, 1992, PEDIATR PATHOL, V12, P707, DOI 10.3109/15513819209024224; MATHUR R P, 1987, Indian Pediatrics, V24, P1144; MCCRAY MK, 1981, ARCH DERMATOL, V117, P460, DOI 10.1001/archderm.117.8.460; MYERS JP, 1981, PEDIATRICS, V67, P89; NARANBHAI RC, 1989, ARCH DIS CHILD, V64, P738, DOI 10.1136/adc.64.5.738; NEMIR RL, 1985, AM J DIS CHILD, V139, P284, DOI 10.1001/archpedi.1985.02140050078028; NILES RA, 1982, AM J OBSTET GYNECOL, V144, P131, DOI 10.1016/0002-9378(82)90611-1; PETRINI B, 1983, SCAND J INFECT DIS, V15, P403, DOI 10.3109/inf.1983.15.issue-4.12; RATNER B, 1951, AMA AM J DIS CHILD, V81, P471, DOI 10.1001/archpedi.1951.02040030482002; RICH AR, 1951, PATHOGENESIS TUBERCU, P72; SATHIAKUMAR N, 1987, Nigerian Journal of Paediatrics, V14, P27; SCHAAF HS, 1989, CLIN PEDIATR, V28, P474, DOI 10.1177/000992288902801010; SIEGEL M, 1934, AM REV TUBERC, V29, P297; SMITH MHD, 1990, INFECT DIS, P839; STALLWORTH JR, 1980, AM J DIS CHILD, V134, P320, DOI 10.1001/archpedi.1980.02130150074021; THORA S, 1985, Indian Journal of Pediatrics, V52, P425, DOI 10.1007/BF02806636; VALLEJO JG, 1992, CLIN CHEST MED, V13, P693; Vidwans M A, 1992, Indian Pediatr, V29, P763; YEN CM, 1984, ACTA PAEDIATR SIN, V25, P412; [No title captured]; 1993, MMWR MORB MORTAL WKL, V42, P1	35	227	249	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 14	1994	330	15					1051	1054		10.1056/NEJM199404143301505	http://dx.doi.org/10.1056/NEJM199404143301505			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF022	8127333				2022-12-28	WOS:A1994NF02200005
J	CALIFF, RM; SHADOFF, N; VALETT, N; BATES, E; GALEANA, A; KNOPF, W; SHAFTEL, J; BENDER, MJ; AVERSANO, T; RAQUENO, J; GURBEL, P; COWFER, J; COHEN, M; CROSS, P; BITTL, J; EDDINGS, K; TAYLOR, M; DEROSA, K; HATTEL, L; COOPER, L; ESHELMAN, B; FINTEL, D; NIEMYSKI, P; KLEIN, L; KENNEDY, H; THORNTON, T; KEREIAKES, D; MARTIN, L; ANDERSON, L; HIGBY, N; ELLIS, S; BREZINA, K; GEORGE, B; CHAPEKIS, A; SMITH, D; ANWAR, A; GERBER, TL; PRITCHARD, GL; MYLER, R; SHAW, R; MURPHY, M; WARD, K; MADIGAN, NP; BLANKENSHIP, J; HALBERT, M; FLANAGAN, C; TANNENBAUM, M; POLICH, M; STEVENSON, C; TCHENG, J; HOFFMAN, S; MOORE, RM; SMITH, J; HENRY, P; MCDONOUGH, TJ; WESZT, S; BRODIE, B; MUNCY, D; KLEIMAN, N; TRAINOR, K; ROSE, D; JOHNSON, S; WILLERSON, J; FERGUSON, JJ; HARLAN, M; BASS, TA; ROHMAN, G; BROWNE, K; CIESLA, C; WORLEY, S; TUZI, J; HETTLEMAN, B; BURKE, WC; OLSEN, G; KENNEDY, SJ; TALLEY, JD; YUSSMAN, ZA; RAWERT, M; GRASSMAN, ED; WRONA, L; SAMAHA, J; EHEMANN, B; BLEICH, SD; LEONHARD, R; CUMMINS, F; NONNWEILER, J; SANZ, M; MAYER, D; CLEMAN, MW; PASCALE, VJ; MCCONNELL, S; DELCORE, M; STENGEL, L; IVANHOE, RJ; GRANGER, N; ROSENBERG, MJ; SCHAECHTER, A; AYCOCK, G; WILCOX, T; GOTTLIEB, R; HUNTER, H; UNTERECKER, W; HART, B; HEUSER, R; HOOPMANN, S; HANOVICH, G; ANTOLICK, A; GACIOCH, G; CHIODO, V; KARSKI, K; TIMMIS, G; SAFIAN, M; AGUIRRE, F; STONNER, T; TAYLOR, GJ; WOMACK, K; RUYLE, B; KRAUTHAMER, D; WELCOM, G; WESTON, M; DILLON, K; FRENCH, WJ; REYNOLDS, GT; NAVETTA, F; MURPHY, G; LEBOEUF, R; SPENCER, S; POPMA, JJ; SWEET, L; TOPOL, EJ; SMITH, CR; WEISMAN, H; LEE, KL; MILLER, J; SIGMON, K; TCHENG, J; LEE, KL; LUI, M; KOSLOFF, A; DIFULVIO, J; WANG, AL; ANDERSON, K; WEISMAN, H; DANN, R; KINGMA, W; NORTON, D; MYER, B; MASEK, R; LEWANDOWSKI, M; BRODERICK, S; MUSCO, M; SCHORR, M; HARTMAN, P; MCCARDLE, L; FAXON, D; ARMSTRONG, P; GORE, J; LOSCALZO, J; MCCULLOUGH, L; VERTER, J; MARK, DB; DAVIDSONRAY, L; CLAPPCHANNING, N; LAM, LC; WAUGH, RA; MCCANTS, CB; HINDMAN, MC; DEHMER, G; HILLEGASS, WB; FRID, DJ; FORTIN, DF; BROTT, BC; FOREST, TL; UNKS, DM; HAMER, ME; WAGNER, GS; GATES, K; SANE, D				CALIFF, RM; SHADOFF, N; VALETT, N; BATES, E; GALEANA, A; KNOPF, W; SHAFTEL, J; BENDER, MJ; AVERSANO, T; RAQUENO, J; GURBEL, P; COWFER, J; COHEN, M; CROSS, P; BITTL, J; EDDINGS, K; TAYLOR, M; DEROSA, K; HATTEL, L; COOPER, L; ESHELMAN, B; FINTEL, D; NIEMYSKI, P; KLEIN, L; KENNEDY, H; THORNTON, T; KEREIAKES, D; MARTIN, L; ANDERSON, L; HIGBY, N; ELLIS, S; BREZINA, K; GEORGE, B; CHAPEKIS, A; SMITH, D; ANWAR, A; GERBER, TL; PRITCHARD, GL; MYLER, R; SHAW, R; MURPHY, M; WARD, K; MADIGAN, NP; BLANKENSHIP, J; HALBERT, M; FLANAGAN, C; TANNENBAUM, M; POLICH, M; STEVENSON, C; TCHENG, J; HOFFMAN, S; MOORE, RM; SMITH, J; HENRY, P; MCDONOUGH, TJ; WESZT, S; BRODIE, B; MUNCY, D; KLEIMAN, N; TRAINOR, K; ROSE, D; JOHNSON, S; WILLERSON, J; FERGUSON, JJ; HARLAN, M; BASS, TA; ROHMAN, G; BROWNE, K; CIESLA, C; WORLEY, S; TUZI, J; HETTLEMAN, B; BURKE, WC; OLSEN, G; KENNEDY, SJ; TALLEY, JD; YUSSMAN, ZA; RAWERT, M; GRASSMAN, ED; WRONA, L; SAMAHA, J; EHEMANN, B; BLEICH, SD; LEONHARD, R; CUMMINS, F; NONNWEILER, J; SANZ, M; MAYER, D; CLEMAN, MW; PASCALE, VJ; MCCONNELL, S; DELCORE, M; STENGEL, L; IVANHOE, RJ; GRANGER, N; ROSENBERG, MJ; SCHAECHTER, A; AYCOCK, G; WILCOX, T; GOTTLIEB, R; HUNTER, H; UNTERECKER, W; HART, B; HEUSER, R; HOOPMANN, S; HANOVICH, G; ANTOLICK, A; GACIOCH, G; CHIODO, V; KARSKI, K; TIMMIS, G; SAFIAN, M; AGUIRRE, F; STONNER, T; TAYLOR, GJ; WOMACK, K; RUYLE, B; KRAUTHAMER, D; WELCOM, G; WESTON, M; DILLON, K; FRENCH, WJ; REYNOLDS, GT; NAVETTA, F; MURPHY, G; LEBOEUF, R; SPENCER, S; POPMA, JJ; SWEET, L; TOPOL, EJ; SMITH, CR; WEISMAN, H; LEE, KL; MILLER, J; SIGMON, K; TCHENG, J; LEE, KL; LUI, M; KOSLOFF, A; DIFULVIO, J; WANG, AL; ANDERSON, K; WEISMAN, H; DANN, R; KINGMA, W; NORTON, D; MYER, B; MASEK, R; LEWANDOWSKI, M; BRODERICK, S; MUSCO, M; SCHORR, M; HARTMAN, P; MCCARDLE, L; FAXON, D; ARMSTRONG, P; GORE, J; LOSCALZO, J; MCCULLOUGH, L; VERTER, J; MARK, DB; DAVIDSONRAY, L; CLAPPCHANNING, N; LAM, LC; WAUGH, RA; MCCANTS, CB; HINDMAN, MC; DEHMER, G; HILLEGASS, WB; FRID, DJ; FORTIN, DF; BROTT, BC; FOREST, TL; UNKS, DM; HAMER, ME; WAGNER, GS; GATES, K; SANE, D			USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVATED CLOTTING TIME; CREATINE KINASE-MB; MYOCARDIAL-INFARCTION; THROMBOLYTIC THERAPY; TASK-FORCE; DIPYRIDAMOLE; TRANSFUSION; PREDICTORS; PREVENTION; INFECTION	Background. Platelets are believed to play a part in the ischemic complications of coronary angioplasty, such as abrupt closure of the coronary vessel during or soon after the procedure. Accordingly, we evaluated the effect of a chimeric monoclonal-antibody Fab fragment (c7E3 Fab) directed against the platelet glycoprotein IIb/IIIa receptor, in patients undergoing angioplasty who were at high risk for ischemic complications. This receptor is the final common pathway for platelet aggregation. Methods. In a prospective, randomized, double-blind trial, 2099 patients treated at 56 centers received a bolus and an infusion of placebo, a bolus of c7E3 Fab and an infusion of placebo, or a bolus and an infusion of c7E3 Fab. They were scheduled to undergo coronary angioplasty or atherectomy in high-risk clinical situations involving severe unstable angina, evolving acute myocardial infarction, or high-risk coronary morphologic characteristics. The primary study end point consisted of any of the following: death, nonfatal myocardial infarction, unplanned surgical revascularization, unplanned repeat percutaneous procedure, unplanned implantation of a coronary stent, or insertion of an intraaortic balloon pump for refractory ischemia. The numbers of end-point events were tabulated for 30 days after randomization. Results. As compared with placebo, the c7E3 Fab bolus and infusion resulted in a 35 percent reduction in the rate of the primary end point (12.8 vs. 8.3 percent, P = 0.008), whereas a 10 percent reduction was observed with the c7E3 Fab bolus alone (12.8 vs. 11.5 percent, P = 0.43). The reduction in the number of events with the c7E3 Fab bolus and infusion was consistent across the end points of unplanned revascularization procedures and nonfatal myocardial infarction. Bleeding episodes and transfusions were more frequent in the group given the c7E3 Fab bolus and infusion than in the other two groups. Conclusions. Ischemic complications of coronary angioplasty and atherectomy were reduced with a monoclonal antibody directed against the platelet IIb/IIIa glycoprotein receptor, although the risk of bleeding was increased.	PRESBYTERIAN HOSP,ALBUQUERQUE,NM; UNIV MICHIGAN,MED CTR,ANN ARBOR,MI 48109; ST JOSEPH HOSP,ATLANTA,GA; JOHNS HOPKINS UNIV HOSP,BALTIMORE,MD 21205; UNIV MARYLAND HOSP,BALTIMORE,MD 21201; ST FRANCIS HOSP,BEECH GROVE,IN; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; DEBORAH HEART & LUNG CTR,BROWNS MILLS,NJ 08015; DEPAUL HOSP,CHEYENNE,WY; NORTHWESTERN UNIV,CHICAGO,IL 60611; RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612; CHRIST HOSP,CINCINNATI,OH 45219; CLEVELAND CLIN,CLEVELAND,OH 44106; METHODISTS HOSP,COLUMBUS,OH; BAYLOR UNIV,DALLAS,TX; SAN FRANCISCO HEART INST,DALY CITY,CA; GEISINGER MED CTR,DANVILLE,PA 17822; MERCY HOSP,IOWA HEART CTR,DES MOINES,IA; DUKE UNIV,DURHAM,NC 27706; ST VINCENT HLTH CTR,ERIE,PA; EVANSTON HOSP CORP,EVANSTON,IL 60201; MOSES CONE HOSP,GREENSBORO,NC; BAYLOR UNIV,METHODIST BEN TAUB GEN HOSP,HOUSTON,TX; TEXAS HEART INST,HOUSTON,TX 77025; UNIV FLORIDA,MED CTR,JACKSONVILLE,FL; LAKELAND GEN HOSP,LAKELAND,FL; LANCASTER GEN HOSP,LANCASTER,PA; HITCHCOCK MED CTR,LEBANON,NH; UNIV LOUISVILLE,LOUISVILLE,KY 40292; LOYOLA UNIV HOSP,MAYWOOD,IL; BAPTIST MEM HOSP,MEMPHIS,TN 38146; E JEFFERSON HOSP,METAIRIE,LA; ST LUKES HOSP,MILWAUKEE,WI; ST PATRICKS HOSP,MISSOULA,MT; YALE UNIV,MED CTR,NEW HAVEN,CT 06520; CREIGHTON UNIV,CTR CARDIAC,OMAHA,NE 68178; FLORIDA HOSP,ORLANDO,FL; LUTHERAN GEN HOSP,PARK RIDGE,IL 60068; SACRED HEART,PENSACOLA,FL; GRAD HOSP PHILADELPHIA,PHILADELPHIA,PA 19146; PHILADELPHIA HEART INST,PHILADELPHIA,PA; ARIZONA HEART INST & FDN,PHOENIX,AZ; N MEM MED CTR,ROBBINSDALE,MN; ROCHESTER GEN HOSP,ROCHESTER,NY 14621; WILLIAM BEAUMONT HOSP,ROYAL OAK,MI 48072; ST LOUIS UNIV,ST LOUIS,MO 63103; ST JOHNS HOSP,SPRINGFIELD,IL; S MIAMI HOSP,MIAMI,FL; TAMPA GEN HOSP,TAMPA,FL 33606; UCLA,HARBOR MED CTR,TORRANCE,CA; MOTHER FRANCES HOSP,TYLER,TX; WASHINGTON HOSP CTR,WASHINGTON,DC 20010	University of Michigan System; University of Michigan; Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore; Harvard University; Brigham & Women's Hospital; Northwestern University; Rush University; Christ Hospital - Ohio; Cleveland Clinic Foundation; Baylor University; Geisinger Medical Center; Duke University; NorthShore University Health System; Moses Cone Memorial Hospital; Baylor University; Texas Heart Institute; State University System of Florida; University of Florida; University of Louisville; Loyola University Chicago; Baptist Memorial Hospital Memphis; Yale University; Creighton University; Adventist Health Services; AdventHealth; University of Pennsylvania; Pennsylvania Medicine; Arizona Heart Institute; Rochester General Hospital; Beaumont Health; Saint Louis University; Tampa General Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; MedStar Washington Hospital Center	CALIFF, RM (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DIV CARDIOL,BOX 31123,DURHAM,NC 27710, USA.		Smith, Jane/B-6254-2009; Loscalzo, Joseph/ABD-8980-2021; Blankenship, James/AAX-4084-2020; Dehmer, Gregory/AAQ-9380-2021	Blankenship, James/0000-0003-4966-533X; 				BARNATHAN ES, 1987, CIRCULATION, V76, P125, DOI 10.1161/01.CIR.76.1.125; CALIFF RM, 1990, CIRCULATION, V82, P1847, DOI 10.1161/01.CIR.82.5.1847; COLLER BS, 1985, BLOOD, V66, P1456; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; DETRE KM, 1990, CIRCULATION, V82, P739, DOI 10.1161/01.CIR.82.3.739; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; DOUGHERTY KG, 1990, CIRCULATION, V82, P189; ELLIS SG, 1988, CIRCULATION, V77, P372, DOI 10.1161/01.CIR.77.2.372; ELLIS SG, 1991, J AM COLL CARDIOL, V17, pB89; ELLIS SG, 1993, CORONARY ARTERY DIS, V4, P167, DOI 10.1097/00019501-199302000-00007; GRUENTZIG AR, 1987, NEW ENGL J MED, V316, P1127, DOI 10.1056/NEJM198704303161805; HARKER LA, 1987, AM J CARDIOL, V60, pB20; HUNT AC, 1991, EUR HEART J, V12, P690; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLEIN LW, 1991, J AM COLL CARDIOL, V17, P621, DOI 10.1016/S0735-1097(10)80174-3; LANDEFELD CS, 1987, AM J MED, V82, P703, DOI 10.1016/0002-9343(87)90004-0; LINCOFE AM, 1992, J AM COLL CARDIOL, V19, P926, DOI 10.1016/0735-1097(92)90272-O; MOUSHMOUSH B, 1992, CATHETER CARDIO DIAG, V27, P97, DOI 10.1002/ccd.1810270204; MYLER RK, 1990, CIRCULATION, V82, P88; NELSON KE, 1992, ANN INTERN MED, V117, P554, DOI 10.7326/0003-4819-117-7-554; OGILBY JD, 1989, CATHETER CARDIO DIAG, V18, P206, DOI 10.1002/ccd.1810180403; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PAULETTO P, 1987, AM J CARDIOL, V59, P999, DOI 10.1016/0002-9149(87)91145-3; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; RATH B, 1990, BRIT HEART J, V63, P18; RYAN TJ, 1988, CIRCULATION, V78, P486, DOI 10.1161/01.CIR.78.2.486; SANE DC, 1989, ANN INTERN MED, V111, P1010, DOI 10.7326/0003-4819-111-12-1010; SCHWARTZ L, 1988, NEW ENGL J MED, V318, P1714, DOI 10.1056/NEJM198806303182603; SIMOONS ML, 1994, CIRCULATION, V89, P596, DOI 10.1161/01.CIR.89.2.596; SPADARO JJ, 1986, CATHETER CARDIO DIAG, V12, P230, DOI 10.1002/ccd.1810120406; TENAGLIA AM, IN PRESS J AM COLL C; TENAGLIA AN, 1993, AM J CARDIOL, V72, P21, DOI 10.1016/0002-9149(93)90212-U; WALL TC, 1993, J AM COLL CARDIOL, V21, P597, DOI 10.1016/0735-1097(93)90090-N; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	37	2087	2124	0	33	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 7	1994	330	14					956	961		10.1056/nejm199404073301402	http://dx.doi.org/10.1056/nejm199404073301402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND793	8121459	Bronze			2022-12-28	WOS:A1994ND79300002
J	HERR, SS; HOPKINS, BL				HERR, SS; HOPKINS, BL			HEALTH-CARE DECISION-MAKING FOR PERSONS WITH DISABILITIES - AN ALTERNATIVE TO GUARDIANSHIP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SELF-DETERMINATION ACT; INFORMED CONSENT; PATIENT		BALTIMORE CITY COMMUNITY COLL,BALTIMORE,MD		HERR, SS (corresponding author), UNIV MARYLAND,SCH LAW,510 W BALTIMORE ST,BALTIMORE,MD 21201, USA.							APPLEBAUM PS, 1988, NEW ENGL J MED, V319, P1635; Barnes Alison Patrucco, 1992, Emory Law J, V41, P633; CASSILETH BR, 1980, NEW ENGL J MED, V302, P896, DOI 10.1056/NEJM198004173021605; FROLIK LA, 1991, HASTINGS LAW J, V42, P683; FROLIK LA, 1991, TRUSTS ESTATES, V130, P41; GILFIX MG, 1992, TRIAL, V28, P42; GOLD M, 1988, SURROGATE DECISION M; Goodenough Gerald K, 1988, J Contemp Law, V14, P53; HAFEMEISTER TL, 1984, LAW HUMAN BEHAV, V8, P335, DOI 10.1007/BF01044700; HIGH DM, 1988, GERONTOLOGIST, V28, P46, DOI 10.1093/geront/28.Suppl.46; Hipshman L, 1987, Bull Am Acad Psychiatry Law, V15, P235; Hoffman Diane, 1991, MD Law Rev, V50, P746; Hommel P A, 1990, Law Med Health Care, V18, P213; Katz J., 1984, SILENT WORLD DOCTOR; LAPUMA J, 1991, JAMA-J AM MED ASSOC, V266, P402, DOI 10.1001/jama.266.3.402; LEE FR, 1993, NY TIMES        0404, P35; MILLER T, 1990, GERONTOLOGIST, V30, P462, DOI 10.1093/geront/30.4.462; MITCHELL AM, 1979, SOUTHERN CALIF LAW R, V52, P1405; REGAN J, 1992, TAX ESTATE FINANCIAL; STANLEY B, 1984, JAMA-J AM MED ASSOC, V252, P1302, DOI 10.1001/jama.252.10.1302; SUNDRAM CJ, 1988, NEW ENGL J MED, V318, P1368, DOI 10.1056/NEJM198805263182105; WHITE ML, 1991, JAMA-J AM MED ASSOC, V266, P410, DOI 10.1001/jama.1991.03470030110035; 1987, GUARDIANS ELDERLY AI; 1991, 1990 1991 OFF HUM RI; 1992, INNOVATIONS, P2; 1993, SURROGATE PROJECT RE; 1991, 119 ENGL LAW COMM CO; 1989, GUARDIANSHIP AGENDA; 1991, COURT RELATED NEEDS; 1986, JAMA-J AM MED ASSOC, V256, P2234	30	19	19	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	1994	271	13					1017	1022		10.1001/jama.271.13.1017	http://dx.doi.org/10.1001/jama.271.13.1017			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ND949	8139060				2022-12-28	WOS:A1994ND94900033
J	SCHAEFER, EJ; LAMONFAVA, S; JENNER, JL; MCNAMARA, JR; ORDOVAS, JM; DAVIS, CE; ABOLAFIA, JM; LIPPEL, K; LEVY, RI				SCHAEFER, EJ; LAMONFAVA, S; JENNER, JL; MCNAMARA, JR; ORDOVAS, JM; DAVIS, CE; ABOLAFIA, JM; LIPPEL, K; LEVY, RI			LIPOPROTEIN(A) LEVELS AND RISK OF CORONARY HEART-DISEASE IN MEN - THE LIPID RESEARCH CLINICS CORONARY PRIMARY PREVENTION TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-DENSITY-LIPOPROTEIN; FAMILIAL HYPERCHOLESTEROLEMIA; ARTERY DISEASE; MYOCARDIAL-INFARCTION; SERUM LIPOPROTEIN(A); LP(A) LIPOPROTEIN; PLASMA-LEVELS; APOLIPOPROTEIN(A); PLASMINOGEN; ATHEROSCLEROSIS	Objective.-To examine the relationship between elevated levels of lipoprotein(a) [Lp(a)] and coronary heart disease (CHD) risk in a prospective study. Design.-Nested case-control study. The cohort consisted of participants in the Lipid Research Clinics Coronary Primary Prevention Trial. Setting.-Lipid research clinics. Participants.-The Lipid Research Clinics Coronary Primary Prevention Trial participants (n=3806) were men, aged 35 to 59 years, with plasma cholesterol levels of 6.85 mmol/L (265 mg/dL) or greater, low-density lipoprotein cholesterol levels of 4.91 mmol/L (190 mg/dL) or greater, and triglyceride levels less than 3.39 mmol/L. Subjects were randomly assigned to either cholestyramine or placebo treatment. The Lp(a) levels were measured in plasma samples obtained prior to randomization in 233 cases (participants who developed CHD in the course of the study) and 390 matched CHD-free controls. A total of 96.95% of the subjects were white, 2.25% were black, and 0.80% were of other race. Main Outcome Measure.-Coronary heart disease (either fatal or nonfatal) events during a follow-up of 7 to 10 years. Results.-The Lp(a) levels were significantly higher (21%) in cases than in controls (23.7 mg/dL [0.59 mmol/L] and 19.5 mg/dL [0.49 mmol/L], respectively; P<.02). This difference was still statistically significant (P<.01) after controlling for age, body mass index, cigarette smoking, blood pressure, low-density lipoprotein cholesterol level, and high-density lipoprotein cholesterol level. When subjects were divided by treatment, both cholestyramine-treated and placebo-treated CHD subjects had Lp(a) levels 200/. to 220/o greater than their matched controls. However, possibly because of smaller sample sizes, these differences were no longer statistically significant. Conclusions.-Our data are consistent with the concept that an elevated Lp(a) level is an independent risk factor for CHD in hypercholesterolemic white men.	UNIV N CAROLINA,DEPT BIOSTAT,CHAPEL HILL,NC 27514; NHLBI,DIV HEART & VASC DIS,BETHESDA,MD 20892	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	SCHAEFER, EJ (corresponding author), TUFTS UNIV,USDA,HUMAN NUTR RES CTR AGING,LIPID METAB LAB,711 WASHINGTON ST,BOSTON,MA 02111, USA.		Ordovas, Jose/B-8727-2013	Ordovas, Jose/0000-0002-7581-5680	NHLBI NIH HHS [HV83-03] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS JJ, 1977, J LIPID RES, V18, P331; BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; Berg K, 1981, Prog Clin Biol Res, V69 Pt C, P117; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; BRESLOW NE, 1982, ANAL CASE CONTROL ST, V1; Brewer Jr HB, 1990, LIPOPROTEIN A, P211; CRAIG WY, 1992, ATHEROSCLEROSIS, V93, P261, DOI 10.1016/0021-9150(92)90264-H; CRAIG WY, 1992, KLIN CHEM, V38, P550; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; GAUBATZ JW, 1990, J LIPID RES, V31, P603; GAVISH D, 1989, J CLIN INVEST, V84, P4171; GENEST J, 1991, AM J CARDIOL, V67, P1039, DOI 10.1016/0002-9149(91)90862-F; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HIRAGA T, 1993, METABOLISM, V42, P1327, DOI 10.1016/0026-0495(93)90133-9; HOEFLER G, 1988, ARTERIOSCLEROSIS, V8, P398, DOI 10.1161/01.ATV.8.4.398; HOFMANN SL, 1990, J CLIN INVEST, V85, P1542, DOI 10.1172/JCI114602; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; JENNER JL, 1993, CIRCULATION, V87, P1135, DOI 10.1161/01.CIR.87.4.1135; LAMONFAVA S, 1991, ATHEROSCLEROSIS, V91, P97, DOI 10.1016/0021-9150(91)90191-5; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; LUBIN JH, 1984, BIOMETRICS, V40, P63, DOI 10.2307/2530744; MBEWU AD, 1991, ARTERIOSCLER THROMB, V11, P940, DOI 10.1161/01.ATV.11.4.940; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MEDDINGS JB, 1986, CIRCULATION, V74, P805, DOI 10.1161/01.CIR.74.4.805; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MORRISETT JD, 1987, PLASMA LIPOPROTEINS, P129; NARUSZEWICZ M, 1992, METABOLISM, V41, P1215, DOI 10.1016/0026-0495(92)90012-Y; RADER DJ, 1993, J CLIN INVEST, V91, P443, DOI 10.1172/JCI116221; RADER DJ, 1992, JAMA-J AM MED ASSOC, V267, P1109, DOI 10.1001/jama.267.8.1109; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; SANDHOLZER C, 1991, HUM GENET, V86, P607; SANDKAMP M, 1990, CLIN CHEM, V36, P20; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SEED M, 1990, NEW ENGL J MED, V322, P1494, DOI 10.1056/NEJM199005243222104; SEMAN LJ, 1986, BIOCHEM CELL BIOL, V64, P999, DOI 10.1139/o86-133; SIMON DI, 1991, BIOCHEMISTRY-US, V30, P6671, DOI 10.1021/bi00241a006; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1989, P NATL ACAD SCI USA, V86, P4171, DOI 10.1073/pnas.86.11.4171; WIKLUND O, 1990, LANCET, V335, P1360, DOI 10.1016/0140-6736(90)91242-3; 1979, J CHRON DIS, V32, P609; 1984, JAMA-J AM MED ASSOC, V251, P1365; 1984, JAMA-J AM MED ASSOC, V251, P351	44	442	449	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	1994	271	13					999	1003		10.1001/jama.271.13.999	http://dx.doi.org/10.1001/jama.271.13.999			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND949	8139085				2022-12-28	WOS:A1994ND94900029
J	STERN, Y; GURLAND, B; TATEMICHI, TK; TANG, MX; WILDER, D; MAYEUX, R				STERN, Y; GURLAND, B; TATEMICHI, TK; TANG, MX; WILDER, D; MAYEUX, R			INFLUENCE OF EDUCATION AND OCCUPATION ON THE INCIDENCE OF ALZHEIMERS-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARIETOTEMPORAL PERFUSION; DEMENTIA; PREVALENCE; AGE; POPULATION; DIAGNOSIS; MEMORY	Objective.-Several cross-sectional studies have found an association between Alzheimer's disease (AD) and limited education experience. It has been difficult to establish whether educational experience is a risk factor for AD because educational attainment can influence performance on diagnostic tests. This study was designed to determine whether limited educational level and oocupational attainment are risk factors for incident dementia. Design.-Cohort incidence study. Setting.-General community. Participants.-A total of 593 nondemented individuals aged 60 years or older who were listed in a registry of individuals at risk for dementia in North Manhattan, NY, were identified and followed up. Interventions.-We reexamined subjects 1 to 4 years later with the identical standardized neurological and neuropsychological measures. Main Outcome Measure.-Incident dementia. Results.-We used Cox proportional hazards models, adjusting for age and gender, to estimate the relative risk (RR) of incident dementia associated with low educational and occupational attainment. Of the 593 subjects, 106 became demented; all but five of these met research criteria for AD. The risk of dementia was increased in subjects with either low education (RR, 2.02; 95% confidence interval [CI], 1.33 to 3.06) or low lifetime occupational attainment (RR, 2.25; 95% CI, 1.32 to 3.84). Risk was greatest for subjects with both low education and low lifetime occupational attainment (RR, 2.87; 95% CI, 1.32 to 3.84). Conclusions.-The data suggest that increased educational and occupational attainment may reduce the risk of incident AD, either by decreasing ease of clinical detection of AD or by imparting a reserve that delays the onset of clinical manifestations.	CTR GERIATR & GERONTOL, NEW YORK, NY USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT NEUROL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PSYCHIAT, NEW YORK, NY 10032 USA	Columbia University; Columbia University	STERN, Y (corresponding author), GERTRUDE H SERGIEVSKY CTR, 630 W 168TH ST, NEW YORK, NY 10032 USA.			Stern, Yaakov/0000-0001-7542-3241	NIA NIH HHS [AG07370, AG07232] Funding Source: Medline; NINDS NIH HHS [NS26179] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG007232, R01AG007370] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARONSON MK, 1990, NEUROLOGY, V40, P1102, DOI 10.1212/WNL.40.7.1102; BEARD CM, 1992, NEUROLOGY, V42, P2063, DOI 10.1212/WNL.42.11.2063; BENTON AL, 1955, VISUAL RETENTION; BENTON AL, 1975, MULTILINGUAL APHASIA; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BONAIUTO S, 1990, NEUROLOGY S1, V40, P346; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CHAPMAN J, 1991, NEUROEPIDEMIOLOGY, V10, P228, DOI 10.1159/000110276; DARTIGUES JF, 1991, REV NEUROL-FRANCE, V147, P225; FRATIGLIONI L, 1991, NEUROLOGY, V41, P1886, DOI 10.1212/WNL.41.12.1886; FRIEDLAND RP, 1985, LANCET, V1, P228; FRIEDLAND RP, 1993, NEUROLOGY, V43, P246, DOI 10.1212/WNL.43.2.246; Goodglass H., 1983, BOSTON NAMING TEST; Goodglass H., 1983, ASSESSMENT APHASIA R, V2nd; Gurland B. J., 1981, AGING-US, V15, P61; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; KATZMAN R, 1993, NEUROLOGY, V43, P13, DOI 10.1212/WNL.43.1_Part_1.13; KITTNER SJ, 1986, J CHRON DIS, V39, P163, DOI 10.1016/0021-9681(86)90019-6; LAWLESS JF, 1982, STATISTICAL MODELS M; MATTIS S, 1976, GERIATRIC PSYCHIATRY; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mortimer J. A., 1988, ETIOLOGY DEMENTIA AL, P39; Risberg J., 1988, HDB REGIONAL CEREBRA, P219; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P311; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Schwab R.S., 1969, 3 S PARK DIS, P152; Spitzer RL, 1986, STRUCTURED CLIN INTE; STERN Y, 1992, ANN NEUROL, V32, P371, DOI 10.1002/ana.410320311; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009; STERN Y, 1992, ANN NEUROL, V32, P270; SULKAVA R, 1985, NEUROLOGY, V35, P1025, DOI 10.1212/WNL.35.7.1025; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; ZHANG MY, 1990, ANN NEUROL, V27, P428, DOI 10.1002/ana.410270412; ZIMETBAUM P, 1991, ARCH INTERN MED, V151, P240, DOI 10.1001/archinte.151.2.240; 1987, DIAGNOSTIC STATISTIC; 1981, ROSEN DRAWING TEST	40	1051	1065	4	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	1994	271	13					1004	1010		10.1001/jama.1994.03510370056032	http://dx.doi.org/10.1001/jama.1994.03510370056032			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND949	8139057	Green Submitted			2022-12-28	WOS:A1994ND94900030
J	BASSON, CT; COWLEY, GS; SOLOMON, SD; WEISSMAN, B; POZNANSKI, AK; TRAILL, TA; SEIDMAN, JG; SEIDMAN, CE				BASSON, CT; COWLEY, GS; SOLOMON, SD; WEISSMAN, B; POZNANSKI, AK; TRAILL, TA; SEIDMAN, JG; SEIDMAN, CE			THE CLINICAL AND GENETIC SPECTRUM OF THE HOLT-ORAM SYNDROME (HEART-HAND SYNDROME)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. The Holt-Gram syndrome is an autosomal dominant condition characterized by skeletal abnormalities that are frequently accompanied by congenital cardiac defects. The cause of these disparate clinical features is unknown. To identify the chromosomal location of the Holt-Gram syndrome gene, we performed clinical and genetic studies. Methods. Two large families with the Holt-Gram syndrome were evaluated by radiography of the hands, electrocardiography, and transthoracic echocardiography. Genetic-linkage analyses were performed with polymorphic DNA loci dispersed throughout the genome to identify a locus that was inherited with the Holt-Gram syndrome in family members. Results. A total of 19 members of Family A had Holt-Oram syndrome with mild-to-moderate skeletal deformities, including triphalangeal thumbs and carpal-bone dysmorphism. All affected members of Family A had moderate-to-severe congenital cardiac abnormalities, such as ventricular or atrial septal defects or atrioventricular-canal defects. Eighteen members of a second kindred (Family B) had Holt-Gram syndrome with moderate-to-severe skeletal deformities, including phocomelia. Twelve of the affected members had no cardiac defects; six had only atrial septal defects. Genetic analyses demonstrated linkage of the disease in each family to polymorphic loci on the long arm of chromosome 12 (combined multipoint lod score, 16.8). These data suggest odds greater than 10(16):1 that the genetic defect for Holt-Gram syndrome is present on the long arm of chromosome 12 (12q2). Conclusions. Mutations in a gene on chromosome 12q2 can produce a wide range of disease phenotypes characteristic of the Holt-Gram syndrome. This gene has an important role in both skeletal and cardiac development.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RADIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; CHILDRENS MEM HOSP,DEPT RADIOL,CHICAGO,IL 60614; JOHNS HOPKINS UNIV HOSP,DEPT MED,DIV CARDIOVASC,BALTIMORE,MD	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Ann & Robert H. Lurie Children's Hospital of Chicago; Johns Hopkins University; Johns Hopkins Medicine			Solomon, Scott/I-5789-2013					CHANTHOMAS PS, 1993, J CELL BIOCHEM     S, V17, P209; CHOU YHW, 1992, NAT GENET, V1, P295, DOI 10.1038/ng0792-295; Csaba E, 1991, ORVOSI HETILAP, V132, P73; FUKUI K, 1992, J BIOL CHEM, V267, P18631; GALL JC, 1966, AM J HUM GENET, V18, P187; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HOLT M, 1960, BRIT HEART J, V22, P236; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MATTEI MG, 1991, GENOMICS, V10, P1061, DOI 10.1016/0888-7543(91)90199-O; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCKUSICK VA, 1992, MENDELIAN INHERITANC, V1, P542; MENDELSOHN C, 1992, DEV BIOL, V152, P50, DOI 10.1016/0012-1606(92)90155-A; POZNANSK AK, 1970, RADIOLOGY, V94, P45, DOI 10.1148/94.1.45; SMITH AT, 1979, J PEDIATR-US, V95, P538, DOI 10.1016/S0022-3476(79)80758-1; TURLEAU C, 1984, ANN GENET-PARIS, V27, P237; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; YANG S, 1990, PEDIATR RES, V27, pA137	17	234	240	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	1994	330	13					885	891		10.1056/NEJM199403313301302	http://dx.doi.org/10.1056/NEJM199403313301302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC608	8114858				2022-12-28	WOS:A1994NC60800002
J	ROBERTSON, DE; FARID, RS; MOSER, CC; URBAUER, JL; MULHOLLAND, SE; PIDIKITI, R; LEAR, JD; WAND, AJ; DEGRADO, WF; DUTTON, PL				ROBERTSON, DE; FARID, RS; MOSER, CC; URBAUER, JL; MULHOLLAND, SE; PIDIKITI, R; LEAR, JD; WAND, AJ; DEGRADO, WF; DUTTON, PL			DESIGN AND SYNTHESIS OF MULTI-HEME PROTEINS	NATURE			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; BLODGETT MONOLAYER FILMS; VIRIDIS REACTION CENTER; CYTOCHROME-C; RHODOPSEUDOMONAS-VIRIDIS; RHODOBACTER-SPHAEROIDES; DESULFOVIBRIO-VULGARIS; TRANSFER MECHANISMS; REDOX; COMPLEX	A water-soluble, 62-residue, di-alpha-helical peptide has been synthesized which accommodates two bis-histidyl haem groups. The peptide assembles into a four-helix dimer with 2-fold symmetry and four parallel haems that closely resemble native haems in their spectral and electro-chemical properties, including haem-haem redox interaction. This protein is an essential intermediate in the synthesis of molecular 'maquettes', a novel class of simplified versions of the metalloproteins involved in redox catalysis and in energy conversion in respiratory and photosynthetic electron transfer.	UNIV ILLINOIS,SCH CHEM SCI,DEPT BIOCHEM,URBANA,IL 61801; DUPONT CO INC,DEPT CENT RES & DEV,WILMINGTON,DE 19880	University of Illinois System; University of Illinois Urbana-Champaign; DuPont	ROBERTSON, DE (corresponding author), UNIV PENN,DEPT BIOCHEM & BIOPHYS,JOHNSON RES FDN,PHILADELPHIA,PA 19104, USA.		Moser, Christopher C/O-6559-2014	Moser, Christopher C/0000-0003-4814-8568				ALEGRIA G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P258, DOI 10.1016/S0005-2728(05)80108-2; ALEGRIA G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P239, DOI 10.1016/S0005-2728(05)80107-0; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BETZ SF, 1993, CURR OPIN STRUC BIOL, V3, P601, DOI 10.1016/0959-440X(93)90090-8; BROWN S, 1993, FEBS LETT, V316, P216, DOI 10.1016/0014-5793(93)81296-C; CHOMA CT, 1994, J AM CHEM SOC, V118, P856; CHURG AK, 1986, BIOCHEMISTRY-US, V25, P1675, DOI 10.1021/bi00355a035; Cramer W., 1987, STRUCTURE FUNCTION P; CROFTS A, 1992, BIOCHIM BIOPHYS ACTA, V1101, P162, DOI 10.1016/S0005-2728(05)80009-X; CROFTS A, 1987, CYTOCHROME SYSTEMS M, P617; DAVIES AM, 1993, BIOCHEMISTRY-US, V32, P5431, DOI 10.1021/bi00071a019; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; DeGrado WF, 1991, CURR OPIN STRUC BIOL, V1, P984, DOI 10.1016/0959-440X(91)90095-B; Dutton P L, 1978, Methods Enzymol, V54, P411; DUTTON PL, 1972, EUR J BIOCHEM, V30, P495, DOI 10.1111/j.1432-1033.1972.tb02121.x; FAN K, 1990, BIOCHEMISTRY-US, V29, P2257, DOI 10.1021/bi00461a008; FIELDS GB, 1989, INT J PEPT PROT RES, V33, P1; GLASER EG, 1984, BIOCHIM BIOPHYS ACTA, V766, P322, DOI 10.1016/0005-2728(84)90248-2; GUNNER MR, 1991, P NATL ACAD SCI USA, V88, P9151, DOI 10.1073/pnas.88.20.9151; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; HARBURY HA, 1965, P NATL ACAD SCI USA, V54, P1658, DOI 10.1073/pnas.54.6.1658; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; HOWELL N, 1993, BIOCHEMISTRY-US, V32, P1310; HOWELL N, 1987, CYTOCHROME SYSTEMS M, P79; LEITCH FA, 1985, BIOCHIM BIOPHYS ACTA, V808, P213, DOI 10.1016/0005-2728(85)90001-5; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MOORE GR, 1983, FEBS LETT, V161, P171, DOI 10.1016/0014-5793(83)81001-1; MOSER CC, 1992, BIOCHIM BIOPHYS ACTA, V1101, P171, DOI 10.1016/S0005-2728(05)80012-X; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; MOURA JJG, 1982, EUR J BIOCHEM, V127, P151, DOI 10.1111/j.1432-1033.1982.tb06849.x; NICHOLLS P, 1974, BIOCHIM BIOPHYS ACTA, V357, P462, DOI 10.1016/0005-2728(74)90038-3; ORMEJOHNSON NR, 1974, J BIOL CHEM, V249, P1928; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PALMER G, 1985, BIOCHEM SOC T, V13, P548, DOI 10.1042/bst0130548; ROBERTSON DE, 1988, BIOCHIM BIOPHYS ACTA, V935, P273, DOI 10.1016/0005-2728(88)90223-X; SALERNO JC, 1984, J BIOL CHEM, V259, P2331; SANTOS H, 1984, EUR J BIOCHEM, V141, P283, DOI 10.1111/j.1432-1033.1984.tb08190.x; SARASTE M, 1984, FEBS LETT, V166, P367, DOI 10.1016/0014-5793(84)80114-3; WALKER FA, 1986, J AM CHEM SOC, V108, P5288, DOI 10.1021/ja00277a038; WEST IC, 1988, BIOCHIM BIOPHYS ACTA, V933, P35, DOI 10.1016/0005-2728(88)90053-9; WIKSTROM MKF, 1976, FEBS LETT, V65, P259, DOI 10.1016/0014-5793(76)80127-5; WILLIE A, 1992, BIOCHEMISTRY-US, V31, P7237, DOI 10.1021/bi00147a005; WUTTKE DS, 1992, SCIENCE, V256, P1007, DOI 10.1126/science.256.5059.1007; YUN CH, 1991, BIOCHEMISTRY-US, V30, P6747, DOI 10.1021/bi00241a017	49	464	469	1	71	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 31	1994	368	6470					425	431		10.1038/368425a0	http://dx.doi.org/10.1038/368425a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	8133888				2022-12-28	WOS:A1994ND12000053
J	DULIC, V; KAUFMANN, WK; WILSON, SJ; TLSTY, TD; LEES, E; HARPER, JW; ELLEDGE, SJ; REED, SI				DULIC, V; KAUFMANN, WK; WILSON, SJ; TLSTY, TD; LEES, E; HARPER, JW; ELLEDGE, SJ; REED, SI			P53-DEPENDENT INHIBITION OF CYCLIN-DEPENDENT KINASE-ACTIVITIES IN HUMAN FIBROBLASTS DURING RADIATION-INDUCED G1 ARREST	CELL			English	Article							WILD-TYPE P53; RETINOBLASTOMA GENE-PRODUCT; HUMAN CELL-CYCLE; ATAXIA-TELANGIECTASIA; PROTEIN-KINASE; FISSION YEAST; S-PHASE; TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION	Gamma-irradiation of human diploid fibroblasts in the G1 interval caused arrest of the cell cycle prior to S phase. This cell cycle block was correlated with a lack of activation of both cyclin E-Cyclin-dependent kinase 2 (Cdk2) and cyclin A-Cdk2 kinases and depended on wild-type p53. Although the accumulation of cyclin A was strongly inhibited in gamma-irradiated cells, cyclin E accumulated and bound Cdk2 at normal levels but remained in an inactive state. We found that both whole-cell lysates and inactive cyclin E-Cdk2 complexes prepared from irradiated cells contained an activity capable of inactivating cyclin E-Cdk2 complexes. The protein responsible for this activity was shown to be p21CIP1/WAF1, recently described as a p53-inducible Cdk inhibitor. Our data suggest a model in which ionizing radiation confers G1 arrest via the p53-mediated induction of a Cdk inhibitor protein.	SCRIPPS RES INST, DEPT MOLEC BIOL MB7, LA JOLLA, CA 92037 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; MASSACHUSETTS GEN HOSP, CTR CANC, MOLEC ONCOL LAB, BOSTON, MA 02129 USA; BAYLOR COLL MED, INST MOLEC GENET, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, INST MOLEC GENET, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Scripps Research Institute; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Massachusetts General Hospital; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute				Dulic, Vjekoslav/0000-0003-1201-3901; Harper, Jeffrey/0000-0002-6944-7236	NCI NIH HHS [CA42765, CA55339] Funding Source: Medline; NIGMS NIH HHS [GM46006] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055339, P01CA042765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM046006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GREIDER CW, 1990, BIOESSAYS, V12, P363, DOI 10.1002/bies.950120803; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HENGST L, 1994, IN PRESS P NATL ACAD; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAUFMANN WK, 1990, MUTAT RES, V236, P107, DOI 10.1016/0921-8777(90)90038-7; KAUFMANN WK, 1994, MUTAT RES, V314, P67, DOI 10.1016/0921-8777(94)90062-0; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; Lew D J, 1992, Trends Cell Biol, V2, P77, DOI 10.1016/0962-8924(92)90076-Y; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LITTLE JB, 1985, RADIAT RES, V101, P81, DOI 10.2307/3576305; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOCK RB, 1990, CANCER RES, V50, P3761; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Prives C, 1993, CURR OPIN CELL BIOL, V5, P214, DOI 10.1016/0955-0674(93)90105-Y; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHAY JW, 1993, ONCOGENE, V8, P1407; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SLINGERLAND JM, 1994, IN PRESS MOL CELL BI; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; STUDIER FW, 1990, GENE EXPRESSION TECH, V185, P60; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; WHITE S, 1994, IN PRESS GENES DEV; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	81	1457	1491	2	43	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 25	1994	76	6					1013	1023		10.1016/0092-8674(94)90379-4	http://dx.doi.org/10.1016/0092-8674(94)90379-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137420				2022-12-28	WOS:A1994ND24600008
J	VANADELSBERG, J; EDWARDS, JC; TAKITO, J; KISS, B; ALAWQATI, Q				VANADELSBERG, J; EDWARDS, JC; TAKITO, J; KISS, B; ALAWQATI, Q			AN INDUCED EXTRACELLULAR-MATRIX PROTEIN REVERSES THE POLARITY OF BAND-3 IN INTERCALATED EPITHELIAL-CELLS	CELL			English	Article							MEMBRANE CYTOSKELETAL COMPLEX; MDCK CELLS; CYTOPLASMIC DOMAIN; BASEMENT-MEMBRANE; KIDNEY; ANKYRIN; SURFACE; FODRIN; IDENTIFICATION; BIOGENESIS	The intercalated epithelial cell exists in two interconvertible forms in vivo, one where band 3 protein is apical and the other where it is basolateral. We seeded an immortalized clone of these cells at low density and found that band 3 was apical at confluence. There was little or no apical endocytosis. But when the cells were plated at high density, band 3 was basolateral, and there was vigorous apical endocytosis. Extracellular matrix produced by high density cells was able to retarget band 3 in low density cells and to induce apical endocytosis, as did a 230 kd protein partially purified from this matrix. Therefore, polarized targeting of some proteins is determined by external cues that might determine their polarity by reorganizing the cytoplasm.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL,NEW YORK,NY 10032	Columbia University	VANADELSBERG, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032, USA.		Al-Awqati, Qais/B-2465-2009	Al-Awqati, Qais/0000-0001-7141-1040	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK020999, R01DK020999] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-20999] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1992, RENAL PHYSL, V1, P323; BARTLES JR, 1984, ANAL BIOCHEM, V140, P284, DOI 10.1016/0003-2697(84)90166-0; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BROWN D, 1987, J CELL BIOL, V105, P1637, DOI 10.1083/jcb.105.4.1637; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DAVIS J, 1989, J BIOL CHEM, V264, P6417; DRENCKHAHN D, 1985, SCIENCE, V230, P1287, DOI 10.1126/science.2933809; EDWARDS JC, 1992, AM J PHYSIOL, V263, pC521, DOI 10.1152/ajpcell.1992.263.2.C521; GOTTARDI CJ, 1993, SCIENCE, V260, P552, DOI 10.1126/science.8386395; GUNDERSEN D, 1993, J CELL BIOL, V121, P335, DOI 10.1083/jcb.121.2.335; GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HARLOW E, 1988, ANTIBODIES LABORATOR; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Kopito R R, 1988, Soc Gen Physiol Ser, V43, P151; LEHIR M, 1982, AM J PHYSIOL, V242, pC117, DOI 10.1152/ajpcell.1982.242.1.C117; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISAWNTI M, 1990, TRENDS BIOCHEM SCI, V15, P133; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; OSTEDGAARD LS, 1991, P NATL ACAD SCI USA, V88, P981, DOI 10.1073/pnas.88.3.981; PATHAK RK, 1990, J CELL BIOL, V112, P863; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SAMBUY Y, 1988, P NATL ACAD SCI USA, V85, P1529, DOI 10.1073/pnas.85.5.1529; SCHUSTER VL, 1993, ANNU REV PHYSIOL, V55, P267, DOI 10.1146/annurev.ph.55.030193.001411; SCHWARTZ GJ, 1985, NATURE, V318, P368, DOI 10.1038/318368a0; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; STEULI CH, 1990, J CELL BIOL, V110, P1405; STOW JL, 1987, J CELL BIOL, V105, P529, DOI 10.1083/jcb.105.1.529; STOW JL, 1989, AM J PATHOL, V135, P637; THORENS B, 1990, AM J PHYSIOL, V259, pC286; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANADELSBERG J, 1989, AM J PHYSIOL, V256, pC1004, DOI 10.1152/ajpcell.1989.256.5.C1004; VANADELSBERG JS, 1993, J BIOL CHEM, V268, P11283; ZURZOLO C, 1993, SCIENCE, V260, P550, DOI 10.1126/science.8386394; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031	39	83	83	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1053	1061		10.1016/0092-8674(94)90382-4	http://dx.doi.org/10.1016/0092-8674(94)90382-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137422				2022-12-28	WOS:A1994ND24600011
J	TANEV, PT; CHIBWE, M; PINNAVAIA, TJ				TANEV, PT; CHIBWE, M; PINNAVAIA, TJ			TITANIUM-CONTAINING MESOPOROUS MOLECULAR-SIEVES FOR CATALYTIC-OXIDATION OF AROMATIC-COMPOUNDS	NATURE			English	Article							SILICALITE	TITANIUM silicalite is an effective molecular-sieve catalyst for the selective oxidation of alkanes, the hydroxylation of phenol and the epoxidation of alkenes in the presence of H2O2 (refs 1-3). The range of organic compounds that can be oxidized is greatly limited, however, by the relatively small pore size (about 0.6 nm) of the host framework(4). Large-pore (mesoporous) silica-based molecular sieves have been prepared recently by Kresge et al.(5-7) and Kuroda et al.(8); the former used a templating approach in which the formation of an inorganic mesoporous structure is assisted by self-organization of surfactants, and the latter involved topochemical rearrangement of a layered silica precursor. Here we describe the use of the templating approach to synthesize mesoporous silica-based molecular sieves partly substituted with titanium-large-pore analogues of titanium silicalite. We find that these materials show selective catalytic activity towards the oxidation of 2,6-di-tert-butyl phenol to the corresponding quinone and the conversion of benzene to phenol.	MICHIGAN STATE UNIV, DEPT CHEM, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, CTR FUNDAMENTAL MAT RES, E LANSING, MI 48824 USA	Michigan State University; Michigan State University								BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020; FLANIGEN EM, 1978, NATURE, V271, P512, DOI 10.1038/271512a0; HORVATH G, 1983, J CHEM ENG JPN, V16, P470, DOI 10.1252/jcej.16.470; HUYBRECHTS DRC, 1990, NATURE, V345, P240, DOI 10.1038/345240a0; INAGAKI S, 1993, J CHEM SOC CHEM COMM, P680, DOI 10.1039/c39930000680; Kresge C.T., 1992, US Patent, Patent No. [5,098,684, 5098684]; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299; NEUMANN R, 1993, J CHEM SOC CHEM COMM, P1685, DOI 10.1039/c39930001685; NOTARI B, 1991, STUD SURF SCI CATAL, V67, P243, DOI 10.1016/S0167-2991(08)61943-6; SHELDON RA, 1990, STUD SURF SCI CATAL, V55, P1; SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603; TANGARAJ A, 1991, J CATAL, V130, P1; Taramasso M., 1983, US Patent, Patent No. [4410501, US4410501]	14	1603	1717	10	488	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					321	323		10.1038/368321a0	http://dx.doi.org/10.1038/368321a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127366				2022-12-28	WOS:A1994NB98500041
J	TSUKIYAMA, T; BECKER, PB; WU, C				TSUKIYAMA, T; BECKER, PB; WU, C			ATP-DEPENDENT NUCLEOSOME DISRUPTION AT A HEAT-SHOCK PROMOTER MEDIATED BY BINDING OF GAGA TRANSCRIPTION FACTOR	NATURE			English	Article							TUMOR VIRUS PROMOTER; DROSOPHILA-MELANOGASTER; CHROMATIN STRUCTURE; GENE; PROTEINS; DNA; COMPLEX; ACTIVATION; ENCODES; EXTRACTS	Genetic control elements are usually situated in local regions of chromatin that are hypersensitive to structural probes such as DNase I. We have reconstructed the chromatin structure of the hsp70 promoter using an in vitro nucleosome assembly system. Binding of the GAGA transcription factor on existing nucleosomes leads to nucleosome disruption, DNase I hypersensitivity at the TATA box and heat-shock elements, and rearrangement of adjacent nucleosomes. ATP hydrolysis facilitates this process, suggesting that an energy-dependent pathway is involved in chromatin remodelling.	NCI,BIOCHEM LAB,BLDG 37,ROOM 4C-09,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Becker, Peter/0000-0001-7186-0372				ALMOUZNI G, 1993, EXP CELL RES, V205, P1, DOI 10.1006/excr.1993.1051; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ASHBURNER M, 1972, DEV STUDIES GIANT CH; AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BLACKMAN RK, 1986, J MOL BIOL, V188, P499, DOI 10.1016/S0022-2836(86)80001-8; BROWN JL, 1993, DEVELOPMENT, V117, P45; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; Croston G.E., 1991, Protein Expression and Purification, V2, P162, DOI 10.1016/1046-5928(91)90066-R; DEVLIN C, 1991, MOL CELL BIOL, V11, P3642, DOI 10.1128/MCB.11.7.3642; DIBELLO PR, 1991, GENETICS, V129, P385; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; ELGIN SCR, 1973, BIOCHEMISTRY-US, V12, P4984, DOI 10.1021/bi00748a026; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; HAYES JJ, 1992, BIOESSAYS, V14, P597, DOI 10.1002/bies.950140905; HENIKOFF S, 1993, TRENDS BIOCHEM SCI, V18, P291, DOI 10.1016/0968-0004(93)90037-N; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LORCH Y, 1992, GENE DEV, V6, P2282, DOI 10.1101/gad.6.12a.2282; LUE Q, 1993, MOL CELL BIOL, V13, P2802; MASON PJ, 1982, J MOL BIOL, V156, P21, DOI 10.1016/0022-2836(82)90456-9; MORROW BE, 1993, MOL CELL BIOL, V13, P1173, DOI 10.1128/MCB.13.2.1173; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PURNELL BA, 1993, MOL CELL BIOL, V13, P2593, DOI 10.1128/MCB.13.4.2593; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SCHMID A, 1992, CELL, V71, P1; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; van Holde K.E., 1989, CHROMATIN, P16; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; WU C, 1984, NATURE, V309, P229, DOI 10.1038/309229a0; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	51	569	573	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					525	532		10.1038/367525a0	http://dx.doi.org/10.1038/367525a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	8107823	Green Submitted			2022-12-28	WOS:A1994MV86300049
J	GRONBAEK, M; DEIS, A; SORENSEN, TIA; BECKER, U; BORCHJOHNSEN, K; MULLER, C; SCHNOHR, P; JENSEN, G				GRONBAEK, M; DEIS, A; SORENSEN, TIA; BECKER, U; BORCHJOHNSEN, K; MULLER, C; SCHNOHR, P; JENSEN, G			INFLUENCE OF SEX, AGE, BODY-MASS INDEX, AND SMOKING ON ALCOHOL INTAKE AND MORTALITY	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; MALE JAPANESE PHYSICIANS; U-SHAPED CURVE; CIGARETTE-SMOKING; CONSUMPTION; COHORT; WEIGHT; MEN	Objective-To examine the association between self reported alcohol intake and subsequent mortality from all causes and if the effect of alcohol intake on the risk of death is modified by sex, age, body mass index, and smoking. Design-Prospective population study with baseline assessment of alcohol and tobacco consumption and body mass index, and 10-12 years' follow up of mortality. Setting-Copenhagen city heart study, Denmark. Subjects-7234 women and 6051 men aged 30-79 years. Main outcome measure-Number and time of deaths from 1976 to 1988. Results-A total of 2229 people died, 1398 being men. All shaped curve described the relation between alcohol intake and mortality. The lowest risk was observed at one to six alcoholic beverages a week (relative risk set at 1). Abstainers had a relative risk of 1.37 (95% confidence interval 1.20 to 1.56) whereas those drinking more than 70 beverages a week had a relative risk of 2.29 (1.75 to 3.00). Among the drinkers, the risk was significantly increased only among those drinking more than 42 beverages a week. Sex, age, body mass index, and smoking did not significantly modify the risk function. The risk among heavy drinkers was slightly reduced when smoking was controlled for. The risk function was similar in the first and second period of six years of observation. Conclusion-Alcohol intake showed a U shaped relation to mortality with the nadir at one to six beverages a week. The risk function was not modified by sex, age, body mass index, or smoking and remained stable over 12 years.	KOMMUNE HOSP COPENHAGEN,COPENHAGEN HLTH SERV,INST PREVENT MED,DK-1399 COPENHAGEN K,DENMARK; DANISH COMM ASSESSMENT SUBSTAND LIVES,COPENHAGEN,DENMARK; UNIV COPENHAGEN,HVIDOVRE HOSP,DEPT MED GASTROENTEROL,ALCOHOL UNIT,DK-2650 HVIDOVRE,DENMARK; UNIV COPENHAGEN,RIGSHOSP,COPENHAGEN CITY HEART STUDY,DEPT 7117,DK-2100 COPENHAGEN,DENMARK	University of Copenhagen; Rigshospitalet; University of Copenhagen			Becker, Ulrik/D-2657-2012	Becker, Ulrik/0000-0002-1678-7771; Gronbaek, Morten Klocker/0000-0002-8473-6474				BOFFETTA P, 1990, EPIDEMIOLOGY, V1, P337; CAMACHO TC, 1987, J CHRON DIS, V40, P229, DOI 10.1016/0021-9681(87)90158-5; COLDITZ GA, 1991, AM J CLIN NUTR, V54, P49, DOI 10.1093/ajcn/54.1.49; CRIQUI MH, 1990, BRIT J ADDICT, V85, P854; CULLEN K, 1982, INT J EPIDEMIOL, V11, P67, DOI 10.1093/ije/11.1.67; DELABRY LO, 1992, J STUD ALCOHOL, V53, P25, DOI 10.15288/jsa.1992.53.25; GORDON T, 1987, AM J EPIDEMIOL, V125, P263, DOI 10.1093/oxfordjournals.aje.a114525; JACKSON R, 1991, BRIT MED J, V303, P211, DOI 10.1136/bmj.303.6796.211; JENSEN G, 1984, ACTA MED SCAND S, V682, P13; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KLATSKY AL, 1977, AM J EPIDEMIOL, V105, P321; KONO S, 1987, JPN J CANCER RES, V78, P1323; KONO S, 1986, INT J EPIDEMIOL, V15, P527, DOI 10.1093/ije/15.4.527; KORZAREVIC D, 1980, LANCET, V1, P613; KULLER LH, 1991, PREV MED, V20, P638, DOI 10.1016/0091-7435(91)90060-H; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; MIDANIK L, 1982, BRIT J ADDICT, V77, P357; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; MORGAN MY, 1977, BRIT MED J, V1, P939, DOI 10.1136/bmj.1.6066.939; Payne R. W., 1987, GENSTAT 5 REFERENCE; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, LANCET, V2, P1267; WANNAMETHEE G, 1989, BRIT MED J, V299, P1497, DOI 10.1136/bmj.299.6714.1497; WILLIAMSON DF, 1987, AM J PUBLIC HEALTH, V77, P1324, DOI 10.2105/AJPH.77.10.1324; 1989, SCAND J SOC MED S, V170, P1	28	150	151	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 29	1994	308	6924					302	306		10.1136/bmj.308.6924.302	http://dx.doi.org/10.1136/bmj.308.6924.302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MU492	8124118	Green Published			2022-12-28	WOS:A1994MU49200020
J	LAGNADO, L; BAYLOR, DA				LAGNADO, L; BAYLOR, DA			CALCIUM CONTROLS LIGHT-TRIGGERED FORMATION OF CATALYTICALLY ACTIVE RHODOPSIN	NATURE			English	Article							ROD OUTER SEGMENTS; RETINAL RODS; GUANYLATE-CYCLASE; SALAMANDER RODS; TOAD RODS; PHOTORECEPTORS; SENSITIVITY; ACTIVATION; PROTEIN; PHOTOTRANSDUCTION	BACKGROUND light reduces the gain of phototransduction in retinal rods so that the ability to register changes in light intensity is not prevented by saturation of the cell's response1,2. The gain is reduced by a light-induced fall in the intracellular calcium concentration which results from blockage of Ca2+ entry through the channels closed by light and continued Ca2+ extrusion by the Na:Ca,K exchanger3-7. Calcium seems to exert several coordinated effects on the cyclic GMP cascade: a fall in [Ca2+] stimulates cGMP synthesis8,9, increases the affinity of the cGMP-gated channel for cGMP10 and accelerates rhodopsin deactivation by phosphorylation11. We now report that lowering intracellular [Ca2+] reduces the catalytic rhodopsin activity produced by light. The effect is operationally equivalent to a fourfold reduction in the number of rhodopsin molecules available for activation. The reduction in gain is cooperative and half-maximal at about 35 nM Ca2+, suggesting that it is mediated by a specific Ca2+-binding protein. Reduced rhodopsin activity in low Ca2+ should contribute to adaptation in background light.	STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University								BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; BAYLOR DA, 1974, J PHYSIOL-LONDON, V242, P729, DOI 10.1113/jphysiol.1974.sp010732; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FAIN GL, 1976, J PHYSIOL-LONDON, V261, P71, DOI 10.1113/jphysiol.1976.sp011549; GORDON SE, 1992, NEURON, V9, P739, DOI 10.1016/0896-6273(92)90036-D; HODGKIN AL, 1986, J PHYSIOL-LONDON, V372, pP54; HODGKIN AL, 1985, J PHYSIOL-LONDON, V358, P447, DOI 10.1113/jphysiol.1985.sp015561; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KOCH KW, 1990, J BIOL CHEM, V265, P9659; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; LAGNADO L, 1992, J PHYSIOL-LONDON, V455, P111, DOI 10.1113/jphysiol.1992.sp019293; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAMB TD, 1981, J PHYSIOL-LONDON, V319, P463, DOI 10.1113/jphysiol.1981.sp013921; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; LAMB TD, 1986, J PHYSIOL-LONDON, V372, P315, DOI 10.1113/jphysiol.1986.sp016011; LOLLEY RN, 1982, VISION RES, V22, P1481, DOI 10.1016/0042-6989(82)90213-9; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MCCARTHY ST, 1993, THESIS U CALIFORNIA; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; NAKATANI K, 1988, J PHYSIOL-LONDON, V395, P731, DOI 10.1113/jphysiol.1988.sp016943; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0; YOUNGER JP, 1992, INVEST OPHTH VIS SCI, V33, P1104	29	117	118	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 20	1994	367	6460					273	277		10.1038/367273a0	http://dx.doi.org/10.1038/367273a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	8121492				2022-12-28	WOS:A1994MR49400057
J	WORONICZ, JD; CALNAN, B; NGO, V; WINOTO, A				WORONICZ, JD; CALNAN, B; NGO, V; WINOTO, A			REQUIREMENT FOR THE ORPHAN STEROID-RECEPTOR NUR77 IN APOPTOSIS OF T-CELL HYBRIDOMAS	NATURE			English	Article							GROWTH-FACTORS ENCODES; FACTOR-INDUCIBLE GENE; DNA-BINDING; EXPRESSION VECTORS; NGFI-B; DEATH; PROTEIN; SUPERFAMILY; INDUCTION; MEMBER	APOPTOSIS is a phenomenon observed during development of many cell types in many organisms. It is an internal, programmed cell death characterized by DNA fragmentation into nucleosome-size pieces1-3. Anti-CD3-induced apoptosis in T-cell hybridomas and immature thymocytes requires new gene transcription and may be related to negative selection during T-cell development4-6. Using subtractive hybridization, we isolated a complementary DNA clone encoding the orphan steroid receptor Nur77 (refs 7-9). It shows different patterns of messenger RNA induction between apoptotic and stimulated T cells. We report here the use of gel shift analysis to demonstrate that the Nur77 protein is present at high levels in apoptotic T-cell hybridomas and apoptotic thymocytes, but not in growing T cells or stimulated splenocytes. A Nur77 dominant negative protected T-cell hybridomas from activation-induced apoptosis. Hence Nur77 is necessary for induced apoptosis in T-cell hybridomas.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley				Ngo, Vu/0000-0002-9501-6990				CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COHEN PL, 1992, IMMUNOL TODAY, V13, P427, DOI 10.1016/0167-5699(92)90066-G; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARINE J, 1991, P NATL ACAD SCI USA, V88, P7284, DOI 10.1073/pnas.88.16.7284; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MERCEP M, 1989, J IMMUNOL, V142, P4085; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHASTRI N, 1986, J EXP MED, V164, P882, DOI 10.1084/jem.164.3.882; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1990, J IMMUNOL, V144, P3326; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	31	507	519	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 20	1994	367	6460					277	281		10.1038/367277a0	http://dx.doi.org/10.1038/367277a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	8121493				2022-12-28	WOS:A1994MR49400058
J	LAAN, RFJM; VANRIEL, PLCM; VANDEPUTTE, LBA; VANERNING, LJTO; VANTHOF, MA; LEMMENS, JAM				LAAN, RFJM; VANRIEL, PLCM; VANDEPUTTE, LBA; VANERNING, LJTO; VANTHOF, MA; LEMMENS, JAM			LOW-DOSE PREDNISONE INDUCES RAPID REVERSIBLE AXIAL BONE LOSS IN PATIENTS WITH RHEUMATOID-ARTHRITIS - A RANDOMIZED, CONTROLLED-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						PREDNISONE; ARTHRITIS, RHEUMATOID; BONE DENSITY; BONE RESORPTION	QUANTITATIVE COMPUTED-TOMOGRAPHY; ANTIRHEUMATIC DRUGS; DISEASE-ACTIVITY; CORTICOSTEROIDS; MASS; PATHOGENESIS; OSTEOPOROSIS; DENSITY; SINGLE; TRIAL	Objective: To determine the effects of a short course of a low dose of a glucocorticoid agent on bone mass. Design: Double-blind, placebo-controlled, randomized study. Setting: Outpatient clinic of a university hospital. Patients: Forty patients with active rheumatoid arthritis. Intervention: All patients started receiving intramuscular gold salts. In addition, they were randomly allocated to receive either prednisone or placebo. The initial dose was 10 mg/d, which was tapered between weeks 12 and 20. Thereafter, patients were followed for an additional 24 weeks. Measurements: Lumbar bone mineral density was measured with dual-energy, quantitative computed tomography in a trabecular and a cortical region of interest. Results: Despite favorable effects on disease activity and functional capacity, trabecular bone mineral density decreased in the prednisone-treated patients between baseline and week 20 (mean change, -8.2%; 95% CI, -1 2.7% to -3.7%; P = 0.001). Little change was found in the placebo-treated patients (P > 0.2), and the prednisone group had a greater mean bone loss than the placebo group (9.5%; CI, 3.4% to 15.6%; P = 0.003). After discontinuation of prednisone, an increase was found in trabecular bone mineral density between weeks 20 and 44 (mean change, 5.3%; CI, 0.7% to 9.9%; P = 0.03). Little change was found after withdrawal of placebo (P > 0.2). The mean improvement in the prednisone group was 6.8% (CI, 0.8% to 12.8%; P = 0.03) greater than for placebo. In both treatment groups, cortical bone mineral density did not change markedly in either period (P greater-than-or-equal-to 0.2). Conclusions: Low doses of glucocorticoid agents cause marked vertebral trabecular bone loss in the initial months of therapy in patients with active rheumatoid arthritis. After discontinuation of treatment, this bone loss seems to be (partially) reversible.			LAAN, RFJM (corresponding author), UNIV HOSP NIJMEGEN, DEPT RHEUMATOL, POB 9101, 6500 HB NIJMEGEN, NETHERLANDS.		van Riel, P.L.C.M./H-8082-2014; Laan, R.F.J.M./H-8064-2014; Erning, L.J.T.O./L-4296-2015					CALDWELL JR, 1991, SEMIN ARTHRITIS RHEU, V21, P1, DOI 10.1016/0049-0172(91)90051-Z; CORKILL MM, 1990, BRIT J RHEUMATOL, V29, P274; DYKMAN TR, 1985, ARTHRITIS RHEUM, V28, P361, DOI 10.1002/art.1780280402; GENANT HK, 1982, ANN INTERN MED, V97, P699, DOI 10.7326/0003-4819-97-5-699; JULIAN BA, 1991, NEW ENGL J MED, V325, P544, DOI 10.1056/NEJM199108223250804; KALENDER WA, 1989, EUR J RADIOL, V9, P75; KALENDER WA, 1987, RADIOLOGY, V164, P419, DOI 10.1148/radiology.164.2.3602380; KALLA AA, 1991, BRIT J RHEUMATOL, V30, P91; KLOTZ E, 1989, IEEE T MED IMAGING, V8, P371, DOI 10.1109/42.41490; KROLNER B, 1983, CLIN SCI, V64, P537, DOI 10.1042/cs0640537; LAAN RFJM, 1992, ANN RHEUM DIS, V51, P826, DOI 10.1136/ard.51.6.826; LOCASCIO V, 1990, BONE MINER, V8, P39, DOI 10.1016/0169-6009(91)90139-Q; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; MANNING P, 1990, OSTEOPOROSIS 1990, P1585; REID DM, 1986, BRIT J RHEUMATOL, V25, P253; REID IR, 1989, CLIN ENDOCRINOL, V30, P83, DOI 10.1111/j.1365-2265.1989.tb03730.x; RITCHIE DM, 1968, Q J MED, V37, P393; RIZZATO G, 1992, BONE MINER, V17, P265; ROPES M W, 1958, Bull Rheum Dis, V9, P175; SAMBROOK PN, 1989, ANN RHEUM DIS, V48, P535, DOI 10.1136/ard.48.7.535; VANDERHEIJDE DMFM, 1990, ANN RHEUM DIS, V49, P916, DOI 10.1136/ard.49.11.916; VANDERHEIJDE DMFM, 1992, ANN RHEUM DIS, V51, P177, DOI 10.1136/ard.51.2.177; VANDERHEIJDE DMFM, 1990, SCAND J RHEUMATOL, V19, P407, DOI 10.3109/03009749009097629; VARGAS SJ, 1987, J BONE MINER RES, V2, P183	24	361	378	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1993	119	10					963	968		10.7326/0003-4819-119-10-199311150-00001	http://dx.doi.org/10.7326/0003-4819-119-10-199311150-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG672	8105737				2022-12-28	WOS:A1993MG67200001
J	SOUMERAI, SB; SALEMSCHATZ, S; AVORN, J; CASTERIS, CS; ROSSDEGNAN, D; POPOVSKY, MA				SOUMERAI, SB; SALEMSCHATZ, S; AVORN, J; CASTERIS, CS; ROSSDEGNAN, D; POPOVSKY, MA			A CONTROLLED TRIAL OF EDUCATIONAL OUTREACH TO IMPROVE BLOOD-TRANSFUSION PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRACTICE GUIDELINES; DECISION-MAKING; STRATEGIES; SURGERY; POLICY; CARE	Objective.-To determine whether brief, face-to-face educational outreach visits can improve the appropriateness of blood product utilization. Design.-Randomized, controlled multicenter trial with 6-month follow-up. Setting.-Surgical and medical services of two pairs of matched community and teaching hospitals in Massachusetts. Participants.-One hundred one transfusing staff surgeons and attending medical physicians. Intervention.-A professionally based transfusion specialist presented one surgical- or medical-service-wide lecture emphasizing appropriate indications, risks, and benefits of red blood cell transfusions; brief, graphic, printed educational guidelines; and one 30-minute visit with each transfusing physician. No data feedback was provided. Educational messages emphasized the lack of utility of the traditional threshold for red blood cell transfusions (hematocrit, 30%) and transfusion risks (eg, viral hepatitis). Measures.-Proportion of red blood cell transfusions classified as compliant or noncompliant with blood transfusion guidelines, or indeterminate 6 months before and 6 months after an experimental educational intervention. Results.-Based on analyses of 1449 medical record audits of red blood cell transfusions that occurred 6 months before and 6 months after the educational intervention, the average proportion of transfusions not in compliance with criteria declined from 0.40 to 0.24 among study surgeons (-40%) compared with an increase from 0.40 to 0.44 (+9%) among control surgeons (P=.006). These effects were consistent across procedure type and specialty. On average, study surgeons in the postintervention period performed transfusions when hematocrits were 2.0 percentage points lower than before the intervention (28.3% preintervention vs 26.3% postintervention), and lower than in the control group (28.3% preintervention and postintervention; P=.04). Likely savings in blood use for surgical services probably exceeded program costs, even without considering reduced risks of infection. No effects were observed among transfusions occurring in medical services, possibly because of substantially lower transfusion rates and lower pretransfusion hematocrits. Conclusions.-Brief, focused educational outreach visits by transfusion specialists can substantially improve the appropriateness and cost-effectiveness of blood product use in surgery. More data are needed regarding the durability of changes in practice patterns and the health and economic benefits of such interventions.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM ANAL CLIN STRATEGIES,BOSTON,MA 02115; AMER RED CROSS,BLOOD SERV,NE REG,DEDHAM,MA; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; American Red Cross; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	SOUMERAI, SB (corresponding author), HARVARD UNIV,SCH MED,DEPT SOCIAL MED,643 HUNTINGTON AVE,2ND FLOOR,BOSTON,MA 02115, USA.				AHRQ HHS [HSO5300] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALTER HJ, 1989, CURRENT PERSPECTIVES, P83; [Anonymous], 1977, 9 REV C; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; BLUMBERG N, 1986, TRANSFUSION, V26, P511, DOI 10.1046/j.1537-2995.1986.26687043615.x; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; FORBES JM, 1991, TRANSFUSION, V31, P318, DOI 10.1046/j.1537-2995.1991.31491213295.x; GOODNOUGH LT, 1991, JAMA-J AM MED ASSOC, V265, P86, DOI 10.1001/jama.265.1.86; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MOZES B, 1989, TRANSFUSION, V29, P473, DOI 10.1046/j.1537-2995.1989.29689318442.x; PALERMO G, 1980, TRANSFUSION, V20, P704, DOI 10.1046/j.1537-2995.1980.20681057160.x; RASKIN IE, 1991, EVAL HEALTH PROF, V14, P161, DOI 10.1177/016327879101400203; SALEMSCHATZ SR, 1990, JAMA-J AM MED ASSOC, V264, P476, DOI 10.1001/jama.264.4.476; SALEMSCHATZ SR, IN PRESS MED CARE; SNEDECOR GW, 1985, JAMA-J AM MED ASSOC, V253, P1774; SOUMERAI SB, 1984, MILBANK FUND Q, V62, P447, DOI 10.2307/3349860; SOUMERAI SB, 1986, MED CARE, V24, P313, DOI 10.1097/00005650-198604000-00003; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; TARTTER PI, 1985, TRANSFUSION, V25, P113, DOI 10.1046/j.1537-2995.1985.25285169199.x; TRIULZI DJ, 1992, SURGERY, V32, P517; WALKER RH, 1987, AM J CLIN PATHOL, V88, P374, DOI 10.1093/ajcp/88.3.374; WATKINS GM, 1974, SURG GYNECOL OBSTET, V139, P161; WELCH HG, 1992, ANN INTERN MED, V116, P393, DOI 10.7326/0003-4819-116-5-393; 1992, ANN INTERN MED, V116, P403	26	158	158	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1993	270	8					961	966		10.1001/jama.270.8.961	http://dx.doi.org/10.1001/jama.270.8.961			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LT567	8123097	Green Submitted			2022-12-28	WOS:A1993LT56700027
J	MORREY, BF				MORREY, BF			ORTHOPEDICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											MORREY, BF (corresponding author), MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905, USA.							BAUER TW, 1991, J BONE JOINT SURG AM, V73A, P1439, DOI 10.2106/00004623-199173100-00001; BOSHUIZEN HC, 1993, SPINE, V18, P35, DOI 10.1097/00007632-199301000-00007; CARL AL, 1992, SPINE, V17, pS317; GOODFELLOW J, 1992, J BONE JOINT SURG BR, V74, P645, DOI 10.1302/0301-620X.74B5.1527107; HOLMSTROM EB, 1992, SPINE, V17, P663, DOI 10.1097/00007632-199206000-00005; JOHANSON NA, 1992, J BONE JOINT SURG AM, V74A, P587, DOI 10.2106/00004623-199274040-00015; KIENAPFEL H, 1992, J ORTHOPAED RES, V10, P423, DOI 10.1002/jor.1100100315; LANCOURT J, 1992, SPINE, V17, P629, DOI 10.1097/00007632-199206000-00002; MARCHESI DG, 1992, SPINE, V17, pS304; PETERS PC, 1992, J BONE JOINT SURG AM, V74A, P864, DOI 10.2106/00004623-199274060-00007; PETERSSON BM, 1992, J BONE JOINT SURG AM, V74, P1530; ROCK MG, 1993, BIOL MATERIAL MECHAN; SCHMALZRIED TP, 1992, J BONE JOINT SURG AM, V74A, P849, DOI 10.2106/00004623-199274060-00006; SOBALLE K, 1992, J ORTHOPAED RES, V10, P285, DOI 10.1002/jor.1100100216; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V268, P489, DOI 10.1001/jama.268.4.489; TURNER JA, 1992, JAMA-J AM MED ASSOC, V268, P907, DOI 10.1001/jama.268.7.907	16	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					240	242		10.1001/jama.270.2.240	http://dx.doi.org/10.1001/jama.270.2.240			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8123078				2022-12-28	WOS:A1993LL36800034
J	WEISSE, AB				WEISSE, AB			REWARDING WOMEN IN ACADEMIC MEDICINE	ANNALS OF INTERNAL MEDICINE			English	Letter																		CARR PL, 1993, ANN INTERN MED, V119, P908, DOI 10.7326/0003-4819-119-9-199311010-00008	1	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1994	120	8					697	698		10.7326/0003-4819-120-8-199404150-00032	http://dx.doi.org/10.7326/0003-4819-120-8-199404150-00032			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE850	8135467				2022-12-28	WOS:A1994NE85000031
J	ENGELS, WR; PRESTON, CR; JOHNSONSCHLITZ, DM				ENGELS, WR; PRESTON, CR; JOHNSONSCHLITZ, DM			LONG-RANGE CIS PREFERENCE IN DNA HOMOLOGY SEARCH OVER THE LENGTH OF A DROSOPHILA CHROMOSOME	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; GENE CONVERSION; ESCHERICHIA-COLI; MAMMALIAN-CELLS; RECOMBINATION; REQUIREMENTS; MELANOGASTER; REPLACEMENT; SEQUENCES; RATES	P element-induced chromosome breakage on the X chromosome of Drosophila melanogaster was repaired six times more frequently when a homologous template was located anywhere on the X chromosome rather than on an autosome. Cis-trans comparisons confirmed that recombinational repair was more frequent when the interacting sequences were physically connected. These results suggest that the search for homology between the broken ends and a matching template sequence occurs preferentially in the cis configuration. This cis advantage operates over more than 15 megabases of DNA.			ENGELS, WR (corresponding author), UNIV WISCONSIN, DEPT GENET, MADISON, WI 53706 USA.				NIGMS NIH HHS [GM30948] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030948, R56GM030948] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1988, MOL CELL BIOL, V8, P2442, DOI 10.1128/MCB.8.6.2442; BAKER BS, 1983, ANNU REV GENET, V17, P345, DOI 10.1146/annurev.ge.17.120183.002021; DENG CX, 1992, MOL CELL BIOL, V12, P3365, DOI 10.1128/MCB.12.8.3365; ENGELS WR, 1979, ENVIRON MUTAGEN, V1, P37, DOI 10.1002/em.2860010110; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; ENGELS WR, 1986, FOCUS, V8, P6; Erlich H.A., 1989, PCR TECHNOLOGY; GLOOR GB, 1991, SCIENCE, V253, P1110, DOI 10.1126/science.1653452; GLOOR GB, 1993, GENETICS, V135, P81; JEONGYU S, 1992, MOL CELL BIOL, V12, P5426, DOI 10.1128/MCB.12.12.5426; JOHNSONSCHLITZ DM, 1993, MOL CELL BIOL, V13, P7006, DOI 10.1128/MCB.13.11.7006; KUPIEC M, 1988, MOL CELL BIOL, V8, P2942, DOI 10.1128/MCB.8.7.2942; LICHTEN M, 1989, GENETICS, V123, P261; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LISKAY RM, 1987, GENETICS, V115, P161; MEZARD C, 1992, CELL, V70, P659, DOI 10.1016/0092-8674(92)90434-E; NASSIF N, 1993, P NATL ACAD SCI USA, V90, P1262, DOI 10.1073/pnas.90.4.1262; RAO BJ, 1993, P NATL ACAD SCI USA, V90, P6646, DOI 10.1073/pnas.90.14.6646; ROBERTSON HM, 1988, GENETICS, V118, P461; ROEDER GS, 1984, MOL CELL BIOL, V4, P703, DOI 10.1128/MCB.4.4.703; RUBIN GM, 1982, CELL, V29, P987, DOI 10.1016/0092-8674(82)90462-7; RUBNITZ J, 1984, MOL CELL BIOL, V4, P2253, DOI 10.1128/MCB.4.11.2253; SHEN P, 1986, GENETICS, V112, P441; SINGER BS, 1982, CELL, V31, P25, DOI 10.1016/0092-8674(82)90401-9; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; THOMAS KR, 1992, MOL CELL BIOL, V12, P2919, DOI 10.1128/MCB.12.7.2919; WALDMAN AS, 1987, P NATL ACAD SCI USA, V84, P5340, DOI 10.1073/pnas.84.15.5340; WATT VM, 1985, P NATL ACAD SCI USA, V82, P4768, DOI 10.1073/pnas.82.14.4768	29	54	56	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 18	1994	263	5153					1623	1625		10.1126/science.8128250	http://dx.doi.org/10.1126/science.8128250			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	8128250				2022-12-28	WOS:A1994NB67300035
J	SEHGAL, A; PRICE, JL; MAN, B; YOUNG, MW				SEHGAL, A; PRICE, JL; MAN, B; YOUNG, MW			LOSS OF CIRCADIAN BEHAVIORAL RHYTHMS AND PER RNA OSCILLATIONS IN THE DROSOPHILA MUTANT TIMELESS	SCIENCE			English	Article							PERIOD GENE-PRODUCT; VISUAL-SYSTEM; NUCLEAR-PROTEIN; CLOCK MUTANTS; AH-RECEPTOR; MELANOGASTER; EXPRESSION; IDENTIFICATION; ENCODES; CLONING	Eclosion, or emergence of adult flies from the pupa, and locomotor activity of adults occur rhythmically in Drosophila melanogaster, with a circadian period of about 24 hours. Here, a clock mutation, timeless (tim), is described that produces arrhythmia for both behaviors. The effects of tim on behavioral rhythms are likely to involve products of the X chromesome-linked clock gene period (per), because tim alters circadian oscillations of per RNA. Genetic mapping places tim on the left arm of the second chromosome between dumpy (dp) and decapentaplegic (dpp).	ROCKEFELLER UNIV,NATL SCI FDN SCI & TECHNOL CTR BIOL TIMING,HOWARD HUGHES MED INST,NEW YORK,NY 10021; ROCKEFELLER UNIV,GENET LAB,NEW YORK,NY 10021	Howard Hughes Medical Institute; National Science Foundation (NSF); Rockefeller University; Rockefeller University			, 机智的马小跳和机智的羊不愁/ABC-5169-2020; Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X				BAYLIES MK, 1993, MOL GENETICS BIOL RH, P123; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DANIELS SB, 1993, GENETICS, V133, P623; DOWSE HB, 1987, BEHAV GENET, V17, P19, DOI 10.1007/BF01066008; DUSHAY MS, 1989, J BIOL RHYTHM, V4, P1, DOI 10.1177/074873048900400101; DUSHAY MS, 1990, GENETICS, V125, P557; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; HAMBLEN M, 1986, J NEUROGENET, V3, P249, DOI 10.3109/01677068609106855; HAMBLENCOYLE MJ, 1992, J INSECT BEHAV, V5, P417, DOI 10.1007/BF01058189; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HELFRICH C, 1987, Z NATURFORSCH C, V42, P1335; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Jackson FR, 1983, J NEUROGENET, V1, P3, DOI 10.3109/01677068309107068; JACKSON FR, 1993, MOL GENETICS BIOL RH, P91; JAMES AA, 1986, EMBO J, V5, P2313, DOI 10.1002/j.1460-2075.1986.tb04499.x; KIDWELL MG, 1986, DROSOPHILA PRACTICAL, pCH3; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KONOPKA RJ, 1991, J NEUROGENET, V7, P103, DOI 10.3109/01677069109066214; LIU X, 1992, J NEUROSCI, V12, P2735; LIU X, 1988, GENE DEV, V2, P228, DOI 10.1101/gad.2.2.228; PITTENDRIGH CS, 1974, NEUROSCIENCES 3RD ST, pCH38; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; ROBERTSON HM, 1988, GENETICS, V118, P461; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; SAEZ L, 1988, MOL CELL BIOL, V8, P5378, DOI 10.1128/MCB.8.12.5378; SEHGAL A, 1992, P NATL ACAD SCI USA, V89, P1423, DOI 10.1073/pnas.89.4.1423; SEHGAL A, UNPUB; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106; ZERR DM, 1990, J NEUROSCI, V10, P2749; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	39	477	497	4	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 18	1994	263	5153					1603	1606		10.1126/science.8128246	http://dx.doi.org/10.1126/science.8128246			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	8128246				2022-12-28	WOS:A1994NB67300029
J	GRIFFIN, TC; MCINTIRE, D; BUCHANAN, GR				GRIFFIN, TC; MCINTIRE, D; BUCHANAN, GR			HIGH-DOSE INTRAVENOUS METHYLPREDNISOLONE THERAPY FOR PAIN IN CHILDREN AND ADOLESCENTS WITH SICKLE-CELL DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; RISK-FACTORS; CRISIS; HYDROXYUREA; MANAGEMENT; MENINGITIS; ANEMIA	Background and Methods. The management of episodes of severe pain in patients with sickle cell disease is a difficult clinical problem. We studied 36 children and adolescents with sickle cell disease who had 56 acute episodes of severe pain (44 in 27 patients with sickle cell anemia, 8 in 7 patients with sickle cell-hemoglobin C disease, and 4 in 2 patients with sickle cell-beta(+)-thalassemia). The patients were randomly assigned in double-blind fashion to receive an intravenous infusion of either saline placebo or high-dose methylprednisolone (15 mg per kilogram of body weight, to a maximum of 1000 mg) on their admission to the hospital and again 24 hours later. All the patients received intravenous morphine sulfate until severe pain abated and were then given acetaminophen with codeine. Results. For all episodes of pain, the duration of inpatient analgesic therapy (intravenous and oral) was significantly shorter for the patients who received methylprednisolone than for those given placebo (mean, 41.3 vs. 71.3 hours; P = 0.030). The difference was still significant (31.0 vs. 62.5 hours; P = 0.010) when we excluded seven episodes that were complicated by the chest syndrome (three in the methylprednisolone group and four in the placebo group). The patients who received methylprednisolone had recurrent episodes of pain shortly after the discontinuation of therapy more often than did the patients receiving placebo. No adverse effects of methylprednisolone were observed. Conclusions. A short course of high-dose methylprednisolone decreased the duration of severe pain in children and adolescents with sickle cell disease, but patients who received methylprednisolone had more rebound attacks after therapy was discontinued. On balance, corticosteroids are promising as an adjunct to supportive therapy for painful episodes in children and adolescents with sickle cell disease.	UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DIV HEMATOL ONCOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,CTR ACAD COMP,DALLAS,TX 75235; CHILDRENS MED CTR,CTR CANC & BLOOD DISORDERS,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NCI NIH HHS [T-32-CAO9640] Funding Source: Medline; NICHD NIH HHS [T-32-HD07308] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007308] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009640] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANIAN R, 1975, BLOOD, V45, P769; ALUOCH JR, 1984, TROP GEOGR MED, V36, pS1; ARAUJO JT, 1990, BLOOD S, V76, pA54; BAUM KF, 1987, ARCH INTERN MED, V147, P1231, DOI 10.1001/archinte.147.7.1231; BENJAMIN LJ, 1986, BLOOD, V67, P1442; BENJAMIN LJ, 1992, 17TH P ANN SICKL CEL, pA78; BEYER JE, 1989, PEDIATR CLIN N AM, V36, P837; BRUERA E, 1985, CANCER TREAT REP, V69, P751; CHARACHE S, 1992, BLOOD, V79, P2555; CLAMAN HN, 1984, CLIN IMMUNOL ALLERGY, V4, P317; COLE TB, 1986, AM J DIS CHILD, V140, P1255, DOI 10.1001/archpedi.1986.02140260057025; DECEULAER K, 1982, LANCET, V2, P229; FRANCIS RB, 1991, 16TH P ANN SICKL CEL, pA51; HALL TC, 1967, ANN INTERN MED, V66, P1144, DOI 10.7326/0003-4819-66-6-1144; ISAACS WA, 1972, LANCET, V1, P570; KENNEDY WA, 1991, AM J DIS CHILD, V145, P1374, DOI 10.1001/archpedi.1991.02160120042016; LANDE WM, 1988, BLOOD, V72, P2056; LEBEL MH, 1988, NEW ENGL J MED, V319, P964, DOI 10.1056/NEJM198810133191502; LUNDH B, 1970, SCAND J HAEMATOL, V7, P389; MENICHELLI A, 1984, ARCH DIS CHILD, V59, P777, DOI 10.1136/adc.59.8.777; MENTZER WC, 1969, BLOOD-J HEMATOL, V34, P733; MILLER JJ, 1980, PEDIATRICS, V65, P989; MUSSCHE MM, 1976, NEPHRON, V16, P287, DOI 10.1159/000180613; PERLIN E, 1986, BLOOD S, V68, pA64; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056/NEJM199301143280202; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; ROBINSON B, 1979, LANCET, V1, P1088; RODGERS GP, 1990, NEW ENGL J MED, V322, P1037, DOI 10.1056/NEJM199004123221504; RUCKNAGEL DL, 1991, LANCET, V337, P831, DOI 10.1016/0140-6736(91)92525-7; SCHELL HW, 1972, GERIATRICS, V27, P131; SERJEANT GR, 1992, SICKLE CELL DISEASE, P440; SHAPIRO BS, 1989, PEDIATR CLIN N AM, V36, P1029; TEMPLE JD, 1987, BLOOD S, V70, pA69; VANHOFF J, 1988, J PEDIATR-US, V113, P563, DOI 10.1016/S0022-3476(88)80654-1; VERMYLEN C, 1991, ARCH DIS CHILD, V66, P1195, DOI 10.1136/adc.66.10.1195; VICHINSKY EP, 1982, AM J PEDIAT HEMATOL, V4, P328; ZANGER B, 1974, J LAB CLIN MED, V84, P889	37	128	131	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 17	1994	330	11					733	737		10.1056/NEJM199403173301101	http://dx.doi.org/10.1056/NEJM199403173301101			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA742	8107739	Bronze			2022-12-28	WOS:A1994NA74200001
J	MISIANI, R; BELLAVITA, P; FENILI, D; VICARI, O; MARCHESI, D; SIRONI, PL; ZILIO, P; VERNOCCHI, A; MASSAZZA, M; VENDRAMIN, G; TANZI, E				MISIANI, R; BELLAVITA, P; FENILI, D; VICARI, O; MARCHESI, D; SIRONI, PL; ZILIO, P; VERNOCCHI, A; MASSAZZA, M; VENDRAMIN, G; TANZI, E			INTERFERON ALFA-2A THERAPY IN CRYOGLOBULINEMIA ASSOCIATED WITH HEPATITIS-C VIRUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESSENTIAL MIXED CRYOGLOBULINEMIA; TERM FOLLOW-UP; ALPHA-INTERFERON; INFECTION; PLASMAPHERESIS; RNA	Background. Essential mixed cryoglobulinemia is frequently associated with hepatitis C virus (HCV) infection. A beneficial effect of interferon alfa therapy has been reported, but we do not know whether the antiviral activity of the drug affects the clinical and biochemical manifestations of disease. Methods. In a prospective randomized, controlled trial, we studied 53 patients with HCV-associated type II cryoglobulinemia. A group of 27 patients received recombinant interferon alfa-2a thrice weekly at a dose of 1.5 million units for a week and then 3 million units thrice weekly for the following 23 weeks. The 26 control patients did not receive anything apart from previously prescribed treatments. All patients were then followed for an additional 24 to 48 weeks. Results. Interferon was usually well tolerated, but it was permanently discontinued in two patients because of atrial fibrillation and depression. Two of the 26 patients in the control group were lost to follow-up. After the treatment period, serum HCV RNA was undetectable in 15 of the remaining 25 patients who received interferon on alfa-2a, but in none of the controls. In comparison with the control group, the 15 patients with undetectable levels of HCV RNA in serum had significant improvement in cutaneous vasculitis (P = 0.04) and significant decreases in serum levels of anti-HCV-antibody activity (P = 0.007), cryoglobulins (P = 0.002), IgM (P = 0.002), rheumatoid factor (P = 0.001), and creatinine (P = 0.006). After treatment with interferon alfa-2a was discontinued, viremia and cryoglobulinemia recurred in all 15.HCV RNA-negative patients. On resumption of treatment, three of four patients had a virologic, clinical, and biochemical response. Conclusions. The therapeutic efficacy of interferon alfa-2a in HCV-associated cryoglobulinemia is closely related to its antiviral activity, thus supporting the idea that HCV infection may be a cause of this disease.	OSPED RIUNITI BERGAMO,DEPT IMMUNOHEMATOL,DIV NEPHROL & DIALYSIS,I-24128 BERGAMO,ITALY; OSPED RIUNITI BERGAMO,CTR BLOOD TRANSFUS,I-24128 BERGAMO,ITALY; OSPED RIUNITI BERGAMO,CLIN CHEM LAB,I-24128 BERGAMO,ITALY; OSPED RIUNITI BERGAMO,DIV MED 1,I-24128 BERGAMO,ITALY; OSPED TREVIGLIO & CARAVAGGIO,DIALYSIS UNIT,TREVIGLIO,ITALY; UNIV MILAN,SCH MED,INST VIROL,MILAN,ITALY; OSPED TREVIGLIO & CARAVAGGIO,CLIN CHEM LAB,TREVIGLIO,ITALY	Ospedali Riuniti di Bergamo; Ospedali Riuniti di Bergamo; Ospedali Riuniti di Bergamo; Ospedali Riuniti di Bergamo; Ospedale di Treviglio-Caravaggio; University of Milan; Ospedale di Treviglio-Caravaggio			Tanzi, Elisabetta/M-9066-2016	Tanzi, Elisabetta/0000-0002-4119-701X				AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; BERKMAN EM, 1980, TRANSFUSION, V20, P171, DOI 10.1046/j.1537-2995.1980.20280169957.x; BONOMO L, 1987, AM J MED, V83, P726, DOI 10.1016/0002-9343(87)90904-1; BRILLANTI S, 1991, J MED VIROL, V34, P136, DOI 10.1002/jmv.1890340213; CASATO M, 1991, BLOOD, V78, P3142; CREAM JJ, 1971, BRIT J DERMATOL, V84, P48, DOI 10.1111/j.1365-2133.1971.tb14196.x; DEVECCHI A, 1983, CLIN NEPHROL, V19, P221; DURAND JM, 1992, J INFECT DIS, V165, P778, DOI 10.1093/infdis/165.4.778; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P621; FERRI C, 1993, BLOOD, V81, P1132; FRANKEL AH, 1992, Q J MED, V82, P101; GARSON JA, 1992, J MED VIROL, V37, P210, DOI 10.1002/jmv.1890370311; GELTNER D, 1981, ARTHRITIS RHEUM, V24, P1121, DOI 10.1002/art.1780240902; GERMAIN MJ, 1982, AM J NEPHROL, V2, P221, DOI 10.1159/000166650; GOREVIC PD, 1980, AM J MED, V69, P287, DOI 10.1016/0002-9343(80)90390-3; HOLLANDER M, 1973, NONPARAMETRIC STATIS; KNOX TA, 1991, AM J MED, V91, P554, DOI 10.1016/0002-9343(91)90196-5; L'Abbate A, 1977, Proc Eur Dial Transplant Assoc, V14, P486; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; MISIANI R, 1993, NEW ENGL J MED, V328, P1121, DOI 10.1056/NEJM199304153281511; PASCUAL M, 1990, J INFECT DIS, V162, P569, DOI 10.1093/infdis/162.2.569; PUOTI M, 1992, HEPATOLOGY, V16, P877, DOI 10.1002/hep.1840160404; SHINDO M, 1992, HEPATOLOGY, V15, P1013, DOI 10.1002/hep.1840150607; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SINICO RA, 1988, KIDNEY INT, V34, P109, DOI 10.1038/ki.1988.152; TAILLAN B, 1991, PRESSE MED, V20, P2160	26	553	568	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 17	1994	330	11					751	756		10.1056/NEJM199403173301104	http://dx.doi.org/10.1056/NEJM199403173301104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA742	8107741				2022-12-28	WOS:A1994NA74200004
J	STAPLETON, FB; LINSHAW, MA				STAPLETON, FB; LINSHAW, MA			URIC-ACID CRYSTALS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Tufts University	STAPLETON, FB (corresponding author), SUNY BUFFALO, BUFFALO, NY USA.								0	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 17	1994	330	11					762	762						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA742	8107742				2022-12-28	WOS:A1994NA74200006
J	STIELL, IG; MCKNIGHT, RD; GREENBERG, GH; MCDOWELL, I; NAIR, RC; WELLS, GA; JOHNS, C; WORTHINGTON, JR				STIELL, IG; MCKNIGHT, RD; GREENBERG, GH; MCDOWELL, I; NAIR, RC; WELLS, GA; JOHNS, C; WORTHINGTON, JR			IMPLEMENTATION OF THE OTTAWA ANKLE RULES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-ASSESSMENT; X-RAYS; INJURIES; FRACTURE; RADIOGRAPHY	Objective.-To assess the impact on clinical practice of implementing the Ottawa ankle rules. Design.-Nonrandomized, controlled trial with before-after and concurrent controls. Setting.-Emergency departments of a university (intervention) hospital and a community (control) hospital. Patients.-All 2342 adults seen with acute ankle injuries during 5-month periods before and after the intervention. Intervention.-The implementation of the Ottawa ankle rules by emergency department physicians. Main Outcome Measure.-Proportions of patients referred for standard ankle and foot radiographic series. Results.-There was a relative reduction in ankle radiography by 28% at the intervention hospital but an increase by 2% at the control hospital (P<.001). Foot radiography was reduced by 14% at the intervention hospital but increased by 13% at the control hospital (P<.05). Compared with nonfracture patients who had radiography during the after period at the intervention hospital, those discharged without radiography spent less time in the emergency department (80 minutes vs 116 minutes; P<.0001), had lower estimated total medical costs for physician visits and radiography ($62 vs $173; P<.001), but did not differ in the proportion satisfied with emergency physician care (95% vs 96%) or undergoing subsequent radiography (5% vs 5%). The rules were found to have sensitivities of 1.0 (95% confidence interval [Cl], 0.95 to 1.0) for detecting 74 malleolar fractures and 1.0 (95% Cl, 0.82 to 1.0) for detecting 19 midfoot fractures. In the following 12 months at the intervention hospital, use of radiography did not increase. Conclusions.-Implementation of the Ottawa ankle rules led to a decrease in use of ankle radiography, waiting times, and costs without patient dissatisfaction or missed fractures. Future studies should address the generalizability of these decision rules in a variety of hospital settings.	UNIV OTTAWA,FAC MED,DIV EMERGENCY MED,OTTAWA,ON,CANADA; UNIV OTTAWA,FAC MED,DIV EPIDEMIOL & COMMUNITY MED,OTTAWA,ON,CANADA; UNIV OTTAWA,FAC MED,DEPT MED,OTTAWA,ON,CANADA; ONTARIO MINIST HLTH,HLTH RES PERSONNEL DEV PROGRAM,TORONTO,ON,CANADA	University of Ottawa; University of Ottawa; University of Ottawa	STIELL, IG (corresponding author), OTTAWA CIVIC HOSP,LOEB MED RES INST,CLIN EPIDEMIOL UNIT,1053 CARLING AVE,OTTAWA K1Y 4E9,ON,CANADA.		Nair, Rama C/G-5674-2011	Nair, Rama C/0000-0002-9101-0516; Stiell, Ian/0000-0002-2583-6408				ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; BRAND DA, 1982, NEW ENGL J MED, V306, P333, DOI 10.1056/NEJM198202113060604; BROOKS SC, 1981, BRIT MED J, V282, P607, DOI 10.1136/bmj.282.6264.607; DIAMOND GA, 1989, AM J CARDIOL, V63, P99, DOI 10.1016/0002-9149(89)91084-9; DUNLOP MG, 1986, BRIT MED J, V293, P603, DOI 10.1136/bmj.293.6547.603; FEINSTEIN AR, 1985, ARCH INTERN MED, V145, P1257, DOI 10.1001/archinte.145.7.1257; Feinstein AR, 1987, CLINIMETRICS; Fleiss JL, 1981, STAT METHODS RATES P; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; LEE TH, 1990, J GEN INTERN MED, V5, P528, DOI 10.1007/BF02600886; LLOYD S, 1986, CAN MED ASSOC J, V135, P973; Long A E, 1985, Emerg Med Clin North Am, V3, P437; MATTHEWS MG, 1986, BRIT MED J, V293, P959; MOLONEY TW, 1979, NEW ENGL J MED, V301, P1413, DOI 10.1056/NEJM197912273012603; MONTAGUE AP, 1985, INJURY, V16, P545, DOI 10.1016/0020-1383(85)90082-8; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; RYD L, 1992, ACTA ORTHOP SCAND, V63, P443, DOI 10.3109/17453679209154764; SIMON RR, 1987, EMERGENCY ORTHOPEDIC; STIELL IG, 1992, AM J EMERG MED, V10, P14, DOI 10.1016/0735-6757(92)90117-G; STIELL IG, 1992, CAN MED ASSOC J, V147, P1671; STIELL IG, 1993, JAMA-J AM MED ASSOC, V269, P1127, DOI 10.1001/jama.269.9.1127; STIELL IG, 1992, ANN EMERG MED, V21, P384, DOI 10.1016/S0196-0644(05)82656-3; SUJITKUMAR P, 1986, ARCH EMERG MED, V3, P101; SVENSON J, 1988, LANCET, V1, P244; VARGISH T, 1983, INJURY, V14, P507, DOI 10.1016/0020-1383(83)90053-0; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306	26	319	320	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					827	832		10.1001/jama.271.11.827	http://dx.doi.org/10.1001/jama.271.11.827			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ498	8114236				2022-12-28	WOS:A1994MZ49800028
J	BRANDA, N; WYLER, R; REBEK, J				BRANDA, N; WYLER, R; REBEK, J			ENCAPSULATION OF METHANE AND OTHER SMALL MOLECULES IN A SELF-ASSEMBLING SUPERSTRUCTURE	SCIENCE			English	Article							CAVITANDS	Physical inclusion of small molecules in larger structural lattices is well known in the crystalline state and is a common feature of the chemistry of zeolites. In the liquid state, a variety of synthetic macrocyclic molecules are available to complex and contain smaller guest species. An alternative strategy for binding is explored: assembly of cavity-forming structures from smaller subunits. Encapsulation of small guest molecules such as methane can be achieved with a synthetic structure that assembles reversibly through hydrogen bonding.			BRANDA, N (corresponding author), MIT,DEPT CHEM,CAMBRIDGE,MA 02139, USA.							ANDREU C, 1993, PURE APPL CHEM, V65, P2313, DOI 10.1351/pac199365112313; BAXTER P, 1993, ANGEW CHEM INT EDIT, V32, P69, DOI 10.1002/anie.199300691; BONARLAW RP, 1993, TETRAHEDRON LETT, V34, P1677, DOI 10.1016/0040-4039(93)85039-Y; BONDI A, 1964, J PHYS CHEM-US, V68, P441, DOI 10.1021/j100785a001; CANCEILL J, 1985, J CHEM SOC CHEM COMM, P361, DOI 10.1039/c39850000361; COLLET A, 1987, TETRAHEDRON, V43, P5725, DOI 10.1016/S0040-4020(01)87780-2; CRAM DJ, 1993, J AM CHEM SOC, V115, P10111, DOI 10.1021/ja00075a029; CRAM DJ, 1985, J AM CHEM SOC, V107, P2575, DOI 10.1021/ja00294a076; DIETRICH B, 1969, TETRAHEDRON LETT, P2885; GAREL L, 1993, ANGEW CHEM INT EDIT, V32, P1169, DOI 10.1002/anie.199311691; GHADIRI MR, 1993, NATURE, V366, P324, DOI 10.1038/366324a0; LEHN JM, 1988, ANGEW CHEM INT EDIT, V27, P89, DOI 10.1002/anie.198800891; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; MORAN JR, 1982, J AM CHEM SOC, V104, P5826, DOI 10.1021/ja00385a064; SETO CT, 1991, J AM CHEM SOC, V113, P712, DOI 10.1021/ja00002a071; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WYLER R, 1993, ANGEW CHEM INT EDIT, V32, P1699, DOI 10.1002/anie.199316991	17	177	178	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 4	1994	263	5151					1267	1268		10.1126/science.8122107	http://dx.doi.org/10.1126/science.8122107			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	8122107				2022-12-28	WOS:A1994MY57000032
J	ALLEN, PM				ALLEN, PM			PEPTIDES IN POSITIVE AND NEGATIVE SELECTION - A DELICATE BALANCE	CELL			English	Review							ANTIGEN				ALLEN, PM (corresponding author), WASHINGTON UNIV,DEPT PATHOL,ST LOUIS,MO 63130, USA.							ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BHARDWAJ V, 1993, J IMMUNOL, V151, P5000; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; JANEWAY C, 1992, Current Biology, V2, P26, DOI 10.1016/0960-9822(92)90419-B; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MOLLER G, 1993, IMMUNOL REV, V135, P1; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; SYKULEV Y, 1994, IN PRESS IMMUNITY, V1; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1	17	147	148	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 25	1994	76	4					593	596		10.1016/0092-8674(94)90497-9	http://dx.doi.org/10.1016/0092-8674(94)90497-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124703				2022-12-28	WOS:A1994MZ28500002
J	DOXSEY, SJ; STEIN, P; EVANS, L; CALARCO, PD; KIRSCHNER, M				DOXSEY, SJ; STEIN, P; EVANS, L; CALARCO, PD; KIRSCHNER, M			PERICENTRIN, A HIGHLY CONSERVED CENTROSOME PROTEIN INVOLVED IN MICROTUBULE ORGANIZATION	CELL			English	Article							COIL RELATED PROTEIN; CELL-CYCLE; PROTOFILAMENT NUMBER; ORGANIZING CENTERS; GAMMA-TUBULIN; MOUSE OOCYTES; SITES; SEQUENCE; GENE; IDENTIFICATION	Antisera from scleroderma patients that react widely with centrosomes in plants and animals were used to isolate cDNAs encoding a novel centrosomal protein. The nucleotide sequence is consistent with a 7 kb mRNA and contains an open reading frame encoding a protein with a putative large coiled-coil domain flanked by noncoiled ends. Antisera recognize a 220 kd protein and stain centrosomes and acentriolar microtubule-organizing centers, where the protein is localized to the pericentriolar material (hence, the name pericentrin). Anti-pericentrin antibodies disrupt mitotic and meiotic divisions in vivo and block microtubule aster formation in Xenopus extracts, but do not block gamma-tubulin assembly or microtubule nucleation from mature centrosomes. These results suggest that pericentrin is a conserved integral component of the filamentous matrix of the centrosome involved in the initial establishment of organized microtubule arrays.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco								AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BARON AT, 1988, J CELL BIOL, V107, P2669, DOI 10.1083/jcb.107.6.2669; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BORNENS M, 1987, CELL MOTIL CYTOSKEL, V8, P238, DOI 10.1002/cm.970080305; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; BUENDIA B, 1992, J CELL BIOL, V117, P1055; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CALARCO PD, 1983, J CELL BIOL, V101, P319; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CLAYTON L, 1985, CELL, V35, P621; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COHEN C, 1987, BIOSCIENCE REP, V7, P11, DOI 10.1007/BF01122722; EVANS L, 1985, J CELL BIOL, V100, P1185, DOI 10.1083/jcb.100.4.1185; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; GARD DL, 1987, J CELL BIOL, V105, P2191, DOI 10.1083/jcb.105.5.2191; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOULD RR, 1977, J CELL BIOL, V73, P601, DOI 10.1083/jcb.73.3.601; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; HARLOW E, 1988, ANTIBODIES LABORATOR; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; Kalt Astrid, 1993, Trends in Cell Biology, V3, P118, DOI 10.1016/0962-8924(93)90174-Y; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KRSTIC K, 1976, ULTRASTRUCTURE MAMMA; Kuriyama Ryoko, 1992, P131; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MANDELKOW EM, 1986, J CELL BIOL, V102, P1067, DOI 10.1083/jcb.102.3.1067; MIRZAYAN C, 1992, J CELL BIOL, V116, P1319, DOI 10.1083/jcb.116.6.1319; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; OAKLEY BR, 1990, NATURE, V338, P662; PAINTRAND M, 1992, J STRUCT BIOL, V108, P107, DOI 10.1016/1047-8477(92)90011-X; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSON JB, 1976, J CELL SCI, V22, P219; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J, 1989, MOL CLONING LABORATO; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIMERLY C, 1990, J CELL BIOL, V111, P1491, DOI 10.1083/jcb.111.4.1491; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNYDER M, 1988, CELL, V54, P743, DOI 10.1016/S0092-8674(88)90977-4; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; SZOLLOSI D, 1972, J CELL SCI, V11, P521; TUCKER JB, 1986, EUR J CELL BIOL, V41, P279; TUFFANELLI DL, 1983, ARCH DERMATOL, V119, P560, DOI 10.1001/archderm.119.7.560; VALE RD, 1993, GUIDEBOOK CYTOSKELET; VIDAIR CA, 1993, J CELL PHYSIOL, V154, P443, DOI 10.1002/jcp.1041540302; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WHEATLEY DN, 1982, CENTRIOLE CENTRAL EN; YANG CH, 1992, J CELL BIOL, V116, P1303, DOI 10.1083/jcb.116.6.1303	55	493	498	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	1994	76	4					639	650		10.1016/0092-8674(94)90504-5	http://dx.doi.org/10.1016/0092-8674(94)90504-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124707				2022-12-28	WOS:A1994MZ28500007
J	CHENOY, R; HUSSAIN, S; TAYOB, Y; OBRIEN, PMS; MOSS, MY; MORSE, PF				CHENOY, R; HUSSAIN, S; TAYOB, Y; OBRIEN, PMS; MOSS, MY; MORSE, PF			EFFECT OF ORAL GAMOLENIC ACID FROM EVENING PRIMROSE OIL ON MENOPAUSAL FLUSHING	BRITISH MEDICAL JOURNAL			English	Article							HORMONE	Objective--To evaluate the efficacy of gamolenic acid provided by evening primrose oil in treating hot flushes and sweating associated with the menopause. Design-Randomised, double blind, placebo controlled study. Setting-District general hospital and teaching hospital. Subjects-56 menopausal women suffering hot flushes at least three times a day. Intervention-Four capsules twice a day of 500 mg evening primrose oh with 10 mg natural vitamin E or 500 mg liquid paraffin for six months. Main outcome measures-Change in the number of hot flushes or sweating episodes a month. Results-56 diaries were analysed, 28 from women taking gamolenic acid and 28 from those taking placebo. Only 18 women given gamolenic acid and 17 given placebo completed the trial. The mean (SE) improvement in the number of flushes in the last available treatment cycle compared with the control cycle was 1.9 (0.4) (P < O.OOl) for daytime hushes and 0.7 (0.3) (P < O.05) for night time flushes in women taking placebo; the corresponding values for women taking gamolenic acid were 0.5 (0.1) and 0.5 (0.3). In women taking gamolenic acid the only significant improvement was a reduction in the maximum number of night time flushes (1.4 (0.6); P < 0.05). Conclusion-Gamolenic acid offers no benefit over placebo in treating menopausal flushing.	ROYAL FREE HOSP,SCH MED,LONDON NW3,ENGLAND; SCOTIA PHARMACEUT,GUILDFORD,SURREY,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	CHENOY, R (corresponding author), KEELE UNIV,N STAFFORDSHIRE MED CTR,ACAD DEPT OBSTET & GYNAECOL,STOKE ON TRENT ST4 6QG,STAFFS,ENGLAND.							BEYENE Y, 1986, CULT MED PSYCHIAT, V10, P47, DOI 10.1007/BF00053262; ERLIK Y, 1982, OBSTET GYNECOL, V59, P403; HORROBIN DF, 1980, LANCET, V1, P935; HORROBIN DF, 1990, OMEGA 6 ESSENTIAL FA, P21; LOCK M, 1991, PROGR BASIC CLIN PHA, V6, P40; LOMAX P, 1979, THERMOREGULATORY MEC, P208; NOTELOVITZ M, 1988, MENOPAUSE, P102; OJEDA SR, 1977, ENDOCRINOLOGY, V100, P1595, DOI 10.1210/endo-100-6-1595; SONNENDECKER EWW, 1980, S AFR MED J, V58, P753; TULANDI T, 1985, OBSTET GYNECOL SURV, V40, P24; VANKEEP PA, 1990, MATURITAS, V12, P163, DOI 10.1016/0378-5122(90)90002-N; WESEL S, 1984, CURR MED RES OPIN, V8, P696, DOI 10.1185/03007998409110119	12	108	109	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	1994	308	6927					501	503		10.1136/bmj.308.6927.501	http://dx.doi.org/10.1136/bmj.308.6927.501			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX814	8136666	Green Published			2022-12-28	WOS:A1994MX81400019
J	HANDYSIDES, S				HANDYSIDES, S			ENRICHING CAREERS IN GENERAL-PRACTICE - NEW ROLES FOR GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article							NEED; RECONSTRUCTION; PARTNERS	General practice is likely to change greatly over the next few years. Increases in care in the community and day surgery will lead to more work, and the demand for better data on practice activity will mean the development of audit and epidemiological work. To make time general practitioners will have to learn to delegate work that does not require a doctor, Fundholding has already stimulated some practices to bring services to patients rather than send patients to hospital, and this trend seems set to continue. It is important to pool resources, not only within practices but among other practices in the area-joint action will increase the ability to improve the services for patients. If general practitioners take the opportunity to gain control of the changes the morale of the profession should improve.										ALSHEHRI A, 1993, BMJ-BRIT MED J, V307, P101, DOI 10.1136/bmj.307.6896.101; BERLIN A, 1993, BRIT J GEN PRACT, V43, P70; CARTWRIGHT A, 1981, GENERAL PRACTICE REV; Cole D, 1993, BMJ, V306, P1416; DONALDSON L, 1992, BRIT MED J, V305, P597, DOI 10.1136/bmj.305.6854.597; EVE R, 1991, BRIT MED J, V303, P167, DOI 10.1136/bmj.303.6795.167; Gray D J, 1979, J R Coll Gen Pract, V29, P666; GRAY DP, 1992, PLANNING PRIMARY CAR; HANDYSIDES S, 1993, BRIT MED J, V306, P741; HANDYSIDES S, 1989, MEDECONOMICS     MAY, P54; HANNAY DR, 1993, BRIT MED J, V307, P516, DOI 10.1136/bmj.307.6903.516; Hart, 1988, NEW KIND DOCTOR; HASLER J, 1992, BRIT MED J, V305, P232, DOI 10.1136/bmj.305.6847.232; HOBBS FDR, 1991, BRIT MED J, V302, P329, DOI 10.1136/bmj.302.6772.329; HONIGSBAUM F, 1985, BRIT MED J, V290, P823, DOI 10.1136/bmj.290.6471.823; HONIGSBAUM F, 1985, BRIT MED J, V290, P904, DOI 10.1136/bmj.290.6472.904; HURWITZ B, 1993, BRIT MED J, V306, P624, DOI 10.1136/bmj.306.6878.624; ILIFFE S, 1991, BRIT MED J, V302, P1584, DOI 10.1136/bmj.302.6792.1584; ILIFFE S, 1994, BRIT MED J, V303, P3; IRVINE D, 1993, BRIT J GEN PRACT, V43, P121; IRVINE D, 1993, BRIT MED J, V307, P696, DOI 10.1136/bmj.307.6906.696; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; KEELEY D, 1991, BMJ-BRIT MED J, V302, P1514, DOI 10.1136/bmj.302.6791.1514; LOWY A, 1993, BRIT MED J, V307, P413, DOI 10.1136/bmj.307.6901.413; MARINKER M, 1986, BRIT MED J, V292, P1374, DOI 10.1136/bmj.292.6532.1374; MARINKER M, 1984, NEW NHS 1996; MARSH GN, 1991, BRIT MED J, V303, P1312, DOI 10.1136/bmj.303.6813.1312; MARSH GN, 1991, EFFICIENT CARE GENER; MOORE GT, 1992, MILBANK Q, V70, P361, DOI 10.2307/3350064; Pickles W, 1984, EPIDEMIOLOGY COUNTRY; ROSS FM, 1994, BRIT J GEN PRACT, V44, P15; SALISBURY C, 1993, BRIT MED J, V306, P762, DOI 10.1136/bmj.306.6880.762; SCOTT MGB, 1992, BRIT MED J, V304, P1548, DOI 10.1136/bmj.304.6841.1548; SHEPPARD J, 1992, BRIT MED J, V305, P288, DOI 10.1136/bmj.305.6848.288; SMITH R, 1990, BRIT MED J, V301, P679, DOI 10.1136/bmj.301.6754.679; STOTT N, 1994, BRIT J GEN PRACT, V44, P2; STOTT NCH, 1993, BRIT J GEN PRACT, V43, P254; WINKLER F, 1993, BRIT MED J, V306, P472, DOI 10.1136/bmj.306.6876.472; 1983, GENERAL PRACTICE BRI; 1993, HOSPITAL DOCTORS TRA; 1992, YOUR CHOICES FUTURE	41	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	1994	308	6927					513	516		10.1136/bmj.308.6927.513	http://dx.doi.org/10.1136/bmj.308.6927.513			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX814	8136671	Green Published			2022-12-28	WOS:A1994MX81400025
J	HANDYSIDES, S				HANDYSIDES, S			ENRICHING CAREERS IN GENERAL-PRACTICE .5. COULD THE RIGHT CONTRACT IMPROVE MORALE	BRITISH MEDICAL JOURNAL			English	Article							PRACTITIONERS CONTRACT; RECONSTRUCTION; PATIENT; DOCTOR	Many general practitioners still blame the 1990 contract for the problems in general practice, claiming it has reduced morale to levels of the 1950s and 1960s. The contract was introduced to improve the quality of care and to provide some measures of standards, but the government failed to convince general practitioners that the contract was what the profession needed. Further change seems inevitable. Ideally a contract should improve efficiency, enable rationale planning, and ensure public accountability. This article gives the history of the 1990 contract and discusses changes which could be made towards reaching this ideal.										[Anonymous], OPEN SOC ITS ENEMIES; BEECHAM L, 1989, BRIT MED J, V298, P1457; BEECHAM L, 1989, BRIT MED J, V299, P57; BOGLE I, 1992, WHICH WAY FORWARD; BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; CARTWRIGHT A, 1981, GENERAL PRACTICE REV; GIBSON R, 1981, FAMILY DOCTOR; GRAY DP, 1986, BRIT MED J, V292, P1313, DOI 10.1136/bmj.292.6531.1313; HANNAY DR, 1992, BRIT J GEN PRACT, V42, P178; HONIGSBAUM F, 1985, BRIT MED J, V290, P823, DOI 10.1136/bmj.290.6471.823; HONIGSBAUM F, 1985, BRIT MED J, V290, P904, DOI 10.1136/bmj.290.6472.904; HORDER J, 1986, J ROY COLL GEN PRACT, V36, P517; ILIFFE S, 1993, BRIT MED J, V306, P946, DOI 10.1136/bmj.306.6883.946; ILIFFE S, 1992, BRIT MED J, V304, P1456, DOI 10.1136/bmj.304.6840.1456; IRVINE D, 1993, BRIT J GEN PRACT, V43, P121; MARINKER M, 1986, BRIT MED J, V292, P1374, DOI 10.1136/bmj.292.6532.1374; MARINKER M, 1984, NEW HS ACT 1996; MORRELL D, 1989, BRIT MED J, V298, P1005, DOI 10.1136/bmj.298.6679.1005; OWEN M, 1993, GENERAL PRACTITI NOV, V5, P92; SCOTT MGB, 1992, BRIT MED J, V304, P1548, DOI 10.1136/bmj.304.6841.1548; 1987, CMD249; 1989, GENERAL PRACTICE NAT; 1983, COST EFFECTIVENESS G; 1983, GENERAL PRACTICE BRI; 1986, CMND9771; 1992, YOUR CHOICES FUTURE	26	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	1994	308	6926					455	458		10.1136/bmj.308.6926.455	http://dx.doi.org/10.1136/bmj.308.6926.455			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW976	8124181	Green Published			2022-12-28	WOS:A1994MW97600028
J	LAW, MR; WALD, NJ; WU, T; HACKSHAW, A; BAILEY, A				LAW, MR; WALD, NJ; WU, T; HACKSHAW, A; BAILEY, A			SYSTEMATIC UNDERESTIMATION OF ASSOCIATION BETWEEN SERUM-CHOLESTEROL CONCENTRATION AND ISCHEMIC-HEART-DISEASE IN OBSERVATIONAL STUDIES - DATA FROM THE BUPA STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; RESEARCH-CLINICS PREVALENCE; PLASMA; RISK; TRIGLYCERIDE; VARIABILITY	Objective-To estimate the size of the association between serum concentration of low density lipoprotein cholesterol and mortality from ischaemic heart disease. Design-Prospective study of total serum cholesterol concentration and mortality from ischaemic heart disease in 21 515 men (538 deaths) and study of total cholesterol concentration measured on two occasions an average of three years apart in 5696 men in whom low density lipoprotein cholesterol concentration was also measured on the second occasion. Subjects-Men who attended the medical centre of the British United Provident Association (BUPA) in London between 1975 and 1982. Main outcome measure-The difference in mortality from ischaemic heart disease for a 0.6 mmol/l difference in concentration of low density lipoprotein cholesterol after adjustment for, firstly, regression dilution bias, which arises from the random fluctuation of serum cholesterol concentration in people over time, and, secondly, the surrogate dilution effect, which arises because differences in total cholesterol concentration between people reflect smaller differences in low density lipoprotein cholesterol concentration. Results-The observed difference in mortality from ischaemic heart disease associated with a difference of 0.6 mmol/l in total serum cholesterol concentration was 17% but increased to 24% after correction for the regression dilution bias and to 27% (95% confidence interval 21% to 33%) after adjustment for both sources of underestimation, which provides an estimate of the difference in mortality for a true difference of 0.6 mmol/l in low density lipoprotein cholesterol concentration. The association was greater at younger ages. The estimated decrease in mortality from all causes was 6% before and 10% (1% to 17%) after adjustment for the two sources of underestimation. There was no excess mortality from any cause associated with low cholesterol concentration. Conclusions-The association between serum cholesterol concentration and ischaemic heart disease is materially stronger than directly inferred from prospective studies. This has important implications for the health benefit of achieving low cholesterol concentrations.	ST BARTHOLOMEWS HOSP, COLL MED,WOLFSON INST PREVENT MED, DEPT ENVIRONM & PREVENT MED,BUPA, LONDON EC1M 6BQ, ENGLAND	University of London; Queen Mary University London			Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; CREMER P, 1988, KLIN WOCHENSCHR, V66, P42; DAVIS CE, 1990, JAMA-J AM MED ASSOC, V264, P3044, DOI 10.1001/jama.264.23.3044; DELONG DM, 1986, JAMA-J AM MED ASSOC, V256, P2372, DOI 10.1001/jama.256.17.2372; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FROST CD, 1991, BRIT MED J, V302, P815, DOI 10.1136/bmj.302.6780.815; GARDNER MJ, 1973, J CHRON DIS, V26, P781, DOI 10.1016/0021-9681(73)90013-1; GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2351, DOI 10.1001/jama.256.17.2351; HARLAN WR, 1967, ANN INTERN MED, V66, P540, DOI 10.7326/0003-4819-66-3-540; JACOBS DR, 1982, AM J EPIDEMIOL, V116, P878, DOI 10.1093/oxfordjournals.aje.a113490; LENTNER C, 1984, GEIGY SCI TABLES, V3; RAO A, 1988, CLIN CHEM, V34, P2532; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; THOMPSON SG, 1990, J CLIN EPIDEMIOL, V43, P783, DOI 10.1016/0895-4356(90)90238-K; TORNBERG SA, 1988, INT J EPIDEMIOL, V17, P797, DOI 10.1093/ije/17.4.797; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1; WALD NJ, 1989, BRIT J CANCER, V59, P936, DOI 10.1038/bjc.1989.198; WILLIAMS GZ, 1978, CLIN CHEM, V24, P313; 1968, CIRCULATION S, V37, P428; 1979, PREV MED, V8, P625	21	260	266	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 5	1994	308	6925					363	366		10.1136/bmj.308.6925.363	http://dx.doi.org/10.1136/bmj.308.6925.363			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV862	8124143	Green Published			2022-12-28	WOS:A1994MV86200017
J	HAY, PE; LAMONT, RF; TAYLORROBINSON, D; MORGAN, DJ; ISON, C; PEARSON, J				HAY, PE; LAMONT, RF; TAYLORROBINSON, D; MORGAN, DJ; ISON, C; PEARSON, J			ABNORMAL BACTERIAL-COLONIZATION OF THE GENITAL-TRACT AND SUBSEQUENT PRETERM DELIVERY AND LATE MISCARRIAGE	BRITISH MEDICAL JOURNAL			English	Article							PLACEBO-CONTROLLED TRIAL; ERYTHROMYCIN TREATMENT; VAGINAL FLORA; DOUBLE-BLIND; GRAM STAIN; LABOR; PREGNANCY; VAGINOSIS; INFECTION; DIAGNOSIS	Objective-To find out whether women with bacterial vaginosis detected early in pregnancy are at increased risk of preterm delivery. Design-Prospective description cohort study. Setting-Antenatal clinic in a district general hospital. Subjects-783 women examined during their first antenatal clinic visit and screened for recognised risk factors for preterm delivery and the presence of bacterial vaginosis or intermediate abnormal flora detected by examination of a vaginal smear stained by Gram's method. Main outcome measures-Gestational age at delivery classified as late miscarriage (16-24 weeks' gestation), preterm delivery (24-37 weeks' gestation), term delivery (greater-than-or-equal-to 37 weeks' gestation). Results-Multiple logistic analysis showed that there was an increased incidence of preterm delivery in women with a previous preterm delivery (9/24; odds ratio 25; 95% confidence interval 9 to 70; P < 0.001) and bacterial vaginosis (9/115; 2.8; 1.1 to 7.4; P = 0.04). A further logistic analysis of data from women recruited before 16 weeks' gestation showed that preterm deliveries or late miscarriages occurred more often in women with bacterial vaginosis (12/7; 5.5; 2.3 to 13.3; P < 0.001). Conclusions-Late miscarriage and preterm delivery are associated with the presence of bacterial vaginosis in early pregnancy. This is independent of recognised risk factors such as previous preterm delivery.	NORTHWICK PK HOSP & CLIN RES CTR,DEPT OBSTET & GYNAECOL,HARROW HA1 3UJ,MIDDX,ENGLAND; CLIN RES CTR,DIV SEXUALLY TRANSMITTED DIS,HARROW HA1 3UJ,MIDDX,ENGLAND; ST MARYS HOSP,SCH MED,DEPT MED MICROBIOL,LONDON W2 1PG,ENGLAND; CLIN RES CTR,DEPT MED STAT,HARROW HA1 3UJ,MIDDX,ENGLAND	Imperial College London; Imperial College London								GIBBS RS, 1992, AM J OBSTET GYNECOL, V166, P1515, DOI 10.1016/0002-9378(92)91628-N; GRAVETT MG, 1986, JAMA-J AM MED ASSOC, V256, P1899; HAY PE, 1992, BRIT J OBSTET GYNAEC, V99, P63, DOI 10.1111/j.1471-0528.1992.tb14395.x; HEMMINKI E, 1978, BRIT J OBSTET GYNAEC, V85, P411, DOI 10.1111/j.1471-0528.1978.tb14906.x; HILLIER SL, 1992, AM J OBSTET GYNECOL, V166, P938, DOI 10.1016/0002-9378(92)91368-K; HOSMER DW, 1989, APPL LOGISTIC REGRES, P80; KURKI T, 1992, OBSTET GYNECOL, V80, P173; Lamont RFFN, 1993, PROGR OBSTETRICS GYN, V10, P135; LEVENO KJ, 1992, NEW ENGL J MED, V327, P349, DOI 10.1056/NEJM199207303270510; LOCKWOOD CJ, 1991, NEW ENGL J MED, V325, P669, DOI 10.1056/NEJM199109053251001; MCGREGOR JA, 1991, AM J OBSTET GYNECOL, V165, P867, DOI 10.1016/0002-9378(91)90430-Y; MCGREGOR JA, 1986, AM J OBSTET GYNECOL, V154, P98, DOI 10.1016/0002-9378(86)90401-1; MCGREGOR JA, 1990, AM J OBSTET GYNECOL, V163, P1580, DOI 10.1016/0002-9378(90)90632-H; MCGREGOR JA, 1988, AM J REPROD IMMUNOL, V16, P123; MIETTINEN OS, 1976, AM J EPIDEMIOL, V104, P609, DOI 10.1093/oxfordjournals.aje.a112339; MINKOFF H, 1984, AM J OBSTET GYNECOL, V150, P965, DOI 10.1016/0002-9378(84)90392-2; NEWCOMBE RG, 1981, PRETERM LABOUR, P47; ROMERO R, 1988, SEMIN PERINATOL, V12, P262; SPIEGEL CA, 1983, J CLIN MICROBIOL, V18, P170, DOI 10.1128/JCM.18.1.170-177.1983; 1992, NEW ENGL J MED, V327, P308	20	481	505	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 29	1994	308	6924					295	298		10.1136/bmj.308.6924.295	http://dx.doi.org/10.1136/bmj.308.6924.295			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU492	8124116	Green Published			2022-12-28	WOS:A1994MU49200018
J	ARTALEJO, CR; ADAMS, ME; FOX, AP				ARTALEJO, CR; ADAMS, ME; FOX, AP			3 TYPES OF CA2+ CHANNEL TRIGGER SECRETION WITH DIFFERENT EFFICACIES IN CHROMAFFIN CELLS	NATURE			English	Article							CALCIUM CHANNELS; CAPACITANCE MEASUREMENTS; OMEGA-CONOTOXIN; FACILITATION	To determine whether the different types of Ca2+ channels present in the same secretory cell contribute equally to secretion, we used chromaffin cells to analyse the coupling between three distinct types of Ca2+ channel1 and exocytosis2,3. These are omega-conotoxin-GVIA-sensitive4,5 N-type channels, omega-agatoxin-IVA-sensitive P-type Ca2+ channels6 and dihydropyridine-sensitive facilitation Ca2+ channels, which are normally quiescent but are activated by depolarizing pre-pulses, repetitive depolarizations to physiological potentials7,8, or agents that raise cyclic AMP9. We have simultaneously monitored changes in capacitance as an assay of catecholamine secretion10, and Ca2+ currents. Although all three types of Ca2+ channel trigger secretion individually, facilitation channels produce much greater secretion for a given size of Ca2+ current, indicating that they are coupled more efficiently to exocytosis. These results indicate that facilitation Ca2+ channels may be physically nearer vesicle release sites. They also show that low efficiency P- and N-type channels could trigger mild release and that high-efficiency facilitation channels may underlie the massive catecholamine release that occurs during the 'fight or flight' response.	UNIV AUTONOMA MADRID,FAC MED,DEPT FARMACOL,E-28029 MADRID,SPAIN; UNIV CALIF RIVERSIDE,DEPT ENTOMOL & NEUROSCI,RIVERSIDE,CA 92521; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637	Autonomous University of Madrid; University of California System; University of California Riverside; University of Chicago	ARTALEJO, CR (corresponding author), NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,2153 N CAMPUS DR,EVANSTON,IL 60208, USA.							AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; ARTALEJO CR, 1991, J PHYSIOL-LONDON, V432, P681, DOI 10.1113/jphysiol.1991.sp018406; ARTALEJO CR, 1990, NATURE, V348, P239, DOI 10.1038/348239a0; ARTALEJO CR, 1992, NEURON, V8, P85, DOI 10.1016/0896-6273(92)90110-Y; ARTALEJO CR, 1991, J PHYSIOL-LONDON, V444, P213, DOI 10.1113/jphysiol.1991.sp018874; ARTALEJO CR, 1992, NATURE, V358, P63, DOI 10.1038/358063a0; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; COUPLAND RE, 1968, NATURE, V217, P384, DOI 10.1038/217384a0; FIDLER N, 1989, BIOPHYS J, V56, P1153, DOI 10.1016/S0006-3495(89)82762-6; HANS M, 1990, NEUROSCI LETT, V114, P63, DOI 10.1016/0304-3940(90)90429-D; JOSHI C, 1988, BIOPHYS J, V53, P885, DOI 10.1016/S0006-3495(88)83169-2; LEMOS JR, 1989, NEURON, V2, P1419, DOI 10.1016/0896-6273(89)90187-6; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORGAN A, 1993, EMBO J, V12, P3747, DOI 10.1002/j.1460-2075.1993.tb06052.x; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; NOWYCKY MC, 1993, BIOPHYS J, V64, P77, DOI 10.1016/S0006-3495(93)81342-0; NOWYCKY MC, 1992, BIOPHYS J, V64, pA230; PUMPLIN DW, 1981, P NATL ACAD SCI-BIOL, V78, P7210, DOI 10.1073/pnas.78.11.7210	22	250	251	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 6	1994	367	6458					72	76		10.1038/367072a0	http://dx.doi.org/10.1038/367072a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	8107778				2022-12-28	WOS:A1994MP86500062
J	HUGHES, KA; CHARLESWORTH, B				HUGHES, KA; CHARLESWORTH, B			A GENETIC-ANALYSIS OF SENESCENCE IN DROSOPHILA	NATURE			English	Article							MELANOGASTER; SELECTION; COMPONENT; VARIANCE	Two attractive theories for the evolution of senescence are based on the principle that the force of natural selection decreases with age1-5. The theories differ in the type of age-specific gene action that they assume. Antagonistic pleiotropy2-5 postulates that pleiotropic genes with positive effects early in life and negative effects of comparable magnitude late in life are favoured by selection, whereas genes with the reverse pattern of action are selected against. Mutation accumulation1,3-5 assumes that deleterious mutant alleles with age-specific effects will equilibrate at a lower frequency if their effects are expressed early rather than late in life. Explicit models demonstrate that both mechanisms can lead to the evolution of senescent life histories under reasonable conditions3-5. Antagonistic pleiotropy has gained considerable empirical support4-6, but the evidence in support of mutation accumulation is more sparse4,5,7. Here we report that the genetic variability of mortality in male Drosophila melanogaster increases greatly at very late ages, as predicted by the mutation accumulation hypothesis3-5. The rate of increase in mortality with age exhibits substantial genetic and environmental variability. This result provides a possible explanation for recent observations of non-increasing mortality rates in very old flies8,9.	UNIV CHICAGO, COMM EVOLUT BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT ECOL & EVOLUT, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago								CAREY JR, 1992, SCIENCE, V258, P457, DOI 10.1126/science.1411540; CHARLESWORTH B, 1990, EVOLUTION, V44, P520, DOI 10.1111/j.1558-5646.1990.tb05936.x; CHARLESWORTH B, 1985, HEREDITY, V54, P71, DOI 10.1038/hdy.1985.10; Charlesworth B., 1994, EVOLUTION AGE STRUCT, V2nd ed, edited by C. Cannings, F. C. Hoppensteadt, and L. A. Segel.; Charlesworth B, 1987, SEXUAL SELECTION TES, P21; COMSTOCK RE, 1952, HETEROSIS; CURTSINGER JW, 1992, SCIENCE, V258, P461, DOI 10.1126/science.1411541; Engels WR, 1989, MOBILE DNA; Falconer D. S., 1989, Introduction to quantitative genetics.; FINCH CE, 1990, SCIENCE, V249, P902, DOI 10.1126/science.2392680; Finch CE, 1990, LONGEVITY SENESCENCE; HARTLEY HO, 1967, BIOMETRICS, V23, P105, DOI 10.2307/2528284; HOULE D, 1992, GENETICS, V130, P195; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Medawar P., 1952, UNSOLVED PROBLEM BIO; MUKAI T, 1974, GENETICS, V78, P1195; PARTRIDGE L, 1993, NATURE, V362, P305, DOI 10.1038/362305a0; ROPER C, 1993, EVOLUTION, V47, P445, DOI 10.1111/j.1558-5646.1993.tb02105.x; ROSE M. R., 1991, EVOLUTIONARY BIOL AG; ROSE MR, 1981, GENETICS, V97, P172; ROSE MR, 1984, EVOLUTION, V38, P516, DOI 10.1111/j.1558-5646.1984.tb00317.x; SEARLE SR, 1971, BIOMETRICS, V27, P1, DOI 10.2307/2528928; SERVICE PM, 1993, EVOLUTION, V47, P387, DOI 10.1111/j.1558-5646.1993.tb02101.x; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; Wright S., 1977, EVOLUTION GENETICS P, V3	25	142	144	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	1994	367	6458					64	66		10.1038/367064a0	http://dx.doi.org/10.1038/367064a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	8107775				2022-12-28	WOS:A1994MP86500059
J	MCMURRAY, JE; SCHWARTZ, MD; GENERO, NP; LINZER, M				MCMURRAY, JE; SCHWARTZ, MD; GENERO, NP; LINZER, M			THE ATTRACTIVENESS OF INTERNAL-MEDICINE - A QUALITATIVE-ANALYSIS OF THE EXPERIENCES OF FEMALE AND MALE MEDICAL-STUDENTS	ANNALS OF INTERNAL MEDICINE			English	Article							CHOICE; CARE	Objective: To understand better the decline in medical student interest in internal medicine. Design: Qualitative analysis of 500 essays from respondents who participated in a national survey of graduating medical students from the class of 1990 in 16 medical schools. Medical students were asked the open-ended question, ''What suggestions do you have for improving the attractiveness of internal medicine?'' A model of career choice was developed for the analysis that included the following factors: ambulatory care exposure and primary care (including relationships with patients); attending physician-student interactions and learning climate; stress and workload; income and prestige; and intellectual stimulation. Participants: The original survey included 1650 fourth-year medical students; 500 essay respondents were stratified by sex and then randomly chosen for the analysis. Results: Students most frequently suggested that ambulatory care experiences be increased and that better relationships with patients be established during medical training (65% of women and 50% of men, P < 0.01). The second most frequent suggestion was to improve internal medicine attending physicians' interactions with students (51% and 48% of women and men, respectively). Students who had seriously considered a career in medicine but switched to other primary care careers (general pediatrics, family medicine) had few concerns about income and prestige, whereas those who chose internal medicine had reservations about expected workload and income. Women were more likely than men to reject internal medicine for other primary care fields (26% of women compared with 16% of men, P = 0.05). Conclusions: Students, particularly female students, expressed a strong interest in establishing better relationships with patients. Lack of respect by medical attendings and negative teaching methods were important sources of dissatisfaction among both men and women. Attention to these relationship issues, in addition to housestaff stress and expected future income, may improve the attractiveness of internal medicine.	NYU, SCH MED, NEW YORK, NY 10003 USA; WELLESLEY COLL, DEPT PSYCHOL, WELLESLEY, MA 02181 USA; TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	New York University; Wellesley College; Tufts Medical Center; Tufts University				Schwartz, Mark/0000-0002-7123-0060				Baker-Miller JB, 1976, NEW PSYCHOL WOMEN; BEAN G, 1982, SOC SCI MED, V16, P1377, DOI 10.1016/0277-9536(82)90035-1; BECKER HS, 1958, AM SOCIOL REV, V23, P50, DOI 10.2307/2088623; BLUESTONE NR, 1978, AM J PUBLIC HEALTH, V68, P760, DOI 10.2105/AJPH.68.8.760; BOWMAN MW, 1980, J FAM PRACTICE, V10, P655; Calkins E V, 1987, J Am Med Womens Assoc (1972), V42, P170; CLARK EJ, 1986, J MED EDUC, V61, P32; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; CREMIN LA, 1978, TEACH COLL REC, V79, P683; DROSSMAN DA, 1978, ANN INTERN MED, V88, P366, DOI 10.7326/0003-4819-88-3-366; Eccles J, 1986, ED RES, V15, P15, DOI DOI 10.2307/1175495; FUNKENSTEIN DH, 1978, FACTORS AFFECTING CA; Gilligan C., 1982, DIFFERENT VOICE; Grant L, 1988, J Am Med Womens Assoc (1972), V43, P109; KASSIRER JP, 1993, NEW ENGL J MED, V328, P648, DOI 10.1056/NEJM199303043280910; KRIS KB, 1985, J AM MED WOMEN ASSOC, V43, P77; LANGWELL KM, 1982, J HUM RESOUR, V17, P261, DOI 10.2307/145472; LESERMAN J, 1981, MEN WOMEN MED SCH; LEVINSKY NG, 1993, NEW ENGL J MED, V328, P656, DOI 10.1056/NEJM199303043280913; LEWIS CE, 1991, ANN INTERN MED, V114, P1, DOI 10.7326/0003-4819-114-1-1; Lincoln Y, 1985, NATURALISTIC ENQUIRY; Maheux B, 1988, J Am Med Womens Assoc (1972), V43, P73; MCGRATH E, 1977, J MED EDUC, V52, P293; Miles M.B., 1994, ANAL DONNEES QUALITA, V2nd; PERRICONE PJ, 1974, J MED EDUC, V49, P541; ROOS NP, 1974, J MED EDUC, V49, P1057; SCHROEDER SA, 1986, ANN INTERN MED, V104, P554, DOI 10.7326/0003-4819-104-4-554; SCHWARTZ MD, 1991, ANN INTERN MED, V114, P6, DOI 10.7326/0003-4819-114-1-6; SHUMWAY JM, 1988, CLIN RES, V36, pA736; SKEFF KM, 1992, ARCH INTERN MED, V152, P1156, DOI 10.1001/archinte.1992.00400180028004	30	68	69	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1993	119	8					812	818		10.7326/0003-4819-119-8-199310150-00007	http://dx.doi.org/10.7326/0003-4819-119-8-199310150-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB496	8135923				2022-12-28	WOS:A1993MB49600007
J	SMIRNOVA, T; LAROCHE, S; ERRINGTON, ML; HICKS, AA; BLISS, TVP; MALLET, J				SMIRNOVA, T; LAROCHE, S; ERRINGTON, ML; HICKS, AA; BLISS, TVP; MALLET, J			TRANSSYNAPTIC EXPRESSION OF A PRESYNAPTIC GLUTAMATE-RECEPTOR DURING HIPPOCAMPAL LONG-TERM POTENTIATION	SCIENCE			English	Article							DENTATE GYRUS; NMDA RECEPTORS; AMINO-ACIDS; RAT; INDUCTION; RELEASE	Repetitive activation of excitatory synapses in the hippocampus produces a persistent enhancement of synaptic efficiency known as long-term potentiation (LTP). In anesthetized and in freely moving rats, the induction of LTP in the perforant path led to a transient increase in the amount of messenger RNA (mRNA) coding for a presynaptic glutamate receptor (GR33) in dentate granule cells. The amount of GR33 mRNA was increased for at least 5 hours after the induction of LTP but was indistinguishable from control values 1 day after induction. The N-methyl-D-aspartate receptor antagonist 2-aminophosphonovalerate prevented the induction of both LTP and the increase in GR33 mRNA. The amount of GR33 protein was increased in the mossy fiber terminal zone of dentate granule cells 5 hours after the induction of LTP. These results suggest that the induction of LTP in synapses at one stage in a neural network may lead to modification in synaptic function at the next stage in the network.	LAB GENET MOLEC & NEUROTRANSMISS & PROC, NEURODEGENERAT, CNRS, C9923, F-91198 GIF SUR YVETTE, FRANCE; NATL INST MED RES, DIV NEUROPHYSIOL & NEUROPHARMACOL, LONDON NW7 1AA, ENGLAND; UNIV PARIS 11, NEUROBIOL APPRENTISSAGE & MEMOIRE LAB, CNRS, URA 1491, F-91405 ORSAY, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; MRC National Institute for Medical Research; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Hicks, Andrew Anthony/E-9518-2017	Hicks, Andrew Anthony/0000-0001-6320-0411				ALZHEIMER C, 1991, BRAIN RES, V543, P163, DOI 10.1016/0006-8993(91)91061-5; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CLAIBORNE BJ, 1986, J COMP NEUROL, V246, P435, DOI 10.1002/cne.902460403; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; DOYERE V, 1992, HIPPOCAMPUS, V2, P39, DOI 10.1002/hipo.450020106; GANNON RL, 1991, NEUROSCIENCE, V41, P401, DOI 10.1016/0306-4522(91)90336-M; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; JAFFE D, 1990, J NEUROPHYSIOL, V64, P948, DOI 10.1152/jn.1990.64.3.948; LAROCHE S, 1989, NEUROSCIENCE, V28, P375, DOI 10.1016/0306-4522(89)90184-X; LOVINGER DM, 1986, BRAIN RES, V399, P205, DOI 10.1016/0006-8993(86)91510-6; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MORRIS RGM, 1990, PHILOS T ROY SOC B, V329, P187, DOI 10.1098/rstb.1990.0164; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; SMIRNOVA T, 1993, SCIENCE, V262, P430, DOI 10.1126/science.8105537; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	18	55	61	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1993	262	5132					433	436		10.1126/science.8105538	http://dx.doi.org/10.1126/science.8105538			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	8105538				2022-12-28	WOS:A1993MB85900062
J	SOUTHWICK, F				SOUTHWICK, F			WHO WAS CARING FOR MARY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						HOSPITALIZATION; ACADEMIC MEDICAL CENTERS; QUALITY OF HEALTH CARE		An academic physician gives a personal account of his wife's progressive deterioration during her hospitalization at a university medical center. He encounters physicians who are too distracted by other academic pursuits to care adequately for his wife. Her hospital course is complicated by bilateral pulmonary emboli, which occur during inadequate heparin therapy and are followed by myocardial infarction, shock, and the adult respiratory distress syndrome. His experience exemplifies the importance of closely supervised care. He calls on the leaders of academic medical centers to make excellence in patient care a top priority and recommends that clinical as well as research skills be rewarded.			SOUTHWICK, F (corresponding author), UNIV FLORIDA, COLL MED, INFECT DIS SECT, BOX 100277, GAINESVILLE, FL 32610 USA.							1992, ANN INTERN MED, V118, P146	1	23	22	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1993	118	2					146	148		10.7326/0003-4819-118-2-199301150-00011	http://dx.doi.org/10.7326/0003-4819-118-2-199301150-00011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF918	8123053				2022-12-28	WOS:A1993KF91800011
J	GARCIA, PJ; SCHEIN, RMH; BURNETT, JW				GARCIA, PJ; SCHEIN, RMH; BURNETT, JW			FULMINANT HEPATIC-FAILURE FROM A SEA-ANEMONE STING	ANNALS OF INTERNAL MEDICINE			English	Note							JELLYFISH STINGS		UNIV MARYLAND, SCH MED, DEPT DERMATOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	GARCIA, PJ (corresponding author), VET AFFAIRS MED CTR, MED SERV 111, NW 16TH ST, MIAMI, FL 33125 USA.							Burnett J W, 1992, Md Med J, V41, P509; BURNETT JW, 1988, COMP BIOCHEM PHYS C, V91, P79, DOI 10.1016/0742-8413(88)90172-7; BURNETT JW, 1987, ANN EMERG MED, V16, P1000, DOI 10.1016/S0196-0644(87)80748-5; BURNETT JW, 1987, CLIN DERMATOL, V5, P14, DOI 10.1016/S0738-081X(87)80004-4; FILLINGKATZ MR, 1984, ANN NEUROL, V15, P213, DOI 10.1002/ana.410150223; HALSTEAD BW, 1988, POISONOUS VENOMOUS M, P105; MARETIC Z, 1983, AM J TROP MED HYG, V32, P891, DOI 10.4269/ajtmh.1983.32.891; MCGOLDRICK J, 1992, Journal of Emergency Medicine, V10, P71, DOI 10.1016/0736-4679(92)90014-K; MUHVICH KH, 1991, TOXICON, V29, P857, DOI 10.1016/0041-0101(91)90222-D; RODERICK NM, 1979, PATHOLOGY LIVER, P335	10	24	24	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1994	120	8					665	666		10.7326/0003-4819-120-8-199404150-00007	http://dx.doi.org/10.7326/0003-4819-120-8-199404150-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE850	8135451				2022-12-28	WOS:A1994NE85000007
J	IRWIG, L; TOSTESON, ANA; GATSONIS, C; LAU, J; COLDITZ, G; CHALMERS, TC; MOSTELLER, F				IRWIG, L; TOSTESON, ANA; GATSONIS, C; LAU, J; COLDITZ, G; CHALMERS, TC; MOSTELLER, F			GUIDELINES FOR METAANALYSES EVALUATING DIAGNOSTIC-TESTS	ANNALS OF INTERNAL MEDICINE			English	Review							FACTORS AFFECTING SENSITIVITY; URINARY-TRACT INFECTION; DESIGN AFFECTS OUTCOMES; CLINICAL RESEARCH; PUBLICATION BIAS; DISEASE VERIFICATION; LIKELIHOOD RATIOS; SELECTION BIAS; LUNG-CANCER; ROC CURVE	Objectives: To introduce guidelines for the conduct, reporting, and critical appraisal of meta-analyses evaluating diagnostic tests and to apply these guidelines to recently published meta-analyses of diagnostic tests. Data Sources: Based on current concepts of how to assess diagnostic tests and conduct meta-analyses. They are applied to all meta-analyses evaluating diagnostic tests published in English-language journals from January 1990 through December 1991, identified through MEDLINE searching and by experts in the field. Study Selection: Meta-analyses were included if at least two of three independent readers regarded their main purpose as the evaluation of diagnostic tests against a concurrent reference standard. Data Extraction: By three independent readers on the extent to which meta-analyses fulfilled each guideline, with consensus defined as agreement by at least two readers. Data Synthesis: The guidelines are concerned with determining the objective of the meta-analysis, identifying the relevant literature and extracting the data, estimating diagnostic accuracy, and identifying the extent to which variability is explained by study design characteristics and characteristics of the patients and diagnostic test. In general, the guidelines were only partially fulfilled. Conclusion: Meta-analysis is potentially important in the assessment of diagnostic tests. Those reading meta-analyses evaluating diagnostic tests should critically appraise them; those doing meta-analyses should apply recently developed methods. The conduct and reporting of primary studies on which meta-analyses are based require improvement.	DARTMOUTH COLL, HITCHCOCK MED CTR, CLIN RES SECT, LEBANON, NH 03756 USA; HARVARD UNIV, SCH MED, DEPT HLTH CARE POLICY, BOSTON, MA 02115 USA; TUFTS UNIV NEW ENGLAND MED CTR, CTR CARDIOVASC HLTH SERV RES, BOSTON, MA 02111 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, TECHNOL ASSESSMENT GRP, BOSTON, MA 02115 USA	Dartmouth College; Harvard University; Harvard Medical School; Tufts Medical Center; Harvard University; Harvard T.H. Chan School of Public Health	IRWIG, L (corresponding author), UNIV SYDNEY, DEPT PUBL HLTH, BLDG A27, SYDNEY, NSW 2006, AUSTRALIA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS005936] Funding Source: NIH RePORTER; AHRQ HHS [HS05936] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALBERT A, 1982, CLIN CHEM, V28, P1113; BANALES JL, 1991, CHEST, V99, P355, DOI 10.1378/chest.99.2.355; BEGG CB, 1989, J NATL CANCER I, V81, P107, DOI 10.1093/jnci/81.2.107; BEGG CB, 1983, BIOMETRICS, V39, P207, DOI 10.2307/2530820; BEGG CB, 1987, STAT MED, V6, P411, DOI 10.1002/sim.4780060402; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; BERMAN DS, 1990, AM J CARDIOL, V66, pE72, DOI 10.1016/0002-9149(90)90616-9; CHALMERS TC, 1990, JAMA-J AM MED ASSOC, V263, P1392, DOI 10.1001/jama.263.10.1392; CLERMONT RJ, 1967, MEDICINE, V46, P197, DOI 10.1097/00005792-196703000-00012; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; DALES RE, 1990, AM REV RESPIR DIS, V141, P1096, DOI 10.1164/ajrccm/141.5_Pt_1.1096; DETRANO R, 1988, AM J MED, V84, P699, DOI 10.1016/0002-9343(88)90107-6; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; EMERSON JD, 1990, CONTROL CLIN TRIALS, V11, P339, DOI 10.1016/0197-2456(90)90175-2; FLEISS JL, 1991, J CLIN EPIDEMIOL, V44, P127, DOI 10.1016/0895-4356(91)90261-7; Fletcher RH, 1988, CLIN EPIDEMIOLOGY ES, V2nd; GIANROSSI R, 1990, AM HEART J, V120, P1179, DOI 10.1016/0002-8703(90)90134-J; GORIS ML, 1991, J NUCL MED, V32, P887; GRAY R, 1984, MED DECIS MAKING, V4, P151, DOI 10.1177/0272989X8400400204; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; GUYATT GH, 1992, J GEN INTERN MED, V7, P145, DOI 10.1007/BF02598003; GUYATT GH, 1986, CAN MED ASSOC J, V134, P587; HANLEY JA, 1989, CRIT REV DIAGN IMAG, V29, P307; HARTZ A, 1986, MED DECIS MAKING, V6, P149, DOI 10.1177/0272989X8600600304; HLATKY MA, 1984, AM J MED, V77, P64, DOI 10.1016/0002-9343(84)90437-6; HOFFMAN RM, 1991, SPINE, V16, P623, DOI 10.1097/00007632-199106000-00005; HUNINK MGM, 1990, MED DECIS MAKING, V10, P201, DOI 10.1177/0272989X9001000307; HURLBUT TA, 1991, AM J CLIN PATHOL, V96, P582, DOI 10.1093/ajcp/96.5.582; IRWIG L, 1992, J CLIN EPIDEMIOL, V45, P1335, DOI 10.1016/0895-4356(92)90174-L; JENICEK M, 1989, J CLIN EPIDEMIOL, V42, P35, DOI 10.1016/0895-4356(89)90023-1; KARDAUN JWPF, 1990, METHOD INFORM MED, V29, P12; KNOTTNERUS JA, 1992, J CLIN EPIDEMIOL, V45, P1143; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LACHS MS, 1992, ANN INTERN MED, V117, P135, DOI 10.7326/0003-4819-117-2-135; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MCCLISH DK, 1990, MED DECIS MAKING, V10, P283, DOI 10.1177/0272989X9001000406; MCCLISH DK, 1989, MED DECIS MAKING, V9, P190, DOI 10.1177/0272989X8900900307; MEZGER J, 1990, J THORAC CARDIOV SUR, V100, P860; MILLER JN, 1989, STAT MED, V8, P455, DOI 10.1002/sim.4780080409; MOENS HJB, 1992, MED DECIS MAKING, V12, P250, DOI 10.1177/0272989X9201200402; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; MULROW CD, 1989, J GEN INTERN MED, V4, P288, DOI 10.1007/BF02597398; NG PC, 1990, ACTA PAEDIATR SCAND, V79, P286, DOI 10.1111/j.1651-2227.1990.tb11458.x; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P1271, DOI 10.1016/0895-4356(91)90160-B; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; Panzer RI, 1991, DIAGNOSTIC STRATEGIE; PHILLIPS KA, 1991, J CLIN EPIDEMIOL, V44, P925, DOI 10.1016/0895-4356(91)90055-E; PINSON AG, 1991, J NUCL MED, V32, P2324; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; Reed J F 3rd, 1991, Biomed Instrum Technol, V25, P465; ROSEN Y, 1990, CANCER, V66, P2001, DOI 10.1002/1097-0142(19901101)66:9<2001::AID-CNCR2820660926>3.0.CO;2-X; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; Sox HC, 1988, MED DECISION MAKING; TOSTESON ANA, 1988, MED DECIS MAKING, V8, P204, DOI 10.1177/0272989X8800800309; WIEAND S, 1989, BIOMETRIKA, V76, P585, DOI 10.1093/biomet/76.3.585	57	625	640	0	25	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1994	120	8					667	676		10.7326/0003-4819-120-8-199404150-00008	http://dx.doi.org/10.7326/0003-4819-120-8-199404150-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE850	8135452				2022-12-28	WOS:A1994NE85000008
J	COHENTANNOUDJI, M; BABINET, C; WASSEF, M				COHENTANNOUDJI, M; BABINET, C; WASSEF, M			EARLY DETERMINATION OF A MOUSE SOMATOSENSORY CORTEX MARKER	NATURE			English	Article							CEREBRAL-CORTEX; VISUAL-CORTEX; SPECIFICATION; NEOCORTEX; NEURONS; RAT; ORGANIZATION; UNITS; LACZ	THE mammalian neocortex is subdivided into functionally distinct areas differing in cytoarchitecture and connectivity. Areal specification is thought to occur late in development1-3 and to be controlled by extrinsic cues, particularly thalamic afferents4. We have produced a transgenic mouse line in which beta-galactosidase expression in the neocortex is largely restricted to layer-IV neurons of the somatosensory area. Transgene expression in these mice may be considered as an intrinsic marker of a somatosensory cortex identity. We investigated whether the fate of pieces of embryonic cortex from transgenic embryos is modified after transplantation to ectopic locations. Parietal or occipital cortex obtained on embryonic days 14-16 maintained their characteristics with respect to transgene expression after heterotopic transplantation to the cerebellum or neocortex of newborn hosts. This shows that the specification of neocortical areas involves a previously unsuspected early step of areal determination.	HOP LA PITIE SALPETRIERE,INSERM,U106,F-75651 PARIS 13,FRANCE; INST PASTEUR,F-75724 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Cohen-Tannoudji, Michel/0000-0002-6405-2657				ARIMATSU Y, 1992, P NATL ACAD SCI USA, V89, P8879, DOI 10.1073/pnas.89.19.8879; BARBE MF, 1991, J NEUROSCI, V11, P519; CATALANO SM, 1991, P NATL ACAD SCI USA, V88, P2999, DOI 10.1073/pnas.88.8.2999; COHENTANNOUDJI M, 1992, MOL REPROD DEV, V33, P149, DOI 10.1002/mrd.1080330206; DAWSON DR, 1987, J COMP NEUROL, V256, P246, DOI 10.1002/cne.902560205; FAIREN A, 1986, J COMP NEUROL, V251, P67, DOI 10.1002/cne.902510105; FERRI RT, 1993, CEREB CORTEX, V3, P187, DOI 10.1093/cercor/3.3.187; KENNEDY H, 1993, CEREB CORTEX, V3, P171, DOI 10.1093/cercor/3.3.171; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; OLEARY DDM, 1992, EXP NEUROL, V115, P121, DOI 10.1016/0014-4886(92)90234-H; OLEARY DDM, 1989, J NEUROSCI, V9, P2230; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1991, P NATL ACAD SCI USA, V88, P2083, DOI 10.1073/pnas.88.6.2083; SCHLAGGAR BL, 1991, SCIENCE, V252, P1556, DOI 10.1126/science.2047863; SHATZ CJ, 1992, SCIENCE, V258, P237, DOI 10.1126/science.1357747; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WOOLSEY CN, 1958, BIOL BIOCH BASES BEH, P62; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X	18	174	175	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 31	1994	368	6470					460	463		10.1038/368460a0	http://dx.doi.org/10.1038/368460a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	8133892				2022-12-28	WOS:A1994ND12000065
J	PASTUSZAK, AL; LEVY, M; SCHICK, B; ZUBER, C; FELDKAMP, M; GLADSTONE, J; BARLEVY, F; JACKSON, E; DONNENFELD, A; MESCHINO, W; KOREN, G				PASTUSZAK, AL; LEVY, M; SCHICK, B; ZUBER, C; FELDKAMP, M; GLADSTONE, J; BARLEVY, F; JACKSON, E; DONNENFELD, A; MESCHINO, W; KOREN, G			OUTCOME AFTER MATERNAL VARICELLA INFECTION IN THE FIRST 20 WEEKS OF PREGNANCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ZOSTER VIRUS; CONGENITAL-MALFORMATIONS; 1ST TRIMESTER; FETAL; WOMEN	Background. Infection with the varicellazoster virus during pregnancy can produce an embryopathy characterized by limb hypoplasia, eye and brain damage, and skin lesions. The risk is greatest when infection occurs during the first 20 weeks of pregnancy, but the magnitude of the risk is uncertain. Methods. We studied 106 women with clinically diagnosed varicella infection in the first 20 weeks of pregnancy and compared the outcomes with those in 106 age-matched, nonexposed controls. Results. Among the women with varicella, there was a trend toward more elective terminations of pregnancy (14 percent, vs. 7.5 percent among the controls; P = 0.1), corresponding to a significantly higher perception of teratogenic risk (P = 0.03). The proportions of miscarriages and live births and the mean birth weights were similar in the two study groups; there were more premature births (less than or equal to 37 weeks) among the women with varicella infection (14.3 percent vs. 5.6 percent, P = 0.05). Congenital defects occurred in four infants born to the women with varicella (varicella embryopathy, hydrocephalus, meningocele and clubfeet, and hammer toe) and two infants born to the controls (ventricular septal defect and hip dislocation). The risk of varicella embryopathy after infection in the first 20 weeks was 1.2 percent (95 percent confidence interval, 0 to 2.4 percent). When we pooled our results with those from other prospective studies, the mean risk of embryopathy after infection with varicella-zoster virus in the first trimester was 2.2 percent (95 percent confidence interval, 0 to 4.6 percent). Conclusions. The absolute risk of embryopathy after maternal varicella infection in the first 20 weeks of pregnancy is about 2 percent.	HOSP SICK CHILDREN,DIV CLIN PHARMACOL,MOTHERISK PROGRAM,TORONTO M5G 1X8,ON,CANADA; PENN HOSP,PHILADELPHIA,PA 19107; PREGNANCY RISK INFORMAT SERV,CAMDEN,NJ; UNIV UTAH,SALT LAKE CITY,UT; N YORK HOSP,DEPT GENET,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Pennsylvania; Pennsylvania Medicine; Utah System of Higher Education; University of Utah; University of Toronto; University Toronto Affiliates; North York General Hospital								ALKALAY AL, 1987, J PEDIATR-US, V111, P320, DOI 10.1016/S0022-3476(87)80447-X; BALDUCCI J, 1992, OBSTET GYNECOL, V79, P5; BRUNELL PA, 1983, SEMIN PERINATOL, V7, P47; CEDERQVIST LL, 1978, AM J OBSTET GYNECOL, V131, P520, DOI 10.1016/0002-9378(78)90113-8; EDER SE, 1988, AM J PERINAT, V5, P16, DOI 10.1055/s-2007-999644; EINARSON TR, 1988, DRUG INTEL CLIN PHAR, V22, P813, DOI 10.1177/106002808802201021; ENDERS G, 1984, PROG MED VIROL, V29, P166; HARRIS RE, 1965, OBSTET GYNECOL, V25, P734; HIGA K, 1987, OBSTET GYNECOL, V69, P214; KOREN G, 1990, TERATOLOGY, V41, P657, DOI 10.1002/tera.1420410602; KOREN G, 1989, AM J OBSTET GYNECOL, V160, P1190, DOI 10.1016/0002-9378(89)90186-5; KOREN G, 1991, JAMA-J AM MED ASSOC, V266, P1824, DOI 10.1001/jama.266.13.1824; LAFORET EG, 1947, NEW ENGL J MED, V236, P534, DOI 10.1056/NEJM194704102361504; PARYANI SG, 1986, NEW ENGL J MED, V314, P1542, DOI 10.1056/NEJM198606123142403; SEVER J, 1968, ANNU REV MED, V19, P471, DOI 10.1146/annurev.me.19.020168.002351; SIEGEL M, 1973, JAMA-J AM MED ASSOC, V226, P1521, DOI 10.1001/jama.226.13.1521	16	230	238	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	1994	330	13					901	905		10.1056/NEJM199403313301305	http://dx.doi.org/10.1056/NEJM199403313301305			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC608	8114861				2022-12-28	WOS:A1994NC60800005
J	TODD, KH; LEE, T; HOFFMAN, JR				TODD, KH; LEE, T; HOFFMAN, JR			THE EFFECT OF ETHNICITY ON PHYSICIAN ESTIMATES OF PAIN SEVERITY IN PATIENTS WITH ISOLATED EXTREMITY TRAUMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EMERGENCY	Objective.-To determine whether physician estimates of pain severity are influenced by patient ethnicity. Design.-Prospective cohort study. Setting.-UCLA Emergency Medicine Center, a level I trauma center, Los Angeles, Calif. Participants.-Hispanic and non-Hispanic white patients presenting to the emergency department with extremity trauma when research assistants were present. Exclusion criteria were patient refusal, altered mentation, or severe injury interfering with the interview process. Main Outcome Measures.-The difference between patient and physician estimates of pain severity as assessed on a visual analog scale for Hispanics and non-Hispanic whites. Results.-A total of 138 non-Hispanic white and 69 Hispanic patients participated in the study. The groups differed in language use, insurance status, and proportions suffering occupational injury. There were no differences between non-Hispanic white and Hispanic patients in patient pain assessments (mean, 39.8 mm vs 39.0 mm, respectively; P=.86), physician pain assessments (mean, 33.6 mm vs 29.7 mm; P=.23), or the disparity between patient and physician pain assessments (mean 6.1 mm vs 9.4 mm; P=.38). The degree of disparity between patient and physician pain assessments remained similar for both groups even after controlling for multiple potential confounders. Conclusions.-Physician ability to assess pain severity does not differ for Hispanic and non-Hispanic white patients. Other explanations for a difference in analgesic practice as a function of ethnicity should be explored.	UNIV CALIF LOS ANGELES, SCH MED, CTR EMERGENCY MED, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	TODD, KH (corresponding author), EMORY UNIV, SCH MED, DIV EMERGENCY MED, 69 BUTLER ST SE, ATLANTA, GA 30303 USA.							GREENWALD HP, 1991, PAIN, V44, P157, DOI 10.1016/0304-3959(91)90130-P; KELSEY JL, 1986, METHODS OBSERVATIONA; MAX MB, 1990, ANN INTERN MED, V113, P885, DOI 10.7326/0003-4819-113-11-885; SELBST SM, 1990, ANN EMERG MED, V19, P1010, DOI 10.1016/S0196-0644(05)82565-X; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; WILSON JE, 1989, AM J EMERG MED, V7, P620, DOI 10.1016/0735-6757(89)90286-6; ZATZICK DF, 1990, PSYCHOSOM MED, V52, P544, DOI 10.1097/00006842-199009000-00007; 1992, PHS920032 US DEP HLT; 1992, STATA REFERENCE MANU	9	189	190	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	1994	271	12					925	928		10.1001/jama.271.12.925	http://dx.doi.org/10.1001/jama.271.12.925			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA743	8120961				2022-12-28	WOS:A1994NA74300028
J	DEANGELIS, CD				DEANGELIS, CD			NURSE PRACTITIONER REDUX	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											DEANGELIS, CD (corresponding author), JOHNS HOPKINS UNIV, SCH MED, OFF DEAN ACAD AFFAIRS, 720 ROUND AVE, ROOM 106, BALTIMORE, MD 21205 USA.							AUSTIN G, 1968, PEDIATRICS, V41, P115; Bergman A B, 1974, Pediatrics, V54, P533; BROWN SA, 1993, META ANAL PROCESS CA; BUTLER AM, 1969, CLIN PEDIATR, V8, P624, DOI 10.1177/000992286900801105; CONNELLY JP, 1966, NEW ENGL J MED, V275, P765, DOI 10.1056/NEJM196610062751406; DAY LR, 1970, AM J DIS CHILD, V119, P204, DOI 10.1001/archpedi.1970.02100050206003; De Angelis C, 1974, Nurs Clin North Am, V9, P403; EGEBERG RO, 1971, EXTENDING SCOPE NURS; Ford L.C., 1967, NURS OUTLOOK, V15, P43; FORD PA, 1966, AM J PUBLIC HEALTH N, V56, P1097, DOI 10.2105/AJPH.56.7.1097; KELLY LY, 1974, AM J NURS, V74, P1310, DOI 10.2307/3423249; Kirk R F, 1971, Med Care, V9, P160, DOI 10.1097/00005650-197103000-00008; KLETKE PR, 1990, AM J PUBLIC HEALTH, V80, P300, DOI 10.2105/AJPH.80.3.300; MAUKSCH IG, 1978, AM J PUBLIC HEALTH, V68, P1074, DOI 10.2105/AJPH.68.11.1074; MUNROE D, 1982, AM J NURS, V82, P1538; PEARSON L, 1993, NURSE PRACT      JUN; Repicky P A, 1980, Nurse Pract, V5, P33; ROSENAUR J, 1984, AM J PUBLIC HEALTH, V74, P10, DOI 10.2105/AJPH.74.1.10; SCHIFF DW, 1969, PEDIATRICS, V44, P62; SIEGEL E, 1963, AM J PUBLIC HEALTH N, V53, P1015, DOI 10.2105/AJPH.53.7.1015; SILVER HK, 1967, PEDIATRICS, V39, P756; SILVER HK, 1968, J AMER MED ASSOC, V204, P298, DOI 10.1001/jama.204.4.298; SKINNER AL, 1968, PEDIATRICS, V41, P1003; SPITZER WO, 1974, NEW ENGL J MED, V290, P251, DOI 10.1056/NEJM197401312900506; SULTZ HA, 1978, US DHEW HRSA78092 HL; YANKAUER A, 1972, AM J PUBLIC HEALTH N, V62, P347, DOI 10.2105/AJPH.62.3.347; 1992, NATIONAL SAMPLE SURV; 1970, AM J NURS, V70, P691; 1971, US DHEW HSM7211 HLTH, P37; 1993, 1993 ANN MEMBERSHIP; 1971, AM J NURS, V71, P509; 1992, PHYSICIAN ASSISTANT; 1993, DIRECTORY PRIMARY CA	33	32	32	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					868	871		10.1001/jama.271.11.868	http://dx.doi.org/10.1001/jama.271.11.868			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ498	8114243				2022-12-28	WOS:A1994MZ49800035
J	HENSEL, WA				HENSEL, WA			THE PROMOTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					730	730						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY288	8114197				2022-12-28	WOS:A1994MY28800002
J	LENFANT, C				LENFANT, C			REDUCING THE DELAYS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LENFANT, C (corresponding author), NHLBI,BETHESDA,MD 20892, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					738	738						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY288	8114202				2022-12-28	WOS:A1994MY28800009
J	AMREIN, H; HEDLEY, ML; MANIATIS, T				AMREIN, H; HEDLEY, ML; MANIATIS, T			THE ROLE OF SPECIFIC PROTEIN-RNA AND PROTEIN-PROTEIN INTERACTIONS IN POSITIVE AND NEGATIVE CONTROL OF PRE-MESSENGER-RNA SPLICING BY TRANSFORMER-2	CELL			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; DROSOPHILA DOUBLESEX GENE; SEX DETERMINATION GENE; BINDING PROTEINS; U1 RNA; CLONED GENES; A-PROTEIN; MELANOGASTER; EXPRESSION; DIFFERENTIATION	We have investigated the function of different structural domains of the Drosophila splicing regulator Transformer 2 (Tra2). We find that the ribonucleoprotein consensus sequence (RNP-CS) of Tra2 is required for male fertility and positive and negative control of alternative splicing in transgenic flies, as well as for in vitro binding of recombinant Trail to doublesex and tra2 pre-mRNAs. Thus, all of the known functions of Tra2 require specific protein-RNA interactions. We also show that one of the two arginine-serine (RS)-rich domains of Tra2 is dispensable, while the other is essential for all of the in vivo functions. Part of this domain is also required for RNA binding in vitro. Significantly, the essential RS domain is also required for specific protein-protein interactions. We find that Tra2 interacts with itself, with the splicing regulator Transformer, and with the general splicing factor SF2 in vitro and in the yeast two-hybrid system. These results demonstrate that both protein-RNA and protein-protein interactions are involved in tra2-dependent activation and repression of alternative splicing.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Harvard University	AMREIN, H (corresponding author), COLUMBIA UNIV, HOWARD HUGHES MED INST, 701 W 168TH ST, NEW YORK, NY 10032 USA.		Amrein, Hubert/AAG-9480-2021	Amrein, Hubert/0000-0001-8799-7250				AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; AMREIN H, 1990, EMBO J, V9, P3619, DOI 10.1002/j.1460-2075.1990.tb07573.x; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BECKER DM, 1991, GUDIE YEAST GENETICS, P186; BELOTE JM, 1982, P NATL ACAD SCI-BIOL, V79, P1568, DOI 10.1073/pnas.79.5.1568; BELOTE JM, 1983, DEV BIOL, V95, P512, DOI 10.1016/0012-1606(83)90054-4; BOELENS W, 1991, NUCLEIC ACIDS RES, V19, P4611, DOI 10.1093/nar/19.17.4611; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HABETS WJ, 1987, P NATL ACAD SCI USA, V84, P2421, DOI 10.1073/pnas.84.8.2421; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; INOUE K, 1992, P NATL ACAD SCI USA, V89, P8092, DOI 10.1073/pnas.89.17.8092; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MATTOX W, 1990, GENE DEV, V4, P789, DOI 10.1101/gad.4.5.789; MATTOX W, 1992, J BIOL CHEM, V267, P19023; MATTOX W, 1991, GENE DEV, V5, P786, DOI 10.1101/gad.5.5.786; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; McKeown M, 1990, Genet Eng (N Y), V12, P139; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; Rio Donald C., 1992, Gene Expression, V2, P1; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; Sambrook J, 1989, MOL CLONING LABORATO; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SILLEKENS PTG, 1987, EMBO J, V6, P3841, DOI 10.1002/j.1460-2075.1987.tb02721.x; SPRITZ RA, 1987, NUCLEIC ACIDS RES, V15, P10373, DOI 10.1093/nar/15.24.10373; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; WATANABE TK, 1975, JPN J GENET, V50, P269, DOI 10.1266/jjg.50.269; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5; [No title captured]	64	174	181	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	1994	76	4					735	746		10.1016/0092-8674(94)90512-6	http://dx.doi.org/10.1016/0092-8674(94)90512-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124712				2022-12-28	WOS:A1994MZ28500015
J	ASHTONRICKARDT, PG; BANDEIRA, A; DELANEY, JR; VANKAER, L; PIRCHER, HP; ZINKERNAGEL, RM; TONEGAWA, S				ASHTONRICKARDT, PG; BANDEIRA, A; DELANEY, JR; VANKAER, L; PIRCHER, HP; ZINKERNAGEL, RM; TONEGAWA, S			EVIDENCE FOR A DIFFERENTIAL AVIDITY MODEL OF T-CELL SELECTION IN THE THYMUS	CELL			English	Article							CLASS-I MOLECULES; RESTRICTED ANTIGEN PRESENTATION; POSITIVE SELECTION; TRANSGENIC MICE; LYMPHOCYTES-T; VIRAL PEPTIDES; SELF-PEPTIDES; MHC MOLECULES; H-2 ANTIGENS; RECEPTOR	Positive and negative selection of a lymphocytic choriomeningitis virus (LCMV) peptide-specific, H-2D(b)-restricted T cell clone (P14) was studied using TAP1(-) and TAP1(+) mice transgenic for P14 T cell receptor (TCR) alpha and beta genes. Positive selection of transgenic CD8(+) P14 cells was impaired in TAP1- mice. Addition of the LCMV peptide to TAP1(-) fetal thymic organ cultures (FTOCs) at low and high concentrations induced positive and negative selection of CD8(+) P14 cells, respectively, while addition of the same peptide to TAP1(+) FTOCs induced negative selection even at low concentrations. Both types of selection were peptide specific. Thus, a critical parameter that controls the fate of a thymocyte seems to be the number of TCRs engaged with complexes of peptide and major histocompatibility complex. When this number is low, positive selection occurs, and when it is high, negative selection takes place. These findings support a differential avidity model of T cell selection.	UNIV ZURICH,DEPT PATHOL,INST EXPTL IMMUNOL,CH-8091 ZURICH,SWITZERLAND	University of Zurich	ASHTONRICKARDT, PG (corresponding author), MIT,DEPT BIOL,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139, USA.		Van Kaer, Luc/H-1033-2015	Van Kaer, Luc/0000-0001-5275-2309; Bandeira Ferreira, Antonio/0000-0002-8054-8716	NATIONAL CANCER INSTITUTE [R35CA053874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI017879, R01AI017879] Funding Source: NIH RePORTER; NCI NIH HHS [CA53874] Funding Source: Medline; NIAID NIH HHS [AI17879] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1989, SCIENCE; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FINK PJ, 1978, J EXP MED, V148, P766, DOI 10.1084/jem.148.3.766; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; HOGQUIST KA, 1993, J EXP MED, V177, P1464; HUGO P, 1993, IMMUNOL REV, V135, P133, DOI 10.1111/j.1600-065X.1993.tb00647.x; JACOBS H, 1990, EUR J IMMUNOL, V20, P2333, DOI 10.1002/eji.1830201024; JANEWAY C, 1992, Current Biology, V2, P26, DOI 10.1016/0960-9822(92)90419-B; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LO D, 1986, NATURE, V319, P672, DOI 10.1038/319672a0; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; OHASHI PS, 1993, INT IMMUNOL, V5, P131, DOI 10.1093/intimm/5.2.131; PAWLOWSKI T, 1993, NATURE, V364, P642, DOI 10.1038/364642a0; PIRCHER H, 1993, EUR J IMMUNOL, V23, P669, DOI 10.1002/eji.1830230315; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PIRCHER HP, 1990, NATURE, V346, P624; ROBEY EA, 1992, CELL, V64, P1084; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SPRENT J, 1988, IMMUNOL REV, V101, P173, DOI 10.1111/j.1600-065X.1988.tb00737.x; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; ZIEGLER K, 1981, J IMMUNOL, V127, P1869; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	46	639	648	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 25	1994	76	4					651	663		10.1016/0092-8674(94)90505-3	http://dx.doi.org/10.1016/0092-8674(94)90505-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124708				2022-12-28	WOS:A1994MZ28500008
J	ZHANG, FM; STRAND, A; ROBBINS, D; COBB, MH; GOLDSMITH, EJ				ZHANG, FM; STRAND, A; ROBBINS, D; COBB, MH; GOLDSMITH, EJ			ATOMIC-STRUCTURE OF THE MAP KINASE ERK2 AT 2.3-ANGSTROM RESOLUTION	NATURE			English	Article							SIGNAL-REGULATED KINASES; DEPENDENT PROTEIN-KINASE; ADENOSINE-MONOPHOSPHATE; CATALYTIC SUBUNIT; GROWTH-FACTOR; SUBSTRATE RECOGNITION; PHOSPHORYLATION; INSULIN; ACTIVATION; TYROSINE	The structure of the MAP kinase ERK2, a ubiquitous protein kinase target for regulation by Ras and Raf, has been solved in its unphosphorylated low-activity conformation to a resolution of 2.3 angstrom. The two domains of unphosphorylated ERK2 are farther apart than in the active conformation of cAMP-dependent protein kinase and the peptide-binding site is blocked by tyrosine 185, one of the two residues that are phosphorylated in the active enzyme. Activation of ERK2 is thus likely to involve both global and local conformational changes.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute				Cobb, Melanie/0000-0003-0833-5473				AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSI DR, 1993, ONCOGENE, V8, P2015; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARLSSON R, 1993, ACTA CRYSTALLOGR D, V49, P381, DOI 10.1107/S0907444993002306; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE RM, 1992, J BIOL CHEM, V267, P1088; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RINGE D, 1985, PROG BIOPHYS MOL BIO, V45, P197, DOI 10.1016/0079-6107(85)90002-1; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; ROSSOMANDO AJ, 1992, P NATL ACAD SCI USA, V89, P5779, DOI 10.1073/pnas.89.13.5779; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; Schulz GE, 1991, CURR OPIN STRUC BIOL, V1, P883, DOI 10.1016/0959-440X(91)90082-5; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SPRANG SR, 1991, SCIENCE, V254, P1367, DOI 10.1126/science.1962195; STEIGEMANN W, 1989, PROTEIN PROGRAM SYST; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSAO H, 1990, J BIOL CHEM, V265, P15471; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WANG BC, 1985, METHOD ENZYMOL, V115, P90; ZHANG FM, 1993, J MOL BIOL, V233, P550, DOI 10.1006/jmbi.1993.1532; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	54	523	542	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					704	711		10.1038/367704a0	http://dx.doi.org/10.1038/367704a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	8107865				2022-12-28	WOS:A1994MX63100048
J	MILLER, JD; BERNSTEIN, HD; WALTER, P				MILLER, JD; BERNSTEIN, HD; WALTER, P			INTERACTION OF ESCHERICHIA-COLI FFH/4.5S RIBONUCLEOPROTEIN AND FTSY MIMICS THAT OF MAMMALIAN SIGNAL RECOGNITION PARTICLE AND ITS RECEPTOR	NATURE			English	Article							ESCHERICHIA-COLI; PROTEIN SECRETION; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; SEQUENCE RECOGNITION; NASCENT PREPROLACTIN; TRANSLOCATION; POLYPEPTIDE; MEMBRANE	THE mechanism of-protein translocation across the endoplasmic reticulum membrane of eukaryotic cells and the plasma membrane of prokaryotic cells are thought to be evolutionarily related(1-7). Protein targeting to the eukaryotic translocation apparatus is mediated by the signal recognition particle (SRP), a cytosolic ribonucleoprotein, and the SRP receptor, an endoplasmic reticulum membrane protein(8,9). During targeting, the 54K SRP subunit (M(r), 54,000; SRP54), a GTP-binding protein(10-12), binds to signal sequences(13,14) and then interacts with the alpha-subunit of the SRP receptor (SR alpha), another GTP-binding protein(12,15). Two proteins from Escherichia coli, Ffh and FtsY, structurally resemble SRP54 and SR alpha(10,11,16). Like SRP54, Ffh is a subunit of a cytosolic ribonucleoprotein that also contains the E. coli 4.5S RNA(17,18). Although there is genetic and biochemical evidence that the E. coli Ffh/ 4.5S ribonucleoprotein has an SRP-like function(19-21), there is no evidence for an SR alpha-like role for FtsY. Here we show that the Ffh/ 4.5S ribonucleoprotein binds tightly to FtsY in a GTP-dependent manner. This interaction results in the stimulation of GTP hydrolysis which can be inhibited by synthetic signal peptides. These properties mimic those of mammalian SRP and its receptor, suggesting that the E. coli Ffh/4.5S ribonucleoprotein and FtsY have functions in protein targeting that are similar to those of their mammalian counterparts.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BERNSTEIN HD, 1993, P NATL ACAD SCI USA, V90, P5229, DOI 10.1073/pnas.90.11.5229; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRIGGS MS, 1986, ADV PROTEIN CHEM, V38, P109, DOI 10.1016/S0065-3233(08)60527-6; CHEN LL, 1987, J BIOL CHEM, V262, P1427; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; MCKNIGHT CJ, 1989, J BIOL CHEM, V264, P17293; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; MULLER M, 1982, J BIOL CHEM, V257, P1860; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; PORITZ MA, 1990, SCIENCE, V250, P111; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROGGENKAMP R, 1981, P NATL ACAD SCI-BIOL, V78, P4466, DOI 10.1073/pnas.78.7.4466; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SAMMUELSSON T, 1993, NUCLEIC ACIDS RES, V21, P847; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH RA, 1985, SCIENCE, V229, P1219, DOI 10.1126/science.3939723	27	155	160	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 17	1994	367	6464					657	659		10.1038/367657a0	http://dx.doi.org/10.1038/367657a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	8107852				2022-12-28	WOS:A1994MW68800058
J	HODGKINSON, DW; KURDY, N; NICHOLSON, DA; DRISCOLL, PA				HODGKINSON, DW; KURDY, N; NICHOLSON, DA; DRISCOLL, PA			ABC OF EMERGENCY RADIOLOGY - THE HAND	BRITISH MEDICAL JOURNAL			English	Article											HODGKINSON, DW (corresponding author), HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND.								0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	1994	308	6925					401	405		10.1136/bmj.308.6925.401	http://dx.doi.org/10.1136/bmj.308.6925.401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV862	8124151	Green Published			2022-12-28	WOS:A1994MV86200029
J	ARENAS, E; PERSSON, H				ARENAS, E; PERSSON, H			NEUROTROPHIN-3 PREVENTS THE DEATH OF ADULT CENTRAL NORADRENERGIC NEURONS IN-VIVO	NATURE			English	Article							NERVE GROWTH-FACTOR; CHOLINERGIC NEURONS; LOCUS-CERULEUS; MESSENGER-RNA; FACTOR FAMILY; RAT-BRAIN; MOLECULAR-CLONING; CELL-DEATH; TRK FAMILY; EXPRESSION	NEUROTROPHIN-3 (NT-3)1-4 and neurotrophin-4/5 (NT4)5-7, together with nerve growth factor and brain-derived neurotrophic factor, are members of the neurotrophin family of proteins8,9 which supports the survival of vertebrate neurons. However, no function in vivo has been described for NT4 and limited information is available on the role of the other neurotrophins in the central nervous system in vivo. Nerve growth factor prevents the degeneration of lesioned septal cholinergic neurons in the adult brain10-13, whereas brain-derived neurotrophic factor prevents the death of developing motor neurons14-16 and a subpopulation of adult septal cholinergic neurons17. Finally, NT-3 partially prevents the death of facial motor neurons in newborn rats16. To assess the role of NT-3 and NT4 in the adult brain in vivo, we implanted genetically modified fibroblasts that constitutively express high levels of NT-3 or NT-4. The results show that NT-3, but no other neurotrophin, prevents the degeneration of noradrenergic neurons of the locus coeruleus in a 6-hydroxydopamine lesion model that resembles the pattern of cell loss found in Alzheimer's disease18,19. These results imply that NT-3 may have therapeutic potential for preventing the death of noradrenergic neurons in the locus coeruleus.			ARENAS, E (corresponding author), KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,MOLEC NEUROBIOL LAB,S-17177 STOCKHOLM,SWEDEN.		Arenas, Ernest/AAO-5231-2020	Arenas, Ernest/0000-0003-0197-6577				ALTAR CA, 1993, J NEUROSCI, V13, P733; BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; CHANPALAY V, 1991, PROG BRAIN RES, V88, P625; ERNFORS P, 1989, P NATL ACAD SCI USA, V86, P4756, DOI 10.1073/pnas.86.12.4756; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; ERNFORS P, 1991, EUR J NEUROSCI, V3, P953, DOI 10.1111/j.1460-9568.1991.tb00031.x; FRIEDMAN WJ, 1993, EXP NEUROL, V119, P72, DOI 10.1006/exnr.1993.1007; FRIEDMAN WJ, 1991, J NEUROSCI, V11, P1577; GERMAN DC, 1992, ANN NEUROL, V32, P667, DOI 10.1002/ana.410320510; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HARLEY C, 1991, PROG BRAIN RES, V88, P307; HEFTI F, 1986, J NEUROSCI, V6, P2155; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; IBANEZ CF, 1993, DEVELOPMENT, V117, P1345; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; KNUSEL B, 1992, J NEUROSCI, V12, P4391; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; PERSSON H, 1993, CURR OPIN NEUROL NEU, V6, P11; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; ROSENBERG MB, 1988, SCIENCE, V242, P1575, DOI 10.1126/science.3201248; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0	33	192	203	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					368	371		10.1038/367368a0	http://dx.doi.org/10.1038/367368a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	8114936				2022-12-28	WOS:A1994MT54000067
J	GOUNNI, AS; LAMKHIOUED, B; OCHIAI, K; TANAKA, Y; DELAPORTE, E; CAPRON, A; KINET, JP; CAPRON, M				GOUNNI, AS; LAMKHIOUED, B; OCHIAI, K; TANAKA, Y; DELAPORTE, E; CAPRON, A; KINET, JP; CAPRON, M			HIGH-AFFINITY IGE RECEPTOR ON EOSINOPHILS IS INVOLVED IN DEFENSE AGAINST PARASITES	NATURE			English	Article							EPIDERMAL LANGERHANS CELLS; FC-EPSILON-RI; IMMUNOGLOBULIN-E; ALPHA-SUBUNIT; 2ND RECEPTOR; CHAIN; GENE; RESISTANCE; EXPRESSION; PRODUCTS	PARASITIC infections are often associated with eosinophilia and high levels of immunoglobulin E (IgE). This observation has led to speculation that eosinophils and IgE may act together in the immune response against parasites. In support of this hypothesis, IgE and eosinophils participate in cytotoxic reactions directed against Schistosoma mansoni larvae in vitro1,2. Furthermore, epidemiological studies have shown an inverse correlation between levels of specific IgE and rates of infection with Schistosoma3-5. The low-affinity IgE receptor (FcepsilonRII/CD23) was first incriminated in eosinophil activation 6,7. The fact that the high-affinity IgE receptor (FcepsilonRI)8,9 is not only expressed on mast cells and basophils but also on Langerhans cells10,11 led us to investigate the presence of FcepsilonRI on eosinophils. Here we show that FcepsilonRI is expressed on eosinophils from hypereosinophilic patients, is involved in eosinophil degranulation, and participates in eosinophil-mediated cytotoxicity against S. mansoni. Our results indicate that FcepsilonRI may play a major part in immune defence against parasites.	INST PASTEUR, CTR IMMUNOL & BIOL PARASITAIRE,UNITE MIXTE,INSERM, U167,CNRS 624, F-59019 LILLE, FRANCE; NIAID, MOLEC ALLERGY & IMMUNOL SECT, BETHESDA, MD 20892 USA; CTR HOSP REG UNIV LILLE, SERV DERMATOL A, F-59000 LILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Universite de Lille - ISITE; CHU Lille			LAMKHIOUED, Bouchaib/AAL-4201-2021; Gounni, Abdelilah Soussi/AAH-3456-2020	Gounni, Abdelilah/0000-0003-1265-6560; Soussi Gounni, Abdelilah/0000-0002-7282-0388				BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BLANK U, 1991, J BIOL CHEM, V266, P2639; CAPRON A, 1986, IMMUNOL TODAY, V7, P15, DOI 10.1016/0167-5699(86)90184-2; CAPRON A, 1987, SCIENCE, V238, P1065, DOI 10.1126/science.3317823; CAPRON M, 1989, CHEM IMMUNOL, V47, P128; CAPRON M, 1991, EUR J IMMUNOL, V21, P2423, DOI 10.1002/eji.1830211019; CAPRON M, 1986, J EXP MED, V164, P72, DOI 10.1084/jem.164.1.72; DUNNE DW, 1992, EUR J IMMUNOL, V22, P1483, DOI 10.1002/eji.1830220622; FISCHKOFF SA, 1984, J EXP MED, V160, P179, DOI 10.1084/jem.160.1.179; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; KHALIFE J, 1986, J IMMUNOL, V137, P1659; KINET JP, 1992, INFLAMMATION BASIC P, P701; KOCHAN J, 1988, NUCLEIC ACIDS RES, V16, P3584, DOI 10.1093/nar/16.8.3584; KUSTER H, 1992, J BIOL CHEM, V267, P12782; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RIHET P, 1991, EUR J IMMUNOL, V21, P2679, DOI 10.1002/eji.1830211106; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; TOMASSINI M, 1991, J ALLERGY CLIN IMMUN, V88, P365, DOI 10.1016/0091-6749(91)90099-A; TRUONG MJ, 1993, J EXP MED, V177, P243, DOI 10.1084/jem.177.1.243; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353	23	448	455	1	3	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 13	1994	367	6459					183	186		10.1038/367183a0	http://dx.doi.org/10.1038/367183a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ780	8114916				2022-12-28	WOS:A1994MQ78000064
J	ACHARYA, KR; PASSALACQUA, EF; JONES, EY; HARLOS, K; STUART, DI; BREHM, RD; TRANTER, HS				ACHARYA, KR; PASSALACQUA, EF; JONES, EY; HARLOS, K; STUART, DI; BREHM, RD; TRANTER, HS			STRUCTURAL BASIS OF SUPERANTIGEN ACTION INFERRED FROM CRYSTAL-STRUCTURE OF TOXIC-SHOCK SYNDROME TOXIN-1	NATURE			English	Article							STAPHYLOCOCCAL ENTEROTOXIN-B; RECEPTOR BETA-CHAIN; V-BETA; T-CELLS; BINDING; IDENTIFICATION; RESIDUES; STIMULATION; RESPONSES; MOLECULES	SUPERANTIGENS stimulate T cells bearing particular T-cell receptor Vbeta sequences1,2, so they are extremely potent polyclonal T-cell mitogens. T-cell activation is preceded by binding of superantigens to class II major histocompatibility complex (MHC) molecules3. To further the structural characterization of these interactions, the crystal structure of a toxin associated with toxic-shock syndrome, TSST-1, which is a microbial superantigen, has been determined at 2.5 angstrom resolution. The N- and C-terminal domains of the structure both contain regions involved in MHC class II association; the C-terminal domain is also implicated in binding the T-cell receptor. Despite low sequence conservation, the TSST-1 topology is similar to the structure reported for the superantigen staphylococcal enterotoxin B4. But TSST-1 lacks several of the structural features highlighted as central to superantigen activity in the staphylococcal enterotoxin B and we therefore reappraise the structural basis of superantigen action.	OXFORD CTR MOLEC SCI, OXFORD OX1 3QU, ENGLAND; LAB MOLEC BIOPHYS, OXFORD OX1 3QU, ENGLAND; PUBL HLTH LAB SERV, CTR APPL MICROBIOL & RES, DIV BIOL, SALISBURY SP4 0JG, ENGLAND	University of Oxford; University of Oxford	ACHARYA, KR (corresponding author), UNIV BATH, SCH BIOL & BIOCHEM, CLAVERTON DOWN, BATH BA2 7AY, AVON, ENGLAND.		Jones, Yvonne/J-2293-2016; Jones, Yvonne/N-8111-2019	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Stuart, David/0000-0002-3426-4210; Acharya, K. Ravi/0000-0002-3009-4058				BJORKMAN PJ, 1989, COLD SH Q B, V54, P365; BLANCO L, 1990, INFECT IMMUN, V58, P3020, DOI 10.1128/IAI.58.9.3020-3028.1990; BONVENTRE PF, 1988, INFECT IMMUN, V56, P135, DOI 10.1128/IAI.56.1.135-141.1988; BONVENTRE PF, 1993, INFECT IMMUN, V61, P793, DOI 10.1128/IAI.61.3.793-799.1993; BRAUNSTEIN NS, 1992, J EXP MED, V175, P1301, DOI 10.1084/jem.175.5.1301; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHOI YW, 1990, NATURE, V346, P471, DOI 10.1038/346471a0; EDWIN C, 1989, INFECT IMMUN, V57, P2230, DOI 10.1128/IAI.57.7.2230-2236.1989; EDWIN C, 1991, J INFECT DIS, V163, P524, DOI 10.1093/infdis/163.3.524; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; GRIGGS ND, 1992, J IMMUNOL, V148, P2516; IRWIN MJ, 1992, NATURE, V359, P841, DOI 10.1038/359841a0; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; JONES EY, 1991, ACTA CRYSTALLOGR A, V47, P753, DOI 10.1107/S0108767391006839; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAPPLER JW, 1992, J EXP MED, V175, P387, DOI 10.1084/jem.175.2.387; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MURRAY DL, 1993, 93RD GEN M AM SOC MI, P64; MURZIN AG, 1992, NATURE, V360, P635, DOI 10.1038/360635a0; PANINABORDIGNON P, 1992, J EXP MED, V176, P1779, DOI 10.1084/jem.176.6.1779; PASSALACQUA EF, 1992, J MOL BIOL, V228, P983, DOI 10.1016/0022-2836(92)90882-K; PONTZER CH, 1991, P NATL ACAD SCI USA, V88, P125, DOI 10.1073/pnas.88.1.125; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; PULLEN AM, 1991, J EXP MED, V173, P1183, DOI 10.1084/jem.173.5.1183; SOOS JM, 1993, BIOCHEM BIOPH RES CO, V191, P1211, DOI 10.1006/bbrc.1993.1346; SPERO L, 1988, HDB NATURAL TOXINS, V4, P131; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WOODLAND DL, 1993, IMMUNOL TODAY, V14, P208, DOI 10.1016/0167-5699(93)90164-G	30	147	157	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	1994	367	6458					94	97		10.1038/367094a0	http://dx.doi.org/10.1038/367094a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	8107781				2022-12-28	WOS:A1994MP86500068
J	SYLVESTER, SHH				SYLVESTER, SHH			GENERAL-PRACTITIONERS ATTITUDES TO PROFESSIONAL REACCREDITATION	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the views, of general practitioners about professional reaccreditation. Design-Postal questionnaire. Subjects-All 278 general practitioner principals working in Cleveland. Main outcome measures-General practitioner characteristics; attitudes to reaccreditation; and views on the development, conduct, content, and format of reaccreditation. Results-210 out of 278 (76%) general practitioners responded to the questionnaire. 128 (61%) agreed that general practitioners should undergo reaccreditation. 149 (72%) thought the General Medical Services Committee and local medical committees were appropriate bodies to lead its development. 120 respondents suggested that reaccreditation should be carried out by assessors appointed by the doctor's own local medical committee. The most favoured interval between reaccreditation episodes was 10 or more years. 152 doctors thought that doctors who failed reaccreditation should be advised on education and reassessed soon afterwards. Clinical knowledge (82%), clinical skill (82%), prescribing practices (67%), standards of medical record keeping (60%), and consultation behaviour (58%) were the most popular subjects for scrutiny. 138 (67%) respondents felt that reaccreditation should be part of continuing medical eduction. Conclusion-Most general practitioners support professional reaccreditation. They believe the process should be led by the profession, be educational, and take account of a range of professional activities.			SYLVESTER, SHH (corresponding author), TENNANT ST SURGERY,STOCKTON ON TEES TS18 2AT,ENGLAND.							LITTLE S, 1991, PULSE           0724, P24; ORMELL C, 1992, MEDECONOMICS     MAR, P63; RETHANS JJ, 1991, BRIT J GEN PRACT, V41, P97; 1990, 50 ROYAL COLL GEN PR; 1992, YOUR CHOICES FUTURE; 1991, REPORT WORKING PARTY	6	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1993	307	6909					912	914		10.1136/bmj.307.6909.912	http://dx.doi.org/10.1136/bmj.307.6909.912			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB847	8110242	Green Published, Bronze			2022-12-28	WOS:A1993MB84700022
J	MICHELS, R; MARZUK, PM				MICHELS, R; MARZUK, PM			MEDICAL PROGRESS - PROGRESS IN PSYCHIATRY .2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							OBSESSIVE-COMPULSIVE DISORDER; HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-RELATED COMPLEX; MAJOR DEPRESSIVE DISORDER; POSTTRAUMATIC-STRESS-DISORDER; GLUCOSE METABOLIC RATES; INTRAVENOUS-DRUG-USERS; NEW-YORK-CITY; D-TYPE SCORES; PANIC DISORDER		CORNELL UNIV,MED CTR,OFF DEAN,NEW YORK,NY 10021	Cornell University	MICHELS, R (corresponding author), CORNELL UNIV,MED CTR,DEPT PSYCHIAT,1300 YORK AVE,NEW YORK,NY 10021, USA.				NIDA NIH HHS [1-RO1 DAO6534-01] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006534] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARANA GW, 1991, HDB PSYCHIATRIC DRUG, P38; ATKINSON JH, 1988, ARCH GEN PSYCHIAT, V45, P859; AYD FJ, 1987, TREATING RESISTANT D, P343; Azmitia E. C., 1987, PSYCHOPHARMACOLOGY 3, P61; BAER JW, 1989, AM J PSYCHIAT, V146, P1285; BALLENGER JC, 1988, ARCH GEN PSYCHIAT, V45, P413; BARLOW DH, 1989, BEHAV THER, V20, P261, DOI 10.1016/S0005-7894(89)80073-5; BAXTER LR, 1987, ARCH GEN PSYCHIAT, V44, P211; BEASLEY CM, 1991, J CLIN PSYCHOPHARM, V11, P166; BECH P, 1988, ADV BIOL PSYCHIAT, V17, P58; BEGLEITER H, 1984, SCIENCE, V225, P1493, DOI 10.1126/science.6474187; BERGER U, 1991, CANCER RES, V51, P239; BERNSTEIN JG, 1988, HDB DRUG THERAPY PSY, P161; BLIER P, 1986, J PHARMACOL EXP THER, V237, P987; BOARD F, 1956, PSYCHOSOM MED, V18, P324, DOI 10.1097/00006842-195607000-00006; BOYD JH, 1984, ARCH GEN PSYCHIAT, V41, P983; BRANTIGAN CO, 1982, AM J MED, V72, P88, DOI 10.1016/0002-9343(82)90592-7; BREITBART W, 1988, LANCET, V2, P1488; BROWN R, 1989, J CLIN PSYCHIAT, V50, P13; BUTLER G, 1989, CLIN PSYCHOL REV, V9, P91, DOI 10.1016/0272-7358(89)90049-4; CHAISSON RE, 1989, JAMA-J AM MED ASSOC, V261, P561, DOI 10.1001/jama.261.4.561; CHAPUT Y, 1986, N-S ARCH PHARMACOL, V333, P342, DOI 10.1007/BF00500007; CHARNEY DS, 1988, ARCH GEN PSYCHIAT, V45, P177; CHECKLEY SA, 1981, BRIT J PSYCHIAT, V138, P51, DOI 10.1192/bjp.138.1.51; CHOUINARD G, 1985, J CLIN PSYCHIAT, V46, P32; CHOUINARD G, 1983, BIOL PSYCHIAT, V18, P451; CLARK D B, 1989, Annals of Behavioral Medicine, V11, P28, DOI 10.1207/s15324796abm1101_4; CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604; COOPER JR, 1989, JAMA-J AM MED ASSOC, V262, P1664, DOI 10.1001/jama.262.12.1664; COOPER NA, 1989, BEHAV THER, V20, P381, DOI 10.1016/S0005-7894(89)80057-7; CORYELL W, 1984, ARCH GEN PSYCHIAT, V41, P787; COWDRY RW, 1983, ARCH GEN PSYCHIAT, V40, P414; COXHEAD N, 1992, ACTA PSYCHIAT SCAND, V85, P114, DOI 10.1111/j.1600-0447.1992.tb01453.x; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; CUSHMAN P, 1985, ALCOHOL CLIN EXP RES, V9, P103, DOI 10.1111/j.1530-0277.1985.tb05527.x; CZEISLER CA, 1987, PSYCHIAT CLIN N AM, V10, P687; DACKIS CA, 1985, NEUROSCI BIOBEHAV R, V9, P469, DOI 10.1016/0149-7634(85)90022-3; DARCOURT G, 1988, Psychiatrie and Psychobiologie, V3, p85S; DAVIDSON J, 1990, ARCH GEN PSYCHIAT, V47, P259; DEMONTIGNY C, 1981, BRIT J PSYCHIAT, V138, P252, DOI 10.1192/bjp.138.3.252; DESJARLAIS DC, 1990, J CONSULT CLIN PSYCH, V58, P50, DOI 10.1037/0022-006X.58.1.50; DORUS W, 1987, ALCOHOL CLIN EXP RES, V11, P1150; DUNNER DL, 1974, ARCH GEN PSYCHIAT, V30, P229; ESMAN AH, 1989, J AM PSYCHOANAL ASS, V37, P319, DOI 10.1177/000306518903700203; FEIGHNER J, 1986, J CLIN PSYCHOPHARM, V6, P27; FELDMAN DJ, 1975, AM J PSYCHIAT, V132, P407; FERNANDEZ F, 1988, PSYCHOSOMATICS, V29, P38, DOI 10.1016/S0033-3182(88)72420-2; FOA EB, 1984, BEHAV THER, V15, P4450; FRANCES RJ, 1989, REV PSYCHIAT, V8, P341; FRANK E, 1991, ARCH GEN PSYCHIAT, V48, P1053; FULLER RK, 1986, JAMA-J AM MED ASSOC, V256, P1449, DOI 10.1001/jama.256.11.1449; FULLILOVE RE, 1990, JAMA-J AM MED ASSOC, V263, P851, DOI 10.1001/jama.263.6.851; GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107; GAWIN FH, 1988, NEW ENGL J MED, V318, P1173, DOI 10.1056/NEJM198805053181806; GAWIN FH, 1988, J CLIN PSYCHIAT, V49, P11; GELENBERG AJ, 1989, NEW ENGL J MED, V321, P1489, DOI 10.1056/NEJM198911303212201; GOLD PW, 1988, NEW ENGL J MED, V319, P413, DOI 10.1056/NEJM198808183190706; GOLDEN RN, 1985, AM J PSYCHIAT, V142, P1459; GOODMAN WK, 1990, ARCH GEN PSYCHIAT, V47, P577; GOODMAN WK, 1990, J CLIN PSYCHIAT, V51, P36; GOODWIN FK, 1982, AM J PSYCHIAT, V139, P34; GOODWIN FK, 1990, MANIC DEPRESSIVE ILL, P603; Goodwin FK, 1984, NEUROBIOLOGY MOOD DI, P20; GOODWIN FK, 1990, MANIC DEPRESSIVE ILL, P56; GOODWIN FK, 1990, MANIC DEPRESSIVE ILL, P630; GORMAN JM, 1984, AM J PSYCHIAT, V141, P857; GREENBLATT M, 1975, NEW ENGL J MED, V292, P246, DOI 10.1056/NEJM197501302920506; HAYASHIDA M, 1989, NEW ENGL J MED, V320, P358, DOI 10.1056/NEJM198902093200605; HENINGER GR, 1990, REV PSYCHIATRY, V9, P33; HIMMELHOCH JM, 1976, ARCH GEN PSYCHIAT, V33, P1062; HOLLAND JC, 1985, ANN INTERN MED, V103, P760, DOI 10.7326/0003-4819-103-5-760; HOLMES VF, 1989, J CLIN PSYCHIAT, V50, P5; HOROWSKI R, 1985, CURR THER RES CLIN E, V38, P23; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; JAMES IM, 1983, J ROY SOC MED, V76, P194, DOI 10.1177/014107688307600308; JARVIK ME, 1990, SCIENCE, V250, P387, DOI 10.1126/science.2218544; JENIKE MA, 1991, ARCH GEN PSYCHIAT, V48, P548; JENIKE MA, 1989, AM J PSYCHIAT, V146, P1328; JENIKE MA, 1988, AM J PSYCHIAT, V145, P1285; JUDD FK, 1985, J AFFECT DISORDERS, V9, P271, DOI 10.1016/0165-0327(85)90058-8; KAPLAN RF, 1988, PROG NEURO-PSYCHOPH, V12, P873, DOI 10.1016/0278-5846(88)90083-8; KASPER S, 1989, ARCH GEN PSYCHIAT, V46, P823; KELLER MB, 1983, AM J PSYCHIAT, V140, P689; KENDLER KS, 1986, ARCH GEN PSYCHIAT, V43, P213; Klein DF, 1980, DIAGNOSIS DRUG TREAT; KOCSIS JH, 1985, PSYCHOPHARMACOL BULL, V21, P698; KRAUS ML, 1985, NEW ENGL J MED, V313, P905, DOI 10.1056/NEJM198510103131501; KUKOPULOS A, 1980, NEUROPSYCHOPHARMAKOL, V13, P156; KUPFER DJ, 1988, AM J PSYCHIAT, V145, P804; KUPFER DJ, 1980, COMPR PSYCHIAT, V21, P212, DOI 10.1016/0010-440X(80)90005-X; KUPFER DJ, 1983, PSYCHIAT CLIN N AM, V6, P3; LAVERDURE B, 1991, Encephale, V17, P481; LEVINE SR, 1990, NEW ENGL J MED, V323, P699, DOI 10.1056/NEJM199009133231102; LIEBOWITZ MR, 1984, ARCH GEN PSYCHIAT, V41, P669; LIEBOWITZ MR, 1989, BRIT J PSYCHIAT, V155, P46, DOI 10.1192/S0007125000297481; LINDBERG FH, 1985, CHILD ABUSE NEGLECT, V9, P329, DOI 10.1016/0145-2134(85)90028-6; LOCKWOOD AH, 1989, NEW ENGL J MED, V320, P221, DOI 10.1056/NEJM198901263200405; LOOSEN PT, 1982, AM J PSYCHIAT, V139, P405; LOWENSTEIN DH, 1987, AM J MED, V83, P841, DOI 10.1016/0002-9343(87)90640-1; LUXENBERG JS, 1988, AM J PSYCHIAT, V145, P1089; LYDIARD RB, 1985, J CLIN PSYCHIAT, V46, P412; LYDIARD RB, 1987, J AFFECT DISORDERS, V13, P153, DOI 10.1016/0165-0327(87)90020-6; MARKOWITZ J, 1987, AM J PSYCHIAT, V144, P1025; Marotta R, 1989, J Neuropsychiatry Clin Neurosci, V1, P225; MARZUK PM, 1992, AM J PSYCHIAT, V149, P371; MARZUK PM, 1990, JAMA-J AM MED ASSOC, V263, P250, DOI 10.1001/jama.263.2.250; MAVISSAKALIAN MR, 1990, J NERV MENT DIS, V178, P268, DOI 10.1097/00005053-199004000-00010; MCGRATH PJ, 1987, PSYCHOPHARMACOL BULL, V23, P169; MCTAVISH D, 1990, DRUGS, V39, P136, DOI 10.2165/00003495-199039010-00010; MILLER F, 1987, J CLIN PSYCHOPHARM, V7, P89; MILLER SB, 1989, ALCOHOL CLIN EXP RES, V13, P505, DOI 10.1111/j.1530-0277.1989.tb00367.x; MURPHY DL, 1987, 140TH ANN M APA CHIC; Naranjo C A, 1986, Recent Dev Alcohol, V4, P265; NEFTEL KA, 1982, PSYCHOSOM MED, V44, P461, DOI 10.1097/00006842-198211000-00008; NEMEROFF CB, 1988, PHARMACOPSYCHIATRY, V21, P76, DOI 10.1055/s-2007-1014652; NORDAHL TE, 1989, NEUROPSYCHOPHARMACOL, V2, P23, DOI 10.1016/0893-133X(89)90003-1; OBRIEN CP, 1988, J CLIN PSYCHIAT, V49, P17; OSTROW D, 1988, J CLIN PSYCHIAT, V49, P14; OSTROW DG, 1990, AIDS, V4, P759, DOI 10.1097/00002030-199008000-00007; PAPP LA, 1992, REV PSYCHIAT, V11, P307; PAUL SM, 1988, J CLIN PSYCHIAT, V49, P13; PAULS DL, 1986, ARCH GEN PSYCHIAT, V43, P1180; PERRY S, 1990, AM J PSYCHIAT, V147, P89; PERRY S, 1992, ARCH GEN PSYCHIAT, V49, P396; PERRY S, 1991, ARCH GEN PSYCHIAT, V48, P143; PERRY SW, 1990, AM J PSYCHIAT, V147, P696; PETRACCA A, 1990, J CLIN PSYCHIAT, V51, P31; PIGOTT TA, 1990, ARCH GEN PSYCHIAT, V47, P926; PITMAN RK, 1987, AM J PSYCHIAT, V144, P1166; PLANT MA, 1990, ALCOHOL ALCOHOLISM, V25, P293, DOI 10.1093/oxfordjournals.alcalc.a045003; POLLACK MH, 1989, COMPR PSYCHIAT, V30, P31, DOI 10.1016/0010-440X(89)90116-8; POST RM, 1986, BRIT J PSYCHIAT, V149, P191, DOI 10.1192/bjp.149.2.191; POST RM, 1984, NEUROBIOLOGY MOOD DI, P432; POST RM, 1990, REV PSYCHIATRY, V9, P170; POTTER WZ, 1989, ARCH GEN PSYCHIAT, V46, P269; PRICE RW, 1988, J INFECT DIS, V158, P1079, DOI 10.1093/infdis/158.5.1079; PRIEN RF, 1984, ARCH GEN PSYCHIAT, V41, P1096; QUITKIN FM, 1984, ARCH GEN PSYCHIAT, V41, P238; RAPOPORT JL, 1988, PSYCHOPHARMACOL BULL, V24, P380; RAPOPORT JL, 1992, ARCH GEN PSYCHIAT, V49, P517; REIMHERR FW, 1990, J CLIN PSYCHIAT, V51, P18; REIMHERR FW, 1984, PSYCHOPHARMACOL BULL, V20, P70; REIST C, 1989, AM J PSYCHIAT, V146, P513; RICKELS K, 1990, J CLIN PSYCHIAT, V51, P51; ROSENTHAL NE, 1984, ARCH GEN PSYCHIAT, V41, P72; Rosenthal NE, 1988, J BIOL RHYTHM, V3, P101, DOI 10.1177/074873048800300202; ROUNSAVILLE BJ, 1986, AM J PSYCHIAT, V143, P463; Roy-Byrne P.P., 1991, BENZODIAZEPINES CLIN; RUDORFER MV, 1989, DRUGS, V37, P713, DOI 10.2165/00003495-198937050-00006; SACKHEIM HA, 1990, REV PSYCHIATRY, V9, P91; SACKS M, 1992, HOSP COMMUNITY PSYCH, V43, P736; SACKS MH, 1990, HOSP COMMUNITY PSYCH, V41, P449; SARTORIUS N, 1992, IRISH J PSYCHOL MED, V9, P3, DOI 10.1017/S0790966700013811; SCHATZBERG AF, 1989, ARCH GEN PSYCHIAT, V46, P260; SCHERER MA, 1988, BIOL PSYCHIAT, V24, P865; SCHILDKRAUT JJ, 1978, ARCH GEN PSYCHIAT, V35, P1436; SCHMAUSS M, 1988, PROG NEURO-PSYCHOPH, V12, P523, DOI 10.1016/0278-5846(88)90111-X; SCHMITT FA, 1988, NEW ENGL J MED, V319, P1573, DOI 10.1056/NEJM198812153192404; SCHNEIER FR, 1990, J CLIN PSYCHOPHARM, V10, P119, DOI 10.1097/00004714-199004000-00007; SCHUCKIT MA, 1984, ARCH GEN PSYCHIAT, V41, P879; SCHUCKIT MA, 1985, ARCH GEN PSYCHIAT, V42, P375; SCHUCKIT MA, 1987, AM J PSYCHIAT, V144, P854; SCHUCKIT MA, 1987, ARCH GEN PSYCHIAT, V44, P942; SHEAR MK, 1991, AM J PSYCHIAT, V148, P795; SIMPSON GM, 1976, ARCH GEN PSYCHIAT, V33, P1093; SIMPSON SG, 1991, J CLIN PSYCHOPHARM, V11, P52; SMALL JG, 1988, ARCH GEN PSYCHIAT, V45, P727; SMALL JG, 1991, ARCH GEN PSYCHIAT, V48, P915; SOLOMON K, 1978, J CLIN PSYCHIAT, V39, P823; SPIKER DG, 1985, AM J PSYCHIAT, V142, P430; SPIKER DG, 1986, J CLIN PSYCHOPHARM, V6, P339; STARK P, 1985, J CLIN PSYCHIAT, V46, P53; STERN WC, 1983, J CLIN PSYCHIAT, V44, P148; STRATTA P, 1991, INT CLIN PSYCHOPHARM, V6, P193, DOI 10.1097/00004850-199100630-00007; SWEDO SE, 1989, ARCH GEN PSYCHIAT, V46, P518; SWENSON JR, 1989, GEN HOSP PSYCHIAT, V11, P248, DOI 10.1016/0163-8343(89)90070-4; WEHR TA, 1979, SCIENCE, V206, P710, DOI 10.1126/science.227056; WEHR TA, 1987, AM J PSYCHIAT, V144, P1403; WEHR TA, 1987, AM J PSYCHIAT, V144, P201; WEILBURG JB, 1989, J CLIN PSYCHIAT, V50, P447; 1987, DIAGNOSTIC STATISTIC; 1990, PRACTICE ELECTROCONV, P61; [No title captured]	183	43	43	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1993	329	9					628	638		10.1056/NEJM199308263290908	http://dx.doi.org/10.1056/NEJM199308263290908			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LU217	8129808				2022-12-28	WOS:A1993LU21700008
J	ELLIS, RW; DOUGLAS, RG				ELLIS, RW; DOUGLAS, RG			NEW VACCINE TECHNOLOGIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MOUSE MUSCLE; PERTUSSIS		MERCK & CO INC,MERCK VACCINE DIV,WHITE HOUSE STN,NJ	Merck & Company	ELLIS, RW (corresponding author), MERCK & CO INC,MERCK RES LABS,BLDG 16,ROOM 101,SUMNEYTOWN PIKE,W POINT,PA 19486, USA.							AGUADO MT, 1993, VACCINE, V11, P596, DOI 10.1016/0264-410X(93)90241-O; ALLISON AC, 1992, VACCINES NEW APPROAC, P431; BAKER JD, 1992, J PEDIATR-US, V121, P523, DOI 10.1016/S0022-3476(05)81138-2; CLEMENS JD, 1992, JAMA-J AM MED ASSOC, V267, P673, DOI 10.1001/jama.267.5.673; ELLIS RW, 1994, VACCINES, V2; PARADISO PR, 1993, PEDIATRICS, V92, P827; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363	9	16	19	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	1994	271	12					929	931		10.1001/jama.271.12.929	http://dx.doi.org/10.1001/jama.271.12.929			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA743	8120962				2022-12-28	WOS:A1994NA74300029
J	VOSSHALL, LB; PRICE, JL; SEHGAL, A; SAEZ, L; YOUNG, MW				VOSSHALL, LB; PRICE, JL; SEHGAL, A; SAEZ, L; YOUNG, MW			BLOCK IN NUCLEAR-LOCALIZATION OF PERIOD PROTEIN BY A 2ND CLOCK MUTATION, TIMELESS	SCIENCE			English	Article							MESSENGER-RNA LEVELS; MINDED GENE ENCODES; AH DIOXIN RECEPTOR; DROSOPHILA-MELANOGASTER; CIRCADIAN-RHYTHMS; DNA INTERACTIONS; VISUAL-SYSTEM; PRODUCT; TRANSLOCATION; EXPRESSION	In wild-type Drosophila, the period protein (PER) is found in nuclei of the eyes and brain, and PER immunoreactivity oscillates with a circadian rhythm. The studies described here indicate that the nuclear localization of PER is blocked by timeless (tim), a second chromosome mutation that, like per null mutations, abolishes circadian rhythms. PER fusion proteins without a conserved domain (PAS) and some flanking sequences are nuclear in tim mutants. This suggests that a segment of PER inhibits nuclear localization in firn mutants. The tim gene may have a role in establishing rhythms of PER abundance and nuclear localization in wild-type flies.	ROCKEFELLER UNIV,NATL SCI FDN SCI & TECHNOL CTR BIOL TIMING,HOWARD HUGHES MED INST,NEW YORK,NY 10021; ROCKEFELLER UNIV,GENET LAB,NEW YORK,NY 10021	Howard Hughes Medical Institute; National Science Foundation (NSF); Rockefeller University; Rockefeller University			, 机智的马小跳和机智的羊不愁/ABC-5169-2020	Vosshall, Leslie/0000-0002-6060-8099	NIGMS NIH HHS [GM07982-09] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAYLIES MK, 1992, NEURON, V9, P575, DOI 10.1016/0896-6273(92)90194-I; BAYLIES MK, 1993, MOL GENETICS BIOL RH, P123; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; COLOT HV, 1988, EMBO J, V7, P3929, DOI 10.1002/j.1460-2075.1988.tb03279.x; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EWER J, 1992, J NEUROSCI, V12, P3321; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; KARENLAMPI SO, 1988, J BIOL CHEM, V263, P10111; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU X, 1992, J NEUROSCI, V12, P2735; LIU X, 1991, NEURON, V6, P753, DOI 10.1016/0896-6273(91)90172-V; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; OKEY AB, 1980, J BIOL CHEM, V255, P1415; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; SAEZ L, 1988, MOL CELL BIOL, V8, P5378, DOI 10.1128/MCB.8.12.5378; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VOSSHALL LB, 1993, THESIS ROCKEFELLER U; VOSSHALL LB, UNPUB; ZERR DM, 1990, J NEUROSCI, V10, P2749; ZWIEBEL LJ, 1991, P NATL ACAD SCI USA, V88, P3882, DOI 10.1073/pnas.88.9.3882	32	289	305	3	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 18	1994	263	5153					1606	1609		10.1126/science.8128247	http://dx.doi.org/10.1126/science.8128247			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	8128247				2022-12-28	WOS:A1994NB67300030
J	TAN, KL; GOH, KT; OON, CJ; CHAN, SH				TAN, KL; GOH, KT; OON, CJ; CHAN, SH			IMMUNOGENICITY OF RECOMBINANT YEAST-DERIVED HEPATITIS-B VACCINE IN NONRESPONDERS TO PERINATAL IMMUNIZATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ENDEMIC AREA SENEGAL; ANTIBODY-RESPONSE; EFFICACY; ANTIGEN; TRANSMISSION; SINGAPORE; INFANTS; TRIAL	Objective.-Nonresponse to hepatitis B vaccine in the perinatal period occasionally occurs. This report documents the results of reimmunization of nonrespenders to perinatal immunization. Design.-From a cohort of 1154 infants immunized with plasma-based vaccine in the perinatal period and followed up for more than 8 years, 45 nonresponders were identified. These children were reimmunized at 4 years of age. Each child received a yeast-derived recombinant hepatitis B vaccine on a 0-, 1-, and 5-month schedule, 33 children with 10-mu g and 12 with 5-mu g doses. Blood was sampled 1 month after the third vaccination and thereafter at 1, 2, and 4 years. Setting.-The follow-up clinic where the cohort of children was regularly seen. Patients.-Forty-five 4-year-old children who had no antibody to hepatitis B despite perinatal immunization. Main Outcome Measure.-Antibody levels to hepatitis B surface antigen. Results.-Seroconversion with titers higher than 10 mlU/mL occurred in all children. More than 70% still had titers higher than 10 mlU/mL 4 years after vaccination. Conclusion.-Nonresponders to perinatal hepatitis B vaccination respond well to subsequent vaccination.	MINIST ENVIRONM,DEPT QUARANTINE & EPIDEMIOL,SINGAPORE,SINGAPORE; SINGAPORE GEN HOSP,DEPT CLIN RES,SINGAPORE,SINGAPORE; NATL UNIV SINGAPORE,DEPT MICROBIOL,SINGAPORE,SINGAPORE	Singapore General Hospital; National University of Singapore	TAN, KL (corresponding author), NATL UNIV SINGAPORE HOSP,DEPT NEONATOL,5 LOWER KENT RIDGE RD,SINGAPORE 0511,SINGAPORE.		Chan, Soh Ha/B-6709-2009					ALPER CA, 1989, NEW ENGL J MED, V321, P708, DOI 10.1056/NEJM198909143211103; CHAN SH, 1985, INT J EPIDEMIOL, V14, P173, DOI 10.1093/ije/14.1.173; COURSAGET P, 1986, LANCET, V2, P1143; EGEA E, 1991, J EXP MED, V173, P531, DOI 10.1084/jem.173.3.531; FLEWETT TH, 1986, BRIT MED J, V293, P404, DOI 10.1136/bmj.293.6544.404; INSKIP HM, 1991, INT J EPIDEMIOL, V20, P764, DOI 10.1093/ije/20.3.764; MAUPAS P, 1981, LANCET, V1, P289; OON CJ, 1986, J INFECTION, V13, P155; PROZESKY OW, 1983, J INFECTION, V7, P53, DOI 10.1016/S0163-4453(83)96649-5; SHIRAKI K, 1977, AM J DIS CHILD, V131, P644, DOI 10.1001/archpedi.1977.02120190038007; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; Stevens CE, 1988, VIRAL HEPATITIS LIVE, P982; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; TAN KL, 1990, ACTA PAEDIATR SCAND, V79, P593, DOI 10.1111/j.1651-2227.1990.tb11522.x; YAP EH, 1972, VOX SANG, V22, P371, DOI 10.1111/j.1423-0410.1972.tb03982.x; 1991, MMWR MORB MORTAL WKL, V40, P1; 1991, EPIDEMIOL NEWS B SIN, V17, P37; 1992, PEDIATRICS, V89, P795; 1992, EPIDEMIOL NEWS B SIN, V18, P39	19	25	28	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					859	861		10.1001/jama.271.11.859	http://dx.doi.org/10.1001/jama.271.11.859			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ498	8114241				2022-12-28	WOS:A1994MZ49800033
J	SCHNABEL, R				SCHNABEL, R			AUTONOMY AND NONAUTONOMY IN CELL FATE SPECIFICATION OF MUSCLE IN THE CAENORHABDITIS-ELEGANS EMBRYO - A RECIPROCAL INDUCTION	SCIENCE			English	Article							C-ELEGANS; GLP-1; GENE	EMS, a blastomere of the Caenorhabditis elegans embryo, produces body wall muscle cell-autonomously in isolation. Within the embryonic context, however, the specification of body wall muscle derived from EMS depends on inductive interactions between its daughter MS and ABa descendants that are required to overcome inhibitory interactions with other cells. The inductive events between the MS and ABa descendants are reciprocal, specifying subsequent fates in both lineages. Both induction events are blocked by mutations in the gene glp-1, known to encode a Notch-like transmembrane receptor protein.			SCHNABEL, R (corresponding author), MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY.							AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; COWAN AE, 1985, CELL, V41, P923, DOI 10.1016/S0092-8674(85)80073-8; GOH PY, 1991, DEVELOPMENT, V111, P667; GROBSTEIN C, 1955, J EXP ZOOL, V130, P319, DOI 10.1002/jez.1401300207; HUTTER H, UNPUB; KIMBLE J, 1992, COLD SPRING HARB SYM, V57, P401, DOI 10.1101/SQB.1992.057.01.045; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; SCHNABEL R, 1991, MECH DEVELOP, V34, P85, DOI 10.1016/0925-4773(91)90046-9; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4	15	41	42	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1449	1452		10.1126/science.8128230	http://dx.doi.org/10.1126/science.8128230			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128230				2022-12-28	WOS:A1994MZ92700036
J	IGLEHART, JK				IGLEHART, JK			HEALTH-CARE REFORM - THE ROLE OF PHYSICIANS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		KASSIRER JP, 1993, NEW ENGL J MED, V328, P1268, DOI 10.1056/NEJM199304293281710; LARKIN H, 1993, AM MED NEWS     1227, P11; LEVIT KR, 1993, HEALTH AFFAIR, V12, P7, DOI 10.1377/hlthaff.12.3.7; MEYER H, 1993, AM MED NEWS     0308, P1; MITKA M, 1994, AM MED NEWS     0110, P1; MORSE LJ, 1993, NEW ENGL J MED, V329, P804, DOI 10.1056/NEJM199309093291112; PEAR R, 1993, NY TIMES        1217, pA26; Pear Robert, 1994, NY TIMES        0507, P1; RELMAN AS, 1993, NEW ENGL J MED, V329, P1574, DOI 10.1056/NEJM199311183292113; STOUT H, 1994, WALL STREET J   0112, pB3; ZELMAN WA, 1994, HEALTH AFFAIR, V13, P9, DOI 10.1377/hlthaff.13.1.9	11	7	7	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 10	1994	330	10					728	731		10.1056/NEJM199403103301028	http://dx.doi.org/10.1056/NEJM199403103301028			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY575	8107738				2022-12-28	WOS:A1994MY57500035
J	YUAN, Y; ALTMAN, S				YUAN, Y; ALTMAN, S			SELECTION OF GUIDE SEQUENCES THAT DIRECT EFFICIENT CLEAVAGE OF MESSENGER-RNA BY HUMAN RIBONUCLEASE-P	SCIENCE			English	Article							RNASE-P; TARGETED CLEAVAGE; MESSENGER-RNA; INVITRO; ENZYME; TETRAHYMENA; EVOLUTION; RIBOZYMES	Any RNA, when in a complex with another oligoribonucleotide known as an external guide sequence (EGS), can become a substrate for ribonuclease P. Simulation of evolution in vitro was used to select EGSs that bind tightly to a target substrate messenger RNA and that increase the efficiency of cleavage of the target by human ribonuclease P to a level equal to that achieved with natural substrates. The most efficient EGSs form transfer RNA precursor-like structures with the target RNA, in which the analog of the anticodon stem has been disrupted, an indication that selection for the optimal substrate for ribonuclease P yields an RNA structure different from that of present-day transfer RNA precursors.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520	Yale University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031876] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019422, R37GM019422] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31876] Funding Source: Medline; NIGMS NIH HHS [GM19422] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN S, 1990, J BIOL CHEM, V265, P20053; ALTMAN S, 1974, BROOKHAVEN S BIOL, V26, P12; ALTMAN S, 1988, STRUCTURE FUNCTION M, P183; BARTKIEWICZ M, 1989, GENE DEV, V3, P488, DOI 10.1101/gad.3.4.488; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; DARR SC, 1992, TRENDS BIOCHEM SCI, V17, P178, DOI 10.1016/0968-0004(92)90262-8; DOERSEN CJ, 1985, J BIOL CHEM, V260, P5942; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; INOKUCHI H, COMMUNICATION; LI Y, 1992, P NATL ACAD SCI USA, V89, P3185, DOI 10.1073/pnas.89.8.3185; LI Y, UNPUB; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; RICH A, 1976, ANNU REV BIOCHEM, V45, P805, DOI 10.1146/annurev.bi.45.070176.004105; SMITH JD, 1974, BROOKHAVEN SYM BIOL, V26, P1; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; YUAN Y, 1992, P NATL ACAD SCI USA, V89, P8006, DOI 10.1073/pnas.89.17.8006; YUAN YC, UNPUB	22	84	118	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 4	1994	263	5151					1269	1273		10.1126/science.8122108	http://dx.doi.org/10.1126/science.8122108			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	8122108				2022-12-28	WOS:A1994MY57000033
J	GINOCCHIO, CC; OLMSTED, SB; WELLS, CL; GALAN, JE				GINOCCHIO, CC; OLMSTED, SB; WELLS, CL; GALAN, JE			CONTACT WITH EPITHELIAL-CELLS INDUCES THE FORMATION OF SURFACE APPENDAGES ON SALMONELLA-TYPHIMURIUM	CELL			English	Article							MAMMALIAN-CELLS; MOLECULAR CHARACTERIZATION; ESCHERICHIA-COLI; GROWTH-FACTORS; A431 CELLS; INVASION; IDENTIFICATION; REORGANIZATION; FIBROBLASTS; PENETRATION	The enteric bacteria Salmonella typhimurium has the ability to invade (enter) nonphagocytic cells. The internalization process occurs as a result of an intimate interaction between the bacteria and the host cell, in which S. typhimurium triggers a cascade of host cell-signaling events leading to the formation of host cell membrane ruffles and bacterial uptake. Using high resolution scanning electron microscopy, we have observed that contact with cultured epithelial cells results in the formation of appendages on the surface of S. typhimurium. The formation of such appendages did not require de novo protein synthesis, and it was transient, since these surface structures were no longer present on bacteria that had initiated the internalization event. Salmonella mutants defective in the transient formation of these surface organelles were unable to enter into cultured epithelial cells, indicating that such structures are required for bacterial internalization.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023484, R37AI030492, R23AI023484, R29AI023484, R29AI030492, R01AI030492] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30492, AI23484] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAOUI A, 1993, MOL MICROBIOL, V7, P759; Allen Terence D., 1993, Trends in Cell Biology, V3, P205, DOI 10.1016/0962-8924(93)90215-M; ALTMEYER RM, 1993, MOL MICROBIOL, V7, P89, DOI 10.1111/j.1365-2958.1993.tb01100.x; ANDERSON TF, 1951, T NEW YORK ACAD SCI, V13, P130, DOI 10.1111/j.2164-0947.1951.tb01007.x; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; EISENSTEIN BI, 1987, CELLULAR MOL BIOL, P84; ELSINGHORST EA, 1989, P NATL ACAD SCI USA, V86, P5173, DOI 10.1073/pnas.86.13.5173; ERNST RK, 1990, INFECT IMMUN, V58, P2014, DOI 10.1128/IAI.58.6.2014-2016.1990; FALKOW S, 1992, ANNU REV CELL BIOL, V8, P333, DOI 10.1146/annurev.cb.08.110192.002001; FENSELAU S, 1992, MOL PLANT MICROBE IN, V5, P390, DOI 10.1094/MPMI-5-390; FINLAY BB, 1990, J INFECT DIS, V162, P1096, DOI 10.1093/infdis/162.5.1096; FINLAY BB, 1989, SCIENCE, V243, P940, DOI 10.1126/science.2919285; FINLAY BB, 1988, J CELL BIOL, V107, P221, DOI 10.1083/jcb.107.1.221; FRANCIS CL, 1992, MOL MICROBIOL, V6, P3077, DOI 10.1111/j.1365-2958.1992.tb01765.x; GALAN JE, 1990, INFECT IMMUN, V58, P1879; GALAN JE, 1992, NATURE, V357, P588, DOI 10.1038/357588a0; GALAN JE, 1992, J BACTERIOL, V174, P4338; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; GIRON JA, 1991, SCIENCE, V254, P710, DOI 10.1126/science.1683004; GOUGH CL, 1993, MOL GEN GENET, V239, P378, DOI 10.1007/BF00276936; HE SY, 1993, CELL, V73, P1255, DOI 10.1016/0092-8674(93)90354-S; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KIHLSTROM E, 1976, INFECT IMMUN, V14, P851; LEE CA, 1992, P NATL ACAD SCI USA, V89, P1847, DOI 10.1073/pnas.89.5.1847; LEE CA, 1990, P NATL ACAD SCI USA, V87, P4304, DOI 10.1073/pnas.87.11.4304; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; MACBETH KJ, 1993, INFECT IMMUN, V61, P1544, DOI 10.1128/IAI.61.4.1544-1546.1993; MACNAB RM, 1987, CELLULAR MOL BIOL, P70; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; MIYATA Y, 1989, EXP CELL RES, V175, P286; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RIJKEN PJ, 1991, J CELL SCI, V100, P491; SANSONETTI PJ, 1992, CURR TOP MICROBIOL, V180, P1; SCHNEIDER HA, 1956, J EXP MED, V103, P207, DOI 10.1084/jem.103.2.207; STONE BJ, 1992, J BACTERIOL, V174, P3945, DOI 10.1128/jb.174.12.3945-3952.1992; STRALEY SC, 1993, INFECT IMMUN, V61, P3105, DOI 10.1128/IAI.61.8.3105-3110.1993; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; VENKATESAN MM, 1992, J BACTERIOL, V174, P1990, DOI 10.1128/jb.174.6.1990-2001.1992; VITANEN AM, 1990, J BACTERIOL, V172, P3152; VOGLER AP, 1991, J BACTERIOL, V173, P3564, DOI 10.1128/jb.173.11.3564-3572.1991	48	231	237	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 25	1994	76	4					717	724		10.1016/0092-8674(94)90510-X	http://dx.doi.org/10.1016/0092-8674(94)90510-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124710				2022-12-28	WOS:A1994MZ28500013
J	SWISHER, CC; CURTIS, GH; JACOB, T; GETTY, AG; SUPRIJO, A				SWISHER, CC; CURTIS, GH; JACOB, T; GETTY, AG; SUPRIJO, A			AGE OF THE EARLIEST KNOWN HOMINIDS IN JAVA, INDONESIA	SCIENCE			English	Article							KENYA; CALIBRATION; CONSTANTS; BOUNDARY	40Ar/39Ar laser-incremental heating of hornblende separated from pumice recovered at two hominid sites in Java, Indonesia, has yielded well-defined plateaus with weighted mean ages of 1.81 +/- 0.04 and 1.66 +/- 0.04 million years ago (Ma). The hominid fossils, a juvenile calvaria of Pithecanthropus and a partial face and cranial fragments of Meganthropus, commonly considered part of the Asian Homo erectus hypodigm, are at least 0.6 million years older than fossils referred to as Homo erectus (OH-9) from Olduvai Gorge, Tanzania, and comparable in age with the oldest Koobi Fora Homo cf. erectus (Homo ergaster) in Kenya. These ages lend further credence to the view that Homo erectus may have evolved outside of Africa. If the ancestor of Homo erectus ventured out of Africa before 1.8 Ma, the dispersal would have predated the advent of the Acheulean culture at 1.4 Ma, possibly explaining the absence of these characteristic stone cleavers and hand axes in East Asia.	GADJAH MADA UNIV, FAC MED, BIOL & PALEOANTHROPOL LAB, YOGYAKARTA, INDONESIA	Gadjah Mada University	SWISHER, CC (corresponding author), INST HUMAN ORIGINS, CTR GEOCHRONOL, 2453 RIDGE RD, BERKELEY, CA 94709 USA.							Andrews P., 1984, Courier Forschungsinstitut Senckenberg, V69, P167; ANDREWS P, 1984, NEW SCI, V102, P24; ASFAW B, 1992, NATURE, V360, P732, DOI 10.1038/360732a0; BASU AR, 1993, SCIENCE, V261, P902, DOI 10.1126/science.261.5123.902; BROCA P, 1865, RELIQUIAE ACQUITANIC, P97; Campbell B.G., 1964, CLASSIFICATION HUMAN, P50; CANDE SC, 1992, J GEOPHYS RES-SOL EA, V97, P13917, DOI 10.1029/92JB01202; Cebula G.T., 1986, TERRA COGNITA, V6, P139; DALRYMPLE GB, 1979, GEOLOGY, V7, P558, DOI 10.1130/0091-7613(1979)7<558:CTFCOK>2.0.CO;2; DAY MH, 1986, GUIDE FOSSIL MAN; de Vos J., 1985, P215; DEINO A, 1990, J GEOPHYS RES-SOLID, V95, P8453, DOI 10.1029/JB095iB06p08453; DEINO A, 1990, J GEOL, V98, P567, DOI 10.1086/629425; Dubois E, 1892, VERSL MIJNW BATAVIA, V3, P10; DUBOIS E, 1894, BATAVIA LANDESDRUCKE; Dubois E, 1895, B SOC BELG GEOL, V9, P151; DUYFJES J, 1936, INGENIEUR NED INDIE, V3, P136; DUYFJES J, 1938, DIENST V D MIJN NED, V1, P1; FEIBEL CS, 1989, AM J PHYS ANTHROPOL, V78, P595, DOI 10.1002/ajpa.1330780412; FLECK RJ, 1977, GEOCHIM COSMOCHIM AC, V41, P15, DOI 10.1016/0016-7037(77)90184-3; Franzen J.L., 1985, P221; Howell F.C., 1978, P154; HYODO M, 1993, ANTHROPOL SCI, V101, P157, DOI 10.1537/ase.101.157; ITIHARA M, 1985, GEOLOGICAL RES DEV C, V4, P11; JACOB T, 1973, J HUM EVOL, V2, P473, DOI 10.1016/0047-2484(73)90125-5; JACOB T, 1980, CURRENT ARGUMENT EAR, P170; JACOB T, 1971, CONTRIB U CALIF ARCH, V11, P50; King William, 1864, Q J SCI, V1, P88; KUMAI H, 1985, GEOL RES DEV CTR SPE, V4, P55; LEAKEY LS, 1961, NATURE, V191, P478, DOI 10.1038/191478a0; LEAKEY M D, 1971, P306; MATSUURA S, 1986, 10TH P C INT PRIM SO, V1, P115; Movius H.L., 1948, T AM PHILOS SOC, V38, P329; NINKOVICH D, 1978, NATURE, V275, P306, DOI 10.1038/275306a0; Orchiston D.W., 1982, Modern Quaternary Research in Southeast Asia, V7, P131; Pope G.G., 1985, Modern Quaternary Research in Southeast Asia, V9, P65; POPE GG, 1988, ANNU REV ANTHROPOL, V17, P43; POPE GG, 1984, EVOLUTION E ASIAN EN, V1, P822; RENNE PR, 1991, SCIENCE, V253, P176, DOI 10.1126/science.253.5016.176; Rightmire G. P., 1990, EVOLUTION HOMO ERECT; SAMSON SD, 1987, CHEM GEOL, V66, P27, DOI 10.1016/0168-9622(87)90025-X; Sartono S., 1978, Modern Quaternary Research in Southeast Asia, V4, P19; Sartono S., 1981, Modern Quaternary Research in Southeast Asia, V6, P91; Sartono S., 1985, Modern Quaternary Research in Southeast Asia, V9, P115; SARTONO S, 1982, C INT PALEONTOLOGIE, P491; SARTONO S, 1984, MOD QUAT RES SE ASIA, V8, P129; SEMAH F, 1981, ANTHROPOLOGIE, V85-6, P509; Semah F., 1982, MOD QUATERNARY RES S, V7, P151; SEMAH F, 1982, C INT PALEONTOLOGIE, P542; SEMAH F, 1981, MQRSEA, V6, P103; SHIMIZU Y, 1985, GEOLOGICAL RES DEV C, V4, P275; STEIGER RH, 1977, EARTH PLANET SC LETT, V36, P359, DOI 10.1016/0012-821X(77)90060-7; Stringer C., 1984, HOMININD EVOLUTION C, P55; Stringer C. B., 1981, ANTHROPOLOGIE BRNO, V19, P3; SWISHER CC, 1990, SCIENCE, V249, P760, DOI 10.1126/science.249.4970.760; SWISHER CC, 1992, SCIENCE, V257, P954, DOI 10.1126/science.257.5072.954; SWISHER CC, UNPUB; Taylor JR., 1982, INTRO ERROR ANAL, V2nd edition; VONKOENIGSWALD GHR, 1936, INGENIEUR NED INDIE, V8, P149; VONKOENIGSWALD GHR, 1969, 8 P INT C ANTHR ETHN, V1, P104; Weidenreich F, 1940, AM ANTHROPOL, V42, P375, DOI 10.1525/aa.1940.42.3.02a00010; WOOD B, 1992, NATURE, V355, P783, DOI 10.1038/355783a0; Wood B., 1991, HOMINID CRANIAL REMA, V4	63	359	370	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 25	1994	263	5150					1118	1121		10.1126/science.8108729	http://dx.doi.org/10.1126/science.8108729			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	8108729				2022-12-28	WOS:A1994MX75900026
J	RAUMANN, BE; ROULD, MA; PABO, CO; SAUER, RT				RAUMANN, BE; ROULD, MA; PABO, CO; SAUER, RT			DNA RECOGNITION BY BETA-SHEETS IN THE ARC REPRESSOR-OPERATOR CRYSTAL-STRUCTURE	NATURE			English	Article							MOLECULAR-DYNAMICS; BINDING; REFINEMENT	TRANSCRIPTION of the ant gene during lytic growth of bacteriophage P22 (ref. 1) is regulated by the cooperative binding of two Arc repressor dimers to a 21-base-pair operator site2,3. Here we report the co-crystal structure of this Arc tetramer-operator complex at 2.6 angstrom resolution. As expected from genetic4-6 and structural studies7 and from the co-crystal structure of the homologous Escherichia coli MetJ repressor8, each Arc dimer uses an antiparallel beta-sheet to recognize bases in the major groove. However, the Arc and MetJ complexes differ in several important ways: the beta-sheet-DNA interactions of Arc are far less symmetrical; DNA binding by Arc is accompanied by important conformational changes in the beta-sheet; and Arc uses a different part of its protein surface for dimer-dimer interactions.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	RAUMANN, BE (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.			Sauer, Robert/0000-0002-1719-5399				BOWIE JU, 1989, P NATL ACAD SCI USA, V86, P2152, DOI 10.1073/pnas.86.7.2152; BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; BROWN BM, 1993, BIOCHEMISTRY-US, V32, P1354, DOI 10.1021/bi00056a022; BROWN BM, 1990, BIOCHEMISTRY-US, V29, P11189, DOI 10.1021/bi00503a006; BROWN BM, IN PRESS NATURE STRU; BRUNGER A, 1992, X PLOR V3 1 MANUAL; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KNIGHT KL, 1989, P NATL ACAD SCI USA, V86, P797, DOI 10.1073/pnas.86.3.797; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; RAVISHANKER G, 1989, J BIOMOL STRUCT DYN, V6, P669, DOI 10.1080/07391102.1989.10507729; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; SUSSKIND MM, 1983, LAMBDA, V2, P347; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VERSHON A K, 1986, Proteins Structure Function and Genetics, V1, P302, DOI 10.1002/prot.340010404; VERSHON AK, 1987, J MOL BIOL, V195, P323, DOI 10.1016/0022-2836(87)90653-X; VERSHON AK, 1989, J BIOL CHEM, V264, P3267; 1979, SERC4 DAR LAB COLL C	20	259	264	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					754	757		10.1038/367754a0	http://dx.doi.org/10.1038/367754a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	8107872				2022-12-28	WOS:A1994MX63100063
J	ELLIOTT, BJ; POLKINHORN, JS				ELLIOTT, BJ; POLKINHORN, JS			PROVISION OF CONSUMER HEALTH INFORMATION IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							WAITING AREA		THE SURGERY,WICKHAMBROOK CB8 8XU,SUFFOLK,ENGLAND; NEWNHAM COLL,CAMBRIDGE CB3 9RF,CAMBS,ENGLAND	University of Cambridge								COLLINGS LH, 1991, BRIT J GEN PRACT, V41, P466; KOPERSKI M, 1989, J ROY COLL GEN PRACT, V39, P328; PHILIP R, 1990, J ROY SOC HLTH, V1, P10; STANLEY I, 1991, BRIT J GEN PRACT, V41, P499; VARNAVIDES CK, 1984, BRIT MED J, V288, P535, DOI 10.1136/bmj.288.6416.535	5	5	5	2	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	1994	308	6927					509	510		10.1136/bmj.308.6927.509	http://dx.doi.org/10.1136/bmj.308.6927.509			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MX814	8136669	Green Published			2022-12-28	WOS:A1994MX81400022
J	MINOR, DL; KIM, PS				MINOR, DL; KIM, PS			MEASUREMENT OF THE BETA-SHEET-FORMING PROPENSITIES OF AMINO-ACIDS	NATURE			English	Article							COIL STABILITY-CONSTANTS; STREPTOCOCCAL PROTEIN-G; N-15 NMR; HELIX; TENDENCIES; WATER	SEVERAL model systems have been used to evaluate the alpha-helical propensities of different amino acids(1-7). In contrast, experimental quantitation of beta-sheet preferences has been addressed in only one model system, a zinc-finger peptide(8). Here we measure the relative propensity for beta-sheet formation of the twenty naturally occurring amino acids in a variant of the small, monomeric, beta-sheet-rich, IgG-binding domain from protein G. Amino-acid substitutions were made at a guest site on the solvent-exposed surface of the beta-sheet. Several criteria were used to establish that the mutations did not cause significant structural changes: binding to the Fc domain of IgG, calorimetric unfolding and NMR spectroscopy. Characterization of the thermal stabilities of these proteins leads to a thermodynamic scale for beta-sheet propensities that spans a range of similar to 2 kcal mol(-1) for the naturally occurring amino acids, excluding proline. The magnitude of the differences suggests that beta-sheet preferences can be important determinants of protein stability.	MIT,HOWARD HUGHES MED INST,WHITEHEAD INST BIOMED RES,DEPT BIOL,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute	MINOR, DL (corresponding author), MIT,HOWARD HUGHES MED INST,WHITEHEAD INST BIOMED RES,DEPT CHEM,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; CHAKRABARTTY A, 1993, BIOCHEMISTRY-US, V32, P5560, DOI 10.1021/bi00072a010; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; DEMARCO A, 1977, J MAGN RESON, V26, P527, DOI 10.1016/0022-2364(77)90104-4; DOERING D, 1992, FUNCTIONAL STRUCTURA; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FAHNESTOCK SR, 1986, J BACTERIOL, V167, P870, DOI 10.1128/jb.167.3.870-880.1986; FAHNESTOCK SR, 1990, BACTERIAL IMMUNOGLOB; GRONENBORN AM, 1991, SCIENCE, V253, P657, DOI 10.1126/science.1871600; HARLOW E, 1988, ANTIBODIES LABORATOR; HOROVITZ A, 1992, J MOL BIOL, V227, P560, DOI 10.1016/0022-2836(92)90907-2; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MCINTOSH LP, 1990, BIOCHEMISTRY-US, V29, P6341, DOI 10.1021/bi00479a003; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; Sambrook J, 1989, MOL CLONING LABORATO; SCHERAGA HA, 1978, PURE APPL CHEM, V50, P315, DOI 10.1351/pac197850040315; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VILLEUMIER S, 1993, BIOCHEMISTRY-US, V32, P10303; WOJCIK J, 1990, BIOPOLYMERS, V30, P121, DOI 10.1002/bip.360300113; Wuthrich K., 1986, NMR PROTEINS NUCL AC	29	545	566	2	85	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 17	1994	367	6464					660	663		10.1038/367660a0	http://dx.doi.org/10.1038/367660a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	8107853				2022-12-28	WOS:A1994MW68800059
J	HEILBRON, JL; BYNUM, WF				HEILBRON, JL; BYNUM, WF			1894 AND ALL THAT	NATURE			English	Editorial Material									WELLCOME INST HIST MED,LONDON NW1 2BE,ENGLAND	University of London; University College London	HEILBRON, JL (corresponding author), UNIV CALIF BERKELEY,BERKELEY,CA 94720, USA.							CONDORCET, ESQUISSE TABLEAU HIS; Descartes, 1644, PRINCIPIA PHILOS; Galileo, 1632, DIALOGO; GILBERT W, 1600, MAGNETE; GODDARD RH, METHOD REACHING EXTR; KRAUSS F, HOHLENKUNDE; PENCK A, MORPHOLOGIE ERDOBERF; RUSSELL B, INTRO PHILOS MATH; SOMMERFELD A, ATOMBAU SPEKTRALLINI; Stifel M, 1544, ARITHMETICA INTEGRA; STRUTT JW, THEORY SOUND; Torricelli E., 1644, OPERA GEOMETRICA	12	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 6	1994	367	6458					11	14		10.1038/367011a0	http://dx.doi.org/10.1038/367011a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	8107763				2022-12-28	WOS:A1994MP86500024
J	MCLAURIN, KE; SENANAYAKE, P; TOUBIA, N; LADIPO, OA				MCLAURIN, KE; SENANAYAKE, P; TOUBIA, N; LADIPO, OA			POSTABORTION FAMILY-PLANNING - REVERSING A LEGACY OF NEGLECT	LANCET			English	Editorial Material									POPULAT COUNCIL,NEW YORK,NY; SOUTH TO SOUTH COOPERAT REPRODUCT HLTH,BAHLA,BRAZIL; INT PLANNED PARENTHOOD FEDERAT,LONDON SW1Y 4PW,ENGLAND	Population Council	MCLAURIN, KE (corresponding author), IPAS,POB 100,CARRBORO,NC 27510, USA.							MCLAURIN KE, M WOMENS NEEDS POST	1	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1099	1100		10.1016/0140-6736(93)92070-A	http://dx.doi.org/10.1016/0140-6736(93)92070-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ME822	8105318				2022-12-28	WOS:A1993ME82200016
J	TANENBAUM, SJ				TANENBAUM, SJ			WHAT PHYSICIANS KNOW	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MEDICAL-CARE; HEALTH-CARE; EXPERIENCE				TANENBAUM, SJ (corresponding author), OHIO STATE UNIV,COLL MED,COLUMBUS,OH 43210, USA.							ARMSTRONG D, 1977, SOC SCI MED, V11, P599, DOI 10.1016/0037-7856(77)90041-5; BERESFORD EB, 1991, HASTINGS CENT REP, V21, P6, DOI 10.2307/3562993; BROWN LD, 1992, HEALTH AFFAIR, V11, P17, DOI 10.1377/hlthaff.11.4.17; Bursztajn HJ, 1981, MED CHOICES MED CHAN; CAPER P, 1988, NEW ENGL J MED, V318, P1535, DOI 10.1056/NEJM198806093182310; Cassell EJ, 1991, NATURE SUFFERING GOA; Dreyfus H.L., 1986, MIND MACHINE POWER H; Eddy D M, 1984, Health Aff (Millwood), V3, P74, DOI 10.1377/hlthaff.3.2.74; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P877; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; EPSTEIN AM, 1990, NEW ENGL J MED, V323, P266, DOI 10.1056/NEJM199007263230410; GARNICK DW, 1991, JAMA-J AM MED ASSOC, V266, P2856, DOI 10.1001/jama.266.20.2856; Gordon DR., 1988, BIOMEDICINE EXAMINED, P257; GOROVITZ S, 1976, J MED PHILOS, V1, P51, DOI 10.1093/jmp/1.1.51; GRAY BH, 1992, HEALTH AFFAIR, V11, P38, DOI 10.1377/hlthaff.11.4.38; GRUMBACH K, 1990, HEALTH AFFAIR, V9, P120, DOI 10.1377/hlthaff.9.4.120; GRUMET GW, 1989, NEW ENGL J MED, V321, P607, DOI 10.1056/NEJM198908313210909; HUNTER KM, 1986, PERSPECT BIOL MED, V29, P619; LEE PR, 1989, LANCET, V1, P263; Polanyi M., 1975, MEANING; RELMAN AS, 1988, NEW ENGL J MED, V319, P1220, DOI 10.1056/NEJM198811033191810; TANENBAUM SJ, IN PRESS J HLTH POLI; TOULMIN S, 1976, J MED PHILOS, V1, P32, DOI 10.1093/jmp/1.1.32; WARTOFSKY MW, 1986, J MED PHILOS, V11, P81, DOI 10.1093/jmp/11.1.81; WELLSTONE PD, 1993, NEW ENGL J MED, V328, P1489, DOI 10.1056/NEJM199305203282013; Wennberg J E, 1984, Health Manage Q, P6, DOI 10.1377/hlthaff.3.2.6; Wulff HR, 1990, PHILOS MED INTRO; 1992, JAMA-J AM MED ASSOC, V268, P2420; 1992, GUIDELINES CLIN PRAC	29	169	173	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1993	329	17					1268	1271		10.1056/NEJM199310213291713	http://dx.doi.org/10.1056/NEJM199310213291713			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MB988	8123111				2022-12-28	WOS:A1993MB98800013
J	CARMELIET, P; SCHOONJANS, L; KIECKENS, L; REAM, B; DEGEN, J; BRONSON, R; DEVOS, R; VANDENOORD, JJ; COLLEN, D; MULLIGAN, RC				CARMELIET, P; SCHOONJANS, L; KIECKENS, L; REAM, B; DEGEN, J; BRONSON, R; DEVOS, R; VANDENOORD, JJ; COLLEN, D; MULLIGAN, RC			PHYSIOLOGICAL CONSEQUENCES OF LOSS OF PLASMINOGEN-ACTIVATOR GENE-FUNCTION IN MICE	NATURE			English	Article							UROKINASE-TYPE; MESSENGER-RNA; TISSUE; MOUSE; LOCALIZATION; INHIBITOR; FIBRINOLYSIS; DEGRADATION; TROPHOBLAST; MECHANISMS	Indirect evidence suggests a crucial role for the fibrinolytic system and its physiological triggers, tissue-type (t-PA) and urokinase-type (u-PA) plasminogen activator, in many proteolytic processes. Inactivation of the t-PA gene impairs clot lysis and inactivation of the u-PA gene results in occasional fibrin deposition. Mice with combined t-PA and u-PA deficiency suffer extensive spontaneous fibrin deposition, with its associated effects on growth, fertility and survival.	CATHOLIC UNIV LEUVEN, CTR MOLEC & VASC BIOL, B-3000 LOUVAIN, BELGIUM; MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA; UNIV CINCINNATI, CHILDRENS HOSP RES FDN, CINCINNATI, OH 45229 USA; TUFTS UNIV, SCH VET MED, BOSTON, MA 02111 USA; CATHOLIC UNIV LEUVEN, HISTO & CYTOCHEM LAB, B-3000 LOUVAIN, BELGIUM	KU Leuven; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Tufts University; KU Leuven			Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821; Neugeboren, Beverly/0000-0003-3127-9369				ASTRUP T, 1952, ARCH BIOCHEM BIOPHYS, V40, P346, DOI 10.1016/0003-9861(52)90121-5; ASTRUP T, 1987, PROGR CHEM FIBRINOLY, V3, P1; BAKER MS, 1990, CANCER RES, V50, P4676; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BUSSO N, 1989, J BIOL CHEM, V264, P7455; CANIPARI R, 1987, J CELL BIOL, V105, P977, DOI 10.1083/jcb.105.2.977; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; COLLEN D, 1991, BLOOD, V78, P3114; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P8270, DOI 10.1021/bi00399a038; Denker H W, 1977, Adv Anat Embryol Cell Biol, V53, P3; FREYRIA AM, 1991, COMP BIOCHEM PHYS A, V99, P517, DOI 10.1016/0300-9629(91)90125-V; GRANELLIPIPERNO A, 1977, J EXP MED, V146, P1693, DOI 10.1084/jem.146.6.1693; HUARTE J, 1985, CELL, V43, P551, DOI 10.1016/0092-8674(85)90184-9; HUARTE J, 1987, J CELL BIOL, V104, P1281, DOI 10.1083/jcb.104.5.1281; IDELL S, 1989, J CLIN INVEST, V84, P695, DOI 10.1172/JCI114217; Juhan-Vague I, 1992, Ann Epidemiol, V2, P427; KLUFT C, 1988, TISSUE TYPE PLASMINO, V1, P47; LALA PK, 1990, CANCER METAST REV, V9, P369, DOI 10.1007/BF00049525; MENOUD PA, 1989, ROUX ARCH DEV BIOL, V198, P219, DOI 10.1007/BF00375908; MORIOKA S, 1987, J INVEST DERMATOL, V88, P418, DOI 10.1111/1523-1747.ep12469754; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NILSSON IM, 1985, BRIT MED J, V290, P1453, DOI 10.1136/bmj.290.6480.1453; OSSOWSKI L, 1979, CELL, V16, P929, DOI 10.1016/0092-8674(79)90108-9; PENG F, 1990, J BIOL CHEM, V265, P2022; RICKLES RJ, 1988, J BIOL CHEM, V263, P1563; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; STASSEN JM, 1990, FIBRINOLYSIS, V4, P15, DOI 10.1016/0268-9499(90)90349-O; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; TOMOOKA S, 1992, KIDNEY INT, V42, P1462, DOI 10.1038/ki.1992.442; TSAFRIRI A, 1989, ENDOCRINOLOGY, V124, P415, DOI 10.1210/endo-124-1-415; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UNKELESS JC, 1974, J EXP MED, V139, P834, DOI 10.1084/jem.139.4.834; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; VERHEIJEN JH, 1984, THROMB HAEMOSTASIS, V51, P392; WAGNER EF, 1990, EMBO J, V9, P3025, DOI 10.1002/j.1460-2075.1990.tb07498.x	38	914	939	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	1994	368	6470					419	424		10.1038/368419a0	http://dx.doi.org/10.1038/368419a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	8133887				2022-12-28	WOS:A1994ND12000052
J	FRECHET, JMJ				FRECHET, JMJ			FUNCTIONAL POLYMERS AND DENDRIMERS - REACTIVITY, MOLECULAR ARCHITECTURE, AND INTERFACIAL ENERGY	SCIENCE			English	Article							CONVERGENT-GROWTH APPROACH; DENDRITIC MACROMOLECULES; STARBURST DENDRIMERS; BLENDS; COPOLYMERS; MICELLES; MISCIBILITY; POLYESTERS; CHEMISTRY; BEHAVIOR	The interaction of polymers with their environment depends largely on the functional groups they carry. Interfaces between different polymers or between polymers and other surfaces can be strengthened through the design of molecular interactions such as hydrogen bonding and through the control of polymer architecture. The placement of functional groups at polymer chain ends or in well-defined segments can determine the ultimate properties. Three-dimensional synthetic polymers such as dendrimers can be fashioned to encapsulate reactive sites or provide highly controlled surfaces and interfaces.			FRECHET, JMJ (corresponding author), CORNELL UNIV,DEPT CHEM,BAKER LAB,ITHACA,NY 14853, USA.		FRECHET, Jean M/P-1497-2016	Frechet, Jean/0000-0001-6419-0163	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044885] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 44885-04] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN HR, 1991, MACROMOLECULES, V24, P2752, DOI 10.1021/ma00010a018; BROWN HR, 1989, NATURE, V341, P221, DOI 10.1038/341221a0; CAMINATI G, 1990, J AM CHEM SOC, V112, P8515, DOI 10.1021/ja00179a041; DAI K, UNPUB; de Gennes P. G., 1983, J PHYS LETT, V44, P351, DOI DOI 10.1051/IPHYSLET:01983004409035100; DEMEFTAHI MV, 1988, POLYMER, V29, P477, DOI 10.1016/0032-3861(88)90366-7; GIBSON HW, 1993, ADV MATER, V5, P11, DOI 10.1002/adma.19930050103; GITSOV I, 1993, MACROMOLECULES, V26, P6536, DOI 10.1021/ma00076a035; GITSOV I, 1992, ANGEW CHEM INT EDIT, V31, P1200, DOI 10.1002/anie.199212001; GITSOV I, 1993, MACROMOLECULES, V26, P5621, DOI 10.1021/ma00073a014; GOPIDAS KR, 1991, J AM CHEM SOC, V113, P7335, DOI 10.1021/ja00019a034; HAWKER CJ, 1991, J AM CHEM SOC, V113, P4583, DOI 10.1021/ja00012a030; HAWKER CJ, 1990, J AM CHEM SOC, V112, P7638, DOI 10.1021/ja00177a027; HAWKER CJ, 1992, J CHEM SOC PERK T 1, P2459, DOI 10.1039/p19920002459; HAWKER CJ, 1993, J CHEM SOC PERK T 1, P1287, DOI 10.1039/p19930001287; HAWKER CJ, 1992, J AM CHEM SOC, V114, P8405, DOI 10.1021/ja00048a009; HAWKER CJ, 1992, POLYMER, V33, P1507, DOI 10.1016/0032-3861(92)90128-J; HAWKER CJ, 1993, J AM CHEM SOC, V115, P4375, DOI 10.1021/ja00063a071; HAWKER CJ, 1990, MACROMOLECULES, V23, P4726, DOI 10.1021/ma00223a036; JIANG M, 1991, PROG POLYM SCI, V16, P977; JIN RH, 1993, J CHEM SOC CHEM COMM, P1260, DOI 10.1039/c39930001260; KIM YH, 1992, MACROMOLECULES, V25, P5561, DOI 10.1021/ma00047a001; KIM YH, 1990, J AM CHEM SOC, V112, P4592, DOI 10.1021/ja00167a094; LEE JY, 1988, MACROMOLECULES, V21, P954, DOI 10.1021/ma00182a019; Legge N. R., 1987, THERMOPLASTIC ELASTO; LESCANEC RL, 1990, MACROMOLECULES, V23, P2280, DOI 10.1021/ma00210a026; MILLER TM, 1992, J AM CHEM SOC, V114, P1018, DOI 10.1021/ja00029a034; Morrison N. J., 1989, COMPREHENSIVE POLYM, V6, P115; MOUREY TH, 1992, MACROMOLECULES, V25, P2401, DOI 10.1021/ma00035a017; NAYLOR AM, 1989, J AM CHEM SOC, V111, P2339, DOI 10.1021/ja00188a079; NEWKOME GR, 1991, ANGEW CHEM INT EDIT, V30, P1178, DOI 10.1002/anie.199111781; NEWKOME GR, 1985, J ORG CHEM, V50, P2003, DOI 10.1021/jo00211a052; NEWKOME GR, 1991, ANGEW CHEM INT EDIT, V30, P1176, DOI 10.1002/anie.199111761; NOVAK BM, 1992, ADV POLYM SCI, V102, P47; Odian G., 1991, PRINCIPLES POLYM, V3; Olabisi O., 1969, POLYM POLYM MISCIBIL; PAUL DR, 1978, POLYM BLENDS; PERCEC C, 1989, COMPREHENSIVE POLYM, V6, P281; POWERS KW, 1993, Patent No. 5182333; PUGH C, 1986, MACROMOLECULES, V19, P65, DOI 10.1021/ma00155a012; Quirk R. P., 1989, COMPREHENSIVE POLYM, P1; QUIRK RP, 1982, MAKROMOL CHEM, V183, P2071; REED SF, 1971, J POLYM SCI A1, V9, P2029, DOI 10.1002/pol.1971.150090719; REED SF, 1971, J POLYM SCI A1, V9, P2147, DOI 10.1002/pol.1971.150090804; REIN D, 1993, ACTA POLYM, V44, P225, DOI 10.1002/actp.1993.010440503; Rempp P., 1991, POLYM SYNTHESIS; Rempp P, 1989, ENCY POLYM SCI ENG, P793; RUTKOWSKA M, 1984, MACROMOLECULES, V17, P821, DOI 10.1021/ma00134a050; SAVILLE PM, 1993, J PHYS CHEM-US, V97, P293, DOI 10.1021/j100104a006; SAWAMOTO M, 1988, MAKROMOL CHEM-M SYMP, V13-4, P513, DOI 10.1002/masy.19880130137; SHULL KR, 1992, J CHEM PHYS, V97, P2095, DOI 10.1063/1.463148; SMIGOL V, 1993, MACROMOLECULES, V26, P5615, DOI 10.1021/ma00073a013; Sparow D.J., 1989, TELECHELIC POLYM SYN, P181; SPINDLER R, 1993, MACROMOLECULES, V26, P4809, DOI 10.1021/ma00070a013; STUPP SI, 1993, SCIENCE, V259, P59, DOI 10.1126/science.259.5091.59; TEZUKA Y, 1992, PROG POLYM SCI, V17, P471, DOI 10.1016/0079-6700(92)90022-Q; TOMALIA DA, 1993, TOP CURR CHEM, V165, P193; TOMALIA DA, 1985, POLYM J, V17, P117, DOI 10.1295/polymj.17.117; TURNER SR, 1993, MACROMOLECULES, V26, P4617, DOI 10.1021/ma00069a031; VORENKAMP EJ, 1988, POLYMER, V29, P86, DOI 10.1016/0032-3861(88)90204-2; WANG HC, 1989, OCT AM CHEM SOC RUBB; WASHIYAMA J, 1993, MACROMOLECULES, V26, P6011, DOI 10.1021/ma00074a025; WOOLEY KL, 1994, POLYM J, V26, P187, DOI 10.1295/polymj.26.187; WOOLEY KL, 1993, J AM CHEM SOC, V115, P11496, DOI 10.1021/ja00077a055; WOOLEY KL, 1991, J CHEM SOC PERK T 1, P1059, DOI 10.1039/p19910001059; WOOLEY KL, IN PRESS POLYMER; WULFF G, 1986, ACS SYM SER, V308, P186	67	1785	1835	2	385	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 25	1994	263	5154					1710	1715		10.1126/science.8134834	http://dx.doi.org/10.1126/science.8134834			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC040	8134834				2022-12-28	WOS:A1994NC04000024
J	USHEVA, A; SHENK, T				USHEVA, A; SHENK, T			TATA-BINDING PROTEIN-INDEPENDENT INITIATION - YY1, TFIIB, AND RNA POLYMERASE-II DIRECT BASAL TRANSCRIPTION ON SUPERCOILED TEMPLATE DNA	CELL			English	Article							PREINITIATION COMPLEX; MONOCLONAL-ANTIBODY; LESS PROMOTER; PURIFICATION; COMPONENTS; ACTIVATOR; INVITRO; REGION; DELTA	YY1 is a zinc finger transcription factor whose DNA-binding motif exhibits the properties of an initiator element. Only three factors were required to direct specific basal transcription on a supercoiled template DNA carrying the YY1 initiator: YY1, general transcription factor IIB, and RNA polymerase II. This minimal in vitro reaction did not require the TATA-binding protein (TBP). We propose that, under appropriate conditions, YY1 can function like TBP, as a factor that binds to the core promoter and recruits the polymerase to the initiation complex.			USHEVA, A (corresponding author), PRINCETON UNIV,HOWARD HUGHES MED INST,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.				NATIONAL CANCER INSTITUTE [R37CA038965, R01CA038965] Funding Source: NIH RePORTER; NCI NIH HHS [CA38965] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CHRISTMANN JL, 1981, J BIOL CHEM, V256, P1798; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HUET J, 1992, NUCLEIC ACIDS RES, V20, P6451, DOI 10.1093/nar/20.24.6451; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LUSBY EW, 1982, J VIROL, V41, P518, DOI 10.1128/JVI.41.2.518-526.1982; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1991, NATURE, V354, P369; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; Weinmann Roberto, 1992, Gene Expression, V2, P81; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; ZAWAL L, 1993, PROG NUCLEIC ACID RE, V44, P67; ZAWAL L, 1992, CURR OPIN CELL BIOL, V4, P488; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	41	246	254	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1115	1121		10.1016/0092-8674(94)90387-5	http://dx.doi.org/10.1016/0092-8674(94)90387-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137426				2022-12-28	WOS:A1994ND24600016
J	AVERY, JK				AVERY, JK			WHEN THE PATIENT PAID	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					818	818						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ498	8114227				2022-12-28	WOS:A1994MZ49800009
J	COOK, DG; WHINCUP, PH; JARVIS, MJ; STRACHAN, DP; PAPACOSTA, O; BRYANT, A				COOK, DG; WHINCUP, PH; JARVIS, MJ; STRACHAN, DP; PAPACOSTA, O; BRYANT, A			PASSIVE EXPOSURE TO TOBACCO-SMOKE IN CHILDREN AGED 5-7 YEARS - INDIVIDUAL, FAMILY, AND COMMUNITY FACTORS	BRITISH MEDICAL JOURNAL			English	Article							COTININE CONCENTRATIONS; SALIVARY COTININE; NICOTINE; MARKERS	Objective-To examine the importance of parental smoking on passive exposure to tobacco smoke in children and the social and geographical patterns of exposure. Design-Cross sectional study. Setting-Schools in 10 towns in England and Wales; five towns with high adult cardiovascular mortality and five with low rates. Subjects-4043 children aged 5-7 years of European origin. Main outcome measures-Salivary cotinine concentration and parents self reported smoking habits. Results-1061 (53.0%) children were exposed to cigarette smoke at home or by an outside carer. Geometric mean cotinine rose from 0.29 (95% confidence interval 0.28 to 0.31) ng/ml in children with no identified exposure to 4.05 (3.71 to 4.42) ng/ml in households where both parents smoked and 9.03 (6.73 to 12.10) ng/ml if both parents smoked more than 20 cigarettes a day. The effect of mothers' smoking was greater than that of fathers', especially at high levels of consumption. After adjustment for known exposures geometric mean cotinine concentrations rose from 0.52 ng/ml in social class I to 1.36 ng/ml in social class V (P<0.0001); and were doubled in high mortality towns compared with the low mortality towns (P=0.002). In children with no identified exposure similar trends by social class and town were observed and the cotinine concentrations correlated with the prevalence of parental smoking, both between towns (r=0.69, P=0.02) and between schools within towns (r=0.50, P<0.001). Conclusions-Mothers' smoking is more important that fathers' despite the lower levels of smoking by mothers. Children not exposed at home had low cotinine concentration, the level depending on the prevalence of smoking in the community.	ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH & PRIMARY CARE,LONDON,ENGLAND; INST PSYCHIAT,IMPERIAL CANC RES FUND,HLTH BEHAV UNIT,LONDON SE5 8AF,ENGLAND; NEW CROSS HOSP,NATL POISONS UNIT,LONDON SE14 5ER,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Cancer Research UK; University of London; King's College London; New Cross Hospital	COOK, DG (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Jarvis, Martin J/B-1034-2008	Jarvis, Martin J/0000-0001-9238-8038; Cook, Derek/0000-0002-9723-5759; Whincup, Peter/0000-0002-5589-4107; Papacosta, Olia/0000-0001-8781-6747	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; COOK DG, 1993, THORAX, V48, P14, DOI 10.1136/thx.48.1.14; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; IDLE JR, 1990, J CLIN EPIDEMIOL, V43, P313, DOI 10.1016/0895-4356(90)90117-8; JARVIS M, 1984, J EPIDEMIOL COMMUN H, V38, P335, DOI 10.1136/jech.38.4.335; JARVIS MJ, 1991, INT J EPIDEMIOL, V20, P126, DOI 10.1093/ije/20.1.126; JARVIS MJ, 1992, AM J PUBLIC HEALTH, V82, P1225, DOI 10.2105/AJPH.82.9.1225; JARVIS MJ, 1989, MUTAT RES, V222, P101, DOI 10.1016/0165-1218(89)90023-2; MCNEILL AD, 1987, BRIT J ADDICT, V82, P1355; STRACHAN DP, 1990, AM REV RESPIR DIS, V142, P147, DOI 10.1164/ajrccm/142.1.147; STRACHAN DP, 1989, BRIT MED J, V298, P1549, DOI 10.1136/bmj.298.6687.1549; WHINCUP PH, 1993, ARCH DIS CHILD, V68, P729, DOI 10.1136/adc.68.6.729; WHINCUP PH, 1992, J EPIDEMIOL COMMUN H, V46, P396, DOI 10.1136/jech.46.4.396; WHINCUP PH, 1991, THESIS U LONDON LOND, P222; 1988, OCCUPATIONAL MORTALI; 1985, SAS USERS GUIDE BASI; 1992, SMOKING YOUNG	17	108	110	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	1994	308	6925					384	389						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MV862	8124146	Green Published			2022-12-28	WOS:A1994MV86200021
J	ECKMAN, MH; LEVINE, HJ; PAUKER, SG				ECKMAN, MH; LEVINE, HJ; PAUKER, SG			EFFECT OF LABORATORY VARIATION IN THE PROTHROMBIN-TIME RATIO ON THE RESULTS OF ORAL ANTICOAGULANT-THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-VALVE REPLACEMENT; ARTERIAL THROMBOEMBOLIC COMPLICATIONS; JUDE MEDICAL VALVE; QUALITY-OF-LIFE; BJORK-SHILEY; MEDTRONIC-HALL; CARDIAC-VALVE; DIFFERENT INTENSITIES; PERSONAL-COMPUTER; DECISION-ANALYSIS	Background. Patients receiving long-term anticoagulant therapy may be subject to unnecessary risks of bleeding or thromboembolism because of variability in the commercial thromboplastins used to determine prothrombin time and consequent uncertainty about the actual intensity of anticoagulation. Methods. We explored the effect of this uncertainty on the benefits and risks of anticoagulation in patients with prosthetic heart valves, using models of thromboembolic and hemorrhagic complications as a function of the intensity of anticoagulation, with quality-adjusted life expectancy and average variable costs used to describe outcomes. Results. Anticoagulation provides a striking benefit for patients whose treatment is conducted within the recommended range of the international normalized ratio (INR) - i.e., 2.5 to 3.5 - but if uncertainty about the laboratory results causes the intensity of anticoagulation to fall outside this range, the gain becomes smaller. Uncertainty about the true intensity of anticoagulation may reduce the potential gain in life expectancy, adjusted for quality of life, by more than half and may increase the ratio of costs to effectiveness to almost five times the optimal value. Variability in the intensity of anticoagulation is even greater if older recommendations advocating a higher level of anticoagulation are followed. Conclusions. Uncertainty about the sensitivities of the commercially available thromboplastins used in the United States can have important clinical and economic effects. This problem could be eliminated if clinical laboratories uniformly reported the intensity of anticoagulation as the INR, by adjusting prothrombin-time ratios for variability in thromboplastins.	TUFTS UNIV NEW ENGLAND MED CTR, DEPT MED, DIV CARDIOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University	ECKMAN, MH (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DEPT MED, DIV CLIN DECIS MAKING, BOX 302, 750 WASHINGTON ST, BOSTON, MA 02111 USA.			Eckman, Mark/0000-0001-8253-269X	AHRQ HHS [HS-06503] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AKBARIAN M, 1968, CIRCULATION, V37, P826, DOI 10.1161/01.CIR.37.5.826; ALTMAN R, 1976, J THORAC CARDIOV SUR, V72, P127; ALTMAN R, 1991, J THORAC CARDIOV SUR, V101, P427; ANSELL JE, 1992, AM J CLIN PATHOL, V98, P237, DOI 10.1093/ajcp/98.2.237; BAUDET EM, 1985, J THORAC CARDIOV SUR, V90, P137; BEAUDET RL, 1986, ANN THORAC SURG, V42, P644, DOI 10.1016/S0003-4975(10)64598-5; BJORK VO, 1979, J THORAC CARDIOV SUR, V78, P331; BJORK VO, 1975, SCAND J THORAC CARD, V9, P183, DOI 10.3109/14017437509138637; BUSSEY HI, 1992, ARCH INTERN MED, V152, P278, DOI 10.1001/archinte.152.2.278; CHESEBRO JH, 1983, AM J CARDIOL, V51, P1537, DOI 10.1016/0002-9149(83)90673-2; COPELAND JG, 1977, J THORAC CARDIOV SUR, V74, P875; CORTINA JM, 1986, J THORAC CARDIOV SUR, V91, P174; CZER LSC, 1990, J THORAC CARDIOV SUR, V100, P44; DALE J, 1977, AM HEART J, V93, P715, DOI 10.1016/S0002-8703(77)80066-5; DALE J, 1977, AM HEART J, V94, P101, DOI 10.1016/S0002-8703(77)80351-7; DALE J, 1976, AM HEART J, V91, P653, DOI 10.1016/S0002-8703(76)80152-4; DESESA VJ, 1989, ANN THORAC SURG, V48, P280; DUVOISIN GE, 1967, CIRCULATION       S1, V35, P70; EBERLEIN U, 1990, EUR J CARDIO-THORAC, V4, P605, DOI 10.1016/1010-7940(90)90020-Z; ECKMAN MH, 1992, CHEST, V102, pS538, DOI 10.1378/chest.102.4_Supplement.538S; EDMUNDS LH, 1982, ANN THORAC SURG, V34, P96, DOI 10.1016/S0003-4975(10)60862-4; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; HIRSCH J, 1992, ARCH INTERN MED, V152, P959; HIRSH J, 1992, ARCH INTERN MED, V152, P257, DOI 10.1001/archinte.152.2.257; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; HIRSH J, 1992, CHEST, V102, pS312, DOI 10.1378/chest.102.4.312S; HIRSH J, 1991, ARCH INTERN MED, V151, P1921, DOI 10.1001/archinte.151.10.1921; Hirsh J, 1989, CHEST, V96, P962; HORSTKOTTE D, 1983, CIRCULATION S2, V68, P75; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; KOPF GS, 1987, CIRCULATION, V76, P132; LANCASTER TR, 1991, ARCH INTERN MED, V151, P1944, DOI 10.1001/archinte.151.10.1944; LANCASTER TR, 1992, ARCH INTERN MED, V152, P825; LANDEFELD CS, 1989, AM J MED, V87, P153; LARSEN GL, 1977, ANN THORAC SURG, V23, P323, DOI 10.1016/S0003-4975(10)64133-1; LAU J, 1983, MED DECIS MAKING, V3, P39, DOI 10.1177/0272989X8300300110; MOGGIO RA, 1978, J THORAC CARDIOV SUR, V75, P296; PAUKER SG, 1981, ARCH INTERN MED, V141, P1831, DOI 10.1001/archinte.141.13.1831; Poller L., 1987, HEMATOLOGY REV, V1, P225; Quick AJ, 1935, AM J MED SCI, V190, P501, DOI 10.1097/00000441-193510000-00009; RACKLEY CE, 1986, HEART, P754; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P338; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; SETHIA B, 1986, J THORAC CARDIOV SUR, V91, P350; SINGER RB, 1976, MED RISKS PATTERNS M, P3; SONNENBERG FA, 1986, P MEDINFO 86, P1152; STEIN DW, 1976, J THORAC CARDIOV SUR, V71, P680; STEIN PD, 1992, CHEST, V102, pS445, DOI 10.1378/chest.102.4_Supplement.445S; SULLIVAN JM, 1971, NEW ENGL J MED, V284, P1391, DOI 10.1056/NEJM197106242842501; SULLIVAN JM, 1969, CIRCULATION       S1, V39, P149; TURPIE A G G, 1992, Journal of the American College of Cardiology, V19, p103A; TURPIE AGG, 1988, LANCET, V1, P1242; VALLEJO JL, 1990, ANN THORAC SURG, V50, P429, DOI 10.1016/0003-4975(90)90489-S; VIDNE B, 1974, ISRAEL J MED SCI, V10, P586; VOGT S, 1990, EUR HEART J, V11, P583, DOI 10.1093/oxfordjournals.eurheartj.a059763; 1987, DHSS PHS901101 PUBL; 1982, LANCET, V1, P64; 1990, SAS PROCEDURES GUIDE, P210; 1991, CGD2 COLL AM PATH CO	59	70	72	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1993	329	10					696	702		10.1056/NEJM199309023291005	http://dx.doi.org/10.1056/NEJM199309023291005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU583	8135917				2022-12-28	WOS:A1993LU58300005
J	LANG, CA; RANSOHOFF, DF				LANG, CA; RANSOHOFF, DF			FECAL OCCULT BLOOD SCREENING FOR COLORECTAL-CANCER - IS MORTALITY REDUCED BY CHANCE SELECTION FOR SCREENING COLONOSCOPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED TRIAL; SIGMOIDOSCOPY	Annual fecal occult blood test (FOBT) screening using rehydrated Hemoccult slides has been reported in the Minnesota Colon Cancer Control Study to reduce colorectal cancer mortality by about 33%. However, some of the benefit of FOBT screening may come from ''chance'' selection of persons for colonoscopic examination because of the high positivity rate of FOBT (about 1 0%) that may occur for reasons other than a bleeding cancer or polyp. To determine how much this mechanism could account for the benefit of FOBT screening, we used a simple mathematical model to simulate the course of a cohort of screened persons, incorporating published data including those f rom the Minnesota study. The results suggest that one third to one half of the mortality reduction observed from FOBT screening in the Minnesota study may be attributable to chance selection for colonoscopy. We conclude that annual FOBT screening with rehydration is a haphazard method for selecting persons for colonoscopy.	UNIV N CAROLINA, CB 7105, 5034 OLD CLIN BLDG, CHAPEL HILL, NC 27599 USA; UNIV COLORADO, COLORADO PERMANENTE MED GRP, DENVER, CO 80202 USA; UNIV COLORADO, DEPT MED, DENVER, CO 80202 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; BOLAND CR, 1993, MAY AM GASTR ASS M B; CLAYMAN CB, 1989, JAMA-J AM MED ASSOC, V261, P609, DOI 10.1001/jama.261.4.609; HARDCASTLE JD, 1989, LANCET, V1, P1160; KEWENTER J, 1988, CANCER, V62, P645, DOI 10.1002/1097-0142(19880801)62:3<645::AID-CNCR2820620333>3.0.CO;2-#; KNIGHT KK, 1989, JAMA-J AM MED ASSOC, V261, P587; KRONBORG O, 1987, SCAND J GASTROENTERO, V22, P677, DOI 10.3109/00365528709011142; LEVIN B, 1992, CA-CANCER J CLIN, V42, P296, DOI 10.3322/canjclin.42.5.296; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MILLER BA, 1992, 922789 NAT I HLTH PU; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; RANSOHOFF DF, 1993, JAMA-J AM MED ASSOC, V269, P1278, DOI 10.1001/jama.269.10.1278; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SMART CR, 1990, MAYO CLIN PROC, V65, P892, DOI 10.1016/S0025-6196(12)62581-6; WINAWER SJ, 1993, J NATL CANCER I, V85, P1311, DOI 10.1093/jnci/85.16.1311; WINAWER SJ, 1993, NEW ENGL J MED, V328, P1416, DOI 10.1056/NEJM199305133281909; 1993, NY TIMES        0521, pA26; 1989, SUMMARY CURRENT GUID; 1992, VITAL STATISTICS US, V11; 1990, SCREENING COLORECTAL; 1987, WORKING GUIDELINES E	24	122	125	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	1994	271	13					1011	1013		10.1001/jama.271.13.1011	http://dx.doi.org/10.1001/jama.271.13.1011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND949	8139058				2022-12-28	WOS:A1994ND94900031
J	BONDY, CA; UNDERWOOD, LE; CLEMMONS, DR; GULER, HP; BACH, MA; SKARULIS, M				BONDY, CA; UNDERWOOD, LE; CLEMMONS, DR; GULER, HP; BACH, MA; SKARULIS, M			CLINICAL USES OF INSULIN-LIKE GROWTH-FACTOR-I	ANNALS OF INTERNAL MEDICINE			English	Article							STRUCTURAL DETERMINANTS; LINEAR GROWTH; LARON-TYPE; IGF-I; HORMONE; RECEPTOR; DWARFISM; INFUSION; BINDING; SERUM	Insulin-like growth factor I (IGF-I) has acute insulinlike metabolic effects and long-term anabolic actions. The therapeutic potential of recombinant human IGF-I treatment is being investigated in various growth hormone-resistant and insulin-resistant disorders. Recent studies have shown that IGF-I may substitute for growth hormone in promoting linear growth in children with growth hormone insensitivity. The anabolic, protein-sparing action of IGF-I is being evaluated as a potential therapy for adults with catabolic diseases. Patients with insulin-dependent diabetes mellitus have reduced endogenous IGF-I production, and studies are in progress to determine whether treatment with IGF-I in addition to insulin may improve their metabolic/ anabolic status. Insulin-like growth factor I treatment may reduce glucose and triglyceride levels in adults with non-insulin-dependent diabetes mellitus and in some patients with extreme insulin resistance. Further studies are needed to evaluate the efficacy and safety of IGF-I treatment in these and other conditions and to provide a better understanding of this hormone's normal physiologic role(s) and complex relations with growth hormone and insulin.			BONDY, CA (corresponding author), NIH, BLDG 10, ROOM 10N 262, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							ADAMO M, 1992, BIOFACTORS, V3, P151; BACH MA, 1993, PEDIATR RES, V33, P190; BACKELJAUW PF, 1993, 4TH JOINT M L WILK P; BAXTER RC, 1993, TRENDS ENDOCRIN MET, V4, P91, DOI 10.1016/1043-2760(93)90085-S; BAXTER RC, 1992, J BIOL CHEM, V267, P60; BELCHER HJCR, 1989, BURNS, V15, P99, DOI 10.1016/0305-4179(89)90138-1; BOLINDER J, 1987, J CLIN ENDOCR METAB, V65, P732, DOI 10.1210/jcem-65-4-732; CARO JF, 1988, J CLIN INVEST, V81, P976, DOI 10.1172/JCI113451; CHIN E, 1992, J CLIN ENDOCR METAB, V75, P962, DOI 10.1210/jc.75.3.962; CLEMMONS DR, 1992, J CLIN ENDOCR METAB, V75, P234, DOI 10.1210/jc.75.1.234; DAHN MS, 1988, ARCH SURG-CHICAGO, V123, P1409; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; GREEN H, 1985, DIFFERENTIATION, V29, P195, DOI 10.1111/j.1432-0436.1985.tb00316.x; GULER HP, 1987, NEW ENGL J MED, V317, P137, DOI 10.1056/NEJM198707163170303; GULER HP, 1989, P NATL ACAD SCI USA, V86, P2868, DOI 10.1073/pnas.86.8.2868; HALL K, 1989, J INTERN MED, V225, P273, DOI 10.1111/j.1365-2796.1989.tb00078.x; HONE J, 1993, 76TH ANN END SOC M, P1319; IRANMANESH A, 1991, J CLIN ENDOCR METAB, V73, P1081, DOI 10.1210/jcem-73-5-1081; KUPFER SR, 1993, J CLIN INVEST, V91, P391, DOI 10.1172/JCI116212; KUZUYA H, 1993, DIABETES, V42, P696, DOI 10.2337/diabetes.42.5.696; LANES R, 1985, DIABETES, V34, P156, DOI 10.2337/diabetes.34.2.156; LARON Z, 1992, LANCET, V339, P1258, DOI 10.1016/0140-6736(92)91594-X; LARON Z, 1971, J CLIN ENDOCR METAB, V33, P332, DOI 10.1210/jcem-33-2-332; LIVINGSTON N, 1988, DIABETOLOGIA, V31, P871; MAES M, 1984, MOL CELL ENDOCRINOL, V37, P301, DOI 10.1016/0303-7207(84)90100-X; McCusker RH, 1992, INSULIN LIKE GROWTH, P110; MOHAN S, 1988, BIOCHIM BIOPHYS ACTA, V966, P44, DOI 10.1016/0304-4165(88)90127-4; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MORROW L, 1993, DIABETES S, V42, P269; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; PHILLIPS LS, 1990, P NUTR SOC, V49, P451, DOI 10.1079/PNS19900053; PRESS M, 1984, NEW ENGL J MED, V310, P810, DOI 10.1056/NEJM198403293101302; QUIN JD, 1990, NEW ENGL J MED, V323, P1425; RENNERT NJ, 1993, J CLIN ENDOCR METAB, V76, P804, DOI 10.1210/jc.76.3.804; SCHALCH DS, 1991, MODERN CONCEPTS INSU, P705; SCHOENLE EJ, 1991, DIABETOLOGIA, V34, P675, DOI 10.1007/BF00400998; SKARULIS MC, 1993, 76TH ANN END SOC M, P729; SNYDER DK, 1988, J CLIN ENDOCR METAB, V67, P54, DOI 10.1210/jcem-67-1-54; SOOS MA, 1993, BIOCHEM J, V290, P419, DOI 10.1042/bj2900419; TAYLOR SI, 1990, DIABETES CARE, V13, P257, DOI 10.2337/diacare.13.3.257; THISSEN JP, 1992, AM J PHYSIOL, V262, pE406, DOI 10.1152/ajpendo.1992.262.4.E406; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; UNDERWOOD LE, 1986, CLIN ENDOCRINOL META, V15, P59, DOI 10.1016/S0300-595X(86)80042-1; WALKER JL, 1991, NEW ENGL J MED, V324, P1483, DOI 10.1056/NEJM199105233242107; WALKER JL, 1992, J PEDIATR-US, V121, P641, DOI 10.1016/S0022-3476(05)81163-1; WINTER RJ, 1979, DIABETES, V28, P952, DOI 10.2337/diabetes.28.10.952; ZENOBI PD, 1992, J CLIN INVEST, V90, P2234, DOI 10.1172/JCI116109; ZHOU JA, 1993, BIOL REPROD, V48, P467, DOI 10.1095/biolreprod48.3.467; ZIEGLER TR, 1988, ANN SURG, V208, P6, DOI 10.1097/00000658-198807000-00002	50	121	135	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					593	601		10.7326/0003-4819-120-7-199404010-00011	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8116999				2022-12-28	WOS:A1994NC76400011
J	BLENDON, RJ; DONELAN, K; HILL, CA; CARTER, W; BEATRICE, D; ALTMAN, D				BLENDON, RJ; DONELAN, K; HILL, CA; CARTER, W; BEATRICE, D; ALTMAN, D			PAYING MEDICAL BILLS IN THE UNITED-STATES - WHY HEALTH-INSURANCE ISNT ENOUGH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									UNIV CHICAGO,NATL OPIN RES CTR,CHICAGO,IL 60637; HENRY J KAISER FAMILY FDN,MENLO PK,CA	University of Chicago	BLENDON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Donelan, Karen/R-6162-2019	Hill, Craig/0000-0002-0826-2019				DARNELL J, 1993, SUMMARY MAJOR HLTH C; 1993, KAISER COMMONWEALTH; 1994, SOURCES HLTH INSURAN	3	18	18	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	1994	271	12					949	951		10.1001/jama.271.12.949	http://dx.doi.org/10.1001/jama.271.12.949			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NA743	8120967				2022-12-28	WOS:A1994NA74300035
J	MARKOWITZ, SB; NUNEZ, CM; KLITZMAN, S; MUNSHI, AA; KIM, WS; EISINGER, J; LANDRIGAN, PJ				MARKOWITZ, SB; NUNEZ, CM; KLITZMAN, S; MUNSHI, AA; KIM, WS; EISINGER, J; LANDRIGAN, PJ			LEAD-POISONING DUE TO HAI GE FEN - THE PORPHYRIN CONTENT OF INDIVIDUAL ERYTHROCYTES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PUBLIC-HEALTH SURVEILLANCE; PHYSICIAN RECOGNITION; BLOOD LEAD; INTOXICATION; PROTOPORPHYRIN; EXPOSURE; EVENTS	A 45-year-old Korean man developed abdominal colic, muscle pain, and fatigue. Following a 3-week hospitalization, acute intermittent porphyria was diagnosed based on the symptoms and a high level of urinary delta-aminolevulinic acid (378 mu mol/L [4.95 mg/dL]). However, discovery of an elevated blood lead level (3.7 mu mol/L [76 mu g/dL]) subsequently led to the correct diagnosis. No occupational source of lead exposure was identified. The patient reported ingesting a Chinese herbal preparation for 4 weeks prior to becoming ill. A public health investigation revealed that the source of lead exposure was hai ge fen (clamshell powder), one of the 36 ingredients of the Chinese herbal medicine. We used fluorescence image-based cytometry to determine the frequency distribution of the zinc protoporphyrin content in circulating red blood cells and found that 70% of the patient's cells contained elevated levels of zinc protoporphyrin consistent with the duration of lead exposure and effect of lead on heme synthesis. Analysis of zinc protoporphyrin content in circulating red blood cell distributions may be useful in the diagnosis, therapy, and kinetic modeling of lead poisoning. Environmental lead poisoning is best addressed through the close collaboration of clinicians, public health specialists, and laboratory scientists.	MT SINAI SCH MED, DEPT PHYSIOL & BIOPHYS, NEW YORK, NY USA; NEW YORK CITY DEPT HLTH, NEW YORK, NY USA	Icahn School of Medicine at Mount Sinai; New York City Department of Health & Mental Hygiene	MARKOWITZ, SB (corresponding author), MT SINAI SCH MED, DIV ENVIRONM & OCCUPAT MED, BOX 1057, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA.				PHS HHS [P30E500928] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BASER ME, 1992, AM J PUBLIC HEALTH, V82, P1113, DOI 10.2105/AJPH.82.8.1113; BIRD TD, 1982, JAMA-J AM MED ASSOC, V247, P813, DOI 10.1001/jama.247.6.813; BLUMBERG WE, 1977, J LAB CLIN MED, V89, P712; CHAMBERLAIN AC, 1985, PROC R SOC SER B-BIO, V224, P149, DOI 10.1098/rspb.1985.0027; EISINGER J, 1978, Q REV BIOPHYS, V11, P439, DOI 10.1017/S0033583500005631; EISINGER J, 1982, MED HIST, V26, P279, DOI 10.1017/S0025727300041508; FRANZBLAU A, 1989, ARCH ENVIRON HEALTH, V44, P385, DOI 10.1080/00039896.1989.9935912; HARRIS RW, 1967, J AMER MED ASSOC, V202, P544, DOI 10.1001/jama.202.6.544; HINDMARSH JT, 1986, CRC CR REV CL LAB SC, V23, P315, DOI 10.3109/10408368609167122; HRYHORCZUK DO, 1985, AM J IND MED, V8, P33, DOI 10.1002/ajim.4700080105; KARLOG O, 1958, ACTA PHARMACOL TOX, V15, P8; KLEIN M, 1970, NEW ENGL J MED, V283, P669, DOI 10.1056/NEJM197009242831302; MULLAN RJ, 1991, AM J IND MED, V19, P775, DOI 10.1002/ajim.4700190610; NORTIER JWR, 1980, VET HUM TOXICOL, V22, P145; PIOMELLI S, 1977, CLIN CHEM, V23, P264; PIOMELLI S, 1975, J CLIN INVEST, V56, P1519, DOI 10.1172/JCI108233; RUTSTEIN DD, 1983, AM J PUBLIC HEALTH, V73, P1054, DOI 10.2105/AJPH.73.9.1054; SASSAROLI M, 1992, CYTOMETRY, V13, P339, DOI 10.1002/cyto.990130403; SMITH DC, 1992, MMWR-MORBID MORTAL W, V41, P781; 1993, MMWR MORB MORTAL WKL, V42, P254; 1993, DRINKING WATER REGUL; 1984, MMWR MORB MORTAL WKL, V33, P45	22	67	69	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	1994	271	12					932	934		10.1001/jama.271.12.932	http://dx.doi.org/10.1001/jama.271.12.932			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA743	8120963				2022-12-28	WOS:A1994NA74300030
J	ARONSON, BD; JOHNSON, KA; LOROS, JJ; DUNLAP, JC				ARONSON, BD; JOHNSON, KA; LOROS, JJ; DUNLAP, JC			NEGATIVE FEEDBACK DEFINING A CIRCADIAN CLOCK - AUTOREGULATION OF THE CLOCK GENE-FREQUENCY	SCIENCE			English	Article							MESSENGER-RNA LEVELS; NEUROSPORA-CRASSA; PERIOD GENE; PROTEIN-SYNTHESIS; DROSOPHILA-MELANOGASTER; VISUAL-SYSTEM; PHASE; RHYTHMS; PRODUCT; TRANSCRIPTION	The frequency(frq) locus of Neurospora crassa was originally identified in searches for loci encoding components of the circadian clock. The frq gene is now shown to encode a central component in a molecular feedback loop in which the product of frq negatively regulated its own transcript, which resulted in a daily oscillation in the amount of frq transcript. Rhythmic messenger RNA expression was essential for overt rhythmicity in the organism and no amount of constitutive expression rescued normal rhythmicity in frq loss-of-function mutants. Step reductions in the amount of FRQ-encoding transcript set the clock to a specific and predicted phase. These results establish frq as encoding a central component in a circadian oscillator.	DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03755; SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Dartmouth College; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Rice University			Loros, Jennifer/B-6293-2014; Dunlap, Jay/L-6232-2013	Dunlap, Jay/0000-0003-1577-0457; Johnson, Keith/0000-0001-6404-4780	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034985, R37GM034985, F32GM014465] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34985, GM14465] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONSON BD, 1994, IN PRESS P NATL ACAD; ARONSON BD, IN PRESS MOL GEN GEN; ARPAIA G, 1993, PLANT PHYSIOL, V102, P1299, DOI 10.1104/pp.102.4.1299; BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; BELLPEDERSEN D, 1992, GENE DEV, V6, P2382, DOI 10.1101/gad.6.12a.2382; BELLPEDERSEN D, UNPUB; CHADWICK DJ, IN PRESS CIBA F S, V183; CHALEFF RS, 1974, J GEN MICROBIOL, V81, P357, DOI 10.1099/00221287-81-2-357; CHARY P, 1990, J BIOL CHEM, V265, P18961; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; DHARMANANDA S, 1979, PLANT PHYSIOL, V63, P1049, DOI 10.1104/pp.63.6.1049; DUNLAP JC, 1988, P NATL ACAD SCI USA, V85, P1096, DOI 10.1073/pnas.85.4.1096; DUNLAP JC, 1980, J COMP PHYSIOL, V138, P1, DOI 10.1007/BF00688728; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; DUNLAP JC, 1990, TRENDS GENET, V6, P159, DOI 10.1016/0168-9525(90)90151-U; DUNLAP JL, UNPUB; EBBOLE D, 1990, FUNGAL GENET NEWSL, V37, P15; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; EDERY I, IN PRESS P NAT ACAD; Edmunds LN, 1988, CELLULAR MOL BASES B; EWER J, 1988, NATURE, V333, P82, DOI 10.1038/333082a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FELDMAN J F, 1973, Genetics, V75, P605; FRISCH B, 1994, IN PRESS NEURON; GILES NH, 1985, MICROBIOL REV, V49, P338, DOI 10.1128/MMBR.49.3.338-358.1985; Goodwin B., 1963, TEMPORAL ORG CELLS; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HASTINGS JW, 1959, ANNU REV MICROBIOL, V13, P297, DOI 10.1146/annurev.mi.13.100159.001501; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JACKLET JW, 1977, SCIENCE, V198, P69, DOI 10.1126/science.897685; KHALSA SBS, 1992, P NATL ACAD SCI USA, V89, P10862, DOI 10.1073/pnas.89.22.10862; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LAKINTHOMAS PL, 1990, CRIT REV MICROBIOL, V17, P365, DOI 10.3109/10408419009114762; LAUTER FR, 1992, GENE DEV, V6, P2373, DOI 10.1101/gad.6.12a.2373; LAUTER FR, 1993, P NATL ACAD SCI USA, V90, P8249, DOI 10.1073/pnas.90.17.8249; LINDGREN K, UNPUB; LIU X, 1991, NEURON, V6, P753, DOI 10.1016/0896-6273(91)90172-V; Loros J J, 1986, J Biol Rhythms, V1, P187, DOI 10.1177/074873048600100302; LOROS JJ, 1986, GENETICS, V114, P1095; LOROS JJ, 1989, SCIENCE, V243, P385, DOI 10.1126/science.2563175; LOROS JJ, 1991, MOL CELL BIOL, V11, P558, DOI 10.1128/MCB.11.1.558; MCCLUNG CR, 1989, NATURE, V339, P558, DOI 10.1038/339558a0; MERROW M, IN PRESS EMBO J; MICHEL S, 1993, SCIENCE, V259, P239, DOI 10.1126/science.8421785; MILLAR AJ, 1991, PLANT CELL, V3, P541, DOI 10.1105/tpc.3.5.541; Moore-Ede MC., 1982, CLOCKS TIME US; NAKASHIMA H, 1981, AM J PHYSIOL, V241, pR31, DOI 10.1152/ajpregu.1981.241.1.R31; NAKASHIMA H, 1981, PLANT CELL PHYSIOL, V22, P231; PAVLIDIS T, 1969, ARCH BIOCHEM BIOPHYS, V132, P338, DOI 10.1016/0003-9861(69)90371-3; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; SMITH RF, 1982, MOL GEN GENET, V185, P30, DOI 10.1007/BF00333786; TAKAHASHI JS, 1993, CURR OPIN GENET DEV, V3, P301, DOI 10.1016/0959-437X(93)90038-Q; TYSON J, 1976, MOL BASIS CIRCADIAN, P85; VOLLMER SJ, 1986, P NATL ACAD SCI USA, V83, P4869, DOI 10.1073/pnas.83.13.4869; YEUNG SJ, 1988, J BIOL RHYTHM, V3, P225, DOI 10.1177/074873048800300301; ZATZ M, 1992, DISCUSS NEUROSCI, V8, P67; ZERR DM, 1990, J NEUROSCI, V10, P2749	58	506	515	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 18	1994	263	5153					1578	1584		10.1126/science.8128244	http://dx.doi.org/10.1126/science.8128244			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	8128244				2022-12-28	WOS:A1994NB67300021
J	GREF, R; MINAMITAKE, Y; PERACCHIA, MT; TRUBETSKOY, V; TORCHILIN, V; LANGER, R				GREF, R; MINAMITAKE, Y; PERACCHIA, MT; TRUBETSKOY, V; TORCHILIN, V; LANGER, R			BIODEGRADABLE LONG-CIRCULATING POLYMERIC NANOSPHERES	SCIENCE			English	Article							PARTICLES; LIPOSOMES	Injectable nanoparticulate carriers have important potential applications such as site-specific drug delivery or medical imaging. Conventional carriers, however, cannot generally be used because they are eliminated by the reticulo-endothelial system within seconds or minutes after intravenous injection. To address these limitations, monodisperse biodegradable nanospheres were developed from amphiphilic copolymers composed of two biocompatible blocks. The nanospheres exhibited dramatically increased blood circulation times and reduced liver accumulation in mice. Furthermore, they entrapped up to 45 percent by weight of the drug in the dense core in a one-step procedure and could be freeze-dried and easily redispersed without additives in aqueous solutions.	MIT,HARVARD MIT DIV HLTH SCI,DEPT CHEM ENGN,CAMBRIDGE,MA 02139; MASSACHUSETTS GEN HOSP E,DEPT RADIOL,BOSTON,MA 02129; MIT,WHITAKER COLL HLTH SCI,CAMBRIDGE,MA 02139; CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115	Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital			Gref, Ruxandra/F-1487-2011	Gref, Ruxandra/0000-0002-7869-0908	NATIONAL CANCER INSTITUTE [U01CA052857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026698] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA52857] Funding Source: Medline; NIGMS NIH HHS [GM 26698] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1068, P133, DOI 10.1016/0005-2736(91)90201-I; BAZILE D, 1993, YANUZAIGAKU, V53, P10; BECK LR, 1986, ADV CONTRACEP DELIVE, V1, P79; BLUME G, 1993, BIOCHIM BIOPHYS ACTA, V1149, P180, DOI 10.1016/0005-2736(93)90039-3; DONBROW M, 1992, MICROCAPSULES NANOPA; GOTTLIEB S, 1990, J AM SOC ECHO, V3, P238; GREF R, UNPUB; HOLLAND S J, 1986, Journal of Controlled Release, V4, P155, DOI 10.1016/0168-3659(86)90001-5; ILLUM L, 1987, BIOMATERIALS, V8, P113, DOI 10.1016/0142-9612(87)90099-8; KELLY RJ, 1970, REV SURG, V2, P142; KIM SW, 1992, POLYM DRUG DELIVERY, P193; Kimmel G., 1977, CONTEMP TOP POLYM S, P251; LASIC DD, 1991, BIOCHIM BIOPHYS ACTA, V1070, P187, DOI 10.1016/0005-2736(91)90162-2; LEE J, 1989, J COLLOID INTERF SCI, V131, P252, DOI 10.1016/0021-9797(89)90166-5; Muller B., 1993, PHARM PHARM LETT, V3, P67; MULLER RH, 1992, J CONTROL RELEASE, V20, P237, DOI 10.1016/0168-3659(92)90126-C; Saphiro J., 1990, J AM COLL CARDIOL, V16, P1603; SUGIBAYASHI K, 1977, CHEM PHARM BULL, V25, P3433; TORCHILIN VP, 1992, FASEB J, V6, P2716, DOI 10.1096/fasebj.6.9.1612296; VERRECCHIA T, 1993, 8 JORUN SCI GROUP TH; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410	21	2437	2620	15	802	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 18	1994	263	5153					1600	1603		10.1126/science.8128245	http://dx.doi.org/10.1126/science.8128245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	8128245				2022-12-28	WOS:A1994NB67300028
J	MOORE, RD; STANTON, D; GOPALAN, R; CHAISSON, RE				MOORE, RD; STANTON, D; GOPALAN, R; CHAISSON, RE			RACIAL-DIFFERENCES IN THE USE OF DRUG-THERAPY FOR HIV DISEASE IN AN URBAN-COMMUNITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; PNEUMOCYSTIS-CARINII PNEUMONIA; PLACEBO-CONTROLLED TRIAL; AIDS-RELATED COMPLEX; DOUBLE-BLIND; AZIDOTHYMIDINE AZT; ZIDOVUDINE AZT; SAN-FRANCISCO; PROPHYLAXIS; EFFICACY	Background. Guidelines for drug therapy in human immunodeficiency virus (HIV) disease are based primarily on the stage of the disease. To determine whether sociodemographic characteristics of patients influence drug therapy in practice, we analyzed the use of antiretroviral therapy and prophylactic therapy for Pneumocystis carinii pneumonia (PCP) in an urban population infected with HIV. Methods. All patients presenting for the first time to our HIV clinic from March 1990 through December 1992 were enrolled. Data on sociodemographic and clinical variables and on drug use were collected at the time of presentation and after six months. We asked whether patients with CD4+ cell counts of 500 or less per cubic millimeter were receiving antiretroviral therapy at the time of presentation, and whether patients with CD4+ cell counts of 200 or less per cubic millimeter were receiving PCP prophylaxis. Results. Among the 838 patients enrolled, 656 (79 percent) were blacks, 167 (20 percent) were non-Hispanic whites, and 15 (2 percent) were Asian or Hispanic or were not racially classified. There were no racial differences in the stage of HIV disease at the time of presentation. However, there were racial disparities in the receipt of antiretroviral therapy: 63 percent of eligible whites but only 48 percent of eligible blacks received such therapy (P = 0.003). PCP prophylaxis was received by 82 percent of eligible whites but only 58 percent of eligible blacks (P<0.001). There were no significant differences in the receipt of drug therapy with respect to age, sex, mode of HIV transmission, type of insurance, income, education, or place of residence. In a logistic-regression analysis, race was the feature most strongly associated with the receipt of drug therapy. When blacks were compared with whites, the adjusted relative odds were 0.59 (95 percent confidence interval, 0.38 to 0.93) for the receipt of an antiretroviral agent and 0.27 (95 percent confidence interval, 0.13 to 0.56) for the receipt of PCP prophylaxis. Conclusions. Among patients infected with HIV, blacks were significantly less likely than whites to have received antiretroviral therapy or PCP prophylaxis when they were first referred to an HIV clinic. This disparity suggests a need for culturally specific interventions to ensure uniform access to care, including drug therapy, and uniform standards of care.			MOORE, RD (corresponding author), JOHNS HOPKINS UNIV,SCH MED,1830 E MONUMENT ST,RM 8059,BALTIMORE,MD 21205, USA.				AHRQ HHS [R01-HS07809-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; BLUM RN, 1992, J ACQ IMMUN DEF SYND, V5, P341; BONE LR, 1989, AM J EMERG MED, V7, P16, DOI 10.1016/0735-6757(89)90077-6; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; CHAISSON RE, 1993, AIDS, V7, P857, DOI 10.1097/00002030-199306000-00015; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; DIEHR P, 1989, MED CARE, V27, P942, DOI 10.1097/00005650-198910000-00005; EASTERBROOK PJ, 1991, JAMA-J AM MED ASSOC, V266, P2713, DOI 10.1001/jama.266.19.2713; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FOLSOM AR, 1988, AM J PREV MED, V4, P121, DOI 10.1016/S0749-3797(18)31183-8; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P737; Guinan M E, 1993, Ann Epidemiol, V3, P193; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; KAHN HA, 1989, STATISTICAL METHODS; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KEMPER CA, 1992, ANN INTERN MED, V116, P466, DOI 10.7326/0003-4819-116-6-466; LAGAKOS S, 1991, JAMA-J AM MED ASSOC, V266, P2709, DOI 10.1001/jama.266.19.2709; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; Levine David M., 1992, Ethnicity and Disease, V2, P296; LEVINE DM, 1990, J HUM HYPERTENS, V4, P317; LEVINE DM, 1992, AM J PREV MED, V8, P319, DOI 10.1016/S0749-3797(18)30799-2; MAYNARD C, 1986, AM J PUBLIC HEALTH, V76, P1446, DOI 10.2105/AJPH.76.12.1446; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; MINDEL A, 1988, LANCET, V1, P926; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; PERUGA A, 1992, AIDS EDUC PREV, V4, P52; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PIETTE JD, 1993, AM J PUBLIC HEALTH, V83, P510, DOI 10.2105/AJPH.83.4.510; POWDERLY WG, 1992, NEW ENGL J MED, V326, P793, DOI 10.1056/NEJM199203193261203; POWE NR, 1992, JAMA-J AM MED ASSOC, V268, P1434, DOI 10.1001/jama.268.11.1434; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; Singer M, 1991, AIDS Educ Prev, V3, P258; SKOWRON G, 1993, ANN INTERN MED, V118, P321, DOI 10.7326/0003-4819-118-5-199303010-00001; SMITH MD, 1991, JAMA-J AM MED ASSOC, V266, P2750, DOI 10.1001/jama.266.19.2750; STEIN MD, 1991, J GEN INTERN MED, V6, P35, DOI 10.1007/BF02599388; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; VOLBERDING PA, 1985, ANN INTERN MED, V103, P729, DOI 10.7326/0003-4819-103-5-729; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1981, CA-CANCER J CLIN, V31, P212; 1991, MMWR MORB MORTAL WKL, V40, P358; 1985, REPORT SECRETARYS TA, V1; 1993, HIV AIDS SURVEILLANC, P1; 1990, JAMA-J AM MED ASSOC, V263, P1606; 1992, NEW ENGL J MED, V326, P213	49	268	269	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 17	1994	330	11					763	768		10.1056/NEJM199403173301107	http://dx.doi.org/10.1056/NEJM199403173301107			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA742	8107743	Bronze			2022-12-28	WOS:A1994NA74200007
J	SCHWARZ, DF; GRISSO, JA; MILES, CG; HOLMES, JH; WISHNER, AR; SUTTON, RL				SCHWARZ, DF; GRISSO, JA; MILES, CG; HOLMES, JH; WISHNER, AR; SUTTON, RL			A LONGITUDINAL-STUDY OF INJURY MORBIDITY IN AN AFRICAN-AMERICAN POPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NORTHEASTERN OHIO TRAUMA; CHILDHOOD; MASSACHUSETTS; ADOLESCENTS; COMMUNITY; CHILDREN; DEATHS; RATES	Objective.-To improve understanding of the patterns of injury morbidity and mortality in an urban African-American population. Design.-Prospective survey of emergency department records for a geographically defined population from 1987 through 1990. Setting.-Eleven hospital emergency departments in Philadelphia, Pa. Participants.-The approximately 68 000 people living in 17 census tracts in western Philadelphia. Results.-A total of 46260 injury events were identified in the survey (168.8 events per 1000 population annually). Half of the population made an emergency department visit for one or more injuries during the 4 years of study. There were 2796 hospital admissions (10.2/1000 population) and 403 deaths (1.5/1000 population) as a result of these injuries. Although in 1987 falls were the most frequent type of injury resulting in an emergency department visit, by 1989 the number of interpersonal intentional injury events exceeded the number of falls. Interpersonal intentional injuries accounted for 31.2% of hospital admissions and 42.7% of deaths. Of men 20 through 29 years old, 94.3% visited an emergency department at least once in the 4 years because of an injury, and 40.9% of men in this age group sought treatment for one or more interpersonal intentional injuries. The likelihood of future interpersonal intentional injury-related visits increased with the number of previous injuries of this type. Conclusions.-lnterpersonal intentional injury occurs frequently in this population. More attention needs to be paid to prevention and intervention to reduce the toll of this violence. The high prevalence of injury in certain age strata may make general, population-based efforts for injury prevention more efficient than efforts targeted to subgroups.	UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,CLIN EPIDEMIOL UNIT,PHILADELPHIA,PA 19104; PHILADELPHIA DEPT PUBL HLTH,PHILADELPHIA,PA	University of Pennsylvania; Childrens Hospital of Philadelphia	SCHWARZ, DF (corresponding author), UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT PEDIAT,DIV GEN PEDIAT,PHILADELPHIA,PA 19104, USA.				PHS HHS [U50/CCU300738-03, R49/CCR303282-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS PF, 1991, VITAL HLTH STAT, V181, P1; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; BARANCIK JI, 1983, AM J PUBLIC HEALTH, V73, P746, DOI 10.2105/AJPH.73.7.746; Davidson L L, 1992, Paediatr Perinat Epidemiol, V6, P153, DOI 10.1111/j.1365-3016.1992.tb00757.x; FIFE D, 1984, AM J PUBLIC HEALTH, V74, P473, DOI 10.2105/AJPH.74.5.473; FINGERHUT LA, 1992, JAMA-J AM MED ASSOC, V267, P3054, DOI 10.1001/jama.267.22.3054; GALLAGHER SS, 1984, AM J PUBLIC HEALTH, V74, P1340, DOI 10.2105/AJPH.74.12.1340; GOLDBERG WG, 1984, JAMA-J AM MED ASSOC, V251, P8263; GRISSO JA, 1990, J AM GERIATR SOC, V38, P1326, DOI 10.1111/j.1532-5415.1990.tb03456.x; GRISSO JA, 1991, AM J EPIDEMIOL, V134, P59, DOI 10.1093/oxfordjournals.aje.a115993; GUYER B, 1989, NEW ENGL J MED, V321, P1584, DOI 10.1056/NEJM198912073212306; HODGES K, 1984, MAY ANN POP ASS AM M; HOLMES JH, 1990, MMWR-MORBID MORTAL W, V39, P1; Langan P., 1986, PREVENTING DOMESTIC; MANHEIMER DI, 1986, PUBLIC HLTH REP, V81, P519; MITCHELL MA, 1992, CHILDREN VIOLENCE; PROTHROWSTITH D, 1991, DEADLY CONSEQUENCES; RICE DP, 1992, MMWR MORB MORTAL WKL, V41, P10; RIVARA FP, 1989, AM J PUBLIC HEALTH, V79, P990, DOI 10.2105/AJPH.79.8.990; RUNYAN CW, 1985, AM J PUBLIC HEALTH, V75, P1429, DOI 10.2105/AJPH.75.12.1429; STARK E, 1981, MONOGRAPH OFFICE DOM, V7; TIRET L, 1989, AM J PUBLIC HEALTH, V79, P316, DOI 10.2105/AJPH.79.3.316; WISHNER AR, 1991, AM J PUBLIC HEALTH, V81, P1474, DOI 10.2105/AJPH.81.11.1474; 1992, MMWR MORB MORTAL WKL, V41, P313; 1980, INT CLASSIFICATION D; 1985, INJURY AM; 1988, MMWR MORB MORTAL WKL, V37, P27; 1991, FATAL ACCIDENT REPOR; 1992, PREVENTION YOUTH VIO; 1993, VITAL STATISTICS U A, V2	30	60	61	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					755	760		10.1001/jama.271.10.755	http://dx.doi.org/10.1001/jama.271.10.755			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MY288	8114212				2022-12-28	WOS:A1994MY28800029
J	MORISATO, D; ANDERSON, KV				MORISATO, D; ANDERSON, KV			THE SPATZLE GENE ENCODES A COMPONENT OF THE EXTRACELLULAR SIGNALING PATHWAY ESTABLISHING THE DORSAL-VENTRAL PATTERN OF THE DROSOPHILA EMBRYO	CELL			English	Article							SERINE PROTEASE; TOLL GENE; TRANSMEMBRANE PROTEIN; POLARITY; MORPHOGEN; PRODUCT; EASTER; TWIST; LOCALIZATION; MELANOGASTER	spatzle is a maternal effect gene required in the signal transduction pathway that establishes the dorsal-ventral pattern of the Drosophila embryo. spatzle acts immediately upstream of the membrane protein Toll in the genetic pathway, suggesting that spatzle could encode the ventrally localized ligand that activates the receptor activity of Toll. The spatzle gene encodes a novel secreted protein that appears to require activation by a proteolytic processing reaction, which is controlled by the genes that act upstream of spatzle in the genetic pathway. We propose that proteolytic processing of the spatzle protein is confined to the ventral side of the embryo and that the localization of processed spatzle determines where the receptor, Toll, is active.			MORISATO, D (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV GENET, BERKELEY, CA 94720 USA.				NIGMS NIH HHS [GM 35437] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035437] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ANDERSON KV, 1984, PATTERN FORMATION, P269; ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHASAN R, 1992, DEVELOPMENT, V115, P607; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HECHT PM, 1993, GENETICS, V135, P405; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; IP YT, 1991, CELL, V64, P439; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; JIN YS, 1990, CELL, V60, P873, DOI 10.1016/0092-8674(90)90100-S; LEVIS R, 1982, P NATL ACAD SCI-BIOL, V79, P564, DOI 10.1073/pnas.79.2.564; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; PAN DJ, 1991, GENE DEV, V5, P1892, DOI 10.1101/gad.5.10.1892; RAY RP, 1991, DEVELOPMENT, V113, P35; ROBERTSON HM, 1988, GENETICS, V118, P461; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; Saiki R. K., 1988, Genome analysis: a practical approach., P141; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SEIFERT E, 1987, ROUX ARCH DEV BIOL, V196, P78, DOI 10.1007/BF00402028; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	42	273	282	0	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	1994	76	4					677	688		10.1016/0092-8674(94)90507-X	http://dx.doi.org/10.1016/0092-8674(94)90507-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124709				2022-12-28	WOS:A1994MZ28500010
J	CLESHAM, GJ; SCOTT, J; OAKLEY, CM; MCCARTHY, A; WALPORT, MJ; HUGHES, JMB; SILVERMAN, M				CLESHAM, GJ; SCOTT, J; OAKLEY, CM; MCCARTHY, A; WALPORT, MJ; HUGHES, JMB; SILVERMAN, M			BETA-ADRENERGIC AGONISTS AND PULMONARY-EDEMA IN PRETERM LABOR	BRITISH MEDICAL JOURNAL			English	Discussion							RITODRINE HYDROCHLORIDE; INFUSION				CLESHAM, GJ (corresponding author), HAMMERSMITH HOSP,DEPT MED,LONDON W12 0NN,ENGLAND.			Walport, Mark/0000-0001-7220-5273				Hankins G.D.V., 1991, CRITICAL CARE OBSTET, P231; HAUTH JC, 1983, AM J OBSTET GYNECOL, V146, P916, DOI 10.1016/0002-9378(83)90964-X; HENDRICKS SK, 1986, AM J OBSTET GYNECOL, V154, P921, DOI 10.1016/0002-9378(86)90486-2; KING JF, 1988, BRIT J OBSTET GYNAEC, V95, P211, DOI 10.1111/j.1471-0528.1988.tb06860.x; LARSEN JF, 1986, OBSTET GYNECOL, V67, P607, DOI 10.1097/00006250-198605000-00001; LEVENO KJ, 1990, OBSTET GYNECOL, V76, P12; LEVENO KJ, 1986, LANCET, V1, P1293; PHILIPSEN T, 1981, OBSTET GYNECOL, V58, P304; 1992, NEW ENGL J MED, V327, P308	9	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 22	1994	308	6923					260	262		10.1136/bmj.308.6923.260	http://dx.doi.org/10.1136/bmj.308.6923.260			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT539	8111264	Green Published			2022-12-28	WOS:A1994MT53900027
J	NAIK, PC; JONES, RG				NAIK, PC; JONES, RG			ALCOHOL HISTORIES TAKEN FROM ELDERLY PEOPLE ON ADMISSION	BRITISH MEDICAL JOURNAL			English	Article									STONEBRIDGE CTR,NOTTINGHAM NG3 2FH,ENGLAND; QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								BARRISON IG, 1980, BRIT MED J, V281, P1040, DOI 10.1136/bmj.281.6247.1040; BLAZER DG, 1984, ALCOHOLISM ELDERLY, P25; CURTIS JR, 1989, J AM GERIATR SOC, V37, P310, DOI 10.1111/j.1532-5415.1989.tb05496.x; JANIK SW, 1983, J STUD ALCOHOL, V44, P307, DOI 10.15288/jsa.1983.44.307; 1988, ADIY GUIDE OLDER PEO	5	24	24	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 22	1994	308	6923					248	248		10.1136/bmj.308.6923.248	http://dx.doi.org/10.1136/bmj.308.6923.248			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MT539	8111261	Green Published			2022-12-28	WOS:A1994MT53900023
J	LIMA, CD; WANG, JC; MONDRAGON, A				LIMA, CD; WANG, JC; MONDRAGON, A			3-DIMENSIONAL STRUCTURE OF THE 67K N-TERMINAL FRAGMENT OF ESCHERICHIA-COLI DNA TOPOISOMERASE-I	NATURE			English	Article							RAY-DIFFRACTION DATA; ESCHERICHIA-COLI; MACROMOLECULAR CRYSTALLOGRAPHY; TYPE-1 TOPOISOMERASES; CRYSTAL-STRUCTURES; ACTIVE-SITE; PROTEIN; BINDING; RESOLUTION; IDENTIFICATION	The three-dimensional structure of the 67K amino-terminal fragment of Escherichia coli DNA topoisomerase I has been determined to 2.2 angstrom resolution. The polypeptide folds in an unusual way to give four distinct domains enclosing a hole large enough to accommodate a double-stranded DNA. The active-site tyrosyl residue, which is involved in the transient breakage of a DNA strand and the formation of a covalent enzyme-DNA intermediate, is present at the interface of two domains. The structure suggests a plausible mechanism by which E. coli DNA topoisomerase I and other members of the same DNA topoisomerase subfamily could catalyse the passage of one DNA strand through a transient break in another strand.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138; NORTHWESTERN AVE,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208	Harvard University				Lima, Christopher/0000-0002-9163-6092	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051350] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM051350] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANHOH T, 1993, P INT S DNA TOOISOME; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERANSTEED RK, 1989, PROTEINS, V6, P249, DOI 10.1002/prot.340060307; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRANDEN CI, 1980, Q REV BIOPHYS, V13, P317, DOI 10.1017/S0033583500001712; BROWN PO, 1981, P NATL ACAD SCI-BIOL, V78, P843, DOI 10.1073/pnas.78.2.843; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; DEAN F, 1983, COLD SPRING HARB SYM, V47, P769; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DOMANICO PL, 1991, J INORG BIOCHEM, V42, P87, DOI 10.1016/0162-0134(91)80035-G; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; DURBIN RM, 1986, SCIENCE, V232, P1127, DOI 10.1126/science.3704639; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GILSON MK, 1987, J COMPUT CHEM, V9, P327; GRAU UM, 1981, J MOL BIOL, V151, P289, DOI 10.1016/0022-2836(81)90516-7; HARRISON SC, 1968, J APPL CRYSTALLOGR, V1, P84, DOI 10.1107/S0021889868005054; HENDRICKSON WA, 1980, BIOMOLECULAR STRUCTU, V1, P43; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOPE H, 1988, ACTA CRYSTALLOGR B, V44, P22, DOI 10.1107/S0108768187008632; IVEY DM, 1992, NUCLEIC ACIDS RES, V20, P4928, DOI 10.1093/nar/20.18.4928; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM RA, 1992, J BIOL CHEM, V267, P17178; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; KIRKEGAARD K, 1984, COLD SPRING HARB SYM, V49, P411, DOI 10.1101/SQB.1984.049.01.047; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; LIMA CD, 1993, J MOL BIOL, V232, P1213, DOI 10.1006/jmbi.1993.1474; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LYNN RM, 1989, PROTEINS, V6, P231, DOI 10.1002/prot.340060305; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SIM GA, 1960, ACTA CRYSTALLOGR, V13, P511, DOI 10.1107/S0365110X60001266; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TSE Y, 1980, CELL, V22, P269, DOI 10.1016/0092-8674(80)90174-9; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; TSEDINH YC, 1991, J BIOL CHEM, V266, P14217; VANDERLAAN JM, 1989, BIOCHEMISTRY-US, V28, P7199, DOI 10.1021/bi00444a011; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JC, 1982, NUCLEASES, P41; ZUMSTEIN L, 1986, J MOL BIOL, V191, P333, DOI 10.1016/0022-2836(86)90130-0; 1979, 4 DAR LAB COLL COMP	62	265	269	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 13	1994	367	6459					138	146		10.1038/367138a0	http://dx.doi.org/10.1038/367138a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ780	8114910				2022-12-28	WOS:A1994MQ78000050
J	CZAJA, R; MCFALL, SL; WARNECKE, RB; FORD, L; KALUZNY, AD				CZAJA, R; MCFALL, SL; WARNECKE, RB; FORD, L; KALUZNY, AD			PREFERENCES OF COMMUNITY PHYSICIANS FOR CANCER SCREENING GUIDELINES	ANNALS OF INTERNAL MEDICINE			English	Article							FAMILY PHYSICIANS; PRIMARY CARE; PATTERNS; MAMMOGRAPHY; PREVENTION; MEDICINE	Objective: To assess factors related to consensus among community physicians regarding appropriate screening intervals for eight cancer screening procedures for which guidelines have been published. Design: Interviews were conducted with a national random sample of 3436 physicians in family practice, internal medicine, general surgery, and gynecology by mail or telephone or both. The overall response rate was 67%. Measurements: Consensus by specialization and by physician and practice characteristics on the appropriate screening intervals for early detection of cancers of the breast, cervix, colon and rectum, and lung for asymptomatic adults at normal risk. ii Results: More than 60% of the physicians surveyed agreed on the length of the screening intervals for six of eight procedures. Consensus most closely followed American Cancer Society- and National Cancer Institute-recommended screening intervals for all procedures except chest roentgenogram Acceptance of screening intervals was not related to the extent of agreement among published guidelines. Surgeons tended to favor more aggressive screening than family physicians and internists; gynecologists most consistently favored aggressive screening for cancers occurring in women. Older physicians and those in solo practice tended to favor outmoded procedures such as routine chest roentgenograms and to be more conservative about screening intervals. Conclusions: Physicians stated that they follow the American Cancer Society and National Cancer Institute guidelines for cancer screening more than the guidelines published by their own specialty societies, but they also reported procedures not recommended in any guidelines. These findings suggest that changing physician screening practices will be difficult.	UNIV ILLINOIS, SURVEY RES LAB, CHICAGO, IL USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT HLTH PROMOT SCI, OKLAHOMA CITY, OK 73190 USA; NCI, BETHESDA, MD 20892 USA; UNIV N CAROLINA, CECIL G SHEPS HLTH SERV RES CTR, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH PUBL HLTH, CHAPEL HILL, NC 27599 USA; N CAROLINA STATE UNIV, RALEIGH, NC USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Oklahoma System; University of Oklahoma Health Sciences Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; North Carolina State University					DIVISION OF CANCER PREVENTION AND CONTROL [N01CN075435] Funding Source: NIH RePORTER; NCI NIH HHS [N01CN75435] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANES D, 1988, PREV MED, V17, P643, DOI 10.1016/0091-7435(88)90057-6; [Anonymous], COMMON SCREENING TES; [Anonymous], 1989, GUIDE CLIN PREVENTIV; BASSETT LW, 1986, AM J ROENTGENOL, V147, P689, DOI 10.2214/ajr.147.4.689; BATTISTA RN, 1988, ANNU REV PUBL HEALTH, V9, P21; BATTISTA RN, 1985, CAN MED ASSOC J, V132, P1013; BATTISTA RN, 1983, AM J PUBLIC HEALTH, V73, P1036, DOI 10.2105/AJPH.73.9.1036; BERGNER M, 1990, ARCH INTERN MED, V150, P431, DOI 10.1001/archinte.150.2.431; COLEMAN JS, 1986, MED INNOVATION DIFFU; DIETRICH AJ, 1984, AM J PUBLIC HEALTH, V74, P223, DOI 10.2105/AJPH.74.3.223; EISENBERG JM, 1985, MED CARE, V23, P461, DOI 10.1097/00005650-198505000-00010; FOX SA, 1988, RADIOLOGY, V166, P431, DOI 10.1148/radiology.166.2.3336718; GEMSON DH, 1987, NEW YORK STATE J MED, V87, P643; GREENWALD P, 1986, NCI MONOGRAPH, V2; Havlicek P L, 1984, IMJ Ill Med J, V166, P285; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; KALUZNY AD, 1989, J NATL CANCER I, V81, P1717, DOI 10.1093/jnci/81.22.1717; Kanouse DE, 1989, CHANGING MED PRACTIC; KANOUSE DE, 1991, DISSEMINATION PRACTI; LEMESHOW S, 1984, AM J EPIDEMIOL, V119, P147, DOI 10.1093/oxfordjournals.aje.a113732; LOMAS J, 1991, ANNU REV PUBL HEALTH, V12, P41, DOI 10.1146/annurev.pu.12.050191.000353; MCPHEE SJ, 1986, J GEN INTERN MED, V1, P275, DOI 10.1007/BF02596202; MILLER AB, 1986, J CHRON DIS, V39, P1067, DOI 10.1016/0021-9681(86)90140-2; Nash D B, 1991, Front Health Serv Manage, V8, P3; WARNER SL, 1989, J FAM PRACTICE, V29, P281; WEISMAN CS, 1986, PREV MED, V15, P342, DOI 10.1016/0091-7435(86)90002-2; WOOLF SH, 1990, ARCH INTERN MED, V150, P1811, DOI 10.1001/archinte.150.9.1811; 1990, OM900086 AG HLTH CAR; 1979, CAN MED ASS J, V121, P1193; 1985, CA-CANCER J CLIN, V35, P197; 1987, JAMA-J AM MED ASSOC, V257, P2196; 1978, I MED PREVENTION PRO, P1; 1987, WORKING GUIDELINES E; 1980, PROMOTING HLTH PREVE; 1990, CONSENSUS DEV NIH IM; 1989, JAMA-J AM MED ASSOC, V261, P2535	36	73	73	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					602	608		10.7326/0003-4819-120-7-199404010-00012	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8117000				2022-12-28	WOS:A1994NC76400012
J	LIPSCHUTZ, JH; ARIEFF, AI				LIPSCHUTZ, JH; ARIEFF, AI			RESET OSMOSTAT IN A HEALTHY PATIENT	ANNALS OF INTERNAL MEDICINE			English	Note							HORMONE-SECRETION; HYPONATREMIA		VET AFFAIRS MED CTR, SAN FRANCISCO, CA 94121 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)					NIA NIH HHS [R01AG08575] Funding Source: Medline; NIDDK NIH HHS [DK07219] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008575] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ASSADI FK, 1986, J PEDIATR-US, V108, P262, DOI 10.1016/S0022-3476(86)81000-9; BANNISTER P, 1984, J PEDIATR-US, V104, P97, DOI 10.1016/S0022-3476(84)80601-0; COOKE CR, 1979, MEDICINE, V58, P240, DOI 10.1097/00005792-197905000-00004; COOPER PE, 1991, CLIN NEUROLOGY, V3, P50; DEFRONZO RA, 1976, ANN INTERN MED, V84, P538, DOI 10.7326/0003-4819-84-5-538; HILL AR, 1990, AM J MED, V88, P357, DOI 10.1016/0002-9343(90)90489-Z; HOWE JG, 1983, ANN NEUROL, V13, P201, DOI 10.1002/ana.410130217; ROBERTSON GL, 1991, KIDNEY, P710; ROWE JW, 1976, NEPHRON, V17, P270, DOI 10.1159/000180731; WALL BM, 1992, AM J MED, V93, P223, DOI 10.1016/0002-9343(92)90055-G	10	11	11	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					574	576		10.7326/0003-4819-120-7-199404010-00007	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8116995				2022-12-28	WOS:A1994NC76400007
J	TURA, S; BACCARANI, M; ZUFFA, E; RUSSO, D; ZACCARIA, A; FIACCHINI, M; TESTONI, N; ZAMAGNI, MD; MARTINELLI, G; DAMIANI, D; MICHIELI, M; FOWST, C; HOLDENER, EE; SPECCHIA, G; LISO, V; MORRA, E; BERNASCONI, C; ALIMENA, G; MANDELLI, F; LEONI, P; DANIELI, G; NOSARI, A; DECATALDO, F; MAJOLINO, I; CARONIA, F; LIBERATI, AM; GRIGNANI, F; TABILIO, A; MARTELLI, M; PAOLINO, F; RESEGOTTI, L; DITUCCI, A; BROCCIA, G; LEONI, F; CIOLLI, S; LUCIANO, L; ROTOLI, B; PERRICONE, R; CAJOZZO, A; MONTUORO, A; DELAURENZI, A; VOLPE, E; DEMILIO, A; BATTISTA, R; CAPUCCI, A; IZZI, T; SCAPOLI, GL; CASTOLDI, GL; LOMBARDO, M; TORLONTANO, G; LANDOLFI, R; LEONE, G; DELFINI, C; SPARAVENTI, G; PAPINESCHI, F; SPREMOLLA, G; RISSO, M; MARMONT, AM; DINI, D; DIPRISCO, U; MANGONI, L; RIZZOLI, V; GIRINO, M; ASCARI, E; BODENIZZA, CA; CAROTENUTO, M; DIFRANCESCO, A; QUAGLINO, D; NARDELLI, S; CICCONE, F; MIRAGLIA, E; DEBIASE, R; GALLO, E; PILERI, A; RAMBALDI, A; BARBUI, T; MORANDI, S; BIANCHINI, E; DEROSA, C; CIMINO, R; RONCA, F; NOBILE, F; CANTONETTI, M; PAPA, G; GALLAMINI, A; BUFFA, F; MUSOLINO, C; SQUADRITO, G; CAPALDI, A; GIOVANNELLI, E; PINOTTI, G; VENCO, A; ZAGONEL, V; PINTO, A; GENTILINI, I; COSER, P; GUGLIELMO, P; CACCIOLA, E; PIZZUTI, M; RICCIUTI, F; FANIN, R; CRISCUOLO, D; MONTEFUSCO, E				TURA, S; BACCARANI, M; ZUFFA, E; RUSSO, D; ZACCARIA, A; FIACCHINI, M; TESTONI, N; ZAMAGNI, MD; MARTINELLI, G; DAMIANI, D; MICHIELI, M; FOWST, C; HOLDENER, EE; SPECCHIA, G; LISO, V; MORRA, E; BERNASCONI, C; ALIMENA, G; MANDELLI, F; LEONI, P; DANIELI, G; NOSARI, A; DECATALDO, F; MAJOLINO, I; CARONIA, F; LIBERATI, AM; GRIGNANI, F; TABILIO, A; MARTELLI, M; PAOLINO, F; RESEGOTTI, L; DITUCCI, A; BROCCIA, G; LEONI, F; CIOLLI, S; LUCIANO, L; ROTOLI, B; PERRICONE, R; CAJOZZO, A; MONTUORO, A; DELAURENZI, A; VOLPE, E; DEMILIO, A; BATTISTA, R; CAPUCCI, A; IZZI, T; SCAPOLI, GL; CASTOLDI, GL; LOMBARDO, M; TORLONTANO, G; LANDOLFI, R; LEONE, G; DELFINI, C; SPARAVENTI, G; PAPINESCHI, F; SPREMOLLA, G; RISSO, M; MARMONT, AM; DINI, D; DIPRISCO, U; MANGONI, L; RIZZOLI, V; GIRINO, M; ASCARI, E; BODENIZZA, CA; CAROTENUTO, M; DIFRANCESCO, A; QUAGLINO, D; NARDELLI, S; CICCONE, F; MIRAGLIA, E; DEBIASE, R; GALLO, E; PILERI, A; RAMBALDI, A; BARBUI, T; MORANDI, S; BIANCHINI, E; DEROSA, C; CIMINO, R; RONCA, F; NOBILE, F; CANTONETTI, M; PAPA, G; GALLAMINI, A; BUFFA, F; MUSOLINO, C; SQUADRITO, G; CAPALDI, A; GIOVANNELLI, E; PINOTTI, G; VENCO, A; ZAGONEL, V; PINTO, A; GENTILINI, I; COSER, P; GUGLIELMO, P; CACCIOLA, E; PIZZUTI, M; RICCIUTI, F; FANIN, R; CRISCUOLO, D; MONTEFUSCO, E			INTERFERON ALFA-2A AS COMPARED WITH CONVENTIONAL CHEMOTHERAPY FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; BONE-MARROW TRANSPLANTATION; THERAPY	Background. In view of studies showing that interferon alfa was effective treatment for chronic myeloid leukemia and that it prolonged survival, we organized a prospective, controlled comparative study of this treatment. Methods. We compared recombinant interferon alfa-2a with conventional chemotherapy (hydroxyurea or busulfan) in a trial designed to have a power of 80 percent to detect a difference of 20 percent in median survival between the group given interferon and the group given conventional chemotherapy. Between 1986 and 1988, 322 patients with previously untreated or minimally treated Philadelphia chromosome-positive chronic myeloid leukemia were randomly assigned to treatment with either interferon alfa-2a (218 patients) or conventional chemotherapy (104 patients). Results. The rate of karyotypic response (defined as >33 percent of metaphases negative for the Philadelphia chromosome) was 30 percent in the interferon groupand 5 percent in the conventional-chemotherapy group (P<0.001). The time to progression from the chronic phase of leukemia to an accelerated or a blastic phase was longer in the interferon group than in the conventional-chemotherapy group (median, >72 vs. 45 months; P<0.001), as was survival (median, 72 vs. 52 months; 6-year survival, 50 percent vs. 29 percent; P = 0.002 for both comparisons). There was one treatment-related death in each group. Treatment was discontinued because of side effects (mainly influenza-like, gastrointestinal, or neurologic symptoms) in 35 patients given interferon alfa-2a (16 percent). The cost of interferon treatment was 200 times that of the conventional treatment. Conclusions. During long-term treatment of Philadelphia chromosome-positive chronic myeloid leukemia, interferon alfa-2a induced more karyotypic responses than conventional chemotherapy, delayed disease progression longer, and prolonged overall survival more.	UNIV BOLOGNA,INST HEMATOL L&A SERAGNOLI,BOLOGNA,ITALY; UNIV UDINE,CHAIR HEMATOL,UDINE,ITALY; HOFFMAN LAROCHE,MILAN,ITALY; HOFFMANN LA ROCHE AG,CH-4002 BASEL,SWITZERLAND; UNIV BARI,BARI,ITALY; UNIV PAVIA,I-27100 PAVIA,ITALY; UNIV ROMA LA SAPIENZA,ROME,ITALY; UNIV ANCONA,ANCONA,ITALY; OSPED NIGUARDA CA GRANDA,MILAN,ITALY; OSPED CERVELLO,PALERMO,ITALY; UNIV PERUGIA,I-06100 PERUGIA,ITALY; OSPED MOLINETTE,TURIN,ITALY; OSPED ONCOL BUSINCO,CAGLIARI,ITALY; UNIV FLORENCE,FLORENCE,ITALY; UNIV NAPLES,NAPLES,ITALY; UNIV PALERMO,PALERMO,ITALY; OSPED SAN CAMILLO LELLIS,ROME,ITALY; OSPED AVELLINO,AVELLINO,ITALY; OSPED VICENZA,VICENZA,ITALY; OSPED BRESCIA,BRESCIA,ITALY; UNIV FERRARA,I-44100 FERRARA,ITALY; UNIV CHIETI,CHIETI,ITALY; UNIV CATTOLICA,ROME,ITALY; OSPED PESARO,PESARO,ITALY; UNIV PISA,PISA,ITALY; OSPED SAN MARTINO GENOVA,GENOA,ITALY; UNIV MODENA,I-41100 MODENA,ITALY; UNIV PARMA,I-43100 PARMA,ITALY; CASA SOLLIEVO SOFFERENZA,SAN GIOVANNI ROTO,ITALY; UNIV LAQUILA,I-67100 LAQUILA,ITALY; OSPED LATINA,LATINA,ITALY; OSPED NUOVO PELLEGRINI,NAPLES,ITALY; UNIV TURIN,TURIN,ITALY; OSPED RIUNITI BERGAMO,I-24100 BERGAMO,ITALY; OSPED CREMONA,CREMONA,ITALY; OSPED REGGIO CALABRIA,CALABRIA,ITALY; OSPED CARDARELLI,NAPLES,ITALY; UNIV ROMA TOR VERGATA,ROME,ITALY; OSPED CUNEO,CUNEO,ITALY; UNIV MESSINA,MESSINA,ITALY; OSPED MAURIZIANO UMBERTO 1,TURIN,ITALY; OSPED VARESE,VARESE,ITALY; CTR REG RIFERIMENTO ONCOL,AVIANO,ITALY; OSPED BOLZANO,BOLZANO,ITALY; UNIV CATANIA,CATANIA,ITALY; OSPED POTENZA,POTENZA,ITALY	University of Bologna; University of Udine; Roche Holding; Universita degli Studi di Bari Aldo Moro; University of Pavia; Sapienza University Rome; Marche Polytechnic University; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; University of Perugia; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Florence; University of Naples Federico II; University of Palermo; Hospital Spedali Civili Brescia; University of Ferrara; G d'Annunzio University of Chieti-Pescara; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Pisa; University of Genoa; IRCCS AOU San Martino IST; Universita di Modena e Reggio Emilia; University of Parma; IRCCS Casa Sollievo Della Sofferenza; University of L'Aquila; University of Turin; Ospedali Riuniti di Bergamo; Antonio Cardarelli Hospital; University of Rome Tor Vergata; University of Messina; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; Mauritian Umberto I Hospital; IRCCS Aviano (CRO); University of Catania			Rambaldi, Alessandro/M-6172-2019; Giuseppe Leone, Full Professor/I-9166-2019; zagonel, vittorina/F-4226-2014; Cantonetti, Maria/AAB-9806-2019; Rambaldi, Alessandro/P-2603-2018; Russo, Domenico/C-3947-2011	Rambaldi, Alessandro/0000-0002-3739-7502; Giuseppe Leone, Full Professor/0000-0002-7812-5300; zagonel, vittorina/0000-0002-0829-2525; Rambaldi, Alessandro/0000-0002-3739-7502; 				ALIMENA G, 1988, BLOOD, V72, P642; ARCESE W, 1990, BONE MARROW TRANSPL, V5, P309; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHAMPLIN RE, 1988, SEMIN HEMATOL, V25, P74; COX DR, 1972, J R STAT SOC B, V34, P187; Cox DR., 1970, ANAL BINARY DATA; DECARLI A, 1986, TUMORI, V72, P231, DOI 10.1177/030089168607200303; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; SOKAL JE, 1988, SEMIN HEMATOL, V25, P49; SOKAL JE, 1984, BLOOD, V63, P789, DOI 10.1182/blood.V63.4.789.789; TALPAZ M, 1991, ANN INTERN MED, V114, P532, DOI 10.7326/0003-4819-114-7-532; TALPAZ M, 1987, BLOOD, V69, P1280; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; TALPAZ M, 1983, BLOOD, V62, P689; TALPAZ M, 1988, SEMIN HEMATOL, V25, P62; TURA S, 1986, HAEMATOLOGICA, V71, P169; TURA S, 1990, BLOOD S, V76, pA329; 1992, HAEMATOLOGICA, V77, P204	19	503	509	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 24	1994	330	12					820	825						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB803	8114834				2022-12-28	WOS:A1994NB80300004
J	PLEIMAN, CM; HERTZ, WM; CAMBIER, JC				PLEIMAN, CM; HERTZ, WM; CAMBIER, JC			ACTIVATION OF PHOSPHATIDYLINOSITOL-3' KINASE BY SRC-FAMILY KINASE SH3 BINDING TO THE P85 SUBUNIT	SCIENCE			English	Article							RECEPTOR TYROSINE KINASES; CELL ANTIGEN RECEPTOR; FACTOR-I RECEPTOR; LYMPHOCYTES-B; GROWTH-FACTOR; PDGF RECEPTOR; MIDDLE-T; C-SRC; PROTEIN; 3-KINASE	Engagement of antigen receptor complexes induces rapid activation of Src-family kinases and association with phosphatidylinositol-3' kinase (Pl-3 kinase). Here it was found that the Src homology 3 (SH3) domain of Lyn and Fyn bound to a proline-rich region (residues 84 to 99) within the 85-kilodalton subunit (p85) of Pl-3 kinase. The binding of SH3 to the purified kinase led to a five- to sevenfold increase in the specific activity of Pl-3 kinase. Ligand-induced receptor stimulation activated Pl-3 kinase, and this activation was blocked by a peptide containing residues 84 to 99 of p85. These data demonstrate a mechanism for Pl-3 kinase activation and show that binding of SH3 domains to proline-rich target sequences can regulate enzymatic activity.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV BASIC SCI, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, DEPT MICROBIOL & IMMUNOL, DENVER, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Cambier, John/0000-0002-7803-242X	PHS HHS [A129903, A121768, A120519] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DEFRANCO AL, 1989, NATURE, V342, P340, DOI 10.1038/342340a0; DEFRANCO AL, 1987, ANNU REV CELL BIOL, V3, P143; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOLD MR, 1992, J IMMUNOL, V148, P2012; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; PLEIMAN CM, UNPUB; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WARD SG, 1992, J BIOL CHEM, V267, P23862; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMAMOTO T, 1992, SCIENCE, V89, P1118; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	57	425	434	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 18	1994	263	5153					1609	1612		10.1126/science.8128248	http://dx.doi.org/10.1126/science.8128248			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	8128248				2022-12-28	WOS:A1994NB67300031
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW REGULATION REQUIRES IMPRINTING ON SOLID ORAL DOSAGE FORM-DRUG PRODUCTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					812	812						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ498	8114223				2022-12-28	WOS:A1994MZ49800004
J	BARFORD, D; FLINT, AJ; TONKS, NK				BARFORD, D; FLINT, AJ; TONKS, NK			CRYSTAL-STRUCTURE OF HUMAN PROTEIN-TYROSINE-PHOSPHATASE 1B	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; HUMAN-PLACENTA; MACROMOLECULAR CRYSTALLOGRAPHY; SEQUENCE HOMOLOGY; CATALYTIC SUBUNIT; SH2 DOMAIN; EXPRESSION; CLONING; KINASE; LAR	Protein tyrosine phosphatases (PTPs) constitute a family of receptor-like and cytoplasmic signal transducing enzymes that catalyze the dephosphorylation of phosphotyrosine residues and are characterized by homologous catalytic domains. The crystal structure of a representative member of this family, the 37-kilodalton form (residues 1 to 321) of PTP1 B, has been determined at 2.8 Angstrom resolution. The enzyme consists of a single domain with the catalytic site located at the base of a shallow cleft. The phosphate recognition site is created from a loop that is located at the amino-terminus of an or helix. This site is formed from an 11-residue sequence motif that is diagnostic of PTPs and the dual specificity phosphatases, and that contains the catalytically essential cysteine and arginine residues. The position of the invariant cysteine residue within the phosphate binding site is consistent with its role as a nucleophile in the catalytic reaction. The structure of PTP1B should serve as a model for other members of the PTP family and as a framework for understanding the mechanism of tyrosine dephosphorylation.			BARFORD, D (corresponding author), COLD SPRING HARBOR LAB, WM KECK STRUCT BIOL LAB, COLD SPRING HARBOR, NY 11724 USA.				NCI NIH HHS [CA53840] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053840, R37CA053840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABADZAPATERO C, 1987, J MOL BIOL, V198, P445, DOI 10.1016/0022-2836(87)90293-2; ALESSI DR, 1993, ONCOGENE, V8, P2015; BARFORD D, UNPUB DESCRIPTION CO; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BROWNSHIMER S, 1992, CANCER RES, V52, P478; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CHHO H, 1993, PROTEIN SCI, V2, P977; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KENNER KA, 1993, J BIOL CHEM, V268, P25455; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LIVINGSTON CD, IN PRESS INT J PEPTI; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; POT DA, 1991, J BIOL CHEM, V266, P19688; POTTS M, 1993, J BIOL CHEM, V268, P7632; RAMALINGAM R, 1993, J BIOL CHEM, V268; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SCHNEIDER G, 1993, EMBO J, V12, P2609, DOI 10.1002/j.1460-2075.1993.tb05921.x; Schultz Leonard D., 1993, Cell, V73, P1445; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STRAUSS MG, 1991, P SOC PHOTO I ENG, V1447, P12; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tonks N K, 1993, Semin Cell Biol, V4, P373, DOI 10.1006/scel.1993.1044; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TSAI AYM, 1991, J BIOL CHEM, V266, P10534; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WARY KK, 1993, CANCER RES, V53, P1498; WEISSMAN L, 1982, COMPUTATIONAL CRYSTA, P56; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; [No title captured]	76	673	690	3	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 11	1994	263	5152					1397	1404		10.1126/science.8128219	http://dx.doi.org/10.1126/science.8128219			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128219				2022-12-28	WOS:A1994MZ92700020
J	PASCUALLEONE, A; GRAFMAN, J; HALLETT, M				PASCUALLEONE, A; GRAFMAN, J; HALLETT, M			MODULATION OF CORTICAL MOTOR OUTPUT MAPS DURING DEVELOPMENT OF IMPLICIT AND EXPLICIT KNOWLEDGE	SCIENCE			English	Article							FREQUENCY-DISCRIMINATION TASK; FOCAL MAGNETIC STIMULATION; ADULT OWL MONKEYS; FUNCTIONAL REORGANIZATION; MEMORY; CORTEX; BRAIN; SYSTEM; DEAFFERENTATION; REPRESENTATION	The excitability of the human motor cortex during the development of implicit and declarative knowledge of a motor task was examined. During a serial reaction time test, subjects developed implicit knowledge of the test sequence, which was reflected by diminishing response times. Motor cortical mapping with transcranial magnetic stimulation revealed that the cortical output maps to the muscles involved in the task became progressively larger until explicit knowledge was achieved, after which they returned to their baseline topography. These results illustrate the rapid functional plasticity of cortical outputs associated with learning and with the transfer of knowledge from an implicit to explicit state.	NINCDS, MED NEUROL BRANCH, COGNIT NEUROSCI SECT, BETHESDA, MD 20892 USA; NINCDS, MED NEUROL BRANCH, HUMAN MOTOR CONTROL SECT, BETHESDA, MD 20892 USA; UNIV VALENCIA, DEPT FISIOL, UNIDAD NEUROBIOL, VALENCIA, SPAIN	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Valencia			Pascual-Leone, Alvaro/AAC-5101-2019; Pascual-Leone, Alvaro/G-6566-2011	Pascual-Leone, Alvaro/0000-0001-8975-0382; Grafman, Jordan H./0000-0001-8645-4457				ASANUMA H, 1991, NEUROREPORT, V2, P217, DOI 10.1097/00001756-199105000-00001; BRASILNETO JP, 1993, BRAIN, V116, P511, DOI 10.1093/brain/116.3.511; BRASILNETO JP, 1992, NEUROLOGY, V42, P1302, DOI 10.1212/WNL.42.7.1302; CAREW TJ, 1986, ANNU REV NEUROSCI, V9, P435, DOI 10.1146/annurev.ne.09.030186.002251; COHEN LG, 1990, ELECTROEN CLIN NEURO, V75, P350, DOI 10.1016/0013-4694(90)90113-X; COHEN LG, 1991, BRAIN, V114, P615, DOI 10.1093/brain/114.1.615; FABRETHORPE M, 1991, BEHAV NEUROSCI, V105, P176, DOI 10.1037/0735-7044.105.1.176; GLUCK MA, 1993, ANNU REV NEUROSCI, V16, P667, DOI 10.1146/annurev.ne.16.030193.003315; GRAFTON ST, 1992, J NEUROSCI, V12, P2542; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; JENKINS WM, 1990, NEUROPSYCHOLOGIA, V28, P573, DOI 10.1016/0028-3932(90)90035-M; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; LEVY WJ, 1990, BRAIN RES, V510, P130, DOI 10.1016/0006-8993(90)90738-W; LEVY WJ, 1991, ELECTROEN CLIN NEURO, P51; MACCABEE PJ, 1990, ELECTROEN CLIN NEURO, V76, P131, DOI 10.1016/0013-4694(90)90211-2; MERZENICH MM, 1990, COLD SPRING HARB SYM, V55, P873; NUDO RJ, 1992, J NEUROSCI, V12, P2918, DOI 10.1523/JNEUROSCI.12-08-02918.1992; PASCUALLEONE A, 1993, ANN NEUROL, V34, P33, DOI 10.1002/ana.410340108; PASCUALLEONE A, 1993, NEUROLOGY, V43, pA157; PASCUALLEONE A, 1993, BRAIN, V116, P39, DOI 10.1093/brain/116.1.39; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RAMACHANDRAN VS, 1992, SCIENCE, V258, P1159, DOI 10.1126/science.1439826; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1071, DOI 10.1152/jn.1992.67.5.1071; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1015, DOI 10.1152/jn.1992.67.5.1015; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1057, DOI 10.1152/jn.1992.67.5.1057; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031, DOI 10.1152/jn.1992.67.5.1031; ROTH BJ, 1991, ELECTROEN CLIN NEURO, V81, P47, DOI 10.1016/0168-5597(91)90103-5; SANES JN, 1992, CEREB CORTEX, V2, P141, DOI 10.1093/cercor/2.2.141; SAYPOL JM, 1991, ANN BIOMED ENG, V19, P317, DOI 10.1007/BF02584306; SCHACTER DL, 1993, ANNU REV NEUROSCI, V16, P159, DOI 10.1146/annurev.ne.16.030193.001111; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; Schieber M. H., 1992, Society for Neuroscience Abstracts, V18, P504; Seitz R J, 1990, Neuroreport, V1, P57, DOI 10.1097/00001756-199009000-00016; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; SQUIRE LR, 1988, TRENDS NEUROSCI, V11, P170, DOI 10.1016/0166-2236(88)90144-0; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519; TOFTS PS, 1990, PHYS MED BIOL, V35, P1119, DOI 10.1088/0031-9155/35/8/008; Wassermann E. M., 1992, Society for Neuroscience Abstracts, V18, P939; WASSERMANN EM, 1992, ELECTROEN CLIN NEURO, V85, P1, DOI 10.1016/0168-5597(92)90094-R; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; WILLINGHAM DB, 1989, J EXP PSYCHOL LEARN, V15, P1047, DOI 10.1037/0278-7393.15.6.1047; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555	42	518	524	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 4	1994	263	5151					1287	1289		10.1126/science.8122113	http://dx.doi.org/10.1126/science.8122113			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	8122113				2022-12-28	WOS:A1994MY57000039
J	TIEMEI, C; QUAN, Y; EN, W				TIEMEI, C; QUAN, Y; EN, W			ANTIQUITY OF HOMO-SAPIENS IN CHINA	NATURE			English	Article							ESR	TEN years ago a well-preserved skull of an early form of Home sapiens was unearthed from Pleistocene cave deposits at the Jinniushan site in China. Here we present electron-spin resonance (ESR) and uranium-series dates from five fossil animal teeth collected from the hominid locality. The minimum ESR ages (195-165 kyr) are about 50 kyr younger than the uranium-series dates. Taken together, the results suggest an age of about 200 kyr or older for the Jinniushan skull, making it among the oldest H. sapiens material found in China, and almost as old as some of the latest Chinese H. erectus. This raises the possibility of the coexistence of the two species in China. The morphology of the skull suggests a strong local component of evolution, consonant with the 'multiregional continuity' model of the evolution of H. sapiens.	BEIJING UNIV,DEPT PHYS,BEIJING 100871,PEOPLES R CHINA	Peking University	TIEMEI, C (corresponding author), BEIJING UNIV,DEPT ARCHAEOL,BEIJING 100871,PEOPLES R CHINA.							Chen T, 1991, World Archaeol, V23, P147; CHEN TM, 1988, ARCHAEOMETRY, V30, P59; DECANNIERE P, 1986, NUCL TRACKS RAD MEAS, V11, P211; GRUN R, 1991, NUCL TRACKS RAD MEAS, V18, P143; GRUN R, 1989, APPL RADIAT ISOTOPES, V40, P1045; Grun R, 1985, SONDERVEROFFENTLICHU, V59, P1; LI TY, 1992, NATURE, V357, P404; LU ZE, 1989, LIAOHAL WENWU XUEKAI, P44; NAMBI KSV, 1986, ARCHAEOMETRY, V28, P202, DOI 10.1111/j.1475-4754.1986.tb00388.x; Wu RK., 1988, ACTA ANTHROPOL SIN, V7, P97; ZIMMERMA.DW, 1971, ARCHAEOMETRY, V13, P29, DOI 10.1111/j.1475-4754.1971.tb00028.x	11	26	31	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					55	56		10.1038/368055a0	http://dx.doi.org/10.1038/368055a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MY569	8107882				2022-12-28	WOS:A1994MY56900050
J	MARTIN, JR; RAIBAUD, A; OLLO, R				MARTIN, JR; RAIBAUD, A; OLLO, R			TERMINAL PATTERN ELEMENTS IN DROSOPHILA EMBRYO INDUCED BY THE TORSO-LIKE PROTEIN	NATURE			English	Article							RECEPTOR TYROSINE KINASE; GENE; MELANOGASTER; SEQUENCE; POLARITY; SITES	THE genes torso (tor)1 and torso-like (tsl)2 are two of the Drosophila maternal group genes implicated in a receptor tyrosine kinase signalling pathway that specifies terminal cell fate (reviewed in ref. 3). Loss-of function mutations in these loci cause an identical phenotype in which pattern elements from the anterior (acron) and posterior (telson) ends have been deleted. We have cloned the tsl gene and demonstrate here that, in agreement with previous genetic data, it encodes a protein that is secreted and whose transcription is restricted to specialized categories of follicle cells localized at the poles of the egg chamber. At early blastoderm, stage, tsl protein forms a symmetrical concentration gradient at the poles on the surface of the devitellinized embryo. Unrestricted expression of the tsl protein in tsl female mutants induces terminal pattern elements and suppresses the formation of abdomen in embryos. These results suggest that the tsl protein is the ligand that binds to the torso receptor.			MARTIN, JR (corresponding author), INST PASTEUR, BIOL MOLEC DROSOPHILE LAB, 25 RUE DOCTEUR ROUX, F-75724 PARIS 15, FRANCE.							ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ASHBURNER M, 1989, DROSOPHILA LABORATOR; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASANOVA J, 1993, NATURE, V362, P152, DOI 10.1038/362152a0; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; DEGELMANN A, 1986, DEV BIOL, V115, P479, DOI 10.1016/0012-1606(86)90268-X; King R. C., 1970, OVARIAN DEV DROSOPHI; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maniatis T., 1982, MOL CLONING; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; PERRIMON N, 1986, GENETICS, V113, P695; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Roberts D. B, 1986, DROSOPHILA PRACTICAL; ROBERTSON HM, 1988, GENETICS, V118, P461; SCHUEPBACH T, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P302; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STEINHAUER WR, 1989, MOL CELL BIOL, V9, P5726, DOI 10.1128/MCB.9.12.5726; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	25	84	86	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	1994	367	6465					741	745		10.1038/367741a0	http://dx.doi.org/10.1038/367741a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	8107870				2022-12-28	WOS:A1994MX63100060
J	TOWNER, EML; JARVIS, SN; WALSH, SSM; AYNSLEYGREEN, A				TOWNER, EML; JARVIS, SN; WALSH, SSM; AYNSLEYGREEN, A			MEASURING EXPOSURE TO INJURY RISK IN SCHOOLCHILDREN AGED 11-14	BRITISH MEDICAL JOURNAL			English	Article								Objective-To apply a measure of exposure to injury risk for schoolchildren aged 11-14 across a population and to examine how risk factors vary with sex, age, and affluence. Design-Self completion questionnaire survey administered in schools in May 1990. Setting-24 schools in Newcastle upon Tyne. Subjects-5334 pupils aged 11-14, of whom 4637 (87%) completed the questionnaire. Results-Boys were exposed to greater risk than girls in journeys to places to play outdoors: they took longer trips and were more likely to ride bicycles (relative risk 5.30 (95% confidence interval 4.23 to 6.64)) and less likely to travel by public transport or car. Younger pupils (aged 11-12) were less exposed to traffic during journeys to and from school: their journeys were shorter, they were less likely to walk (trip to school, relative risk 0.88 (0.83 to 0.94)), and they were more likely to travel by car (trip to school, relative risk 1.33 (1.13 to 1.56)) or school bus (1.33 (1.10 to 1.62)). Poorer children were exposed to greater risk than affluent children (from families that owned a car and a telephone): they were less likely to travel to school by car (relative risk 0.26 (0.20 to 0.33)) or to be accompanied by an adult (0.39 (0.32 to 0.48)). Conclusion-Injury risk data can provide useful information on child injury prevention and can be used to identify priorities and target resources for injury prevention on a citywide scale or for an individual school.			TOWNER, EML (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT CHILD HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND.							Dean A. G., 1990, EPI INFO VERSION 5 W; HACKETT A F, 1990, Journal of Human Nutrition and Dietetics, V3, P323, DOI 10.1111/j.1365-277X.1990.tb00243.x; HILLMAN M, 1990, ONE FALSE MOVE STUDY; Jones D., 1990, ROAD ACCIDENTS GREAT, P36; Reid K, 1985, TRUANCY SCH ABSENTEE; ROBERTS I, 1993, BRIT MED J, V302, P1737; TIGHT MR, 1987, THESIS U COLLEGE LON; TOWNER EML, 1993, REDUCING ACCIDENTS E; WALSH SS, 1992, J EPIDEMIOL COMMUN H, V46, P26, DOI 10.1136/jech.46.1.26; 1989, ED OBSERVED, V13, P6; 1992, HLTH NAITON STRATEGY; 1990, CHILDREN ROADS SAFER	12	44	44	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	1994	308	6926					449	452		10.1136/bmj.308.6926.449	http://dx.doi.org/10.1136/bmj.308.6926.449			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW976	8124176	Green Published			2022-12-28	WOS:A1994MW97600023
J	WEBB, AK; DAVID, TJ				WEBB, AK; DAVID, TJ			CLINICAL MANAGEMENT OF CHILDREN AND ADULTS WITH CYSTIC-FIBROSIS	BRITISH MEDICAL JOURNAL			English	Article							DIABETES-MELLITUS		MONSALL HOSP,MANCHESTER M10 8WR,LANCS,ENGLAND; UNIV MANCHESTER,MANCHESTER,ENGLAND	University of Manchester								BILTON D, 1992, RESP MED, V86, P507, DOI 10.1016/S0954-6111(96)80012-6; COHEN AM, 1990, RADIOLOGY, V175, P401, DOI 10.1148/radiology.175.2.2326467; DAVID TJ, 1982, LANCET, V2, P1204; Dodge J A, 1993, Paediatr Perinat Epidemiol, V7, P157, DOI 10.1111/j.1365-3016.1993.tb00390.x; DURIE PR, 1989, J ROY SOC MED, V82, P11; GOVAN JRW, 1993, LANCET, V342, P15, DOI 10.1016/0140-6736(93)91881-L; GRUNOW JC, 1994, RECENT ADV PEDIAT, V12, P23; HODSON ME, 1991, EUR RESPIR J, V4, P524; KEREM E, 1992, NEW ENGL J MED, V326, P1187, DOI 10.1056/NEJM199204303261804; LANNG S, 1992, EUR J PEDIATR, V151, P684, DOI 10.1007/BF01957574; NIXON PA, 1992, NEW ENGL J MED, V327, P1785, DOI 10.1056/NEJM199212173272504; PRYOR JA, 1993, PHYSIOTHERAPY J, V78, P105; RANASINHA C, 1993, LANCET, V342, P199, DOI 10.1016/0140-6736(93)92297-7; RAYNER RJ, 1991, RESPIR MED, V85, P19; REISMAN J, 1990, PEDIATRICS, V86, P374; VALERIUS NH, 1991, LANCET, V338, P725, DOI 10.1016/0140-6736(91)91446-2; 1993, ACCESS AVAILABILITY	17	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	1994	308	6926					459	462		10.1136/bmj.308.6926.459	http://dx.doi.org/10.1136/bmj.308.6926.459			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW976	8124182	Green Published			2022-12-28	WOS:A1994MW97600029
J	CANESSA, CM; SCHILD, L; BUELL, G; THORENS, B; GAUTSCHI, I; HORISBERGER, JD; ROSSIER, BC				CANESSA, CM; SCHILD, L; BUELL, G; THORENS, B; GAUTSCHI, I; HORISBERGER, JD; ROSSIER, BC			AMILORIDE-SENSITIVE EPITHELIAL NA+ CHANNEL IS MADE OF 3 HOMOLOGOUS SUBUNITS	NATURE			English	Article							ION CHANNEL; SODIUM-CHANNEL; HAIR CELL; MEMBRANE; PROTEIN; STRETCH; CHICK; EXPRESSION; CURRENTS; OOCYTES	THE amiloride-sensitive epithelial sodium channel constitutes the rate-limiting step for sodium reabsorption in epithelial cells that line the distal part of the renal tubule, the distal colon, the duct of several exocrine glands, and the lung. The activity of this channel is upregulated by vasopressin and aldosterone, hormones involved in the maintenance of sodium balance, blood volume and blood pressure1,2. We have identified the primary structure of the alpha-subunit of the rat epithelial sodium channel by expression cloning in Xenopus laevis oocytes3. An identical subunit has recently been reported4. Here we identify two other subunits (beta and gamma) by functional complementation of the alpha-subunit of the rat epithelial Na+ channel. The ion-selective permeability, the gating properties and the pharmacological profile of the channel formed by coexpressing the three subunits in oocytes are similar to that of the native channel.	UNIV LAUSANNE,INST PHARMACOL & TOXIKOL,BUGNON 27,CH-1005 LAUSANNE,SWITZERLAND; GLAXO INST MOLEC BIOL,CH-1228 PLAN LES OUATES,SWITZERLAND	University of Lausanne; GlaxoSmithKline			Horisberger, Jean-Daniel/A-2538-2009					AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; BEAR CE, 1990, AM J PHYSIOL, V258, pC421, DOI 10.1152/ajpcell.1990.258.3.C421; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; Canessa C. M., 1993, Journal of the American Society of Nephrology, V4, P864; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CHALFIE M, 1993, NATURE, V361, P504, DOI 10.1038/361504a0; CUTHBERT AW, 1992, J ROY SOC MED, V85, P2; DRISCOLL M, 1992, TRENDS NEUROSCI, V15, P15, DOI 10.1016/0166-2236(92)90343-7; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; HUDSPETH AJ, 1986, HEARING RES, V22, P21, DOI 10.1016/0378-5955(86)90070-5; JORGENSEN F, 1988, J PHYSIOL-LONDON, V403, P577, DOI 10.1113/jphysiol.1988.sp017265; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; OHMORI H, 1984, J PHYSIOL-LONDON, V350, P561, DOI 10.1113/jphysiol.1984.sp015218; PALMER LG, 1990, J GEN PHYSIOL, V96, P23, DOI 10.1085/jgp.96.1.23; PALMER LG, 1986, P NATL ACAD SCI USA, V83, P2767, DOI 10.1073/pnas.83.8.2767; PALMER LGA, 1992, REV PHYSL, V54, P51; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; Rossier BC, 1992, KIDNEY PHYSL PATHOPH, P1373; SARIBANSOHRABY S, 1992, AM J PHYSIOL, V263, pC1111, DOI 10.1152/ajpcell.1992.263.5.C1111; STAUB O, 1992, J CELL BIOL, V119, P1497, DOI 10.1083/jcb.119.6.1497; TAGLIETTI V, 1988, J PHYSIOL-LONDON, V407, P311, DOI 10.1113/jphysiol.1988.sp017417; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1; VANRENTERGHEM C, 1991, PFLUG ARCH EUR J PHY, V419, P401, DOI 10.1007/BF00371123; VIGNE P, 1989, J BIOL CHEM, V264, P7663	33	1703	1741	2	48	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					463	467		10.1038/367463a0	http://dx.doi.org/10.1038/367463a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	8107805				2022-12-28	WOS:A1994MU67900055
J	ANDERSON, BL				ANDERSON, BL			THE ROLE OF PARTIAL OCCLUSION IN STEREOPSIS	NATURE			English	Article							PERCEPTION; DEPTH	MODELS of stereopsis typically assume that all the information about stereoscopic depth is contained in the disparity field, that is, the positional differences of image features that arise from surfaces visible to both eyes. But such models have difficulty in resolving image regions containing occlusions, because a portion of the occluded surface is visible to only one of the two eyes ('half-occlusions')1. Here I present displays revealing an unexpected relationship between interocular differences in image position and occluding contours. The partial occlusion of contours can give rise to both horizontal and vertical image differences that are not disparities. The results show that the visual system interprets these image differences as signalling the presence of occluding contours. Even when a single line segment serves as a binocular target, subjective contours form that can appear both oriented and in depth. These local subjective contours have a strong tendency to interact cooperatively and form global contours not present in the monocular images. These and other findings2-4 show that stereoscopic processing actively decomposes vertical and horizontal image differences into disparities and half-occlusions. The two sources of information are complementary: while disparity provides relative depth information about surface features visible to both eyes, half-occlusions provide information to segment the visual world into coherent objects at object boundaries.			ANDERSON, BL (corresponding author), RUTGERS UNIV,VIS RES LAB,PISCATAWAY,NJ 08854, USA.			Anderson, Barton/0000-0003-0313-4285				ANDERSON BL, IN PRESS PSYCHOL REV; Belhumeur P. N., 1992, Proceedings. 1992 IEEE Computer Society Conference on Computer Vision and Pattern Recognition (Cat. No.92CH3168-2), P506, DOI 10.1109/CVPR.1992.223143; CUMMING BG, 1991, NATURE, V349, P411, DOI 10.1038/349411a0; GILLAM B, 1988, PERCEPTION, V17, P603, DOI 10.1068/p170603; GROSSBERG S, 1987, PERCEPT PSYCHOPHYS, V41, P117, DOI 10.3758/BF03204875; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; LAWSON RB, 1967, VISION RES, V7, P271, DOI 10.1016/0042-6989(67)90091-0; Marr D., 1982, VISION; MAYHEW JEW, 1982, NATURE, V297, P376, DOI 10.1038/297376a0; NAKAYAMA K, 1990, VISION RES, V30, P1811, DOI 10.1016/0042-6989(90)90161-D; OGLE KN, 1950, BINOCULAR VISION; POLLARD SB, 1985, PERCEPTION, V14, P449, DOI 10.1068/p140449; ROGERS BJ, 1993, NATURE, V361, P253, DOI 10.1038/361253a0	13	84	85	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					365	368		10.1038/367365a0	http://dx.doi.org/10.1038/367365a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	8114935				2022-12-28	WOS:A1994MT54000066
J	WRIGHT, JL				WRIGHT, JL			A DIFFICULT DECISION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2658	2658						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	8133570				2022-12-28	WOS:A1993MJ82100001
J	FANAROFF, AA; KORONES, SB; WRIGHT, LL; WRIGHT, EC; POLAND, RL; BAUER, CB; TYSON, JE; PHILIPS, JB; EDWARDS, W; LUCEY, JF; CATZ, CS; SHANKARAN, S; OH, W; CASSADY, G; BRAUNE, K; HACK, M; NEWMAN, NS; LITTLE, G; NATTIE, C; BAIN, RP; VERTER, J; YOUNES, N; HAWES, S; MURAN, G; BANDSTRA, ES; MARTINEZ, S; YAFFE, SJ; MALLOY, M; COOKE, R; MOORE, J; BURCHFIELD, J; HORBAR, JD; LEAHY, K				FANAROFF, AA; KORONES, SB; WRIGHT, LL; WRIGHT, EC; POLAND, RL; BAUER, CB; TYSON, JE; PHILIPS, JB; EDWARDS, W; LUCEY, JF; CATZ, CS; SHANKARAN, S; OH, W; CASSADY, G; BRAUNE, K; HACK, M; NEWMAN, NS; LITTLE, G; NATTIE, C; BAIN, RP; VERTER, J; YOUNES, N; HAWES, S; MURAN, G; BANDSTRA, ES; MARTINEZ, S; YAFFE, SJ; MALLOY, M; COOKE, R; MOORE, J; BURCHFIELD, J; HORBAR, JD; LEAHY, K			A CONTROLLED TRIAL OF INTRAVENOUS IMMUNE GLOBULIN TO REDUCE NOSOCOMIAL INFECTIONS IN VERY-LOW-BIRTH-WEIGHT INFANTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTENSIVE-CARE UNITS; PREMATURE-INFANTS; NEONATAL SEPSIS; CLINICAL-TRIALS; IMMUNOGLOBULIN; PREVENTION; PROPHYLAXIS; EFFICACY; THERAPY	Background. Nosocomial infections are a major cause of morbidity and mortality in premature infants. As a rule, their low serum gamma globulin levels at birth subsequently decline to hypogammaglobulinemic values; hence, prophylactic administration of intravenous immune globulin may reduce the rate of hospital-acquired infections. Methods. In this prospective, multicenter, two-phase controlled trial, 2416 infants were stratified according to birth weight (501 to 1000 g and 1001 to 1500 g) and randomly assigned to an intravenous immune globulin group (n = 1204) or a control group (n = 1212). Control infants were given placebo infusions during phase 1 of the study (n = 623) but were not given any infusions during phase 2 (n = 589). Infants weighing 501 to 1000 g at birth were given 900 mg of immune globulin per kilogram of body weight, and infants weighing 1001 to 1500 g at birth were given a dose of 700 mg per kilogram. The immune globulin infusions were repeated every 14 days until the infants weighed 1800 g, were transferred to another center, died, or were sent home from the hospital. Results. Nosocomial infections of the blood, meninges, or urinary tract occurred in 439 of the 2416 infants (18.2 percent): 208 (17.3 percent) in the immune globulin group and 231 (19.1 percent) in the control group (relative risk, 0.91; 95 percent confidence interval, 0.77 to 1.08). Septicemia occurred in 15.5 percent of the immune globulin recipients and 17.2 percent of the controls. During phase 1 the rate of nosocomial infections was 13.4 percent in the immune globulin group and 17.8 percent in the control group; the respective rates during phase 2 were 21.0 percent and 20.4 percent. The predominant organisms included gram-positive cocci (53.0 percent), gram-negative bacilli (22.4 percent), and candida species (16.0 percent). Adverse reactions were rarely observed during the infusions. Immune globulin therapy had no effect on respiratory distress syndrome, bronchopulmonary dysplasia, intracranial hemorrhage, the duration of hospitalization, or mortality. The incidence of necrotizing enterocolitis was 12.0 percent in the immune globulin group and 9.5 percent in the control group. Conclusions. Prophylactic use of intravenous immune globulin failed to reduce the incidence of hospital-acquired infections in very-low-birth-weight infants.	CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; UNIV TENNESSEE CTR HLTH SCI,MEMPHIS,TN 38163; NICHHD,BETHESDA,MD 20892; GEORGE WASHINGTON UNIV,CTR BIOSTAT,ROCKVILLE,MD; WAYNE STATE UNIV,DETROIT,MI 48202; UNIV MIAMI,MIAMI,FL 33152; UNIV TEXAS,SW MED CTR,DALLAS,TX 75230; UNIV ALABAMA,BIRMINGHAM,AL 35294; DARTMOUTH COLL,HITCHCOCK MED CTR,HANOVER,NH 03756; UNIV VERMONT,BURLINGTON,VT 05405; BROWN UNIV,PROVIDENCE,RI 02912	Case Western Reserve University; University of Tennessee System; University of Tennessee Health Science Center; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); George Washington University; Wayne State University; University of Miami; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Alabama System; University of Alabama Birmingham; Dartmouth College; University of Vermont; Brown University					NICHD NIH HHS [U10 HD21364, U10 HD21415, U10 HD19897] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD021364] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD021415, U01HD019897] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAKER CJ, 1992, NEW ENGL J MED, V327, P213, DOI 10.1056/NEJM199207233270401; Baley Jill E., 1992, P477; BALLOW M, 1986, PEDIATR RES, V20, P899, DOI 10.1203/00006450-198609000-00019; BUSSEL JB, 1990, REV INFECT DIS, V12, pS457; CHIRICO G, 1987, J PEDIATR-US, V110, P437, DOI 10.1016/S0022-3476(87)80514-0; CLAPP DW, 1989, J PEDIATR-US, V115, P973, DOI 10.1016/S0022-3476(89)80753-X; CONWAY SP, 1987, ARCH DIS CHILD, V62, P1252, DOI 10.1136/adc.62.12.1252; FREEMAN J, 1990, NEW ENGL J MED, V323, P301, DOI 10.1056/NEJM199008023230504; GAYNES RP, 1991, AM J MED, V91, pS192, DOI 10.1016/0002-9343(91)90368-8; GIVNER LB, 1990, PEDIATRICS, V86, P955; HACK M, 1991, PEDIATRICS, V87, P587; HAQUE KN, 1986, PEDIATR INFECT DIS J, V5, P622, DOI 10.1097/00006454-198611000-00004; KINNEY J, 1991, AM J DIS CHILD, V145, P1233, DOI 10.1001/archpedi.1991.02160110025013; KLIEGMAN RM, 1990, J PEDIATR-US, V117, pS2, DOI 10.1016/S0022-3476(05)81123-0; KLIEGMAN RM, 1990, REV INFECT DIS S4, V4, pS443; KYLLONEN KS, 1989, J PEDIATR-US, V115, P1013, DOI 10.1016/S0022-3476(89)80761-9; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LUNDBLAD JL, 1988, J HOSP INFECT, V12, P3, DOI 10.1016/0195-6701(88)90025-4; MAGNY JF, 1991, PEDIATRICS, V88, P437; NAHMIAS AJ, 1971, PEDIATR RES, V5, P405, DOI 10.1203/00006450-197108000-00144; NOLAN BM, 1988, J PEDIATR, V112, P325; SIDIROPOULOS D, 1986, PEDIATR INFECT DIS J, V5, pS193; STABILE A, 1988, ARCH DIS CHILD, V63, P441, DOI 10.1136/adc.63.4.441; WALSH MC, 1986, PEDIATR CLIN N AM, V33, P179, DOI 10.1016/s0031-3955(16)34975-6; WEISMAN LE, 1990, PEDIATR RES, V27, pA277; WILSON CB, 1986, J PEDIATR-US, V108, P1, DOI 10.1016/S0022-3476(86)80761-2; 1990, SAS STAT USERS GUIDE; 1990, NIH CONSENSUS STATE, V8, P1	29	133	136	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 21	1994	330	16					1107	1113		10.1056/NEJM199404213301602	http://dx.doi.org/10.1056/NEJM199404213301602			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF699	8133853	Bronze			2022-12-28	WOS:A1994NF69900002
J	FERNANDEZSOLA, J; ESTRUCH, R; GRAU, JM; PARE, JC; RUBIN, E; URBANOMARQUEZ, A				FERNANDEZSOLA, J; ESTRUCH, R; GRAU, JM; PARE, JC; RUBIN, E; URBANOMARQUEZ, A			THE RELATION OF ALCOHOLIC MYOPATHY TO CARDIOMYOPATHY	ANNALS OF INTERNAL MEDICINE			English	Article						CARDIOMYOPATHY, ALCOHOLIC; CARDIOMYOPATHY, CONGESTIVE; ALCOHOLISM; CORONARY DISEASE; MUSCULAR DISEASES	CONGESTIVE-HEART-FAILURE; BODY-SURFACE AREA; SKELETAL-MUSCLE; DILATED CARDIOMYOPATHY; BLOOD-FLOW; EXERCISE; ABNORMALITIES; MORTALITY; DRINKING; NOMOGRAM	Objective: To evaluate the relation between skeletal muscle disease (myopathy) and degenerative changes in cardiac muscle (cardiomyopathy) in patients with chronic alcoholism. Design: A cross-sectional study. Setting: University medical center. Participants: Group A included 24 patients with chronic alcoholism who had dilated cardiomyopathy; group B, 24 patients with chronic alcoholism who had normal cardiac function; group C, 12 patients with dilated cardiomyopathy because of coronary heart disease; group D, 12 patients with idiopathic dilated cardiomyopathy; group E, 24 normal participants; and group F, 5 young men who died suddenly in traffic accidents. Measurements: Clinical assessment of muscle strength, echocardiography, radionuclide cardiac angiography (groups A to E), muscle biopsy (groups A, B, E), endomyocardial biopsy of the left ventricle (group A), and examination of postmortem specimens of the left ventricle (group F). Results: Alcoholic patients with cardiomyopathy had less muscle strength than did alcoholic patients with normal cardiac function, patients with idiopathic dilated cardiomyopathy, and patients with coronary heart disease (all P < 0.01). Among alcoholic patients with cardiomyopathy, 20 of 24 (83%) had histologic findings of skeletal myopathy compared with 1 of 24 (4%) alcoholic patients with normal cardiac function (P < 0.001). Interstitial fibrosis occurred in all cardiac biopsy specimens, hypertrophy of the myocytes occurred in 95%, and myocytolysis occurred in 83%. Those patients with more severe cellular hypertrophy and interstitial fibrosis of the myocardium had a greater decrease in deltoid muscle strength and had worse histologic myopathy. Conclusions: Diseases of skeletal and cardiac muscle in patients with chronic alcoholism are clinically and histologically related. The presence of muscle weakness in an alcoholic person suggests the likelihood of an accompanying cardiomyopathic abnormality.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA; UNIV BARCELONA, HOSP CLIN & PROVINCIAL, DEPT MED, ALCOHOL RES UNIT, E-08036 BARCELONA, SPAIN; UNIV BARCELONA, HOSP CLIN & PROVINCIAL, DEPT MED, CARDIAC UNIT, E-08036 BARCELONA, SPAIN	Jefferson University; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona			SOLA, JOAQUIM FERNANDEZ/K-3991-2019	SOLA, JOAQUIM FERNANDEZ/0000-0002-3218-0582				BLACKWELDER WC, 1980, AM J MED, V68, P164, DOI 10.1016/0002-9343(80)90350-2; BRAUNWALD E, 1984, HEART DISEASE, P1399; CANALE DE, 1986, HDB MICROSCOPIC ANAT, P52; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; DANCY M, 1985, LANCET, V1, P1122; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DIAMOND I, 1989, NEW ENGL J MED, V320, P458, DOI 10.1056/NEJM198902163200709; DIXON WJ, 1985, BMDP STATISTICAL SOF; DUBOWITZ V, 1973, MUSCLE BIOPSY MODERN, P1; DYER AR, 1981, CIRCULATION, V64, P20; ELKARDT MJ, 1981, JAMA-J AM MED ASSOC, V246, P648; ESTRUCH R, IN PRESS ALCOHOL ALC; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; GODMAN L, 1981, CIRCULATION, V64, P1227; GURNEY JM, 1973, AM J CLIN NUTR, V26, P912, DOI 10.1093/ajcn/26.9.912; GUTGESELL HP, 1990, AM J CARDIOL, V65, P662, DOI 10.1016/0002-9149(90)91048-B; HAISSAGUERRE M, 1989, PRESSE MED, V18, P711; HALLER RG, 1984, MED CLIN N AM, V68, P91, DOI 10.1016/S0025-7125(16)31243-3; HENRY WL, 1978, CIRCULATION, V57, P278, DOI 10.1161/01.CIR.57.2.278; JELLIFFE DB, 1966, WHO MONOGR SER, V53, P3; JOHNSON RA, 1982, NEW ENGL J MED, V307, P1051, DOI 10.1056/NEJM198210213071704; KUNKEL B, 1978, CARDIOMYOPATHY MYOCA, P271; KUPARI M, 1984, POSTGRAD MED J, V60, P151, DOI 10.1136/pgmj.60.700.151; LIPKIN DP, 1986, BRIT MED J, V292, P1030, DOI 10.1136/bmj.292.6527.1030; LIPKIN DP, 1988, INT J CARDIOL, V18, P187, DOI 10.1016/0167-5273(88)90164-7; MASTAGLIA FL, 1982, SKELETAL MUSCLE PATH, P1; Meckel C R, 1989, Am J Cardiovasc Pathol, V2, P309; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; MINOTTI JR, 1991, J CLIN INVEST, V88, P2077, DOI 10.1172/JCI115537; NOE DA, 1991, J PHARM SCI, V80, P501, DOI 10.1002/jps.2600800520; POOLEWILSON PA, 1988, AM J CARDIOL, V62, pE49, DOI 10.1016/S0002-9149(88)80011-0; PREEDY VR, 1993, BRIT HEART J, V69, P197; REGAN TJ, 1984, PROG CARDIOVASC DIS, V27, P141, DOI 10.1016/0033-0620(84)90001-X; REGAN TJ, 1981, CIRCULATION, V64, P14; ROBIN E, 1970, AM HEART J, V80, P103, DOI 10.1016/0002-8703(70)90043-8; RUBIN E, 1976, AM J PATHOL, V83, P499; RUBIN E, 1979, NEW ENGL J MED, V301, P28; SANTILLI S, 1982, MINERVA MED, V73, P1509; SOBELL LC, 1979, BEHAV RES THER, V17, P157, DOI 10.1016/0005-7967(79)90025-1; SONG SK, 1972, SCIENCE, V175, P327, DOI 10.1126/science.175.4019.327; STEINBERG JD, 1981, AM HEART J, V101, P461, DOI 10.1016/0002-8703(81)90137-X; STLEGER AS, 1979, LANCET, V1, P1017, DOI 10.1016/S0140-6736(79)92765-X; SZLACHCIC J, 1985, AM J CARDIOL, V55, P1037, DOI 10.1016/0002-9149(85)90742-8; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701; VANDENBERG BF, 1989, CURR OPIN CARDIOL, V4, P815, DOI 10.1097/00001573-198912000-00011; Weibel ER, 1979, PRACTICAL METHODS BI, V1; WIENER DH, 1986, CIRCULATION, V73, P1127, DOI 10.1161/01.CIR.73.6.1127; WILSON JR, 1985, CIRCULATION, V71, P57, DOI 10.1161/01.CIR.71.1.57; 1982, LANCET, V1, P1987; 1987, DIAGNOSTIC STATISTIC	50	117	118	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					529	536		10.7326/0003-4819-120-7-199404010-00001	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8116990				2022-12-28	WOS:A1994NC76400001
J	SILVERMAN, DA				SILVERMAN, DA			CONFLUENCE AT LIFES EXTREMES	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											SILVERMAN, DA (corresponding author), HEBREW HOME & HOSP, 1 ABRAHMS BLVD, W HAVEN, CT 06117 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					615	615		10.7326/0003-4819-120-7-199404010-00014	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00014			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8117002				2022-12-28	WOS:A1994NC76400014
J	LEHMAN, W; CRAIG, R; VIBERT, P				LEHMAN, W; CRAIG, R; VIBERT, P			CA2+-INDUCED TROPOMYOSIN MOVEMENT IN LIMULUS THIN-FILAMENTS REVEALED BY 3-DIMENSIONAL RECONSTRUCTION	NATURE			English	Article							ELECTRON-MICROSCOPY; MUSCLE; TROPONIN; ACTIN; MYOSIN; BINDING	THE steric model of muscle regulation holds that tropomyosin strands running along thin filaments move away from myosin-binding sites on actin when muscle is activated. Exposing these sites would permit actomyosin interaction and contraction to proceed. This compelling and widely cited model is based on changes observed in X-ray diffraction patterns of skeletal muscle following activation(1-3) Although analysis of X-ray patterns can suggest models of filament structure, unambiguous interpretation is not possible. In contrast, three-dimensional reconstruction of thin-filament electron micrographs could, in principle, offer direct confirmation of the predicted tropomyosin movement, but so far tropomyosin in skeletal muscle has been resolved definitively only in the 'on' state but not in the 'off' state(4). Thin filaments from the arthropod Limulus have a similar composition to those from vertebrate skeletal muscle(5), and troponin-tropomyosin is distributed in both species with the same characteristic 38-nm periodicity(6) Limulus thin filaments activate skeletal muscle myosin ATPase at micromolar Ca2+ concentrations and confer a high calcium dependence on the enzyme. Arthropod and vertebrate troponin subunits form functional hybrids in vitro(7) and the respective tropomyosins are functionally interchangeable(8,9), arguing for a common mechanism of thin-filament-linked regulation in the two phyla. Here we report that tropomyosin is readily resolved in native filaments of troponin-regulated Limulus muscle in both the 'on' and 'off' states, and demonstrate tropomyosin movement, providing support for the importance of steric effects in muscle activation.	UNIV MASSACHUSETTS,SCH MED,DEPT CELL BIOL,WORCESTER,MA 01655; BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254	University of Massachusetts System; University of Massachusetts Worcester; Brandeis University	LEHMAN, W (corresponding author), BOSTON UNIV,SCH MED,DEPT PHYSIOL,80 E CONCORD ST,BOSTON,MA 02118, USA.			Lehman, William/0000-0002-9430-9521				AMOS LA, 1975, J MOL BIOL, V99, P51, DOI 10.1016/S0022-2836(75)80158-6; BULLARD B, 1988, J MOL BIOL, V204, P621, DOI 10.1016/0022-2836(88)90360-9; CHALOVICH JM, 1981, J BIOL CHEM, V256, P575; COHEN C, 1972, COLD SPRING HARB SYM, V37, P287; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; HASELGROVE JC, 1972, COLD SPRING HARB SYM, V37, P225; Holmes KC, 1991, CURR OPIN STRUC BIOL, V1, P270, DOI 10.1016/0959-440X(91)90073-3; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; LEHMAN W, 1975, NATURE, V255, P424, DOI 10.1038/255424a0; LEHMAN W, 1982, J MOL BIOL, V154, P385, DOI 10.1016/0022-2836(82)90071-7; LEHMAN W, 1976, BIOCHIM BIOPHYS ACTA, V434, P215, DOI 10.1016/0005-2795(76)90053-2; LEHMAN W, 1975, J GEN PHYSIOL, V59, P375; MILLIGAN RA, 1987, J CELL BIOL, V105, P29, DOI 10.1083/jcb.105.1.29; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MOODY C, 1990, J MUSCLE RES CELL M, V11, P176, DOI 10.1007/BF01766496; OBRIEN EJ, 1983, ACTIN STRUCTURE FUNC, P3; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; REGENSTEIN JM, 1975, BIOCHEMISTRY-US, V14, P917, DOI 10.1021/bi00676a007; SEYMOUR J, 1980, NATURE, V283, P680, DOI 10.1038/283680a0; SQUIRE JM, 1993, J CHEM SOC FARADAY T, V89, P2717, DOI 10.1039/ft9938902717; TOYOSHIMA C, 1985, J BIOCHEM-TOKYO, V97, P245, DOI 10.1093/oxfordjournals.jbchem.a135049; TRACHTENBERG S, 1987, J MOL BIOL, V195, P581, DOI 10.1016/0022-2836(87)90184-7; VIBERT P, 1993, J CELL BIOL, V123, P313, DOI 10.1083/jcb.123.2.313	25	277	280	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					65	67		10.1038/368065a0	http://dx.doi.org/10.1038/368065a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	8107884				2022-12-28	WOS:A1994MY56900054
J	JOHANSEN, S; VOGT, VM				JOHANSEN, S; VOGT, VM			AN INTRON IN THE NUCLEAR RIBOSOMAL DNA OF DIDYMIUM-IRIDIS CODES FOR A GROUP-I RIBOZYME AND A NOVEL RIBOZYME THAT COOPERATE IN SELF-SPLICING	CELL			English	Article							PHYSARUM-POLYCEPHALUM; SECONDARY STRUCTURE; SEQUENCE-ANALYSIS; SUBUNIT RNA; GENE; SITE; RDNA; EVOLUTION; SUGGESTS; VIROIDS	We have discovered a unique group I intron-like insertion (DiSSU) in the nuclear small subunit ribosomal RNA gene of the myxomycete Didymium iridis. By sequence, DiSSU consists of a group I ribozyme at the 5' end, an open reading frame (ORF) in the middle, and a novel element at the 3' end. Intron RNA self-splices in vitro to yield ten major processed RNAs, including a full-length circle. The group I ribozyme can efficiently cleave at an internal processing site, which separates the group I ribozyme from the ORF. Surprisingly, deletions that remove the entire group I ribozyme do not impair cleavage at the 3' splice site, implying that the 3' element itself is a catalytic RNA. Deletions that remove portions of the 3' element prevent utilization of the 5' splice site, suggesting that this element cooperates with the upstream group I ribozyme in splicing. DiSSU appears to be the first example for the cooperative interaction of distinct ribozymes in RNA splicing.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Cornell University	JOHANSEN, S (corresponding author), UNIV TROMSO,INST MED BIOL,DEPT CELL BIOL,N-9037 TROMSO,NORWAY.				NIGMS NIH HHS [GM-31577] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031577] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARFOD ET, 1989, MOL CELL BIOL, V9, P3657, DOI 10.1128/MCB.9.9.3657; BEEN MD, 1985, NUCLEIC ACIDS RES, V13, P8389, DOI 10.1093/nar/13.23.8389; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1992, J BIOL CHEM, V267, P17479; COLLINS OR, 1976, AM J BOT, V63, P138, DOI 10.2307/2441693; DAVILAAPONTE JA, 1991, NUCLEIC ACIDS RES, V19, P4429, DOI 10.1093/nar/19.16.4429; DEPRIEST PT, 1992, J MOL BIOL, V228, P315, DOI 10.1016/0022-2836(92)90819-6; DEWACHTER R, 1992, NUCLEIC ACIDS RES, V20, P1251; DIENER TO, 1989, P NATL ACAD SCI USA, V86, P9370, DOI 10.1073/pnas.86.23.9370; DINTERGOTTLIEB G, 1986, P NATL ACAD SCI USA, V83, P6250, DOI 10.1073/pnas.83.17.6250; EMBLEY TM, 1992, NUCLEIC ACIDS RES, V20, P6411, DOI 10.1093/nar/20.23.6411; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HADIDI A, 1986, PLANT MOL BIOL, V7, P129, DOI 10.1007/BF00040139; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JAKUBCZAK JL, 1991, P NATL ACAD SCI USA, V88, P3295, DOI 10.1073/pnas.88.8.3295; JOHANSEN S, 1992, CURR GENET, V22, P305, DOI 10.1007/BF00317926; JOHANSEN S, 1992, CURR GENET, V22, P297, DOI 10.1007/BF00317925; JOHANSEN S, 1993, NUCLEIC ACIDS RES, V21, P4405, DOI 10.1093/nar/21.18.4405; JOHANSEN T, 1988, CURR GENET, V14, P265, DOI 10.1007/BF00376747; JOHANSEN T, 1988, DNA PROT ENG TECH, V1, P57; LIN H, 1992, GENE, V119, P163, DOI 10.1016/0378-1119(92)90268-T; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MUSCARELLA DE, 1990, MOL CELL BIOL, V10, P3386, DOI 10.1128/MCB.10.7.3386; MUSCARELLA DE, 1989, CELL, V56, P443, DOI 10.1016/0092-8674(89)90247-X; NEEFS JM, 1990, NUCLEIC ACIDS RES, V18, P2237, DOI 10.1093/nar/18.suppl.2237; OBERBAUMER I, 1992, NUCLEIC ACIDS RES, V20, P671; PERLMAN PS, 1990, INTERVENING SEQUENCE, P112; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROGERS SO, 1993, CURR GENET, V23, P338, DOI 10.1007/BF00310896; RUOFF B, 1992, NUCLEIC ACIDS RES, V20, P5899, DOI 10.1093/nar/20.22.5899; SAVILLE BJ, 1990, CELL, V61, P685, DOI 10.1016/0092-8674(90)90480-3; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; THOMPSON AJ, 1991, NUCLEIC ACIDS RES, V19, P661; VANDERHORST G, 1993, J MOL BIOL, V229, P685, DOI 10.1006/jmbi.1993.1072; WILCOX LW, 1992, MOL BIOL EVOL, V9, P1103	41	66	70	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 25	1994	76	4					725	734		10.1016/0092-8674(94)90511-8	http://dx.doi.org/10.1016/0092-8674(94)90511-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124711				2022-12-28	WOS:A1994MZ28500014
J	ISACSSON, G; HOLMGREN, P; WASSERMAN, D; BERGMAN, U				ISACSSON, G; HOLMGREN, P; WASSERMAN, D; BERGMAN, U			USE OF ANTIDEPRESSANTS AMONG PEOPLE COMMITTING SUICIDE IN SWEDEN	BRITISH MEDICAL JOURNAL			English	Article							DRUGS; PRESCRIPTION; POPULATION; OVERDOSE; RISK	Objective-To analyse the outcome of depression in the Swedish population as reflected by the detection of antidepressants in a national forensic toxicological screening programme of unnatural deaths. Design-Antidepressants detected by the National Laboratory of Forensic Chemistry were related to data on use expressed in person years of exposure. Subjects-All 7000 cases of unnatural death with results from forensic toxicological screening in 199O-1; this included 3400 (85%) of the 4000 cases of suicide in Sweden. Main outcome measures-Number of findings of antidepressants in the screening programme and number of findings of different antidepressants in relation to their use. Results-Antidepressants were found in 585 screening tests, corresponding to 542 subjects or less than 16% of the 3400 cases of suicide. Newer, less toxic antidepressants were found more often than the older compounds. Toxic concentrations of antidepressants were found in only 190 cases (5.6%). Conclusion-A consistent finding in surveys of suicide is that about half of the patients who commit suicide are depressed. The current data suggest that most depressed patients who commit suicide are not taking antidepressants immediately before death. Therapeutic failure may be a greater problem with antidepressants than toxicity as the results did not indicate any advantage of the newer, less toxic antidepressants. Ah causes of death should be included in risk analyses, thereby providing an estimate of effectiveness as web as toxicity of antidepressants.	NATL LAB FORENS CHEM,DEPT TOXICOL,LINKOPING,SWEDEN; KAROLINSKA HOSP,CTR SUICIDE RES & PREVENT,STOCKHOLM,SWEDEN; KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT MED LAB SCI & TECHNOL,DIV CLIN PHARMACOL,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	ISACSSON, G (corresponding author), KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT CLIN NEUROSCI & FAMILY MED,PSYCHIAT SECT,S-14186 HUDDINGE,SWEDEN.		anand, amit/A-7222-2009					BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BERGMAN U, 1992, J CLIN EPIDEMIOL, V45, P313, DOI 10.1016/0895-4356(92)90092-2; BESKOW J, 1979, ACTA PSYCHIATR SCA S, V277; CASSIDY S, 1987, BRIT MED J, V295, P1021, DOI 10.1136/bmj.295.6605.1021; DERBY LE, 1992, J CLIN PSYCHOPHARM, V12, P235; EKLUND A, 1983, J ANAL TOXICOL, V7, P24, DOI 10.1093/jat/7.1.24; FORSTER DP, 1985, ACTA PSYCHIAT SCAND, V71, P567, DOI 10.1111/j.1600-0447.1985.tb02550.x; GUESS HA, 1987, AM J EPIDEMIOL, V125, P340, DOI 10.1093/oxfordjournals.aje.a114535; HANZLICK R, 1989, AM J FOREN MED PATH, V10, P326, DOI 10.1097/00000433-198912000-00009; HORTE LG, 1983, HYGIEA, V92, P251; ISACSSON G, 1992, ACTA PSYCHIAT SCAND, V85, P444, DOI 10.1111/j.1600-0447.1992.tb03209.x; JOHNSON DAW, 1986, INT MED S, V11, P14; KELLEHER MJ, 1992, BRIT J PSYCHIAT, V161, P625, DOI 10.1192/bjp.161.5.625; Moffat A.C, 1986, CLARKES ISOLATION ID, DOI DOI 10.1002/JPS.2600760520; MONTGOMERY SA, 1988, INT CLIN PSYCHOPHARM, V3, P15; REGIER DA, 1988, AM J PSYCHIAT, V145, P1351; RORSMAN B, 1982, NEUROPSYCHOBIOLOGY, V8, P233, DOI 10.1159/000117904; WESSLING A, 1991, EUR J CLIN PHARMACOL, V40, P495, DOI 10.1007/BF00315229; 1992, LANCET, V340, P700; 1993, J AFFECT DISORDERS, V28, P105; 1993, CAUSES DEATH 1989 19	21	122	122	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	1994	308	6927					506	509		10.1136/bmj.308.6927.506	http://dx.doi.org/10.1136/bmj.308.6927.506			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MX814	8136668	Green Published			2022-12-28	WOS:A1994MX81400021
J	LAW, MR; THOMPSON, SG; WALD, NJ				LAW, MR; THOMPSON, SG; WALD, NJ			ASSESSING POSSIBLE HAZARDS OF REDUCING SERUM-CHOLESTEROL	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; FACTOR INTERVENTION TRIAL; RISK-FACTORS; FOLLOW-UP; PLASMA-CHOLESTEROL; LOWERING DRUGS; DIETARY-FAT; MORTALITY; CANCER; MEN	Objective-To assess whether low serum cholesterol concentration increases mortality from any cause. Design-Systematic review of published data on mortality from causes other than ischaemic heart disease derived from the 10 largest cohort studies, two international studies, and 28 randomised trials, supplemented by unpublished data on causes of death obtained when necessary. Main outcome measures-Excess cause specific mortality associated with low or lowered serum cholesterol concentration. Results-The only cause of death attributable to low serum cholesterol concentration was haemorrhagic stroke. The excess risk was associated only with concentrations below about 5 mmol/l (relative risk 1.9, 95% confidence interval 1.4 to 2.5), affecting about 6% of people in Western populations. For non-circulatory causes of death there was a pronounced difference between cohort studies of employed men, likely to be healthy at recruitment, and cohort studies of subjects in community settings, necessarily including some with existing disease. The employed cohorts showed no excess mortality. The community cohorts showed associations between low cholesterol concentration and lung cancer, haemopoietic cancers, suicide, chronic bronchitis, and chronic fiver and bowel diseases; these were most satisfactorily explained by early disease or by factors that cause the disease lowering serum cholesterol concentration (depression causes suicide and lowers cholesterol concentration, for example). In the randomised trials nine deaths (from a total of 687 deaths not due to ischaemic heart disease in treated subjects) were attributed to known adverse effects of the specific treatments, but otherwise there was no evidence of an increased mortality from any cause arising from reduction in cholesterol concentration. Conclusions-There is no evidence that low or reduced serum cholesterol concentration increases mortality from any cause other than haemorrhagic stroke. This risk affects only those people with a very low concentration and even in these will be outweighed by the benefits from the low risk of ischaemic heart disease.			LAW, MR (corresponding author), ST BARTHOLOMEWS HOSP MED COLL,WOLFSON INST PREVENT MED,DEPT ENVIRONM & PREVENT MED,LONDON EC1M 6BQ,ENGLAND.		Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021					ALVAREZ C, 1986, CLIN CHEM, V32, P142; [Anonymous], 1992, Arch Intern Med, V152, P1399; BAPTISTE MS, 1992, INT J EPIDEMIOL, V21, P16, DOI 10.1093/ije/21.1.16; BLACKBURN H, 1989, CIRCULATION, V79, P718, DOI 10.1161/01.CIR.79.3.718; CAMBIEN F, 1980, AM J EPIDEMIOL, V112, P388, DOI 10.1093/oxfordjournals.aje.a113004; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; CHEN ZM, 1993, BMJ-BRIT MED J, V306, P890, DOI 10.1136/bmj.306.6882.890; DEWAR HA, 1972, BRIT MED J, V1, P506, DOI 10.1136/bmj.1.5798.506-a; DOWNS JR, 1993, JAMA-J AM MED ASSOC, V269, P3107, DOI 10.1001/jama.269.24.3107; DUJOVNE CA, 1991, AM J MED, V91, pS25, DOI 10.1016/0002-9343(91)90053-Z; DYER AR, 1981, J CHRON DIS, V34, P249, DOI 10.1016/0021-9681(81)90030-8; FRANK JW, 1992, J CLIN EPIDEMIOL, V45, P333, DOI 10.1016/0895-4356(92)90034-K; GLUECK CJ, 1990, J LAB CLIN MED, V116, P377; GOBLE AJ, 1992, BRIT MED J, V305, P773, DOI 10.1136/bmj.305.6856.773; Gregory F., 1990, DIETARY NUTR SURVEY; HEADY JA, 1974, BRIT MED J, V1, P115, DOI 10.1136/bmj.1.5898.115-c; HOLE DJ, 1993, J EPIDEMIOL COMMUNIT, V3, P47; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; KERTTULA Y, 1988, ANN CLIN RES, V20, P184; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1991, CANCER CAUSE CONTROL, V2, P253, DOI 10.1007/BF00052142; LAW MR, IN PRESS EUR J CLIN; LEREN P, 1970, CIRCULATION, V42, P935, DOI 10.1161/01.CIR.42.5.935; LINDBERG G, 1992, BRIT MED J, V305, P277, DOI 10.1136/bmj.305.6848.277; MAGNI G, 1988, NEUROPSYCHOBIOLOGY, V20, P126, DOI 10.1159/000118485; MENOTTI A, 1990, INT J EPIDEMIOL, V19, P309, DOI 10.1093/ije/19.2.309; MORGAN RE, 1993, LANCET, V341, P75, DOI 10.1016/0140-6736(93)92556-9; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; OLIVER MF, 1988, J AM COLL CARDIOL, V12, P814, DOI 10.1016/0735-1097(88)90327-0; OONEDA G, 1978, BLOOD VESSELS, V15, P148; PEARCE ML, 1971, LANCET, V1, P464; PERSSON B, 1984, ACTA MED SCAND, V216, P485; PETO R, 1989, BRIT MED J, V298, P1249, DOI 10.1136/bmj.298.6682.1249; PRENTICE RL, 1990, CANCER CAUSE CONTROL, V1, P81, DOI 10.1007/BF00053187; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; SEPPA K, 1992, ARCH INTERN MED, V152, P297, DOI 10.1001/archinte.152.2.297; SHIMAMOTO T, 1989, CIRCULATION, V79, P503, DOI 10.1161/01.CIR.79.3.503; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; SZATROWSKI TP, 1984, J CHRON DIS, V37, P569, DOI 10.1016/0021-9681(84)90007-9; TAKEYA Y, 1984, STROKE, V15, P15, DOI 10.1161/01.STR.15.1.15; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; UESHIMA H, 1980, PREV MED, V9, P722, DOI 10.1016/0091-7435(80)90017-1; WESTLUND K, 1972, SCAND J CLIN LAB INV, V30, P1; WYNDER EL, 1987, J NATL CANCER I, V79, P631; WYSOWSKI DK, 1990, ARCH INTERN MED, V150, P2169, DOI 10.1001/archinte.150.10.2169	51	288	290	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	1994	308	6925					373	379		10.1136/bmj.308.6925.373	http://dx.doi.org/10.1136/bmj.308.6925.373			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV862	8124144	Green Published			2022-12-28	WOS:A1994MV86200019
J	LEVINE, RS; HENNEKENS, CH; JESSE, MJ				LEVINE, RS; HENNEKENS, CH; JESSE, MJ			BLOOD-PRESSURE IN PROSPECTIVE POPULATION-BASED COHORT OF NEWBORN AND INFANT TWINS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW-BIRTH-WEIGHT; GENETIC VARIANCE; ADULT LIFE; FETAL; GROWTH; RISK	Objective-To describe blood pressure in twins during infancy. Design-Prospective study of cohort of twins. Setting-Teaching hospital in Florida. Subjects-166 viable twin pairs born between July 1976 and December 1989. Main outcome measures-Blood pressure and body weight at birth, at 14 days, and at 1, 3, 6, 9, and 12 months. Results-Both systolic and diastolic pressure correlated with body weight throughout infancy (at birth r = 0.41, P < 0.001 and r = 0.42, P < 0.001 respectively; at 1 year r=0.23, P < 0.001 and r=0.26, P < 0.001 respectively). In infants weighing < 1500 g at birth mean blood pressure rose from about 45/25 mm Hg to 101/55 mm Hg from birth to the age of 1 year, while in infants weighing > 3000 g at birth it rose from 63/39 mm Hg to 100/61 mm Hg; corresponding mean body weights at 1 year were 7.86 kg and 9.58 kg. Differences in birth weight within pairs of monozygotic twins were negatively correlated with such differences in systolic blood pressure at 1 year (r = -0.37, P < 0.01). Conclusions-Blood pressure and body weights in twins showed strongly positive but generally declining correlations throughout infancy. Twins Of lower birth weight showed a more rapid rate of rise in blood pressure during infancy. At 1 year the catch up in blood pressure exceeded that in body weight. Greater differences in birth weights between monozygotic twins were associated with smaller differences in systolic blood pressure at 1 year, suggesting that intrauterine environmental factors related to birth weight are important in determining blood pressure in infancy.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; UNIV CINCINNATI, SCH MED, CINCINNATI, OH 45221 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Cincinnati	LEVINE, RS (corresponding author), MEHARRY MED COLL, DEPT FAMILY & PREVENT MED, NASHVILLE, TN 37208 USA.				NHLBI NIH HHS [HL 00286, HL 19930] Funding Source: Medline; PHS HHS [52119-6] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARMITAGE P, 1971, STATISTICAL METHODS; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; BURKE GL, 1987, PEDIATRICS, V80, P784; CHRISTIAN JC, 1977, ACTA GENET MED GEMEL, V26, P49, DOI 10.1017/S0001566000010187; DESWIET M, 1992, BRIT MED J, V304, P23, DOI 10.1136/bmj.304.6818.23; GEMELLI M, 1990, EUR J PEDIATR, V149, P318, DOI 10.1007/BF02171556; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; HIGGINS M, 1980, AM J EPIDEMIOL, V111, P142, DOI 10.1093/oxfordjournals.aje.a112882; KRAMER AA, 1984, AM J EPIDEMIOL, V119, P651, DOI 10.1093/oxfordjournals.aje.a113785; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LEVINE RS, 1978, PEDIATRICS, V61, P121; LEVINE RS, 1987, AM J EPIDEMIOL, V126, P929, DOI 10.1093/oxfordjournals.aje.a114730; LEVINE RS, 1982, AM J EPIDEMIOL, V116, P759, DOI 10.1093/oxfordjournals.aje.a113465; LOGGIE J, 1988, PEDIATRICS, V81, P328; MCGARVEY ST, 1991, HYPERTENSION, V17, P218, DOI 10.1161/01.HYP.17.2.218; PARK MK, 1989, AM J DIS CHILD, V143, P860, DOI 10.1001/archpedi.1989.02150190110034; PERSSON E, 1992, ACTA PHYSIOL SCAND, V145, P195, DOI 10.1111/j.1748-1716.1992.tb09356.x; PIAZZA SF, 1985, AM J DIS CHILD, V139, P797, DOI 10.1001/archpedi.1985.02140100059030; RANKOVA S, 1989, Tokai Journal of Experimental and Clinical Medicine, V14, P181; SCHACHTER J, 1982, AM J EPIDEMIOL, V116, P29, DOI 10.1093/oxfordjournals.aje.a113400; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; SPINAZZOLA RM, 1990, J PERINATOL, V11, P147; TAN KL, 1988, J PEDIATR-US, V112, P266, DOI 10.1016/S0022-3476(88)80068-4; UHARI M, 1980, ACTA PAEDIATR SCAND, V69, P613, DOI 10.1111/j.1651-2227.1980.tb07331.x; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L; ZINNER SH, 1985, HYPERTENSION, V7, P411, DOI 10.1161/01.HYP.7.3_Pt_1.411; 1992, HLTH PEOPLE 2000 SUM, P110	30	70	71	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 29	1994	308	6924					298	302		10.1136/bmj.308.6924.298	http://dx.doi.org/10.1136/bmj.308.6924.298			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU492	8124117	Green Published			2022-12-28	WOS:A1994MU49200019
J	KERSANACH, R; BRINKMANN, H; LIAUD, MF; ZHANG, DX; MARTIN, W; CERFF, R				KERSANACH, R; BRINKMANN, H; LIAUD, MF; ZHANG, DX; MARTIN, W; CERFF, R			5 IDENTICAL INTRON POSITIONS IN ANCIENT DUPLICATED GENES OF EUBACTERIAL ORIGIN	NATURE			English	Article							CHLOROPLAST GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; SELF-SPLICING ACTIVITY; GROUP-II INTRON; SEQUENCE-ANALYSIS; NUCLEAR GENE; MAIZE; EVOLUTION; CLONING; FAMILY; PEA	IN 1985 Cornish-Bowden wrote ''although there is now much to suggest that introns are an ancient relic of primordial genes, convincing proof must await the discovery of clearly corresponding intron arrangements in genes that arose by duplication before the separation of prokaryotes and eukaryotes''1. Genes for chloroplast and cytosolic glyceraldehyde-3-phosphate dehydrogenases of eukaryotes are descendants of an ancient gene family that existed in the common ancestor of extant eubacteria. During eukaryotic evolution, both genes were transferred to the nucleus from the antecedents of present-day chloroplasts and mitochondria. respectively2-5. Here we report the discovery of five spliceosomal introns at positions that are precisely conserved between nuclear genes for this chloroplast/cytosol enzyme pair. These data provide strong evidence in favour of the 'introns early' hypothesis, which proposes that introns were present in the earliest cells, consistent with the idea that introns facilitated the assembly of primordial genes by accelerating the rate of exon shuffling6-13.	TECH UNIV CAROLO WILHELMINA BRAUNSCHWEIG,INST GENET,POSTFACH 3329,D-38023 BRAUNSCHWEIG,GERMANY	Braunschweig University of Technology			Zhang, De-Xing/D-9830-2011; Martin, William F./O-5446-2015; Martin, William/C-5680-2008	Zhang, De-Xing/0000-0002-9114-8996; Martin, William F./0000-0003-1478-6449; 				ALEFOUNDER PR, 1989, MOL MICROBIOL, V3, P723, DOI 10.1111/j.1365-2958.1989.tb00221.x; BRINKMANN H, 1989, PLANT MOL BIOL, V13, P81, DOI 10.1007/BF00027337; BRINKMANN H, 1987, J MOL EVOL, V26, P320, DOI 10.1007/BF02101150; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; CORNISHBOWDEN A, 1985, NATURE, V313, P434, DOI 10.1038/313434b0; DOOLITTLE F, 1993, NATURE, V361, P403; DOOLITTLE WF, 1989, HIERARCHY LIFE, P65; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; GIBSON JL, 1988, J BACTERIOL, V170, P2153, DOI 10.1128/jb.170.5.2153-2158.1988; GILBERT W, 1987, COLD SPRING HARB SYM, V52, P901, DOI 10.1101/SQB.1987.052.01.098; HARMSEN MC, 1992, CURR GENET, V22, P447, DOI 10.1007/BF00326409; IWABE N, 1990, J MOL EVOL, V31, P205, DOI 10.1007/BF02109497; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KOCH JL, 1992, MOL CELL BIOL, V12, P1950, DOI 10.1128/MCB.12.5.1950; LI WH, 1985, MOL BIOL EVOL, V2, P150; LIAUD MF, 1990, P NATL ACAD SCI USA, V87, P8918, DOI 10.1073/pnas.87.22.8918; LIAUD MF, 1992, PLANT MOL BIOL, V18, P639, DOI 10.1007/BF00020007; LIAUD MF, IN PRESS J MOL EVOL; MARTIN W, 1986, EUR J BIOCHEM, V159, P323, DOI 10.1111/j.1432-1033.1986.tb09871.x; MARTIN W, 1993, P NATL ACAD SCI USA, V90, P8692, DOI 10.1073/pnas.90.18.8692; MARTINEZ P, 1989, J MOL BIOL, V208, P551, DOI 10.1016/0022-2836(89)90147-2; Palmer JD, 1991, CURR OPIN GENET DEV, V1, P470, DOI 10.1016/S0959-437X(05)80194-7; QUIGLEY F, 1988, P NATL ACAD SCI USA, V85, P2672, DOI 10.1073/pnas.85.8.2672; ROGER AJ, 1993, NATURE, V364, P289, DOI 10.1038/364289a0; RUSSELL DA, 1989, PLANT CELL, V1, P793, DOI 10.1105/tpc.1.8.793; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; STONE EM, 1990, INTERVENING SEQUENCE; SUCHY M, 1991, J MOL BIOL, V222, P179, DOI 10.1016/0022-2836(91)90204-J; TITTIGER C, 1993, NATURE, V361, P470, DOI 10.1038/361470a0	30	97	100	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					387	389		10.1038/367387a0	http://dx.doi.org/10.1038/367387a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	8114942				2022-12-28	WOS:A1994MT54000074
J	OLIVIERI, NF; LIU, PP; SHER, GD; DALY, PA; GREIG, PD; MCCUSKER, PJ; COLLINS, AF; FRANCOMBE, WH; TEMPLETON, DM; BUTANY, J				OLIVIERI, NF; LIU, PP; SHER, GD; DALY, PA; GREIG, PD; MCCUSKER, PJ; COLLINS, AF; FRANCOMBE, WH; TEMPLETON, DM; BUTANY, J			COMBINED LIVER AND HEART-TRANSPLANTATION FOR END-STAGE IRON-INDUCED ORGAN FAILURE IN AN ADULT WITH HOMOZYGOUS BETA-THALASSEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CHELATION-THERAPY; SUBCUTANEOUS DEFEROXAMINE; CARDIAC DISEASE; SURVIVAL; STORES; REDUCTION; PATIENT		HOSP SICK CHILDREN, LONDON WC1N 3JH, ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	OLIVIERI, NF (corresponding author), TORONTO HOSP, DEPT PATHOL, 200 ELIZABETH ST, TORONTO M5G 2C4, ON, CANADA.		Olivieri, Nancy/AAI-2250-2020	Templeton, Douglas/0000-0003-0693-662X				ALDOURI MA, 1990, ACTA HAEMATOL-BASEL, V84, P113; ANGELUCCI E, 1993, BLOOD, V82, pA290; Bahnson H T, 1990, Cardiovasc Clin, V20, P237; BARRY M, 1974, BMJ-BRIT MED J, V2, P16, DOI 10.1136/bmj.2.5909.16; BERKOVITCH M, 1993, BLOOD, V82, pA359; BRITTENHAM G, 1988, BLOOD S, V72, pA56; BRONSPIEGELWEINTROB N, 1990, NEW ENGL J MED, V323, P713, DOI 10.1056/NEJM199009133231104; Cohen A, 1987, Hematol Oncol Clin North Am, V1, P521; COHEN A, 1984, BRIT J HAEMATOL, V58, P369, DOI 10.1111/j.1365-2141.1984.tb06096.x; EHLERS KH, 1991, J PEDIATR-US, V118, P540, DOI 10.1016/S0022-3476(05)83374-8; ENGLE MA, 1964, CIRCULATION, V30, P698, DOI 10.1161/01.CIR.30.5.698; FIGUERA D, 1986, Journal of Heart Transplantation, V5, P327; FOSBURG MT, 1990, BLOOD, V76, P435; LERNER N, 1990, AM J PEDIAT HEMATOL, V12, P56; MCGEE A, 1989, BLOOD S, V74, pA1172; MODELL B, 1984, CLIN APPROACH THALAS, P211; OLIVIERI NF, 1992, BLOOD, V79, P2741; OLIVIERI NF, 1992, AM J HEMATOL, V41, P61, DOI 10.1002/ajh.2830410112; OLIVIERI NF, 1990, ANN NY ACAD SCI, V612, P585; OLIVIERI NF, 1991, BLOOD S, V78, pA196; Orkin S., 1987, MOL BASIS BLOOD DISE, P106; PERRIMOND H, 1991, BRIT J HAEMATOL, V78, P467, DOI 10.1111/j.1365-2141.1991.tb04471.x; SHAW BW, 1985, ANN SURG, V202, P667, DOI 10.1097/00000658-198512000-00001; STARZL TE, 1984, LANCET, V1, P1382; WALLWORK J, 1987, LANCET, V2, P182; WOLFE L, 1985, NEW ENGL J MED, V312, P1600, DOI 10.1056/NEJM198506203122503; ZURLO MG, 1989, LANCET, V2, P27, DOI 10.1016/S0140-6736(89)90264-X	27	62	63	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 21	1994	330	16					1125	1127		10.1056/NEJM199404213301605	http://dx.doi.org/10.1056/NEJM199404213301605			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF699	8133854	Bronze			2022-12-28	WOS:A1994NF69900005
J	WALTUCK, J; BUYON, JP				WALTUCK, J; BUYON, JP			AUTOANTIBODY-ASSOCIATED CONGENITAL HEART-BLOCK - OUTCOME IN MOTHERS AND CHILDREN	ANNALS OF INTERNAL MEDICINE			English	Article						HEART BLOCK; AUTOANTIBODIES; AUTOIMMUNE DISEASES; RHEUMATIC DISEASES; PACEMAKER, ARTIFICIAL	SYSTEMIC LUPUS-ERYTHEMATOSUS; CONNECTIVE-TISSUE DISEASE; COMPLETE ATRIOVENTRICULAR-BLOCK; SS-A ANTIBODIES; NEONATAL LUPUS; RO; LA; ANTIGEN; PREDNISOLONE; EXPERIENCE	Objective: To determine the initial clinical status and the long-term outcome of mothers and their children with autoantibody-associated congenital heart block. Design: Dynamic, longitudinal cohort study. Patients: 55 children with isolated congenital heart block, their 52 mothers, and 5 other women currently carrying fetuses with congenital heart block. All maternal sera contained antibodies to SSA/Ro alone or to both SSA/Ro and SSB/La. Measurements: Clinical information obtained from mailed questionnaires, telephone interviews, primary physicians, and chart reviews. Results: When congenital heart block was identified in the children, 23 women were asymptomatic, 15 had systemic lupus erythematosus, 8 had the Sjogren syndrome, and 11 had an undifferentiated autoimmune syndrome. Follow-up ranged from 1 week to 20 years (median, 3.7 years). Eleven (48%) of the 23 initially asymptomatic mothers developed symptoms of a rheumatic disease (0.15 status changes/patient-year of follow-up; 6 (26%) developed an undifferentiated autoimmune syndrome, 2 (9%) developed the Sjogren syndrome, and 3 (13%) developed systemic lupus erythematosus. One mother with the Sjogren syndrome progressed to systemic lupus erythematosus. Four (16%) of 25 subsequent pregnancies in 22 women were complicated by heart block. Seventeen affected children died, 12 within 1 month of birth. Pacemakers were implanted in 37 (67%) of the 55 children, 27 within 3 months after birth. Conclusion: The development of rheumatic disease in asymptomatic mothers identified by the birth of a child with congenital heart block is common but not universal. The risk for congenital heart block in subsequent pregnancies is low. One third of the children with autoantibody-associated congenital heart block die in the early neonatal period and, of those who survive, most require pacemakers.	NYU, HOSP JOINT DIS, SCH MED, NEW YORK, NY 10003 USA	New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC				Buyon, Jill/0000-0002-3852-7129				ALEXANDER E, 1992, ARTHRITIS RHEUM-US, V35, P176, DOI 10.1002/art.1780350209; ALEXANDER EL, 1989, J INVEST DERMATOL, V93, P751, DOI 10.1111/1523-1747.ep12284404; [Anonymous], ARCH MED ENFANTS; BABOONIAN C, 1989, CLIN EXP IMMUNOL, V78, P454; BEITINS IZ, 1972, J PEDIATR-US, V81, P936, DOI 10.1016/S0022-3476(72)80547-X; BIERMAN FZ, 1988, J PEDIATR-US, V112, P646, DOI 10.1016/S0022-3476(88)80189-6; BLANFORD AT, 1977, AM J OBSTET GYNECOL, V127, P264, DOI 10.1016/0002-9378(77)90466-5; BUYON JP, 1990, ARTHRITIS RHEUM, V33, P609, DOI 10.1002/art.1780330502; BUYON JP, 1989, J CLIN INVEST, V84, P627, DOI 10.1172/JCI114208; BUYON JP, 1993, ARTHRITIS RHEUM, V36, P1263, DOI 10.1002/art.1780360911; BUYON JP, 1987, ARTHRITIS RHEUM, V30, P44, DOI 10.1002/art.1780300106; BUYON JP, 1990, J IMMUNOL METHODS, V129, P207, DOI 10.1016/0022-1759(90)90440-7; CARREIRA PE, 1993, J RHEUMATOL, V20, P1204; CARTER JB, 1974, ARCH PATHOL, V97, P51; CHAMEIDES L, 1977, NEW ENGL J MED, V297, P1204, DOI 10.1056/NEJM197712012972203; DENG JS, 1985, J INVEST DERMATOL, V85, P412, DOI 10.1111/1523-1747.ep12277079; DERKSEN RHWM, 1992, ARTHRITIS RHEUM, V35, P953, DOI 10.1002/art.1780350817; DEWEY RC, 1987, NEW ENGL J MED, V316, P835, DOI 10.1056/NEJM198704023161403; ELKAYAM U, 1990, CARDIAC PROBLEMS PRE, P611; ESSCHER E, 1983, PEDIATR CARDIOL, V4, P121, DOI 10.1007/BF02076336; FOX RI, 1986, SCAND J RHEUMATOL, P28; FOX RJ, 1979, ARCH DERMATOL, V115, P340, DOI 10.1001/archderm.115.3.340; HARLEY JB, 1985, ARTHRITIS RHEUM, V28, P1321, DOI 10.1002/art.1780281202; HERREMAN G, 1985, NEW ENGL J MED, V312, P1329; HORSFALL AC, 1991, J AUTOIMMUN, V4, P165, DOI 10.1016/0896-8411(91)90015-5; JACKSON R, 1979, BRIT J DERMATOL, V101, P81, DOI 10.1111/j.1365-2133.1979.tb15297.x; JORDAN JM, 1989, PEDIATRICS, V84, P574; KEPHART DC, 1981, J INVEST DERMATOL, V77, P331, DOI 10.1111/1523-1747.ep12482531; LAXER RM, 1990, J PEDIATR-US, V116, P238, DOI 10.1016/S0022-3476(05)82880-X; LEE L A, 1983, Arthritis and Rheumatism, V26, pS24; LITSEY SE, 1985, NEW ENGL J MED, V312, P98, DOI 10.1056/NEJM198501103120206; LOCKSHIN MD, 1988, ARTHRITIS RHEUM, V31, P697, DOI 10.1002/art.1780310601; MACHADO MV, 1988, BRIT HEART J, V60, P512; MADISON JP, 1979, AM HEART J, V98, P505, DOI 10.1016/0002-8703(79)90257-6; MANTHORPE R, 1986, SCAND J RHEUMATOL, P19; MCCUE CM, 1977, CIRCULATION, V56, P82, DOI 10.1161/01.CIR.56.1.82; MCCUISTION CH, 1954, AMA ARCH DERM SYPH, V70, P782, DOI 10.1001/archderm.1954.01540240088009; MCCUNE AB, 1987, ANN INTERN MED, V106, P518, DOI 10.7326/0003-4819-106-4-518; Michaelsson M, 1972, Cardiovasc Clin, V4, P85; PINSKY WW, 1982, PEDIATRICS, V69, P728; PLANT RK, 1945, AM HEART J, V30, P615, DOI 10.1016/0002-8703(45)90220-1; PROVOST TT, 1987, J RHEUMATOL, V14, P199; RAMSEYGOLDMAN R, 1986, ARTHRITIS RHEUM, V29, P1269, DOI 10.1002/art.1780291013; RIDER LG, 1993, J RHEUMATOL, V20, P1208; SCHMIDT KG, 1991, J AM COLL CARDIOL, V17, P1360, DOI 10.1016/S0735-1097(10)80148-2; SCHOENLEBE J, 1993, AM J DIS CHILD, V147, P1072, DOI 10.1001/archpedi.1993.02160340058014; SCOTT JS, 1983, NEW ENGL J MED, V309, P209, DOI 10.1056/NEJM198307283090403; SINGSEN BH, 1985, AM J OBSTET GYNECOL, V152, P655, DOI 10.1016/S0002-9378(85)80039-9; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; VITALI C, 1993, ARTHRITIS RHEUM, V36, P340, DOI 10.1002/art.1780360309; WASICEK CA, 1982, J CLIN INVEST, V69, P835, DOI 10.1172/JCI110523; WATSON R, 1988, ARCH DERMATOL, V124, P560, DOI 10.1001/archderm.124.4.560; WATSON RM, 1984, MEDICINE, V63, P362, DOI 10.1097/00005792-198411000-00003; WINKLER RB, 1977, CIRCULATION, V56, P1103, DOI 10.1161/01.CIR.56.6.1103	54	241	259	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					544	551		10.7326/0003-4819-120-7-199404010-00003	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8116991				2022-12-28	WOS:A1994NC76400003
J	KELLY, DP; STRAUSS, AW				KELLY, DP; STRAUSS, AW			MECHANISMS OF DISEASE - INHERITED CARDIOMYOPATHIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; A DEHYDROGENASE-DEFICIENCY; IDIOPATHIC DILATED CARDIOMYOPATHY; DUCHENNE MUSCULAR-DYSTROPHY; MYOSIN HEAVY-CHAIN; CARNITINE PALMITOYLTRANSFERASE-II; SUDDEN CHILD-DEATH; MITOCHONDRIAL-DNA; MOLECULAR-BASIS; GENETIC-HETEROGENEITY		WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	KELLY, DP (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,DIV CARDIOVASC,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.							ALMAHDAWI S, 1993, BRIT HEART J, V69, P136; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ARAHATA K, 1988, NATURE, V333, P861, DOI 10.1038/333861a0; BARTH PG, 1983, J NEUROL SCI, V62, P327, DOI 10.1016/0022-510X(83)90209-5; BERKO BA, 1987, NEW ENGL J MED, V316, P1186, DOI 10.1056/NEJM198705073161904; BIES RD, 1992, CIRCULATION, V86, P147, DOI 10.1161/01.CIR.86.1.147; CARRIER L, 1993, NAT GENET, V4, P311, DOI 10.1038/ng0793-311; CIRO E, 1983, CIRCULATION, V67, P1227, DOI 10.1161/01.CIR.67.6.1227; COATES PM, 1992, NEW DEV FATTY ACID O, P409; CORR PB, 1989, J CLIN INVEST, V83, P927, DOI 10.1172/JCI113978; CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370; CUDA G, 1993, J CLIN INVEST, V91, P2861, DOI 10.1172/JCI116530; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; DURAN M, 1986, PEDIATRICS, V78, P1052; EPSTEIN ND, 1992, CIRCULATION, V86, P345, DOI 10.1161/01.CIR.86.2.345; EPSTEIN ND, 1992, CIRCULATION, V85, P635, DOI 10.1161/01.CIR.85.2.635; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FANANAPAZIR L, 1994, CIRCULATION, V89, P22, DOI 10.1161/01.CIR.89.1.22; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GRABER HL, 1986, CIRCULATION, V74, P21, DOI 10.1161/01.CIR.74.1.21; GREGERSEN N, 1991, HUM GENET, V86, P545; HALE DE, 1985, PEDIATR RES, V19, P666, DOI 10.1203/00006450-198507000-00006; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; HUG G, 1991, NEW ENGL J MED, V325, P1862, DOI 10.1056/NEJM199112263252607; JARCHO JA, 1989, NEW ENGL J MED, V321, P1372, DOI 10.1056/NEJM198911163212005; KELLY DP, 1990, P NATL ACAD SCI USA, V87, P9236, DOI 10.1073/pnas.87.23.9236; KELLY DP, 1992, J INHERIT METAB DIS, V15, P171, DOI 10.1007/BF01799626; KELLY DP, 1993, AM J CARDIOL, V71, P731; KO YL, 1992, HUM GENET, V89, P597; MANOLIO TA, 1992, AM J CARDIOL, V69, P1458, DOI 10.1016/0002-9149(92)90901-A; MARIAN AJ, 1992, J CLIN INVEST, V90, P2156, DOI 10.1172/JCI116101; MARIAN AJ, 1992, CIRCULATION S1, V86, P1; MARON BJ, 1984, AM J CARDIOL, V53, P1087, DOI 10.1016/0002-9149(84)90643-X; MASTAGLIA FL, 1982, SKELETAL MUSCLE PATH; MATSUBARA Y, 1990, LANCET, V335, P1589, DOI 10.1016/0140-6736(90)91413-5; MATSUBARA Y, 1991, LANCET, V338, P552, DOI 10.1016/0140-6736(91)91110-G; MESTRONI L, 1990, AM J CARDIOL, V65, P1449, DOI 10.1016/0002-9149(90)91353-8; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; NAITO E, 1990, J CLIN INVEST, V85, P1575, DOI 10.1172/JCI114607; NAITO E, 1989, J CLIN INVEST, V83, P1605, DOI 10.1172/JCI114058; NEELY J R, 1972, Progress in Cardiovascular Diseases, V15, P289, DOI 10.1016/0033-0620(72)90029-1; NIGRO G, 1990, INT J CARDIOL, V26, P271, DOI 10.1016/0167-5273(90)90082-G; PERLOFF JK, 1966, CIRCULATION, V33, P625, DOI 10.1161/01.CIR.33.4.625; ROCCHICCIOLI F, 1990, PEDIATR RES, V28, P657, DOI 10.1203/00006450-199012000-00023; ROE CR, 1989, METABOLIC BASIS INHE, V1, P889; SCHWARTZ K, 1992, CIRC RES, V71, P3, DOI 10.1161/01.RES.71.1.3; SOLOMON SD, 1990, J CLIN INVEST, V86, P993, DOI 10.1172/JCI114802; STANLEY CA, 1992, NEW ENGL J MED, V327, P19, DOI 10.1056/NEJM199207023270104; SUOMALAINEN A, 1992, LANCET, V340, P1319, DOI 10.1016/0140-6736(92)92496-3; Tanaka K., 1992, Human Mutation, V1, P271, DOI 10.1002/humu.1380010402; TANIIKE M, 1992, BIOCHEM BIOPH RES CO, V186, P47, DOI 10.1016/S0006-291X(05)80773-9; TARONI F, 1992, P NATL ACAD SCI USA, V89, P8429, DOI 10.1073/pnas.89.18.8429; TEIN I, 1990, PEDIATR RES, V28, P247, DOI 10.1203/00006450-199009000-00020; THIERFELDER L, 1993, P NATL ACAD SCI USA, V90, P6270, DOI 10.1073/pnas.90.13.6270; TOWBIN JA, 1993, CIRCULATION, V87, P1854, DOI 10.1161/01.CIR.87.6.1854; WALLACE DC, 1986, SOMAT CELL MOLEC GEN, V12, P41, DOI 10.1007/BF01560726; WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WATKINS H, 1993, NAT GENET, V3, P333, DOI 10.1038/ng0493-333; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703; WATKINS H, 1992, J CLIN INVEST, V90, P1666, DOI 10.1172/JCI116038; YOKOTA I, 1990, J CLIN INVEST, V86, P1000, DOI 10.1172/JCI114761; ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D	65	284	289	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	1994	330	13					913	919						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC608	8114864				2022-12-28	WOS:A1994NC60800008
J	KLAHR, S; LEVEY, AS; BECK, GJ; CAGGIULA, AW; HUNSICKER, L; KUSEK, JW; STRIKER, G; BUCKALEW, V; BURKART, J; FURBERG, C; FELTS, J; MOORE, M; ROCCO, H; DOLECEK, T; WARREN, S; BEARDEN, B; STARKEY, C; HARVEY, J; POOLE, D; DAHLQUIST, S; DOROSHENKO, L; BRADHAM, K; WEST, D; AGOSTINO, J; COLE, L; BAKER, B; HAIRSTON, K; BURGOYNE, S; LAZARUS, J; STEINMAN, T; SEIFTER, J; DESMOND, M; FIORENZO, M; CHIAVACCI, A; METALIDES, T; KORZECRAMIREZ, D; GOULD, S; PICKETT, V; PORUSH, J; FAUBERT, P; SPITALEWITZ, S; FAUBERT, J; ZIMMER, G; SAUM, D; BLOCK, M; WOEL, J; ROSE, M; DENNIS, V; SCHWAB, S; MINDA, S; CONDON, S; JENKS, B; ECKARD, L; GEDON, G; MITCH, W; MARONI, B; ENGLAND, B; SOUCIE, J; PEDERSEN, M; AKPELE, L; CALLAHAN, P; HALL, B; SHELTON, S; BOSCH, J; HABWE, V; CULBERTSON, B; STACKDUNNE, M; HANKEY, M; ONEILL, S; WITZMANN, K; GOLDMAN, C; JONES, T; BOYLE, D; SALMON, L; KOPPLE, J; ADLER, S; HIRSCHBERG, R; DICHIRO, J; SNIDER, K; DEVINE, W; MCKAY, S; MCDONALD, J; CARTER, J; NELSON, W; LEVEY, A; COGGINS, C; DWYER, J; MCLAUGHLIN, M; GRONICH, J; KING, A; STOLLAR, C; RAIZMAN, D; CASTALDO, L; DESIMONE, D; EFSTATHION, A; YONKER, K; FINE, J; SAUL, N; HUGGINS, N; MARTIN, A; BALDI, S; MOLESKE, C; SHEEHAN, K; FURLONG, D; HEBERT, L; NAHMAN, N; DRIVER, V; COSIO, M; HARTMAN, J; LEVY, C; LONDERGAN, D; GILLIGAN, M; BECKMAN, T; SMITH, E; ZACHRICH, D; TISHER, C; PETERSON, J; WINGO, C; FINLAY, R; PARRIS, E; IVEY, G; GREGORY, P; HOFFINGER, R; GARCIA, D; PRESTON, C; BERTOLATUS, J; LIM, V; SNETSELAAR, L; WELCH, B; BROOKS, L; HOLLINGER, D; LICHTY, I; MUELLER, D; EASTIN, S; TANNA, A; STEELE, J; RIECK, K; BOURGOIGNIE, J; ROTH, D; GREEN, D; BUTCHER, C; MERRILL, D; DEVELASCO, A; GARCON, M; ROJAS, C; ZARAGOZA, M; BARTON, S; MASSRY, S; AKMAL, M; FADDA, G; SMORGORZERSKI, M; KIEFER, S; RAUCH, S; EYERMAN, M; KIGAWA, L; RICHARDSON, A; LIFSCHITZ, M; KUNAU, R; NOLAN, C; GOUGE, S; BAKRIS, G; HURA, C; YOUNG, E; ARMES, C; WARNER, C; TANSEY, A; FLORES, M; DELEA, C; TESCHAN, P; HAKIM, R; BREYER, J; SCHULMAN, G; ROGERS, N; POWERS, S; MCLEROY, S; FISCHER, S; DEERE, M; CUTLER, E; KUSEK, J; AGODOA, L; ANDERSON, A; BECK, G; WILLIAMS, G; GASSMAN, J; GREENE, T; SCHLUCHTER, M; BERG, R; BROWN, M; CHU, L; DRABIK, M; FATICA, K; KNUTH, T; LAMBDIN, K; LEATHERMAN, J; MCPHERSON, J; MIDCALF, V; MOORE, B; PARANANDI, L; PEARCE, G; SWINDERMAN, D; WANG, S; WEBB, L; YANCHAR, K; CAGGIULA, A; MILAS, N; YAMAMOTO, M; AMOROSO, W; AVERBACH, F; COYNE, T; GILLIS, B; JONES, F; MAURER, E; MEEHAN, R; NAUJELIS, J; OLSON, M; SCHERCH, L; STANO, E; STEGINK, L; BRUMMEL, M; LUDWIG, B; VANLENTE, F; WALETZKY, J; ERDEI, L; SOUTH, C; SPAGNOLA, C; OLAUGHLIN, C; PROUDFIT, W; UNDERWOOD, D; HALL, P; ROLIN, H; PEXA, D; JONES, E; BASCH, M; CHUMLEA, W; DOLLIFF, G; KAPLAN, R; WING, R; DAMICO, G; DIRKS, J; GRANTHAM, J; HARPER, A; PETERS, K; STEIN, J; PELLEGRINO, E; VANYPERSELE, C; BAIN, R; GRIZZLE, J; HAWKINS, C; HOLLIDAY, M; LUKE, R; MYERS, B; RUDMAN, D; WHELTON, P; YOUNG, D; YOUNG, V				KLAHR, S; LEVEY, AS; BECK, GJ; CAGGIULA, AW; HUNSICKER, L; KUSEK, JW; STRIKER, G; BUCKALEW, V; BURKART, J; FURBERG, C; FELTS, J; MOORE, M; ROCCO, H; DOLECEK, T; WARREN, S; BEARDEN, B; STARKEY, C; HARVEY, J; POOLE, D; DAHLQUIST, S; DOROSHENKO, L; BRADHAM, K; WEST, D; AGOSTINO, J; COLE, L; BAKER, B; HAIRSTON, K; BURGOYNE, S; LAZARUS, J; STEINMAN, T; SEIFTER, J; DESMOND, M; FIORENZO, M; CHIAVACCI, A; METALIDES, T; KORZECRAMIREZ, D; GOULD, S; PICKETT, V; PORUSH, J; FAUBERT, P; SPITALEWITZ, S; FAUBERT, J; ZIMMER, G; SAUM, D; BLOCK, M; WOEL, J; ROSE, M; DENNIS, V; SCHWAB, S; MINDA, S; CONDON, S; JENKS, B; ECKARD, L; GEDON, G; MITCH, W; MARONI, B; ENGLAND, B; SOUCIE, J; PEDERSEN, M; AKPELE, L; CALLAHAN, P; HALL, B; SHELTON, S; BOSCH, J; HABWE, V; CULBERTSON, B; STACKDUNNE, M; HANKEY, M; ONEILL, S; WITZMANN, K; GOLDMAN, C; JONES, T; BOYLE, D; SALMON, L; KOPPLE, J; ADLER, S; HIRSCHBERG, R; DICHIRO, J; SNIDER, K; DEVINE, W; MCKAY, S; MCDONALD, J; CARTER, J; NELSON, W; LEVEY, A; COGGINS, C; DWYER, J; MCLAUGHLIN, M; GRONICH, J; KING, A; STOLLAR, C; RAIZMAN, D; CASTALDO, L; DESIMONE, D; EFSTATHION, A; YONKER, K; FINE, J; SAUL, N; HUGGINS, N; MARTIN, A; BALDI, S; MOLESKE, C; SHEEHAN, K; FURLONG, D; HEBERT, L; NAHMAN, N; DRIVER, V; COSIO, M; HARTMAN, J; LEVY, C; LONDERGAN, D; GILLIGAN, M; BECKMAN, T; SMITH, E; ZACHRICH, D; TISHER, C; PETERSON, J; WINGO, C; FINLAY, R; PARRIS, E; IVEY, G; GREGORY, P; HOFFINGER, R; GARCIA, D; PRESTON, C; BERTOLATUS, J; LIM, V; SNETSELAAR, L; WELCH, B; BROOKS, L; HOLLINGER, D; LICHTY, I; MUELLER, D; EASTIN, S; TANNA, A; STEELE, J; RIECK, K; BOURGOIGNIE, J; ROTH, D; GREEN, D; BUTCHER, C; MERRILL, D; DEVELASCO, A; GARCON, M; ROJAS, C; ZARAGOZA, M; BARTON, S; MASSRY, S; AKMAL, M; FADDA, G; SMORGORZERSKI, M; KIEFER, S; RAUCH, S; EYERMAN, M; KIGAWA, L; RICHARDSON, A; LIFSCHITZ, M; KUNAU, R; NOLAN, C; GOUGE, S; BAKRIS, G; HURA, C; YOUNG, E; ARMES, C; WARNER, C; TANSEY, A; FLORES, M; DELEA, C; TESCHAN, P; HAKIM, R; BREYER, J; SCHULMAN, G; ROGERS, N; POWERS, S; MCLEROY, S; FISCHER, S; DEERE, M; CUTLER, E; KUSEK, J; AGODOA, L; ANDERSON, A; BECK, G; WILLIAMS, G; GASSMAN, J; GREENE, T; SCHLUCHTER, M; BERG, R; BROWN, M; CHU, L; DRABIK, M; FATICA, K; KNUTH, T; LAMBDIN, K; LEATHERMAN, J; MCPHERSON, J; MIDCALF, V; MOORE, B; PARANANDI, L; PEARCE, G; SWINDERMAN, D; WANG, S; WEBB, L; YANCHAR, K; CAGGIULA, A; MILAS, N; YAMAMOTO, M; AMOROSO, W; AVERBACH, F; COYNE, T; GILLIS, B; JONES, F; MAURER, E; MEEHAN, R; NAUJELIS, J; OLSON, M; SCHERCH, L; STANO, E; STEGINK, L; BRUMMEL, M; LUDWIG, B; VANLENTE, F; WALETZKY, J; ERDEI, L; SOUTH, C; SPAGNOLA, C; OLAUGHLIN, C; PROUDFIT, W; UNDERWOOD, D; HALL, P; ROLIN, H; PEXA, D; JONES, E; BASCH, M; CHUMLEA, W; DOLLIFF, G; KAPLAN, R; WING, R; DAMICO, G; DIRKS, J; GRANTHAM, J; HARPER, A; PETERS, K; STEIN, J; PELLEGRINO, E; VANYPERSELE, C; BAIN, R; GRIZZLE, J; HAWKINS, C; HOLLIDAY, M; LUKE, R; MYERS, B; RUDMAN, D; WHELTON, P; YOUNG, D; YOUNG, V			THE EFFECTS OF DIETARY-PROTEIN RESTRICTION AND BLOOD-PRESSURE CONTROL ON THE PROGRESSION OF CHRONIC RENAL-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LONGITUDINAL DATA; INSUFFICIENCY; FAILURE; TRIAL	Background. Restricting protein intake and controlling hypertension delay the progression of renal disease in animals. We tested these interventions in 840 patients with various chronic renal diseases.	NIDDKD,BETHESDA,MD 20892; WASHINGTON UNIV,MED CTR,ST LOUIS,MO; UNIV PITTSBURGH,PITTSBURGH,PA; UNIV IOWA HOSP & CLIN,IOWA CITY,IA; BOWMAN GRAY SCH MED,WINSTON SALEM,NC; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; BETH ISRAEL HOSP,BOSTON,MA 02215; BROOKDALE HOSP MED CTR,BROOKLYN,NY; DUKE UNIV,SCH MED,DURHAM,NC; EMORY UNIV,ATLANTA,GA 30322; GEORGE WASHINGTON UNIV,WASHINGTON,DC; HARBOR UCLA MED CTR,TORRANCE,CA; TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114; OHIO STATE UNIV,COLUMBUS,OH 43210; UNIV FLORIDA,GAINESVILLE,FL; UNIV IOWA HOSP & CLIN,IOWA CITY,IA 52242; UNIV MIAMI,CORAL GABLES,FL 33124; JACKSON MEM HOSP,MED CTR,MIAMI,FL; UNIV SO CALIF,LOS ANGELES,CA; UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX; VANDERBILT UNIV,MED CTR,NASHVILLE,TN; HLTH CARE FINANCING ADM,SEATTLE,WA; UNIV PITTSBURGH,CTR NUTR COORDINATING,PITTSBURGH,PA; UNIV IOWA,CENT AMINO ACID LAB,IOWA CITY,IA; CLEVELAND CLIN FDN,CENT BIOCHEM LAB,CLEVELAND,OH; CLEVELAND CLIN FDN,CENT GLOMERULAR FILTRAT RATE LAB,CLEVELAND,OH; CLEVELAND CLIN FDN,CTR DRUG DISTRIBUT,CLEVELAND,OH; CLEVELAND CLIN FDN,CENT ELECTROCARDIOG LAB,CLEVELAND,OH	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Iowa; Wake Forest University; Wake Forest Baptist Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Duke University; Emory University; George Washington University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Tufts Medical Center; Harvard University; Massachusetts General Hospital; University System of Ohio; Ohio State University; State University System of Florida; University of Florida; University of Iowa; University of Miami; University of Southern California; University of Texas System; University of Texas Health San Antonio; Vanderbilt University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Iowa; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	KLAHR, S (corresponding author), CLEVELAND CLIN FDN,MDRD STUDY DATA COORDINATING CTR,DEPT BIOSTAT & EPIDEMIOL,P88,CLEVELAND,OH 44195, USA.		Lifschitz, Meyer/AAJ-5578-2020; Faubert, Jocelyn/E-2207-2011					BECK GJ, 1991, CONTROL CLIN TRIALS, V12, P566, DOI 10.1016/0197-2456(91)90069-X; BRENNER BM, 1983, KIDNEY INT, V23, P647, DOI 10.1038/ki.1983.72; FOUQUE D, 1992, BMJ-BRIT MED J, V304, P216, DOI 10.1136/bmj.304.6821.216; Frisancho AR, 1990, ANTHROPOMETRIC STAND; GREENE T, 1993, J AM SOC NEPHROL, V3, P1819; HUNSICKER LG, 1989, SEMIN NEPHROL, V9, P380; IHLE BU, 1989, NEW ENGL J MED, V321, P1773, DOI 10.1056/NEJM198912283212601; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEANE WF, 1989, ANN INTERN MED, V111, P503, DOI 10.7326/0003-4819-111-6-503; KING AJ, 1993, J AM SOC NEPHROL, V3, P1723; KLAHR S, 1983, KIDNEY INT, V24, P579, DOI 10.1038/ki.1983.197; KLAHR S, 1989, NEW ENGL J MED, V320, P864, DOI 10.1056/NEJM198903303201310; Kopple J D, 1989, Kidney Int Suppl, V27, pS184; KUSEK J, 1991, CONTRIB NEPHROL, V81, P50; KUSEK JW, 1993, CONTROL CLIN TRIALS, V14, P538, DOI 10.1016/0197-2456(93)90033-A; LEVEY AS, 1991, J AM SOC NEPHROL, V1, P1087; LEVEY AS, 1989, KIDNEY INT, V36, pS73; LEVEY AS, 1993, J AM SOC NEPHROL, V4, P1159; LOCATELLI F, 1991, LANCET, V337, P1299, DOI 10.1016/0140-6736(91)92977-A; MARONI BJ, 1985, KIDNEY INT, V27, P58, DOI 10.1038/ki.1985.10; MITCH WE, 1984, NEW ENGL J MED, V311, P623, DOI 10.1056/NEJM198409063111002; PERRONE RD, 1990, AM J KIDNEY DIS, V16, P224, DOI 10.1016/S0272-6386(12)81022-5; ROSMAN JB, 1984, LANCET, V2, P1291; SCHLUCHTER MD, 1992, STAT MED, V11, P1861, DOI 10.1002/sim.4780111408; WALSER M, 1993, KIDNEY INT, V43, P933, DOI 10.1038/ki.1993.131; YAMAMOTO ME, 1992, J RENAL NUTR, V2, P117; 1993, ARCH INTERN MED, V153, P154	28	1814	1870	3	61	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	1994	330	13					877	884		10.1056/NEJM199403313301301	http://dx.doi.org/10.1056/NEJM199403313301301			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC608	8114857				2022-12-28	WOS:A1994NC60800001
J	PINN, A				PINN, A			SCIENTISTS MOVING INTO SALES	NATURE			English	Article											PINN, A (corresponding author), DELTA CONSULTANTS,OLD COURTHOUSE,PRIORY RD,HUNTINGDON PE17 4BB,CAMBS,ENGLAND.								0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 31	1994	368	6470					480	480		10.1038/368480a0	http://dx.doi.org/10.1038/368480a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	8133897	Bronze			2022-12-28	WOS:A1994ND12000071
J	ANDERSSON, L; HALEY, CS; ELLEGREN, H; KNOTT, SA; JOHANSSON, M; ANDERSSON, K; ANDERSSONEKLUND, L; EDFORSLILJA, I; FREDHOLM, M; HANSSON, I; HAKANSSON, J; LUNDSTROM, K				ANDERSSON, L; HALEY, CS; ELLEGREN, H; KNOTT, SA; JOHANSSON, M; ANDERSSON, K; ANDERSSONEKLUND, L; EDFORSLILJA, I; FREDHOLM, M; HANSSON, I; HAKANSSON, J; LUNDSTROM, K			GENETIC-MAPPING OF QUANTITATIVE TRAIT LOCI FOR GROWTH AND FATNESS IN PIGS	SCIENCE			English	Article							MENDELIAN FACTORS; IDENTIFICATION; MARKERS	The European wild boar was crossed with the domesticated Large White pig to genetically dissect phenotypic differences between these populations for growth and fat deposition. The most important effects were clustered on chromosome 4, with a single region accounting for a large part of the breed difference in growth rate, fatness, and length of the small intestine. The study is an advance in genome analyses and documents the usefulness of crosses between divergent outbred populations for the detection and characterization of quantitative trait loci. The genetic mapping of a major locus for fat deposition in the pig could have implications for understanding human obesity.	AFRC,ROSLIN INST EDINBURGH,ROSLIN EH25 9PS,MIDLOTHIAN,SCOTLAND; INRA,GENET QUANTITAT & APPL STN,F-78350 JOUY EN JOSAS,FRANCE; UNIV EDINBURGH,INST CELL ANIM & POPULAT BIOL,EDINBURGH EH9 3JT,SCOTLAND; ROYAL VET & AGR UNIV,DEPT ANIM PROD & ANIM HLTH,DIV ANIM GENET,DK-1870 FREDERIKSBERG C,DENMARK; SWEDISH UNIV AGR SCI,DEPT FOOD SCI,S-75007 UPPSALA,SWEDEN; SWEDISH UNIV AGR SCI,DEPT ANIM NUTR & MANAGEMENT,S-75007 UPPSALA,SWEDEN	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; INRAE; UDICE-French Research Universities; Universite Paris Saclay; University of Edinburgh; University of Copenhagen; Swedish University of Agricultural Sciences; Swedish University of Agricultural Sciences	ANDERSSON, L (corresponding author), SWEDISH UNIV AGR SCI,DEPT ANIM BREEDING & GENET,BOX 7023,S-75007 UPPSALA,SWEDEN.		Haley, Chris S/F-3110-2013; Knott, Sara A/H-2466-2013; Kijas, James W/A-4656-2011; Giuffra, Elisabetta/J-8080-2014	Knott, Sara A/0000-0002-4568-2928; Kijas, James W/0000-0002-1417-8278; Fredholm, Merete/0000-0002-3563-7648; Haley, Chris/0000-0002-9811-0210; Moller, Maria/0000-0001-9750-6101				ABBOTT CM, 1993, MAMM GENOME, V4, pS58, DOI 10.1007/BF00360830; ANDERSSON L, 1993, ANIM GENET, V24, P205, DOI 10.1111/j.1365-2052.1993.tb00290.x; ANDERSSON L, UNPUB; BOUCHARD C, 1993, ANNU REV NUTR, V13, P337, DOI 10.1146/annurev.nu.13.070193.002005; CECI JD, 1993, MAMM GENOME, V4, pS121, DOI 10.1007/BF00360834; DARWIN C, 1882, VARIATION ANIMALS PL, V1, P77; ELLEGREN H, IN PRESS GENETICS; HALEY CS, 1992, HEREDITY, V69, P315, DOI 10.1038/hdy.1992.131; HALEY CS, IN PRESS; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JOHANSSON M, 1992, GENOMICS, V14, P965, DOI 10.1016/S0888-7543(05)80118-1; LANDER ES, 1989, GENETICS, V121, P185; OBRIEN SJ, 1993, NAT GENET, V3, P103, DOI 10.1038/ng0293-103; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; PEARSON, 1988, SAS PROCEDURES GUIDE; PETERSSON H, 1979, SWED J AGR RES, V9, P75; PETERSSON H, 1990, THESIS SWEDISH U AGR, P57; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591; SOLLER M, 1983, THEOR APPL GENET, V67, P25, DOI 10.1007/BF00303917; STUBER CW, 1992, GENETICS, V132, P823; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; VANOOIJEN JW, 1992, THEOR APPL GENET, V84, P803, DOI 10.1007/BF00227388; Wiseman J, 1986, HIST BRIT PIG	23	546	605	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 25	1994	263	5154					1771	1774		10.1126/science.8134840	http://dx.doi.org/10.1126/science.8134840			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC040	8134840				2022-12-28	WOS:A1994NC04000038
J	ROCHAT, A; KOBAYASHI, K; BARRANDON, Y				ROCHAT, A; KOBAYASHI, K; BARRANDON, Y			LOCATION OF STEM-CELLS OF HUMAN HAIR-FOLLICLES BY CLONAL ANALYSIS	CELL			English	Article							OUTER ROOT SHEATH; HUMAN EPIDERMAL-KERATINOCYTES; DERMAL PAPILLA CELLS; SERIAL CULTIVATION; INVITRO; GROWTH; CULTURE; CYCLE; UNIT	We have examined the growth capacity of keratinocytes isolated from human scalp hair follicles. Like the keratinocytes of glabrous epidermis, most of the colony-forming cells are classified as holoclones or meroclones when analyzed in a clonal assay. Some of them have extensive growth potential, as they are able to undergo at least 130 doublings. Therefore, the hair follicle, like the epidermis, contains keratinocytes with the expected property of stem cells: an extensive proliferative capacity permitting the generation of a large amount of epithelium. We have also examined the distribution of clonogenic keratinocytes within the hair follicle. Several hundred colony-forming cells are concentrated at a region below the midpoint of the follicle and outside the hair bulb. This region lies deeper than the site of insertion of the arrector pili muscle, which corresponds with the position of the bulge when the latter can be identified. In contrast, few colony-forming cells are present in the hair bulb, where most of the mitotic activity is observed during the active growth phase of the follicle. Paraclones, which are present both in the midregion and in the bulb of hair follicles, are unlikely to be the transient amplifying cells expected from kinetic studies.			ROCHAT, A (corresponding author), ECOLE NORMALE SUPER, DEPT BIOL, 46 RUE ULM, F-75230 PARIS 05, FRANCE.							ALBARWARI SE, 1976, INT J RADIAT BIOL, V30, P201, DOI 10.1080/09553007614550981; ALLENHOFFMANN BL, 1984, P NATL ACAD SCI-BIOL, V81, P7802, DOI 10.1073/pnas.81.24.7802; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; BARRANDON Y, 1985, P NATL ACAD SCI USA, V82, P5390, DOI 10.1073/pnas.82.16.5390; BARRANDON Y, 1988, J INVEST DERMATOL, V91, P315, DOI 10.1111/1523-1747.ep12475646; BERGSTRESSER PR, 1978, J INVEST DERMATOL, V70, P280, DOI 10.1111/1523-1747.ep12541516; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; DEXTER TM, 1987, ANNU REV CELL BIOL, V3, P423; HEID HW, 1986, DIFFERENTIATION, V32, P101, DOI 10.1111/j.1432-0436.1986.tb00562.x; HOLBROOK KA, 1979, INT J DERMATOL, V18, P329, DOI 10.1111/ijd.1979.18.5.329; HOLECEK BU, 1993, AM J DERMATOPATH, V15, P235, DOI 10.1097/00000372-199306000-00007; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KOBAYASHI K, 1993, P NATL ACAD SCI USA, V90, P7391, DOI 10.1073/pnas.90.15.7391; LAJTHA LG, 1979, DIFFERENTIATION, V14, P23, DOI 10.1111/j.1432-0436.1979.tb01007.x; LAVKER RM, 1991, ANN NY ACAD SCI, V642, P214; LAVKER RM, 1983, J INVEST DERMATOL, V81, pS121, DOI 10.1111/1523-1747.ep12540880; LAVKER RM, 1982, SCIENCE, V215, P1239, DOI 10.1126/science.7058342; LENOIR MC, 1988, DEV BIOL, V130, P610, DOI 10.1016/0012-1606(88)90356-9; LENOIRVIALE MC, 1993, ARCH DERMATOL RES, V285, P197, DOI 10.1007/BF00372009; LIMAT A, 1991, EXP CELL RES, V194, P218, DOI 10.1016/0014-4827(91)90357-Z; LIMAT A, 1986, J INVEST DERMATOL, V87, P485, DOI 10.1111/1523-1747.ep12455548; LYNCH MH, 1986, J CELL BIOL, V103, P2593, DOI 10.1083/jcb.103.6.2593; MONTAGNA W, 1958, BIOL HAIR GROWTH, P39; MORRIS RJ, 1985, J INVEST DERMATOL, V84, P277, DOI 10.1111/1523-1747.ep12265358; MYERS RJ, 1951, ANN NY ACAD SCI, V53, P562, DOI 10.1111/j.1749-6632.1951.tb31957.x; PENNEYS NS, 1970, ARCH DERMATOL, V101, P323, DOI 10.1001/archderm.101.3.323; PHILPOTT MP, 1990, J CELL SCI, V97, P463; PINKUS F, 1910, MANUAL HUMAN EMBRYOL, P243; PINKUS H., 1958, BIOL HAIR GROWTH, P1; POTTEN CS, 1973, INT J RADIAT BIOL, V24, P537, DOI 10.1080/09553007314551441; POTTEN CS, 1983, STEM CELLS THEIR IDE, P200; REYNOLDS AJ, 1993, J INVEST DERMATOL, V101, P634, DOI 10.1111/1523-1747.ep12366095; REYNOLDS AJ, 1991, J CELL SCI, V99, P373; REYNOLDS AJ, 1992, DEVELOPMENT, V115, P587; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; UNNA PG, 1876, ARCH MIKROSK ANAT, V12, P665; VANNESTE D, 1983, BRIT J DERMATOL, V108, P433; VANSCOTT EJ, 1963, J INVEST DERMATOL, V41, P269, DOI 10.1038/jid.1963.110; WEINSTEIN GD, 1984, J INVEST DERMATOL, V82, P623, DOI 10.1111/1523-1747.ep12261462; YANG JS, 1993, J INVEST DERMATOL, V101, P652, DOI 10.1111/1523-1747.ep12371671	44	424	458	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 25	1994	76	6					1063	1073		10.1016/0092-8674(94)90383-2	http://dx.doi.org/10.1016/0092-8674(94)90383-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137423				2022-12-28	WOS:A1994ND24600012
J	MARQUIS, MS; BUCHANAN, JL				MARQUIS, MS; BUCHANAN, JL			HOW WILL CHANGES IN HEALTH-INSURANCE TAX POLICY AND EMPLOYER HEALTH PLAN CONTRIBUTIONS AFFECT ACCESS TO HEALTH-CARE AND HEALTH-CARE COSTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPENDITURES; SERVICES	Objective.-To understand how changes in federal taxation of and employer contributions to health insurance benefits affect the decisions of firms to offer insurance, the willingness of households to purchase different health plans, and the resultant health expenditures. Design.-Economic policy simulation. Setting.-Secondary data analysis. Participants.-A total of 18343 sampled families (representing 77 million total families throughout the United States) with a working household head from the 1988 Current Population Survey who were not covered by either Medicare, Medicaid, or CHAMPUS (Civilian Health and Medical Program of the Uniformed Services) insurance. Interventions-one intervention limits the amounts of tax-free employer contributions to health insurance premiums to 80% of our estimate of the base plan in the market and assumes that employer contributions will also be limited to this maximum. A second intervention eliminates the favorable tax treatment of employer-paid premiums altogether and assumes that employees will pay the full price of insurance. Main Outcome Measures.-Change in the number of working families offered employment-based insurance, change in insurance plan choice, and change in medical spending. Results.-Capping the favorable tax treatment and employer contributions decreases the number of families offered employment-based insurance by approximately 91000, increases the number of families selecting the least generous insurance plan from 20% under the current situation to 33%, and reduces overall health spending by less than 2%. By eliminating the tax exemption altogether, the number of families offered employment-based insurance decreases by approximately half a million families, the number of families selecting the least generous plan goes from 20% to 40%, and overall spending falls by about $16 billion. Conclusions.-Eliminating the tax subsidy and limiting employer-paid contributions to the low-cost plan substantially increases the number of low-income uninsured under a voluntary insurance system, decreases overall spending only modestly, but would raise tax revenues by $36 billion. These tax revenues could be used to assist low-income families to obtain insurance coverage.	RAND CORP,SANTA MONICA,CA	RAND Corporation	MARQUIS, MS (corresponding author), RAND CORP,2100 M ST NW,WASHINGTON,DC 20037, USA.							AARON HJ, 1993, HEALTH AFFAIR, V12, P204, DOI 10.1377/hlthaff.12.suppl_1.204; BERGTHOLD LA, 1993, HEALTH AFFAIR, V12, P99, DOI 10.1377/hlthaff.12.suppl_1.99; BUCHANAN JL, 1991, MANAGE SCI, V37, P1067, DOI 10.1287/mnsc.37.9.1067; CHERNICK HA, 1987, J HEALTH ECON, V6, P1, DOI 10.1016/0167-6296(87)90028-2; Ellwood P M, 1992, Health Econ, V1, P149, DOI 10.1002/hec.4730010303; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; KEELER EB, 1988, RANDR3454HHS; LONG SH, 1992, HLTH BENEFITS WORKFO; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MARQUIS MS, 1991, RAND R4105HCFA; MARQUIS MS, 1992, HLTH BENEFITS WORKFO; MARQUIS MS, 1986, RAND N2516HHS; MARQUIS MS, 1985, RAND R3262HCFA; Pauly M.V., 1976, ROLE HLTH INSURANCE, P73; Sonnefeld S T, 1991, Health Care Financ Rev, V13, P1; Waldo D R, 1989, Health Care Financ Rev, V10, P111	16	11	11	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	1994	271	12					939	944		10.1001/jama.271.12.939	http://dx.doi.org/10.1001/jama.271.12.939			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NA743	8120964				2022-12-28	WOS:A1994NA74300032
J	PHELPS, CE				PHELPS, CE			AN APPLE A DAY - A FUTURISTIC PARABLE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note																			0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 17	1994	330	11					797	799		10.1056/NEJM199403173301124	http://dx.doi.org/10.1056/NEJM199403173301124			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA742	8107759				2022-12-28	WOS:A1994NA74200035
J	WYLER, DJ; SACKNOFF, R; MATTIA, AR; MARK, EJ; RYAN, ET; HARMON, JV				WYLER, DJ; SACKNOFF, R; MATTIA, AR; MARK, EJ; RYAN, ET; HARMON, JV			A 35-YEAR-OLD ETHIOPIAN MAN WITH SPLENOMEGALY AND RECURRENT FEVER - PLASMODIUM-VIVAX MALARIA - SPLENOMEGALY, CHRONIC	NEW ENGLAND JOURNAL OF MEDICINE			English	Discussion							VISCERAL LEISHMANIASIS; DIAGNOSIS; SPLEEN		TUFTS UNIV, SCH MED, MEDFORD, MA USA	Tufts University	WYLER, DJ (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DIV GEOG MED & INFECT DIS, BOSTON, MA 02111 USA.							ALMOHAYA S, 1986, AM J TROP MED HYG, V35, P995, DOI 10.4269/ajtmh.1986.35.995; ANTHONY RL, 1992, J PARASITOL, V78, P994, DOI 10.2307/3283219; ARMSTRONG JC, 1978, T ROY SOC TROP MED H, V72, P342, DOI 10.1016/0035-9203(78)90123-2; ASHFORD RW, 1985, LEISHMANIASIS, V1, P377; BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003; Barranger J. A., 1989, METABOLIC BASIS INHE, P1677; BERENGUER J, 1989, ANN INTERN MED, V111, P129, DOI 10.7326/0003-4819-111-2-129; BERMAN JD, 1988, REV INFECT DIS, V10, P560; BOONPUCKNAVIG V, 1988, MALARIA PRINCIPLES P, V1, P673; BOWDLER AJ, 1983, CLIN HAEMATOL, V12, P467; CARTWRIGHT GE, 1948, BLOOD, V3, P249, DOI 10.1182/blood.V3.3.249.249; CARVALHO EM, 1983, AM J TROP MED HYG, V32, P61, DOI 10.4269/ajtmh.1983.32.61; Centers for Disease Control (CDC), 1992, MMWR Morb Mortal Wkly Rep, V41, P131; CHANG KP, 1983, INT REV CYTOL, P267; CHEEVER AW, 1967, T ROY SOC TROP MED H, V61, P626, DOI 10.1016/0035-9203(67)90125-3; CRANE G G, 1986, Parasitology Today, V2, P4, DOI 10.1016/0169-4758(86)90067-0; DEBRITO T, 1975, AM J TROP MED HYG, V24, P9, DOI 10.4269/ajtmh.1975.24.9; FLEMING AF, 1981, CLIN HAEMATOL, V10, P983; GARCIA JJG, 1986, T ROY SOC TROP MED H, V80, P549, DOI 10.1016/0035-9203(86)90136-7; GREENWOOD BM, 1979, ROLE SPLEEN IMMUNOLO, P229; HOFFMAN SL, 1984, NEW ENGL J MED, V310, P337, DOI 10.1056/NEJM198402093100601; HOMEIDA M, 1988, AM J TROP MED HYG, V39, P196, DOI 10.4269/ajtmh.1988.39.196; HOOGSTRAAL H, 1969, AM J TROP MED HYG, V18, P1091, DOI 10.4269/ajtmh.1969.18.1091; KAGER PA, 1983, TROP GEOGR MED, V35, P125; KREUTZER RD, 1980, AM J TROP MED HYG, V29, P199, DOI 10.4269/ajtmh.1980.29.199; MAKLER MT, 1991, CLIN LAB MED, V11, P941, DOI 10.1016/S0272-2712(18)30529-8; MAKLER MT, 1992, CLIN LAB MED, V12, pRM; MANSON-BAHR P. E. C., 1956, TRANS ROY SOC TROP MED AND HYG, V50, P465, DOI 10.1016/0035-9203(56)90095-5; Manson-Bahr P. E. C., 1987, The leishmaniases in biology and medicine. Volume II. Clinical aspects and control, P703; MARU M, 1979, AM J TROP MED HYG, V28, P15, DOI 10.4269/ajtmh.1979.28.15; MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602; MURRAY CJL, 1990, T ROY SOC TROP MED H, V84, P1, DOI 10.1016/0035-9203(90)90364-K; PRATT DM, 1981, NATURE, V291, P581, DOI 10.1038/291581a0; Rees P. H., 1987, The leishmaniases in biology and medicine. Volume II. Clinical aspects and control, P583; RICKMAN LS, 1989, LANCET, V1, P68; SAGOE AS, 1970, BRIT MED J, V3, P378, DOI 10.1136/bmj.3.5719.378; STRAUS DJ, 1983, CANCER, V51, P101, DOI 10.1002/1097-0142(19830101)51:1<101::AID-CNCR2820510121>3.0.CO;2-W; Strickland G.T., 1991, HUNTERS TROPICAL MED, P586; WILSON M, 1991, WORLD GUIDE INFECTIO; Wilson M. E., 1990, Modern parasite biology: cellular, immunological, and molecular aspects., P200; WIRTH DF, 1986, SCIENCE, V234, P975, DOI 10.1126/science.3535070; WONGSRICHANALAI C, 1991, AM J TROP MED HYG, V44, P17, DOI 10.4269/ajtmh.1991.44.17; Wyler D.J., 1990, Gastrointestinal infections in the tropics., P129	43	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 17	1994	330	11					775	781						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA742	8107745				2022-12-28	WOS:A1994NA74200009
J	GAO, SW; DROUIN, R; HOLMQUIST, GP				GAO, SW; DROUIN, R; HOLMQUIST, GP			DNA-REPAIR RATES MAPPED ALONG THE HUMAN PGK1 GENE AT NUCLEOTIDE RESOLUTION	SCIENCE			English	Article							LIGATION-MEDIATED PCR; PYRIMIDINE DIMERS; DHFR GENE; REMOVAL; CELLS	The repair of cyclobutane pyrimidine dimers (CPDs), DNA lesions induced by ultraviolet light, was studied at nucleotide resolution. Human fibroblasts were irradiated with ultraviolet light and allowed to repair. The DNA was enzymatically cleaved at the CPDs, and the induced breaks along the promoter and exon 1 of the PGK1 gene were mapped by ligation-mediated polymerase chain reaction. Repair rates within the nontranscribed strand varied as much as 15-fold, depending on nucleotide position. Preferential repair of the transcribed strand began just downstream of the transcription start site but was most pronounced beginning at nucleotide +140 in exon 1. The promoter contained two slowly repaired regions that coincided with two transcription factor binding sites.	BECKMAN RES INST CITY HOPE,DEPT BIOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NCI NIH HHS [CA54773] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; GORDON LK, 1980, J BIOL CHEM, V255, P2047; KANTOR GJ, 1981, CANCER RES, V41, P819; KUNALA S, 1992, P NATL ACAD SCI USA, V89, P11031, DOI 10.1073/pnas.89.22.11031; Maxam A M, 1980, Methods Enzymol, V65, P499; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PFEIFER GP, 1991, MOL CELL BIOL, V12, P1798; PFEIFER GP, 1993, METHOD ENZYMOL, V225, P557; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; SINGERSAM J, 1984, GENE, V32, P409, DOI 10.1016/0378-1119(84)90016-7; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VANZEELAND AA, 1990, MUTATION ENV A, P249	17	121	121	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1438	1440		10.1126/science.8128226	http://dx.doi.org/10.1126/science.8128226			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128226				2022-12-28	WOS:A1994MZ92700032
J	LENFANT, C				LENFANT, C			HOSPITAL DELAYS COMPOUND PATIENT AND TRANSPORT DELAYS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LENFANT, C (corresponding author), NHLBI,BETHESDA,MD 20892, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					738	738						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY288	8114202				2022-12-28	WOS:A1994MY28800008
J	MCDERMOTT, J				MCDERMOTT, J			EVALUATING HEALTH SYSTEM REFORM - THE CASE FOR A SINGLE-PAYER APPROACH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											MCDERMOTT, J (corresponding author), US HOUSE REPRESENTAT,LONGWORTH HOUSE OFF BLDG 1707,WASHINGTON,DC 20515, USA.							ANGELL M, 1993, NEW ENGL J MED, V328, P1778, DOI 10.1056/NEJM199306173282409; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2509, DOI 10.1001/jama.267.18.2509; FORD M, 1992, CRS92168EPW C RES SE; FUCHS B, 1990, CRS9095 EPW C RES SE; GLASER WA, 1993, JAMA-J AM MED ASSOC, V270, P980, DOI 10.1001/jama.270.8.980; HIMMELSTEIN DU, 1991, NEW ENGL J MED, V324, P1253; IGLEHART J, 1992, NEW ENGL J MED, V326, P1716; LEVINSKY NG, 1993, NEW ENGL J MED, V328, P656, DOI 10.1056/NEJM199303043280913; MERLIS M, 1990, CRS9064 EPW C RES SE; RICH S, 1993, WASHINGTON POST 0509; Schieber G J, 1992, Health Care Financ Rev, V13, P1; SHIKLES J, 1991, GAOHRD9190 REP; SWARTZ K, 1994, JAMA-J AM MED ASSOC, V271, P64; 1993, MANAGED COMPETITION; 1994, JAMA-J AM MED ASSOC, V271, P64; 1993, PRESIDENTS DRAFT PRO	16	15	15	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					782	784						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY288	8114216				2022-12-28	WOS:A1994MY28800034
J	LEE, DY; MALPELI, JG				LEE, DY; MALPELI, JG			GLOBAL FORM AND SINGULARITY - MODELING THE BLIND SPOTS ROLE IN LATERAL GENICULATE MORPHOGENESIS	SCIENCE			English	Article							VISUAL-FIELD; NUCLEUS; MONKEY	Optic nerve terminals segregate by functional class into distinct layers in the lateral geniculate nucleus, the thalamic relay nucleus of the visual system. In the rhesus monkey, the number of geniculate layers changes abruptly from six posteriorly (central vision) to four anteriorly (peripheral vision). The plane of transition between these patterns passes through small laminar gaps corresponding to the perceptual blind spot caused by the exit of the optic nerve from the eyeball. However, this plane of transition has no apparent functional link to the blind spot. A thermodynamic model of geniculate morphogenesis supports the hypothesis that the blind spot traps the transition in its stereotypic position by introducing a singularity in an otherwise smooth gradient in forces guiding the development of geniculate morphogenesis. This relation suggests that small-scale anomalies may be important in the determination of large-scale patterns in biological structure.	UNIV ILLINOIS,DEPT PSYCHOL,CHAMPAIGN,IL 61820; UNIV ILLINOIS,NEUROSCI PROGRAM,CHAMPAIGN,IL 61820	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			Lee, Daeyeol/A-6794-2008	Lee, Daeyeol/0000-0003-3474-019X	NEI NIH HHS [EY02695] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002695] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aarts E., 1989, SIMULATED ANNEALING; BISHOP PO, 1962, J PHYSIOL-LONDON, V163, P503, DOI 10.1113/jphysiol.1962.sp006991; Clark WEL, 1941, J ANAT, V75, P419; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P219, DOI 10.1113/jphysiol.1984.sp015498; KAAS J H, 1972, Brain Behavior and Evolution, V6, P253, DOI 10.1159/000123713; KAAS JH, 1973, J COMP NEUROL, V147, P163, DOI 10.1002/cne.901470203; MALPELI JG, 1975, J COMP NEUROL, V161, P569, DOI 10.1002/cne.901610407; MALPELI JG, 1993, INVEST OPHTH VIS SCI, V34, P812; MICHAEL CR, 1988, P NATL ACAD SCI USA, V85, P4914, DOI 10.1073/pnas.85.13.4914; RAKIC P, 1981, SCIENCE, V214, P923; SANDERSON KJ, 1971, EXP BRAIN RES, V13, P159; SCHILLER PH, 1978, J NEUROPHYSIOL, V41, P788, DOI 10.1152/jn.1978.41.3.788; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P115	13	18	18	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 4	1994	263	5151					1292	1294		10.1126/science.8122115	http://dx.doi.org/10.1126/science.8122115			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	8122115				2022-12-28	WOS:A1994MY57000041
J	MURFETT, J; ATHERTON, TL; MOU, B; GASSER, CS; MCCLURE, BA				MURFETT, J; ATHERTON, TL; MOU, B; GASSER, CS; MCCLURE, BA			S-RNASE EXPRESSED IN TRANSGENIC NICOTIANA CAUSES S-ALLELE-SPECIFIC POLLEN REJECTION	NATURE			English	Article							SELF-INCOMPATIBILITY LOCUS; SEQUENCE VARIABILITY; RIBONUCLEASE-ACTIVITY; PETUNIA-INFLATA; ALATA; GENE; PROTEINS; TRANSFORMATION; BRASSICA; PLANTS	MANY angiosperms employ self-incompatibility systems to prevent inbreeding1,2. The simple genetics of such systems3-6 have made them attractive models of plant cellular communication. Implicit in the single locus genetics is that only one or a few gene products are necessary for recognition and rejection of incompatible pollen. Results in the sporophytic system of the Brassicaceae suggest that different S-locus products are responsible for the pollen and pistil parts of the recognition and rejection response7,8. In solanaceous plants, which have a gametophytic self-incompatibility system, the S-locus product responsible for the pollen portion of the interaction has not been identified, but ribonucleases encoded by the S-locus (S-RNases) are strongly implicated in the style part of the recognition and rejection reaction9-14. In Nicotiana alata, pollen r cognition and rejection occur if its S-allele matches either S-allele in the style. The putative stylar S-RNase is abundant in the transmitting tract15, and pollen rejection may be related to action of S-RNaSe on pollen RNAs10. Efforts to understand the molecular basis for pollen recognition and rejection have been limited by the lack of a system for manipulating and expressing S-RNases4-6,16. Here we use the promoter of a style-expressed gene from tomato to obtain high levels of S-RNase expression in transgenic Nicotiana. Recognition and rejection of N. alata pollen S-alleles occur faithfully in the transgenic plants. Our results show that S-RNases alone are sufficient for pollen rejection in this system.	UNIV MISSOURI,DEPT BIOCHEM,117 SCHWEITZER HALL,COLUMBIA,MO 65211; UNIV CALIF DAVIS,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616	University of Missouri System; University of Missouri Columbia; University of California System; University of California Davis				Gasser, Charles/0000-0001-5735-8175				AI YJ, 1990, SEX PLANT REPROD, V3, P130, DOI 10.1007/BF00198857; ANDERSON MA, 1989, PLANT CELL, V1, P483, DOI 10.1105/tpc.1.5.483; ANDERSON MA, 1986, NATURE, V321, P38, DOI 10.1038/321038a0; BERNATZKY R, 1986, THEOR APPL GENET, V72, P314, DOI 10.1007/BF00288567; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BROOTHAERTS W, 1991, SEX PLANT REPROD, V4, P258, DOI 10.1007/BF00200545; CLARK KR, 1990, PLANT CELL, V2, P815, DOI 10.1105/tpc.2.8.815; COLEMAN CE, 1992, PLANT MOL BIOL, V18, P725, DOI 10.1007/BF00020014; de Nettancourt D., 1977, INCOMPATIBILITY ANGI; EBERT PR, 1990, PLANT MOL BIOL, V14, P815, DOI 10.1007/BF00016514; GASSER CS, 1989, PLANT CELL, V1, P15, DOI 10.1105/tpc.1.1.15; GASSER CS, 1993, MOL BIOL TOMATO, P161; GORING DR, 1993, PLANT CELL, V5, P531, DOI 10.1105/tpc.5.5.531; HARING V, 1990, SCIENCE, V250, P937, DOI 10.1126/science.2237440; IOERGER TR, 1991, SEX PLANT REPROD, V4, P81; JAHNEN W, 1989, PLANT CELL, V1, P493, DOI 10.1105/tpc.1.5.493; KAUFMANN H, 1991, MOL GEN GENET, V226, P457, DOI 10.1007/BF00260659; KHEYRPOUR A, 1990, SEX PLANT REPROD, V3, P88, DOI 10.1007/BF00198851; KHO YO, 1968, EUPHYTICA, V17, P299; MCCLURE BA, 1989, SCIENCE, V243, P91, DOI 10.1126/science.11540631; MCCLURE BA, 1990, NATURE, V347, P757, DOI 10.1038/347757a0; MCCLURE BA, 1989, NATURE, V342, P955, DOI 10.1038/342955a0; MURFETT J, 1992, PLANT CELL, V4, P1063, DOI 10.2307/3869475; MURFETT J, 1993, MOL BIOL TOMATO, P139; NASRALLAH JB, 1991, ANNU REV PLANT PHYS, V42, P393, DOI 10.1146/annurev.pp.42.060191.002141; SIMS TL, 1993, CRIT REV PLANT SCI, V12, P129, DOI 10.1080/07352689309382359; SINGH A, 1991, PLANT PHYSIOL, V96, P61, DOI 10.1104/pp.96.1.61; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; Stevens WL, 1942, J GENET, V43, P301, DOI 10.1007/BF02982905; THOMPSON RD, 1992, TRENDS GENET, V8, P381, DOI 10.1016/0168-9525(92)90299-J	30	310	340	2	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					563	566		10.1038/367563a0	http://dx.doi.org/10.1038/367563a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	8107825				2022-12-28	WOS:A1994MV86300060
J	HE, Y; LAM, TH; LI, LS; LI, LS; DU, RY; JIA, GL; HUANG, JY; ZHENG, JS				HE, Y; LAM, TH; LI, LS; LI, LS; DU, RY; JIA, GL; HUANG, JY; ZHENG, JS			PASSIVE SMOKING AT WORK AS A RISK FACTOR FOR CORONARY HEART-DISEASE IN CHINESE WOMEN WHO HAVE NEVER SMOKED	BRITISH MEDICAL JOURNAL			English	Article								Objective-To study whether passive smoking at work is a risk factor for coronary heart disease. Design-Case-control study. Setting-Xi'an, China. Subject-59 patients with coronary heart disease and 126 controls, all Chinese women with full time jobs, who had never smoked cigarettes. Results-The crude odds ratio for passive smoking from husband was 2.12 (95% confidence interval 1.06 to 4.25) and at work was 2.45 (1.23 to 4.88). The final logistic regression model, with passive smoking from husband and at work as the base, included age, history of hypertension, type A personality, and total cholesterol and high density lipoprotein cholesterol concentrations; the adjusted odds ratios for passive smoking from husband and at work were 1.24 (0.56 to 2.72) and 1.85 (0.86 to 4.00) respectively. For passive smoking at work, statistically significant linear trends of increasing risks (for both crude and adjusted odds ratios) with increasing exposures (amount exposed daily, number of smokers, number of hours exposed daily, and cumulative exposure) were observed. When these exposure variables were analysed as continuous variables, the crude and adjusted odds ratios were also significant. Conclusion-Passive smoking at work is a risk factor for coronary heart disease. Urgent public health measures are needed to reduce smoking and to protect non-smokers from passive smoking in China.	UNIV HONG KONG,DEPT COMMUNITY MED,5 SASSOON RD,HONG KONG,HONG KONG; MIL MED UNIV 4,DEPT EPIDEMIOL,XIAN,PEOPLES R CHINA; MIL MED UNIV,DEPT CARDIOL,XIAN,PEOPLES R CHINA	University of Hong Kong; Air Force Military Medical University; Air Force Military Medical University; Army Medical University; Naval Medical University			; Lam, Tai Hing/C-4317-2009	He, Yao/0000-0001-6205-7895; Lam, Tai Hing/0000-0002-2033-9971				Breslow N, 1980, STATISTICAL METHODS, V32; CUMMINGS KM, 1989, AM J EPIDEMIOL, V130, P122, DOI 10.1093/oxfordjournals.aje.a115303; DOBSON AJ, 1991, MED J AUSTRALIA, V154, P793, DOI 10.5694/j.1326-5377.1991.tb121366.x; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; HE Y, 1989, CHIN J PREV MED, V23, P19; JUDKINS MP, 1967, RADIOLOGY, V89, P815, DOI 10.1148/89.5.815; LEE PN, 1986, BRIT J CANCER, V54, P97, DOI 10.1038/bjc.1986.157; MACKAY J, 1993, TOB CONTROL, V2, P7; Nomenclature and criteria for diagnosis of ischemic heart disease, 1979, CIRCULATION, V59, P607; STEENLAND K, 1992, JAMA-J AM MED ASSOC, V267, P94, DOI 10.1001/jama.267.1.94; TAYLOR AE, 1992, CIRCULATION, V86, P699, DOI 10.1161/01.CIR.86.2.699; VECCHIA CL, 1993, LANCET, V341, P505; WENG XZ, 1987, COLLECTION DATA 1984; 1992, RESPIRATORY HLTH EFF	14	66	71	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	1994	308	6925					380	384		10.1136/bmj.308.6925.380	http://dx.doi.org/10.1136/bmj.308.6925.380			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV862	8124145	Green Published			2022-12-28	WOS:A1994MV86200020
J	KASHANCHI, F; PIRAS, G; RADONOVICH, MF; DUVALL, JF; FATTAEY, A; CHIANG, CM; ROEDER, RG; BRADY, JN				KASHANCHI, F; PIRAS, G; RADONOVICH, MF; DUVALL, JF; FATTAEY, A; CHIANG, CM; ROEDER, RG; BRADY, JN			DIRECT INTERACTION OF HUMAN TFIID WITH THE HIV-1 TRANSACTIVATOR TAT	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; III TRANSCRIPTION FACTOR; RNA POLYMERASE-II; BINDING PROTEIN; ELONGATION; COMPONENTS; ACTIVATION; COMPLEXES; PROMOTER; INVITRO	THE tat gene of the human immunodeficiency virus (HIV) plays a central role in the activation and life cycle of HIV. The tat protein (Tat) specifically transactivates HIV transcription in vivo and in vitro1-8, exerting its effects at the level of transcriptional initiation and elongation. Here we report that Tat binds directly to the basal transcription factor TFIID. The transcriptional activity of HeLa extracts was depleted after chromatography on a rat affinity column, which specifically retained the polymerase II-specific factor TFIID: Direct interaction of Tat with holo-TFIID, composed of TATA-binding protein (TBP) and associated factors (TAFs), was observed. Tat binds, through amino acids 36-50, directly to the TBP subunit of TFIID. Our results suggest that Tat may transduce upstream or downstream regulatory signals by direct interaction with the basal transcription factor TFIID.	MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129; ROCKEFELLER UNIV,NEW YORK,NY 10021	Harvard University; Massachusetts General Hospital; Rockefeller University	KASHANCHI, F (corresponding author), NCI,MOLEC VIROL LAB,BETHESDA,MD 20892, USA.							BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Bohan Cindy A., 1992, Gene Expression, V2, P391; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CLLE BR, 1992, MICROBIOL REV, V56, P375; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FORMOSA T, 1991, METHOD ENZYMOL, V208, P24; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KASHANCHI F, 1992, NUCLEIC ACIDS RES, V20, P4673, DOI 10.1093/nar/20.17.4673; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; KPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V7, P3551; LASPIA MF, 1990, GENE DEV, V4, P2397, DOI 10.1101/gad.4.12b.2397; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; RICE AP, 1990, J VIROL, V64, P1864, DOI 10.1128/JVI.64.4.1864-1868.1990; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TILEY LS, 1990, VIROLOGY, V178, P560, DOI 10.1016/0042-6822(90)90354-T; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V	30	245	249	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 20	1994	367	6460					295	299		10.1038/367295a0	http://dx.doi.org/10.1038/367295a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	8121496				2022-12-28	WOS:A1994MR49400063
J	FIORE, MC; HARTMAN, MJ				FIORE, MC; HARTMAN, MJ			SIDE-EFFECTS OF NICOTINE PATCHES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											FIORE, MC (corresponding author), UNIV WISCONSIN,SCH MED,CTR TOBACCO RES & INTERVENT,MADISON,WI 53706, USA.							FIORE MC, 1992, JAMA-J AM MED ASSOC, V268, P2687, DOI 10.1001/jama.268.19.2687; FIORE MC, 1991, JAMA-J AM MED ASSOC, V266, P3183, DOI 10.1001/jama.266.22.3183; GLYNN TJ, 1989, NIH893064 US DEP HLT; 1991, MMWR MORB MORTAL WKL, V40, P62	4	3	3	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2735	2735						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	8133595				2022-12-28	WOS:A1993MJ82100037
J	FOURNIER, AM; PEREZSTABLE, A; GREER, PJ				FOURNIER, AM; PEREZSTABLE, A; GREER, PJ			LESSONS FROM A CLINIC FOR THE HOMELESS - THE CAMILLUS HEALTH CONCERN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRAINING INTERNISTS; CARE; PHYSICIANS; MEDICINE; CHILDREN	Objective.-To present the educational opportunities provided by a model clinic for homeless persons. Design.-Descriptive. Patients or Other Participants.-Patients are those who are cared for at Camillus Health Concern clinic for the homeless in Miami, Fla. Other participants include students, residents, and faculty affiliated with the University of Miami (Fla) School of Medicine. Intervention.-Affiliation of the clinic with the medical school has shifted the clinic from a pure service model to an education and service model. Main Outcome Measures.-Numbers of patients and encounters are presented, as well as student and resident rotations, numbers, and hours. Results.-Shifting to an education and service model has increased productivity of the clinic while providing a unique, multifaceted educational experience to students, residents, and faculty. Conclusions.-Those factors that contribute to the success of this education and service model include the professional satisfaction that results from providing care to patients who previously have not had access to health care; a team approach that includes faculty, students, nurses, and social workers; an environment that fosters clinical judgment rather than expensive tests; and the opportunity to teach social responsibility in the process of providing health care. We encourage other schools to consider the development of clinics for the homeless as alternative ambulatory training sites.			FOURNIER, AM (corresponding author), UNIV MIAMI,SCH MED,DEPT MED,BOX 016960,R13,MIAMI,FL 33101, USA.							ALPERSTEIN G, 1988, PEDIATR CLIN N AM, V35, P1413; ANDERSEN RM, 1988, ANN INTERN MED, V1, P62; [Anonymous], 1988, HOMELESSNESS HLTH HU; BASSUK EL, 1986, AM J PUBLIC HEALTH, V76, P1097, DOI 10.2105/AJPH.76.9.1097; BASSUK EL, 1992, 921848 US DEP HLTH H; BROOK RH, 1987, ANN INTERN MED, V107, P392, DOI 10.7326/0003-4819-107-2-392; BUSS TF, 1991, CASE W RESERVE GERIA, P55; Colwill J M, 1988, Fam Med, V20, P250; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; GELBERG L, 1989, JAMA-J AM MED ASSOC, V262, P1973, DOI 10.1001/jama.262.14.1973; GOODSON JD, 1986, ARCH INTERN MED, V146, P1805, DOI 10.1001/archinte.146.9.1805; KARPF M, 1986, ANN INTERN MED, V104, P567, DOI 10.7326/0003-4819-104-4-567; LAMBERT EY, 1990, 901678 US DEP HLTH H; MILLER DS, 1988, PEDIATRICS, V81, P673; PETERSDORF RG, 1989, JAMA-J AM MED ASSOC, V262, P826, DOI 10.1001/jama.262.6.826; RIESELBACH RE, 1986, NEW ENGL J MED, V314, P32, DOI 10.1056/NEJM198601023140106; Schroeder S A, 1987, Int J Technol Assess Health Care, V3, P39; SCHROEDER SA, 1986, ARCH INTERN MED, V146, P1685, DOI 10.1001/archinte.146.9.1685; SCHROEDER SA, 1986, ANN INTERN MED, V104, P554, DOI 10.7326/0003-4819-104-4-554; SCHROEDER SA, 1992, J GEN INTERN MED, V7, P528, DOI 10.1007/BF02599458; WOOD DL, 1990, PEDIATRICS, V86, P858; WRIGHT JD, 1987, HOMELESSNESS HLTH; 1982, 1982 GRADUATION QUES; 1991, NRMP 1991 RESULTS; 1989, 1989 GRADUATION QUES; 1986, NRMP 1986 RESULTS	26	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2721	2724		10.1001/jama.270.22.2721	http://dx.doi.org/10.1001/jama.270.22.2721			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	8133591				2022-12-28	WOS:A1993MJ82100033
J	ROSENTHAL, NE				ROSENTHAL, NE			DIAGNOSIS AND TREATMENT OF SEASONAL AFFECTIVE-DISORDER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							BRIGHT LIGHT THERAPY; WINTER DEPRESSION; PATTERNS; MOOD				ROSENTHAL, NE (corresponding author), NIMH, CLIN PSYCHOL BRANCH,ENVIRONM PSYCHIAT SECT, BLDG 10,ROOM 4S-239, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							ALBERT PS, 1991, PSYCHIAT RES, V36, P51, DOI 10.1016/0165-1781(91)90117-8; AVERY DH, 1993, AM J PSYCHIAT, V150, P113; BAUER MS, 1991, 3RD ANN C SOC LIGHT; CARLSSON A, 1980, ACTA PSYCHIAT SCAND, V61, P75, DOI 10.1111/acps.1980.61.s280.75; DILSAVER SC, 1992, J CLIN PSYCHIAT, V53, P252; FAEDDA GL, 1993, ARCH GEN PSYCHIAT, V50, P17; GARVEY MJ, 1988, AM J PSYCHIAT, V145, P100; GENHART MJ, 1993, PSYCHIAT RES, V47, P87, DOI 10.1016/0165-1781(93)90058-O; JACOBSEN FM, 1990, BIOL PSYCHIAT, V27, P372, DOI 10.1016/0006-3223(90)90011-P; JACOBSEN FM, 1989, SEASONAL AFFECTIVE D, P333; JAMISON KR, 1989, PSYCHIATRY, V52, P125, DOI 10.1080/00332747.1989.11024436; JOSEPHVANDERPOOL JR, 1993, BIOL PSYCHIAT, V33, P496, DOI 10.1016/0006-3223(93)90003-V; KASPER S, 1989, ARCH GEN PSYCHIAT, V46, P823; KASPER S, 1990, J AFFECT DISORDERS, V19, P243, DOI 10.1016/0165-0327(90)90101-D; LEWY AJ, 1987, SCIENCE, V235, P352, DOI 10.1126/science.3798117; Madden Pamela A., 1992, Behavior Genetics, V22, P733; MEESTERS Y, 1992, 4TH ANN C SOC LIGHT; OREN DA, 1991, COMPR PSYCHIAT, V32, P147, DOI 10.1016/0010-440X(91)90007-Y; OREN DA, 1992, HDB AFFECTIVE DISORD, P551; OREN DA, 1992, 4TH ANN C SOC LIGHT; OROURKE D, 1989, J CLIN PSYCHIAT, V50, P343; PLEETER JD, 1993, 48TH ANN BIOL PSYCH; RAFFERTY B, 1990, 2ND ANN C SOC LIGHT; ROSEN LN, 1990, PSYCHIAT RES, V31, P131, DOI 10.1016/0165-1781(90)90116-M; ROSENTHAL NE, 1984, ARCH GEN PSYCHIAT, V41, P72; ROSENTHAL NE, 1992, PHARMACOPSYCHIATRY, V25, P56, DOI 10.1055/s-2007-1014389; ROSENTHAL NE, 1989, J CLIN PSYCHIAT, V50, P469; ROSENTHAL NE, 1986, J NEURAL TRANSM, P257; ROSENTHAL NE, 1988, AM J PSYCHIAT, V145, P52; ROSENTHAL NE, 1993, WINTER BLUES SEASONA; Rosenthal NE, 1988, J BIOL RHYTHM, V3, P101, DOI 10.1177/074873048800300202; Ruhrmann S, 1992, Med Monatsschr Pharm, V15, P293; SACK RL, 1990, ARCH GEN PSYCHIAT, V47, P343; SCHLAGER D, 1993, 5TH ANN C SOC LIGHT; TAKAHASHI K, 1991, J AFFECT DISORDERS, V21, P57, DOI 10.1016/0165-0327(91)90019-O; TERMAN JS, 1990, PSYCHOPHARMACOL BULL, V26, P3; TERMAN JS, 1993, 5TH ANN C SOC LIGHT; TERMAN M, 1989, BIOL PSYCHIAT, V25, P966, DOI 10.1016/0006-3223(89)90276-X; TERMAN M, 1990, PHOTOCHEM PHOTOBIOL, V51, P781, DOI 10.1111/php.1990.51.6.781; THASE M, 1986, PSYCHIAT ANN, V16, P733; WAXLER M, 1992, AM J PSYCHIAT, V149, P1610; WIRZJUSTICE A, 1990, PSYCHOPHARMACOL BULL, V26, P511; WIRZJUSTICE A, 1993, ARCH GEN PSYCHIAT, V50, P929; 1987, DIAGNOSTIC STATISTIC	44	46	46	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2717	2720		10.1001/jama.270.22.2717	http://dx.doi.org/10.1001/jama.270.22.2717			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	8133590				2022-12-28	WOS:A1993MJ82100032
J	STEELE, G				STEELE, G			ACCOMPLISHMENT AND PROMISE IN THE UNDERSTANDING AND TREATMENT OF COLORECTAL-CANCER	LANCET			English	Article							CARCINOMA; SURGERY				STEELE, G (corresponding author), HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, DEPT SURG, BOSTON, MA 02215 USA.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ANDREWS CW, 1992, HUM PATHOL, V23, P774, DOI 10.1016/0046-8177(92)90347-6; ARNOLD MW, 1992, ANN SURG, V216, P627, DOI 10.1097/00000658-199212000-00003; BLEDAY R, 1993, CURR PROB CANCER, V17, P1; BLEDAY R, 1991, SEMIN SURG ONCOL, V7, P171, DOI 10.1002/ssu.2980070311; Eddy D, 1980, CA Cancer J Clin, V30, P193; HOOVER HC, 1993, J CLIN ONCOL, V11, P390, DOI 10.1200/JCO.1993.11.3.390; IRVINE K, 1993, CANCER IMMUNOL IMMUN, V36, P281, DOI 10.1007/BF01741166; JESSUP JM, 1992, CURR PROB CANCER, V16, P265; LEVIN B, 1992, NEW ENGL J MED, V326, P700, DOI 10.1056/NEJM199203053261009; LINDEMANN F, 1992, LANCET, V340, P685, DOI 10.1016/0140-6736(92)92230-D; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; OCONNELL M, 1993, P AN M AM SOC CLIN, V12, pA564; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; SACCARIDES TJ, 1993, DIS COLON RECTUM, V36, P425; STEELE G, 1991, J CLIN ONCOL, V9, P1105, DOI 10.1200/JCO.1991.9.7.1105; STEELE G, 1991, ARCH SURG-CHICAGO, V126, P696; STEELE GD, 1990, JAMA-J AM MED ASSOC, V264, P1444; STEELE GD, 1993, NATIONAL CANCER DATA; UNPUB CONSERVATIVE T	21	20	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 30	1993	342	8879					1092	1096		10.1016/0140-6736(93)92068-5	http://dx.doi.org/10.1016/0140-6736(93)92068-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105316				2022-12-28	WOS:A1993ME82200014
J	WESTENDORP, RGJ; VANDERHOEVEN, HG; FROLICH, M; MEINDERS, AE				WESTENDORP, RGJ; VANDERHOEVEN, HG; FROLICH, M; MEINDERS, AE			CARDIAC-ENDOTHELIUM FEEDBACK	LANCET			English	Letter							HYPOXIA; ATRIAL; RATS		UNIV HOSP LEIDEN,DEPT CLIN CHEM,2300 RC LEIDEN,NETHERLANDS; UNIV HOSP LEIDEN,DEPT CLIN EPIDEMIOL,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	WESTENDORP, RGJ (corresponding author), UNIV HOSP LEIDEN,DEPT GEN INTERNAL MED,CO-P45,POB 9600,2300 RC LEIDEN,NETHERLANDS.							HORGAN MJ, 1991, CIRC RES, V69, P157, DOI 10.1161/01.RES.69.1.157; HORIO T, 1991, METABOLISM, V40, P999, DOI 10.1016/0026-0495(91)90119-H; JIN HK, 1991, J APPL PHYSIOL, V71, P807, DOI 10.1152/jappl.1991.71.3.807; KOHNO M, 1991, J CLIN INVEST, V87, P1999, DOI 10.1172/JCI115228; MANYTMAA P, 1990, ENDOCRINOLOGY, V126, P587; REMUZZI, 1993, LANCET, V342, P589; WESTENDORP RGJ, 1993, AM REV RESPIR DIS, V148, P304, DOI 10.1164/ajrccm/148.2.304	7	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1121	1122		10.1016/0140-6736(93)92111-6	http://dx.doi.org/10.1016/0140-6736(93)92111-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105350				2022-12-28	WOS:A1993ME82200062
J	BUKRINSKY, MI; HAGGERTY, S; DEMPSEY, MP; SHAROVA, N; ADZHUBEI, A; SPITZ, L; LEWIS, P; GOLDFARB, D; EMERMAN, M; STEVENSON, M				BUKRINSKY, MI; HAGGERTY, S; DEMPSEY, MP; SHAROVA, N; ADZHUBEI, A; SPITZ, L; LEWIS, P; GOLDFARB, D; EMERMAN, M; STEVENSON, M			A NUCLEAR-LOCALIZATION SIGNAL WITHIN HIV-1 MATRIX PROTEIN THAT GOVERNS INFECTION OF NONDIVIDING CELLS	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY SYNDROME; RETROVIRAL DNA; COMPLEX; GENE; INTEGRATION; MONOCYTES; INVITRO; VIRIONS	PERMISSIVENESS of the host cell to productive infection by onco-retroviruses is cell-cycle dependent1, and nuclear localization of viral nucleoprotein preintegration complexes will occur only after cells have passed through mitosis2. In contrast, establishment of an integrated provirus after infection by the lentivirus HIV-1 is independent of host cell proliferation3-5. The ability of HIV-1 to replicate in non-dividing cells is partly accounted for by the karvophilic properties of the viral preintegration complex which, after virus infection, is actively transported to the host cell nucleus. Here we report that the gag matrix protein of HIV-1 contains a nuclear localization sequence which, when conjugated to a heterologous protein, directs its nuclear import. In addition, HIV-1 mutants containing amino-acid substitutions in this nuclear localization signal integrate and replicate within dividing but not growth-arrested cells, and thus display a phenotype more representative of an onco-retrovirus.	UNIV NEBRASKA,MED CTR,DEPT PATHOL & MICROBIOL,OMAHA,NE 68198; IMPERIAL CANC RES FUND,BIOMOLEC MODELLING LAB,LONDON WC2A 3PX,ENGLAND; UNIV NEBRASKA,MED CTR,EPPLEY INST RES,OMAHA,NE 68198; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627; FRED HUTCHINSON CANC RES CTR,PROGRAM MOLEC MED,SEATTLE,WA 98104	University of Nebraska System; University of Nebraska Medical Center; Cancer Research UK; University of Nebraska System; University of Nebraska Medical Center; University of Rochester; Fred Hutchinson Cancer Center					NCRR NIH HHS [R01 RR011589] Funding Source: Medline; NIAID NIH HHS [R21 AI127091, R37 AI037475] Funding Source: Medline; NIMH NIH HHS [R01 MH064411, R01 MH093306] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; ELIOPOULOS E, 1982, INT J BIOL MACROMOL, V4, P263, DOI 10.1016/0141-8130(82)90053-8; FARNET CM, 1991, J VIROL, V65, P1990; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GENDELMAN HE, 1986, J VIROL, V58, P67, DOI 10.1128/JVI.58.1.67-74.1986; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; HAASE AT, 1982, VIROLOGY, V119, P399, DOI 10.1016/0042-6822(82)90099-X; HSU WS, 1990, SCIENCE, V250, P1227; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LORI F, 1992, J VIROL, V66, P5067, DOI 10.1128/JVI.66.8.5067-5074.1992; MEYERS G, 1992, HUMAN RETROVIRUSES A; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; STEVENSON M, 1990, J VIROL, V64, P3792, DOI 10.1128/JVI.64.8.3792-3803.1990; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089	27	709	741	0	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					666	669		10.1038/365666a0	http://dx.doi.org/10.1038/365666a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	8105392	Green Accepted			2022-12-28	WOS:A1993MB84600065
J	NEWMAN, LS				NEWMAN, LS			TO BE(2+) OR NOT TO BE(2+) - IMMUNOGENETICS AND OCCUPATIONAL EXPOSURE	SCIENCE			English	Editorial Material							CHRONIC BERYLLIUM DISEASE; HLA SYSTEM; CLASS-II		UNIV COLORADO,SCH MED,NATL JEWISH CTR IMMUNOL & RESP MED,DIV PULM,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT MED,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT PREVENT MED & BIOMETR,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	NEWMAN, LS (corresponding author), UNIV COLORADO,SCH MED,NATL JEWISH CTR IMMUNOL & RESP MED,DIV ENVIRONM MED,DENVER,CO 80262, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES006538, R01ES006538] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL273353] Funding Source: Medline; NIEHS NIH HHS [ES00173, ES06538] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BODMER JG, 1992, IMMUNOGENETICS, V36, P135, DOI 10.1007/BF00661090; BOST T, 1993, CHEST, V103, pS138, DOI 10.1378/chest.103.2_Supplement.138S-a; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CAMPBELL RD, 1993, IMMUNOL TODAY, V14, P349, DOI 10.1016/0167-5699(93)90234-C; EPSTEIN PE, 1982, ANN INTERN MED, V97, P213, DOI 10.7326/0003-4819-97-2-213; FRIEMAN DG, 1970, HUM PATHOL, V1, P25; HOOVER M, 1990, OVERVIEW PUBLICATION; KAPPES D, 1988, ANNU REV BIOCHEM, V57, P991, DOI 10.1146/annurev.bi.57.070188.005015; KREISS K, 1989, J OCCUP ENVIRON MED, V31, P603, DOI 10.1097/00043764-198907000-00011; KREISS K, 1993, J OCCUP ENVIRON MED, V35, P267; KREISS K, IN PRESS AM REV RESP; MROZ MM, 1991, J ALLERGY CLIN IMMUN, V88, P54, DOI 10.1016/0091-6749(91)90300-D; Newman L.S., 1992, HAZARDOUS MAT TOXICO, P882; NEWMAN LS, 1989, AM REV RESPIR DIS, V139, P1479, DOI 10.1164/ajrccm/139.6.1479; OTTENHOFF THM, 1985, HUM IMMUNOL, V13, P1015; REEVES AL, 1983, IMMUNOTOXICOLOGY, P261; RICHELDI L, 1993, SCIENCE, V262, P242, DOI 10.1126/science.8105536; ROSE CS, 1993, INTERSTITIAL LUNG DI, P321; ROSSMAN MD, 1988, ANN INTERN MED, V108, P687, DOI 10.7326/0003-4819-108-5-687; STROMINGER JL, 1986, J CLIN INVEST, V77, P1411, DOI 10.1172/JCI112451; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; WILLIAMS WJ, 1986, J CLIN PATHOL, V39, P900, DOI 10.1136/jcp.39.8.900; 1991, JAMA-J AM MED ASSOC, V266, P1827; 1990, OTABA455 US C OFF TE	26	39	40	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 8	1993	262	5131					197	198		10.1126/science.8105535	http://dx.doi.org/10.1126/science.8105535			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA665	8105535				2022-12-28	WOS:A1993MA66500022
J	MATSUMOTO, H; MIYATA, M				MATSUMOTO, H; MIYATA, M			IMAGES IN CLINICAL MEDICINE - ADENOMA OF THE SIGMOID COLON	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											MATSUMOTO, H (corresponding author), JICHI MED SCH,OMIYA MED CTR,OMIYA 330,JAPAN.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 21	1994	330	16					1128	1128						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF699	8133855				2022-12-28	WOS:A1994NF69900006
J	GALE, RP; HOROWITZ, MM; ASH, RC; CHAMPLIN, RE; GOLDMAN, JM; RIMM, AA; RINGDEN, O; STONE, JAV; BORTIN, MM				GALE, RP; HOROWITZ, MM; ASH, RC; CHAMPLIN, RE; GOLDMAN, JM; RIMM, AA; RINGDEN, O; STONE, JAV; BORTIN, MM			IDENTICAL-TWIN BONE-MARROW TRANSPLANTS FOR LEUKEMIA	ANNALS OF INTERNAL MEDICINE			English	Article						BONE MARROW TRANSPLANTATION; TWINS, MONOZYGOTIC; LEUKEMIA; HISTOCOMPATIBILITY	ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; VERSUS-HOST DISEASE; CHRONIC GRAFT; CHEMOTHERAPY; SURVIVAL; RELAPSE	Objective: To compare outcomes of identical-twin with HLA-identical sibling bone marrow transplants for leukemia. Design: Matched-pair analysis comparing relapse, treatment-related mortality, and leukemia-free survival in cohorts matched for disease and variables correlated with transplant outcome, with and without adjustment for graft-versus-host disease. Setting: 163 institutions worldwide between 1978 and 1990, reporting to the International Bone Marrow Transplant Registry. Participants: 103 identical-twin transplants: 24 for acute lymphoblastic leukemia (ALL) in first remission, 45 for acute myelogenous leukemia (AML) in first remission, and 34 for chronic myelogenous leukemia (CML) in first chronic phase. Results were compared with those in 1030 concurrent HLA-identical sibling transplants matched for prognostic factors. Results: Three-year probabilities of relapse after identical-twin compared with HLA-identical sibling transplants were as follows: ALL, 36% (95% CI, 17% to 55%) compared with 26% (CI, 20% to 32%); AML, 52% (CI, 37% to 67%) compared with 16% (CI, 12% to 20%); and CML, 40% (CI, 23% to 57%) compared with 7% (CI, 4% to 10%). Increased relapse risks in AML and CML persisted after adjusting for graft-versus-host disease (relative risk, 3.1 [CI, 1.9 to 5.1] and 5.5 [CI, 2.8 to 11.0], respectively). Although twins had less treatment-related mortality than HLA-identical siblings, leukemia-free survival was similar. Three-year leukemia-free survival probabilities after twin compared with HLA-identical sibling transplants were as follows: ALL, 57% (CI, 37% to 77%) compared with 58% (CI, 52% to 64%); AML, 42% (CI, 27% to 57%) compared with 55% (CI, 50% to 60%); and CML, 59% (CI, 42% to 76%) compared with 61% (CI, 56% to 66%). Conclusions: Identical-twin transplants in AML and CML are associated with increased relapse risk compared with HLA-identical sibling transplants. A similar trend was observed in ALL but was not statistically significant. Increased relapse in twin transplants is not explained by lack of graft-versus-host disease. Leukemia-free survival after twin and HLA-identical sibling transplants is similar because increased relapse in twins is offset by decreased treatment-related mortality.	MED COLL WISCONSIN, INT BONE MARROW TRANSPLANT REGISTRY, MILWAUKEE, WI 53226 USA; SALICK HLTH INC, LOS ANGELES, CA 90048 USA; METHODIST HOSP INDIANA, CTR CANC, INDIANAPOLIS, IN 46206 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT HEMATOL, HOUSTON, TX 77030 USA; HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, LRF LEUKEMIA UNIT, LONDON W12 0NN, ENGLAND; CASE WESTERN RESERVE UNIV, SCH MED, DEPT EPIDEMIOL & BIOSTAT, CLEVELAND, OH 44106 USA; HUDDINGE UNIV HOSP, DEPT TRANSPLANTAT IMMUNOL, S-14186 HUDDINGE, SWEDEN	Medical College of Wisconsin; Indiana University System; University of Texas System; UTMD Anderson Cancer Center; Imperial College London; Case Western Reserve University; Karolinska Institutet			horowitz, Mary/ABH-2173-2021		NCI NIH HHS [P01-CA-40053] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040053] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKINSON K, 1988, BONE MARROW TRANSPL, V3, P5; BARRETT AJ, 1992, BLOOD, V79, P3067; BORTIN MM, 1992, ANN INTERN MED, V116, P505, DOI 10.7326/0003-4819-116-6-505; BUTTURINI A, 1987, BONE MARROW TRANSPL, V2, P233; BUTTURINI A, 1990, LANCET, V335, P1255, DOI 10.1016/0140-6736(90)91313-Y; BUTTURINI A, 1992, IMMUNOL RES, V11, P24, DOI 10.1007/BF02918605; CLIFT R, 1989, BONE MARROW TRANSPL, V4, P445; COX DR, 1972, J R STAT SOC B, V34, P187; Fefer A, 1990, Important Adv Oncol, P143; GALE RP, 1989, LANCET, V1, P1119; GALE RP, 1989, LANCET, V2, P315; GALE RP, 1990, ACUTE LYMPHOBLASTIC; GOLDMAN JM, 1993, BLOOD, V82, P2235; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; HOROWITZ MM, 1991, ANN INTERN MED, V115, P13, DOI 10.7326/0003-4819-115-1-13; HOROWITZ MM, 1990, BLOOD, V75, P555; HOROWITZ MM, 1992, BONE MARROW TRANSPL, P367; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; MANTEL N, 1979, CANCER RES, V39, P4308; OKUNEWICK JP, 1981, GRAFT VERSUS LEUKEMI; PRENTICE RL, 1978, BIOMETRICS, V34, P541, DOI 10.2307/2530374; RAPPEPORT J, 1979, LANCET, V2, P717; Rimm A A, 1991, Int J Technol Assess Health Care, V7, P182; SALLERFORS B, 1987, PROGR BONE MARROW TR, P281; SULLIVAN KM, 1989, BLOOD, V73, P1720; WEIDEN PL, 1981, NEW ENGL J MED, V304, P1529, DOI 10.1056/NEJM198106183042507; WEINER R, 1991, BLOOD S, V78, pA244	27	210	215	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1994	120	8					646	652		10.7326/0003-4819-120-8-199404150-00004	http://dx.doi.org/10.7326/0003-4819-120-8-199404150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE850	8135448				2022-12-28	WOS:A1994NE85000004
J	MACKENZIE, TD; BARTECCHI, CE; SCHRIER, RW				MACKENZIE, TD; BARTECCHI, CE; SCHRIER, RW			THE HUMAN COSTS OF TOBACCO USE .2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; CIGARETTES; SMOKING; CALIFORNIA; CHILDREN; SALES; ENFORCEMENT; CONSUMPTION; HEALTH; MINORS		UNIV COLORADO, SCH MED, DEPT MED, DENVER, CO 80262 USA; DENVER HLTH & HOSP, DENVER, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Denver Health Medical Center								BERTERA RL, 1991, J OCCUP ENVIRON MED, V33, P1119, DOI 10.1097/00043764-199111000-00006; BLUM A, 1991, NEW ENGL J MED, V324, P913, DOI 10.1056/NEJM199103283241310; CONNOLLY GN, 1992, MONOGR NCI, V12, P29; DIFRANZA JR, 1992, AM J PUBLIC HEALTH, V82, P1271, DOI 10.2105/AJPH.82.9.1271; DIFRANZA JR, 1991, JAMA-J AM MED ASSOC, V266, P3149, DOI 10.1001/jama.266.22.3149; FALTERMAYER E, 1993, FORTUNE         0419, P174; FEIGHERY E, 1991, JAMA-J AM MED ASSOC, V266, P3168; FISCHER PM, 1991, JAMA-J AM MED ASSOC, V266, P3145, DOI 10.1001/jama.266.22.3145; FLEWELLING RL, 1992, AM J PUBLIC HEALTH, V82, P867, DOI 10.2105/AJPH.82.6.867; GARFINKEL L, 1991, CA-CANCER J CLIN, V41, P137, DOI 10.3322/canjclin.41.3.137; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P904, DOI 10.1001/jama.269.7.904; HARKIN T, 1992, CHRISTIAN SCI M 1013, P19; JASON LA, 1991, JAMA-J AM MED ASSOC, V266, P3159, DOI 10.1001/jama.266.22.3159; KAISERMAN MJ, 1992, CAN J PUBLIC HEALTH, V83, P404; KAISERMAN MJ, 1991, AM J PUBLIC HEALTH, V81, P902, DOI 10.2105/AJPH.81.7.902; LESMES GR, 1992, AM J MED S1A, V93; LESMES GR, 1992, J MED S1A, V93; MANNING WG, 1989, JAMA-J AM MED ASSOC, V261, P1604, DOI 10.1001/jama.261.11.1604; MCGUIRE A, 1983, NEW YORK STATE J MED, V83, P1296; MINTZ M, 1991, PROGRESSIVE      MAY, P24; MORRISSEY M, 1992, NATL J          0912, P2073; NOVAK V, 1993, NATL J          0417, P912; PIERCE JP, 1991, JAMA-J AM MED ASSOC, V266, P3154, DOI 10.1001/jama.266.22.3154; RIGOTTI NA, 1991, JAMA-J AM MED ASSOC, V266, P3162, DOI DOI 10.1001/JAMA.1991.03470220078031; ROVNER J, 1990, C Q             0915, P2922; SAMUELS B, 1991, JAMA-J AM MED ASSOC, V266, P2110, DOI 10.1001/jama.266.15.2110; SAMUELS B, 1992, ADVOCACY I REPOR AUG; SCHELLING TC, 1986, PREV MED, V15, P549, DOI 10.1016/0091-7435(86)90030-7; SESSER S, 1993, NEW YORKER      0913, P78; TOBIAS A, 1992, TIME            1012, P76; WARNER K E, 1989, Journal of Public Health Policy, V10, P32, DOI 10.2307/3342942; WARNER KE, 1988, J NATL CANCER I, V80, P81, DOI 10.1093/jnci/80.2.81; WARNER KE, 1991, AM J PUBLIC HEALTH, V81, P839, DOI 10.2105/AJPH.81.7.839; 1991, MMWR MORB MORTAL WKL, V40, P1; 1992, TS220 DEP AGR EC RES; 1989, TOB YOUTH REP, V4, P1; 1992, FT892 DEP AGR FOR AG; 1990, MMWR MORB MORTAL WKL, V39, P261; 1991, BUSINESS WEEK   0415, P60; 1992, DHHS CDC928421 DEP H; 1988, DHHS CDC888406 DEP H, P15; 1993, MMWR MORB MORTAL WKL, V42, P125; 1991, NIH923316 DEP HLTH H; 1993, WALL STREET J   0405, pA1	44	170	175	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 7	1994	330	14					975	980		10.1056/NEJM199404073301406	http://dx.doi.org/10.1056/NEJM199404073301406			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND793	8121461				2022-12-28	WOS:A1994ND79300006
J	DANIS, M; GARRETT, J; HARRIS, R; PATRICK, DL				DANIS, M; GARRETT, J; HARRIS, R; PATRICK, DL			STABILITY OF CHOICES ABOUT LIFE-SUSTAINING TREATMENTS	ANNALS OF INTERNAL MEDICINE			English	Article						LIFE SUPPORT CARE; PATIENT PARTICIPATION; DECISION MAKING; LIVING WILLS; TREATMENT REFUSAL	ADVANCE DIRECTIVES; HEALTH; CARE	Objective: To examine the stability of patients' choices for life-sustaining treatments. Design: A longitudinal cohort study. Setting: Primary care practices in central North Carolina. Patients: Medicare recipients (n = 2536). Intervention: Participants were asked about demographic characteristics, health status, well-being, depression, social support, use of a living will, and desire for life-sustaining treatments if they were to become terminally ill. These questions were repeated 2 years later (n = 2073, 82% follow-up). Results: The population tended to choose to forego one more treatment at follow-up than they did at baseline. A choice to forego treatment was twice as stable as a choice to receive treatment. Patients with a living will were less likely to change their wishes (14%) than those without a living will (41%). Persons were more likely to want increased treatment at a later time if they had been hospitalized (23% compared with 18%), had had an accident (29% compared with 19%), had become more immobile (23% compared with 19%), had become more depressed (25% compared with 15%), or had less social support (25% compared with 14%). Conclusions: Most patients (85%) who had chosen to forego life-sustaining treatments did not change their choices. Nonetheless, these data suggest that it is important to review patients' preferences for life-sustaining treatments rather than to assume the stability of their choices.	UNIV N CAROLINA, SHEPS CTR HLTH SERV, CHAPEL HILL, NC 27599 USA; UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT HLTH SERV, SEATTLE, WA 98195 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Washington; University of Washington Seattle	DANIS, M (corresponding author), UNIV N CAROLINA, DEPT MED, DIV GEN MED, CB 7110, 5025A OLD CLIN BLDG, CHAPEL HILL, NC 27599 USA.		Patrick, Donald/Y-2460-2019	Patrick, Donald/0000-0003-0756-0492				DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; EVERHART MA, 1990, CHEST, V97, P159, DOI 10.1378/chest.97.1.159; GAMBLE ER, 1991, ARCH INTERN MED, V151, P277, DOI 10.1001/archinte.151.2.277; GARRETT JM, 1993, J GEN INTERN MED, V8, P361, DOI 10.1007/BF02600073; GRECO PJ, 1991, ANN INTERN MED, V115, P639, DOI 10.7326/0003-4819-115-8-639; Kaplan R., 1990, QUALITY LIFE ASSESSM, P131; KAPLAN RM, 1976, HEALTH SERV RES, V11, P478; MENIKOFF JA, 1992, NEW ENGL J MED, V327, P1165, DOI 10.1056/NEJM199210153271612; MOSSEY JM, 1982, AM J PUBLIC HEALTH, V72, P800, DOI 10.2105/AJPH.72.8.800; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; PATRICK DL, 1973, J HEALTH SOC BEHAV, V14, P6, DOI 10.2307/2136932; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; SILVERSTEIN MD, 1991, MAYO CLIN PROC, V66, P906, DOI 10.1016/S0025-6196(12)61577-8; 1987, GUIDELINES TERMINATI	16	194	194	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					567	573		10.7326/0003-4819-120-7-199404010-00006	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8116994				2022-12-28	WOS:A1994NC76400006
J	LEVENSON, D; GULEC, S; SONENBERG, M; LAI, E; GOLDSMITH, SJ; LARSON, SM				LEVENSON, D; GULEC, S; SONENBERG, M; LAI, E; GOLDSMITH, SJ; LARSON, SM			PERIPHERAL FACIAL-NERVE PALSY AFTER HIGH-DOSE RADIOIODINE THERAPY IN PATIENTS WITH PAPILLARY THYROID-CARCINOMA	ANNALS OF INTERNAL MEDICINE			English	Note									MEM SLOAN KETTERING CANC CTR, DEPT RADIOL, NUCL MED SERV, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	LEVENSON, D (corresponding author), MEM SLOAN KETTERING CANC CTR, DEPT MED, ENDOCRINOL SERV, 1275 YORK AVE, NEW YORK, NY 10021 USA.				NIDDK NIH HHS [DK07313] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLWEISS P, 1984, J NUCL MED, V25, P755; ANDREWS JC, 1989, ARCH OTOLARYNGOL, V115, P240; BRAVERMAN LE, 1991, WERNER INGBARS THYRO, P53; COX NH, 1985, BRIT J CLIN PRACT, V39, P158; EARLL JM, 1967, CALIF MED, V106, P56; LEE TC, 1985, J NUCL MED, V26, P49; LOEBINGER R, 1988, MIRD PRIMER ABSORBED; MAIER H, 1987, ACTA OTO-LARYNGOL, V103, P318, DOI 10.3109/00016488709107801; MAY M, 1986, FACIAL NERVE, P182; WOLFF J, 1963, J BIOL CHEM, V238, P847	10	26	26	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					576	578		10.7326/0003-4819-120-7-199404010-00008	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00008			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8116996				2022-12-28	WOS:A1994NC76400008
J	ARMITAGE, JO				ARMITAGE, JO			BONE-MARROW TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							VERSUS-HOST DISEASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; CYTOMEGALO-VIRUS INFECTION; SEVERE APLASTIC-ANEMIA; 1ST COMPLETE REMISSION; NON-HODGKINS-LYMPHOMA; ACUTE MYELOID-LEUKEMIA; SEVERE COMBINED IMMUNODEFICIENCY; HEMATOPOIETIC STEM-CELLS; HIGH-DOSE CHEMOTHERAPY				ARMITAGE, JO (corresponding author), UNIV NEBRASKA, MED CTR, DEPT INTERNAL MED, 600 S 42ND ST, OMAHA, NE 68198 USA.				NCI NIH HHS [CA 36737] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANASETTI C, 1986, ANN INTERN MED, V104, P461, DOI 10.7326/0003-4819-104-4-461; ANDERSON KC, 1991, BLOOD, V77, P712; ANTMAN K, 1992, J CLIN ONCOL, V10, P102, DOI 10.1200/JCO.1992.10.1.102; APPELBAUM FR, 1987, J CLIN ONCOL, V5, P1340, DOI 10.1200/JCO.1987.5.9.1340; APPELBAUM FR, 1978, BLOOD, V52, P85; APPELBAUM FR, 1987, BLOOD, V69, P92; ARMITAGE JO, 1991, AM J MED, V91, P605, DOI 10.1016/0002-9343(91)90213-H; ASH RC, 1990, NEW ENGL J MED, V322, P485, DOI 10.1056/NEJM199002223220801; ATKINSON K, 1990, BLOOD, V75, P2459; ATZPODIEN J, 1987, BLOOD, V70, P484; AUBOURG P, 1990, NEW ENGL J MED, V322, P1860, DOI 10.1056/NEJM199006283222607; BACH FH, 1968, LANCET, V2, P1364; BARRETT AJ, 1992, BLOOD, V79, P3067; BEARMAN SI, 1992, BLOOD, V80, P2458; BEATTY PG, 1985, NEW ENGL J MED, V313, P765, DOI 10.1056/NEJM198509263131301; BEATTY PG, 1988, TRANSPLANTATION, V45, P714, DOI 10.1097/00007890-198804000-00010; BERTHEAS MF, 1988, BLOOD, V72, P89; BIERMAN P, 1992, P AN M AM SOC CLIN, V11, P317; BLUME KG, 1980, NEW ENGL J MED, V302, P1041, DOI 10.1056/NEJM198005083021901; BORTIN MM, 1983, EXP HEMATOL, V11, P916; BORTIN MM, 1977, JAMA-J AM MED ASSOC, V238, P591, DOI 10.1001/jama.238.7.591; BOWDEN RA, 1986, NEW ENGL J MED, V314, P1006, DOI 10.1056/NEJM198604173141602; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; BROUN ER, 1992, ANN INTERN MED, V117, P124, DOI 10.7326/0003-4819-117-2-124; BUCKNER CD, 1984, BLOOD, V64, P630; CARELLA AM, 1993, BONE MARROW TRANSPL, V12, P267; CARELLA AM, 1991, BONE MARROW TRANSPL, V8, P99; CARELLA AM, 1988, J CLIN ONCOL, V6, P1411, DOI 10.1200/JCO.1988.6.9.1411; CHAMPLIN RE, 1989, BLOOD, V73, P606; CHAMPLIN RE, 1990, TRANSPLANTATION, V49, P720, DOI 10.1097/00007890-199004000-00013; CHANG J, 1986, LANCET, V1, P294; CHAO NJ, 1991, BLOOD, V78, P1923; CHAO NJ, 1991, ANN INTERN MED, V114, P145, DOI 10.7326/0003-4819-114-2-145; CHESON BD, 1992, HIGH DOSE CANCER THE, P763; CHOPRA R, 1992, J CLIN ONCOL, V10, P1690, DOI 10.1200/JCO.1992.10.11.1690; CLIFT RA, 1992, J CLIN ONCOL, V10, P1723, DOI 10.1200/JCO.1992.10.11.1723; COCCIA PF, 1980, NEW ENGL J MED, V302, P701, DOI 10.1056/NEJM198003273021301; DONEY K, 1987, BONE MARROW TRANSPL, V2, P355; DOPFER R, 1991, BLOOD, V78, P2780; ELIAS AD, 1992, BLOOD, V79, P3036; ESTROV Z, 1986, NEW ENGL J MED, V315, P538, DOI 10.1056/NEJM198608283150902; FEFER A, 1979, NEW ENGL J MED, V300, P333, DOI 10.1056/NEJM197902153000702; FLOWERS MED, 1992, BONE MARROW TRANSPL, V9, P167; FORKNER CE, 1938, LEUKEMIA ALLIED DISO; FOUCAR K, 1985, CANCER, V56, P553, DOI 10.1002/1097-0142(19850801)56:3<553::AID-CNCR2820560323>3.0.CO;2-Q; FREEDMAN A, 1992, ISSUES HEMATOL ONCOL, V2, P33; FREEDMAN AS, 1991, BLOOD, V77, P2524; GAHRTON G, 1991, NEW ENGL J MED, V325, P1267, DOI 10.1056/NEJM199110313251802; GAHRTON G, 1991, EUR J CANCER, V27, P1537, DOI 10.1016/0277-5379(91)90407-5; GALE RP, 1977, BLOOD, V50, P185; GATTI RA, 1968, LANCET, V2, P1366; GIANNI AM, 1989, LANCET, V2, P580; GINGRICH RD, 1988, BLOOD, V71, P1375; GLUCKMAN E, 1992, BLOOD, V79, P269; GOLDMAN JM, 1986, NEW ENGL J MED, V314, P202, DOI 10.1056/NEJM198601233140403; GOLDMAN JM, 1992, BLOOD S, V80, pA170; GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; GORIN NC, 1990, BLOOD, V75, P1606; GRATWOHL A, 1992, BONE MARROW TRANSPL, V10, P147; GRIBBEN JG, 1989, BLOOD, V73, P340; GRIBBEN JG, 1991, NEW ENGL J MED, V325, P1525, DOI 10.1056/NEJM199111283252201; GULATI SC, 1988, J CLIN ONCOL, V6, P1303, DOI 10.1200/JCO.1988.6.8.1303; HANSEN JA, 1980, NEW ENGL J MED, V303, P565, DOI 10.1056/NEJM198009043031007; HERVE P, 1990, BLOOD, V75, P1017; HOLLAND HK, 1989, ANN INTERN MED, V111, P973, DOI 10.7326/0003-4819-111-12-973; HOROWITZ MM, 1991, ANN INTERN MED, V115, P13, DOI 10.7326/0003-4819-115-1-13; HOROWITZ MM, 1990, BLOOD, V75, P555; JAGANNATH S, 1992, BLOOD, V80, P1666; JAGANNATH S, 1986, ANN INTERN MED, V104, P163, DOI 10.7326/0003-4819-104-2-163; JIN NR, 1987, EXP HEMATOL, V15, P93; JONES RJ, 1990, J CLIN ONCOL, V8, P527, DOI 10.1200/JCO.1990.8.3.527; KAZMIEROWSKI JA, 1976, BLOOD, V47, P555; KENNEDY MS, 1985, AM J MED, V78, P978, DOI 10.1016/0002-9343(85)90221-9; KERSEY JH, 1987, NEW ENGL J MED, V317, P461, DOI 10.1056/NEJM198708203170801; KESSINGER A, 1988, BLOOD, V71, P723; KESSINGER A, 1987, BONE MARROW TRANSPL, V2, P15; KHOURI I, 1992, BLOOD S, V80, pA66; KORBLING M, 1986, BLOOD, V67, P529; KRIVIT W, 1990, NEW ENGL J MED, V322, P28, DOI 10.1056/NEJM199001043220106; LINCH DC, 1993, LANCET, V341, P1051, DOI 10.1016/0140-6736(93)92411-L; LORENZ E, 1951, J NATL CANCER I, V12, P197; LOWENBERG B, 1990, J CLIN ONCOL, V8, P287; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; MARTIN PJ, 1990, BLOOD, V76, P1464, DOI 10.1182/blood.V76.8.1464.1464; McCullough J, 1989, Oncology (Williston Park), V3, P63; MCGLAVE PB, 1987, BLOOD, V70, P1325; MEYERS JD, 1988, NEW ENGL J MED, V318, P70, DOI 10.1056/NEJM198801143180202; MEYERS JD, 1983, ANN INTERN MED, V98, P442, DOI 10.7326/0003-4819-98-4-442; MICHALLET M, 1991, BONE MARROW TRANSPL, V7, P275; MILLER W, 1986, BLOOD, V67, P1162; MILPIED N, 1989, BRIT J HAEMATOL, V73, P82, DOI 10.1111/j.1365-2141.1989.tb00224.x; MITSUYASU RT, 1986, ANN INTERN MED, V105, P20, DOI 10.7326/0003-4819-105-1-20; MORECKI S, 1988, CANCER RES, V48, P4573; NADEMANEE A, 1992, BLOOD, V80, P1130; NICHOLS CR, 1992, J CLIN ONCOL, V10, P558, DOI 10.1200/JCO.1992.10.4.558; O'Reilly R J, 1989, Immunodefic Rev, V1, P273; ODONNELL MR, 1987, J CLIN ONCOL, V5, P1822, DOI 10.1200/JCO.1987.5.11.1822; OREILLY RJ, 1977, NEW ENGL J MED, V297, P1311, DOI 10.1056/NEJM197712152972403; Osgood EE, 1939, ANN INTERN MED, V13, P357, DOI 10.7326/0003-4819-13-2-357; PARKMAN R, 1978, NEW ENGL J MED, V298, P922, DOI 10.1056/NEJM197804272981701; PETERS WP, 1988, J CLIN ONCOL, V6, P1368, DOI 10.1200/JCO.1988.6.9.1368; PETERS WP, 1992, ADV ONCOL, V8, P17; PHILIP I, 1984, J NATL CANCER I, V73, P835; PHILIP T, 1991, J CLIN ONCOL, V9, P1037, DOI 10.1200/JCO.1991.9.6.1037; PHILIP T, 1987, NEW ENGL J MED, V316, P1493, DOI 10.1056/NEJM198706113162401; PHILLIPS GL, 1984, NEW ENGL J MED, V310, P1557, DOI 10.1056/NEJM198406143102403; POLE G, 1991, J CLIN ONCOL, V9, P1094; POLE JG, 1991, J CLIN ONCOL, V9, P152, DOI 10.1200/JCO.1991.9.1.152; RABINOWE SN, 1992, BLOOD S, V80, pA170; RAMSAY NKC, 1982, NEW ENGL J MED, V306, P392, DOI 10.1056/NEJM198202183060703; RAPPEPORT JM, 1984, NEW ENGL J MED, V311, P84, DOI 10.1056/NEJM198407123110203; REIFFERS J, 1989, BRIT J HAEMATOL, V72, P296, DOI 10.1111/j.1365-2141.1989.tb07705.x; ROBBINS RA, 1989, AM J MED, V87, P511; ROHATINER AZS, 1991, AUTOLOGOUS BONE MARR, V5, P465; ROY DC, 1991, BLOOD, V77, P2404; SANTINI G, 1989, BONE MARROW TRANSPL, V4, P399; SANTOS GW, 1983, NEW ENGL J MED, V309, P1347, DOI 10.1056/NEJM198312013092202; SHARP JG, 1992, BLOOD, V79, P1074; SHARP JG, 1987, AUTOLOGOUS BONE MARR, P497; SHEARER WT, 1985, NEW ENGL J MED, V312, P1151, DOI 10.1056/NEJM198505023121804; SHERIDAN WP, 1992, LANCET, V339, P640, DOI 10.1016/0140-6736(92)90795-5; Shpall E J, 1992, J Hematother, V1, P45, DOI 10.1089/scd.1.1992.1.45; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; SHULMAN HM, 1992, BONE MARROW TRANSPL, V10, P197; SONDEL PM, 1986, EXP HEMATOL, V14, P278; STORB R, 1982, BLOOD, V59, P236; STORB R, 1983, ANN INTERN MED, V98, P461, DOI 10.7326/0003-4819-98-4-461; STORB R, 1989, BLOOD, V73, P1729; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; STORB R, 1987, BLOOD, V70, P116; SULLIVAN KM, 1989, NEW ENGL J MED, V320, P828, DOI 10.1056/NEJM198903303201303; SULLIVAN KM, 1988, BLOOD, V72, P546; SULLIVAN KM, 1988, BLOOD, V72, P555; SZER J, 1984, ANN INTERN MED, V101, P193, DOI 10.7326/0003-4819-101-2-193; THOMAS ED, 1979, NEW ENGL J MED, V301, P597, DOI 10.1056/NEJM197909133011109; THOMAS ED, 1970, BLOOD-J HEMATOL, V36, P507, DOI 10.1182/blood.V36.4.507.507; THOMAS ED, 1975, NEW ENGL J MED, V292, P832, DOI 10.1056/NEJM197504172921605; THOMAS ED, 1982, LANCET, V2, P227; THOMAS ED, 1977, BLOOD, V49, P511; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706; TO LB, 1990, EXP HEMATOL, V18, P442; VANBEKKUM DW, 1989, P NATL ACAD SCI USA, V86, P10090; VERMYLEN C, 1988, LANCET, V1, P1427; VOGELSANG GB, 1992, NEW ENGL J MED, V326, P1055, DOI 10.1056/NEJM199204163261604; VOSE JM, 1993, J CLIN ONCOL, V11, P1846, DOI 10.1200/JCO.1993.11.10.1846; WEIDEN PL, 1979, NEW ENGL J MED, V300, P1068, DOI 10.1056/NEJM197905103001902; WEIDEN PL, 1981, NEW ENGL J MED, V304, P1529, DOI 10.1056/NEJM198106183042507; WILLIAMS SF, 1992, J CLIN ONCOL, V10, P1743, DOI 10.1200/JCO.1992.10.11.1743; WINGARD JR, 1989, BLOOD, V74, P1428; WINGARD JR, 1988, BLOOD, V71, P1432; WINGARD JR, 1988, MEDICINE, V67, P175, DOI 10.1097/00005792-198805000-00004; WINSTON DJ, 1987, ANN INTERN MED, V106, P12, DOI 10.7326/0003-4819-106-1-12; YEAGER AM, 1992, BLOOD, V79, P3031	154	588	607	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 24	1994	330	12					827	838		10.1056/NEJM199403243301206	http://dx.doi.org/10.1056/NEJM199403243301206			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB803	8114836				2022-12-28	WOS:A1994NB80300006
J	ARPAIA, E; SHAHAR, M; DADI, H; COHEN, A; ROIFMAN, CM				ARPAIA, E; SHAHAR, M; DADI, H; COHEN, A; ROIFMAN, CM			DEFECTIVE T-CELL RECEPTOR SIGNALING AND CD8(+) THYMIC SELECTION IN HUMANS LACKING ZAP-70 KINASE	CELL			English	Article							PROTEIN-TYROSINE KINASE; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; POSITIVE SELECTION; MICE LACKING; ZETA-CHAIN; PHOSPHORYLATION; ACTIVATION; TRANSDUCTION; CD4	We have previously described a type of selective T cell deficiency (STD) characterized by persistent infections reminiscent of severe combined immunodeficiency. We show here that STD patients carry a mutation of zap-70, resulting in loss of the activity of this kinase. The thymi of zap-70(-/-) patients show the presence of CD4(+)CD8(+) cells in the cortex; however, only CD4, not CD8, single-positive cells are present in the medulla. Peripheral CD4(+) T cells from the zap 70(-/-) patients exhibit markedly reduced tyrosine phosphorylation, fail to produce interleukin-2, and do not proliferate in response to T cell receptor stimulation by mitogens or antigens. Thus, Zap-70 kinase appears to be indispensable for the development of CD8 single-positive T cells as well as for signal transduction and function of single-positive CD4 T cells.	HOSP SICK CHILDREN, DIV IMMUNNOL & ALLERGY, TORONTO M5G 1X8, ON, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BILL J, 1989, NATURE, V341, P649, DOI 10.1038/341649a0; BOSMA GC, 1988, J EXP MED, V167, P1016, DOI 10.1084/jem.167.3.1016; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN IT, 1993, SCIENCE, V261, P1581, DOI 10.1126/science.8372352; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DOHERTY PJ, 1991, MOL IMMUNOL, V28, P607, DOI 10.1016/0161-5890(91)90129-8; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207, DOI 10.1016/S0065-2776(08)60643-4; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GILLILAND LK, 1991, J IMMUNOL, V146, P1759; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GREENE WC, 1986, ANNU REV IMMUNOL, V4, P69, DOI 10.1146/annurev.iy.04.040186.000441; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; MARUSICGALESIC S, 1988, NATURE, V333, P180, DOI 10.1038/333180a0; MILLS GB, 1986, INTERLEUKIN, V2, P113; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MONAFO WJ, 1992, CLIN EXP IMMUNOL, V90, P390; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; ROIFMAN CM, 1986, CLIN EXP IMMUNOL, V66, P139; ROIFMAN CM, 1992, J IMMUNOL, V148, P1136; ROIFMAN CM, 1989, J EXP MED, V170, P2177, DOI 10.1084/jem.170.6.2177; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SEONG RH, 1992, NATURE, V356, P718, DOI 10.1038/356718a0; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAKAHAMA Y, 1992, SCIENCE, V258, P1456, DOI 10.1126/science.1439838; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; VONBOEHMER H, 1989, IMMUNOL TODAY, V10, P57, DOI 10.1016/0167-5699(89)90307-1; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	52	472	479	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 11	1994	76	5					947	958		10.1016/0092-8674(94)90368-9	http://dx.doi.org/10.1016/0092-8674(94)90368-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124727				2022-12-28	WOS:A1994NA89000019
J	GREENE, AE; ALLISON, RF				GREENE, AE; ALLISON, RF			RECOMBINATION BETWEEN VIRAL-RNA AND TRANSGENIC PLANT TRANSCRIPTS	SCIENCE			English	Article							BROME MOSAIC-VIRUS; DEFECTIVE INTERFERING RNA; GENETIC-RECOMBINATION; SEQUENCE; GENOME; COMPONENTS; RESISTANCE; INFECTION	Transformed plants expressing the 3' two-thirds of the cowpea chlorotic mottle virus (CCMV) capsid gene were inoculated with a CCMV deletion mutant lacking the 3' one-third of the capsid gene. Although the deletion inoculum replicates in inoculated cells, systemic infections occur only if recombination restores a functional capsid gene. Four of 125 inoculated transgenic plants, representing three different transgenic lines, became systemically infected. Analysis of viral RNA confirmed that RNA recombination had united the transgenic messenger RNA and the challenging virus through aberrant homologous recombination.	MICHIGAN STATE UNIV,DEPT BOT & PLANT PATHOL,E LANSING,MI 48824	Michigan State University								ALLISON R, 1990, P NATL ACAD SCI USA, V87, P1820, DOI 10.1073/pnas.87.5.1820; ALLISON RF, 1988, J VIROL, V62, P3581, DOI 10.1128/JVI.62.10.3581-3588.1988; ALLISON RF, 1989, VIROLOGY, V172, P321, DOI 10.1016/0042-6822(89)90134-7; An G, 1988, PLANT MOL BIOL MAN A, V3, P1; ANGENENT GC, 1989, VIROLOGY, V171, P271, DOI 10.1016/0042-6822(89)90537-0; BEACHY RN, 1990, ANNU REV PHYTOPATHOL, V28, P451, DOI 10.1146/annurev.py.28.090190.002315; BUJARSKI JJ, 1986, NATURE, V321, P528, DOI 10.1038/321528a0; BURGYAN J, 1989, J GEN VIROL, V70, P235, DOI 10.1099/0022-1317-70-1-235; CASCONE PJ, 1993, SCIENCE, V260, P801, DOI 10.1126/science.8484119; DAWSON WO, 1992, ANNU REV PLANT PHYS, V43, P527, DOI 10.1146/annurev.pp.43.060192.002523; DEZOETEN GA, 1991, PHYTOPATHOLOGY, V81, P585; GRUMET R, 1990, HORTSCIENCE, V25, P508, DOI 10.21273/HORTSCI.25.5.508; HILLMAN BI, 1987, CELL, V51, P427, DOI 10.1016/0092-8674(87)90638-6; KIRKEGAARD K, 1986, CELL, V47, P433, DOI 10.1016/0092-8674(86)90600-8; LAI MMC, 1992, MICROBIOL REV, V56, P61, DOI 10.1128/MMBR.56.1.61-79.1992; Lommel S.A., 1991, J CELL BIOCHEM, V15, P151; MATTHEWS REF, 1991, PLANT VIROLOGY, P376; MAYO MA, 1991, J GEN VIROL, V72, P2591, DOI 10.1099/0022-1317-72-10-2591; MILLER WA, 1986, J MOL BIOL, V187, P537, DOI 10.1016/0022-2836(86)90332-3; NAGY PD, 1993, P NATL ACAD SCI USA, V90, P6390, DOI 10.1073/pnas.90.14.6390; NAGY PD, 1992, J VIROL, V66, P6824, DOI 10.1128/JVI.66.11.6824-6828.1992; RAO ALN, 1993, J VIROL, V67, P969, DOI 10.1128/JVI.67.2.969-979.1993; RAO ALN, 1990, J GEN VIROL, V71, P1403, DOI 10.1099/0022-1317-71-6-1403; ROBINSON DJ, 1987, J GEN VIROL, V68, P2551, DOI 10.1099/0022-1317-68-10-2551	24	140	161	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1423	1425		10.1126/science.8128222	http://dx.doi.org/10.1126/science.8128222			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128222				2022-12-28	WOS:A1994MZ92700027
J	DOHMEN, RJ; WU, PP; VARSHAVSKY, A				DOHMEN, RJ; WU, PP; VARSHAVSKY, A			HEAT-INDUCIBLE DEGRON - A METHOD FOR CONSTRUCTING TEMPERATURE-SENSITIVE MUTANTS	SCIENCE			English	Article							N-END RULE; CEREVISIAE CHROMOSOME-I; SACCHAROMYCES-CEREVISIAE; LETHAL MUTATIONS; ESCHERICHIA-COLI; DIHYDROFOLATE-REDUCTASE; CONDITIONAL MUTATIONS; DEGRADATION SIGNAL; CRYSTAL-STRUCTURE; GENE-EXPRESSION	A temperature-sensitive (ts) mutant retains the function of a gene at a low (permissive) temperature but not at a high (nonpermissive) temperature. Arg-DHFR, a dihydrofolate reductase bearing an amino-terminal (N-terminal) arginine, is long-lived in the yeast Saccharomyces cerevisiae, even though arginine is a destabilizing residue in the N-end rule of protein degradation. A ts derivative of Arg-DHFR was identified that is long-lived at 23 degrees C but rapidly degraded by the N-end rule pathway at 37 degrees C. Fusions of ts Arg-DHFR to either Ura3 or Cdc28 of S. cerevisiae confer ts phenotypes specific for these gene products. Thus, Arg-DHFR(ts) is a heat-inducible degradation signal that can be used to produce ts mutants without a search for ts mutations.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology			Dohmen, R. Jürgen/AAD-6649-2022	Dohmen, R. Jürgen/0000-0002-5756-6780				ALANI E, 1987, GENETICS, V117, P5; Ausubel FM, 1988, MOL REPROD DEV; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; BALAKRISHNAN R, 1988, GENE, V67, P97, DOI 10.1016/0378-1119(88)90012-1; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BARTEL B, 1988, CELL, V52, P935, DOI 10.1016/0092-8674(88)90435-7; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BUSBY S, 1982, J MOL BIOL, V154, P197, DOI 10.1016/0022-2836(82)90060-2; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHOW WY, 1988, P NATL ACAD SCI USA, V85, P6468, DOI 10.1073/pnas.85.17.6468; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; FINLEY D, 1992, MOL CELLULAR BIOL YE, V2, P539; Futcher A B, 1991, Semin Cell Biol, V2, P205; HARRIS SD, 1992, J MOL BIOL, V225, P53, DOI 10.1016/0022-2836(92)91025-K; HARRIS SD, 1991, GENETICS, V127, P279; HARTWELL LH, 1970, P NATL ACAD SCI USA, V66, P352, DOI 10.1073/pnas.66.2.352; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILL A, 1987, MOL CELL BIOL, V7, P2397, DOI 10.1128/MCB.7.7.2397; HILL CP, 1993, P NATL ACAD SCI USA, V90, P4136, DOI 10.1073/pnas.90.9.4136; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; HOROWITZ NH, 1950, ADV GENET, V3, P33, DOI 10.1016/S0065-2660(08)60082-6; HU MCT, 1987, CELL, V48, P555, DOI 10.1016/0092-8674(87)90234-0; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; Johnston J. C., UNPUB; KABACK DB, 1984, GENETICS, V108, P67; MADURA K, 1993, J BIOL CHEM, V268, P12046; MOIR D, 1982, GENETICS, V100, P565; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NASMYTH K, 1991, COLD SPRING HARB SYM, V56, P9; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OEFNER C, 1988, EUR J BIOCHEM, V174, P377, DOI 10.1111/j.1432-1033.1988.tb14108.x; PARK EC, 1992, P NATL ACAD SCI USA, V89, P1249, DOI 10.1073/pnas.89.4.1249; Pringle J R, 1975, Methods Cell Biol, V12, P233; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RILES L, 1988, GENETICS, V118, P601; ROSE M, 1984, GENE, V29, P113, DOI 10.1016/0378-1119(84)90172-0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SIKORSKI RS, 1989, GENETICS, V122, P19; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VOLZ KW, 1982, J BIOL CHEM, V257, P2528; YOSHIMATSU T, 1989, SCIENCE, V244, P1346, DOI 10.1126/science.2544026; ZHANG YF, 1991, P NATL ACAD SCI USA, V88, P1511, DOI 10.1073/pnas.88.4.1511	48	297	318	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 4	1994	263	5151					1273	1276		10.1126/science.8122109	http://dx.doi.org/10.1126/science.8122109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	8122109				2022-12-28	WOS:A1994MY57000034
J	RIDDIHOUGH, G				RIDDIHOUGH, G			FEELING THE GROOVE	NATURE			English	Editorial Material							PROTEINS											BROWN BM, 1994, NAT STRUCT BIOL, V1, P164, DOI 10.1038/nsb0394-164; CARTER CW, 1974, P NATL ACAD SCI USA, V71, P283, DOI 10.1073/pnas.71.2.283; CHOU PY, 1975, J MOL BIOL, V96, P29, DOI 10.1016/0022-2836(75)90180-1; CHURCH GM, 1977, P NATL ACAD SCI USA, V74, P1458, DOI 10.1073/pnas.74.4.1458; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804	10	2	2	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					82	82		10.1038/368082a0	http://dx.doi.org/10.1038/368082a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	8107890				2022-12-28	WOS:A1994MY56900059
J	HODGKINSON, DW; KURDY, N; NICHOLSON, DA; DRISCOLL, PA				HODGKINSON, DW; KURDY, N; NICHOLSON, DA; DRISCOLL, PA			ABC OF EMERGENCY RADIOLOGY - THE WRIST	BRITISH MEDICAL JOURNAL			English	Article											HODGKINSON, DW (corresponding author), HOPE HOSP,SALFORD,LANCS,ENGLAND.								0	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	1994	308	6926					464	468		10.1136/bmj.308.6926.464	http://dx.doi.org/10.1136/bmj.308.6926.464			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW976	8124184	Green Published			2022-12-28	WOS:A1994MW97600031
J	BELL, TW; JOUSSELIN, H				BELL, TW; JOUSSELIN, H			SELF-ASSEMBLY OF A DOUBLE-HELICAL COMPLEX OF SODIUM	NATURE			English	Article							X-RAY CRYSTAL; MOLECULAR-STRUCTURE; METAL-COMPLEXES; LIGANDS; PREFERENCE; CHEMISTRY	SPONTANEOUS self-organization of helical and multiple-helical molecular structures occurs on several levels in living organisms. Key examples are alpha-helical polypeptides, double-helical nucleic acids and helical protein structures, including F-actin, microtubules and the protein sheath of the tobacco mosaic virus1. Although the self-assembly of double-helical transition-metal complexes1-15 bears some resemblance to the molecular organization of double-stranded DNA, selection between monohelical, double-helical and triple-helical structures is determined largely by the size and geometrical preference of the tightly bound metal14. Here we present an example of double-helical assembly induced by the weaker and non-directional interactions of an alkali-metal ion with an organic ligand that is pre-organized into a coil. We have characterized the resulting complex by two-dimensional NMR and fast-atom-bombardment mass spectrometry. These results provide a step toward the creation of molecular tubes or ion channels consisting of intertwined coils.			BELL, TW (corresponding author), SUNY STONY BROOK,DEPT CHEM,STONY BROOK,NY 11794, USA.							BELL TW, 1993, PURE APPL CHEM, V65, P361, DOI 10.1351/pac199365030361; BELL TW, 1991, J AM CHEM SOC, V113, P6283, DOI 10.1021/ja00016a062; BELL TW, 1992, ANGEW CHEM INT EDIT, V31, P345, DOI 10.1002/anie.199203451; BELL TW, 1992, ANGEW CHEM INT EDIT, V31, P348, DOI 10.1002/anie.199203481; BELL TW, 1992, CROWN COMPOUNDS FUTU, P303; BERNARDINELLI G, 1992, ANGEW CHEM INT EDIT, V31, P1622; BRADLEY D, 1993, SCIENCE, V259, P890, DOI 10.1126/science.259.5097.890; CONSTABLE EC, 1992, ANGEW CHEM INT EDIT, V31, P230, DOI 10.1002/anie.199202301; CONSTABLE EC, 1990, NATURE, V346, P314, DOI 10.1038/346314a0; CONSTABLE EC, 1992, POLYHEDRON, V11, P2967, DOI 10.1016/S0277-5387(00)83604-9; CONSTABLE EC, 1992, TETRAHEDRON, V48, P10013, DOI 10.1016/S0040-4020(01)89035-9; CONSTABLE EC, 1987, J CHEM SOC CHEM COMM, P1600, DOI 10.1039/c39870001600; CONSTABLE EC, 1993, NATURE, V362, P412, DOI 10.1038/362412a0; CONSTABLE EC, 1991, ANGEW CHEM INT EDIT, V30, P1450, DOI 10.1002/anie.199114501; DIETRICHBUCHECKER CO, 1990, ANGEW CHEM INT EDIT, V29, P1154, DOI 10.1002/anie.199011541; HUANG CY, 1992, ANGEW CHEM INT EDIT, V31, P1244, DOI 10.1002/anie.199212441; KOERT U, 1990, NATURE, V346, P339, DOI 10.1038/346339a0; Lehn J. M., 1992, PERSPECTIVES COORDIN, P447; LEHN JM, 1987, P NATL ACAD SCI USA, V84, P2565, DOI 10.1073/pnas.84.9.2565; LEHN JM, 1983, NOUV J CHIM, V7, P413; LINDSEY JS, 1991, NEW J CHEM, V15, P153; LORENZI GP, 1991, CHIRALITY, V3, P315, DOI 10.1002/chir.530030416; PFIEL A, 1992, J CHEM SOC CHEM COMM, P838; PIGUET C, 1992, J AM CHEM SOC, V114, P7440, DOI 10.1021/ja00045a016; STUCKMEIER G, 1976, J AM CHEM SOC, V98, P278; THUMMEL RP, 1991, TETRAHEDRON, V47, P6851, DOI 10.1016/S0040-4020(01)96143-5; TOMASIK P, 1985, Z PYRIDINE METAL COM, pCH1; VANSTEIN GC, 1984, J AM CHEM SOC, V106, P4486, DOI 10.1021/ja00328a031; WESTER D, 1975, J CHEM SOC CHEM COMM, P74, DOI 10.1039/c39750000074; WILLIAMS AF, 1991, ANGEW CHEM INT EDIT, V30, P1490, DOI 10.1002/anie.199114901	30	100	100	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					441	444		10.1038/367441a0	http://dx.doi.org/10.1038/367441a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	8107802				2022-12-28	WOS:A1994MU67900048
J	RIVELLESE, AA; AULETTA, P; MAROTTA, G; SALDALAMACCHIA, G; GIACCO, A; MASTRILLI, V; VACCARO, O; RICCARDI, G				RIVELLESE, AA; AULETTA, P; MAROTTA, G; SALDALAMACCHIA, G; GIACCO, A; MASTRILLI, V; VACCARO, O; RICCARDI, G			LONG-TERM METABOLIC EFFECTS OF 2 DIETARY METHODS OF TREATING HYPERLIPEMIA	BRITISH MEDICAL JOURNAL			English	Article							MONOUNSATURATED FATTY-ACIDS; PLASMA-CHOLESTEROL LEVELS; DIABETIC-PATIENTS; SERUM-LIPOPROTEINS; CARBOHYDRATE; GLUCOSE; LIPIDS; WOMEN; FIBER; MEN	Objectives-To compare the long term metabolic effects of two diets for treating hyperlipidaemia. Design-Randomised controlled study: after three weeks of normal (control) diet, subjects were randomly allocated to one of two test diets and followed up for six months. Setting-Lipid clinic of tertiary referral centre in Naples. Subjects-63 subjects with primary type IIa and IIb hyperlipoproteinaemia entered the study, and 44 completed it. Exclusion criteria were taking drugs known to influence lipid metabolism, evidence of cardiovascular disease, homozygous familial hypercholesterolaemia, and body mass index over 30. Interventions-Two test diets with reduced saturated fat (8%) and cholesterol (approximately 200 mg/day): one was also low in total fat and rich in carbohydrate and fibre, and the other was low in carbohydrate and fibre and rich in polyunsaturated and monounsaturated fats. Main outcome measures-Fasting plasma lipid and lipoprotein concentrations; blood glucose, insulin, and triglyceride concentrations before and after a test meal. Results-In comparison with the control diet, both test diets induced significant and similar decreases in low density lipoprotein cholesterol concentrations (by a mean of 0.72 (SE 0.15) mmol/l, P<0.001, for low total fat diet; by 0.49 (0.18) mmol/l, P<0.05, for high unsaturated fat diet) and plasma triglyceride concentrations (by 0.21 (0.09) mmol/l, P < 0.05, for low total fat diet; by 0.39 (0.15) mmol/l, P<0.05, for high unsaturated fat diet), while high density lipoprotein cholesterol concentrations after fasting and plasma glucose and insulin concentrations during test meals were not modified by either diet. Conclusions-Both test diets are suitable (alone or in combination) for treatment of hypercholesterolaemia.			RIVELLESE, AA (corresponding author), FEDERICO II UNIV,SCH MED,INST INTERNAL MED & METAB,I-80131 NAPLES,ITALY.		riccardi, gabriele/A-9269-2012					[Anonymous], 1984, ARTERIOSCLEROSIS, V4, p443A; BAGGIO G, 1988, AM J CLIN NUTR, V47, P960, DOI 10.1093/ajcn/47.6.960; BERRY EM, 1991, AM J CLIN NUTR, V53, P899, DOI 10.1093/ajcn/53.4.899; BRUSSAARD JH, 1980, ATHEROSCLEROSIS, V36, P517; CARLSON K, 1973, J CLIN PATHOL S5, V26, P32; Cochran W.G, 1957, STAT METHODS, V6th ed; COULSTON AM, 1983, METABOLISM, V32, P52, DOI 10.1016/0026-0495(83)90155-5; DUBUQUOIS B, 1971, J CLIN ENDOCR METAB, V33, P732; FIDANZA F, 1982, TABELLE COMPOSIZIONE; GAMMAL EB, 1967, CANCER RES, V27, P1737; GIACCO R, 1991, MEDITERRANEAN DIETS, P3; GINSBERG HN, 1990, NEW ENGL J MED, V322, P574, DOI 10.1056/NEJM199003013220902; GRAFINETTER D, 1972, GIORN ARTERIOSCLER, V2, P113; GRUNDY SM, 1986, NEW ENGL J MED, V314, P745, DOI 10.1056/NEJM198603203141204; KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480; KEYS A, 1965, METABOLIS, V14, P776, DOI 10.1016/0026-0495(65)90004-1; KOSTNER GM, 1976, CLIN CHEM, V22, P695; LEWIS B, 1981, LANCET, V2, P1310; MALENKA DJ, 1989, ARCH INTERN MED, V49, P1981; MATTSON FH, 1985, J LIPID RES, V26, P194; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; MENSINK RP, 1989, METABOLISM, V38, P172, DOI 10.1016/0026-0495(89)90258-8; MENSINK RP, 1989, NEW ENGL J MED, V321, P436, DOI 10.1056/NEJM198908173210705; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RICCARDI G, 1993, CURR OPIN LIPIDOL, V4, P13, DOI 10.1097/00041433-199302000-00003; RICCARDI G, 1991, DIABETES CARE, V14, P1115, DOI 10.2337/diacare.14.12.1115; RICCARDI G, 1987, EUR HEART J, V8, P79, DOI 10.1093/eurheartj/8.suppl_E.79; RICCARDI G, 1988, DIABETES NUTRITION M, V1, P7; RIVELLESE A, 1980, LANCET, V2, P447; RIVELLESE A, 1983, PREV MED, V12, P128, DOI 10.1016/0091-7435(83)90181-0; RIVELLESE AA, 1990, DIABETES CARE, V13, P446, DOI 10.2337/diacare.13.4.446; ZANNI EE, 1987, J LIPID RES, V28, P518; 1991, AM J CARDIOL S, V68, pA1; 1984, JAMA-J AM MED ASSOC, V251, P351; [No title captured]	35	47	47	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 22	1994	308	6923					227	231		10.1136/bmj.308.6923.227	http://dx.doi.org/10.1136/bmj.308.6923.227			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT539	8111257	Green Published			2022-12-28	WOS:A1994MT53900017
J	TOGGAS, SM; MASLIAH, E; ROCKENSTEIN, EM; RALL, GF; ABRAHAM, CR; MUCKE, L				TOGGAS, SM; MASLIAH, E; ROCKENSTEIN, EM; RALL, GF; ABRAHAM, CR; MUCKE, L			CENTRAL-NERVOUS-SYSTEM DAMAGE PRODUCED BY EXPRESSION OF THE HIV-1 COAT PROTEIN GP120 IN TRANSGENIC MICE	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ASTROCYTE-SPECIFIC EXPRESSION; NEOCORTICAL DAMAGE; ACTIVATION; CLEAVAGE; INJURY; RAT	MANY people infected with human immunodeficiency virus type 1 (HIV-1) develop neurological complications that can culminate in dementia and paralysis1. The discrepancy between the severity of impairment and the paucity of detectable HIV-1 within neurons has led to an intense search for diffusible virus- and host-derived factors that might be neurotoxic (see ref. 2 for review). The HIV-1 envelope glycoprotein gp120 is an extracellular protein that is shed from infected cells3 and so has the potential to diffuse and interact with distant uninfected brain cells. Studies on cultured immature cells suggest that gp120 induces neurotoxicity (reviewed in refs 2, 4), and systemic injection of gp120 in neonatal rats5 and intracerebroventricular injection in adult rats results in deleterious effects on the brain6,7. To assess the pathogenic potential of gp120 in the intact brain, we have now produced gp120 in the brains of transgenic mice and found a spectrum of neuronal and glial changes resembling abnormalities in brains of HIV-1-infected humans. The severity of damage correlated positively with the brain level of gp120 expression. These results provide in vivo evidence that gp120 plays a key part in HIV-1-associated nervous system impairment. This model should facilitate the evaluation and development of therapeutic strategies aimed at HIV-brain interactions.	Scripps Res Inst, DEPT NEUROPHARMACOL, DIV VIROL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA; BOSTON UNIV, SCH MED, DEPT MED, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA	Scripps Research Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Boston University; Boston University				Mucke, Lennart/0000-0001-6256-9559; Abraham, Carmela/0000-0002-6649-1960				ABRAHAM CR, 1993, BRAIN RES, V621, P222, DOI 10.1016/0006-8993(93)90110-9; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; Budka H, 1991, BRAIN PATHOL, V1, P163, DOI 10.1111/j.1750-3639.1991.tb00656.x; CAMPBELL I, 1993, SOC NEUR ABSTR, V19; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; EPSTEIN J, 1993, J GEN VIROL, V33, P429; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; FREED EO, 1989, J VIROL, V63, P4670, DOI 10.1128/JVI.63.11.4670-4675.1989; GIULIAN D, 1993, P NATL ACAD SCI USA, V90, P2769, DOI 10.1073/pnas.90.7.2769; GLOWA JR, 1992, BRAIN RES, V570, P49, DOI 10.1016/0006-8993(92)90562-N; HAASS C, 1991, J NEUROSCI, V11, P3783; HILL JM, 1993, BRAIN RES, V603, P222, DOI 10.1016/0006-8993(93)91241-J; JANSSEN RS, 1991, NEUROLOGY, V41, P778; KIMES AS, 1991, EXP NEUROL, V112, P224, DOI 10.1016/0014-4886(91)90073-L; LIPTON SA, 1992, NEUROREPORT, V3, P913, DOI 10.1097/00001756-199210000-00023; MASLIAH E, 1991, EXP NEUROL, V113, P131, DOI 10.1016/0014-4886(91)90169-D; MASLIAH E, 1992, ANN NEUROL, V32, P321, DOI 10.1002/ana.410320304; MASLIAH E, 1992, LAB INVEST, V66, P285; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MIURA M, 1990, J NEUROCHEM, V55, P1180, DOI 10.1111/j.1471-4159.1990.tb03123.x; MUCKE L, 1991, NEW BIOL, V3, P465; MUCKE L, 1993, FASEB J, V7, P1226, DOI 10.1096/fasebj.7.13.8405808; MUCKE L, 1992, Neurobiology of Aging, V13, pS101; MUCKE L, 1993, TRANSGENE, V1, P3; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; SCHNEIDER J, 1986, J GEN VIROL, V67, P2533, DOI 10.1099/0022-1317-67-11-2533; SPENCER DC, 1992, ANNU REV MICROBIOL, V46, P655; WILEY CA, 1991, ANN NEUROL, V29, P651, DOI 10.1002/ana.410290613; WILSON MC, 1989, NEUROMETHODS, V16, P239	31	598	610	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 13	1994	367	6459					188	193		10.1038/367188a0	http://dx.doi.org/10.1038/367188a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ780	8114918				2022-12-28	WOS:A1994MQ78000066
J	SHOEMAKER, WC; JAMES, CB; KING, LM; HARDIN, E; ORDOG, GJ				SHOEMAKER, WC; JAMES, CB; KING, LM; HARDIN, E; ORDOG, GJ			URBAN VIOLENCE IN LOS-ANGELES IN THE AFTERMATH OF THE RIOTS - A PERSPECTIVE FROM HEALTH-CARE PROFESSIONALS, WITH IMPLICATIONS FOR SOCIAL RECONSTRUCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUPRANORMAL VALUES; PROSPECTIVE TRIAL; EMERGENCY; GOALS	Beginning April 29,1992, Los Angeles, Calif, was engulfed in a 3-day insurrection reflecting the residents' responses to a legal ruling. Unlike the media-painted picture, this article argues that the enormous outburst of violence and consequential property destruction was not the exclusive domain of the citizens of South-Central Los Angeles and that available data will not support the maintenance of the prevailing uneven distribution of civic and state resources in health care, educational programs, and economic opportunities. What it does support is the proposal for a more equitable allocation of resources among institutions, groups, and peoples, complemented by community empowerment, a more civic-oriented police operation, and a more rational approach to social reconstruction in which all elements of the society are full participants. Finally, the' article suggests that augmentation of the present ''law and order'' approach and the paramilitary police already have proven economically ineffective. Given the dominant role of the medical profession in social and civic life, it is now appropriate for the medical profession to enter the debate on policies of health improvement, violence deterrence, and the general field of social reconstruction.	KING DREW MED CTR,DEPT PSYCHIAT,LOS ANGELES,CA 90059; KING DREW MED CTR,OFF VICE PRESIDENT,LOS ANGELES,CA 90059; CHARLES A DREW UNIV HLTH & SCI,LOS ANGELES,CA	Charles R. Drew University of Medicine & Science	SHOEMAKER, WC (corresponding author), KING DREW MED CTR,DEPT EMERGENCY MED,12021 WILMINGTON AVE,LOS ANGELES,CA 90059, USA.		ordog, gary/AAB-8399-2019	ordog, gary/0000-0002-6394-6317				ACKENKNECHT ER, 1953, R VIRCHOW STATESMAN, P44; BERLAUK JF, 1991, ANN SURG, V214, P289, DOI 10.1097/00000658-199109000-00011; BISHOP MH, 1993, CRIT CARE MED, V21, P56, DOI 10.1097/00003246-199301000-00013; BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699; Christopher W, 1991, REPORT INDEPENDENT C; COTTON P, 1992, JAMA-J AM MED ASSOC, V267, P3001, DOI 10.1001/jama.267.22.3001; Davidson L L, 1992, Paediatr Perinat Epidemiol, V6, P153, DOI 10.1111/j.1365-3016.1992.tb00757.x; DAVIDSON LL, 1991, AJDC, V145, P385; EISENBERG L, 1984, AM J MED, V77, P524, DOI 10.1016/0002-9343(84)90114-1; FLEMING A, 1992, ARCH SURG-CHICAGO, V127, P1175; FOUCALT M, 1971, BIRTH CLIN, pR16; FRIEDMAN E, 1990, JAMA-J AM MED ASSOC, V264, P310, DOI 10.1001/jama.264.3.310; JAMES CB, 1993, RACE CLASS VIOLENCE; Jankowski Louis W., 1992, CORRECTIONAL POPULAT; KOLTS JG, 1992, LOS ANGELES COURTS S; KOOP CE, 1992, JAMA-J AM MED ASSOC, V267, P3075, DOI 10.1001/jama.267.22.3075; LEE B, 1992, OPPORTUNITY CHAOS GE; MARSHALL J, 1991, PIPE DREAMS BLUES RA; MOORE FA, 1992, J TRAUMA, V33, P58, DOI 10.1097/00005373-199207000-00012; Needlman R, 1990, Pediatr Rev, V11, P259; ORDOG GJ, 1983, J TRAUMA, V23, P832, DOI 10.1097/00005373-198309000-00008; ORDOG GJ, 1993, J TRAUMA, V34, P779, DOI 10.1097/00005373-199306000-00003; ORDOG GJ, 1993, MANAGEMENT GUNSHOT W; ORDOG GJ, IN PRESS J TRAUMA; PROTHROWSTITH D, 1991, DEADLY CONSEQUENCES; Rosenberg Mark L., 1991, VIOLENCE AM PUBLIC H; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SHOEMAKER WC, 1992, RATIONING AM MED CAR; SINGER A, CITED INDIRECTLY; STERN RS, 1991, JAMA-J AM MED ASSOC, V266, P2238, DOI 10.1001/jama.266.16.2238; STHEYER J, 1992, ANN REPORT CHILDREN; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; VIRCHOW R, CITED INDIRECTLY; WEBSTER W, 1992, CITY CRISIS; WEIL DS, 1992, JAMA-J AM MED ASSOC, V267, P3033, DOI 10.1001/jama.267.22.3033; WIGOD R, CITED INDIRECTLY; 1967, GOVERNORS COMMISSION, P1; 1992, JAMA-J AM MED ASSOC, V267, P3067	38	12	12	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1993	270	23					2833	2837		10.1001/jama.270.23.2833	http://dx.doi.org/10.1001/jama.270.23.2833			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MK941	8133623				2022-12-28	WOS:A1993MK94100033
J	ANDERSON, EL; BECHERER, PR; BELSHE, RB				ANDERSON, EL; BECHERER, PR; BELSHE, RB			REVACCINATION WITH PNEUMOCOCCAL AND HEPATITIS-B VACCINES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											ANDERSON, EL (corresponding author), ST LOUIS UNIV,ST LOUIS,MO 63103, USA.							1990, GUIDE ADULT IMMUNIZA, P16; 1991, MMWR MORB MORTAL WKL, V40, P42	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2735	2736						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	8133596				2022-12-28	WOS:A1993MJ82100038
J	REICHLIN, S				REICHLIN, S			NEUROENDOCRINE-IMMUNE INTERACTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CORTICOTROPIN-RELEASING FACTOR; RAT-BRAIN; MESSENGER-RNA; FOLLOW-UP; INTERLEUKIN-1; DEPRESSION; CYTOKINES; DISEASE; SYSTEM; STRESS				REICHLIN, S (corresponding author), TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, DEPT MED, 750 WASHINGTON ST, BOSTON, MA 02111 USA.				PHS HHS [16684] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADASHI EY, 1990, ENDOCR REV, V11, P454, DOI 10.1210/edrv-11-3-454; Ader R, 1991, PSYCHONEUROIMMUNOLOG; Ader R., 1991, PSYCHONEUROIMMUNOLOG, V2nd Edn, P611; ALTSTIEL LD, 1991, PROG NEURO-PSYCHOPH, V15, P481, DOI 10.1016/0278-5846(91)90023-T; ANTONI MH, 1991, BIOL PSYCHIAT, V29, P1023, DOI 10.1016/0006-3223(91)90359-T; BENVENISTE EN, 1992, NEUROIMMUNOENDOCRINO, P84; BLALOCK JE, 1989, PHYSIOL REV, V69, P1, DOI 10.1152/physrev.1989.69.1.1; BREDER CD, 1988, SCIENCE, V240, P321, DOI 10.1126/science.3258444; BRENT GA, 1986, J CLIN ENDOCR METAB, V63, P1; CANNON JG, 1986, J IMMUNOL, V137, P2232; CARR DJJ, 1992, NEUROIMMUNOENDOCRINO, P84; CASSILETH BR, 1985, NEW ENGL J MED, V312, P1551, DOI 10.1056/NEJM198506133122406; CHIKANZA IC, 1992, ARTHRITIS RHEUM, V35, P1281, DOI 10.1002/art.1780351107; Cousins N., 1979, ANATOMY ILLNESS; CROFFORD LJ, 1992, J CLIN INVEST, V90, P2555, DOI 10.1172/JCI116150; DEMITRACK MA, 1991, J CLIN ENDOCR METAB, V73, P1224, DOI 10.1210/jcem-73-6-1224; DENICOFF KD, 1987, ANN INTERN MED, V107, P293, DOI 10.7326/0003-4819-107-2-293; DESIMONI MG, 1990, J EXP MED, V171, P1773, DOI 10.1084/jem.171.5.1773; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DUPONT AG, 1984, J CLIN ENDOCR METAB, V58, P654, DOI 10.1210/jcem-58-4-654; EVANS DL, 1992, ARCH GEN PSYCHIAT, V49, P388; FAWZY FI, 1993, ARCH GEN PSYCHIAT, V50, P681; FAWZY FI, 1990, ARCH GEN PSYCHIAT, V47, P729; FELTEN DL, 1991, NEUR CONT B, V6, P3; FELTEN DL, 1985, J IMMUNOL, V135, pS755; FRIEDMAN WJ, 1990, J NEUROSCI RES, V27, P374, DOI 10.1002/jnr.490270316; GARDNER DF, 1979, NEW ENGL J MED, V300, P579, DOI 10.1056/NEJM197903153001102; GESCHWIND N, 1982, P NATL ACAD SCI-BIOL, V79, P5097, DOI 10.1073/pnas.79.16.5097; GUENARD V, 1991, J NEUROSCI RES, V29, P396, DOI 10.1002/jnr.490290315; GURNEY ME, 1986, SCIENCE, V234, P566, DOI 10.1126/science.3764429; HABICHT GS, 1991, J INFECT DIS, V164, P568, DOI 10.1093/infdis/164.3.568; HALL NR, 1985, J IMMUNOL, V135, pS806; IRWIN M, 1990, J PHARMACOL EXP THER, V255, P101; IRWIN M, 1990, BIOL PSYCHIAT, V27, P22, DOI 10.1016/0006-3223(90)90016-U; IRWIN M, 1992, PSYCHOSOM MED, V54, P10, DOI 10.1097/00006842-199201000-00002; KASL SV, 1979, PSYCHOSOM MED, V41, P445, DOI 10.1097/00006842-197910000-00002; KELLEY KW, 1992, BRAIN BEHAV IMMUN, V6, P317, DOI 10.1016/0889-1591(92)90031-I; KENNEDY RL, 1991, J ENDOCRINOL, V129, P167, DOI 10.1677/joe.0.1290167; KIDD BL, 1989, LANCET, V2, P1128; Kiecolt-Glaser JK, 1991, PSYCHONEUROIMMUNOLOG, P849; KOENIG JI, 1990, ENDOCRINOLOGY, V127, P657; KOENIG JI, 1990, ENDOCRINOLOGY, V126, P3053, DOI 10.1210/endo-126-6-3053; LECHAN RM, 1990, BRAIN RES, V514, P135, DOI 10.1016/0006-8993(90)90445-H; LECHAN RM, 1993, THYROID TODAY, P16; LICINIO J, 1991, ENDOCRINOLOGY, V129, P562, DOI 10.1210/endo-129-1-562; LIPTON JM, 1990, YALE J BIOL MED, V63, P173; MACLEAN D, 1981, PSYCHONEUROIMMUNOLOG, P475; MARTIN RL, 1985, ARCH GEN PSYCHIAT, V42, P58; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MRAZEK DA, 1991, PSYCHONEUROIMMUNOLOG, P1013; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; OLSEN NJ, 1992, ENDOCRINOLOGY, V130, P2113, DOI 10.1210/en.130.4.2113; Ottaway C. A., 1991, PSYCHONEUROIMMUNOLOG, P225; PANG XP, 1989, ENDOCRINOLOGY, V125, P76, DOI 10.1210/endo-125-1-76; PAYAN DG, 1986, ADV IMMUNOL, V39, P299; PERSKY VW, 1987, PSYCHOSOM MED, V49, P435, DOI 10.1097/00006842-198709000-00001; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; PULLIAM L, 1991, J CLIN INVEST, V87, P503, DOI 10.1172/JCI115024; RABKIN JG, 1991, ARCH GEN PSYCHIAT, V48, P111; RADA P, 1991, BRAIN RES, V550, P287, DOI 10.1016/0006-8993(91)91330-4; REICHLIN S, 1958, J EXP MED, V107, P219, DOI 10.1084/jem.107.2.219; REICHLIN S, IN PRESS ENDOCRINOLO; RISKIND PN, 1991, ANN NEUROL, V29, P542, DOI 10.1002/ana.410290514; RIVIER C, 1991, BIOL REPROD, V45, P523, DOI 10.1095/biolreprod45.4.523; ROMERO LI, 1991, 73RD ANN M END SOC W, P150; RUSSELL DH, 1989, TRENDS PHARMACOL SCI, V10, P40, DOI 10.1016/0165-6147(89)90106-5; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; SCARBOROUGH DE, 1989, ENDOCRINOLOGY, V124, P549, DOI 10.1210/endo-124-1-549; SCARBOROUGH DE, 1989, ENDOCRINOLOGY, V124, P2022; SCHOBITZ B, 1992, NEUROSCI LETT, V136, P189, DOI 10.1016/0304-3940(92)90046-A; SCHWARTZ RS, 1989, FUNDAMENTAL IMMUNOLO, P819; SHALTS E, 1992, ENDOCRINOLOGY, V131, P153, DOI 10.1210/en.131.1.153; Siegel BS, 1990, LOVE MED MIRACLES LE; SIMONTON OC, 1978, GETTING WELL AGAIN; SKINNER MK, 1991, ENDOCR REV, V12, P45, DOI 10.1210/edrv-12-1-45; Smith E., 1992, NEUROIMMUNOENDOCRINO, P154; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; SPIEGEL D, 1989, LANCET, V2, P888; STEIN M, 1991, ARCH GEN PSYCHIAT, V48, P171; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P4771, DOI 10.1073/pnas.86.12.4771; STERNBERG EM, 1992, ANN INTERN MED, V117, P854, DOI 10.7326/0003-4819-117-10-854; SUNDAR SK, 1991, P NATL ACAD SCI USA, V88, P11246, DOI 10.1073/pnas.88.24.11246; VANKELECOM H, 1989, NEUROENDOCRINOLOGY, V49, P102, DOI 10.1159/000125097; VITKOVIC L, 1990, J NEUROIMMUNOL, V30, P153, DOI 10.1016/0165-5728(90)90099-9; Weigent D.A., 1990, PROG NEUROENDOCRINIM, V3, P231; WEISS JM, 1992, REVPSYCHIATRY, V11, P145; ZONDERMAN AB, 1989, JAMA-J AM MED ASSOC, V262, P1191, DOI 10.1001/jama.262.9.1191	87	493	504	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1993	329	17					1246	1253						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB988	8105378				2022-12-28	WOS:A1993MB98800008
J	IGLEHART, JK				IGLEHART, JK			HEALTH-CARE REFORM AND GRADUATE MEDICAL-EDUCATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article																		Anders George, 1994, WALL STREET J   0826, pA1; BONDURANT S, 1994, COMMUNICATION   0126; CLYMER A, 1994, NY TIMES        0927, pA1; COHEN J, 1992, COMMUNICATION   1209; COHEN JJ, 1993, NEW ENGL J MED, V329, P1810, DOI 10.1056/NEJM199312093292412; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; KASSIRER JP, 1993, NEW ENGL J MED, V328, P648, DOI 10.1056/NEJM199303043280910; LEVINSKY NG, 1993, NEW ENGL J MED, V328, P656, DOI 10.1056/NEJM199303043280913; MULLAN F, 1993, HEALTH AFFAIR, V12, P138, DOI 10.1377/hlthaff.12.suppl_1.138; PURDUM TS, 1994, NY TIMES        0124, pA1; SCHROEDER SA, 1993, DOMESTIC AFFAIRS WIN, P105; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; 1993, ACADEMIC MED HLTH CA; 1993, PHYSICIAN PAYMENT RE, P55; 1993, PRIMARY CARE WORKFOR; 1993, TAKING CHARGE GRADUA; 1992, TASK FORCE GENERALIS; 1986, FINANCING GRADUATE M; 1980, DHHS HRA8151 DEP HLT	19	22	22	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 21	1994	330	16					1167	1171		10.1056/NEJM199404213301628	http://dx.doi.org/10.1056/NEJM199404213301628			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NF699	8133872				2022-12-28	WOS:A1994NF69900036
J	ANNAS, GJ				ANNAS, GJ			SCIENTIFIC EVIDENCE IN THE COURTROOM - THE DEATH OF THE FRYE RULE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS GJ, 1992, NEW ENGL J MED, V326, P1641, DOI 10.1056/NEJM199206113262418; DANIELS S, 1989, MED PROFESSIONAL LIA, V2, P161; FOSTER KR, 1993, SCIENCE, V261, P1509, DOI 10.1126/science.8372345; FOSTER KR, 1993, SCIENCE, V261, P1614; GOLD JA, 1993, JAMA-J AM MED ASSOC, V270, P2964, DOI 10.1001/jama.270.24.2964; GREEN ED, 1986, FEDERAL RULES EVIDEN; HUBER PW, 1991, GALILEOS REVENGE JUN, P111; JASANOFF S, 1992, JURIMETRICS J, V32, P345; RELMAN AS, 1989, NEW ENGL J MED, V321, P827, DOI 10.1056/NEJM198909213211211; TANOUYE E, 1993, WALL STREET J   0401, pB1	10	18	18	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 7	1994	330	14					1018	1021		10.1056/NEJM199404073301420	http://dx.doi.org/10.1056/NEJM199404073301420			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND793	8121456	Green Published			2022-12-28	WOS:A1994ND79300038
J	WATKINS, PB; ZIMMERMAN, HJ; KNAPP, MJ; GRACON, SI; LEWIS, KW				WATKINS, PB; ZIMMERMAN, HJ; KNAPP, MJ; GRACON, SI; LEWIS, KW			HEPATOTOXIC EFFECTS OF TACRINE ADMINISTRATION IN PATIENTS WITH ALZHEIMERS-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLE-BLIND; TETRAHYDROAMINOACRIDINE; MULTICENTER; TRIAL; LECITHIN	Objective.-To characterize the hepatic effects of tacrine treatment in patients with Alzheimer's disease. Design.-Controlled trials of tacrine therapy consisting of two blinded, parallel-group trials; three blinded, enrichment-design trials; and their respective open-label extensions. Setting.-Multicenter clinical trials in the United States, France, and Canada. Patients.-A total of 2446 men and women at least 50 years of age with a diagnosis of probable Alzheimer's disease of mild to moderate severity and in good health without significant hepatic, cardiovascular, or renal disease. Intervention.-Administration of tacrine vs placebo, with weekly measurement of serum hepatic enzymes. Main Outcome Measures.-Incidence, maximum severity, and timing of event for serum alanine aminotransferase (ALT) elevation. Results.-Among the 2446 patients who received tacrine in clinical trials, ALT levels greater than the upper limit of normal (ULN) occurred on at least one occasion in 1203 patients (49%), ALT levels greater than three times the ULN occurred in 621 patients (25%), and ALT levels greater than 20 times the ULN occurred in 40 patients (2%). The elevated ALT levels were generally asymptomatic and occurred more frequently in women than men. The mean time from initiation of tacrine treatment to first ALT level greater than three times the ULN was 50 days, and 90% of all initial ALT levels greater than three times the ULN occurred during the first 12 weeks of treatment. Of 145 patients who discontinued tacrine treatment because of an ALT level greater than three times the ULN and were rechallenged, 127 (88%) were able to resume long-term therapy with the drug. In all instances, discontinuing tacrine completely reversed elevations in ALT levels, and no deaths related to hepatotoxicity occurred. Conclusions.-These data suggest that the potential for serious hepatic toxicity can be reduced through careful monitoring of ALT levels in patients who may benefit from tacrine therapy.	PARKE DAVIS & CO,PHARMACEUT RES,CLIN RES DEPT,ANN ARBOR,MI 48106; PARKE DAVIS & CO,PHARMACEUT RES,DEPT BIOMETR,ANN ARBOR,MI 48106; GEORGE WASHINGTON UNIV,WASHINGTON,DC 20052; ARMED FORCES INST PATHOL,WASHINGTON,DC 20306	Pfizer; Pfizer; George Washington University; United States Department of Defense	WATKINS, PB (corresponding author), UNIV MICHIGAN HOSP,MED CTR,DEPT INTERNAL MED,A7119,1500 E MED CTR DR,ANN ARBOR,MI 48109, USA.							AMES DJ, 1990, AUST NZ J MED, V20, P193, DOI 10.1111/j.1445-5994.1990.tb01309.x; CHATELLIER G, 1990, BRIT MED J, V300, P495, DOI 10.1136/bmj.300.6723.495; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; DEVINE BJ, 1974, DRUG INTEL CLIN PHAR, V8, P650, DOI 10.1177/106002807400801104; Devries T. M., 1993, Pharmaceutical Research (New York), V10, pS333; DEVRIES TM, 1993, PHARM RES-DORDR, V10, pS377; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; EAGGER SA, 1991, LANCET, V337, P989, DOI 10.1016/0140-6736(91)92656-M; FARLOW M, 1992, JAMA-J AM MED ASSOC, V268, P2523, DOI 10.1001/jama.268.18.2523; FORD JM, 1993, CLIN PHARMACOL THER, V53, P691, DOI 10.1038/clpt.1993.91; FORSYTH DR, 1989, CLIN PHARMACOL THER, V46, P634, DOI 10.1038/clpt.1989.199; GAUTHIER S, 1990, NEW ENGL J MED, V322, P1272, DOI 10.1056/NEJM199005033221804; HAMMEL P, 1990, J CLIN GASTROENTEROL, V12, P329, DOI 10.1097/00004836-199006000-00021; KNAPP MJ, 1994, JAMA-J AM MED ASSOC, V271, P985, DOI 10.1001/jama.271.13.985; MADDEN S, 1993, BIOCHEM PHARMACOL, V46, P13, DOI 10.1016/0006-2952(93)90342-T; MARX JL, 1987, SCIENCE, V238, P1041, DOI 10.1126/science.3317822; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; SUMMERS WK, 1989, LANCET, V1, P729, DOI 10.1016/s0140-6736(89)92246-0; SUMMERS WK, 1988, CURRENT RES ALZHEIME, P259; WATKINS PB, 1992, GASTROENTEROL CLIN N, V21, P511; Welty Devin, 1993, Pharmaceutical Research (New York), V10, pS334	22	638	651	6	37	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	1994	271	13					992	998		10.1001/jama.271.13.992	http://dx.doi.org/10.1001/jama.271.13.992			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND949	8139084				2022-12-28	WOS:A1994ND94900028
J	GROSSMAN, DC; KRIEGER, JW; SUGARMAN, JR; FORQUERA, RA				GROSSMAN, DC; KRIEGER, JW; SUGARMAN, JR; FORQUERA, RA			HEALTH-STATUS OF URBAN AMERICAN-INDIANS AND ALASKA NATIVES - A POPULATION-BASED STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To use vital statistics and communicable disease reports to characterize the health status of an urban American Indian and Alaska Native (Al/AN) population and compare it with urban whites and African Americans and with Al/ ANs living on or near rural reservations. Design.-Descriptive analysis of routinely reported data. Setting.-One metropolitan county and seven rural counties with reservation land in Washington State. Subjects.-All reported births, deaths, and cases of selected communicable diseases occurring in the eight counties from 1981 through 1990. Main Outcome Measures.-Low birth weight, infant mortality, and prevalence of risk factors for poor birth outcomes; age-specific and cause-specific mortality; rates of reported hepatitis A and hepatitis B, tuberculosis, and sexually transmitted diseases. Results.-Urban Al/ANs had a much higher rate of low birth weight compared with urban whites and rural Al/ANs and had a higher rate of infant mortality than urban whites. During the 10 years, urban Al/AN infant mortality rates increased from 9.6 per 1000 live births to 18.6 per 1000 live births compared with no trend among the other populations. Compared with rural Al/AN mothers, urban Al/AN mothers were 50% more likely to receive late or no prenatal care during pregnancy. Relative to urban whites, urban Al/AN risk factors for poor birth outcomes (delayed prenatal care, adolescent age, and use of tobacco and alcohol) were more common and closely resembled the prevalence among the African-American population except for a higher rate of alcohol use among Al/ANs. Compared with urban whites, urban Al/AN mortality rates were higher in every age group except the elderly. Differences between urban whites and Al/ANs were largest for injury- and alcohol-related deaths. All-cause mortality was lower among urban Al/ANs compared with rural Al/ANs and urban African Americans, although injury- and alcohol-related deaths were higher for Al/ANs. All communicable diseases studied were significantly (P<.05) more common among urban Al/ANs compared with whites. Tuberculosis rates were highest in the urban Al/AN group, but rates of sexually transmitted diseases were intermediate between urban whites and African Americans. Conclusions.-In this urban area, great disparities exist between the health of Al/ANs and whites across almost every health dimension we measured. No consistent pattern was found in the comparison of health indicators between urban and rural Al/ANs, though rural Al/ANs had lower rates of low birth weight and higher rates of timely prenatal care use. The poor health status of urban Al/AN people requires greater attention from federal, state, and local health authorities.	UNIV WASHINGTON, SCH MED, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT FAMILY MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH PUBL HLTH, DEPT HLTH SERV, SEATTLE, WA 98195 USA; SEATTLE KING CTY DEPT PUBL HLTH, SEATTLE, WA USA; PORTLAND AREA INDIAN HLTH SERV, DIV RES EVALUAT & EPIDEMIOL, SEATTLE, WA USA; SEATTLE INDIAN HLTH BOARD, SEATTLE, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	GROSSMAN, DC (corresponding author), HARBORVIEW MED CTR, 325 9TH AVE, ZX-10, SEATTLE, WA 98104 USA.		Duran, Bonnie m/A-3029-2009	Sugarman, Jonathan/0000-0001-5588-0250				BAKER SP, 1992, INJURY FACT BOOK, P224; CHIANG CL, 1961, VITAL STATISTICS SPE, V47, P275; Fleiss JL, 1981, STAT METHODS RATES P; FROST F, 1992, J NATL CANCER I, V84, P957, DOI 10.1093/jnci/84.12.957; HAHN RA, 1992, JAMA-J AM MED ASSOC, V267, P259, DOI 10.1001/jama.267.2.259; HURLICH MG, 1992, IHS PRIMARY CARE PRO, V17, P73; KRAMER BJ, 1992, WESTERN J MED, V157, P281; PASSEL JS, 1986, SOC BIOL, V33, P163; PRUCHA FP, 1990, DOCUMENTS US INDIAN, P237; RHOADES ER, 1987, PUBLIC HEALTH REP, V102, P361; SHULTZ JM, 1991, PUBLIC HEALTH REP, V106, P443; SUGARMAN JR, 1993, AM J PUBLIC HEALTH, V83, P681, DOI 10.2105/AJPH.83.5.681; SUGARMAN JR, 1993, AM J KIDNEY DIS, V21, P383, DOI 10.1016/S0272-6386(12)80265-4; SUGARMAN JR, 1992, IHS PROVIDER, V17, P113; TAYLOR TL, 1988, PUBLIC HEALTH REP, V103, P88; 1990, 1990 CENSUS POPULATI; 1986, US DHHS OTAH290 PUBL; 1993, MMWR MORB MORTAL WKL, V42, P220; 1985, REPORTJ SECRETARYS T, V1; 1977, 9TH REV C 1975 GEN; US DHHS PHS931446 PU	21	84	84	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					845	850		10.1001/jama.271.11.845	http://dx.doi.org/10.1001/jama.271.11.845			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ498	8114239				2022-12-28	WOS:A1994MZ49800031
J	PATEL, A; GETSOS, J				PATEL, A; GETSOS, J			OSBORN WAVES OF HYPOTHERMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PATEL, A (corresponding author), JERSEY CITY MED CTR,JERSEY CITY,NJ 07304, USA.								0	22	24	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 10	1994	330	10					680	680						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY575	8107718				2022-12-28	WOS:A1994MY57500005
J	STRYKER, MP				STRYKER, MP			PRECISE DEVELOPMENT FROM IMPRECISE RULES	SCIENCE			English	Editorial Material							CELLS				STRYKER, MP (corresponding author), UNIV CALIF SAN FRANCISCO,WM KECK FDN CTR INTERGRAT NEUROSCI,SAN FRANCISCO,CA 94143, USA.			Stryker, Michael/0000-0003-1546-5831				GALLI L, 1988, SCIENCE, V242, P90, DOI 10.1126/science.3175637; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; KAAS J H, 1972, Brain Behavior and Evolution, V6, P253, DOI 10.1159/000123713; KUNES S, 1993, J NEUROSCI, V13, P752; LEE DY, 1994, SCIENCE, V263, P1292, DOI 10.1126/science.8122115; MASTRONARDE DN, 1987, J NEUROPHYSIOL, V57, P381, DOI 10.1152/jn.1987.57.2.381; MEINERTZHAGEN IA, 1973, DEV NEUROBIOLOGY ART, P52; RAKIC P, 1991, P NATL ACAD SCI USA, V88, P2083, DOI 10.1073/pnas.88.6.2083; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; Thompson D. W., 1917, GROWTH FORM; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8	12	7	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 4	1994	263	5151					1244	1245		10.1126/science.8122106	http://dx.doi.org/10.1126/science.8122106			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	8122106				2022-12-28	WOS:A1994MY57000025
J	SELHUB, J; JACQUES, PF; WILSON, PWF; RUSH, D; ROSENBERG, IH				SELHUB, J; JACQUES, PF; WILSON, PWF; RUSH, D; ROSENBERG, IH			VITAMIN STATUS AND INTAKE AS PRIMARY DETERMINANTS OF HOMOCYSTEINEMIA IN AN ELDERLY POPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLASMA HOMOCYST(E)INE; VASCULAR-DISEASE; RISK FACTOR; INFARCTION; HEALTH; ASSAY	Objective.-To describe the distribution of plasma homocysteine concentrations in an elderly population and to analyze the relationship between homocysteine level and intake of vitamins and serum levels of vitamins that serve as coenzymes in homocysteine metabolism. Design.-Cross-sectional analysis of homocysteine levels and vitamin blood levels and intake in elderly participants in the Framingham Study. Setting.-Population-based cohort in Framingham, Mass. Participants.-A total of 1160 adult survivors, aged 67 to 96 years, from the original Framingham Heart Study cohort. Main Outcome Measures.-Plasma homocysteine concentration correlated with plasma folate, vitamin B-12, pyridoxal-5'-phosphate (PLP), and oral intakes of these vitamins, and the contribution of these vitamins to the prevalence of elevated homocysteine in the population. Results.-Homocysteine levels were positively correlated with age after controlling for vitamin concentrations. After controlling for age, sex, and levels of other vitamins, homocysteine exhibited a strong inverse association with plasma folate. When subjects were grouped by deciles of plasma folate, mean homocysteine was significantly higher in the lowest two folate deciles (1 5.6 and 1 3.7 mumol/L, respectively) than in the highest decile (11.0 mumol/L). Homocysteine demonstrated weaker, inverse associations with plasma vitamin B-12 and PLP. Similar inverse associations were demonstrated between homocysteine and intakes of folate and vitamin B-6, but not vitamin B-12. Prevalence of high homocysteine (> 14 mumol/L) was 29.3% in this cohort, and was greatest among subjects with low folate status. Inadequate plasma concentrations of one or more B vitamins appear to contribute to 67% of the cases of high homocysteine. Conclusions.-These results indicate a strong association between homocysteine concentration and folate, vitamin B-12, and vitamin B-6 status, as well as age. It is possible that a substantial majority of the cases of high homocysteine in this older population can be attributed to vitamin status.	FRAMINGTON MASS HEART STUDY, FRAMINGHAM, MA USA		SELHUB, J (corresponding author), TUFTS UNIV, USDA, HUMAN NUTR RES CTR AGING, 711 WASHINGTON ST, BOSTON, MA 02111 USA.		Wilson, Peter W.F./J-2455-2016					ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; ARAKI A, 1989, ATHEROSCLEROSIS, V79, P139, DOI 10.1016/0021-9150(89)90118-4; BRATTSTROM L, 1990, ATHEROSCLEROSIS, V81, P51, DOI 10.1016/0021-9150(90)90058-Q; CAMP VM, 1983, CLIN CHEM, V29, P642; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; DAWBER T. R., 1957, AMER JOUR PUBL HEALTH, V47, P4, DOI 10.2105/AJPH.47.4_Pt_2.4; GARTLER SM, 1981, P NATL ACAD SCI-BIOL, V78, P1916, DOI 10.1073/pnas.78.3.1916; GENEST JJ, 1990, J AM COLL CARDIOL, V16, P1114, DOI 10.1016/0735-1097(90)90542-W; JACQUES PF, 1993, AM J CLIN NUTR, V57, P182, DOI 10.1093/ajcn/57.2.182; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; MCCULLY KS, 1969, AM J PATHOL, V56, P111; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; ROTHHMAN KJ, 1986, MODERN EPIDEMIOLOGY; RUSSELL RM, 1992, AM J CLIN NUTR, V55, P1203; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; TAMURA T, 1990, CLIN CHEM, V36, P1993; UELAND PM, 1989, J LAB CLIN MED, V114, P473; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; Willett W, 1990, NUTR EPIDEMIOLOGY, P92	20	1602	1663	1	44	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2693	2698		10.1001/jama.270.22.2693	http://dx.doi.org/10.1001/jama.270.22.2693			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	8133587				2022-12-28	WOS:A1993MJ82100028
J	DOLLE, P; DIERICH, A; LEMEUR, M; SCHIMMANG, T; SCHUHBAUR, B; CHAMBON, P; DUBOULE, D				DOLLE, P; DIERICH, A; LEMEUR, M; SCHIMMANG, T; SCHUHBAUR, B; CHAMBON, P; DUBOULE, D			DISRUPTION OF THE HOXD-13 GENE INDUCES LOCALIZED HETEROCHRONY LEADING TO MICE WITH NEOTENIC LIMBS	CELL			English	Article							HOMEOBOX GENE; PATTERN-FORMATION; HOMEOTIC TRANSFORMATIONS; POSITIONAL INFORMATION; DEVELOPMENTAL DEFECTS; TARGETED DISRUPTION; ECTOPIC EXPRESSION; VERTEBRATE LIMB; HOX-4 GENES; STEM-CELLS	Vertebrate Hoxd genes are sequentially activated during the morphogenesis and pattern formation of the limb. Using the approach of gene disruption via homologous recombination in embryonic stem cells, we have assessed the function of the last gene of the complex, Hoxd-13. Mutant mice displayed skeletal alterations along all body axes suggesting the existence of a general multiaxial patterning system. In limbs, abnormalities such as a reduction in the length of some bony elements, loss of phalanges, bone fusions, and the presence of an extra element were observed. We propose that the mutation induces local heterochrony, as illustrated by an important retardation in limb-morphogenesis. The relevance of these observations to our understanding of the development and evolution of the tetrapod limb is discussed.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG 1,GERMANY	European Molecular Biology Laboratory (EMBL)	DOLLE, P (corresponding author), FAC MED STRASBOURG,CNRS,GENET MOLEC EUCARYOTES,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE.		Dolle, Pascal/A-8037-2010; Schimmang, Thomas/Z-2834-2019	Dolle, Pascal/0000-0002-9294-9090; Schimmang, Thomas/0000-0002-3801-1640; duboule, denis/0000-0001-9961-2960				ALBERCH P, 1983, J EMBRYOL EXP MORPH, V76, P177; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; BASTIAN H, 1992, MAMM GENOME, V3, P241, DOI 10.1007/BF00355726; BURKE AC, 1985, J MORPHOL, V186, P119, DOI 10.1002/jmor.1051860111; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; DOLLE P, 1991, MECH DEVELOP, V36, P3, DOI 10.1016/0925-4773(91)90067-G; DOLLE P, 1991, GENE DEV, V5, P1767, DOI 10.1101/gad.5.10.1767; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DOLLE P, 1993, IN PRESS ADV DEV BIO, V2; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; DUBOULE D, 1992, BIOESSAYS, V14, P375, DOI 10.1002/bies.950140606; Garstang W., 1922, Journal of the Linnean Society Zoology, V35, P81; GAUNT SJ, 1988, DEVELOPMENT S, V104, P71; GLUCKSMANN A, 1976, J ANAT, V121, P363; Gould S. J., 1977, ONTOGENY PHYLOGENY; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HARDING K, 1985, SCIENCE, V229, P1236, DOI 10.1126/science.3898362; Hinchliffe J. R., 1980, DEV VERTEBRATE LIMB; HINCHLIFFE JR, 1983, DEV EVOLUTION, P99; Holland P.W.H., 1990, Seminars in Developmental Biology, V1, P135; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V94, P257; HURIE JM, 1991, DEV PATTERNING VERTE; IZPISUABELMONTE JC, 1992, DEV BIOL, V152, P26, DOI 10.1016/0012-1606(92)90153-8; IZPISUABELMONTE JC, 1992, DEVELOPMENT, V115, P553; IZPISUABELMONTE JC, 1992, EMBO J, V11, P1451, DOI 10.1002/j.1460-2075.1992.tb05189.x; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LEWIS J, 1989, NATURE, V342, P734, DOI 10.1038/342734a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MORGANBA, 1992, NATURE, V358, P236; Muller G., 1991, DEV PATTERNING VERTE; MULLER GB, 1990, J MORPHOL, V203, P151, DOI 10.1002/jmor.1052030204; OLIVER G, 1989, GENE DEV, V3, P641, DOI 10.1101/gad.3.5.641; OSTER GF, 1985, J EMBRYOL EXP MORPH, V89, P93; OSTER GF, 1983, J EMBRYOL EXP MORPH, V78, P83; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SHUBIN N, 1991, DEV PATTERNING VERTE; SHUBIN NH, 1986, EVOL BIOL, V20, P319; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SOLURSH M, 1984, CELL DIFFER DEV, V15, P17, DOI 10.1016/0045-6039(84)90025-3; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TABIN CJ, 1992, DEVELOPMENT, V116, P289; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; Wolpert L, 1975, Ciba Found Symp, V0, P95; WOLPERT L, 1989, DEVELOPMENT, V107, P3; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0; [No title captured]	62	405	412	0	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 5	1993	75	3					431	441		10.1016/0092-8674(93)90378-4	http://dx.doi.org/10.1016/0092-8674(93)90378-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MF830	8106170				2022-12-28	WOS:A1993MF83000006
J	DOBSON, A; CARPER, R				DOBSON, A; CARPER, R			BIODIVERSITY	LANCET			English	Article							CALIFORNIA; VIRUS		JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT IMMUNOL & INFECT DIS, BALTIMORE, MD 21218 USA	Johns Hopkins University	DOBSON, A (corresponding author), PRINCETON UNIV, PRINCETON, NJ 08544 USA.							ANDERSON R M, 1991; BELL EA, 1993, PARASITOLOGY, V106, pS47, DOI 10.1017/S003118200008611X; BUCHER EH, 1981, NEW SCI, V92, P321; DOBSON A, 1991, TRENDS ECOL EVOL, V6, P348, DOI 10.1016/0169-5347(91)90223-K; Dobson A., 1992, Global warming and biological diversity., P201; EPSTEIN PR, 1993, LANCET, V341, P1404, DOI 10.1016/0140-6736(93)90962-G; KRAMER LD, 1983, AM J TROP MED HYG, V32, P1130, DOI 10.4269/ajtmh.1983.32.1130; NEWTON P, 1991, TRENDS ECOL EVOL, V6, P297, DOI 10.1016/0169-5347(91)90009-M; Pritchard G., 1985, P237; RALISOA O, 1992, PARASITOLOGIA, V33, P219; REEVES WC, IN PRESS J MED ENTOM; REISEN WK, 1993, J MED ENTOMOL, V30, P151, DOI 10.1093/jmedent/30.1.151; REISEN WK, 1992, J MED ENTOMOL, V29, P582, DOI 10.1093/jmedent/29.4.582; SKOLE D, 1993, SCIENCE, V260, P1905, DOI 10.1126/science.260.5116.1905; Thomas R.J., 1974, Symposia Br Soc Parasit, V12, P13; WALSH JF, 1993, PARASITOLOGY, V106, pS55, DOI 10.1017/S0031182000086121; WASHBURN JO, 1992, J MED ENTOMOL, V29, P995, DOI 10.1093/jmedent/29.6.995; Wilson R.A., 1982, P262	18	41	44	2	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 30	1993	342	8879					1096	1099		10.1016/0140-6736(93)92069-6	http://dx.doi.org/10.1016/0140-6736(93)92069-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105317				2022-12-28	WOS:A1993ME82200015
J	SMIRNOVA, T; STINNAKRE, J; MALLET, J				SMIRNOVA, T; STINNAKRE, J; MALLET, J			CHARACTERIZATION OF A PRESYNAPTIC GLUTAMATE-RECEPTOR	SCIENCE			English	Article							AMINO-ACID RECEPTORS; NMDA RECEPTOR; XENOPUS OOCYTES; BOVINE BRAIN; PROTEIN; CLONING; NEURONS; CHANNEL; PHARMACOLOGY; SELECTIVITY	Glutamate receptors mediate excitatory neurotransmission in the brain and are important in the formation of memory and in some neurodegenerative disorders. A complementary DNA clone that encoded a 33-kilodalton protein (GR33) was obtained by screening a library with an antibody generated against glutamate binding proteins. The sequence of GR33 is identical to that of the recently reported presynaptic protein syntaxin. When GR33 was expressed in Xenopus oocytes, it formed glutamate-activated ion channels that are pharmacologically similar to those of N-methyl-D-aspartate receptors but with different electrophysiological properties. Mutation of the leucine 278 residue in the single putative transmembrane segment of GR33 affects the properties of the channel. Thus, in vivo GR33 may be a presynaptic glutamate receptor.	LAB GENET MOLEC NEUROTRANSMISS & PROC, NEURODEGENERAT, CNRS, C9923, F-91198 GIF SUR YVETTE, FRANCE; LAB NEUROBIOL CELLULAIRE & MOLEC, CNRS, F-91198 GIF SUR YVETTE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BUSTOS G, 1992, BRAIN RES, V585, P105, DOI 10.1016/0006-8993(92)91195-K; CHERNEVSKAYA NI, 1991, NATURE, V349, P418, DOI 10.1038/349418a0; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; CROUCHER MJ, 1982, SCIENCE, V216, P899, DOI 10.1126/science.7079744; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; GROSS RA, 1989, J PHYSIOL-LONDON, V411, P585, DOI 10.1113/jphysiol.1989.sp017592; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; INOUE A, 1992, BIOCHEM BIOPH RES CO, V187, P1144, DOI 10.1016/0006-291X(92)91316-I; INOUE A, 1992, J BIOL CHEM, V267, P10613; KURE S, 1991, BIOCHEM BIOPH RES CO, V179, P39, DOI 10.1016/0006-291X(91)91330-F; MICHAELIS EK, 1984, J NEUROCHEM, V42, P397, DOI 10.1111/j.1471-4159.1984.tb02691.x; MILEDI R, 1982, BIOMED RES-TOKYO, V3, P390, DOI 10.2220/biomedres.3.390; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OLNEY JW, 1990, ANNU REV PHARMACOL, V30, P47; PFEIFFERLINN C, 1991, SYNAPSE, V9, P35, DOI 10.1002/syn.890090106; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; VERDOORN TA, 1988, MOL PHARMACOL, V34, P298	24	99	104	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1993	262	5132					430	433		10.1126/science.8105537	http://dx.doi.org/10.1126/science.8105537			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	8105537				2022-12-28	WOS:A1993MB85900061
J	MAILMAN, DR				MAILMAN, DR			TO RESPOND ALWAYS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											MAILMAN, DR (corresponding author), TEXAS TECH UNIV, HLTH SCI CTR, DEPT INTERNAL MED, 3601 4TH ST, LUBBOCK, TX 79430 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1994	120	8					688	688		10.7326/0003-4819-120-8-199404150-00011	http://dx.doi.org/10.7326/0003-4819-120-8-199404150-00011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE850	8135455				2022-12-28	WOS:A1994NE85000011
J	SMITH, CA; FARRAH, T; GOODWIN, RG				SMITH, CA; FARRAH, T; GOODWIN, RG			THE TNF RECEPTOR SUPERFAMILY OF CELLULAR AND VIRAL-PROTEINS - ACTIVATION, COSTIMULATION, AND DEATH	CELL			English	Review							TUMOR-NECROSIS-FACTOR; VIRUS; FAMILY; MICE; LPR; GLD		IMMUNEX CORP,DEPT MOLEC BIOL,SEATTLE,WA 98101	Immunex Corporation	SMITH, CA (corresponding author), IMMUNEX CORP,DEPT BIOCHEM,SEATTLE,WA 98101, USA.							ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; ALLEN RD, 1990, J EXP MED, V172, P1367, DOI 10.1084/jem.172.5.1367; BAENS M, 1993, GENOMICS, V16, P214, DOI 10.1006/geno.1993.1161; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; CALLARD R, 1993, IMMUNOL TODAY, V564, P559; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ECK MJ, 1992, J BIOL CHEM, V267, P2119; FARRAH T, 1992, NATURE, V358, P26, DOI 10.1038/358026b0; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; MAPARA MY, 1993, EUR J IMMUNOL, V23, P702, DOI 10.1002/eji.1830230320; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; SCHOENFELD H, 1990, J BIOL CHEM, V266, P3863; SHCHELKUNOV SN, 1993, FEBS LETT, V319, P80, DOI 10.1016/0014-5793(93)80041-R; SIDMAN CL, 1992, EUR J IMMUNOL, V22, P499, DOI 10.1002/eji.1830220231; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	26	1819	1965	0	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					959	962		10.1016/0092-8674(94)90372-7	http://dx.doi.org/10.1016/0092-8674(94)90372-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137429				2022-12-28	WOS:A1994ND24600001
J	ZASADZINSKI, JA; VISWANATHAN, R; MADSEN, L; GARNAES, J; SCHWARTZ, DK				ZASADZINSKI, JA; VISWANATHAN, R; MADSEN, L; GARNAES, J; SCHWARTZ, DK			LANGMUIR-BLODGETT-FILMS	SCIENCE			English	Review							ATOMIC FORCE MICROSCOPY; AIR-WATER-INTERFACE; MOLECULAR-RESOLUTION IMAGES; FIELD ELECTRON-MICROSCOPY; X-RAY-DIFFRACTION; REENTRANT APPEARANCE; INSOLUBLE MONOLAYERS; PHASE-TRANSITIONS; ORGANIC MONOLAYER; LIPID MONOLAYERS	The controlled transfer of organized monolayers of amphiphilic molecules from the air-water interface to a solid substrate was the first molecular-scale technology for the creation of new materials. However, the potential benefits of the technology envisioned by Langmuir and Blodgett in the 1930s have yet to be fully realized. Problems of reproducibility and defects and the lack of basic understanding of the packing of complex molecules in thin films have continued to thwart practical applications of Langmuir-Blodgett films and devices made from such films. However, modern high-resolution x-ray diffraction and scanning probe microscopy have proven to be ideal tools to resolve many of the basic questions involving thin organic films. Here, studies are presented of molecular order and organization in thin films of fatty acid salts, the prototypical system of Katharine Blodgett. Even these relatively simple systems present liquid, hexatic, and crystalline order; van der Waals and strained layer epitaxy on various substrates; wide variations in crystal symmetry and interfacial area with counterions; modulated superstructures; and coexisting lattice structures. The wide variety of possible structures presents both a challenge and an opportunity for future molecular design of organic thin-film devices.	DANISH INST FUNDAMENTAL METROL,DK-2800 LYNGBY,DENMARK; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024	Danish Fundamental Metrology; University of California System; University of California Los Angeles	ZASADZINSKI, JA (corresponding author), UNIV CALIF SANTA BARBARA,DEPT CHEM & NUCL ENGN,SANTA BARBARA,CA 93106, USA.		Petty, Michael C/C-4699-2012	Petty, Michael C/0000-0001-5783-678X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047334] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 47334] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn D.J., 1991, J CHEM PHYS, V95, P8486, DOI 10.1063/1.461278; BAREMAN JP, 1988, PHYS REV LETT, V60, P2152, DOI 10.1103/PhysRevLett.60.2152; BINKS BP, 1991, ADV COLLOID INTERFAC, V34, P343, DOI 10.1016/0001-8686(91)80053-M; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BOHM C, 1989, THIN SOLID FILMS, V178, P511, DOI 10.1016/0040-6090(89)90346-5; BONNEROT A, 1985, J CHEM PHYS, V87, P365; BOURDIEU L, 1991, PHYS REV LETT, V67, P2029, DOI 10.1103/PhysRevLett.67.2029; BOURDIEU L, 1993, SCIENCE, V259, P798, DOI 10.1126/science.259.5096.798; CARLSON JM, 1987, PHYS REV A, V36, P3359, DOI 10.1103/PhysRevA.36.3359; CHI LF, 1993, SCIENCE, V259, P213, DOI 10.1126/science.259.5092.213; DARST SA, 1988, J MOL BIOL, V203, P269, DOI 10.1016/0022-2836(88)90107-6; ECKHARDT CJ, 1993, NATURE, V362, P614, DOI 10.1038/362614a0; ECKHARDT CJ, 1992, LANGMUIR, V8, P2591, DOI 10.1021/la00047a003; ECKHARDT CJ, 1992, CHEM PHYS LETT, V194, P370, DOI 10.1016/0009-2614(92)86067-R; EGGER M, 1990, J STRUCT BIOL, V103, P89, DOI 10.1016/1047-8477(90)90089-U; FISCHETTI RF, 1988, PHYS REV B, V37, P4788, DOI 10.1103/PhysRevB.37.4788; FLORSHEIMER M, 1993, SURF SCI, V297, pL39, DOI 10.1016/0039-6028(93)90002-2; FROMMER J, 1992, ANGEW CHEM INT EDIT, V31, P1298, DOI 10.1002/anie.199212981; FRYER JR, 1985, NATURE, V313, P382, DOI 10.1038/313382a0; GARNAES J, 1993, J SYNTHETIC METALS, V57, P3795; GARNAES J, UNPUB; GARNAES J, 1992, NATURE, V357, P5; GAROFF S, 1986, J PHYS-PARIS, V47, P701, DOI 10.1051/jphys:01986004704070100; GOETTGENS BM, 1992, LANGMUIR, V8, P1768, DOI 10.1021/la00043a014; HANSMA HG, 1991, LANGMUIR, V7, P1051, DOI 10.1021/la00054a005; HENON S, 1991, REV SCI INSTRUM, V62, P936, DOI 10.1063/1.1142032; HONIG D, 1992, ADV MATER, V4, P419, DOI 10.1002/adma.19920040610; HUI S, UNPUB; Israelachvili J. N., 1992, INTERMOLECULAR SURFA, V2; JOSEFOWICZ JY, 1993, SCIENCE, V260, P323, DOI 10.1126/science.260.5106.323; KARABORNI S, 1992, J PHYS CHEM-US, V96, P4965, DOI 10.1021/j100191a044; Kitaigorodskii A.I., 1961, ORGANIC CHEM CRYSTAL; KJAER K, 1987, PHYS REV LETT, V58, P2224, DOI 10.1103/PhysRevLett.58.2224; KNOBLER CM, 1990, ADV CHEM PHYS, V77, P398; KOBAYASHI K, 1988, THIN SOLID FILMS, V159, P267, DOI 10.1016/0040-6090(88)90638-4; KOMA A, 1989, APPL SURF SCI, V41-2, P451, DOI 10.1016/0169-4332(89)90102-5; LEVEILLER F, 1991, SCIENCE, V252, P1532, DOI 10.1126/science.252.5012.1532; LUK SY, 1990, THIN SOLID FILMS, V186, P147, DOI 10.1016/0040-6090(90)90508-B; MAJEWSKI J, 1993, SCIENCE, V261, P899, DOI 10.1126/science.261.5123.899; MANN S, 1993, SCIENCE, V261, P1286, DOI 10.1126/science.261.5126.1286; MARTI O, 1988, SCIENCE, V239, P50, DOI 10.1126/science.3336773; MCCONNELL HM, 1991, ANNU REV PHYS CHEM, V42, P171, DOI 10.1146/annurev.physchem.42.1.171; MEYER E, 1991, NATURE, V349, P398, DOI 10.1038/349398a0; MEYER E, 1992, PHYS REV LETT, V69, P1777, DOI 10.1103/PhysRevLett.69.1777; MIKRUT JM, 1993, PHYS REV B, V48, P14479, DOI 10.1103/PhysRevB.48.14479; MOHWALD H, 1990, ANNU REV PHYS CHEM, V41, P441, DOI 10.1146/annurev.pc.41.100190.002301; MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299; OHUCHI FS, 1990, J APPL PHYS, V68, P2168, DOI 10.1063/1.346574; OUTKA DA, 1987, PHYS REV LETT, V59, P1321, DOI 10.1103/PhysRevLett.59.1321; OVERNEY RM, 1992, NATURE, V359, P133, DOI 10.1038/359133a0; PAULING L, 1960, NATURE CHEM BOND, P43; PEARSON C, 1993, ELECTRON LETT, V29, P1377, DOI 10.1049/el:19930922; PELLTONEN JPK, 1993, LANGMUIR, V9, P2363; PELTONEN JPK, 1992, J AM CHEM SOC, V114, P7637, DOI 10.1021/ja00046a005; PETERSON IR, 1990, J PHYS-PARIS, V51, P1003, DOI 10.1051/jphys:0199000510100100300; PIKE JK, 1993, J AM CHEM SOC, V115, P8497, DOI 10.1021/ja00071a089; PRAKASH M, 1984, CHEM PHYS LETT, V111, P395, DOI 10.1016/0009-2614(84)85527-X; PUTNAM CAJ, 1992, LANGMUIR, V8, P3014; QUI X, 1991, PHYS REV LETT, V67, P703; RADMACHER M, 1992, SCIENCE, V257, P1900, DOI 10.1126/science.1411505; RIBI HO, 1988, SCIENCE, V239, P1272, DOI 10.1126/science.3344432; RIES HE, 1976, J COLLOID INTERF SCI, V57, P396, DOI 10.1016/0021-9797(76)90216-2; RIES HE, 1961, SCI AM, V204, P152, DOI 10.1038/scientificamerican0361-152; RIES HE, 1975, ADV CHEM SER, V144, P286; ROBERTS GG, 1990, LANGMUIRBLODGETT FIL; RUGAR D, 1990, PHYS TODAY, V43, P23, DOI 10.1063/1.881238; SAFRAN SA, 1986, PHYS REV A, V33, P2186, DOI 10.1103/PhysRevA.33.2186; SCHLOSSMAN ML, 1991, PHYS REV LETT, V66, P1599, DOI 10.1103/PhysRevLett.66.1599; SCHWARTZ DA, UNPUB; SCHWARTZ DK, 1992, J PHYS CHEM-US, V96, P10444, DOI 10.1021/j100204a059; SCHWARTZ DK, 1993, J AM CHEM SOC, V115, P7374, DOI 10.1021/ja00069a040; SCHWARTZ DK, 1993, LANGMUIR, V9, P1384, DOI 10.1021/la00029a036; SCHWARTZ DK, 1992, J CHEM PHYS, V96, P2356, DOI 10.1063/1.462032; SCHWARTZ DK, 1993, PHYS REV E, V47, P452, DOI 10.1103/PhysRevE.47.452; SCHWARTZ DK, 1992, SCIENCE, V257, P508, DOI 10.1126/science.257.5069.508; SCHWARTZ DK, 1993, PHYS REV LETT, V70, P1267, DOI 10.1103/PhysRevLett.70.1267; SELINGER JV, 1993, PHYS REV LETT, V70, P1139, DOI 10.1103/PhysRevLett.70.1139; SHIH MC, 1993, LANGMUIR, V9, P776, DOI 10.1021/la00027a028; SHNIDMAN Y, 1993, LANGMUIR, V9, P1071, DOI 10.1021/la00028a032; SIEGEL S, 1992, J PHYS CHEM-US, V96, P8157, DOI 10.1021/j100199a062; SIROTA EB, 1993, J CHEM PHYS, V98, P5809, DOI 10.1063/1.464874; SIROTA EB, 1992, PHYS REV LETT, V68, P492, DOI 10.1103/PhysRevLett.68.492; SWALEN JD, 1987, LANGMUIR, V3, P932, DOI 10.1021/la00078a011; TACHIBANA H, 1993, ADV MATER, V5, P796, DOI 10.1002/adma.19930051103; TIPPMANNKRAYER P, 1992, THIN SOLID FILMS, V210, P577, DOI 10.1016/0040-6090(92)90346-D; TSUKRUK VV, 1993, LANGMUIR, V9, P2141, DOI 10.1021/la00032a039; TSUKRUK VV, 1993, LANGMUIR, V9, P3538, DOI 10.1021/la00036a032; UENO K, 1990, J VAC SCI TECHNOL A, V8, P68, DOI 10.1116/1.576983; Ulman A., 1991, INTRO ULTRATHIN ORGA; UYEDA N, 1987, NATURE, V327, P319, DOI 10.1038/327319a0; VAINSHTEIN BK, 1993, P R SOC-MATH PHYS SC, V442, P73, DOI 10.1098/rspa.1993.0091; VISWANATHAN R, 1992, LANGMUIR, V8, P1603, DOI 10.1021/la00042a018; VISWANATHAN R, 1993, SCIENCE, V261, P449, DOI 10.1126/science.8392751; VISWANATHAN R, IN PRESS NATURE; VOGEL C, 1979, J CHIM PHYS PCB, V76, P909, DOI 10.1051/jcp/1979760909; WEISENHORN AL, 1991, LANGMUIR, V7, P8, DOI 10.1021/la00049a003; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; WORTIS M, 1988, CHEM PHYSICS SOLID S, V7, P367; XU S, 1991, J PHYS I, V1, P1131, DOI 10.1051/jp1:1991195; YAZDANIAN M, 1990, LANGMUIR, V6, P1093, DOI 10.1021/la00096a012; YAZDANIAN M, 1992, LANGMUIR, V8, P630, DOI 10.1021/la00038a055; ZASADZINSKI JAN, 1991, BIOPHYS J, V59, P755, DOI 10.1016/S0006-3495(91)82288-3	102	505	516	9	300	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 25	1994	263	5154					1726	1733		10.1126/science.8134836	http://dx.doi.org/10.1126/science.8134836			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC040	8134836				2022-12-28	WOS:A1994NC04000027
J	HANEIN, D; GEIGER, B; ADDADI, L				HANEIN, D; GEIGER, B; ADDADI, L			DIFFERENTIAL ADHESION OF CELLS TO ENANTIOMORPHOUS CRYSTAL-SURFACES	SCIENCE			English	Article								Interactions during cell adhesion to external surfaces may reach the level of discrimination of molecular chirality. Cultured epithelial cells interact differently with the {011} faces of the (R,R) and (S,S) calcium tartrate tetrahydrate crystals. In a modified version of the classical Pasteur experiment, the enantiomorphous crystals were sorted out from a 1:1 mixture by the selective adhesion of cells to the (R,R) crystals. This stereospecificity results from molecular recognition between chiral components on the cell surface and the structured crystal surface. Crystals may allow experimental differentiation between distinct stages in cell substrate contacts, providing mechanistic information not readily attainable on conventional heterogeneous surfaces.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science	HANEIN, D (corresponding author), WEIZMANN INST SCI,DEPT STRUCT BIOL,IL-76100 REHOVOT,ISRAEL.							AMBADY GK, 1968, ACTA CRYSTALL B-STRU, VB 24, P1548, DOI 10.1107/S0567740868004619; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CURTIS ASG, 1990, CRIT REV BIOCOMPAT, V5, P343; GEIGER B, 1992, J CELL SCI, V103, P943; GEIGER B, 1987, J CELL SCI S, V8, P251; GRINNELL F, 1978, EXP CELL RES, V116, P275, DOI 10.1016/0014-4827(78)90449-4; HANEIN D, 1993, LANGMUIR, V9, P1058, DOI 10.1021/la00028a030; HANEIN D, 1993, J CELL SCI, V104, P257; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Pasteur L., 1848, ANN CHIM PHYS, V24, P442; VASILIEV JM, 1981, DEV CELL BIOL SERIES, V8, P19	11	109	111	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1413	1416		10.1126/science.8128221	http://dx.doi.org/10.1126/science.8128221			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128221				2022-12-28	WOS:A1994MZ92700023
J	ZOHARY, E; CELEBRINI, S; BRITTEN, KH; NEWSOME, WT				ZOHARY, E; CELEBRINI, S; BRITTEN, KH; NEWSOME, WT			NEURONAL PLASTICITY THAT UNDERLIES IMPROVEMENT IN PERCEPTUAL PERFORMANCE	SCIENCE			English	Article							PRIMARY VISUAL-CORTEX; CORTICAL PLASTICITY; CELLULAR ANALOGS; DISCRIMINATION; ADULT; REORGANIZATION; EPIGENESIS; MOTION	The electrophysiological properties of sensory neurons in the adult cortex are not immutable but can change in response to alterations of sensory input caused by manipulation of afferent pathways in the nervous system or by manipulation of the sensory environment. Such plasticity creates great potential for flexible processing of sensory information, but the actual effects of neuronal plasticity on perceptual performance are poorly understood. The link between neuronal plasticity and performance was explored here by recording the responses of directionally selective neurons in the visual cortex while rhesus monkeys practiced a familiar task involving discrimination of motion direction. Each animal experienced a short-term improvement in perceptual sensitivity during daily experiments; sensitivity increased by an average of 19 percent over a few hundred trials. The increase in perceptual sensitivity was accompanied by a short-term improvement in neuronal sensitivity that mirrored the perceptual effect both in magnitude and in time course, which suggests that improved psychophysical performance can result directly from increased neuronal sensitivity within a sensory pathway.			ZOHARY, E (corresponding author), STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305, USA.		celebrini, simona/H-2169-2011; Newsome, William T./W-7171-2019					AHISSAR E, 1992, SCIENCE, V257, P1412, DOI 10.1126/science.1529342; AHISSAR M, 1993, P NATL ACAD SCI USA, V90, P5718, DOI 10.1073/pnas.90.12.5718; BALL K, 1987, VISION RES, V27, P953, DOI 10.1016/0042-6989(87)90011-3; BERARDI N, 1987, J PHYSIOL-LONDON, V384, P633, DOI 10.1113/jphysiol.1987.sp016474; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; BRITTEN KH, 1993, VISUAL NEUROSCI, V8, P1157; FREGNAC Y, 1992, J NEUROSCI, V12, P1280; FREGNAC Y, 1988, NATURE, V333, P367, DOI 10.1038/333367a0; GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0; GREUEL JM, 1988, SCIENCE, V242, P74, DOI 10.1126/science.2902687; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; KARNI A, 1991, P NATL ACAD SCI USA, V88, P4966, DOI 10.1073/pnas.88.11.4966; MAUNSELL JHR, 1991, VISUAL NEUROSCI, V7, P561, DOI 10.1017/S095252380001035X; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MURASUGI CM, 1993, J NEUROSCI, V13, P1719; PETTET MW, 1992, P NATL ACAD SCI USA, V89, P8366, DOI 10.1073/pnas.89.17.8366; POGGIO T, 1992, SCIENCE, V256, P1018, DOI 10.1126/science.1589770; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; QUICK RF, 1974, KYBERNETIK, V16, P65, DOI 10.1007/BF00271628; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1071, DOI 10.1152/jn.1992.67.5.1071; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; SALZMAN CD, 1992, J NEUROSCI, V12, P2331; SHULZ D, 1992, J NEUROSCI, V12, P1301; TSO DY, 1986, J NEUROSCI, V6, P1160; WEINBERGER NM, 1993, P NATL ACAD SCI USA, V90, P2394, DOI 10.1073/pnas.90.6.2394	26	159	164	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 4	1994	263	5151					1289	1292		10.1126/science.8122114	http://dx.doi.org/10.1126/science.8122114			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	8122114				2022-12-28	WOS:A1994MY57000040
J	STARK, WM; PARKER, CN; BOOCOCK, MR; HALFORD, SE				STARK, WM; PARKER, CN; BOOCOCK, MR; HALFORD, SE			STEREOSELECTIVITY OF DNA CATENANE FUSION BY RESOLVASE	NATURE			English	Article							SITE-SPECIFIC RECOMBINATION; TN3 RESOLVASE; BACTERIOPHAGE-LAMBDA; SEGMENTS; PRODUCTS; RES	COMMUNICATIONS between distant sites on DNA often depend on the way in which the sites are connected(1,2). For example, site-specific recombination catalysed by Tn3 resolvase is most efficient when the 114-base-pair res recombination sites are directly repeated in the same DNA molecule(3). In vitro a supercoiled plasmid substrate containing two directly repeated res sites gives a resolution product in which the two recombinant circles are topologically linked as a simple (two-noded) catenane (Fig. 1a). Resolvase is highly selective in forming this product rather than unlinked circles or more complex catenanes. It does not catalyse recombination between sites on separate supercoiled molecules, or between inverted sites in the same supercoiled molecule(3-5). Tn3 resolution removes four negative supercoils from the substrate, an energetically favourable change which may drive the reaction(6): in relaxed or nicked circular substrates, resolution is incomplete and slower. Resolvase can catalyse fusion of the circles of a nicked or relaxed catenane, giving a single unknotted circular product(6,7). The fusion is the precise topological reversal of resolution, introducing four negative supercoils into a related catenane substrate(6), and should therefore not proceed if the catenane is already negatively supercoiled. Here we study recombination between res sites in non-supercoiled DNA circles linked into simple catenanes. We used (+2) and (-2) catenanes, which differ only in the direction in which one circle is threaded through the other (Fig. 2a). Although stereoselectivity is a feature of enzyme catalysis, it is not obvious how resolvase can distinguish between these subtly different catenane diastereomers. A model for the intertwining of the res site DNA in the catalytically active complex(4,7) predicts that only the (-2) catenane will recombine, giving unknotted and 4-noded knot circular products. We have confirmed this prediction for the Tn3 and Tn21 resolvases.	UNIV BRISTOL,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol	STARK, WM (corresponding author), UNIV GLASGOW,INST GENET,CHURCH ST,GLASGOW G11 5JS,SCOTLAND.		Boocock, Martin/K-5825-2012		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABREMSKI K, 1985, J MOL BIOL, V184, P211, DOI 10.1016/0022-2836(85)90374-2; BEATTY LG, 1986, J MOL BIOL, V188, P529, DOI 10.1016/S0022-2836(86)80003-1; BENJAMIN HW, 1990, J BIOL CHEM, V165, P6441; BOOCOCK MR, 1986, BIOCHEM SOC T, V14, P214; BOOCOCK MR, 1987, UCLA S MOL CELLULAR, V47, P703; CASTELL SE, 1986, NUCLEIC ACIDS RES, V14, P7213, DOI 10.1093/nar/14.18.7213; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; GELLERT M, 1987, NATURE, V325, P401, DOI 10.1038/325401a0; Hatfull GF, 1988, GENETIC RECOMBINATIO, P357; MIZUUCHI K, 1980, J MOL BIOL, V141, P485, DOI 10.1016/0022-2836(80)90256-9; PARKER CN, 1991, CELL, V66, P781, DOI 10.1016/0092-8674(91)90121-E; POLLOCK TJ, 1983, J MOL BIOL, V170, P1, DOI 10.1016/S0022-2836(83)80224-1; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; STARK WM, 1989, TRENDS GENET, V5, P304, DOI 10.1016/0168-9525(89)90113-3; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; STARK WM, 1991, EMBO J, V10, P3541, DOI 10.1002/j.1460-2075.1991.tb04918.x; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WASSERMAN SA, 1985, SCIENCE, V229, P171, DOI 10.1126/science.2990045; WASSERMAN SA, 1988, NATURE, V334, P448, DOI 10.1038/334448a0; WASSERMAN SA, 1985, P NATL ACAD SCI USA, V82, P1079, DOI 10.1073/pnas.82.4.1079	20	21	21	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					76	78		10.1038/368076a0	http://dx.doi.org/10.1038/368076a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	8107889				2022-12-28	WOS:A1994MY56900058
J	MITSUHASHI, M; COOPER, A; OGURA, M; SHINAGAWA, T; YANO, K; HOSOKAWA, T				MITSUHASHI, M; COOPER, A; OGURA, M; SHINAGAWA, T; YANO, K; HOSOKAWA, T			OLIGONUCLEOTIDE PROBE DESIGN - A NEW APPROACH	NATURE			English	Article							SEQUENCE		HITACHI CHEM RES CTR INC,IRVINE,CA 92715; DIGITALWORD,BELLEVUE,WA 98008; NAGASAKI UNIV,SCH MED,DEPT INTERNAL MED 3,NAGASAKI 852,JAPAN; HITACHI CHEM CO LTD,TOKYO,JAPAN	Hitachi Limited; Nagasaki University; Hitachi Limited	MITSUHASHI, M (corresponding author), ADV GENE COMP TECHNOL INC,2102 BUSINESS CTR DR,SUITE 170,IRVINE,CA 92715, USA.							BERNSTAM VA, 1992, HDB GENE LEVEL DIAGN, P161; IIZUKA N, 1987, VIROLOGY, V156, P64, DOI 10.1016/0042-6822(87)90436-3; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MITSUHASHI M, 1992, NATURE, V357, P519, DOI 10.1038/357519a0; Mitsuhashi M, 1994, Nihon Rinsho, V52, P530; Reynolds T, 1992, J Natl Cancer Inst, V84, P288, DOI 10.1093/jnci/84.5.288; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; WU DY, 1989, GENE, V76, P245, DOI 10.1016/0378-1119(89)90165-0	8	46	52	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					759	761		10.1038/367759a0	http://dx.doi.org/10.1038/367759a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	8107873				2022-12-28	WOS:A1994MX63100064
J	ALLEN, PIM; COLLS, BM				ALLEN, PIM; COLLS, BM			IMPROVING THE PREREGISTRATION EXPERIENCE - THE NEW-ZEALAND APPROACH	BRITISH MEDICAL JOURNAL			English	Article							PERIOD	There is currently much debate about how to improve undergraduate medical education, and in particular on how best to prepare students for clinical responsibility. For 20 years a period of trainee internship has formed part of New Zealand medical students' undergraduate training, and the model could have much to offer the United Kingdom. Students take their final examinations at the end of the second clinical year; they spend their final year in a series of eight clinical attachments, during each of which they shadow a preregistration house officer or senior house officer. As trainee interns they are paid 60% of a house officer's salary for their clinical work, which is supervised by the firm's registrars and consultants under the overall responsibility of the head of the academic department. The order of the attachments is determined on educational, not service, grounds, and trainees have to attend educational sessions and pass assessments on each attachment. The trainee internship, funded jointly by the education and health departments, offers a more seamless transition from student to house officer and aims at improving both general medical education and clinical training.	UNIV OTAGO,CHRISTCHURCH HOSP,CHRISTCHURCH SCH MED,CHRISTCHURCH,NEW ZEALAND	Christchurch Hospital New Zealand; University of Otago								CALMAN KC, 1991, MED EDUC, V25, P51, DOI 10.1111/j.1365-2923.1991.tb00026.x; DALLY P, 1984, MED EDUC, V18, P181, DOI 10.1111/j.1365-2923.1984.tb01002.x; DOWLING S, 1991, DOCTORS MAKING EXPER; FINKELSTEIN DH, 1970, NEW PHYSICIAN, V19, P740; GRANT J, 1988, SENIOR HOUSE OFFICER; MCMANUS IC, 1993, LANCET, V341, P941, DOI 10.1016/0140-6736(93)91225-B; NANSON EM, 1975, NEW ZEAL MED J, V81, P134; PAICE E, 1992, BRIT J HOSP MED, V48, P215; RICHARDS P, 1992, BRIT MED J, V304, P625, DOI 10.1136/bmj.304.6827.625; 1993, PROSPECTUS	10	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	1994	308	6925					398	400		10.1136/bmj.308.6925.398	http://dx.doi.org/10.1136/bmj.308.6925.398			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV862	8124150	Green Published			2022-12-28	WOS:A1994MV86200027
J	SUNDAR, S; THAKUR, BB; TANDON, AK; AGRAWAL, NR; MISHRA, CP; MAHAPATRA, TM; SINGH, VP				SUNDAR, S; THAKUR, BB; TANDON, AK; AGRAWAL, NR; MISHRA, CP; MAHAPATRA, TM; SINGH, VP			CLINICOEPIDEMIOLOGIC STUDY OF DRUG-RESISTANCE IN INDIAN KALAAZAR	BRITISH MEDICAL JOURNAL			English	Article							SODIUM STIBOGLUCONATE		BANARAS HINDU UNIV,INST MED SCI,VARANASI 221005,UTTAR PRADESH,INDIA; SK MED COLL,MUZAFFARPUR,INDIA	Banaras Hindu University (BHU)								HERWALDT BL, 1992, AM J TROP MED HYG, V46, P296, DOI 10.4269/ajtmh.1992.46.296; Jha S N, 1991, J Assoc Physicians India, V39, P314; JHA TK, 1992, J ASSOC PHYSICIAN I, V42, P868; THAKUR CP, 1991, INDIAN J MED RES-A, V93, P103; 1984, WHO TECH REP SER, V701, P99	5	51	52	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 29	1994	308	6924					307	307		10.1136/bmj.308.6924.307	http://dx.doi.org/10.1136/bmj.308.6924.307			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU492	8124119	Green Published			2022-12-28	WOS:A1994MU49200021
J	LARSON, EB; ELLSWORTH, AJ; OAS, J				LARSON, EB; ELLSWORTH, AJ; OAS, J			RANDOMIZED CLINICAL-TRIALS IN SINGLE PATIENTS DURING A 2-YEAR PERIOD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDIVIDUAL PATIENTS; N-OF-1	Objective.-To describe the feasibility of a single patient trial (SPT) service and study the influence of formal SPTs on therapeutic precision. Design.-Descriptive and evaluative study of SPTs. All planned trials were double-blind, randomized, multiple crossover trials. Other key features of individual trials were random assignment of order and assessment of predetermined explicit outcomes. Patients and physicians rated level of confidence in treatment before and after the SPT on visual analog scales. Setting.-Two-year experience (September 1988 to September 1990) of an SPT trial referral service available to physicians in an academic medical center. Outcome Measures.-The number of planned and completed SPTs; proportion of completed trials yielding definitive answers; patient- and physician-rated levels of confidence in treatment pre- and post-SPT; time-motion studies to estimate resource consumption (costs) for selected SPTs. Results.-Of 34 completed trials, 17 were judged to give definitive results whereas 17 showed trends only. Results favored active treatment in 16 trials that led to treatment being continued (nine patients) or started (seven patients). Treatment was discontinued (seven patients) or not started (11 patients) based on 18 trial results that demonstrated active treatment was ineffective (seven), harmful (two), or apparently equivalent (nine). Most patients (65%) reported no change in their already high level of confidence in therapy as a result of trials, whereas physicians' confidence levels in therapy either increased or decreased post-SPT depending on the direction of trial results. Patients consistently rated the SPT service as extremely useful. Time-motion estimates indicate that 16.75 staff hours were spent per trial leading to a direct cost estimate of approximately $450 to $500 per trial. Conclusion.-We conclude that an SPT service is feasible, trial costs compare favorably with other conventional services, and clinicians appear to gain confidence and precision from SPTs. When patients or clinicians are uncertain about the value (including the possibility of side effects) of treatment for symptomatic chronic diseases, we believe an SPT can be offered to a patient and will likely yield results that will effect subsequent treatment.	UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT PHARM,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT FAMILY MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PHARM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					AHRQ HHS [HS06006] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BALESTRA DJ, 1988, JAMA-J AM MED ASSOC, V260, P62, DOI 10.1001/jama.260.1.62; FEATHERSTONE HJ, 1984, MED EDUC, V18, P155, DOI 10.1111/j.1365-2923.1984.tb00996.x; FRASCA MA, 1988, AM FAM PHYSICIAN, V37, P195; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; GUYATT G, 1988, CAN MED ASSOC J, V139, P497; GUYATT G, 1986, NEW ENGL J MED, V314, P889, DOI 10.1056/NEJM198604033141406; GUYATT GH, 1990, WESTERN J MED, V152, P67; GUYATT GH, 1990, ANN INTERN MED, V112, P293, DOI 10.7326/0003-4819-112-4-293; HUNTER KM, 1990, PERSPECT BIOL MED, V33, P237; JAESCHKE R, 1991, J RHEUMATOL, V18, P447; Jaeschke R, 1992, J Am Board Fam Pract, V5, P227; JUOVO J, 1992, J AM BOARD FAM PRACT, V5, P137; LARSON EB, 1990, WESTERN J MED, V152, P52; MCLEOD RS, 1986, LANCET, V1, P726; ROBIN ED, 1986, CHEST, V90, P888, DOI 10.1378/chest.90.6.888; 1986, LANCET, V1, P1254	16	70	76	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2708	2712		10.1001/jama.270.22.2708	http://dx.doi.org/10.1001/jama.270.22.2708			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	8133588				2022-12-28	WOS:A1993MJ82100030
J	BECKER, RC; TERRIN, M; ROSS, R; KNATTERUD, GL; DESVIGNENICKENS, P; GORE, JM; BRAUNWALD, E				BECKER, RC; TERRIN, M; ROSS, R; KNATTERUD, GL; DESVIGNENICKENS, P; GORE, JM; BRAUNWALD, E			COMPARISON OF CLINICAL OUTCOMES FOR WOMEN AND MEN AFTER ACUTE MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY; SEX FACTORS; AGE FACTORS; DIABETES MELLITUS	CORONARY HEART-DISEASE; LONG-TERM SURVIVAL; THROMBOLYTIC THERAPY; DIABETES-MELLITUS; SEX-DIFFERENCES; BYPASS-SURGERY; ARTERY DISEASE; GENDER BIAS; PHASE-II; MORTALITY	Objectives: To assess differences in morbidity and mortality between men and women with acute myocardial infarction treated with thrombolytic therapy and the relation of differences to baseline patient characteristics and clinical features. Design: Secondary analysis of observational findings among women and men enrolled in a clinical trial. Setting: Hospitals participating in the Thrombolysis in Myocardial Infarction Phase II trial. Measurements: Recurrent infarctions and deaths were assessed. Main Results: The 6-week mortality rate was greater for women than for men (9% compared with 4%; adjusted relative risk, 1.54; P = 0.01). Death or reinfarction occurred in 15.9% of women and 9.5% of men (adjusted relative risk, 1.33; P = 0.02). Among patients enrolled for treatment with 100 mg of recombinant tissue plasminogen activator and assigned to a conservative strategy of watchful waiting with appropriate backup, the 6-week incidence of death was 7.5% for women and 3.8% for men (P = 0.01). The 6-week incidences of death or reinfarction were 14.2% and 8.9% (P = 0.01) among women and men, respectively. Conclusions: Among patients in the Thrombolysis in Myocardial Infarction Phase II Trial, who all were diagnosed with myocardial infarction and were eligible to receive thrombolytic therapy, women had higher rates of mortality and morbidity than did men. Older age at the time of myocardial infarction and a history of diabetes accounted for much but probably not all of this difference.	MARYLAND MED RES INST, BALTIMORE, MD 21210 USA; CHILDRENS HOSP PHILADELPHIA, PHILADELPHIA, PA 19104 USA; NHLBI, DHDV, CARDIAC DIS BRANCH, BETHESDA, MD 20892 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Brigham & Women's Hospital	BECKER, RC (corresponding author), UNIV MASSACHUSETTS, THROMBOSIS RES CTR, SCH MED, 55 LAKE AVE N, WORCESTER, MA 01655 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038460, P50HL035058] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35058, HL38460] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1989, NEW ENGL J MED, V320, P618; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; BLOSSFELD HP, 1989, EVENT HIST ANAL, P142; BRAUNWALD E, 1987, J AM COLL CARDIOL, V9, P467, DOI 10.1016/S0735-1097(87)80407-2; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; FLEISS JL, 1989, STATISTICAL METHODS; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; GOLDBERG RJ, 1988, AM HEART J, V115, P761, DOI 10.1016/0002-8703(88)90876-9; GOLDBERG RJ, 1986, JAMA-J AM MED ASSOC, V255, P2774, DOI 10.1001/jama.255.20.2774; GOMEZMARIN O, 1987, NEW ENGL J MED, V316, P1353, DOI 10.1056/NEJM198705283162201; GREENBERG MA, 1993, CIRCULATION, V87, P1030, DOI 10.1161/01.CIR.87.3.1030; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HANLEY PC, 1989, J AM COLL CARDIOL, V13, P624, DOI 10.1016/0735-1097(89)90603-7; Henning R, 1975, Acta Med Scand Suppl, V586, P1; JOHANSSON S, 1984, AM J EPIDEMIOL, V119, P603, DOI 10.1093/oxfordjournals.aje.a113777; JOHANSSON S, 1984, AM J EPIDEMIOL, V119, P610, DOI 10.1093/oxfordjournals.aje.a113778; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; KANNEL WB, 1988, AM HEART J, V115, P869, DOI 10.1016/0002-8703(88)90891-5; KANNEL WB, 1985, AM HEART J, V110, P1100, DOI 10.1016/0002-8703(85)90224-8; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KIMMELSTIEL C, 1990, CARDIOLOGY, V77, P71, DOI 10.1159/000174655; KNATTERUD G, 1988, JAMA-J AM MED ASSOC, V260, P2849; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; MAYNARD C, 1991, AM J CARDIOL, V68, P529, DOI 10.1016/0002-9149(91)90791-I; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; MOY CS, 1990, CIRCULATION, V82, P37, DOI 10.1161/01.CIR.82.1.37; MUELLER HS, 1992, CIRCULATION, V85, P1254, DOI 10.1161/01.CIR.85.4.1254; MURABITO JM, 1993, CIRCULATION, V88, P2548, DOI 10.1161/01.CIR.88.6.2548; PAN WH, 1986, AM J EPIDEMIOL, V123, P504, DOI 10.1093/oxfordjournals.aje.a114266; PELL S, 1985, NEW ENGL J MED, V312, P1005, DOI 10.1056/NEJM198504183121601; PULETTI M, 1984, AM HEART J, V108, P63, DOI 10.1016/0002-8703(84)90545-3; ROBERTS R, 1991, CIRCULATION, V83, P422, DOI 10.1161/01.CIR.83.2.422; ROBINSON K, 1988, J AM COLL CARDIOL, V11, P932, DOI 10.1016/S0735-1097(98)90048-1; ROSENBERG HM, 1978, NIH791610 PUBL, V197, P11; SMITH JW, 1984, AM J CARDIOL, V54, P718, DOI 10.1016/S0002-9149(84)80196-4; SNEDECOR JW, 1967, STATISTICAL METHODS; SORLIE P, 1977, DHEW NIH771247 PUBL; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; VANDEWERF F, 1990, LANCET, V336, P71; WHITE HD, 1993, CIRCULATION, V88, P2097, DOI 10.1161/01.CIR.88.5.2097; WILCOX RG, 1988, LANCET, V2, P525; WILLIAMS DO, 1992, CIRCULATION, V85, P533, DOI 10.1161/01.CIR.85.2.533	49	173	176	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1994	120	8					638	645		10.7326/0003-4819-120-8-199404150-00003	http://dx.doi.org/10.7326/0003-4819-120-8-199404150-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE850	8135447				2022-12-28	WOS:A1994NE85000003
J	COCKCROFT, JR; CHOWIENCZYK, PJ; BENJAMIN, N; RITTER, JM				COCKCROFT, JR; CHOWIENCZYK, PJ; BENJAMIN, N; RITTER, JM			PRESERVED ENDOTHELIUM-DEPENDENT VASODILATATION IN PATIENTS WITH ESSENTIAL-HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-PRESSURE MONITOR; RELAXING FACTOR; NITRIC-OXIDE; VASCULAR RELAXATION; SMOOTH-MUSCLE; RESPONSES; ACETYLCHOLINE; AORTA; ACCUTRACKER; RELEASE	Background. Previous studies suggest that vascular endothelial function may be impaired in essential hypertension. Although muscarinic agonists dilate blood vessels by releasing an endothelium-derived relaxing factor closely related to nitric oxide, nitroprusside dilates vessels by a mechanism that is independent of the endothelium. The finding of an impaired response to muscarinic agonists but a normal response to nitroprusside in patients with hypertension has suggested that endothelial function is abnormal in hypertension. Methods. We reassessed this issue by measuring forearm blood flow by plethysmography during the infusion of vasodilators into the brachial arteries of 95 subjects: 37 normotensive controls (mean [+/-SE] arterial blood pressure, 92+/-1 mm Hg) and 58 patients with essential hypertension (mean arterial blood pressure, 121+/-1 mm Hg). Results. In an initial study, vascular responses to the vasodilators carbachol and nitroprusside were similar in normotensive controls (n = 19) and hypertensive patients (n = 17). We wondered whether this might be attributable to the use of previously untreated patients or to the choice of carbachol as the muscarinic agonist. However, we found that the vasodilator responses to nitroprusside, acetylcholine, carbachol, and isoproterenol were also similar in separate groups of normotensive controls (n = 18) and hypertensive subjects, whether the subjects had never been treated for hypertension (n = 24) or had had therapy withheld for two weeks (n = 17). The 95 percent confidence intervals for the difference between the controls and hypertensive patients in the ratio of endothelium-dependent vasodilatation induced by acetylcholine or carbachol to endothelium-independent vasodilatation induced by nitroprusside were -14 to +23 percent for acetylcholine and -13 to +12 percent for carbachol. Conclusions. In contrast to previous studies, our findings suggest that selective impairment of the responsiveness of the forearm vasculature to muscarinic agonists is not universal in patients with essential hypertension.	UNIV LONDON, UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, GUYS HOSP, DEPT CLIN PHARMACOL, LONDON SE1 9RT, ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London				Chowienczyk, Phil/0000-0003-4507-038X				ANGUS JA, 1992, J HYPERTENS, V10, pS179; ANGUS JA, 1992, KIDNEY INT, V41, pS73; CALVER A, 1992, J HYPERTENS, V10, P1025; CARVALHO MHC, 1987, J HYPERTENS, V5, P377, DOI 10.1097/00004872-198706000-00019; CHOWIENCZYK PJ, IN PRESS CLIN SCI; COLLINS P, 1986, J PHYSIOL-LONDON, V381, P427, DOI 10.1113/jphysiol.1986.sp016336; Crcager MA, 1992, J VASC RES, V29, P97; DEMEY JG, 1985, PROG APPL MICROCIRC, V8, P181; DUFF F, 1953, J PHYSIOL-LONDON, V120, P160, DOI 10.1113/jphysiol.1953.sp004883; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; HIROOKA Y, 1992, HYPERTENSION, V20, P175, DOI 10.1161/01.HYP.20.2.175; HOKANSON DE, 1975, IEEE T BIO-MED ENG, VBM22, P25, DOI 10.1109/TBME.1975.324535; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KOBAYASHI S, 1985, SCIENCE, V229, P553, DOI 10.1126/science.3927484; KONISHI M, 1983, HYPERTENSION, V5, P881, DOI 10.1161/01.HYP.5.6.881; LI JY, 1993, CIRC RES, V72, P290, DOI 10.1161/01.RES.72.2.290; LINDER L, 1990, CIRCULATION, V81, P1762, DOI 10.1161/01.CIR.81.6.1762; LOCKETTE W, 1986, HYPERTENSION, V8, P61, DOI 10.1161/01.HYP.8.6_Pt_2.II61; LUSCHER TF, 1992, EUR HEART J, V13, P50, DOI 10.1093/eurheartj/13.suppl_D.50; LUSCHER TF, 1986, HYPERTENSION, V8, P344, DOI 10.1161/01.HYP.8.4.344; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Murad F, 1978, Adv Cyclic Nucleotide Res, V9, P145; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PANZA JA, 1993, CIRCULATION, V87, P1475, DOI 10.1161/01.CIR.87.5.1475; PANZA JA, 1993, CIRCULATION, V87, P1468, DOI 10.1161/01.CIR.87.5.1468; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; PANZA JA, 1993, J AM COLL CARDIOL, V21, P1145, DOI 10.1016/0735-1097(93)90238-V; PETRIE JC, 1986, BRIT MED J, V293, P611, DOI 10.1136/bmj.293.6547.611; ROBINSON BF, 1990, DOSE RESPONSE RELATI, V3, P40; SHIRASAKI Y, 1988, J PHARMACOL EXP THER, V245, P53; SMITH RP, 1974, J PHARMACOL EXP THER, V191, P557; TADDEI S, 1993, HYPERTENSION, V21, P929, DOI 10.1161/01.HYP.21.6.929; TREASURE CB, 1992, CIRC RES, V71, P776, DOI 10.1161/01.RES.71.4.776; TREASURE CB, 1993, CIRCULATION, V87, P86, DOI 10.1161/01.CIR.87.1.86; VANDEVOORDE J, 1986, AM J PHYSIOL, V250, pH711, DOI 10.1152/ajpheart.1986.250.5.H711; WHITE WB, 1989, J HYPERTENS, V7, P967, DOI 10.1097/00004872-198912000-00007; WHITE WB, 1987, J CLIN HYPERTENS, V3, P500; WHITNEY RJ, 1953, J PHYSIOL-LONDON, V121, P1; Winquist R J, 1984, J Hypertens, V2, P541, DOI 10.1097/00004872-198410000-00015; WRIGHT CE, 1987, HYPERTENSION, V9, P122, DOI 10.1161/01.HYP.9.2.122	41	300	308	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 14	1994	330	15					1036	1040		10.1056/NEJM199404143301502	http://dx.doi.org/10.1056/NEJM199404143301502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF022	8127330	Bronze			2022-12-28	WOS:A1994NF02200002
J	ZAGELBAUM, BM; HERSH, PS; DONNENFELD, ED; PERRY, HD; HOCHMAN, MA				ZAGELBAUM, BM; HERSH, PS; DONNENFELD, ED; PERRY, HD; HOCHMAN, MA			OCULAR TRAUMA IN MAJOR-LEAGUE BASEBALL PLAYERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							EYE INJURY		BRONX LEBANON HOSP CTR,BRONX,NY 10457	BronxCare Health System	ZAGELBAUM, BM (corresponding author), N SHORE UNIV HOSP,LIONS EYE BANK LONG ISL,300 COMMUNITY DR,MANHASSET,NY 11030, USA.							JONES NP, 1989, SPORTS MED, V7, P163, DOI 10.2165/00007256-198907030-00003; Parver L M, 1986, Arch Ophthalmol, V104, P1452; STOCK JG, 1991, AM FAM PHYSICIAN, V44, P515; ZAGELBAUM BM, 1993, PHYSICIAN SPORTSMED, V21, P25, DOI 10.1080/00913847.1993.11710413; 1992, 1991 EYE INJURIES AS; 1991, 1990 SPORTS RECREATI; 1990, 1989 SPORTS RECREATI; 1992, ESTIMATES REPORT BAS	8	15	15	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 7	1994	330	14					1021	1023		10.1056/NEJM199404073301421	http://dx.doi.org/10.1056/NEJM199404073301421			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND793	8121457				2022-12-28	WOS:A1994ND79300039
J	KIMBEL, WH; JOHANSON, DC; RAK, Y				KIMBEL, WH; JOHANSON, DC; RAK, Y			THE 1ST SKULL AND OTHER NEW DISCOVERIES OF AUSTRALOPITHECUS-AFARENSIS AT HADAR, ETHIOPIA	NATURE			English	Article							FUNCTIONAL-MORPHOLOGY; CRANIAL MORPHOLOGY; HOMINIDS; POSITION	THE Hadar Formation in Ethiopia is a prolific source of Pliocene Hominidae attributed to the species Australopithecus afarensis1. Since 1990, three seasons of field work have contributed 53 new specimens to the hominid inventory from Hadar, including the first fairly complete adult skull. Ranging from 3.0 to 3.4 million years in age (Fig. 1)2-4 , the new specimens bear on key debates in hominid palaeontology, including the taxonomic implications of sample variation and the reconstruction of locomotor behaviour. They confirm the taxonomic unity of A. afarensis and constitute the largest body of evidence for about 0.9 million years of stasis in the earliest known hominid species.	TEL AVIV UNIV, SACKLER SCH MED, DEPT ANAT, TEL AVIV, ISRAEL	Tel Aviv University; Sackler Faculty of Medicine	KIMBEL, WH (corresponding author), INST HUMAN ORIGINS, 2453 RIDGE RD, BERKELEY, CA 94709 USA.		Klein, Richard G/B-5910-2009					ASFAW B, 1987, J HUM EVOL, V16, P611, DOI 10.1016/0047-2484(87)90016-9; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P403, DOI 10.1002/ajpa.1330570403; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P373, DOI 10.1002/ajpa.1330570402; JOHANSON DC, 1979, SCIENCE, V203, P321, DOI 10.1126/science.104384; JOHANSON DC, 1978, KIRTLANDIA, V28, P1; JUNGERS WL, 1983, J HUM EVOL, V12, P673, DOI 10.1016/S0047-2484(83)80007-4; KIMBEL WH, 1982, AM J PHYS ANTHROPOL, V57, P453, DOI 10.1002/ajpa.1330570404; KIMBEL WH, 1988, J HUM EVOL, V17, P545, DOI 10.1016/0047-2484(88)90042-5; KIMBEL WH, 1984, AM J PHYS ANTHROPOL, V64, P337, DOI 10.1002/ajpa.1330640403; KIMBEL WH, 1985, AM J PHYS ANTHROPOL, V66, P31, DOI 10.1002/ajpa.1330660104; KIMBEL WH, 1985, ANCESTORS HARD EVIDE, P122; Latimer B., 1991, P169; LOVEJOY CO, 1988, SCI AM, V259, P118, DOI 10.1038/scientificamerican1188-118; LOVEJOY CO, 1982, AM J PHYS ANTHROPOL, V57, P637, DOI 10.1002/ajpa.1330570409; MCHENRY HM, 1980, SCIENCE, V207, P1103, DOI 10.1126/science.207.4435.1103; MCKEE JK, 1989, AM J PHYS ANTHROPOL, V80, P1, DOI 10.1002/ajpa.1330800102; Olson T.R., 1985, P102; Rak Y, 1983, AUSTRALOPITHECINE FA, P1; RENNE P, 1993, J GEOPHYS RES, V20, P1067; SHIPMAN P, 1986, DISCOVER, V7, P87; STERN JT, 1983, AM J PHYS ANTHROPOL, V60, P279, DOI 10.1002/ajpa.1330600302; STRN JT, 1991, ORIGINES BIPEDIE HOM, P99; SUSMAN RL, 1984, FOLIA PRIMATOL, V43, P113, DOI 10.1159/000156176; WALTER RC, 1993, J HUM EVOL, V25, P229, DOI 10.1006/jhev.1993.1046; WALTER RC, 1994, GEOLOGY, V22, P6, DOI 10.1130/0091-7613(1994)022<0006:AOLATF>2.3.CO;2; WARD SC, 1983, AM J PHYS ANTHROPOL, V61, P157, DOI 10.1002/ajpa.1330610204; WHITE TD, 1993, NATURE, V366, P261, DOI 10.1038/366261a0; WHITE TD, 1981, S AFR J SCI, V77, P445; WHITE TD, 1982, AM J PHYS ANTHROPOL, V57, P501, DOI 10.1002/ajpa.1330570405; White TD, 1984, J VERTEBR PALEONTOL, V4, P575, DOI DOI 10.1080/02724634.1984.10012033; WOOD BA, 1991, J ANAT, V174, P185	31	142	143	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	1994	368	6470					449	451		10.1038/368449a0	http://dx.doi.org/10.1038/368449a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	8133889				2022-12-28	WOS:A1994ND12000061
J	CROWLEY, C; SPENCER, SD; NISHIMURA, MC; CHEN, KS; PITTSMEEK, S; ARMANINI, MP; LING, LH; MCMAHON, SB; SHELTON, DL; LEVINSON, AD; PHILLIPS, HS				CROWLEY, C; SPENCER, SD; NISHIMURA, MC; CHEN, KS; PITTSMEEK, S; ARMANINI, MP; LING, LH; MCMAHON, SB; SHELTON, DL; LEVINSON, AD; PHILLIPS, HS			MICE LACKING NERVE GROWTH-FACTOR DISPLAY PERINATAL LOSS OF SENSORY AND SYMPATHETIC NEURONS YET DEVELOP BASAL FOREBRAIN CHOLINERGIC NEURONS	CELL			English	Article							ROOT GANGLION NEURONS; NEUROTROPHIC FACTOR; BIOLOGICAL-ACTIVITY; FACTOR DEPRIVATION; MOLECULAR-CLONING; EXPRESSION; BRAIN; TRK; NGF; PROTOONCOGENE	Homologous recombination was utilized to generate mice with a deletion in the coding sequence of the nerve growth factor (NGF) gene. Animals homozygous for NGF disruption failed to respond to noxious mechanical stimuli, and histological analysis revealed profound cell loss in both sensory and sympathetic ganglia. Within dorsal root ganglia, effects of the mutation appeared to be restricted to small and medium peptidergic neurons. These observations confirm the critical dependence of sensory and sympathetic neurons on NGF and demonstrate that other neurotrophins are not able to compensate for the loss of NGF action on these cells. Examination of the central nervous system revealed that, in marked contrast with neurons of sensory and sympathetic ganglia, basal forebrain cholinergic neurons differentiate and continue to express phenotypic markers for the life span of the null mutant mice. Thus, differentiation and initial survival of central NGF-responsive neurons can occur in the absence of NGF.	UNITED MED & DENT SCH,DEPT PHYSIOL,LONDON SE1 7EH,ENGLAND; GENENTECH INC,DEPT ENDOCRINE RES,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080	University of London; King's College London; Roche Holding; Genentech; Roche Holding; Genentech	CROWLEY, C (corresponding author), GENENTECH INC,DEPT CELL GENET,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.			McMahon, Stephen/0000-0003-4656-5536				BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CARROLL SL, 1992, NEURON, V9, P779, DOI 10.1016/0896-6273(92)90040-K; CHUN LLY, 1977, J CELL BIOL, V75, P694, DOI 10.1083/jcb.75.3.694; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DAVIES AM, 1985, DEV BIOL, V111, P62, DOI 10.1016/0012-1606(85)90435-X; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; GAGE FH, 1989, NEURON, V2, P1177, DOI 10.1016/0896-6273(89)90184-0; GORIN PD, 1979, P NATL ACAD SCI USA, V76, P5382, DOI 10.1073/pnas.76.10.5382; GORIN PD, 1980, DEV BIOL, V80, P13; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HAMBURGER V, 1993, J NEUROBIOL, V24, P893, DOI 10.1002/neu.480240702; HARTIKKA J, 1988, J NEUROSCI RES, V21, P352, DOI 10.1002/jnr.490210227; HEFTI F, 1985, NEUROSCIENCE, V14, P55, DOI 10.1016/0306-4522(85)90163-0; HEFTI F, 1989, NEUROBIOL AGING, V10, P515, DOI 10.1016/0197-4580(89)90118-8; JOHNSON EM, 1983, NEUROSCIENCE, V8, P631, DOI 10.1016/0306-4522(83)90204-X; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNUSEL B, 1991, P NATL ACAD SCI USA, V88, P961, DOI 10.1073/pnas.88.3.961; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LEVIMONTALCINI R, 1966, PHARMACOL REV, V10, P619; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; OTTEN U, 1980, NATURE, V287, P158, DOI 10.1038/287158a0; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; ROSE RD, 1987, J COMP NEUROL, V263, P365, DOI 10.1002/cne.902630305; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; RUIT KG, 1992, NEURON, V8, P1; SELBY MJ, 1987, MOL CELL BIOL, V7, P3057, DOI 10.1128/MCB.7.9.3057; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; VANTINI G, 1989, NEURON, V3, P267, DOI 10.1016/0896-6273(89)90251-1; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; Willis WD, 1991, SENSORY MECH SPINAL	41	876	912	1	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1001	1011		10.1016/0092-8674(94)90378-6	http://dx.doi.org/10.1016/0092-8674(94)90378-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137419				2022-12-28	WOS:A1994ND24600007
J	LODI, PJ; GARRETT, DS; KUSZEWSKI, J; TSANG, MLS; WEATHERBEE, JA; LEONARD, WJ; GRONENBORN, AM; CLORE, GM				LODI, PJ; GARRETT, DS; KUSZEWSKI, J; TSANG, MLS; WEATHERBEE, JA; LEONARD, WJ; GRONENBORN, AM; CLORE, GM			HIGH-RESOLUTION SOLUTION STRUCTURE OF THE BETA-CHEMOKINE HMIP-1-BETA BY MULTIDIMENSIONAL NMR	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; RESTRAINED MOLECULAR-DYNAMICS; HUMAN INTERLEUKIN-8 RECEPTOR; MULTIPLE QUANTUM COHERENCE; 3-DIMENSIONAL STRUCTURE; DISTANCE GEOMETRY; MONOCYTE CHEMOATTRACTANT; CYTOKINE FAMILY; LARGER PROTEINS; ACT-2 CYTOKINE	The three-dimensional structure of a member of the beta subfamily of chemokines, human macrophage inflammatory protein-1 beta (hMIP-1 beta), has been determined with the use of solution multidimensional heteronuclear magnetic resonance spectroscopy. Human MIP-1 beta is a symmetric homodimer with a relative molecular mass of similar to 16 kilodaltons. The structure of the hMIP-1 beta monomer is similar to that of the related alpha chemokine interleukin-8 (IL-8). However, the quaternary structures of the two proteins are entirely distinct, and the dimer interfaceis formed by a completely different set of residues. Whereas the IL-8 dimer is globular, the hMIP-1 beta dimer is elongated and cylindrical. This provides a rational explanation for the absence of cross-binding and reactivity between the alpha and beta chemokine subfamilies. Calculation of the solvation free energies of dimerization suggests that the formation and stabilization of the two different types of dimers arise from the burial of hydrophobic residues.	NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892; R&D SYST INC,MINNEAPOLIS,MN 55413; NHLBI,PULM & MOLEC IMMUNOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Leonard, Warren/AAA-1397-2022; Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525				ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1992, J AM CHEM SOC, V114, P6923, DOI 10.1021/ja00043a052; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROWN KD, 1989, J IMMUNOL, V142, P679; BRUNGER AT, 1993, SCIENCE, V261, P328, DOI 10.1126/science.8332897; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CLORE G M, 1991, Journal of Biomolecular NMR, V1, P13, DOI 10.1007/BF01874566; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P5671, DOI 10.1021/bi00476a004; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P12, DOI 10.1021/bi00215a002; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1993, J MOL BIOL, V231, P82, DOI 10.1006/jmbi.1993.1259; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; CLORE GM, IN PRESS METHODS ENZ; DECASTRO E, 1992, VISP 1 0 USERS GUIDE; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GRAHAM GJ, 1993, CELL GROWTH DIFFER, V4, P137; GRONENBORN AM, 1991, PROTEIN ENG, V4, P263, DOI 10.1093/protein/4.3.263; GRZESIEK S, 1992, J MAGN RESON, V96, P215, DOI 10.1016/0022-2364(92)90307-S; GRZESIEK S, 1993, J BIOMOL NMR, V3, P627; GRZESIEK S, 1993, J BIOMOL NMR, V3, P487; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; JONES TA, 1990, O VERSION 5 MANUAL; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; KUSZEWSKI J, UNPUB; LIPES MA, 1988, P NATL ACAD SCI USA, V85, P9704, DOI 10.1073/pnas.85.24.9704; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NAPOLITANO M, 1990, J EXP MED, V172, P285, DOI 10.1084/jem.172.1.285; NAPOLITANO M, 1991, J BIOL CHEM, V266, P17531; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; POWERS R, 1993, BIOCHEMISTRY-US, V32, P6744, DOI 10.1021/bi00077a030; ROYER WE, 1985, NATURE, V316, P277, DOI 10.1038/316277a0; SAMANTA AK, 1989, J EXP MED, V169, P1185, DOI 10.1084/jem.169.3.1185; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; STEVENS AAE, UNPUB; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; VANKIMMENADE A, 1988, EUR J BIOCHEM, V173, P109; VUISTER GW, 1993, J AM CHEM SOC, V115, P5334, DOI 10.1021/ja00065a071; VUISTER GW, 1993, J MAGN RESON SER B, V101, P210, DOI 10.1006/jmrb.1993.1035; VUISTER GW, IN PRESS METHODS ENZ; VULSTER GW, 1993, J AM CHEM SOC, V115, P7772; WILLIAMSON MP, 1985, J MOL BIOL, V182, P295, DOI 10.1016/0022-2836(85)90347-X; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; YOSHIMURA T, 1990, J IMMUNOL, V145, P292; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	60	217	234	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 25	1994	263	5154					1762	1767		10.1126/science.8134838	http://dx.doi.org/10.1126/science.8134838			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC040	8134838	Green Submitted			2022-12-28	WOS:A1994NC04000036
J	NEDERGAARD, M				NEDERGAARD, M			DIRECT SIGNALING FROM ASTROCYTES TO NEURONS IN CULTURES OF MAMMALIAN BRAIN-CELLS	SCIENCE			English	Article							CALCIUM WAVES; JUNCTION; TRANSIENTS; GLUTAMATE; GROWTH; GLIA	Although astrocytes have been considered to be supportive, rather than transmissive, in the adult nervous system, recent studies have challenged this assumption by demonstrating that astrocytes possess functional neurotransmitter receptors. Astrocytes are now shown to directly modulate the free cytosolic calcium, and hence transmission characteristics, of neighboring neurons. When a focal electric field potential was applied to single astrocytes in mixed cultures of rat forebrain astrocytes and neurons, a prompt elevation of calcium occurred in the target cell. This in turn triggered a wave of calcium increase, which propagated from astrocyte to astrocyte. Neurons resting on these astrocytes responded with large increases in their concentration of cytosolic calcium. The gap junction blocker octanol attenuated the neuronal response, which suggests that the astrocytic-neuronal signaling is mediated through intercellular connections rather than synaptically. This neuronal response to local astrocytic stimulation may mediate local intercellular communication within the brain.			NEDERGAARD, M (corresponding author), CORNELL UNIV,COLL MED,DEPT SURG,DIV NEUROSURG,1300 YORK AVE,NEW YORK,NY 10021, USA.							CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CSERR HF, 1986, ANN NY ACAD SCI, V1, P481; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; DAVENPORT RW, 1992, NEURON, V9, P405, DOI 10.1016/0896-6273(92)90179-H; DERMIETZEL R, 1989, P NATL ACAD SCI USA, V86, P10148, DOI 10.1073/pnas.86.24.10148; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; FLAGGNEWTON JL, 1980, SCIENCE, V207, P771, DOI 10.1126/science.7352287; GOLDMAN SA, 1989, J CEREBR BLOOD F MET, V9, P471, DOI 10.1038/jcbfm.1989.70; HANSEN AJ, 1985, PHYSIOL REV, V65, P101, DOI 10.1152/physrev.1985.65.1.101; JENSEN AM, 1990, J NEUROSCI, V10, P1165; KATZ B, 1967, J PHYSIOL-LONDON, V192, P407, DOI 10.1113/jphysiol.1967.sp008307; KRIEGLER S, 1993, J NEUROSCI, V13, P4229, DOI 10.1523/jneurosci.13-10-04229.1993; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; MANTZ J, 1993, ANESTHESIOLOGY, V78, P892, DOI 10.1097/00000542-199305000-00014; MURPHY TH, 1992, J NEUROSCI, V12, P4834; MURPHY TH, 1993, J NEUROSCI, V13, P2672, DOI 10.1523/JNEUROSCI.13-06-02672.1993; NEDERGAARD M, 1991, J NEUROSCI, V11, P2489; PATEL NB, 1984, J NEUROSCI, V4, P2939; PEINADO A, 1993, NEURON, V10, P103, DOI 10.1016/0896-6273(93)90246-N; REIST NE, 1992, P NATL ACAD SCI USA, V89, P7625, DOI 10.1073/pnas.89.16.7625; ROBINSON SR, 1993, SCIENCE, V262, P1072; Saito R, 1993, J CEREB BLOOD FLO S1, V13, pS86; SHIOSAKA S, 1989, J COMP NEUROL, V281, P282, DOI 10.1002/cne.902810210; TOBIASZ C, 1982, BRAIN RES, V241, P329, DOI 10.1016/0006-8993(82)91071-X; WADE MH, 1986, SCIENCE, V232, P525, DOI 10.1126/science.3961495	28	823	846	0	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 25	1994	263	5154					1768	1771		10.1126/science.8134839	http://dx.doi.org/10.1126/science.8134839			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC040	8134839				2022-12-28	WOS:A1994NC04000037
J	PULLAN, RD; RHODES, J; GANESH, S; MANI, V; MORRIS, JS; WILLIAMS, GT; NEWCOMBE, RG; RUSSELL, MAH; FEYERABEND, C; THOMAS, GAO; SAWE, U				PULLAN, RD; RHODES, J; GANESH, S; MANI, V; MORRIS, JS; WILLIAMS, GT; NEWCOMBE, RG; RUSSELL, MAH; FEYERABEND, C; THOMAS, GAO; SAWE, U			TRANSDERMAL NICOTINE FOR ACTIVE ULCERATIVE-COLITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFLAMMATORY BOWEL-DISEASE; CIGARETTE-SMOKING; SMOKERS; NONSMOKING; PHARMACOKINETICS; CESSATION; COTININE; HABITS; SINGLE	Background. Ulcerative colitis is largely a disease of nonsmokers. Because anecdotal reports suggest that smoking and nicotine may improve the symptoms of the disease, we examined the effect of nicotine as a supplemental treatment for ulcerative colitis. Methods. We treated 72 patients with active ulcerative colitis with either transdermal nicotine patches or placebo patches for six weeks in a randomized, double-blind study. Incremental doses of nicotine were given; most patients tolerated doses of 15 to 25 mg per 24 hours. All the patients had been taking mesalamine, and 12 were receiving low doses of glucocorticoids; these medications were continued without change during the study. Clinical, sigmoidoscopic, and histologic assessments were made at base line and at the end of the study; symptoms were recorded daily on a diary card, and the clinician made a global assessment. Side effects and plasma nicotine and cotinine concentrations were monitored throughout the study. Results. Seventeen of the 35 patients in the nicotine group had complete remissions, as compared with 9 of the 37 patients in the placebo group (P = 0.03). The patients in the nicotine group had greater improvement in the global clinical grade of colitis (P<0.001) and the histologic grade (P = 0.03), lower stool frequency (a difference of 1.6 stools daily; P = 0.008), less abdominal pain (P = 0.05), and less fecal urgency (P = 0.009). More patients in the nicotine group had side effects (23, vs. 11 in the placebo group; P = 0.002), the most common of which were nausea, lightheadedness, headache, and sleep disturbance. Withdrawals due to ineffective therapy were more common in the placebo group (3 vs. 8, P = 0.12). Conclusions. The addition of transdermal nicotine to conventional maintenance therapy improves symptoms in patients with ulcerative colitis.	UNIV HOSP WALES,DEPT GASTROENTEROL,CARDIFF,S GLAM,WALES; LEIGH INFIRM,LEIGH,ENGLAND; PRINCESS WALES HOSP,BRIGEND,M GLAM,WALES; UNIV WALES COLL MED,DEPT PATHOL,CARDIFF CF4 4XN,S GLAM,WALES; UNIV WALES COLL MED,DEPT MED COMP & STAT,CARDIFF,S GLAM,WALES; INST PSYCHIAT,HLTH BEHAV UNIT,LONDON,ENGLAND; MAUDSLEY HOSP & INST PSYCHIAT,LONDON,ENGLAND; NEW CROSS HOSP,POISONS UNIT,NICOTINE LAB,LONDON,ENGLAND; KABI PHARMACIA THERAPEUT AB,HELSINGBORG,SWEDEN	Cardiff University; Cardiff University; Cardiff University; University of London; King's College London; South London & Maudsley NHS Trust; University of London; King's College London; New Cross Hospital			qin, zhen/F-1263-2014; Newcombe, Robert G/B-4897-2009					ALLEN A, 1984, MECHANISMS MUCOSAL P, P195; ALLEN A, 1990, CELL BIOL INFLAMMATI, P113; BARON JH, 1964, BRIT MED J, V1, P89, DOI 10.1136/bmj.1.5375.89; BENONI C, 1984, SCAND J GASTROENTERO, V19, P824, DOI 10.1080/00365521.1984.12005815; BENONI C, 1987, SCAND J GASTROENTERO, V22, P1130, DOI 10.3109/00365528708991970; BENOWITZ NL, 1984, CLIN PHARMACOL THER, V35, P499, DOI 10.1038/clpt.1984.67; COPE GF, 1988, GUT, V29, P229, DOI 10.1136/gut.29.2.229; COPE GF, 1986, GUT, V27, pA618; DECASTELLA H, 1982, BRIT MED J, V284, P1706, DOI 10.1136/bmj.284.6330.1706; DUBOIS JP, 1989, METHOD FIND EXP CLIN, V11, P187; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; FEYERABEND C, 1985, BRIT J CLIN PHARMACO, V19, P239, DOI 10.1111/j.1365-2125.1985.tb02637.x; Fleiss JL, 1981, STAT METHODS RATES P; GALEAZZI RL, 1985, EUR J CLIN PHARMACOL, V28, P301, DOI 10.1007/BF00543327; HARRIES AD, 1982, BRIT MED J, V284, P706, DOI 10.1136/bmj.284.6317.706; HICKEY RJ, 1989, GUT, V30, P416, DOI 10.1136/gut.30.3.416-a; JARVIS MJ, 1987, AM J PUBLIC HEALTH, V77, P1435, DOI 10.2105/AJPH.77.11.1435; LASHNER BA, 1990, DIGEST DIS SCI, V35, P827, DOI 10.1007/BF01536795; LOGAN RFA, 1984, BRIT MED J, V288, P751, DOI 10.1136/bmj.288.6419.751; MOTLEY RJ, 1988, INT J COLORECTAL DIS, V3, P171, DOI 10.1007/BF01648362; MOTLEY RJ, 1990, J PHARM PHARMACOL, V42, P288, DOI 10.1111/j.2042-7158.1990.tb05411.x; MOTLEY RJ, 1987, DIGESTION, V37, P125, DOI 10.1159/000199478; PULLAN RD, IN PRESS GUT; ROBERTS CJ, 1982, BRIT MED J, V285, P440; RUDRA T, 1989, SCAND J GASTROENTE S, V170, P61; Russell MA, 1990, NICOTINE PSYCHOPHARM, P374; RUSSELL MAH, 1978, DRUG METAB REV, V8, P29, DOI 10.3109/03602537808993776; RUSSELL MAH, 1986, J EPIDEMIOL COMMUN H, V40, P80, DOI 10.1136/jech.40.1.80; SRIVASTA ED, 1993, INT J COLORECTAL DIS, V8, P71, DOI 10.1007/BF00299330; SRIVASTAVA ED, 1991, EUR J GASTROEN HEPAT, V3, P815; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; TRUELOVE SC, 1956, BRIT MED J, V1, P1315, DOI 10.1136/bmj.1.4979.1315; TRUELOVE SC, 1955, BRIT MED J, V2, P1041, DOI 10.1136/bmj.2.4947.1041; ZIJLSTRA FJ, 1994, GUT, V35, P247, DOI 10.1136/gut.35.2.247	34	406	477	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 24	1994	330	12					811	815		10.1056/NEJM199403243301202	http://dx.doi.org/10.1056/NEJM199403243301202			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB803	8114833				2022-12-28	WOS:A1994NB80300002
J	VANUUM, SHM; KEUNING, JJ				VANUUM, SHM; KEUNING, JJ			IMAGES IN CLINICAL MEDICINE - GINGIVAL HYPERTROPHY IN MYELOMONOCYTIC LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									ST JOSEPH HOSP,5500 MB VELDHOVEN,NETHERLANDS		VANUUM, SHM (corresponding author), UNIV HOSP NIJMEGEN,6500 HB NIJMEGEN,NETHERLANDS.		van Uum, Stan/G-3351-2011						0	1	1	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 24	1994	330	12					826	826						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB803	8114835				2022-12-28	WOS:A1994NB80300005
J	ROSENTHAL, MP; DIAMOND, JJ; RABINOWITZ, HK; BAUER, LC; JONES, RL; KEARL, GW; KELLY, RB; SHEETS, KJ; JAFFE, A; JONAS, P; RUFFIN, MT				ROSENTHAL, MP; DIAMOND, JJ; RABINOWITZ, HK; BAUER, LC; JONES, RL; KEARL, GW; KELLY, RB; SHEETS, KJ; JAFFE, A; JONAS, P; RUFFIN, MT			INFLUENCE OF INCOME, HOURS WORKED, AND LOAN REPAYMENT ON MEDICAL-STUDENTS DECISION TO PURSUE A PRIMARY-CARE CAREER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPECIALTY SELECTION; CHOICE; SCHOOL; INDEBTEDNESS; COLLEGE; TRENDS	Objective.-To assess the specialty plans of current fourth-year medical students and, for those not choosing primary care specialties, to investigate the potential effect that changes in key economic or lifestyle factors could have in attracting such students to primary care. Design and Participants.-A survey study was sent to 901 fourth-year medical students in the 1993 graduating classes of six US medical schools. Outcome Measures.-Comparisons were made between students choosing and not choosing primary care specialties. For the non-primary care students, we also evaluated whether alteration of income, hours worked, or loan repayment could attract them to primary care careers. Results.-Of the 688 responses (76% response rate), primary care specialties were chosen by 27% of the students and non-primary care specialties by 73%. One quarter (25%) of the non-primary care students indicated they would change to primary care for one of the following factors: income (10%), hours worked (11%), or loan repayment (4%). For students whose debt was $50 000 or greater, the loan repayment option became much more important than for students with lesser debt. In all, a total of 45% (n=313) of the students indicated either they were planning to enter primary care (n=188) or they would change to a primary care specialty (n=125) with appropriate adjustments in income, hours worked, or loan repayment. Conclusion.-Significant changes in economic and lifestyle factors could have a direct effect on the ability to attract students to primary care. Including such changes as part of health system reform, especially within the context of a supportive medical school environment, could enable the United States to approach a goal of graduating 50% generalist physicians.	OHIO STATE UNIV,COLL MED,DEPT FAMILY MED,COLUMBUS,OH 43210; PENN STATE UNIV,COLL MED,DEPT FAMILY & COMMUNITY MED,HERSHEY,PA; SUNY STONY BROOK,SCH MED,DEPT FAMILY PRACTICE,STONY BROOK,NY; UNIV KENTUCKY,COLL MED,DEPT FAMILY PRACTICE,LEXINGTON,KY; UNIV MICHIGAN,SCH MED,DEPT FAMILY PRACTICE,ANN ARBOR,MI	University System of Ohio; Ohio State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Kentucky; University of Michigan System; University of Michigan	ROSENTHAL, MP (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT FAMILY MED,SUITE 401,1015 WALNUT ST,PHILADELPHIA,PA 19107, USA.			Ruffin, Mack/0000-0001-8336-478X				BABBOTT D, 1989, JAMA-J AM MED ASSOC, V261, P2367, DOI 10.1001/jama.261.16.2367; BERNSTEIN DS, 1992, JAMA-J AM MED ASSOC, V267, P1921, DOI 10.1001/jama.1992.03480140047025; Clark L, 1989, Med Econ, V66, P94; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; FINCHER RME, 1992, ACAD MED, V67, P324, DOI 10.1097/00001888-199205000-00011; JARECKY RK, 1991, ACAD MED, V66, P756, DOI 10.1097/00001888-199112000-00011; JOLIN LD, 1992, JAMA-J AM MED ASSOC, V268, P1149, DOI 10.1001/jama.268.9.1149; KASSEBAUM DG, 1992, ACAD MED, V67, P700, DOI 10.1097/00001888-199210000-00018; LIEU TA, 1989, ACAD MED, V64, P622, DOI 10.1097/00001888-198910000-00015; MCLAUGHLIN MA, 1991, ACAD MED, V66, pS43, DOI 10.1097/00001888-199109000-00036; MOWBRAY RM, 1989, AUST NZ J MED, V19, P389, DOI 10.1111/j.1445-5994.1989.tb00286.x; Owens A, 1992, Med Econ, V69, P194; Park R, 1990, Acad Med, V65, P485, DOI 10.1097/00001888-199007000-00024; PETERSDORF RG, 1993, NEW ENGL J MED, V328, P651, DOI 10.1056/NEJM199303043280911; POLITZER RM, 1991, JAMA-J AM MED ASSOC, V266, P104, DOI 10.1001/jama.266.1.104; Rabinowitz H K, 1988, Fam Med, V20, P118; RABINOWITZ HK, 1993, NEW ENGL J MED, V328, P934, DOI 10.1056/NEJM199304013281307; RABINOWITZ HK, 1992, ACAD MED, V67, P150, DOI 10.1097/00001888-199203000-00004; RABINOWITZ HK, 1990, FAM MED, V36, P62; RIVO ML, 1993, ANN INTERN MED, V119, P146, DOI 10.7326/0003-4819-119-2-199307150-00009; ROGERS LQ, 1990, ACAD MED, V65, pS47, DOI 10.1097/00001888-199009000-00038; ROSENTHAL MP, 1992, ACAD MED, V67, P328, DOI 10.1097/00001888-199205000-00012; ROSENTHAL MP, 1992, 25TH ANN SPRING C SO; SCHWARTZ RW, 1990, ACAD MED, V65, P207, DOI 10.1097/00001888-199003000-00016; SCHWARTZ RW, 1989, ACAD MED, V64, P606, DOI 10.1097/00001888-198910000-00012; STARFIELD B, 1993, JAMA-J AM MED ASSOC, V269, P3136, DOI 10.1001/jama.269.24.3136; TARDIFF K, 1986, J MED EDUC, V61, P790; 1992, EXECUTIVE SUMMARY; 1992, 3RD US DEP HLTH HUM; 1993, FACTS FAMILY PRACTIC; 1988, SAS STAT USERS GUIDE; 1992, JAMA-J AM MED ASSOC, V268, P1092	32	72	73	2	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	1994	271	12					914	917		10.1001/jama.271.12.914	http://dx.doi.org/10.1001/jama.271.12.914			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA743	8120959				2022-12-28	WOS:A1994NA74300026
J	COSSON, P; LETOURNEUR, F				COSSON, P; LETOURNEUR, F			COATOMER INTERACTION WITH DI-LYSINE ENDOPLASMIC-RETICULUM RETENTION MOTIFS	SCIENCE			English	Article							TRANSMEMBRANE PROTEINS; SECRETORY PATHWAY; RECEPTOR; TRANSPORT; COMPLEX; SIGNAL; GOLGI	Although signals for retention in the endoplasmic reticulum (ER) have been identified in the cytoplasmic domain of various ER-resident type I transmembrane proteins, the mechanisms responsible for ER retention are still unknown. Yeast and mammalian ER retention motifs interacted specifically in cell lysates with the coatomer, a polypeptide complex implicated in membrane traffic. Mutations that affect the ER retention capacity of the motifs also abolished binding of the coatomer. These results suggest a role for the coatomer in the retrieval of transmembrane proteins to the ER in both yeast and mammals.	BASEL INST IMMUNOL, CH-4005 BASEL, SWITZERLAND					Letourneur, Francois/0000-0003-2232-6127				BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; COSSON P, UNPUB; EMR S, COMMUNICATION; FRANZUSOFF A, 1991, METHOD ENZYMOL, V194, P662; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	24	486	492	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 18	1994	263	5153					1629	1631		10.1126/science.8128252	http://dx.doi.org/10.1126/science.8128252			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	8128252				2022-12-28	WOS:A1994NB67300037
J	OHTO, H; TERAZAWA, S; SASAKI, N; SASAKI, N; HINO, K; ISHIWATA, C; KAKO, M; UJIIE, N; ENDO, C; MATSUI, A; OKAMOTO, H; MISHIRO, S; KOJIMA, M; AIKAWA, T; SHIMODA, K; SAKAMOTO, M; AKAHANE, Y; YOSHIZAWA, H; TANAKA, T; TOKITA, H; TSUDA, F				OHTO, H; TERAZAWA, S; SASAKI, N; SASAKI, N; HINO, K; ISHIWATA, C; KAKO, M; UJIIE, N; ENDO, C; MATSUI, A; OKAMOTO, H; MISHIRO, S; KOJIMA, M; AIKAWA, T; SHIMODA, K; SAKAMOTO, M; AKAHANE, Y; YOSHIZAWA, H; TANAKA, T; TOKITA, H; TSUDA, F			TRANSMISSION OF HEPATITIS-C VIRUS FROM MOTHERS TO INFANTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; ASYMPTOMATIC CARRIER MOTHERS; POLYMERASE CHAIN-REACTION; PUTATIVE CORE GENE; NON-A-HEPATITIS; E-ANTIGEN; NEONATAL TRANSMISSION; VERTICAL TRANSMISSION; INFECTION; ANTIBODIES	Background. Although there are case reports of vertical transmission of hepatitis C virus (HCV), it remains uncertain to what extent infected mothers transmit this virus to their infants. Methods. We investigated the transmission of HCV from infected mothers to their babies by analyzing HCV RNA in the blood. Three independent studies were performed. First, 7698 parturient women were tested for anti-HCV antibodies; 53 were positive. Their 54 infants (including one set of twins) were followed prospectively for at least six months and tested for HCV infection. Second, the babies of six women with known HCV disease were prospectively studied. Third, the families of three HCV-infected infants were examined retrospectively. Results. Of the 53 antibody-positive mothers, 31 were also positive for serum HCV RNA, Three of the 54 babies born to these mothers (5.6 percent) became positive for HCV RNA during the follow-up period. None of the babies of the 22 women who were antibody-positive but HCV RNA-negative became positive for HCV RNA. In the second study, HCV RNA was detected in one of the six infants of infected mothers. In the third study, HCV RNA was detected in the mothers of the three HCV-infected infants. In each of the seven infected infants we studied, the genomic sequence of HCV was almost identical to that from the mother. These seven mothers had significantly higher titers of HCV RNA than did the mothers of infants with no evidence of infection (mean [+/-SD], 10(6.4+/-0.5) VS. 10(4.4+/-1.5) per milliliter; P<0.001). Conclusions. HCV is vertically transmitted from mother to infant, and the risk of transmission is correlated with the titer of HCV RNA in the mother.	INST IMMUNOL,BUNKYO KU,TOKYO,TOKYO 112,JAPAN; FUKUSHIMA MED COLL,BLOOD TRANSFUS SERV,FUKUSHIMA,FUKUSHIMA,JAPAN; FUKUSHIMA MED COLL,DEPT PEDIAT,FUKUSHIMA,FUKUSHIMA,JAPAN; FUKUSHIMA MED COLL,DEPT OBSTET & GYNECOL,FUKUSHIMA,FUKUSHIMA,JAPAN; GIFU KOUSEIREN GIHOKU HOSP,DIV PEDIAT,GIFU,GIFU,JAPAN; JICHI MED SCH,DEPT PEDIAT,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; JICHI MED SCH,DIV IMMUNOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; ONOMICHI GEN HOSP,DEPT PEDIAT,HIROSHIMA,HIROSHIMA,JAPAN; NATL DEF MED COLL,DEPT INTERNAL MED 2,TOKOROZAWA,SAITAMA,JAPAN; ISHIWATA OBSTET & GYNECOL HOSP,IBARAKI,OSAKA,JAPAN; TEIKYO UNIV,SCH MED,DEPT MED 4,SAGAMIKO,KANAGAWA,JAPAN; TEIKYO UNIV,SCH MED,DEPT MED 4,SAGAMIKO,KANAGAWA,JAPAN; AIKAWA INTERNAL HOSP,IBARAKI,OSAKA,JAPAN; YAMANASHI MED COLL,KOFU,YAMANASHI,JAPAN; HIROSHIMA UNIV,SCH MED,HIROSHIMA,HIROSHIMA,JAPAN; JAPANESE RED CROSS,SAITAMA BLOOD CTR,URAWA,SAITAMA,JAPAN; VIRAL HEPATITIS RES FDN JAPAN,TOKYO,TOKYO,JAPAN	Fukushima Medical University; Fukushima Medical University; Fukushima Medical University; Jichi Medical University; Jichi Medical University; National Defense Medical College - Japan; Teikyo University; Teikyo University; University of Yamanashi; Hiroshima University; Japanese Red Cross Medical Center			Okamoto, Hiroaki/H-4371-2011	Okamoto, Hiroaki/0000-0003-0827-0964; Mishiro, Shunji/0000-0001-9618-6468				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1976, NEW ENGL J MED, V295, P909, DOI 10.1056/NEJM197610212951701; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DEGOS F, 1991, LANCET, V338, P758, DOI 10.1016/0140-6736(91)91477-C; HIJIKATA M, 1991, BIOCHEM BIOPH RES CO, V175, P220, DOI 10.1016/S0006-291X(05)81223-9; INOUE Y, 1991, NATURE, V353, P609, DOI 10.1038/353609a0; KATO N, 1991, HEPATOLOGY, V14, pA67; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KOFF RS, 1992, ANN INTERN MED, V117, P967, DOI 10.7326/0003-4819-117-11-967; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAM JPH, 1993, J INFECT DIS, V167, P572, DOI 10.1093/infdis/167.3.572; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; MURATA S, 1977, NEW ENGL J MED, V296, P692; OKADA K, 1976, NEW ENGL J MED, V294, P746, DOI 10.1056/NEJM197604012941402; OKADA K, 1975, J PEDIATR-US, V87, P360, DOI 10.1016/S0022-3476(75)80635-4; OKADA S, 1992, HEPATOLOGY, V16, P619, DOI 10.1002/hep.1840160302; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1992, VIROLOGY, V190, P894, DOI 10.1016/0042-6822(92)90933-G; OKAMOTO H, 1992, HEPATOLOGY, V15, P180, DOI 10.1002/hep.1840150203; OKAMOTO H, 1990, JPN J EXP MED, V60, P223; REESINK HW, 1990, LANCET, V335, P1216, DOI 10.1016/0140-6736(90)92734-Y; REINUS JF, 1992, ANN INTERN MED, V117, P881, DOI 10.7326/0003-4819-117-11-881; ROUDOTTHORAVAL F, 1993, HEPATOLOGY, V17, P772, DOI 10.1002/hep.1840170504; SHIKATA T, 1977, J INFECT DIS, V136, P571, DOI 10.1093/infdis/136.4.571; TAKAHASHI K, 1992, J GEN VIROL, V73, P667, DOI 10.1099/0022-1317-73-3-667; TANIGUCHI S, 1993, VIROLOGY, V195, P297, DOI 10.1006/viro.1993.1378; THALER MM, 1991, LANCET, V338, P17, DOI 10.1016/0140-6736(91)90006-B; VANDENHOEK JAR, 1990, J INFECT DIS, V162, P823, DOI 10.1093/infdis/162.4.823; WEINER AJ, 1993, J VIROL, V67, P4365, DOI 10.1128/JVI.67.7.4365-4368.1993; WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; Wejstal R, 1992, ANN INTERN MED, V117, P887, DOI 10.7326/0003-4819-117-11-887	33	545	552	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 17	1994	330	11					744	750		10.1056/NEJM199403173301103	http://dx.doi.org/10.1056/NEJM199403173301103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA742	8107740	Bronze			2022-12-28	WOS:A1994NA74200003
J	NOFZINGER, EA; REYNOLDS, CF				NOFZINGER, EA; REYNOLDS, CF			REM-SLEEP BEHAVIOR DISORDER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											NOFZINGER, EA (corresponding author), UNIV PITTSBURGH,SCH MED,PITTSBURGH,PA, USA.							BENTAL E, 1979, ISRAEL J MED SCI, V15, P607; HOLLANDER E, 1990, ARCH GEN PSYCHIAT, V47, P27; MAHOWALD MW, 1992, NEUROLOGY, V42, P44; SCHENCK CH, 1987, JAMA-J AM MED ASSOC, V257, P1786, DOI 10.1001/jama.257.13.1786	4	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					820	820		10.1001/jama.271.11.820	http://dx.doi.org/10.1001/jama.271.11.820			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ498	8114229				2022-12-28	WOS:A1994MZ49800012
J	SOH, J; DONNELLY, RJ; KOTENKO, S; MARIANO, TM; COOK, JR; WANG, N; EMANUEL, S; SCHWARTZ, B; MIKI, T; PESTKA, S				SOH, J; DONNELLY, RJ; KOTENKO, S; MARIANO, TM; COOK, JR; WANG, N; EMANUEL, S; SCHWARTZ, B; MIKI, T; PESTKA, S			IDENTIFICATION AND SEQUENCE OF AN ACCESSORY FACTOR REQUIRED FOR ACTIVATION OF THE HUMAN INTERFERON-GAMMA RECEPTOR	CELL			English	Article							HUMAN IMMUNE INTERFERON; EXTRACELLULAR DOMAIN; IFN-GAMMA; TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; SIGNAL TRANSDUCER; ALPHA RECEPTOR; HAMSTER-CELLS; EXPRESSION; CDNA	Human chromosomes 6 and 21 are both necessary to confer sensitivity to human interferon gamma (Hu-IFN-gamma), as measured by induction of class I human leukocyte antigen (HLA) and protection against encephalomyocarditis virus (EMCV) infection. Whereas human chromosome 6 encodes the Hu-IFN-gamma receptor, human chromosome 21 encodes accessary factors for generating biological activity through the Hu-IFN-gamma receptor. Probes from a genomic clone were used to identity cDNA clones expressing a species-specific accessory factor. These cDNA clones are able to substitute for human chromosome 21 to reconstitute the Hu-IFN-gamma receptor-mediated induction of class I HLA antigens. However, the factor encoded by the cDNA does not confer full antiviral protection against EMCV, confirming that an additional factor encoded on human chromosome 21 is required for reconstitution of antiviral activity against EMCV. We conclude that this accessory factor belongs to a family of such accessory factors responsible for different actions of IFN-gamma.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MOLEC GENET & MICROBIOL,PISCATAWAY,NJ 08854; NCI,DIV CANC ETIOL,CELL & MOLEC BIOL LAB,BETHESDA,MD 20892	Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [R01 CA46465] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046465] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1990, CELL, V61, P753, DOI 10.1016/0092-8674(90)90182-E; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BLALOCK JE, 1980, CELL IMMUNOL, V49, P390, DOI 10.1016/0008-8749(80)90041-6; COOK JR, 1994, J BIOL CHEM, V269, P7013; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Familletti P C, 1981, Methods Enzymol, V78, P387; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; HIBINO Y, 1991, J BIOL CHEM, V266, P6948; JUNG V, 1988, SOMAT CELL MOLEC GEN, V14, P583, DOI 10.1007/BF01535312; JUNG V, 1990, J BIOL CHEM, V265, P1827; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; JUNG V, 1991, THESIS RUTGERS STATE; KALINA U, 1993, J VIROL, V67, P1702, DOI 10.1128/JVI.67.3.1702-1706.1993; KINLOCH RA, 1991, J CELL BIOL, V115, P655, DOI 10.1083/jcb.115.3.655; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; KUMAR CS, 1988, J BIOL CHEM, V263, P13493; KUMAR CS, 1989, J BIOL CHEM, V264, P17939; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDOLFO S, 1991, J IMMUNOL RES, V3, P81; LANGER JA, 1990, SOMAT CELL MOLEC GEN, V16, P231, DOI 10.1007/BF01233359; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LIM JK, 1993, BIOCHIM BIOPHYS ACTA, V1173, P314, DOI 10.1016/0167-4781(93)90129-2; LUTFALLA G, 1993, GENOMICS, V16, P366, DOI 10.1006/geno.1993.1199; MARIANO TM, 1987, J BIOL CHEM, V262, P5812; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MOUCHELVIELH E, 1992, FEBS LETT, V313, P255, DOI 10.1016/0014-5793(92)81204-Y; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; RASHIDBAIGI A, 1986, P NATL ACAD SCI USA, V83, P384, DOI 10.1073/pnas.83.2.384; REHBERG E, 1982, J BIOL CHEM, V257, P1497; ROTHERMEL CD, 1983, J IMMUNOL, V131, P2542; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEALEY PG, 1985, NUCLEIC ACIDS RES, V13, P1905, DOI 10.1093/nar/13.6.1905; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, IN PRESS DNA CELL BI; Stark George R., 1993, Journal of Interferon Research, V13, pS54; STONEWOLFF DS, 1984, J EXP MED, V159, P828, DOI 10.1084/jem.159.3.828; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; TYRING S, 1982, INT J CANCER, V30, P59, DOI 10.1002/ijc.2910300111; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VOLLRATH D, 1988, P NATL ACAD SCI USA, V85, P6027, DOI 10.1073/pnas.85.16.6027; WETLING D, 1993, NATURE, V366, P166; WHEELOCK EF, 1965, SCIENCE, V149, P310, DOI 10.1126/science.149.3681.310; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	76	247	259	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 11	1994	76	5					793	802		10.1016/0092-8674(94)90354-9	http://dx.doi.org/10.1016/0092-8674(94)90354-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124716				2022-12-28	WOS:A1994NA89000005
J	RHIM, JA; SANDGREN, EP; DEGEN, JL; PALMITER, RD; BRINSTER, RL				RHIM, JA; SANDGREN, EP; DEGEN, JL; PALMITER, RD; BRINSTER, RL			REPLACEMENT OF DISEASED MOUSE-LIVER BY HEPATIC CELL TRANSPLANTATION	SCIENCE			English	Article							TRANSGENIC MICE; STEM-CELL; HEPATOCYTES; EXPRESSION; REGENERATION; RABBIT	Adult liver has the unusual ability to fully regenerate after injury. Although regeneration is accomplished by the division of mature hepatocytes, the replicative potential of these cells is unknown. Here, the replicative capacity of adult liver cells and their medical usefulness as donor cells for transplantation were investigated by transfer of adult mouse liver cells into transgenic mice that display an endogenous defect in hepatic growth potential and function. The transplanted liver cell populations replaced up to 80 percent of the diseased recipient liver. These findings demonstrate the enormous growth potential of adult hepatocytes, indicating the feasibility of liver cell transplantation as a method to replace lost or diseased hepatic parenchyma.	UNIV PENN,SCH VET MED,DEPT ANIM BIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,CHILDRENS HOSP RES FDN,CINCINNATI,OH 45229; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Pennsylvania; University of Pennsylvania; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				Brinster, Ralph/0000-0003-1408-7656	NICHD NIH HHS [HD-23657, HD09172] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009172, R37HD009172, R37HD023657] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMENTANO D, 1990, P NATL ACAD SCI USA, V87, P6141, DOI 10.1073/pnas.87.16.6141; FAUSTO N, 1990, HEPATOLOGY TXB LIVER, P49; FAUSTO N, 1987, CELL SEPARATION METH, V4, P45; JONES EA, 1990, HEPATOLOGY TXB LIVER, P460; KAY MA, 1992, P NATL ACAD SCI USA, V89, P89, DOI 10.1073/pnas.89.1.89; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; PALMITER RD, 1993, MOL CELL BIOL, V13, P5266, DOI 10.1128/MCB.13.9.5266; PONDER KP, 1991, P NATL ACAD SCI USA, V88, P1217, DOI 10.1073/pnas.88.4.1217; RHIM JS, UNPUB; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; SANDGREN EP, 1991, P NATL ACAD SCI USA, V88, P93, DOI 10.1073/pnas.88.1.93; SELL S, 1990, CANCER RES, V50, P3811; SIGAL SH, 1992, AM J PHYSIOL, V263, pG139, DOI 10.1152/ajpgi.1992.263.2.G139; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P8437, DOI 10.1073/pnas.87.21.8437; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P4421, DOI 10.1073/pnas.85.12.4421	18	482	511	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 25	1994	263	5150					1149	1152		10.1126/science.8108734	http://dx.doi.org/10.1126/science.8108734			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	8108734				2022-12-28	WOS:A1994MX75900036
J	MAHOMED, K; NYONI, R; MULAMBO, T; KASULE, J; JACOBUS, E				MAHOMED, K; NYONI, R; MULAMBO, T; KASULE, J; JACOBUS, E			RANDOMIZED CONTROLLED TRIAL OF INTRAPARTUM FETAL HEART-RATE MONITORING	BRITISH MEDICAL JOURNAL			English	Article								Objective--To compare effectiveness of different methods of monitoring intrapartum fetal heart rate. Design-Prospective randomised controlled trial. Setting-Referral maternity hospital, Harare, Zimbabwe. Subjects-1255 women who were 37 weeks or more pregnant with singleton cephalic presentation and normal fetal heart rate before entry into study. Interventions-Intermittent monitoring of fetal heart rate by electronic monitoring, Doppler ultrasound, use of Pinard stethoscope by a research midwife, or routine use of Pinard stethoscope by attending midwife. Main outcome measures-Abnormal fetal heart rate patterns, need for operative delivery for fetal distress, neonatal mortality, Apgar scores, admission to neonatal unit, neonatal seizures, and hypoxic ischaemic encephalopathy. Results-Abnormalities in fetal heart rate were detected in 54% (172/318) of the electronic monitoring group, 32% (100/312) of the ultrasonography group, 15% (47/310) of the Pinard stethoscope group, and 9% (28/315) of the routine monitoring group. Caesarean sections were performed for 28% (89), 24% (76), 10% (32), and 15% (46) of the four groups respectively. Neonatal outcome was best in the ultrasonography group: hypoxic ischaemic encephalopathy occurred in two, one, seven, and 10 cases in the four groups respectively; neonatal seizures occurred only in the last two groups (six and nine cases respectively); and deaths occurred in eight, two, five, and nine cases respectively. Conclusions-Abnormalities in fetal heart rate were more reliably detected by Doppler ultrasonography than with Pinard stethoscope, and its use resulted in good perinatal outcome. The use of relatively cheap ultrasound monitors should be further evaluated and promoted in obstetric units caring for high risk pregnancies in developing countries with scarce resources.			MAHOMED, K (corresponding author), UNIV ZIMBABWE,DEPT OBSTET,POB A178,HARARE,ZIMBABWE.							ARULKUMARAN S, 1990, PROGR OBSTETRICS GYN, V8, P127; Chalmers I., 1979, PERINATAL MED, P260; CRAWFORD JW, 1986, J PERINAT MED, V14, P379; GARCIA J, 1985, BIRTH-ISS PERINAT C, V12, P79, DOI 10.1111/j.1523-536X.1985.tb00943.x; GRANT A, 1989, EFFECTIVE CARE PREGN, V2, P846; HAVERKAMP AD, 1976, AM J OBSTET GYNECOL, V125, P310, DOI 10.1016/0002-9378(76)90565-2; HAVERKAMP AD, 1979, AM J OBSTET GYNECOL, V134, P399, DOI 10.1016/S0002-9378(16)33082-4; MACDONALD D, 1985, AM J OBSTET GYNECOL, V152, P524, DOI 10.1016/0002-9378(85)90619-2; PHILPOTT RH, 1972, J OBSTET GYN BR COMM, V79, P592; PHILPOTT RH, 1972, J OBSTET GYN BR COMM, V79, P599; RENOU P, 1976, AM J OBSTET GYNECOL, V126, P470, DOI 10.1016/0002-9378(76)90641-4; SARNAT HB, 1993, CLIN PERINATOL, P411; STEER PJ, 1989, OBSTET GYNECOL, V74, P715	13	51	53	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	1994	308	6927					497	500		10.1136/bmj.308.6927.497	http://dx.doi.org/10.1136/bmj.308.6927.497			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX814	8136665	Green Published			2022-12-28	WOS:A1994MX81400018
J	SUZUKI, M; TAKAHASHI, K; IKEDA, M; HAYAKAWA, H; OGAWA, A; KAWAGUCHI, Y; SAKAI, O				SUZUKI, M; TAKAHASHI, K; IKEDA, M; HAYAKAWA, H; OGAWA, A; KAWAGUCHI, Y; SAKAI, O			CLONING OF A PH-SENSITIVE K+ CHANNEL POSSESSING 2 TRANSMEMBRANE SEGMENTS	NATURE			English	Article							POTASSIUM CHANNELS; TEA BLOCKADE; DROSOPHILA; SHAKER; MODULATION; COMPONENT; CALCIUM; TUBULE; LOCUS; BRAIN	THE mammalian renal collecting ducts are responsible for secreting potassium ions into the urine and are a major regulatory site for potassium homeostasis(1), in which a voltage-independent pH-sensitive K+ channel in the apical membrane plays a central role(2,3). Here we describe a complementary DNA encoding a novel K+ channel from rabbit renal cortical collecting tubule cells (RACTK1). RACTK1 has the functional characteristics of the apical K+-permeable channel and consists of 284 amino acids, putatively with two transmembrane segments. The sequence of RACTK1, however, shows no homology to known voltage-dependent or -independent K+ channels, and has a different K+-driving path and regulatory sites, The study of this protein should provide insight into K+ homeostasis and diseases of K+ metabolism.	JIKEIKAI UNIV, SCH MED, MINATO KU, TOKYO, TOKYO 105, JAPAN	Jikei University	SUZUKI, M (corresponding author), JICHI MED SCH, DEPT PHARMACOL, 3311-1 MINAMIKAWACHI, KAWACHI, TOCHIGI 32904, JAPAN.		Ikeda, Masato/AHD-4141-2022	Ikeda, Masato/0000-0003-3583-5975				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHANDY KG, 1990, SCIENCE, V247, P943; GIEBISCH G, 1987, POTASSIUM TRANSPORT, P133; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LEVITAN ES, 1990, NATURE, V348, P545, DOI 10.1038/348545a0; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; Maniatis T., 1982, MOL CLONING; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; MISLER S, 1989, J MEMBRANE BIOL, V109, P135, DOI 10.1007/BF01870852; PAK MD, 1991, J NEUROSCI, V11, P869; PAK MD, 1991, P NATL ACAD SCI USA, V88, P4386, DOI 10.1073/pnas.88.10.4386; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; ROSE GD, 1978, NATURE, V272, P586, DOI 10.1038/272586a0; SUZUKI M, 1993, J MEMBRANE BIOL, V134, P31; SUZUKI M, 1991, J CLIN INVEST, V88, P735, DOI 10.1172/JCI115370; TAKUMI T, 1988, SCIENCE, V242, P1024; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; THREVENOD F, 1992, J MEMBRANE BIOL, V129, P253; WANG WH, 1991, J GEN PHYSIOL, V98, P35, DOI 10.1085/jgp.98.1.35; WANG WH, 1990, AM J PHYSIOL, V259, pF494, DOI 10.1152/ajprenal.1990.259.3.F494; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494	28	68	68	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	1994	367	6464					642	645		10.1038/367642a0	http://dx.doi.org/10.1038/367642a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	8107848				2022-12-28	WOS:A1994MW68800053
J	STUART, MJ; HODGETTS, TJ				STUART, MJ; HODGETTS, TJ			ADULT EPIGLOTTITIS - PROMPT DIAGNOSIS SAVES LIVES	BRITISH MEDICAL JOURNAL			English	Article									HOPE HOSP,DEPT EMERGENCY MED,SALFORD M6 8HD,LANCS,ENGLAND									BASS JW, 1974, JAMA-J AM MED ASSOC, V229, P671, DOI 10.1001/jama.229.6.671; BERENBERG W, 1958, NEW ENGL J MED, V258, P870, DOI 10.1056/NEJM195805012581802; CROSBY E, 1991, CAN J ANAESTH, V38, P914, DOI 10.1007/BF03036974; DAUM RS, 1992, TXB PEDIATRIC INFECT; LAING M, 1989, PRACTITIONER, V233, P835; LEDERMAN MM, 1982, AM REV RESPIR DIS, V125, P117; MAYOSMITH MF, 1986, NEW ENGL J MED, V314, P1133, DOI 10.1056/NEJM198605013141801; NAVARRETE ML, 1991, J LARYNGOL OTOL, V105, P839, DOI 10.1017/S0022215100117487; RIVRON RP, 1991, CLIN OTOLARYNGOL, V16, P338, DOI 10.1111/j.1365-2273.1991.tb00944.x; TVETERAS K, 1987, CLIN OTOLARYNGOL, V12, P337, DOI 10.1111/j.1365-2273.1987.tb00213.x	10	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 29	1994	308	6924					329	330		10.1136/bmj.308.6924.329	http://dx.doi.org/10.1136/bmj.308.6924.329			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU492	8124122	Green Published			2022-12-28	WOS:A1994MU49200026
J	LIU, ZG; SMITH, SW; MCLAUGHLIN, KA; SCHWARTZ, LM; OSBORNE, BA				LIU, ZG; SMITH, SW; MCLAUGHLIN, KA; SCHWARTZ, LM; OSBORNE, BA			APOPTOTIC SIGNALS DELIVERED THROUGH THE T-CELL RECEPTOR OF A T-CELL HYBRID REQUIRE THE IMMEDIATE-EARLY GENE NUR77	NATURE			English	Article							MONOCLONAL-ANTIBODY; ACTIVATION; DEATH; ANTIGEN; THYMOCYTES; FRAGMENTATION; DEGRADATION; INDUCTION	ENGAGEMENT of the T-cell antigen receptor (TCR) on immature thymic T cells induces death by apoptosis1-3. Although several lines of evidence indicate that apoptosis requires de novo gene expression, little is known about the molecular pathways that mediate this response. Here we show that nur77 (refs 4-7), a zinc-finger transcription factor, is expressed in response to TCR engagement in immature T cells and T-cell hybrids. Antisense inhibition of nur77 expression prevents apoptosis in TCR-stimulated cells. nur 7 is also expressed in response to mitogens, but in this case transcription is regulated by 5' upstream elements that are distinct from those used for induction of apoptosis. In addition, polyadenylation is only observed on nur77 transcripts found in condemned cells. These data support a role for nur77 in cell death that may be distinct from that of activation.	UNIV MASSACHUSETTS,DEPT VET & ANIM SCI,AMHERST,MA 01003; UNIV MASSACHUSETTS,DEPT BIOL,AMHERST,MA 01003; UNIV MASSACHUSETTS,PROGRAM MOLEC & CELLULAR BIOL,AMHERST,MA 01003	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst								ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; AUSEBEL FM, 1987, CURRENT PROTOCOLS MO; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MONROE D, 1990, MOL CELL BIOL, V10, P3441; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1990, J IMMUNOL, V144, P3326; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; UCKER DS, 1989, J IMMUNOL, V143, P3461; VARNUM BC, 1989, ONCOGENE, V4, P1263; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	22	496	514	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 20	1994	367	6460					281	284		10.1038/367281a0	http://dx.doi.org/10.1038/367281a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	8121494				2022-12-28	WOS:A1994MR49400059
J	MORENO, S; NURSE, P				MORENO, S; NURSE, P			REGULATION OF PROGRESSION THROUGH THE G1 PHASE OF THE CELL-CYCLE BY THE RUM1(+) GENE	NATURE			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; S-PHASE; MITOSIS; DIVISION; SEQUENCE; P34CDC2	The rum1+ gene is identified as a new regulator of G1 progression in fission yeast. It influences three aspects of G1 regulation: determination of the length of G1, dependence of S phase upon completion of mitosis, and restraint of mitosis until G1 is finished. We propose that it has a central role in regulating the G1 phase of the cell cycle.	ICRF, LONDON WCZA 3PX, ENGLAND; UNIV OXFORD, DEPT BIOCHEM, ICRF, CELL CYCLE GRP, OXFORD OX1 1QU, ENGLAND	University of Oxford			Moreno, Sergio/K-3671-2014	Moreno, Sergio/0000-0002-8039-1413				BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BOSTOCK CJ, 1970, EXP CELL RES, V60, P16, DOI 10.1016/0014-4827(70)90484-2; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CALIGIURI M, 1993, CELL, V72, P607, DOI 10.1016/0092-8674(93)90079-6; CARR AM, 1989, MOL GEN GENET, V218, P41, DOI 10.1007/BF00330563; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; EGEL R, 1990, TRENDS GENET, V6, P369, DOI 10.1016/0168-9525(90)90279-F; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; GENDIMENICO GJ, 1988, ANAL BIOCHEM, V173, P45, DOI 10.1016/0003-2697(88)90156-X; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1977, J CELL BIOL, V75, P422, DOI 10.1083/jcb.75.2.422; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HOFER F, 1979, CURR GENET, V1, P45, DOI 10.1007/BF00413306; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1979, J CELL SCI, V39, P215; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1980, GENETICS, V96, P627; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; NURSE P, 1977, EXP CELL RES, V107, P365, DOI 10.1016/0014-4827(77)90358-5; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; SAZER S, 1990, J CELL SCI, V97, P509; SMITH AV, 1991, DEVELOPMENT, V112, P997; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; TANAKA K, 1992, EMBO J, V11, P4923, DOI 10.1002/j.1460-2075.1992.tb05599.x; THURIAUX P, 1980, J GEN MICROBIOL, V116, P525; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x	44	310	315	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	1994	367	6460					236	242		10.1038/367236a0	http://dx.doi.org/10.1038/367236a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	8121488				2022-12-28	WOS:A1994MR49400045
J	SOUTHALL, DP; SAMUELS, MP				SOUTHALL, DP; SAMUELS, MP			ETHICAL USE OF COVERT VIDEOING FOR POTENTIALLY LIFE-THREATENING CHILD-ABUSE - A RESPONSE	BRITISH MEDICAL JOURNAL			English	Article							MUNCHAUSEN-SYNDROME; PROXY; SURVEILLANCE				SOUTHALL, DP (corresponding author), UNIV KEELE,N STAFFORDSHIRE HOSP,ACAD DEPT PAEDIATR,STOKE ON TRENT ST4 6QG,ENGLAND.							ALEXANDER R, 1990, PEDIATRICS, V86, P581; EPSTEIN MA, 1987, PEDIATRICS, V80, P220; MEADOW R, 1990, J PEDIATR-US, V117, P351, DOI 10.1016/S0022-3476(05)81072-8; ROSEN CL, 1983, PEDIATRICS, V71, P715; SAMUELS MP, 1992, ARCH DIS CHILD, V67, P162, DOI 10.1136/adc.67.2.162; SOUTHALL DP, 1987, BRIT MED J, V294, P1637, DOI 10.1136/bmj.294.6588.1637; WALLER DA, 1983, J AM ACAD CHILD PSY, V22, P80, DOI 10.1097/00004583-198301000-00013; WILLIAMS C, 1988, LANCET, V1, P780	8	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1993	307	6904					613	614		10.1136/bmj.307.6904.613	http://dx.doi.org/10.1136/bmj.307.6904.613			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LW149	8129811	Bronze, Green Published			2022-12-28	WOS:A1993LW14900024
J	BARNSLEY, L; LORD, SM; WALLIS, BJ; BOGDUK, N				BARNSLEY, L; LORD, SM; WALLIS, BJ; BOGDUK, N			LACK OF EFFECT OF INTRAARTICULAR CORTICOSTEROIDS FOR CHRONIC PAIN IN THE CERVICAL ZYGAPOPHYSEAL JOINTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL-EVALUATION; ARTHROGRAPHY; PATTERNS	Background. Chronic pain in the cervical zygapophyseal joints is a common problem after a whiplash injury. Treatment with intraarticular injections of corticosteroid preparations has been advocated, but the value of this approach has not been established. We compared the efficacy of a depot injection of a corticosteroid preparation with the efficacy of an injection of a local anesthetic agent in patients with painful cervical zygapophyseal joints. Methods. Sixteen men and 25 women with pain in one or more cervical zygapophyseal joints after automobile accidents (mean age, 43 years; median duration of pain, 39 months) were randomly assigned to receive a 1-ml intraarticular injection of either bupivacaine (0.5 percent) or betamethasone (5.7 mg) under double-blind conditions. The patients were followed by means of regular telephone contact and clinic visits until they reported a return to a level of pain equivalent to 50 percent of the preinjection level. The time from treatment to a 50 percent return of pain was compared in the two groups with the use of a survival analysis. Results. Less than half the patients reported relief of pain for more than one week, and less than one in five patients reported relief for more than one month, irrespective of the treatment received. The median time to a return of 50 percent of the preinjection level of pain was 3 days in the 21 patients in the corticosteroid group and 3.5 days in the 20 patients in the local-anesthetic group (P = 0.42). Conclusions. Intraarticular injection of betamethasone is not effective therapy for pain in the cervical zygapophyseal joints after a whiplash injury.	MATER MISERICORDIAE HOSP,WARATAH,NSW,AUSTRALIA		BARNSLEY, L (corresponding author), UNIV NEWCASTLE,FAC MED,CERVICAL SPINE RES UNIT,UNIV DR,NEWCASTLE,NSW 2308,AUSTRALIA.		Lord, Susan M/AAG-4342-2021	Lord, Susan M/0000-0002-8990-836X				APRILL C, 1990, SPINE, V15, P458, DOI 10.1097/00007632-199006000-00005; APRILL C, 1992, SPINE, V17, P744, DOI 10.1097/00007632-199207000-00003; ARNER S, 1990, PAIN, V43, P287, DOI 10.1016/0304-3959(90)90026-A; BARNSLEY L, 1993, REGION ANESTH, V18, P343; BARNSLEY L, 1993, PAIN, V55, P99, DOI 10.1016/0304-3959(93)90189-V; BOGDUK N, 1982, SPINE, V7, P319, DOI 10.1097/00007632-198207000-00001; Derogatis L.R, 1983, SCL 90 R ADM SCORING, VII; DORY MA, 1983, RADIOLOGY, V148, P379, DOI 10.1148/radiology.148.2.6867328; DUSSAULT RG, 1985, J CAN ASSOC RADIOL, V36, P79; DWYER A, 1990, SPINE, V15, P453; HOVE B, 1990, NEURORADIOLOGY, V32, P456, DOI 10.1007/BF02426454; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; PECK C, 1991, THEOR MED, V12, P247, DOI 10.1007/BF00489609; ROY DF, 1988, J CAN ASSOC RADIOL, V39, P118; RUBIN AP, 1968, ANAESTHESIA, V23, P327, DOI 10.1111/j.1365-2044.1968.tb00075.x; WATT MJ, 1968, ANAESTHESIA, V23, P331, DOI 10.1111/j.1365-2044.1968.tb00076.x; WEDEL DJ, 1985, REGION ANESTH PAIN M, V10, P7	17	142	147	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 14	1994	330	15					1047	1050		10.1056/NEJM199404143301504	http://dx.doi.org/10.1056/NEJM199404143301504			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF022	8127332				2022-12-28	WOS:A1994NF02200004
J	FERRIS, PJ; GOODENOUGH, UW				FERRIS, PJ; GOODENOUGH, UW			THE MATING-TYPE LOCUS OF CHLAMYDOMONAS-REINHARDTII CONTAINS HIGHLY REARRANGED DNA-SEQUENCES	CELL			English	Article							A-ALPHA; SCHIZOPHYLLUM-COMMUNE; FUNCTIONAL-ANALYSIS; CHLOROPLAST GENES; NEUROSPORA-CRASSA; LINKED MUTATIONS; MUTANTS; YEAST; RECOMBINATION; PROTEINS	The mating-type locus of Chlamydomonas reinhardtii exists as two apparent alleles (mt+ and mt-) that control mating in haploid gametes and sporulation and meiosis in diploid mt+/mt- zygotes. Twelve genes, seven unrelated to life cycle transitions, are tightly linked to mt, suggesting that the locus exerts recombinational suppression. A 1.1 Mb chromosome walk from a gene linked to mt demonstrates that the mt+ and mt- loci carry four intrachromosomal translocations, two inversions, and large deletions and duplications within a 190 kb sector, presumably accounting for the recombinational suppression that extends through 640 kb of flanking homologous DNA. The rearranged domain also carries blocks of mt+- and mt--specific sequences, at least one of which includes a mt+-specific gene. The locus has the properties of an incipient sex chromosome.			FERRIS, PJ (corresponding author), WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130, USA.							ADAMS GMW, 1982, GENETICS, V100, P579; Allen CE, 1932, AM NAT, V66, P97, DOI 10.1086/280416; Allen CE, 1935, BOT REV, V1, P269; [Anonymous], 1966, GENETICS SEXUALITY H; ARMBRUST EV, 1993, CELL, V74, P801, DOI 10.1016/0092-8674(93)90460-8; ARNAISE S, 1993, P NATL ACAD SCI USA, V90, P6616, DOI 10.1073/pnas.90.14.6616; ASTELL CR, 1981, CELL, V27, P15, DOI 10.1016/0092-8674(81)90356-1; BAKKEREN G, 1993, PLANT CELL, V5, P2323; BELL G, 1989, SEX DEATH PROTOZOA; Bull J.J., 1983, EVOLUTION SEX DETERM; BURGOYNE PS, 1992, CELL, V71, P391, DOI 10.1016/0092-8674(92)90509-B; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; DEBUCHY R, 1992, MOL GEN GENET, V233, P113, DOI 10.1007/BF00587568; DEBUCHY R, 1989, EMBO J, V8, P2803, DOI 10.1002/j.1460-2075.1989.tb08426.x; Dee J., 1982, CELL BIOL PHYSARUM D, P211; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; DUTCHER SK, 1992, GENETICS, V131, P593; DZELZKALNS VA, 1992, DEV BIOL, V153, P70, DOI 10.1016/0012-1606(92)90092-U; EBERSOLD WT, 1967, SCIENCE, V157, P447, DOI 10.1126/science.157.3787.447; FERRIS PJ, 1989, GENETICS, V122, P363; FERRIS PJ, 1987, MOL CELL BIOL, V7, P2360, DOI 10.1128/MCB.7.7.2360; GALLOWAY RE, 1985, GENETICS, V111, P447; GILLHAM NW, 1969, AM NAT, V103, P355, DOI 10.1086/282608; GILLHAM NW, 1987, GENETICS, V115, P677; GILLHAM NW, 1978, ORGANELLE HEREDITY; GILLISSEN B, 1992, CELL, V68, P647, DOI 10.1016/0092-8674(92)90141-X; GLASS NL, 1990, P NATL ACAD SCI USA, V87, P4912, DOI 10.1073/pnas.87.13.4912; Goodenough U.W., 1991, MICROBIAL CELL CELL, P71; GOODENOUGH UW, 1982, J CELL BIOL, V92, P378, DOI 10.1083/jcb.92.2.378; GOODENOUGH UW, 1987, GENETIC REGULATION D, P171; GORING DR, 1993, PLANT CELL, V5, P531, DOI 10.1105/tpc.5.5.531; HABER JE, 1991, P NATL ACAD SCI USA, V88, P1120, DOI 10.1073/pnas.88.4.1120; HAMMER MF, 1991, GENETICS, V128, P799; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HICKEY DA, 1982, GENETICS, V101, P519; Hickey DA, 1988, EVOLUTION SEX, P161; HIMMELBAUER H, 1993, GENOMICS, V17, P110, DOI 10.1006/geno.1993.1291; HURST LD, 1991, GENETICS, V128, P841; HURST LD, 1992, P ROY SOC B-BIOL SCI, V247, P189, DOI 10.1098/rspb.1992.0027; HURST LD, 1992, P ROY SOC B-BIOL SCI, V248, P135, DOI 10.1098/rspb.1992.0053; HWANG CJ, 1981, GENETICS, V99, P41; KAISER K, 1985, DNA CLONING PRACTICA, V1, P1; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KUES U, 1992, GENE DEV, V6, P568, DOI 10.1101/gad.6.4.568; LEWIN RA, 1983, EXPERIENTIA, V39, P1397, DOI 10.1007/BF01990124; LOPPES R, 1986, ARCH MICROBIOL, V143, P348, DOI 10.1007/BF00412801; LORENTZ A, 1992, MOL GEN GENET, V233, P436, DOI 10.1007/BF00265441; LYTTLE TW, 1993, TRENDS GENET, V9, P205, DOI 10.1016/0168-9525(93)90120-7; Maniatis T., 1982, MOL CLONING; MATSUDA Y, 1988, CURR GENET, V14, P53, DOI 10.1007/BF00405854; MICHOD RE, 1988, EVOLUTION SEX EXAMIN; MOORE TDE, 1993, MOL CELL BIOL, V13, P1962, DOI 10.1128/MCB.13.3.1962; Roberts PA, 1976, GENETICS BIOL DROS A, P68; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; SAGER R, 1954, P NATL ACAD SCI USA, V40, P356, DOI 10.1073/pnas.40.5.356; SCHMITT R, 1992, INT REV CYTOL, V139, P189, DOI 10.1016/S0074-7696(08)61413-8; SEGAL RA, 1984, J CELL BIOL, V98, P2026, DOI 10.1083/jcb.98.6.2026; SELANDER RK, 1991, EVOLUTON MOL LEVEL; SILVER LM, 1993, TRENDS GENET, V9, P250, DOI 10.1016/0168-9525(93)90090-5; SILVER LM, 1985, ANNU REV GENET, V19, P179, DOI 10.1146/annurev.ge.19.120185.001143; SMYTH RD, 1975, J BACTERIOL, V124, P1615, DOI 10.1128/JB.124.3.1615-1617.1975; SPECHT CA, 1992, P NATL ACAD SCI USA, V89, P7174, DOI 10.1073/pnas.89.15.7174; STABEN C, 1990, P NATL ACAD SCI USA, V87, P4917, DOI 10.1073/pnas.87.13.4917; STANKIS MM, 1992, P NATL ACAD SCI USA, V89, P7169, DOI 10.1073/pnas.89.15.7169; TANTIKANJANA T, 1993, PLANT CELL, V5, P657, DOI 10.1105/tpc.5.6.657; THON G, 1993, GENETICS, V134, P1045; TURGEON BG, 1993, MOL GEN GENET, V238, P270; TURMEL M, 1993, J MOL BIOL, V232, P446, DOI 10.1006/jmbi.1993.1402; TYMON AM, 1992, EMBO J, V11, P1805, DOI 10.1002/j.1460-2075.1992.tb05232.x; WESTERGAARD M, 1958, ADV GENET, V9, P217, DOI 10.1016/S0065-2660(08)60163-7; WU CI, 1991, EVOLUTION AT THE MOLECULAR LEVEL, P177	72	115	117	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1135	1145		10.1016/0092-8674(94)90389-1	http://dx.doi.org/10.1016/0092-8674(94)90389-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137428				2022-12-28	WOS:A1994ND24600018
J	XIE, T; FINELLI, AL; PADGETT, RW				XIE, T; FINELLI, AL; PADGETT, RW			THE DROSOPHILA SAXOPHONE GENE - A SERINE-THREONINE KINASE RECEPTOR OF THE TGF-BETA SUPERFAMILY	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; DECAPENTAPLEGIC GENE; EXPRESSION CLONING; CELL-PROLIFERATION; CATALYTIC SUBUNIT; PATTERN-FORMATION; MELANOGASTER; COMPLEX; FAMILY; INHIBITION	The Drosophila decapentaplegic (dpp) gene encodes a transforming growth factor-beta (TGF-beta)-like protein that plays a key role in several aspects of development. Transduction of the DPP signal was investigated by cloning of serine-threonine kinase transmembrane receptors from Drosophila because this type of receptor is specific for the TGF-beta-like ligands. Here evidence is provided demonstrating that the Drosophila saxophone (sax) gene, a previously identified female sterile locus, encodes a TGF-beta-like type I receptor. Embryos from sax mothers and dpp embryos exhibit similar mutant phenotypes during early gastrulation, and these two loci exhibit genetic interactions, which suggest that they are utilized in the same pathway. These data suggest that sax encodes a receptor for dpp.	RUTGERS STATE UNIV,WAKSMAN INST,PISCATAWAY,NJ 08855; RUTGERS STATE UNIV,DEPT MOLEC BIOL & BIOCHEM,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick								ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FINELLI AL, IN PRESS DEVELOPMENT; FRANZEN P, 1993, CELL, V75, P69; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PADGETT RW, UNPUB; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; SCHUPBACH T, 1989, GENETICS, V121, P101; SEGAL D, 1985, GENETICS, V109, P119; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WEISER R, 1993, MOL CELL BIOL, V13, P7239; WHARTON KA, 1993, DEVELOPMENT, V117, P807; Wieschaus E., 1986, P199; Xie T., UNPUB	43	122	127	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 25	1994	263	5154					1756	1759		10.1126/science.8134837	http://dx.doi.org/10.1126/science.8134837			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC040	8134837				2022-12-28	WOS:A1994NC04000034
J	KOPF, M; BAUMANN, H; FREER, G; FREUDENBERG, M; LAMERS, M; KISHIMOTO, T; ZINKERNAGEL, R; BLUETHMANN, H; KOHLER, G				KOPF, M; BAUMANN, H; FREER, G; FREUDENBERG, M; LAMERS, M; KISHIMOTO, T; ZINKERNAGEL, R; BLUETHMANN, H; KOHLER, G			IMPAIRED IMMUNE AND ACUTE-PHASE RESPONSES IN INTERLEUKIN-6-DEFICIENT MICE	NATURE			English	Article							VACCINIA VIRUS; GROWTH-FACTOR; CYTOKINES; RECEPTOR; CD8+	INTERLEUKIN-6 (IL-6) is a multifunctional cytokine that regulates various aspects of the immune response, acute-phase reaction and haematopoiesis (for reviews see refs 1, 2). In vitro, leukaemia inhibitory factor, oncostatin M, ciliary neurotrophic factor and interleukin-ll display overlapping activities with IL-6. This functional redundancy may be explained by the interactions of specific binding receptors with a common signal-transducing receptor (gp130) (for reviews see refs 3, 4). To elucidate the unique function of IL-6 in vivo, we have disrupted the IL-6 gene by homologous recombination. IL-6-deficient mice develop normally. They fail to control efficiently vaccinia virus and infection with Listeria mono-cytogenes, a facultative intracellular bacterium. The T-cell-dependent antibody response against vesicular stomatitis virus is impaired. Further, the inflammatory acute-phase response after tissue damage or infection is severely compromised, whereas it is only moderately affected after challenge with lipopolysaccharide. We conclude that IL-6 production induced by injury or infection is an important in vivo SOS signal which coordinates activities of liver cells, macrophages and lymphocytes.	ROSWELL PK CANC INST, DEPT MOLEC & CELLULAR BIOL, BUFFALO, NY 14263 USA; UNIV ZURICH, INST EXPTL IMMUNOL, ZURICH, SWITZERLAND; HOFFMANN LA ROCHE AG, DEPT BIOL, CH-4002 BASEL, SWITZERLAND; OSAKA UNIV, SCH MED, DEPT MED 3, OSAKA, OSAKA 565, JAPAN	Roswell Park Cancer Institute; University of Zurich; Roche Holding; Osaka University	KOPF, M (corresponding author), MAX PLANCK INST IMMUNBIOL, STUBEWEG 51, D-79108 FREIBURG, GERMANY.		freer, giulia/H-4609-2012; Kopf, Manfred/B-6907-2009; Kishimoto, Tadamitsu/C-8470-2009	Kopf, Manfred/0000-0002-0628-7140; Freudenberg, Marina Alexandra/0000-0001-5894-1805				BAUMANN H, 1988, METHOD ENZYMOL, V163, P566; BAUMANN H, 1986, ARCH BIOCHEM BIOPHYS, V246, P488, DOI 10.1016/0003-9861(86)90495-9; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BINDER D, 1991, J IMMUNOL, V146, P4301; Blanden R V, 1972, Scand J Immunol, V1, P379, DOI 10.1111/j.1365-3083.1972.tb03304.x; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DING AH, 1988, J IMMUNOL, V141, P2407; DOHERTY PC, 1992, ANNU REV IMMUNOL, V10, P123; GREGORY SH, 1993, J IMMUNOL, V150, P2901; GUPTA SC, 1986, P NATL ACAD SCI USA, V83, P2604, DOI 10.1073/pnas.83.8.2604; HAVELL EA, 1992, J IMMUNOL, V148, P1486; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.immunol.11.1.129; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KOJ A, 1985, INJURY INFECTION, P145; LEIST TP, 1989, SCAND J IMMUNOL, V30, P679, DOI 10.1111/j.1365-3083.1989.tb02476.x; LIEW FY, 1991, IMMUNOPARASITOL TOD, pA17, DOI 10.1016/S0167-5699(05)80006-4; LOTZ M, 1988, J EXP MED, V167, P1253, DOI 10.1084/jem.167.3.1253; NORTH RJ, 1978, J IMMUNOL, V121, P806; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RAMSAY AJ, 1993, IMMUNOL TODAY, V14, P155, DOI 10.1016/0167-5699(93)90277-R; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHSTEIN JL, 1992, GENE DEV, V6, P1190, DOI 10.1101/gad.6.7.1190; SPRIGGS MK, 1992, P NATL ACAD SCI USA, V89, P6070, DOI 10.1073/pnas.89.13.6070; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; UYTTENHOVE C, 1988, J EXP MED, V167, P1417, DOI 10.1084/jem.167.4.1417; VANSNICK J, 1986, P NATL ACAD SCI USA, V83, P9679; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253	30	1491	1533	1	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	1994	368	6469					339	342		10.1038/368339a0	http://dx.doi.org/10.1038/368339a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127368				2022-12-28	WOS:A1994NB98500047
J	HILGEMANN, DW				HILGEMANN, DW			CHANNEL-LIKE FUNCTION OF THE NA,K PUMP PROBED AT MICROSECOND RESOLUTION IN GIANT MEMBRANE PATCHES	SCIENCE			English	Article							TRANSLOCATION; EXCHANGE; SODIUM; CURRENTS; K+	Ion transporters can be thought of as ion channels that open and close only at one end at a time. As in real channels, ions may cross through an electrical field as they diffuse into and bind within the transporter pore, thereby generating electrical current. Extracellular sodium binding by the sodium potassium (Na,K) pump is associated with ultrafast charge movements in giant cardiac membrane patches. The charge movements are complete within 4 microseconds. They occur only when binding sites are open to the extracellular side, and they are abolished by ouabain and by the removal of extracellular sodium. Fast extracellular ion binding may be the exclusive source of Na,K pump electrogenicity.			HILGEMANN, DW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							ALTHOFF G, 1989, J MEMBRANE BIOL, V108, P263, DOI 10.1007/BF01871741; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; FENDLER K, 1987, FEBS LETT, V224, P83, DOI 10.1016/0014-5793(87)80427-1; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; GOLDSHLEGGER R, 1987, J PHYSIOL-LONDON, V387, P331, DOI 10.1113/jphysiol.1987.sp016576; HEYSE S, IN PRESS J GEN PHYSL; HILGEMANN D W, 1992, Biophysical Journal, V61, pA390; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; HILGEMANN DW, 1989, PFLUG ARCH EUR J PHY, V415, P247, DOI 10.1007/BF00370601; LAGNADO L, 1988, P NATL ACAD SCI USA, V85, P4548, DOI 10.1073/pnas.85.12.4548; Lauger P., 1991, ELECTROGENIC ION PUM; LEE KH, 1980, NATURE, V285, P338, DOI 10.1038/285338a0; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Mitchell P., 1974, BIOCHEM SOC SPEC PUB, V4, P91, DOI DOI 10.1042/BST0020463; NAKAO M, 1986, NATURE, V323, P628, DOI 10.1038/323628a0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; RAKAWSKI RF, 1989, J GEN PHYSIOL, V93, P903; RAKOWSKI RF, 1991, J MEMBRANE BIOL, V121, P177, DOI 10.1007/BF01870531; RAKOWSKI RF, 1993, J GEN PHYSIOL, V101, P117, DOI 10.1085/jgp.101.1.117; STURMER W, 1991, J MEMBRANE BIOL, V121, P163, DOI 10.1007/BF01870530; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; VASILETS LA, 1990, J MEMBRANE BIOL, V91, P43	23	167	170	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1429	1432		10.1126/science.8128223	http://dx.doi.org/10.1126/science.8128223			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128223				2022-12-28	WOS:A1994MZ92700029
J	WARD, Y; GUPTA, S; JENSEN, P; WARTMANN, M; DAVIS, RJ; KELLY, K				WARD, Y; GUPTA, S; JENSEN, P; WARTMANN, M; DAVIS, RJ; KELLY, K			CONTROL OF MAP KINASE ACTIVATION BY THE MITOGEN-INDUCED THREONINE/TYROSINE PHOSPHATASE PAC1	NATURE			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE; ENCODED PROTEIN; PHOSPHORYLATION; SEQUENCE; GENE	INTRACELLULAR Signalling following mitogenic stimulation of quiescent cells involves the initiation of a phosphorylation cascade that leads to the rapid and reversible activation of the mitogen-activated protein (MAP) kinases ERK1 and ERK2 (refs 1, 2). MAP kinase activation is mediated by dual phosphorylation within the motif Thr-Glu-Tyr by MAP kinase kinase (MEK)(3). Following activation, the MAP kinases translocate into the nucleus where they phosphorylate several transduction targets, including transcription factors(4-7). We have previously identified PAC1 as an immediate-early mitogen-inducible tyrosine phosphatase in nuclei of T cells(8). Here we present several lines of evidence indicating that PAC1 is a physiologically relevant MAP kinase phosphatase. Recombinant PAC1 in vitro is a dual-specific Thr/Tyr phosphatase with stringent substrate specificity for MAP kinase. Constitutive expression of PAC1 in vivo leads to inhibition of MAP kinase activity normally stimulated by epidermal growth factor, phorbol myristyl acetate, or T-cell receptor crosslinking. The inactivation of MAP kinase by PAC1 results in inhibition of MAP kinase-regulated reporter gene expression.	NCI,PATHOL LAB,BETHESDA,MD 20892; UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester								Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1993, ONCOGENE, V8, P2015; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; Harlow E., 1988, ANTIBODIES LABORATOR, P1; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SETH A, 1992, J BIOL CHEM, V267, P24796; SIEGEL JN, 1991, CURRENT PROTOCOLS IM; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	25	318	329	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 17	1994	367	6464					651	654		10.1038/367651a0	http://dx.doi.org/10.1038/367651a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	8107850	Green Published			2022-12-28	WOS:A1994MW68800056
J	GRAFFY, JP; WILLIAMS, J				GRAFFY, JP; WILLIAMS, J			PURCHASING FOR ALL - AN ALTERNATIVE TO FUNDHOLDING	BRITISH MEDICAL JOURNAL			English	Article							PRACTITIONERS	Objective-To evaluate general practitioner participation in a district health authority's purchasing work. Design-Questionnaire study of 131 Hackney general practitioners and 33 senior health service managers; review of the minutes of 28 meetings of the Hackney General Practitioners' Forum and the contract between City and Hackney Health Authority and the St Bartholomew's NHS Trust. Setting-Hackney General Practitioners' Forum. Main outcome measures-General practitioners' and managers' perceptions of how representative and effective the general practitioners' forum is; proportion of new quality targets and service developments contributed by general practitioners; main issues discussed by the forum and impact on district health authority policy. Results-99 (76%) general practitioners and 27 (82%) managers responded. Both groups perceived the forum as representative. 92% (24/26) of the managers thought the forum was effective but only 74% (70/95) of general practitioners did so, largely because some doubted that the forum was listened to. 75% (103/138) of quality targets and 55% (16/29) of service developments planned in the 1993-4 contract were contributed by general practitioners. They also lobbied successfully for more resources for urology and community mental health services. Conclusions-Input into commissioning via a general practitioners' forum can be both representative and effective. General practitioners need to work closely to achieve a consensus and those involved need administrative support. The relation between general practice and public health medicine needs to be strengthened.	ST BARTHOLOMEWS & ROYAL LONDON HOSP,MED COLL,ACAD DEPT GEN PRACTICE & PRIMARY CARE,LONDON,ENGLAND; HACKNEY GEN PRACTITIONERS FORUM,LONDON E3 2AN,ENGLAND	Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London								BOWLING A, 1991, BRIT MED J, V303, P292, DOI 10.1136/bmj.303.6797.292; EVE R, 1991, BRIT MED J, V303, P167, DOI 10.1136/bmj.303.6795.167; FEDER G, 1992, NEW HORIZONS GENERAL, P44; HANNAY DR, 1993, BRIT MED J, V307, P516, DOI 10.1136/bmj.307.6903.516; HICKS NR, 1991, BRIT MED J, V302, P991, DOI 10.1136/bmj.302.6783.991; KEELEY D, 1993, BRIT MED J, V306, P697, DOI 10.1136/bmj.306.6879.697; MORRIS R, 1992, MED MONITOR     0221, P29; Tomlinson B., 1992, REPORT INQUIRY LONDO; WILKIN D, 1992, HOSPITAL REFERRALS, P76; WISLEY I, 1993, BRIT MED J, V306, P695; 1992, MED LIST; 1986, ADV STATISTICS SPSS; 1993, NHS11 REP; 1993, HLTH CARE SERVICE CO; 1993, QUALITY SERVICE STAN; 1992, COMMISSIONING CARE O	16	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	1994	308	6925					391	394		10.1136/bmj.308.6925.391	http://dx.doi.org/10.1136/bmj.308.6925.391			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV862	8124148	Green Published			2022-12-28	WOS:A1994MV86200024
J	SIMONS, D; SILVEIRA, WR				SIMONS, D; SILVEIRA, WR			POSTTRAUMATIC-STRESS-DISORDER IN CHILDREN AFTER TELEVISION PROGRAMS	BRITISH MEDICAL JOURNAL			English	Article											SIMONS, D (corresponding author), GULSON HOSP,COVENTRY CV1 2HR,ENGLAND.							Garmezy N., 1985, CHILD ADOLESCENT PSY, P152; MCFARLANE AC, 1989, BRIT J MED PSYCHOL, V62, P81, DOI 10.1111/j.2044-8341.1989.tb02813.x; SAIGH PA, 1992, BRIT J PSYCHIAT, V161, P704, DOI 10.1192/bjp.161.5.704; UDWIN O, 1993, J CHILD PSYCHOL PSYC, V34, P115, DOI 10.1111/j.1469-7610.1993.tb00974.x; YULE W, 1991, BRIT J CLIN PSYCHOL, V30, P131, DOI 10.1111/j.2044-8260.1991.tb00928.x	5	31	32	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	1994	308	6925					389	390		10.1136/bmj.308.6925.389	http://dx.doi.org/10.1136/bmj.308.6925.389			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MV862	8124147	Green Published			2022-12-28	WOS:A1994MV86200022
J	ZEHETNER, G; LEHRACH, H				ZEHETNER, G; LEHRACH, H			THE REFERENCE LIBRARY-SYSTEM - SHARING BIOLOGICAL-MATERIAL AND EXPERIMENTAL-DATA	NATURE			English	Article							DENSITY				ZEHETNER, G (corresponding author), IMPERIAL CANC RES FUND,GENOME ANAL LAB,POB 123,LONDON WC2A 3PX,ENGLAND.							LEHRACH H., 1990, GENOME ANAL, P39; MEIEREWERT S, 1993, NATURE, V361, P375, DOI 10.1038/361375a0; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; ROSS M, 1992, TECHNIQUES ANAL COMP; ROSS MT, 1991, CYTOGENET CELL GENET, V58, P2152	5	121	124	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					489	491		10.1038/367489a0	http://dx.doi.org/10.1038/367489a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	8107810				2022-12-28	WOS:A1994MU67900063
J	OKEEFFE, D; NICHOLSON, DA; DRISCOLL, PA; MARSH, D				OKEEFFE, D; NICHOLSON, DA; DRISCOLL, PA; MARSH, D			ABC OF EMERGENCY RADIOLOGY - THE ANKLE	BRITISH MEDICAL JOURNAL			English	Article									HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND		OKEEFFE, D (corresponding author), ROYAL ALBERT & EDWARD INFIRM,WIGAN,ENGLAND.								0	3	3	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 29	1994	308	6924					331	336		10.1136/bmj.308.6924.331	http://dx.doi.org/10.1136/bmj.308.6924.331			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU492	8124123	Green Published			2022-12-28	WOS:A1994MU49200028
J	HANDYSIDES, S				HANDYSIDES, S			ENRICHING CAREERS IN GENERAL-PRACTICE - A CAREER STRUCTURE FOR GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							QUALITY	Training for general practitioners usually provides little experience in research, business management, or dealing with chronic disease. lt is these areas that could provide scope for further training after becoming a general practitioner principal and provided career goals. Formally recognised research practices, perhaps with one partner coordinating research but all participating, and district research facilitators could increase both the quality and the quantity of research in general practice. Recognising the different skills of doctors in the partnership and referring patients to the most appropriate partner will improve care for patients as well as provide career development. Further training could be aimed at filling gaps in the practice's pool of skills. Good management skills are becoming more important as practice teams get bigger and fundholding spreads. Some doctors may wish to become full time or part time managers and the idea of accredited courses for management has been raised.										ALLEN J, 1993, BRIT MED J, V307, P719, DOI 10.1136/bmj.307.6906.719; ASHLEYMILLER M, 1993, BRIT MED J, V307, P886, DOI 10.1136/bmj.307.6909.886; BICHARD A, 1991, BRIT J GEN PRACT, V41, P4; BUCKLEY EG, 1990, BRIT J GEN PRACT, V40, P357; FLEMING DM, 1986, J ROY COLL GEN PRACT, V36, P212; GRAY DP, 1993, BRIT J GEN PRACT, V43, P402; GRAY DP, 1991, BRIT MED J, V302, P1380, DOI 10.1136/bmj.302.6789.1380; Hart, 1988, NEW KIND DOCTOR; HART JT, 1990, BRIT J GEN PRACT, V40, P479; HELLEMA H, 1993, BRIT MED J, V307, P956; HORDER J, 1988, J ROY COLL GEN PRACT, V38, P341; IRVINE D, 1983, J ROY COLL GEN PRACT, V33, P521; IRVINE D, 1993, BRIT J GEN PRACT, V43, P121; IRVINE DH, 1990, BRIT J GEN PRACT, V40, P434; IRVINE DH, 1990, BRIT J GEN PRACT, V40, P75; IRVINE S, 1992, BALANCING DREAMS DIS; JEWELL D, 1991, BRIT J GEN PRACT, V41, P1; JONES R, 1993, BRIT J GEN PRACT, V43, P359; KEELEY D, 1993, BRIT MED J, V306, P697, DOI 10.1136/bmj.306.6879.697; LAWRENCE M, 1992, BRIT MED J, V305, P400, DOI 10.1136/bmj.305.6850.400; MACMILLAN L, 1992, BRIT MED J, V304, P1672, DOI 10.1136/bmj.304.6843.1672; MCAVOY BR, 1993, BRIT MED J, V306, P694, DOI 10.1136/bmj.306.6879.694; PITTS J, 1991, BRIT J GEN PRACT, V41, P34; SYLVESTER SHH, 1993, BRIT MED J, V307, P912, DOI 10.1136/bmj.307.6909.912; WILLIAMS WO, 1990, BRIT J GEN PRACT, V40, P491; WISELY ICF, 1993, BRIT MED J, V306, P695, DOI 10.1136/bmj.306.6879.695; WRIGHT AF, 1991, BRIT J GEN PRACT, V41, P178; 1990, RCGP49 OCC PAP; 1983, JR COLL GEN PRACT, V33, P523; 1983, GENERAL MED SERVICES; 1993, CAREER STRUCTURE ACA; 1968, TODD REPORT; 1992, YOUR CHOICES FUTURE	33	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 22	1994	308	6923					253	256		10.1136/bmj.308.6923.253	http://dx.doi.org/10.1136/bmj.308.6923.253			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT539	8111263	Green Published			2022-12-28	WOS:A1994MT53900025
J	SCHLUTER, H; OFFERS, E; BRUGGEMANN, G; VANDERGIET, M; TEPEL, M; NORDHOFF, E; KARAS, M; SPIEKER, C; WITZEL, H; ZIDEK, W				SCHLUTER, H; OFFERS, E; BRUGGEMANN, G; VANDERGIET, M; TEPEL, M; NORDHOFF, E; KARAS, M; SPIEKER, C; WITZEL, H; ZIDEK, W			DIADENOSINE PHOSPHATES AND THE PHYSIOLOGICAL CONTROL OF BLOOD-PRESSURE	NATURE			English	Article							BOVINE ADRENAL-MEDULLA; ESSENTIAL HYPERTENSIVES; CHROMAFFIN CELLS; INDUCED RELEASE; AP4A; POLYPHOSPHATES; TETRAPHOSPHATE; CHROMATOGRAPHY; ENDOTHELIUM; NUCLEOTIDES	OUR understanding of the regulation of vascular tone has been extended since the identification of vasoactive agents such as the atrial natriuretic peptides1, endothelial-derived relaxing factor2 and endothelin3. Unidentified vasopressive agents have been found in platelets4. Here we isolate these vasopressors and identify them as diadenosine pentaphosphate (AP5A) and diadenosine hexaphosphate (AP6A) by chromatography, mass spectrometry, ultraviolet spectroscopy and enzymatic cleavage. In the vasculature of isolated perfused rat kidney, both diadenosine phosphates were active at a concentration of 10(-9) M; in aortic rings, contractions were elicited at 10(-8) M. Intra-aortic injection in the rat caused a prolonged increase in blood pressure. We conclude that AP5A and AP6A may play a part in local vasoregulation and possibly in the regulation of blood pressure.	UNIV MUNSTER,INST BIOCHEM,MED POLIKLIN,D-48129 MUNSTER,GERMANY	University of Munster	SCHLUTER, H (corresponding author), UNIV MUNSTER,INST MED PHYS,MED POLIKLIN,ALBERT SCHWEITZER STR 33,D-48129 MUNSTER,GERMANY.		Tepel, Martin/GRS-9581-2022; Schluter, Hartmut/D-1371-2015	Schluter, Hartmut/0000-0002-9358-7036; Tepel, Martin/0000-0002-0086-0997				AGHA A, 1992, J VASC RES, V29, P281, DOI 10.1159/000158943; ALLY A, 1992, J CHROMATOGR-BIOMED, V575, P19, DOI 10.1016/0378-4347(92)80499-G; BARIL EF, 1985, CANCER INVEST, V3, P465, DOI 10.3109/07357908509039808; BUSSE R, 1988, AM J PHYSIOL, V254, pH828, DOI 10.1152/ajpheart.1988.254.5.H828; DELCASTILLO AR, 1988, J NEUROCHEM, V51, P1696, DOI 10.1111/j.1471-4159.1988.tb01147.x; FLYNN TG, 1983, BIOCHEM BIOPH RES CO, V117, P859, DOI 10.1016/0006-291X(83)91675-3; FRENZ J, 1985, J CHROMATOGR, V330, P1, DOI 10.1016/S0021-9673(01)81958-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARRISON MJ, 1975, FEBS LETT, V54, P57, DOI 10.1016/0014-5793(75)81067-2; MORII H, 1992, EUR J BIOCHEM, V205, P979, DOI 10.1111/j.1432-1033.1992.tb16864.x; NEES S, 1989, EUR HEART J, V10, P28, DOI 10.1093/eurheartj/10.suppl_F.28; NEUSSER M, 1993, J VASC RES, V30, P116, DOI 10.1159/000158983; NORDHOFF E, 1992, RAPID COMMUN MASS SP, V6, P771, DOI 10.1002/rcm.1290061212; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PINTOR J, 1992, ANAL BIOCHEM, V200, P296, DOI 10.1016/0003-2697(92)90469-N; PINTOR J, 1991, LIFE SCI, V48, P2317, DOI 10.1016/0024-3205(91)90268-G; POHL U, 1991, AM J PHYSIOL, V260, pH1692, DOI 10.1152/ajpheart.1991.260.5.H1692; SULKOWSKI E, 1971, BIOCHIM BIOPHYS ACTA, V240, P443, DOI 10.1016/0005-2787(71)90538-7; WEINMANNDORSCH C, 1984, EUR J BIOCHEM, V138, P179, DOI 10.1111/j.1432-1033.1984.tb07897.x; YAMAGUCHI N, 1985, GASTROENTEROLOGY, V89, P723, DOI 10.1016/0016-5085(85)90565-7; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZAMECNIK PC, 1966, BIOCHEM BIOPH RES CO, V24, P91, DOI 10.1016/0006-291X(66)90415-3; ZIDEK W, 1990, CLIN EXP HYPERTENS A, V12, P365, DOI 10.3109/10641969009074740	23	203	208	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 13	1994	367	6459					186	188		10.1038/367186a0	http://dx.doi.org/10.1038/367186a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ780	8114917				2022-12-28	WOS:A1994MQ78000065
J	SEE, WA; COOPER, CS; FISHER, RJ				SEE, WA; COOPER, CS; FISHER, RJ			PREDICTORS OF LAPAROSCOPIC COMPLICATIONS AFTER FORMAL TRAINING IN LAPAROSCOPIC SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To evaluate the relationship between laparoscopic complication rates and surgeon-dependent variables following a laparoscopic training course. Design.-Participants were surveyed regarding their interval laparoscopic experience 3 months and 12 months after the course. Participants.-Course participants/survey respondents represented a cross section of urologic surgeons in the United States. A total of 181 individuals (61% of 297 participants) completed and returned the 3-month questionnaire. A total of 128 surgeons responded to the 12-month questionnaire (78.5% of 163 participants). Main Outcome Measure.-Logistic regression analysis tested the relationship between surgeons' complication rates and study variables. Results.-At 3 months, surgeons who performed clinical procedures without additional training were 3.39 times more likely to have at least one complication compared with surgeons who sought additional training (P=.03). At 12 months, surgeons who had attended the training course alone, were in solo practice, or performed laparoscopic surgery with a variable assistant were 4.85, 7.74, and 4.80 times more likely, respectively, to have had a complication than their counterparts who attended the course with a partner, were in group practice, or operated with the same assistant (P=.004, P=.0008, and P=.0015, respectively). At both 3 and 12 months, laparoscopic complication rates of individual surgeons demonstrated a significant inverse correlation with the number of laparoscopic procedures performed. Conclusions.-The rate of complications associated with the clinical learning curve can be decreased by additional education following an initial course in laparoscopy. An ongoing clinical association with surgeons performing similar procedures decreases long-term complication rates.			SEE, WA (corresponding author), UNIV IOWA HOSP & CLIN,DEPT UROL,IOWA CITY,IA 52242, USA.			Cooper, Christopher/0000-0002-4169-2088				Airan M C, 1990, Am J Surg, V159, P619, DOI 10.1016/S0002-9610(06)80082-6; ALTMAN LK, 1992, NY TIMES C      0623, P3; ALTMAN LK, 1992, NY TIMES        0726, P1; DENT TL, 1991, AM J SURG, V161, P399, DOI 10.1016/0002-9610(91)90607-F; FISCHER WA, 1993, J UROLOGY, V149, P1054; GREEN FL, 1991, SURG ENDOSC, V6, P271; LICHT J, 1992, WASHINGTON PO Z 0616, P9; WINFIELD HN, 1991, J UROLOGY, V146, P941, DOI 10.1016/S0022-5347(17)37970-3; 1992, NEW YORK STATE DEPT, V9220; 1991, AM J SURG, V161, P324	10	154	164	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2689	2692		10.1001/jama.270.22.2689	http://dx.doi.org/10.1001/jama.270.22.2689			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	8133586				2022-12-28	WOS:A1993MJ82100027
J	COLDITZ, GA; WILLETT, WC; HUNTER, DJ; STAMPFER, MJ; MANSON, JE; HENNEKENS, CH; ROSNER, BA; SPEIZER, FE				COLDITZ, GA; WILLETT, WC; HUNTER, DJ; STAMPFER, MJ; MANSON, JE; HENNEKENS, CH; ROSNER, BA; SPEIZER, FE			FAMILY HISTORY, AGE, AND RISK OF BREAST-CANCER - PROSPECTIVE DATA FROM THE NURSES HEALTH STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE; INDICATOR; ONSET	Objective.-To examine prospectively the risk of breast cancer as influenced by a maternal history of breast cancer, the mother's age at diagnosis, or a sister's history of breast cancer. Design.-Prospective cohort study with biennial follow-up. Setting/Participants.-117 988 women in the Nurses' Health Study aged 30 to 55 years in 1976, followed up through 1988 (1.3 million person-years of follow-up). Results.-We identified 2389 incident Gases of invasive breast cancer. Compared with women without a maternal history of breast cancer, the age-adjusted relative risk (RR) of breast cancer was highest among women whose mother was diagnosed before the age of 40 years (RR, 2.1 [95% confidence interval, 1.6 to 2.8]). The RR decreased with advancing maternal age at time of diagnosis to 1.5 (95% confidence interval, 1.1 to 2.2) for maternal diagnosis after the age of 70 years. Having a sister with a history of breast cancer also was related to increased risk; for women with one sister with breast cancer compared with those with one sister without such a history, the age-adjusted RR was 2.3 (95% confidence interval, 1.6 to 3.4). Women whose mother and sister both had a history of breast cancer had an RR of 2.5 (95% confidence interval, 1.5 to 4.2) compared with those without a family history. These associations did not differ appreciably when stratified by age; menopausal status; history of benign breast disease; body mass index; age at menarche; or parity or age at first birth of the women at risk. The results remained unchanged when we controlled for these risk factors in multivariate models. Despite slightly greater mammography surveillance and earlier detection of tumors among women with a family history of breast cancer, detection bias is unlikely to account for more than a small part of the observed association. Conclusions.-Risk of breast cancer is approximately doubled among women whose mother had breast cancer diagnosed before the age of 40 years or who have a sister with breast cancer, and remains elevated even for those whose mothers were diagnosed with breast cancer at the age of 70 years or older. However, the risk associated with a mother or sister history of breast cancer is smaller than suggested by earlier retrospective studies. Overall, within this population of middle-aged women, only 2.5% of breast cancer cases are attributable to a positive family history.	BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	COLDITZ, GA (corresponding author), BRIGHAM & WOMENS HOSP, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1981, CANCER, V48, P1688, DOI 10.1002/1097-0142(19811001)48:7<1688::AID-CNCR2820480736>3.0.CO;2-W; AMOS CI, 1991, CANCER RES, V51, P1793; ANDERSON DE, 1971, CANCER, V28, P1500, DOI 10.1002/1097-0142(197112)28:6<1500::AID-CNCR2820280623>3.0.CO;2-D; ANDERSON DE, 1974, CANCER, V34, P1090, DOI 10.1002/1097-0142(197410)34:4<1090::AID-CNCR2820340419>3.0.CO;2-J; ANDERSON DE, 1985, CANCER, V56, P3830; BAIN C, 1980, AM J EPIDEMIOL, V111, P301, DOI 10.1093/oxfordjournals.aje.a112901; BRINTON LA, 1982, J NATL CANCER I, V69, P817; BURNS PE, 1981, CAN MED ASSOC J, V124, P1451; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COX DR, 1972, J R STAT SOC B, V34, P187; Floderus B, 1990, Epidemiology, V1, P318, DOI 10.1097/00001648-199007000-00011; HOULSTON RS, 1992, J MED GENET, V29, P154, DOI 10.1136/jmg.29.3.154; ISELIUS L, 1991, ANN HUM GENET, V55, P154; KHOURY MJ, 1987, AM J EPIDEMIOL, V126, P561, DOI 10.1093/oxfordjournals.aje.a114695; KING MC, 1993, JAMA-J AM MED ASSOC, V269, P1975, DOI 10.1001/jama.269.15.1975; LONDON S J, 1989, Journal of the American Medical Association, V262, P2853, DOI 10.1001/jama.262.20.2853; LOVE RR, 1985, J CHRON DIS, V38, P289, DOI 10.1016/0021-9681(85)90074-8; LYNCH HT, 1990, ARCH SURG-CHICAGO, V125, P151; METTLIN C, 1990, AM J EPIDEMIOL, V131, P973, DOI 10.1093/oxfordjournals.aje.a115617; OTTMAN R, 1986, AM J EPIDEMIOL, V123, P15, DOI 10.1093/oxfordjournals.aje.a114209; PAPADIAMANTIS Y, 1990, CANCER J, V3, P244; ROMIEU I, 1989, JNCI-J NATL CANCER I, V81, P1313, DOI 10.1093/jnci/81.17.1313; ROSEMAN DL, 1990, ARCH INTERN MED, V150, P191, DOI 10.1001/archinte.150.1.191; Rothman K, 1986, MODERN EPIDEMIOLOGY; SATTIN RW, 1985, JAMA-J AM MED ASSOC, V253, P1908, DOI 10.1001/jama.253.13.1908; SCHNEIDER NR, 1983, AM J HUM GENET, V35, P454; SELLERS TA, 1992, NEW ENGL J MED, V326, P1323, DOI 10.1056/NEJM199205143262004; SMITHERS DW, 1948, BRIT J CANCER, V2, P163, DOI 10.1038/bjc.1948.24; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Wells HG, 1923, J AMER MED ASSOC, V81, P1017, DOI 10.1001/jama.1923.26510120005012; WILLETT WC, 1992, JAMA-J AM MED ASSOC, V268, P2037, DOI 10.1001/jama.268.15.2037	32	263	268	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1993	270	3					338	343		10.1001/jama.270.3.338	http://dx.doi.org/10.1001/jama.270.3.338			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM435	8123079				2022-12-28	WOS:A1993LM43500028
J	STARFIELD, B; SIMPSON, L				STARFIELD, B; SIMPSON, L			PRIMARY-CARE AS PART OF UNITED-STATES HEALTH-SERVICES REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMBULATORY CARE		UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	STARFIELD, B (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,DIV HLTH POLICY,BALTIMORE,MD 21205, USA.				AHRQ HHS [2T32HS 0026-7] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABELSMITH B, 1992, MILBANK Q, V70, P393, DOI 10.2307/3350128; AIKEN LH, 1979, NEW ENGL J MED, V300, P1363, DOI 10.1056/NEJM197906143002404; Barer Morris L., 1991, INTEGRATED MED RESOU; BARNETT PG, 1989, JAMA-J AM MED ASSOC, V262, P2864, DOI 10.1001/jama.262.20.2864; BLANKENBAKER R, 1990, 1989 NAT COMM VIT HL; BUDETTI PP, 1993, JAMA-J AM MED ASSOC, V269, P498, DOI 10.1001/jama.269.4.498; Ellwood P M, 1992, Health Econ, V1, P149, DOI 10.1002/hec.4730010303; ENTHOVEN AC, 1992, NEW ENGL J MED, V327, P807, DOI 10.1056/NEJM199209103271113; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; GINZBERG E, 1992, JAMA-J AM MED ASSOC, V268, P3115, DOI 10.1001/jama.268.21.3115; GONNELLA JS, 1977, AMBULATORY MED CARE; GRUMBACH K, 1993, NEW ENGL J MED, V328, P940, DOI 10.1056/NEJM199304013281308; HIMMELSTEIN DU, 1992, NATIONAL HLTH PROGRA; HSIAO WC, 1993, NEW ENGL J MED, V328, P928, DOI 10.1056/NEJM199304013281306; IGLEHART JK, 1992, NEW ENGL J MED, V327, P742, DOI 10.1056/NEJM199209033271029; KASSEBAUM D, 1993, ACAD MED, V67, P700; LEE PR, 1989, LANCET, V1, P263; LEE PR, 1992, THESIS WASHINGTON DC; LUFT HS, 1990, HOSPITAL VOLUME PHYS; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MILLER CA, 1987, MATERNAL HLTH INFANT; MITCHELL G, 1993, 5TH ANN C NAT AC SOC; ROEMER MI, 1975, MED CARE, V13, P457, DOI 10.1097/00005650-197506000-00002; SHEA S, 1992, NEW ENGL J MED, V327, P776, DOI 10.1056/NEJM199209103271107; Shi L, 1992, J Health Care Poor Underserved, V3, P321; STARFIELD B, 1991, HEALTH SERV RES, V26, P53; STARFIELD B, 1991, JAMA-J AM MED ASSOC, V266, P2268, DOI 10.1001/jama.266.16.2268; Starfield B., 1992, PRIMARY CARE CONCEPT; STIMMEL B, 1992, JAMA-J AM MED ASSOC, V268, P2060, DOI 10.1001/jama.268.15.2060; Wennberg J E, 1984, Health Manage Q, P6, DOI 10.1377/hlthaff.3.2.6; White KL., 1991, HEALING SCHISM EPIDE; 1992, 4TH ANN REP; 1992, IMPROVING ACCESS HLT; 1993, JAMA-J AM MED ASSOC, V269, P90; 1992, 306 AM MED ASS REF C; 1993, ANN REPORT C; 1993, JAMA-J AM MED ASSOC, V269, P406	37	82	79	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	1993	269	24					3136	3139		10.1001/jama.269.24.3136	http://dx.doi.org/10.1001/jama.269.24.3136			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LH145	8110214				2022-12-28	WOS:A1993LH14500028
J	BENJAMIN, M; COHEN, C; GROCHOWSKI, E				BENJAMIN, M; COHEN, C; GROCHOWSKI, E			WHAT TRANSPLANTATION CAN TEACH US ABOUT HEALTH-CARE REFORM	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											BENJAMIN, M (corresponding author), TRANSPLANT & HLTH POLICY CTR,115 ZINA PITCHER PL,ANN ARBOR,MI 48109, USA.							Angell M, 1993, Kennedy Inst Ethics J, V3, P279; CALLAHAN D, 1990, WHAT KIND LIFE LIMIT; DANIELS N, 1986, NEW ENGL J MED, V314, P1380, DOI 10.1056/NEJM198605223142109; EVANS RW, 1991, BHARC10091 BATT SEAT; GAYLIN W, 1993, HARPERS          OCT, P57; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; LEVINSKY NG, 1984, NEW ENGL J MED, V311, P1573, DOI 10.1056/NEJM198412133112412; Menzel P T, 1993, Kennedy Inst Ethics J, V3, P287; SCHWARTZ WB, 1990, NY TIMES        0709, pA17; WELCH HG, 1988, NEW ENGL J MED, V319, P171, DOI 10.1056/NEJM198807213190310; 1991, DISTRIBUTION ORGANS; 1985, PITTSBURGH PRESS NOV; 1991, POLICY PROPOSAL STAT, P2; 1992, TRANSPLANT P, V24, P2226; 1986, REPORT TASK FORCE OR, P86	15	15	15	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 24	1994	330	12					858	860		10.1056/NEJM199403243301211	http://dx.doi.org/10.1056/NEJM199403243301211			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB803	8114841				2022-12-28	WOS:A1994NB80300011
J	PINALS, RS				PINALS, RS			POLYARTHRITIS AND FEVER	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SYSTEMIC LUPUS-ERYTHEMATOSUS; ACUTE POLYARTICULAR GOUT; ADULT STILLS DISEASE; RHEUMATOID-ARTHRITIS; REITERS-SYNDROME; LYME-DISEASE; MANIFESTATIONS; EXPERIENCE		UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MED,NEW BRUNSWICK,NJ 08903	Rutgers State University New Brunswick; Rutgers State University Medical Center								BISNO AL, 1991, NEW ENGL J MED, V325, P783, DOI 10.1056/NEJM199109123251106; BONG D, 1981, JAMA-J AM MED ASSOC, V246, P1438, DOI 10.1001/jama.246.13.1438; BRADLEY JD, 1983, J RHEUMATOL, V10, P826; CALABRESE LH, 1993, RHEUM DIS CLIN N AM, V19, P477; CAPLAN HI, 1970, ARTHRITIS RHEUM, V13, P101, DOI 10.1002/art.1780130201; CHURCHILL MA, 1977, ANN INTERN MED, V87, P754, DOI 10.7326/0003-4819-87-6-754; COVER TL, 1989, NEW ENGL J MED, V321, P16, DOI 10.1056/NEJM198907063210104; CRONIN ME, 1988, RHEUM DIS CLIN N AM, V14, P99; DORFMAN HD, 1987, ARTHRITIS RHEUM, V30, P155, DOI 10.1002/art.1780300205; FRISCHKNECHT J, 1975, ARCH INTERN MED, V135, P298, DOI 10.1001/archinte.135.2.298; FUCHS HA, 1992, SOUTHERN MED J, V85, P381, DOI 10.1097/00007611-199204000-00011; GARDNER GC, 1990, AM J MED, V88, P503, DOI 10.1016/0002-9343(90)90430-L; GOLDENBERG DL, 1985, NEW ENGL J MED, V312, P764, DOI 10.1056/NEJM198503213121206; GREENBERG SB, 1991, FEVER BASIC MECHANIS, P183; HADLER NM, 1974, AM J MED, V56, P715, DOI 10.1016/0002-9343(74)90639-1; HO G, 1993, ARHTRITIS ALLIED CON, V2, P2003; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; HUNDER GG, 1985, CLIN RHEUM DIS, V11, P471; KEAT A, 1983, NEW ENGL J MED, V309, P1606, DOI 10.1056/NEJM198312293092604; KHAN MA, 1982, ANN INTERN MED, V96, P70, DOI 10.7326/0003-4819-96-1-70; KREY PR, 1979, AM J MED, V67, P436, DOI 10.1016/0002-9343(79)90790-3; LAWRY GV, 1988, MEDICINE, V67, P335, DOI 10.1097/00005792-198809000-00004; MADDISON PJ, 1981, MEDICINE, V60, P87, DOI 10.1097/00005792-198103000-00002; MCDANALD EC, 1978, ANN INTERN MED, V89, P917, DOI 10.7326/0003-4819-89-6-917; Messener R. P., 1993, ARTHRITIS ALLIED CON, V2, P2035; MIELANTS H, 1993, ARTHRITIS ALLIED CON, V1, P1095; MITCHELL M, 1988, RADIOL CLIN N AM, V26, P1295; NAIDES SJ, 1990, ARTHRITIS RHEUM-US, V33, P1297, DOI 10.1002/art.1780330901; OSLER W, 1892, PRINCIPLES PRACTICE, P272; PINALS RS, 1977, J RHEUMATOL, V4, P420; POUCHOT J, 1991, MEDICINE, V70, P118, DOI 10.1097/00005792-199103000-00004; RADDATZ DA, 1983, ANN RHEUM DIS, V42, P117, DOI 10.1136/ard.42.2.117; RAHMAN MU, 1990, AM J MED, V89, P115, DOI 10.1016/0002-9343(90)90110-Y; RAHN DW, 1991, SEMIN ARTHRITIS RHEU, V20, P201, DOI 10.1016/0049-0172(91)90017-T; REGINATO AJ, 1993, RHEUM DIS CLIN N AM, V19, P379; REGINATO AJ, 1987, SEMIN ARTHRITIS RHEU, V17, P39, DOI 10.1016/0049-0172(87)90015-1; ROMPALO AM, 1987, ARCH INTERN MED, V147, P281, DOI 10.1001/archinte.147.2.281; SCHALLER J, 1972, J PEDIATR-US, V81, P793, DOI 10.1016/S0022-3476(72)80108-2; SCHWABE AD, 1974, MEDICINE, V53, P453, DOI 10.1097/00005792-197411000-00005; SHORT CL, 1957, RHEUMATOID ARTHRITIS, P290; SILVEIRA LH, 1993, RHEUM DIS CLIN N AM, V19, P427; SILVEIRA LH, 1993, RHEUM DIS CLIN N AM, V19, P351; SINGLETON JD, 1991, J RHEUMATOL, V18, P1319; SOLINGER AM, 1988, RHEUM DIS CLIN N AM, V14, P187; SOLOMON G, 1991, RHEUM DIS CLIN N AM, V17, P43; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; THOMAS P, 1984, ANN RHEUM DIS, V43, P716, DOI 10.1136/ard.43.5.716; WEINER SR, 1991, SEMIN ARTHRITIS RHEU, V20, P353, DOI 10.1016/0049-0172(91)90011-N; WOODWARD TE, 1991, FEVER BASIC MECHANIS, P83; YAMAGUCHI M, 1992, J RHEUMATOL, V19, P424; YTTERBERG SR, 1993, ARTHRITIS ALLIED CON, V2, P2047	52	44	46	1	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 17	1994	330	11					769	774		10.1056/NEJM199403173301108	http://dx.doi.org/10.1056/NEJM199403173301108			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA742	8107744				2022-12-28	WOS:A1994NA74200008
J	BRUNNER, D; OELLERS, N; SZABAD, J; BIGGS, WH; ZIPURSKY, SL; HAFEN, E				BRUNNER, D; OELLERS, N; SZABAD, J; BIGGS, WH; ZIPURSKY, SL; HAFEN, E			A GAIN-OF-FUNCTION MUTATION IN DROSOPHILA MAP KINASE ACTIVATES MULTIPLE RECEPTOR TYROSINE KINASE SIGNALING PATHWAYS	CELL			English	Article							NERVE GROWTH-FACTOR; EGF RECEPTOR; SEVENLESS; MELANOGASTER; PROTEIN; GENE; HOMOLOG; EYE; TORSO; PATTERN	In the Drosophila eye, activation of the sevenless (sev) receptor tyrosine kinase is required for the specification of the R7 photoreceptor cell fate. In a genetic screen for mutations that result in the activation of the sev signaling pathway in the absence of the inducing signal, we identified a gain-of-function mutation in rolled (rl(Sevenmaker) [rl(Sem)]), which encodes a homolog of mitogen-activated protein (MAP) kinase. In addition to the sev pathway, this mutation activates the pathways controlled by torso and the epidermal growth factor receptor homolog. The rl(Sem) mutation results in the substitution of a single conserved amino acid in the kinase domain. Activation of MAP kinase by the rl(Sem) mutation is both necessary and sufficient to activate multiple signaling pathways controlled by receptor tyrosine kinases.	ALBERT SZENT GYORGYI MED SCH, DEPT BIOL, BIOL RES CTR, INST GENET, H-6720 SZEGED, HUNGARY; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Szeged University; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	BRUNNER, D (corresponding author), UNIV ZURICH, INST ZOOL, WINTERTHURERSTR 190, CH-8057 ZURICH, SWITZERLAND.		Brunner, Damian/F-2024-2011	Zipursky, Stephen/0000-0001-5630-7181; Brunner, Damian/0000-0001-5250-492X				AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BALLINGER DG, 1988, P NATL ACAD SCI USA, V85, P3960, DOI 10.1073/pnas.85.11.3960; BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; BIGGS WH, 1994, IN PRESS EMBO J; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CLIFFORD RJ, 1989, GENETICS, V123, P771; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DIAZBENJUMEA FJ, 1990, P ROY SOC B-BIOL SCI, V242, P36, DOI 10.1098/rspb.1990.0100; DICKSON B, 1992, GENE DEV, V6, P2327, DOI 10.1101/gad.6.12a.2327; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DICKSON B, 1993, DEV DROSOPHILA; DIMITRI P, 1991, GENETICS, V127, P553; DOYLE HJ, 1993, GENE DEV, V7, P633, DOI 10.1101/gad.7.4.633; ERDELYI M, 1989, GENETICS, V122, P111; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS WA, 1976, J PHYSIOL-LONDON, V256, P415; HILLIKER AJ, 1976, GENETICS, V83, P765; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MELNICK MB, 1993, DEVELOPMENT, V118, P127; MORGAN TH, 1925, BIOBLIOG GENET, V2, P233; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; PIGNONI F, 1992, DEVELOPMENT, V115, P239; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROBERTSON HM, 1988, GENETICS, V118, P461; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STARK WS, 1987, J NEUROGENET, V4, P227, DOI 10.3109/01677068709102343; STERNBERG PW, 1993, PHILOS T R SOC B, V340, P259, DOI 10.1098/rstb.1993.0066; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XU T, 1993, DEVELOPMENT, V117, P1223	60	391	395	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 11	1994	76	5					875	888		10.1016/0092-8674(94)90362-X	http://dx.doi.org/10.1016/0092-8674(94)90362-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124723				2022-12-28	WOS:A1994NA89000013
J	LICHTENSTEIN, M; KEINI, G; CEDAR, H; BERGMAN, Y				LICHTENSTEIN, M; KEINI, G; CEDAR, H; BERGMAN, Y			B-CELL-SPECIFIC DEMETHYLATION - A NOVEL ROLE FOR THE INTRONIC KAPPA-CHAIN ENHANCER SEQUENCE	CELL			English	Article							IMMUNOGLOBULIN GENE-TRANSCRIPTION; DNA METHYLATION; GERM-LINE; STABLE INTEGRATION; CONSERVED SEQUENCE; ACTIN GENE; EXPRESSION; ELEMENTS; RECOMBINATION; REARRANGEMENT	We studied the molecular mechanism of demethylation and its role in kappa chain gene regulation. Following transfection into B cell cultures, this gene undergoes regional demethylation in a process that is developmentally regulated in a lineage- and stage-specific manner. Although a germline V kappa promoter is not required for the demodification activity, a fragment containing the intronic kappa chain transcriptional enhancer and the nearby matrix attachment region is essential. In its natural location downstream to the J kappa 5 sequence, this element induces bidirectional demodification of plasmid constructs in a distance- and orientation-independent manner. When this enhancer is placed in an upstream position, however, the kappa gene remains modified and transcriptionally inactive, demonstrating that demethylation is required for kappa chain activation. These studies suggest that the kappa enhancer plays a dual role in regulating B cell differentiation by inducing demethylation and by promoting tissue-specific transcription.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT CELLULAR BIOCHEM,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	LICHTENSTEIN, M (corresponding author), HEBREW UNIV JERUSALEM,HADASSAH MED SCH,HUBERT H HUMPHREY CTR EXPTL MED & CANC RES,IL-91010 JERUSALEM,ISRAEL.							BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; Blackwell T. K., 1988, Molecular Immunology., P1; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; BLASQUEZ VC, 1989, J BIOL CHEM, V264, P21183; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; CALAME KL, 1985, ANNU REV IMMUNOL, V3, P159, DOI 10.1146/annurev.iy.03.040185.001111; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; ENGLER P, 1993, MOL CELL BIOL, V13, P571, DOI 10.1128/MCB.13.1.571; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRANK D, 1990, PHILOS T ROY SOC B, V326, P241, DOI 10.1098/rstb.1990.0008; GREENBERG A, 1987, MOL CELL BIOL, V7, P936, DOI 10.1128/MCB.7.2.936; GROSSVELD FG, 1982, NUCLEIC ACIDS RES, V21, P6725; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KELLEY DE, 1988, MOL CELL BIOL, V8, P930, DOI 10.1128/MCB.8.2.930; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; LECLERCQ L, 1989, NUCLEIC ACIDS RES, V17, P6809, DOI 10.1093/nar/17.17.6809; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIS S, 1982, CELL, V30, P807, DOI 10.1016/0092-8674(82)90285-9; MARTIN DJ, 1990, MOL CELL BIOL, V10, P1950, DOI 10.1128/MCB.10.5.1950; MATHER EL, 1983, P NATL ACAD SCI-BIOL, V80, P4689, DOI 10.1073/pnas.80.15.4689; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; NELSON KJ, 1984, NUCLEIC ACIDS RES, V12, P1911, DOI 10.1093/nar/12.4.1911; OLTZ EM, 1993, MOL CELL BIOL, V13, P6223, DOI 10.1128/MCB.13.10.6223; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; PICARD D, 1985, EMBO J, V4, P2831, DOI 10.1002/j.1460-2075.1985.tb04011.x; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; QUEEN C, 1984, MOL CELL BIOL, V4, P1042, DOI 10.1128/MCB.4.6.1042; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; ROBERTS D, 1985, CELL, V43, P117, DOI 10.1016/0092-8674(85)90017-0; Sambrook J, 1989, MOL CLONING LABORATO; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SERWE M, 1993, EMBO J, V12, P2321, DOI 10.1002/j.1460-2075.1993.tb05886.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STORB U, 1983, P NATL ACAD SCI-BIOL, V80, P6642, DOI 10.1073/pnas.80.21.6642; TAKEDA S, 1993, EMBO J, V12, P2329, DOI 10.1002/j.1460-2075.1993.tb05887.x; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; XU M, 1989, J BIOL CHEM, V264, P21190; YISRAELI J, 1986, CELL, V46, P409, DOI 10.1016/0092-8674(86)90661-6; YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638; Yisraeli J, 1984, DNA METHYLATION, P352	51	175	176	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 11	1994	76	5					913	923		10.1016/0092-8674(94)90365-4	http://dx.doi.org/10.1016/0092-8674(94)90365-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124725				2022-12-28	WOS:A1994NA89000016
J	SANVILLE, P; NICHOLSON, DA; DRISCOLL, PA				SANVILLE, P; NICHOLSON, DA; DRISCOLL, PA			THE HIP	BRITISH MEDICAL JOURNAL			English	Article								The hip joint is a common site for trauma in adults and damage to the hip may be associated with injuries to the rest of the pelvis, the femur, and the knee. This chapter describes a system of assessment to help interpret hip radiographs.	HOPE HOSP,SALFORD,LANCS,ENGLAND		SANVILLE, P (corresponding author), WITHINGTON HOSP,MANCHESTER,LANCS,ENGLAND.								0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	1994	308	6927					524	529		10.1136/bmj.308.6927.524	http://dx.doi.org/10.1136/bmj.308.6927.524			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX814	8136674	Green Published			2022-12-28	WOS:A1994MX81400030
J	MCINNES, E; POWELL, J				MCINNES, E; POWELL, J			DRUG AND ALCOHOL REFERRALS - ARE ELDERLY SUBSTANCE-ABUSE DIAGNOSES AND REFERRALS BEING MISSED	BRITISH MEDICAL JOURNAL			English	Article							ADMISSION	Objective-To examine the diagnosis of problem substance use in hospital inpatients aged 65 years and over and their referral to drug and alcohol services by medical staff. Design-Questionnaire to registrars or house officers caring for patients 65 years of age and over with problem substance use. Setting-5 hospitals in New South Wales, Australia. Subjects-Medical staff caring for 263 inpatients. Results-Medical staff did not recognise substance misuse in older hospital patients and did not seem to be aware of current recommendations of the National Health and Medical Research Council recommendations for safe use of alcohol and benzodiazepines. Three out of 88 problem users of benzodiazepines, 29 out of 76 smokers, and 33 out of 99 problem drinkers were identified by medical staff. Of those identified with problems, 2 benzodiazepine users, 6 smokers, and 19 drinkers were considered for referral to drug and alcohol services. Conclusions-Greater awareness of recommendations for dealing with problem use of benzodiazepines and alcohol needs to be promoted among medical staff, along with an increased emphasis in medical education on substance use as a potentially important problem for older people. Drug and alcohol services also need to promote a broader role, particularly in regard to early intervention in a hospital setting for older patients.	ROYAL PRINCE ALFRED HOSP,DEPT DRUG & ALCOHOL,SYDNEY,NSW,AUSTRALIA	University of Sydney			McInnes, Liz/R-6374-2019	McInnes, Liz/0000-0002-0567-9679				BIENENFELD D, 1987, CLIN GERONTOLOGIST, V7, P3; BROWN BB, 1982, GERONTOLOGIST, V22, P519, DOI 10.1093/geront/22.6.519; CADIEUX RJ, 1989, POSTGRAD MED, V86, P179; COLT HG, 1989, J AM GERIATR SOC, V37, P323, DOI 10.1111/j.1532-5415.1989.tb05498.x; CURTIS JR, 1989, J AM GERIATR SOC, V37, P310, DOI 10.1111/j.1532-5415.1989.tb05496.x; FOY A, 1986, BRIT MED J, V293, P1072, DOI 10.1136/bmj.293.6554.1072; GLANTZ M, 1981, J PSYCHOACTIVE DRUGS, V13, P117, DOI 10.1080/02791072.1981.10524293; GORBIEN MJ, 1989, GERIATRIC MED TODAY, V8, P115; KREJCIE RV, 1970, EDUC PSYCHOL MEAS, V30, P607, DOI 10.1177/001316447003000308; LEAROYD BM, 1982, MED J AUSTRALIA, V1, P1131; POWELL J, 1993, ALCOHOL MED USE OLDE; SHERIN KM, 1982, J FAM PRACTICE, V15, P1091; TOBIAS CR, 1988, POSTGRAD MED, V83, P313, DOI 10.1080/00325481.1988.11700123; 1991, RECOMMENDATIONS REGA; 1987, DIAGNOSTIC STATISTIC; 1991, TOBACCO ALERT WHO PR; 1987, RECOMMENDATIONS REGA	17	68	69	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	1994	308	6926					444	446		10.1136/bmj.308.6926.444	http://dx.doi.org/10.1136/bmj.308.6926.444			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MW976	8124174	Green Published			2022-12-28	WOS:A1994MW97600021
J	CREMER, H; LANGE, R; CHRISTOPH, A; PLOMANN, M; VOPPER, G; ROES, J; BROWN, R; BALDWIN, S; KRAEMER, P; SCHEFF, S; BARTHELS, D; RAJEWSKY, K; WILLE, W				CREMER, H; LANGE, R; CHRISTOPH, A; PLOMANN, M; VOPPER, G; ROES, J; BROWN, R; BALDWIN, S; KRAEMER, P; SCHEFF, S; BARTHELS, D; RAJEWSKY, K; WILLE, W			INACTIVATION OF THE N-CAM GENE IN MICE RESULTS IN SIZE-REDUCTION OF THE OLFACTORY-BULB AND DEFICITS IN SPATIAL-LEARNING	NATURE			English	Article							CELL-ADHESION MOLECULE; NEURAL DEVELOPMENT; POLYSIALIC ACID; DENTATE GYRUS; MUTANT MICE; ADULT-RAT; NCAM; EXPRESSION; MOUSE; PLASTICITY	NEURAL-CELL adhesion molecules (N-CAMs) are members of the immunoglobulin superfamily mediating homo- and heterophilic cell-cell interactions. N-CAM exists in various isoforms which are generated by alternative splicing1-3. During embryonic development, N-CAMs are expressed in derivatives of all three germ layers, whereas in the adult animal they are predominantly present in neural tissue. Processes like neurulation4, axonal outgrowth5, histogenesis of the retina6,7 and development of the olfactory system8-10 are correlated with the regulated expression of N-CAMs11-14. We show here that N-CAM-deficient mice generated by gene targeting appear healthy and fertile, but adult mutants show a 10% reduction in overall brain weight and a 36% decline in size of the olfactory bulb. N-CAM deficiency coincides with almost total loss of protein-bound alpha-(2,8)-linked polysialic acid, a carbohydrate structure thought to be correlated with neural development and plasticity15,16. The animals showed deficits in spatial learning when tested in the Morris water maze17, whereas activity and motor abilities appeared normal.	UNIV COLOGNE,INST GENET,D-50931 COLOGNE,GERMANY; UNIV KENTUCKY,SANDERS BROWN CTR AGING,LEXINGTON,KY 40536	University of Cologne; University of Kentucky	CREMER, H (corresponding author), UNIV COLOGNE,INST GENET,ZULPICHER STR 47,D-50674 COLOGNE,GERMANY.			Cremer, Harold/0000-0002-8673-5176; Roes, Jurgen/0000-0003-3235-2345				BARTHELS D, 1992, EUR J NEUROSCI, V4, P327, DOI 10.1111/j.1460-9568.1992.tb00880.x; BARTHELS D, 1987, EMBO J, V6, P907, DOI 10.1002/j.1460-2075.1987.tb04837.x; Breipohl W., 1986, ONTOGENY OLFACTION, P21; CHUNG WW, 1991, J COMP NEUROL, V314, P290, DOI 10.1002/cne.903140207; CORNWELL CA, 1976, BEHAV BIOL, V17, P131, DOI 10.1016/S0091-6773(76)90377-1; CROSSIN KL, 1990, EXP NEUROL, V109, P6, DOI 10.1016/S0014-4886(05)80004-4; DANILOFF JK, 1986, J CELL BIOL, V103, P929, DOI 10.1083/jcb.103.3.929; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3534; GOLDOWITZ D, 1990, DEV BRAIN RES, V52, P151, DOI 10.1016/0165-3806(90)90230-V; Goridis C, 1992, Semin Cell Biol, V3, P189; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HEMPERLY JJ, 1986, P NATL ACAD SCI USA, V83, P3037, DOI 10.1073/pnas.83.9.3037; JESSELL TM, 1990, NEURON, V1, P3; KEY B, 1991, NEURON, V6, P381, DOI 10.1016/0896-6273(91)90247-W; KEY B, 1990, J CELL BIOL, V110, P1729, DOI 10.1083/jcb.110.5.1729; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P819, DOI 10.1152/physrev.1988.68.3.819; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SCHENK F, 1985, EXP BRAIN RES, V58, P11; SCHOLEY AB, 1993, NEUROSCIENCE, V55, P499, DOI 10.1016/0306-4522(93)90519-L; SEKI T, 1991, NEUROSCI RES, V12, P503, DOI 10.1016/S0168-0102(09)80003-5; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVER J, 1984, DEV BIOL, V106, P485, DOI 10.1016/0012-1606(84)90248-3; THEODOSIS DT, 1991, P NATL ACAD SCI USA, V88, P5494, DOI 10.1073/pnas.88.13.5494; THIEL G, 1993, BRAIN PATHOL, V3, P87, DOI 10.1111/j.1750-3639.1993.tb00729.x; THIERY JP, 1977, J BIOL CHEM, V252, P6841; TOSNEY KW, 1986, DEV BIOL, V114, P437, DOI 10.1016/0012-1606(86)90208-3; ZUBER C, 1992, J BIOL CHEM, V267, P9965	30	881	905	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					455	459		10.1038/367455a0	http://dx.doi.org/10.1038/367455a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	8107803				2022-12-28	WOS:A1994MU67900053
J	PATEL, NH; CONDRON, BG; ZINN, K				PATEL, NH; CONDRON, BG; ZINN, K			PAIR-RULE EXPRESSION PATTERNS OF EVEN-SKIPPED ARE FOUND IN BOTH SHORT-GERM AND LONG-GERM BEETLES	NATURE			English	Article							DROSOPHILA-MELANOGASTER; EMBRYONIC PATTERN; HOMEO BOX; GENE; SEGMENTATION; LOCALIZATION; TRANSCRIPTS; POLARITY; PROTEIN	Now that the genes controlling embryonic patterning have been identified in several model organisms, long-standing questions concerning the evolution of developmental systems are open to investigation. Examination of the expression of even-skipped in a variety of insects reveals that insect germ-type designations apparently do not reflect the variations in the mechanisms of segmentation evident throughout insect phylogeny.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology	PATEL, NH (corresponding author), CARNEGIE INST WASHINGTON,DEPT EMBRYOL,115 W UNIV PKWY,BALTIMORE,MD 21210, USA.		Condron, Barry/AAX-3952-2020	Patel, Nipam/0000-0003-4328-654X; Condron, Barry/0000-0003-2610-5065				AKAM M, 1987, DEVELOPMENT, V101, P1; CARR JN, 1989, DEVELOPMENT, V107, P143; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; FLEIG R, 1990, ROUX ARCH DEV BIOL, V198, P467, DOI 10.1007/BF00399057; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; GUTJAHR T, 1993, DEVELOPMENT, V117, P609; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KELSH R, 1993, DEVELOPMENT, V117, P293; King R.C., 1985, P37; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; MACDONALD PM, 1986, CELL, V47, P721, DOI 10.1016/0092-8674(86)90515-5; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PATEL NH, 1989, DEVELOPMENT, V107, P201; PATEL NH, 1992, NATURE, V357, P339, DOI 10.1038/357339a0; PATEL NH, 1993, EVOLUTIONARY CONSERVATION OF DEVELOPMENTAL MECHANISMS, P85; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; Sander K., 1976, Advances in insect physiology. Volume 12., P125, DOI 10.1016/S0065-2806(08)60255-6; Sander K., 1985, P319; SCHWALM FE, 1988, MONOGRAPHS DEV BIOL, P3; SOMMER RJ, 1993, NATURE, V361, P448, DOI 10.1038/361448a0; SOMMER RJ, 1992, P NATL ACAD SCI USA, V89, P10782, DOI 10.1073/pnas.89.22.10782; STJOHNSTON D, 1992, CELL, V68, P201; TEAR G, 1988, DEVELOPMENT, V104, P135; TEAR G, 1990, DEVELOPMENT, V110, P915	28	243	242	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					429	434		10.1038/367429a0	http://dx.doi.org/10.1038/367429a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	8107801				2022-12-28	WOS:A1994MU67900045
J	LEE, PR				LEE, PR			HEALTH REFORM AND PUBLIC-HEALTH .2. THE SPECIAL NEEDS OF UNDERSERVED POPULATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US PHS,WASHINGTON,DC 20201	United States Public Health Service									0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1993	270	23					2784	2784		10.1001/jama.270.23.2784	http://dx.doi.org/10.1001/jama.270.23.2784			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MK941	8133601				2022-12-28	WOS:A1993MK94100004
J	LEE, PR				LEE, PR			REINVENTING PUBLIC-HEALTH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LEE, PR (corresponding author), US PHS,NEWS OFF,ROOM 719-H,200 INDEPENDENCE AVE SW,WASHINGTON,DC 20201, USA.								0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2670	2670		10.1001/jama.270.22.2670	http://dx.doi.org/10.1001/jama.270.22.2670			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MJ821	8133574				2022-12-28	WOS:A1993MJ82100007
J	DANN, EJ; GILLIS, S; POLLIACK, A; OKON, E; RUND, D; RACHMILEWITZ, EA				DANN, EJ; GILLIS, S; POLLIACK, A; OKON, E; RUND, D; RACHMILEWITZ, EA			TUMOR LYSIS SYNDROME FOLLOWING TREATMENT WITH 2-CHLORODEOXYADENOSINE FOR REFRACTORY CHRONIC LYMPHOCYTIC-LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							FLUDARABINE PHOSPHATE		HADASSAH UNIV HOSP,DEPT PATHOL,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	DANN, EJ (corresponding author), HADASSAH UNIV HOSP,DEPT HEMATOL,KIRYAT HADASSAH,POB 12000,IL-91120 JERUSALEM,ISRAEL.		Rund, Deborah/AFK-2621-2022	Rund, Deborah/0000-0002-4507-7306				CARSON DA, 1984, P NATL ACAD SCI-BIOL, V81, P2232, DOI 10.1073/pnas.81.7.2232; CHUN HG, 1991, J CLIN ONCOL, V9, P175, DOI 10.1200/JCO.1991.9.1.175; GREVER M, 1990, SEMIN ONCOL, V17, P39; JULIUSSON G, 1992, NEW ENGL J MED, V327, P1056, DOI 10.1056/NEJM199210083271504; LIST AF, 1990, AM J MED, V89, P388, DOI 10.1016/0002-9343(90)90358-K; MCCROSKEY RD, 1990, CANCER, V66, P246, DOI 10.1002/1097-0142(19900715)66:2<246::AID-CNCR2820660209>3.0.CO;2-B; PIRO LD, 1990, NEW ENGL J MED, V322, P1117, DOI 10.1056/NEJM199004193221605; PIRO LD, 1988, BLOOD, V72, P1069; SAVEN A, 1991, LEUKEMIA LYMPHOMA, V5, P133, DOI 10.3109/10428199109103394	9	28	30	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1993	329	21					1547	1548		10.1056/NEJM199311183292106	http://dx.doi.org/10.1056/NEJM199311183292106			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG188	8105383				2022-12-28	WOS:A1993MG18800006
J	DUCHIN, JS; KOSTER, FT; PETERS, CJ; SIMPSON, GL; TEMPEST, B; ZAKI, SR; KSIAZEK, TG; ROLLIN, PE; NICHOL, S; UMLAND, ET; MOOLENAAR, RL; REEF, SE; NOLTE, KB; GALLAHER, MM; BUTLER, JC; BREIMAN, RF; BURKHART, M; KALISHMAN, N; VOORHEES, R; VOORHEES, J; SAMUEL, M; TANUZ, M; HUGHES, L; WICTOR, S; OTY, G; NIMS, L; CASTLE, S; BRYT, B; SEWELL, CM; REYNOLDS, P; BROWN, T; SANDS, L; KOMATSU, K; KIOSKI, C; FLEMING, K; DOLL, J; LEVY, C; FINK, TM; MURPHY, P; ENGLAND, B; SMOLINSKI, M; ERICKSON, B; SLANTA, W; GELLERT, G; SCHILLAM, P; HOFFMAN, RE; LANSER, S; NICHOLS, C; HUBBARDPOURIER, L; CHEEK, J; CRAIG, A; HASKINS, R; MUNETA, B; JOHN, S; KITZES, J; HUBBARD, J; CARROLL, M; WOOD, R; NORTH, C; BOHAN, P; COBB, N; ZUMWALT, R; MCFEELY, P; LEVY, H; MERTZ, G; YOUNG, S; FOUCAR, K; HJELLE, B; MCLAUGHLIN, J; ALLEN, S; SIMPSON, S; MERLIN, T; SCHMIDT, M; SIMONSEN, L; VITEK, C; DALTON, C; HELFAND, R; ETTESTADT, P; TAPPERO, J; KHAN, A; CHAPMAN, L; PINNER, R; WACHSMUTH, K; KAUFMANN, A; WENGER, J; MCDADE, J				DUCHIN, JS; KOSTER, FT; PETERS, CJ; SIMPSON, GL; TEMPEST, B; ZAKI, SR; KSIAZEK, TG; ROLLIN, PE; NICHOL, S; UMLAND, ET; MOOLENAAR, RL; REEF, SE; NOLTE, KB; GALLAHER, MM; BUTLER, JC; BREIMAN, RF; BURKHART, M; KALISHMAN, N; VOORHEES, R; VOORHEES, J; SAMUEL, M; TANUZ, M; HUGHES, L; WICTOR, S; OTY, G; NIMS, L; CASTLE, S; BRYT, B; SEWELL, CM; REYNOLDS, P; BROWN, T; SANDS, L; KOMATSU, K; KIOSKI, C; FLEMING, K; DOLL, J; LEVY, C; FINK, TM; MURPHY, P; ENGLAND, B; SMOLINSKI, M; ERICKSON, B; SLANTA, W; GELLERT, G; SCHILLAM, P; HOFFMAN, RE; LANSER, S; NICHOLS, C; HUBBARDPOURIER, L; CHEEK, J; CRAIG, A; HASKINS, R; MUNETA, B; JOHN, S; KITZES, J; HUBBARD, J; CARROLL, M; WOOD, R; NORTH, C; BOHAN, P; COBB, N; ZUMWALT, R; MCFEELY, P; LEVY, H; MERTZ, G; YOUNG, S; FOUCAR, K; HJELLE, B; MCLAUGHLIN, J; ALLEN, S; SIMPSON, S; MERLIN, T; SCHMIDT, M; SIMONSEN, L; VITEK, C; DALTON, C; HELFAND, R; ETTESTADT, P; TAPPERO, J; KHAN, A; CHAPMAN, L; PINNER, R; WACHSMUTH, K; KAUFMANN, A; WENGER, J; MCDADE, J			HANTAVIRUS PULMONARY SYNDROME - A CLINICAL DESCRIPTION OF 17 PATIENTS WITH A NEWLY RECOGNIZED DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISTRESS SYNDROME; KOREAN HEMORRHAGIC-FEVER; PROSPECT-HILL VIRUS; RENAL SYNDROME; UNITED-STATES; EPIZOOTIOLOGY; PERSPECTIVE; INFECTION; RATS	Background. In May 1993 an outbreak of severe respiratory illness occurred in the southwestern United States. A previously unknown hantavirus was identified as the cause. In Asia hantaviruses are associated with hemorrhagic fever and renal disease. They have not been known as a cause of human disease in North America. Methods. We analyzed clinical, laboratory, and autopsy data on the first 17 persons with confirmed infection from this newly recognized strain of hantavirus. Results. The mean age of the patients was 32.2 years (range, 13 to 64); 61 percent were women, 72 percent were Native American, 22 percent white, and 6 percent Hispanic. The most common prodromal symptoms were fever and myalgia (100 percent), cough or dyspnea (76 percent), gastrointestinal symptoms (76 percent), and headache (71 percent). The most common physical findings were tachypnea (100 percent), tachycardia (94 percent), and hypotension (50 percent). The laboratory findings included leukocytosis (median peak cell count, 26,000 per cubic millimeter), often with myeloid precursors, an increased hematocrit, thrombocytopenia (median lowest platelet count, 64,000 per cubic millimeter), prolonged prothrombin and partial-thromboplastin times, an elevated serum lactate dehydrogenase concentration, decreased serum protein concentrations, and proteinuria. Rapidly progressive acute pulmonary edema developed in 15 of the 17 patients (88 percent), and 13 patients, all of whom had profound hypotension, died (case fatality rate, 76 percent). Increases in the hematocrit and partial-thromboplastin time were predictive of death. Conclusions. Infection with a newly described hantavirus causes the hantavirus pulmonary syndrome, which is characterized by a brief prodromal illness followed by rapidly progressive, noncardiogenic pulmonary edema.	UNIV NEW MEXICO HOSP,DEPT INFECT DIS,ALBUQUERQUE,NM; NEW MEXICO DEPT HLTH,SANTA FE,NM 87503; GALLUP INDIAN MED CTR,INDIAN HLTH SERV,GALLUP,NM; OFF MEDICAL INVESTIGATOR,ALBUQUERQUE,NM; NEW MEXICO ENVIRONM DEPT,SANTA FE,NM 87503; ARIZONA DEPT HLTH SERV,PHOENIX,AZ 85034; COLORADO DEPT HLTH,DENVER,CO 80220; UTAH DEPT HLTH,SALT LAKE CITY,UT 84116; INDIAN HLTH SERV,PHOENIX,AZ; LOVELACE MED CTR,ALBUQUERQUE,NM	University of New Mexico; New Mexico Department of Health; Arizona Department of Health Services	DUCHIN, JS (corresponding author), CTR DIS CONTROL,CHILDHOOD & RESP DIS BRANCH,NCID,BLDG 1,MAILSTOP C09,ATLANTA,GA 30333, USA.		Simonsen, Lone/K-4531-2014	Simonsen, Lone/0000-0003-1535-8526; Rollin, Pierre/0000-0002-4608-2641				ANTONIADIS A, 1987, EUR J EPIDEMIOL, V3, P295, DOI 10.1007/BF00149739; BRUNO P, 1990, ANN INTERN MED, V113, P385, DOI 10.7326/0003-4819-113-5-385; CHILDS JE, 1987, AM J EPIDEMIOL, V126, P55, DOI 10.1093/oxfordjournals.aje.a114662; EARLE DP, 1954, AM J MED, V16, P690, DOI 10.1016/0002-9343(54)90279-X; GAJDUSEK DC, 1962, J PEDIATR-US, V60, P841, DOI 10.1016/S0022-3476(62)80170-X; GILES RB, 1954, AM J MED, V16, P629, DOI 10.1016/0002-9343(54)90269-7; GLIGIC A, 1992, J INFECT DIS, V166, P113, DOI 10.1093/infdis/166.1.113; HUGGINS JW, 1991, J INFECT DIS, V164, P1119, DOI 10.1093/infdis/164.6.1119; JOHNSON KM, 1989, VIRAL INFECTIONS HUM, P341; LEDUC JW, 1984, AM J TROP MED HYG, V33, P992, DOI 10.4269/ajtmh.1984.33.992; LEE HW, 1978, J INFECT DIS, V137, P298, DOI 10.1093/infdis/137.3.298; LEE HW, 1989, REV INFECT DIS, V11, pS864; LEE HW, 1982, PROG MED VIROL, V28, P96; LEE M, 1989, REV INFECT DIS S4, V4, pS877; LEE PW, 1985, J INFECT DIS, V152, P826, DOI 10.1093/infdis/152.4.826; LUKES RJ, 1954, AM J MED, V16, P639, DOI 10.1016/0002-9343(54)90270-3; MCKEE KT, 1985, MIL MED, V150, P640, DOI 10.1093/milmed/150.12.640; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; OBUKHOVA GG, 1980, VOP MED KHIM, V26, P118; Outbreak of acute illness - southwestern United States, 1993, MMWR MORB MORTAL WKL, V42, P421; PEPE PE, 1982, AM J SURG, V144, P124, DOI 10.1016/0002-9610(82)90612-2; PETTY TL, 1982, CLIN CHEST MED, V3, P3; RINALDO JE, 1982, NEW ENGL J MED, V306, P900, DOI 10.1056/NEJM198204153061504; SHEEDY JA, 1954, AM J MED, V16, P619, DOI 10.1016/0002-9343(54)90268-5; SIMON RH, 1992, INFLAMMATION BASIC P, P999; STJOHN RC, 1993, CHEST, V103, P932, DOI 10.1378/chest.103.3.932; TSAI TF, 1985, J INFECT DIS, V152, P126, DOI 10.1093/infdis/152.1.126; TSAI TF, 1992, NEW ENGL J MED, V307, P623; YANAGIHARA R, 1990, REV INFECT DIS, V12, P449; YANAGIHARA R, 1984, NEW ENGL J MED, V310, P1325, DOI 10.1056/NEJM198405173102013; Yang Chul Woo, 1992, Journal of Catholic Medical College, V45, P819; 1994, MMWR MORB MORTAL WKL, V43, P45; 1993, B WORLD HEALTH ORGAN, V61, P269; 1993, MMWR MORB MORTAL WKL, V42, P441; 1993, MMWR MORB MORTAL WKL, V42, P1	35	521	541	1	23	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 7	1994	330	14					949	955		10.1056/NEJM199404073301401	http://dx.doi.org/10.1056/NEJM199404073301401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND793	8121458				2022-12-28	WOS:A1994ND79300001
J	VLADECK, BC				VLADECK, BC			FROM THE HEALTH-CARE-FINANCING-ADMINISTRATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											VLADECK, BC (corresponding author), US HLTH CARE FINANCING ADM,WASHINGTON,DC 20201, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	1994	271	13					974	974		10.1001/jama.271.13.974	http://dx.doi.org/10.1001/jama.271.13.974			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ND949	8139071				2022-12-28	WOS:A1994ND94900007
J	REYNOLDS, PP				REYNOLDS, PP			REAFFIRMING PROFESSIONALISM THROUGH THE EDUCATION COMMUNITY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							INTERNAL MEDICINE; RESIDENT; IMPACT; AIDS; TIME	Objective: To determine the role of the clinical training environment and a medical education community in reaffirming medical professionalism among physicians-in-training and faculty. Data sources: Published articles on undergraduate and graduate medical education and sociology works on professionalism were identified through research. Study selection: Studies were selected that illustrated barriers to professionalism in medical education and patient care and the professional conduct of medical students, residents, and faculty. Results: Factors that undermined the medical education community were the specialization of medicine, the faculty reward systems, and the service demands of residency because of the economics of health care. Conclusions: Establishment of a firm system with a core teaching faculty, creation of mentoring and role modeling programs, implementation of a longitudinal curriculum on medical professionalism, evaluation of physicians on professional conduct, and evaluation of the clinical training environment are suggested as strategies to re-establish an education community and reaffirm professionalism in medicine.	VET AFFAIRS MED CTR, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	REYNOLDS, PP (corresponding author), UNIV PENN, SCH MED, ROBERT WOOD JOHNSON FDN, CLIN SCHOLARS PROGRAM, 3615 CHESTNUT ST, PHILADELPHIA, PA 19104 USA.							ANGELL M, 1986, ANN INTERN MED, V104, P261, DOI 10.7326/0003-4819-104-2-261; BELLAH RN, 1986, HABITS HEART INDIVID, P119; BLAND CJ, 1986, J MED EDUC, V61, P22; BOSK CL, 1990, MILBANK Q, V68, P257, DOI 10.2307/3350053; BOSK CL, 1985, SOCIAL CONTROLS MED, P31; BRANDEIS L, 1933, BUSINESS PROFESSION; CHURCHILL LR, 1989, HASTINGS CENT REP, V19, P28, DOI 10.2307/3562740; FICKLIN FL, 1988, J MED EDUC, V63, P392; FITZGERALD FT, 1993, NEW ENGL J MED, V328, P654, DOI 10.1056/NEJM199303043280912; Foa R P, 1986, Pharos Alpha Omega Alpha Honor Med Soc, V49, P21; FOX RC, 1993, ED COMPETENT HUMAN P, P199; GARDNER JW, 1991, BUILDING COMMUNITY, P17; GREGANTI MA, 1990, ARCH INTERN MED, V150, P259; HARRIS ED, 1993, ANN INTERN MED, V119, P430, DOI 10.7326/0003-4819-119-5-199309010-00016; HARRIS MT, 1991, B NEW YORK ACAD MED, V67, P365; HAYWARD RSA, 1991, ANN INTERN MED, V115, P372, DOI 10.7326/0003-4819-115-5-372; Hendelman W J, 1991, Pharos Alpha Omega Alpha Honor Med Soc, V54, P2; Horak B J, 1991, Health Care Manage Rev, V16, P65; Johnson N D, 1992, Crit Care Nurs Q, V15, P37; Konner M., 1987, BECOMING DOCTOR JOUR; LURIE N, 1989, NEW ENGL J MED, V320, P1673, DOI 10.1056/NEJM198906223202507; MCCALL TB, 1988, NEW ENGL J MED, V318, P775, DOI 10.1056/NEJM198803243181210; MCGRORY BJ, 1990, PSYCHOSOMATICS, V31, P426, DOI 10.1016/S0033-3182(90)72139-1; MIRVIS DM, 1993, NEW ENGL J MED, V328, P1346, DOI 10.1056/NEJM199305063281812; OSLER W, 1932, AEQUANIMITAS OTHER A, P311; PARENTI C, 1993, AM J MED, V94, P654, DOI 10.1016/0002-9343(93)90220-J; Parsons T., 1951, SOCIAL SYSTEM; Pellegrino Edmund D., 1987, SEARCH MODERN HIPPOC, P45; Perkoff G T, 1992, Fam Med, V24, P584; Petersdorf R G, 1987, Pharos Alpha Omega Alpha Honor Med Soc, V50, P13; PETERSDORF RG, 1980, NEW ENGL J MED, V303, P489, DOI 10.1056/NEJM198008283030904; PETERSDORF RG, 1986, ANN INTERN MED, V104, P252, DOI 10.7326/0003-4819-104-2-252; PETERSDORF RG, 1992, 1991 GRAD ED TRAIN I, P27; Pike A W, 1991, J Prof Nurs, V7, P351, DOI 10.1016/8755-7223(91)90012-A; Rabkin M T, 1982, N Engl J Med, V307, P1350, DOI 10.1056/NEJM198211183072126; RABKIN MT, 1985, J MED EDUC, V60, P92; RAMSEY PG, 1993, JAMA-J AM MED ASSOC, V269, P1655, DOI 10.1001/jama.269.13.1655; REED RR, 1987, JAMA-J AM MED ASSOC, V258, P3279, DOI 10.1001/jama.258.22.3279; REYNOLDS PP, 1991, B NEW YORK ACAD MED, V67, P369; REYNOLDS PP, 1991, ANN INTERN MED, V114, P91, DOI 10.7326/0003-4819-114-1-91; SCHROEDER SA, 1986, ANN INTERN MED, V104, P554, DOI 10.7326/0003-4819-104-4-554; SHORT JP, 1993, ACAD MED, V68, P522, DOI 10.1097/00001888-199307000-00003; SPIVEY BE, 1990, AM J OPHTHALMOL, V110, P688, DOI 10.1016/S0002-9394(14)77069-2; WARTMAN SA, 1990, J GEN INTERN MED, V5, pS59, DOI 10.1007/BF02600439; Weber M., 1958, PROTESTANT WORK ETHI; WU AW, 1991, JAMA-J AM MED ASSOC, V265, P2089, DOI 10.1001/jama.265.16.2089; 1983, NEW LOOK OLD WAY GET	47	90	90	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					609	614		10.7326/0003-4819-120-7-199404010-00013	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00013			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8117001				2022-12-28	WOS:A1994NC76400013
J	KOLESKE, AJ; YOUNG, RA				KOLESKE, AJ; YOUNG, RA			AN RNA POLYMERASE-II HOLOENZYME RESPONSIVE TO ACTIVATORS	NATURE			English	Article							TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; TERMINAL DOMAIN; INITIATION; PURIFICATION; PROMOTER; INVITRO; PHOSPHORYLATION; IDENTIFICATION; COMPLEXES	RNA POLYMERASE II requires multiple general transcription factors to initiate site-specific transcription1-3. These proteins can assemble in an ordered fashion onto promoter DNA in vitro2-8, and such ordered assembly may occur in vivo (Fig. 1a). Some general transcription factors can interact with RNA polymerase II in the absence of DNA3,9-15, however, suggesting that RNA polymerase II may also assemble into a multi-component complex containing a subset of initiation factors before binding to promoter DNA (Fig. 1b). Here we present evidence from the yeast Saccharomyces cerevisiae for such an RN.A polymerase II holoenzyme, a multi-subunit complex containing roughly equimolar amounts of RNA polymerase II, a subset of general transcription factors, and SRB regulatory proteins. Transcription by this holoenzyme is stimulated by the activator protein GAL4-VP16, a feature not observed with purified RNA polymerase II and general transcription factors alone. We propose that the holoenzyme is a form of RNA polymerase II readily recruited to promoters in vivo.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	KOLESKE, AJ (corresponding author), WHITEHAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CONAWAY RC, 1993, REV BIOCH, V62, P161; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLANAGAN PM, 1992, P NATL ACAD SCI USA, V89, P7659, DOI 10.1073/pnas.89.16.7659; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1992, J BIOL CHEM, V267, P2786; GERARD M, 1991, J BIOL CHEM, V266, P20940; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; HENRY NL, 1992, J BIOL CHEM, V267, P23388; KITAJIMA S, 1990, NUCLEIC ACIDS RES, V18, P4843, DOI 10.1093/nar/18.16.4843; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SOPTA M, 1985, J BIOL CHEM, V260, P353; THOMPSON CM, 1993, CELL, V73, P1367; TSCHOCHNER H, 1992, P NATL ACAD SCI USA, V89, P11292, DOI 10.1073/pnas.89.23.11292; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	30	551	560	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 31	1994	368	6470					466	469		10.1038/368466a0	http://dx.doi.org/10.1038/368466a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	8133894				2022-12-28	WOS:A1994ND12000067
J	DERIJARD, B; HIBI, M; WU, IH; BARRETT, T; SU, B; DENG, TL; KARIN, M; DAVIS, RJ				DERIJARD, B; HIBI, M; WU, IH; BARRETT, T; SU, B; DENG, TL; KARIN, M; DAVIS, RJ			JNK1 - A PROTEIN-KINASE STIMULATED BY UV-LIGHT AND HA-RAS THAT BINDS AND PHOSPHORYLATES THE C-JUN ACTIVATION DOMAIN	CELL			English	Article							DNA-BINDING; MAP KINASE; GENE; SITES; IDENTIFICATION; ONCOPROTEIN; EXPRESSION; CEREVISIAE; SERINE-63; TYROSINE	The ultraviolet (UV) response of mammalian cells is characterized by a rapid and selective increase in gene expression mediated by AP-1 and NF-kappaB. The effect on AP-1 transcriptional activity results, in part, from enhanced phosphorylation of the c-Jun NH2-terminal activation domain. Here, we describe the molecular cloning and characterization of JNK1, a distant relative of the MAP kinase group that is activated by dual phosphorylation at Thr and Tyr during the UV response. Significantly, Ha-Ras partially activates JNK1 and potentiates the activation caused by UV. JNK1 binds to the c-Jun transactivation domain and phosphorylates it on Ser-63 and Ser-73. Thus, JNK1 is a component of a novel signal transduction pathway that is activated by oncoproteins and UV irradiation. These properties indicate that JNK1 activation may play an important role in tumor promotion.	UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,LEHRSTUHL BIOMED SCI,LA JOLLA,CA 92093	University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California San Diego	DERIJARD, B (corresponding author), UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOWARD HUGHES MED INST,WORCESTER,MA 01605, USA.		Hibi, Masahiko/I-6215-2014	Hibi, Masahiko/0000-0002-9142-4444	NATIONAL CANCER INSTITUTE [R01CA058396, P01CA050528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037845] Funding Source: NIH RePORTER; NCI NIH HHS [CA58396, CA50528] Funding Source: Medline; NIGMS NIH HHS [GM37845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, CELL, V55, P85; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P573; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; HUNTER T, 1992, CELL, V70, P3755; KARIN M, 1989, GENES SIGNAL TRANSDU, P415; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LAUTIER D, 1992, CARCINOGENESIS, V13, P227, DOI 10.1093/carcin/13.2.227; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Romerdahl C A, 1989, Cancer Commun, V1, P209; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TORRES L, 1991, MOL MICROBIOL, V5, P2845, DOI 10.1111/j.1365-2958.1991.tb01993.x; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TRUSH MA, 1991, FREE RADICAL BIO MED, V10, P201, DOI 10.1016/0891-5849(91)90077-G; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WEINSTEIN IB, 1988, CANCER RES, V48, P4136	60	2961	3048	1	85	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1025	1037		10.1016/0092-8674(94)90380-8	http://dx.doi.org/10.1016/0092-8674(94)90380-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137421				2022-12-28	WOS:A1994ND24600009
J	HEUSEL, JW; WESSELSCHMIDT, RL; SHRESTA, S; RUSSELL, JH; LEY, TJ				HEUSEL, JW; WESSELSCHMIDT, RL; SHRESTA, S; RUSSELL, JH; LEY, TJ			CYTOTOXIC LYMPHOCYTES REQUIRE GRANZYME-B FOR THE RAPID INDUCTION OF DNA FRAGMENTATION AND APOPTOSIS IN ALLOGENEIC TARGET-CELLS	CELL			English	Article							CYTO-TOXIC LYMPHOCYTE; SERINE PROTEASE GENES; FUNCTIONAL-CHARACTERIZATION; MOUSE CHROMOSOME-14; GLOBIN GENE; T-CELLS; EXPRESSION; GRANULES; PERFORIN; LYSIS	We have generated H-2b mice with a homozygous null mutation in the granzyme (gzm) B gene. Gzm B is a neutral serine protease with Aspase activity that is found only in the granules of activated cytolytic T cells, natural killer cells, and lymphokine-activated killer cells. Gzm B-/- mice develop normally and have normal hematopoiesis and lymphopoiesis. In vitro, cytotoxic T lymphocytes (CTL) derived from gzm B-/- animals are able to induce Cr-51 release from allotarget cells, but with reduced efficiency. However, gzm B-/- CTL have a profound defect in their ability to induce rapid DNA fragmentation and apoptosis in allogeneic target cells. This defect is kinetic since DNA fragmentation is partially compensated and Cr-51 release is completely rescued with long incubation times. We conclude that gzm B serves a critical and nonredundant role for the rapid induction of target cell DNA fragmentation and apoptosis by alloreactive cytotoxic T lymphocytes.	WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	HEUSEL, JW (corresponding author), WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT MED, DIV BONE MARROW TRANSPLANT, ST LOUIS, MO 63110 USA.		Heusel, Jon/AAC-8050-2021	Russell, John/0000-0002-3680-9587	NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NCI NIH HHS [CA-49712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLEACKLEY RC, 1988, IMMUNOL REV, V103, P5, DOI 10.1111/j.1600-065X.1988.tb00746.x; BRUNET JF, 1986, NATURE, V322, P268, DOI 10.1038/322268a0; CAPUTO A, 1993, J BIOL CHEM, V268, P17672; CROSBY JL, 1990, GENOMICS, V6, P252, DOI 10.1016/0888-7543(90)90564-B; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOURMASHKIN RR, 1980, CLIN EXP IMMUNOL, V42, P554; DUKE RC, 1989, J EXP MED, V170, P1451, DOI 10.1084/jem.170.4.1451; EBNET K, 1991, INT IMMUNOL, V3, P9, DOI 10.1093/intimm/3.1.9; EWOLDT GR, 1992, MOL IMMUNOL, V29, P713, DOI 10.1016/0161-5890(92)90181-V; GARCIASANZ JA, 1990, J IMMUNOL, V145, P3111; GRIFFITHS GM, 1993, J CELL BIOL, V120, P885, DOI 10.1083/jcb.120.4.885; GROSCURTH P, 1989, ANAT EMBRYOL, V180, P109, DOI 10.1007/BF00309762; HADDAD P, 1990, GENE, V87, P265, DOI 10.1016/0378-1119(90)90311-E; HAMPSON IN, 1992, BLOOD, V80, P3097; HANSON RD, 1990, MOL CELL BIOL, V10, P5655, DOI 10.1128/MCB.10.11.5655; HANSON RD, 1990, P NATL ACAD SCI USA, V87, P960, DOI 10.1073/pnas.87.3.960; HANSON RD, 1991, J BIOL CHEM, V266, P24433; HARPER K, 1988, IMMUNOGENETICS, V28, P439, DOI 10.1007/BF00355376; HAYES MP, 1989, J EXP MED, V170, P933, DOI 10.1084/jem.170.3.933; HELD W, 1990, INT IMMUNOL, V2, P57, DOI 10.1093/intimm/2.1.57; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HENKART PA, 1993, CYTOTOXIC CELLS, P153; HEUSEL JW, 1993, BLOOD, V81, P1614; HEUSEL JW, 1991, J BIOL CHEM, V266, P6152; HUDIG D, 1991, J IMMUNOL, V147, P1360; HUDIG D, 1993, CURR OPIN IMMUNOL, V5, P90, DOI 10.1016/0952-7915(93)90086-8; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JENNE DE, 1988, IMMUNOL REV, V103, P53, DOI 10.1111/j.1600-065X.1988.tb00749.x; KIM CG, 1992, GENE DEV, V6, P928, DOI 10.1101/gad.6.6.928; KLEIN JL, 1989, GENOMICS, V5, P110, DOI 10.1016/0888-7543(89)90093-1; KRAHENBUHL O, 1988, J IMMUNOL, V141, P3471; LANIER LL, 1986, IMMUNOL TODAY, V7, P132, DOI 10.1016/0167-5699(86)90076-9; LEY TJ, 1989, J CLIN INVEST, V83, P1032, DOI 10.1172/JCI113944; LIPMAN ML, 1992, TRANSPLANTATION, V53, P73, DOI 10.1097/00007890-199201000-00014; LOBE CG, 1988, BIOCHEMISTRY-US, V27, P6941, DOI 10.1021/bi00418a040; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MASSON D, 1985, J BIOL CHEM, V260, P9069; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MILLARD PJ, 1984, J IMMUNOL, V132, P3197; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUELLER C, 1988, J EXP MED, V167, P1124, DOI 10.1084/jem.167.3.1124; Nemeth MJ, 2006, P NATL ACAD SCI USA, V103, P13783, DOI 10.1073/pnas.0604006103; OCONNELL PJ, 1993, J IMMUNOL, V150, P1093; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099; PODACK ER, 1984, J EXP MED, V160, P695, DOI 10.1084/jem.160.3.695; PODACK ER, 1985, P NATL ACAD SCI USA, V82, P8629, DOI 10.1073/pnas.82.24.8629; PODACK ER, 1983, NATURE, V302, P442, DOI 10.1038/302442a0; POE M, 1991, J BIOL CHEM, V266, P98; PRENDERGAST JA, 1992, J BIOL CHEM, V267, P5090; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1983, IMMUNOL REV, V72, P97, DOI 10.1111/j.1600-065X.1983.tb01074.x; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; RUSSELL JH, 1982, J IMMUNOL, V128, P2087; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; SITKOVSKY MV, 1993, CYTOTOXIC CELLS; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; WIJNGAARD PLJ, 1993, TRANSPLANTATION, V55, P103, DOI 10.1097/00007890-199301000-00020; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	65	728	744	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 25	1994	76	6					977	987		10.1016/0092-8674(94)90376-X	http://dx.doi.org/10.1016/0092-8674(94)90376-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137431				2022-12-28	WOS:A1994ND24600005
J	DANDREA, AD; FLIER, J; MOSES, A; LOWELL, B; MONROE, MJ				DANDREA, AD; FLIER, J; MOSES, A; LOWELL, B; MONROE, MJ			SEMINARS IN MEDICINE OF THE BETH-ISRAEL-HOSPITAL, BOSTON - CYTOKINE RECEPTORS IN CONGENITAL HEMATOPOIETIC DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							COLONY-STIMULATING FACTOR; LARON-TYPE DWARFISM; ACUTE MYELOBLASTIC-LEUKEMIA; HUMAN GROWTH-HORMONE; ERYTHROPOIETIN RECEPTOR; IL-2 RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; CYTOPLASMIC REGION; LINEAR GROWTH		DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	DANDREA, AD (corresponding author), DANA FARBER CANC INST,DIV PEDIAT ONCOL,44 BINNEY ST,BOSTON,MA 02115, USA.		Flier, jeffrey/AAG-6223-2019					ALTER BP, 1993, HEMATOLOGY INFANCY C, V1, P216; AMSELEM S, 1989, NEW ENGL J MED, V321, P989, DOI 10.1056/NEJM198910123211501; BAUMANN G, 1987, J CLIN ENDOCR METAB, V65, P814, DOI 10.1210/jcem-65-4-814; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRADLEY TR, 1966, AUST J EXP BIOL MED, V44, P287, DOI 10.1038/icb.1966.28; BUDARF M, 1990, GENOMICS, V8, P575, DOI 10.1016/0888-7543(90)90047-X; CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CROSIER KE, 1991, P NATL ACAD SCI USA, V88, P7744, DOI 10.1073/pnas.88.17.7744; D'Andrea AD, 1990, CURR OPIN CELL BIOL, V2, P648, DOI 10.1016/0955-0674(90)90106-O; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DELACHAPELLE A, 1993, LANCET, V341, P82, DOI 10.1016/0140-6736(93)92558-B; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DONG F, 1993, EXP HEMATOL, V21, P1017; EDERY M, 1993, J CLIN INVEST, V91, P838, DOI 10.1172/JCI116304; EMANUEL PD, 1992, BLOOD, V79, P3019; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; GROOPMAN JE, 1989, NEW ENGL J MED, V321, P1449, DOI 10.1056/NEJM198911233212106; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HOOGHE R, 1993, IMMUNOL TODAY, V14, P212, DOI 10.1016/0167-5699(93)90165-H; ICHIKAWA Y, 1966, P NATL ACAD SCI USA, V56, P488, DOI 10.1073/pnas.56.2.488; JUVONEN E, 1991, BLOOD, V78, P3066; KOBAYASHI M, 1990, BLOOD, V75, P2143; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KURAMOCHI S, 1990, J MOL BIOL, V216, P567, DOI 10.1016/0022-2836(90)90384-X; LARON Z, 1992, LANCET, V339, P1258, DOI 10.1016/0140-6736(92)91594-X; LARON Z, 1971, J CLIN ENDOCR METAB, V33, P332, DOI 10.1210/jcem-33-2-332; LAVER J, 1989, JNCI-J NATL CANCER I, V81, P1370, DOI 10.1093/jnci/81.18.1370; LOWENBERG B, 1993, BLOOD, V81, P281; METCALF D, 1992, TRENDS BIOCHEM SCI, V17, P286, DOI 10.1016/0968-0004(92)90436-D; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MURPHY WJ, 1992, BLOOD, V80, P1443; NAKAMURA Y, 1992, SCIENCE, V257, P1138, DOI 10.1126/science.257.5073.1138; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; QUELLE FW, 1991, J BIOL CHEM, V266, P609; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; WARD JC, 1992, EXP HEMATOL, V20, P371; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WELTE K, 1990, BLOOD, V75, P1056; WINKELMANN JC, 1990, BLOOD, V76, P24; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; YOUNG DC, 1987, J CLIN INVEST, V79, P100, DOI 10.1172/JCI112769; YOUNG DC, 1986, BLOOD, V68, P1178; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	55	22	23	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 24	1994	330	12					839	846						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB803	8114837				2022-12-28	WOS:A1994NB80300007
J	BENJAMIN, EJ; LEVY, D; VAZIRI, SM; DAGOSTINO, RB; BELANGER, AJ; WOLF, PA				BENJAMIN, EJ; LEVY, D; VAZIRI, SM; DAGOSTINO, RB; BELANGER, AJ; WOLF, PA			INDEPENDENT RISK-FACTORS FOR ATRIAL-FIBRILLATION IN A POPULATION-BASED COHORT - THE FRAMINGHAM HEART-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPIDEMIOLOGIC FEATURES; PREVENTION; STROKE; MORTALITY; WARFARIN; DISEASE; RHYTHM; TRIALS; TIME	Objective.-To determine the independent risk factors for atrial fibrillation. Design.-Cohort study. Setting.-The Framingham Heart Study. Subjects.-A total of 2090 men and 2641 women members of the original cohort, free of a history of atrial fibrilltation, between the ages of 55 and 94 years. Main Outcome Measures.-Sex-specific multiple logistic regression models to identify independent risk factors for atrial fibrillation, including age, smoking, diabetes, electrocardiographic left ventricular hypertrophy, hypertension, myocardial infarction, congestive heart failure, and valve disease. Results.-During up to 38 years of follow-up, 264 men and 298 women developed atrial fibrillation, After adjusting for age and other risk factors for atrial fibrillation, men had a 1.5 times greater risk of developing atrial fibrillation than women. In the full multivariable model, the odds ratio (OR) of atrial fibrillation for each decade of advancing age was 2.1 for men and 2.2 for women (P<.0001). In addition, after multivariable adjustment, diabetes (OR, 1.4 for men and 1.6 for women), hypertension (OR, 1.5 for men and 1.4 for women), congestive heart failure (OR, 4.5 for men and 5.9 for women), and valve disease (OR, 1.8 for men and 3.4 for women) were significantly associated with risk for atrial fibrillation in both sexes. Myocardial infarction (OR, 1.4) was significantly associated with the development of atrial fibrillation in men. Women were significantly more likely than men to have valvular heart disease as a risk factor for atrial fibrillation. The multivariable models were largely unchanged after eliminating subjects with valvular heart disease. Conclusion.-In addition to intrinsic cardiac causes such as valve disease and congestive heart failure, risk factors for cardiovascular disease also predispose to atrial fibrillation. Modification of risk factors for cardiovascular disease may have the added benefit of diminishing the incidence of atrial fibrillation.	BOSTON UNIV, BOSTON CITY HOSP, SCH MED, CARDIOL SECT, BOSTON, MA 02118 USA; NHLBI, BETHESDA, MD 20892 USA; BOSTON UNIV, DEPT MATH, BOSTON, MA 02215 USA; BOSTON UNIV, SCH MED, DEPT PREVENT MED, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA; BETH ISRAEL HOSP, DIV CARDIOL, BOSTON, MA USA; BETH ISRAEL HOSP, DIV CLIN EPIDEMIOL, BOSTON, MA USA	Boston Medical Center; Boston University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	BENJAMIN, EJ (corresponding author), FRAMINGHAM HEART DIS EPIDEMIOL STUDY, 5 THURBER ST, FRAMINGHAM, MA 01701 USA.		Levy, Daniel/ABF-6873-2021; Benjamin, Emelia/E-7103-2011	Levy, Daniel/0000-0003-1843-8724; Benjamin, Emelia/0000-0003-4076-2336; Wolf, Philip/0000-0002-3628-301X	NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [2-R01-NS-17950-11] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABERG H, 1968, ACTA MED SCAND, V184, P425; ALBERS GW, 1991, ANN NEUROL, V30, P511, DOI 10.1002/ana.410300402; CAMERON A, 1988, AM J CARDIOL, V61, P714, DOI 10.1016/0002-9149(88)91053-3; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DAVIDSON E, 1989, ARCH INTERN MED, V149, P457, DOI 10.1001/archinte.149.2.457; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; ETTINGER PO, 1978, AM HEART J, V95, P555, DOI 10.1016/0002-8703(78)90296-X; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; GAJEWSKI J, 1981, JAMA-J AM MED ASSOC, V245, P1540; GODTFREDSEN J, 1982, ATRIAL FIBRILLATION, P134; KANNEL WB, 1983, AM HEART J, V106, P389, DOI 10.1016/0002-8703(83)90208-9; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KANNEL WB, 1969, ANN INTERN MED, V71, P89, DOI 10.7326/0003-4819-71-1-89; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; LAKE FR, 1989, AUST NZ J MED, V19, P321, DOI 10.1111/j.1445-5994.1989.tb00271.x; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; McEachern D, 1932, AM J MED SCI, V183, P35, DOI 10.1097/00000441-193201000-00004; ONUNDARSON PT, 1987, EUR HEART J, V8, P521; PETERSEN P, 1989, LANCET, V1, P175; ROBINSON K, 1990, J AM COLL CARDIOL, V15, P1279, DOI 10.1016/S0735-1097(10)80014-2; SAWYER C G, 1958, South Med J, V51, P84; SHERMAN DG, 1984, ARCH NEUROL-CHICAGO, V41, P708, DOI 10.1001/archneur.1984.04050180030011; SHURTLEFF D, 1974, DHEW NIH74599 PUBL; Stroud WD, 1932, AM J MED SCI, V183, P48; VAZIRI SM, 1994, CIRCULATION, V89, P724, DOI 10.1161/01.CIR.89.2.724; WALKER SD, 1976, BIOMETRICS, V32, P829; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; WOOD P, 1954, BRIT MED J, V1, P1063	31	2222	2277	2	65	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					840	844		10.1001/jama.271.11.840	http://dx.doi.org/10.1001/jama.271.11.840			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ498	8114238				2022-12-28	WOS:A1994MZ49800030
J	BELRHALI, H; YAREMCHUK, A; TUKALO, M; LARSEN, K; BERTHETCOLOMINAS, C; LEBERMAN, R; BEIJER, B; SPROAT, B; ALSNIELSEN, J; GRUBEL, G; LEGRAND, JF; LEHMANN, M; CUSACK, S				BELRHALI, H; YAREMCHUK, A; TUKALO, M; LARSEN, K; BERTHETCOLOMINAS, C; LEBERMAN, R; BEIJER, B; SPROAT, B; ALSNIELSEN, J; GRUBEL, G; LEGRAND, JF; LEHMANN, M; CUSACK, S			CRYSTAL-STRUCTURES AT 2.5 ANGSTROM RESOLUTION OF SERYL-TRANSFER-RNA SYNTHETASE COMPLEXED 2 ANALOGS OF SERYL ADENYLATE	SCIENCE			English	Article							TRANSFER-RNA-SYNTHETASE; ESCHERICHIA-COLI; SERINE HYDROXAMATE; SEQUENCE; ATP	Crystal structures of seryl-tRNA synthetase from Thermus thermophilus complexed with two different analogs of seryl adenylate have been determined at 2.5 Angstrom resolution. The first complex is between the enzyme and seryl-hydroxamate-AMP (adenosine monophosphate), produced enzymatically in the crystal from adenosine triphosphate (ATP) and serine hydroxamate, and the second is with a synthetic analog of seryl adenylate (5'-O-[N-(L-seryl)-sulfamoyl]adenosine), which is a strong inhibitor of the enzyme. Both molecules are bound in a similar fashion by a network of hydrogen bond interactions in a deep hydrophilic cleft formed by the antiparallel beta sheet and surrounding loops of the synthetase catalytic domain. Four regions in the primary sequence are involved in the interactions, including the motif 2 and 3 regions of class 2 synthetases. Apart from the specific recognition of the serine side chain, the interactions are likely to be similar in all class 2 synthetases.	ILL GRENOBLE, EMBL, GRENOBLE OUTSTN, F-38042 GRENOBLE 9, FRANCE; EMBL, BIOCHEM INSTRUMENTAT PROGRAMME, D-69012 HEIDELBERG, GERMANY; EUROPEAN SYNCHROTRON RADIAT FACIL, F-38043 GRENOBLE, FRANCE	European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL); European Molecular Biology Laboratory (EMBL); European Synchrotron Radiation Facility (ESRF)				Tukalo, Michael/0000-0002-0982-2372				BEGUM AS, 1988, ACTA CRYSTALLOGR C, V44, P1047; BELRHALI H, UNPUB; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRICK P, 1987, J MOL BIOL, V194, P287, DOI 10.1016/0022-2836(87)90376-7; BRUNGER AT, 1993, X PLOR VERSION 3 1; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CASTROPICHEL J, 1987, TETRAHEDRON, V43, P383, DOI 10.1016/S0040-4020(01)89967-1; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; CUSACK S, 1993, TRANSLATIONAL APPARATUS, P1; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DEPOUPLANA LR, 1993, PROTEIN SCI, V2, P2259; DOUBLIE S, 1993, THESIS U N CAROLINA; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FOURME R, 1992, REV SCI INSTRUM, V63, P982, DOI 10.1063/1.1143716; FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576; GARBER MB, 1990, J MOL BIOL, V213, P631, DOI 10.1016/S0022-2836(05)80251-7; KAST P, 1991, J MOL BIOL, V222, P99, DOI 10.1016/0022-2836(91)90740-W; LARSEN KJ, UNPUB; LEHMANN MS, 1993, NEWSLETTER PROTEIN C; Leslie A, 1992, NEWSLETTER PROTEIN C; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; PERONA JJ, 1993, BIOCHEMISTRY-US, V32, P8758, DOI 10.1021/bi00085a006; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; TOSA T, 1971, J BACTERIOL, V106, P972, DOI 10.1128/JB.106.3.972-982.1971; TOSA T, 1971, J BACTERIOL, V106, P966, DOI 10.1128/JB.106.3.966-971.1971; UEDA H, 1991, BIOCHIM BIOPHYS ACTA, V1080, P126, DOI 10.1016/0167-4838(91)90138-P	31	156	163	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 11	1994	263	5152					1432	1436		10.1126/science.8128224	http://dx.doi.org/10.1126/science.8128224			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	MZ927	8128224				2022-12-28	WOS:A1994MZ92700030
J	GARCIA, CK; GOLDSTEIN, JL; PATHAK, RK; ANDERSON, RGW; BROWN, MS				GARCIA, CK; GOLDSTEIN, JL; PATHAK, RK; ANDERSON, RGW; BROWN, MS			MOLECULAR CHARACTERIZATION OF A MEMBRANE TRANSPORTER FOR LACTATE, PYRUVATE, AND OTHER MONOCARBOXYLATES - IMPLICATIONS FOR THE CORI CYCLE	CELL			English	Article							ERYTHROCYTE-MEMBRANE; SKELETAL-MUSCLE; RAT; IDENTIFICATION; PURIFICATION; MEVALONATE; INHIBITION; MECHANISM; PROTEIN; CARRIER	Lactate and pyruvate cross cell membranes via a monocarboxylate transporter (MCT) with well-defined properties but undefined molecular structure. We report the cloning of a cDNA encoding MCT1, a monocarboxylate transporter whose properties resemble those of the erythrocyte MCT, including proton symport, trans acceleration, and sensitivity to alpha-cyanocinammates. A Phe to Cys substitution in MCT1 converts it to Mev, a mevalonate transporter. MCT1 is abundant in erythrocytes, cardiac muscle, and basolateral intestinal epithelium. In skeletal muscle it is restricted to mitochondria-rich myocytes. As sperm traverse the epididymis, MCT1 switches from sperm to epithelial cells. MCT1 is present at low levels in liver, suggesting another MCT in this tissue. By exporting lactate from intestine and erythrocytes, MCT1 participates in the Cori cycle. It also participates in novel pathways of monocarboxylate metabolism in muscle and sperm.	UNIV TEXAS, SW MED CTR, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	GARCIA, CK (corresponding author), UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM07062, GM08014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN MS, 1978, J BIOL CHEM, V253, P1121; BUCHALTER SE, 1989, DIABETES METAB REV, V5, P379, DOI 10.1002/dmr.5610050405; DEUTICKE B, 1982, BIOCHIM BIOPHYS ACTA, V684, P96, DOI 10.1016/0005-2736(82)90053-0; DRAKE AJ, 1980, CARDIOVASC RES, V14, P65, DOI 10.1093/cvr/14.2.65; DUBINSKY WP, 1978, J MEMBRANE BIOL, V44, P25, DOI 10.1007/BF01940571; Dubowitz V., 1973, MUSCLE BIOPSY MODERN, P34; FAUST J, 1987, J BIOL CHEM, V262, P1996; GLADDEN LB, 1989, EXERCISE SPORT SCI R, V17, P115; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALESTRAP AP, 1974, BIOCHEM J, V138, P313, DOI 10.1042/bj1380313; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; JENNINGS ML, 1982, J BIOL CHEM, V257, P2866; KIM CM, 1992, J BIOL CHEM, V267, P23113; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDERMOTT JC, 1993, MOL CELL BIOCHEM, V122, P113, DOI 10.1007/BF01076095; NAVE JF, 1985, BIOCHEM J, V227, P247, DOI 10.1042/bj2270247; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; POOLE RC, 1992, BIOCHEM J, V283, P855, DOI 10.1042/bj2830855; POOLE RC, 1988, BIOCHEM J, V254, P385, DOI 10.1042/bj2540385; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; POOLE RC, 1990, BIOCHEM J, V269, P827, DOI 10.1042/bj2690827; REICHMANN H, 1982, HISTOCHEMISTRY, V74, P27, DOI 10.1007/BF00495049; ROTH DA, 1990, ARCH BIOCHEM BIOPHYS, V279, P377, DOI 10.1016/0003-9861(90)90505-S; Sambrook J, 1989, MOL CLONING LABORATO; SPENCER TL, 1976, BIOCHEM J, V154, P405, DOI 10.1042/bj1540405; Stein WD, 1986, TRANSPORT DIFFUSION, P231; VOET D, 1990, BIOCHEMISTRY-US, P568	27	420	436	1	52	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 11	1994	76	5					865	873		10.1016/0092-8674(94)90361-1	http://dx.doi.org/10.1016/0092-8674(94)90361-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124722				2022-12-28	WOS:A1994NA89000012
J	EMSLEY, J; WHITE, HE; OHARA, BP; OLIVA, G; SRINIVASAN, N; TICKLE, IJ; BLUNDELL, TL; PEPYS, MB; WOOD, SP				EMSLEY, J; WHITE, HE; OHARA, BP; OLIVA, G; SRINIVASAN, N; TICKLE, IJ; BLUNDELL, TL; PEPYS, MB; WOOD, SP			STRUCTURE OF PENTAMERIC HUMAN SERUM AMYLOID-P COMPONENT	NATURE			English	Article							C-REACTIVE PROTEIN; CYCLIC 4,6-PYRUVATE ACETAL; BINDING-PROTEIN; CONCANAVALIN-A; SENSITIVE SITE; CALCIUM; RESOLUTION; GALACTOSE; SPECIFICITY; REFINEMENT	The three-dimensional structure of pentameric human serum amyloid P component at high resolution, the first reported for a pentraxin, reveals that the tertiary fold is remarkably similar to that of the legume lectins. Carboxylate and phosphate compounds bind directly to two calcium ions; interactions with a carboxyethylidene ring are mediated by Asn 59 and Gln 148 ligands of the calcium ions. These X-ray results indicate the probable modes of binding of the biologically important ligands, DNA and amyloid fibrils.	UNIV LONDON BIRKBECK COLL,MOLEC BIOL LAB,LONDON WC1E 7HX,ENGLAND; UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,ICRF,STRUCT MOLEC BIOL UNIT,LONDON WC1E 7HX,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,IMMUNOL MED UNIT,LONDON W12 0NN,ENGLAND	University of London; Birkbeck University London; University of London; Birkbeck University London; Imperial College London			Wood, Stephen P/B-1438-2009; Oliva, Glaucius/B-9059-2012; emsley, jonas/A-8509-2016	Oliva, Glaucius/0000-0003-2719-0302; emsley, jonas/0000-0002-8949-8030; Tickle, Ian/0000-0003-2977-0650				AGRAWAL A, 1992, J BIOL CHEM, V267, P25352; BREATHNACH SM, 1981, NATURE, V293, P652, DOI 10.1038/293652a0; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; BUTLER PJG, 1990, J EXP MED, V172, P13, DOI 10.1084/jem.172.1.13; CARRINGTON DM, 1985, NATURE, V313, P64, DOI 10.1038/313064a0; CORIA F, 1988, LAB INVEST, V58, P454; DEBEER FC, 1981, J EXP MED, V154, P1134, DOI 10.1084/jem.154.4.1134; DYCK RF, 1980, J EXP MED, V152, P1162, DOI 10.1084/jem.152.5.1162; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; HAMAZAKI H, 1987, J BIOL CHEM, V262, P1456; HANEEF I, 1985, ACTA CRYSTALLOGR A, V41, P426, DOI 10.1107/S0108767385000915; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; HARTSHORN KL, 1993, J CLIN INVEST, V91, P1414, DOI 10.1172/JCI116345; HAWKINS PN, 1991, CLIN EXP IMMUNOL, V84, P308; HAWKINS PN, 1990, NEW ENGL J MED, V323, P508, DOI 10.1056/NEJM199008233230803; HIND CRK, 1984, J EXP MED, V159, P1058, DOI 10.1084/jem.159.4.1058; HIND CRK, 1984, BIOCHIM BIOPHYS ACTA, V802, P148, DOI 10.1016/0304-4165(84)90045-X; HIND CRK, 1984, LANCET, V2, P376; HIND CRK, 1985, BIOCHEM J, V225, P107, DOI 10.1042/bj2250107; HUTCHINSON EG, 1990, PROTEINS, V8, P203, DOI 10.1002/prot.340080303; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P272; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KINOSHITA CM, 1992, PROTEIN SCI, V1, P700, DOI 10.1002/pro.5560010602; KINOSHITA CM, 1989, BIOCHEMISTRY-US, V28, P9840, DOI 10.1021/bi00451a044; LIU TY, 1987, J PROTEIN CHEM, V6, P263; OVERINGTON J, 1990, P ROY SOC B-BIOL SCI, V241, P132, DOI 10.1098/rspb.1990.0077; PEPYS MB, 1977, LANCET, V1, P1029; PEPYS MB, 1979, CLIN EXP IMMUNOL, V38, P284; PEPYS MB, 1987, BIOCHEM BIOPH RES CO, V148, P308, DOI 10.1016/0006-291X(87)91111-9; PEPYS MB, 1978, NATURE, V273, P168, DOI 10.1038/273168a0; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; PEPYS MB, 1993, 41ST P ASMS C MASS S; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; SALI A, 1990, TRENDS BIOCHEM SCI, V15, P235, DOI 10.1016/0968-0004(90)90036-B; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; SWANSON SJ, 1990, MOL IMMUNOL, V27, P679, DOI 10.1016/0161-5890(90)90011-N; TENNENT GA, 1993, EUR J BIOCHEM, V214, P91, DOI 10.1111/j.1432-1033.1993.tb17900.x; TURNELL WG, 1988, FEBS LETT, V232, P263, DOI 10.1016/0014-5793(88)80750-6; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WOOD SP, 1988, J MOL BIOL, V202, P169, DOI 10.1016/0022-2836(88)90529-3	42	415	440	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					338	345		10.1038/367338a0	http://dx.doi.org/10.1038/367338a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	8114934				2022-12-28	WOS:A1994MT54000058
J	ROULEAU, JL; MOYE, LA; PFEFFER, MA; ARNOLD, JMO; BERNSTEIN, V; CUDDY, TE; DAGENAIS, GR; GELTMAN, EM; GOLDMAN, S; GORDON, D; HAMM, P; KLEIN, M; LAMAS, GA; MCCANS, J; MCEWAN, P; MENAPACE, FJ; PARKER, JO; SESTIER, F; SUSSEX, B; BRAUNWALD, E				ROULEAU, JL; MOYE, LA; PFEFFER, MA; ARNOLD, JMO; BERNSTEIN, V; CUDDY, TE; DAGENAIS, GR; GELTMAN, EM; GOLDMAN, S; GORDON, D; HAMM, P; KLEIN, M; LAMAS, GA; MCCANS, J; MCEWAN, P; MENAPACE, FJ; PARKER, JO; SESTIER, F; SUSSEX, B; BRAUNWALD, E			A COMPARISON OF MANAGEMENT PATTERNS AFTER ACUTE MYOCARDIAL-INFARCTION IN CANADA AND THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE SYSTEM; EMERGENCY ROOM PATIENTS; CORONARY; ADMISSION; EXPENDITURES; ONTARIO	Background. There are major differences in the organization of the health care systems in Canada and the United States. We hypothesized that these differences may be accompanied by differences in patient care. Methods. To test our hypothesis, we compared the treatment patterns for patients with acute myocardial infarction in 19 Canadian and 93 United States hospitals participating in the Survival and Ventricular Enlargement (SAVE) study, which tested the effectiveness of captopril in this population of patients after a myocardial infarction. Results. In Canada, 51 percent of the patients admitted to a participating coronary care unit had acute myocardial infarctions, as compared with only 35 percent in the United States (P<0.001). Despite the similar clinical characteristics of the 1573 U.S. patients and 658 Canadian patients participating in the study, coronary arteriography was more commonly performed in the United States than in Canada (in 68 percent vs. 35 percent, P<0.001), as were revascularization procedures before randomization (31 percent vs. 12 percent, P<0.001). During an average follow-up of 42 months, these procedures were also performed more commonly in the United States than in Canada. These differences were not associated with any apparent difference in mortality (22 percent in Canada and 23 percent in the United States) or rate of reinfarction (14 percent in Canada and 13 percent in the United States), but there was a higher incidence of activity-limiting angina in Canada than in the United States (33 percent vs. 27 percent, P<0.007). Conclusions. The threshold for the admission of patients to a coronary care unit or for the use of invasive diagnostic and therapeutic interventions in the early and late periods after an infarction is higher in Canada than in the United States. This is not associated with any apparent difference in the rate of reinfarction or survival, but is associated with a higher frequency of activity-limiting angina.	KINGSTON GEN HOSP, KINGSTON K7L 2V7, ONTARIO, CANADA; MEM UNIV NEWFOUNDLAND, St John A1C 5S7, NEWFOUNDLAND, CANADA; HOP NOTRE DAME DE BON SECOURS, MONTREAL H2L 4K8, QUEBEC, CANADA; UNIV TEXAS, HLTH SCI CTR, HOUSTON, TX 77225 USA; VET AFFAIRS MED CTR, TUCSON, AZ USA; CARDIOL ASSOCIATES, DES MOINES, IA USA; HOP SACRE COEUR, MONTREAL H4J 1C5, QUEBEC, CANADA; SIR MORTIMER B DAVIS JEWISH HOSP, MONTREAL H3T 1E2, QUEBEC, CANADA; WELLESLEY COLL HOSP, TORONTO M4Y 1J3, ONTARIO, CANADA; GEISINGER MED CTR, DANVILLE, PA 17822 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; WASHINGTON UNIV, SCH MED, ST LOUIS, MO 63110 USA; UNIV SHERBROOKE, SHERBROOKE J1K 2R1, QUEBEC, CANADA; VICTORIA HOSP, LONDON N6A 4G5, ONTARIO, CANADA; UNIV BRITISH COLUMBIA, VANCOUVER V6T 1W5, BC, CANADA; UNIV MANITOBA, WINNIPEG R3T 2N2, MANITOBA, CANADA; INST CARDIOL QUEBEC, QUEBEC CITY G1V 4G5, QUEBEC, CANADA	Queens University - Canada; Memorial University Newfoundland; Universite de Montreal; University of Texas System; University of Texas Health Science Center Houston; US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System; Universite de Montreal; McGill University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Geisinger Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Washington University (WUSTL); University of Sherbrooke; University of Victoria; Western University (University of Western Ontario); University of British Columbia; University of Manitoba; Laval University			Arnold, Malcolm/G-2869-2011					ANDERSON GM, 1989, NEW ENGL J MED, V321, P1443, DOI 10.1056/NEJM198911233212105; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1989, NEW ENGL J MED, V320, P618; CHADDA K, 1986, CIRCULATION, V73, P503, DOI 10.1161/01.CIR.73.3.503; COX DR, 1972, J R STAT SOC B, V34, P187; DETSKY AS, 1986, MED CARE, V24, P89, DOI 10.1097/00005650-198601000-00010; DETSKY AS, 1983, NEW ENGL J MED, V309, P151, DOI 10.1056/NEJM198307213090306; Doherty K, 1989, Bus Health, V7, P31; EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; FUCHS R, 1981, JAMA-J AM MED ASSOC, V246, P2037, DOI 10.1001/jama.246.18.2037; FUCHS VR, 1990, NEW ENGL J MED, V323, P884, DOI 10.1056/NEJM199009273231306; GHEORGHIADE M, 1988, AM HEART J, V116, P1212; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; IGLEHART JK, 1990, NEW ENGL J MED, V322, P562, DOI 10.1056/NEJM199002223220827; IGLEHART JK, 1986, NEW ENGL J MED, V315, P1623, DOI 10.1056/NEJM198612183152531; IGLEHART JK, 1986, NEW ENGL J MED, V315, P778, DOI 10.1056/NEJM198609183151238; IGLEHART JK, 1986, NEW ENGL J MED, V315, P202, DOI 10.1056/NEJM198607173150330; KATZ SJ, 1991, JAMA-J AM MED ASSOC, V266, P1108, DOI 10.1001/jama.266.8.1108; LEE TH, 1988, ANN INTERN MED, V108, P887, DOI 10.7326/0003-4819-108-6-887; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Moloney T W, 1989, Health Aff (Millwood), V8, P148, DOI 10.1377/hlthaff.8.2.148; MORIN JE, 1990, CAN J CARDIOL, V6, P319; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; NAYLOR CD, 1991, CAN J CARDIOL, V7, P207; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RELMAN AS, 1986, NEW ENGL J MED, V315, P1608, DOI 10.1056/NEJM198612183152510; SELKER HP, 1987, JAMA-J AM MED ASSOC, V257, P1181, DOI 10.1001/jama.257.9.1181; SINGER DE, 1983, NEW ENGL J MED, V309, P1155, DOI 10.1056/NEJM198311103091905; SLATER DK, 1987, AM J CARDIOL, V60, P766, DOI 10.1016/0002-9149(87)91020-4; TIERNEY WM, 1985, CRIT CARE MED, V13, P526, DOI 10.1097/00003246-198507000-00002; WILLIAMS B, 1981, NEW ZEAL MED J, V93, P158; Woolson R. F, 1987, STATISTICAL METHODS	33	287	290	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 18	1993	328	11					779	784		10.1056/NEJM199303183281108	http://dx.doi.org/10.1056/NEJM199303183281108			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR848	8123063				2022-12-28	WOS:A1993KR84800008
J	STRASSER, A; HARRIS, AW; CORCORAN, LM; CORY, S				STRASSER, A; HARRIS, AW; CORCORAN, LM; CORY, S			BCL-2 EXPRESSION PROMOTES B-LYMPHOID BUT NOT T-LYMPHOID DEVELOPMENT IN SCID MICE	NATURE			English	Article							TRANSGENIC MICE; CELL-RECEPTOR; BONE-MARROW; MOUSE; SURVIVAL; ACTIVATION; APOPTOSIS	EXPRESSION of antigen receptors is vital for the development of B and T lymphocytes. In mice with the scid mutation1,2, which are unable to make productive rearrangements of their immunoglobulin and T-cell receptor (TCR) genes, lymphopoiesis aborts at an early stage. The death of the immature lymphocytes by apoptosis3 is postulated to result from a failure to receive a survival signal induced by receptor engagement4. Consistent with this hypothesis, introduction of immunoglobulin or TCR transgenes into scid mice promoted an increase in B- or T-lymphoid cells, respectively5-7. As the protein encoded by the bcl-2 gene can inhibit cell death8,9, we tested whether lymphopoiesis could be rescued in scid mice by crossing in a bcl-2 transgene. Strikingly, the bcl-2/scid mice accumulated almost normal numbers of B-lymphoid cells which lacked surface immunoglobulin but expressed markers of maturity. T-cell development remained blocked. Introducing a TCR transgene enabled bcl-2/scid mice to develop normal numbers of CD4+8+ thymocytes even in the absence of immunological selection, suggesting that T cells become competent to respond to bcl-2 protein only after the TCR complex is displayed at the cell surface.	ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Cory, Suzanne/E-1642-2013; Strasser, Andreas/C-7581-2013; Corcoran, Lynn M/C-9316-2013	Cory, Suzanne/0000-0002-6818-3451; Strasser, Andreas/0000-0002-5020-4891; 				ASHWELL JD, 1990, REV IMMUNOL, V8, P531; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; HARDY RR, 1989, CURR TOP MICROBIOL, V152, P19; KINOSHITA T, 1988, J IMMUNOL, V140, P3066; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MELCHERS F, 1993, IMMUNOL TODAY, V14, P60, DOI 10.1016/0167-5699(93)90060-X; MULLERSIEBURG CE, 1986, CELL, V44, P653, DOI 10.1016/0092-8674(86)90274-6; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OSMOND DG, 1992, BLOOD, V79, P1695; PENNYCOOK JL, 1993, J EXP MED, V178, P1007, DOI 10.1084/jem.178.3.1007; REICHMANFRIED M, 1990, P NATL ACAD SCI USA, V87, P2730, DOI 10.1073/pnas.87.7.2730; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1994, P NATL ACAD SCI USA, V91, P1376, DOI 10.1073/pnas.91.4.1376; TORRES RM, 1992, J IMMUNOL, V149, P2641; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WALDSCHMIDT TJ, 1988, J IMMUNOL, V140, P2148	28	145	146	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	1994	368	6470					457	460		10.1038/368457a0	http://dx.doi.org/10.1038/368457a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	8133891				2022-12-28	WOS:A1994ND12000064
J	OLIVOTTO, IA; BAJDIK, CD; PLENDERLEITH, IH; COPPIN, CM; GELMON, KA; JACKSON, SM; RAGAZ, J; WILSON, KS; WORTH, A				OLIVOTTO, IA; BAJDIK, CD; PLENDERLEITH, IH; COPPIN, CM; GELMON, KA; JACKSON, SM; RAGAZ, J; WILSON, KS; WORTH, A			ADJUVANT SYSTEMIC THERAPY AND SURVIVAL AFTER BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHEMOTHERAPY	Background and Methods. We examined the effect of adjuvant systemic therapy on survival after breast cancer among the residents of the Canadian province of British Columbia. Data on survival were collected for all women in whom breast cancer was diagnosed in British Columbia during each of three calendar years chosen to represent different province-wide treatment recommendations: 1974, when no adjuvant systemic therapy was recommended; 1980, when adjuvant chemotherapy was recommended only for premenopausal women with node-positive disease; and 1984, when adjuvant chemotherapy was also recommended for premenopausal women with node-negative disease and lymphatic, vascular, or neural invasion and tamoxifen was recommended for postmenopausal women with involved lymph nodes or lymphatic, vascular, or neural invasion unless their tumors were negative for estrogen receptors. Results. For women less than 50 years of age, disease-specific survival at seven years (i.e., with censoring of data on women who died from causes other than breast cancer) improved from 65.2 to 76.3 percent between 1974 and 1984 (P = 0.008), and overall survival improved from 64.8 to 74.6 percent (P = 0.02). For women from 50 through 89 years of age, disease-specific survival at seven years improved from 62.5 to 70.4 percent between 1980 and 1984 (P = 0.001), and overall survival improved from 53.9 to 58.3 percent (P = 0.05). The timing of the improvements in survival correlated with the introduction of adjuvant systemic therapy in each group. Conclusions. Survival among women with breast cancer improved significantly in a geographically defined population during the period when adjuvant systemic therapy became widely used.	BRITISH COLUMBIA CANC AGCY,DIV EPIDEMIOL,VANCOUVER,BC,CANADA; BRITISH COLUMBIA CANC AGCY,DIV MED ONCOL,VANCOUVER,BC,CANADA; BRITISH COLUMBIA CANC AGCY,DIV LAB MED,VANCOUVER,BC,CANADA; UNIV BRITISH COLUMBIA,VANCOUVER,BC,CANADA	British Columbia Cancer Agency; British Columbia Cancer Agency; British Columbia Cancer Agency; University of British Columbia	OLIVOTTO, IA (corresponding author), BRITISH COLUMBIA CANC AGCY,DIV RADIAT ONCOL,600 W 10TH AVE,VANCOUVER V5Z 4E6,BC,CANADA.							BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BURHENNE LJW, 1992, AM J ROENTGENOL, V158, P45, DOI 10.2214/ajr.158.1.1307850; COPPIN C, 1989, P AM SOC CLIN ONCOL, V8, P20; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; ELWOOD JM, 1980, BRIT J CANCER, V42, P635, DOI 10.1038/bjc.1980.296; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HOWARD J, 1987, CA-CANCER J CLIN, V37, P33, DOI 10.3322/canjclin.37.1.33; JOENSUU H, 1991, BRIT MED J, V303, P155, DOI 10.1136/bmj.303.6795.155; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MCBRIDE ML, 1987, BC MED J, V29, P30; MCGUIRE WL, 1978, CANCER RES, V38, P4289; MILLER BA, 1991, CANCER CAUSE CONTROL, V2, P67, DOI 10.1007/BF00053123; Paterson A H, 1981, Breast Cancer Res Treat, V1, P357, DOI 10.1007/BF01806751; POWLES TJ, 1980, LANCET, V1, P580; RAGAZ J, 1991, 3RD P INT C NEOADJ C, P186; 1976, B C MED J, V18, P288; 1992, CANADIAN CANCER STAT; 1992, 93310 STAT CAN CAT; 1992, LANCET, V339, P71	21	72	72	1	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 24	1994	330	12					805	810		10.1056/NEJM199403243301201	http://dx.doi.org/10.1056/NEJM199403243301201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB803	8114832				2022-12-28	WOS:A1994NB80300001
J	VIDGREN, J; SVENSSON, LA; LILJAS, A				VIDGREN, J; SVENSSON, LA; LILJAS, A			CRYSTAL-STRUCTURE OF CATECHOL O-METHYLTRANSFERASE	NATURE			English	Article							RAT-LIVER; PARKINSONS-DISEASE; METHYLATION; INHIBITION; BINDING; PURIFICATION; CLONING; OR-462; MODELS; SITE	CATECHOL O-methyltransferase (COMT, EC 2.1.1.6) is important in the central nervous system because it metabolizes catecholamine neurotransmitters such as dopamine. The enzyme catalyses the transfer of the methyl group from S-adenosyl-L-methionine (AdoMet) to one hydroxyl group of catechols(1-4). COMT also inactivates catechol-type compounds such as L-DOPA. With selective inhibitors of COMT in combination with L-DOPA, a new principle has been realized in the therapy of Parkinson's disease(5-9). Here we solve the atomic structure of COMT to 2.0 Angstrom resolution, which provides new insights into the mechanism of the methyl transfer reaction. The co-enzyme-binding domain is strikingly similar to that of an AdoMet-dependent DNA methylase(10), indicating that all AdoMet methylases may have a common structure.	LUND UNIV,CTR CHEM,S-22100 LUND,SWEDEN	Lund University	VIDGREN, J (corresponding author), ORION CORP,ORION FARMOS,POB 65,SF-02101 ESPOO,FINLAND.							AXELROD J, 1958, J BIOL CHEM, V233, P702; BACKSTROM R, 1989, J MED CHEM, V32, P841, DOI 10.1021/jm00124a017; BALL P, 1972, J CLIN ENDOCR METAB, V34, P736, DOI 10.1210/jcem-34-4-736; BERTOCCI B, 1991, BIOCHIM BIOPHYS ACTA, V1080, P103, DOI 10.1016/0167-4838(91)90135-M; BORCHARDT RT, 1980, ENZYMATIC BASIS DETO, P43; BORGULYA J, 1989, HELV CHIM ACTA, V72, P952, DOI 10.1002/hlca.19890720511; Brunger AT, 1992, X PLOR VERSION 3 0 S; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; COWARD JK, 1973, BIOCHEMISTRY-US, V12, P2291, DOI 10.1021/bi00736a017; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; CREVELING CR, 1972, MOL PHARMACOL, V8, P398; EKLUND H, 1981, J MOL BIOL, V146, P561, DOI 10.1016/0022-2836(81)90047-4; GOMI T, 1992, INT J BIOCHEM, V24, P1639; GULDBERG HC, 1975, PHARMACOL REV, V27, P135; HOWARD A, 1987, J APPL CRYSTALLOGR, V20, P373; JEFFERY DR, 1987, BIOCHEMISTRY-US, V26, P2955, DOI 10.1021/bi00384a042; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LINDEN IB, 1988, J PHARMACOL EXP THER, V247, P289; LUNDSTROM K, 1991, DNA CELL BIOL, V10, P181, DOI 10.1089/dna.1991.10.181; LUNDSTROM K, 1992, BIOCHIM BIOPHYS ACTA, V1129, P149, DOI 10.1016/0167-4781(92)90479-J; Mannisto P. T., 1992, V39, P291; MANNISTO PT, 1989, TRENDS PHARMACOL SCI, V10, P54, DOI 10.1016/0165-6147(89)90075-8; Piedrafita F J, 1990, J Enzyme Inhib, V4, P43, DOI 10.3109/14756369009030387; SALMINEN M, 1990, GENE, V93, P241, DOI 10.1016/0378-1119(90)90231-F; SCHULTZ E, 1989, BIOCHEM PHARMACOL, V38, P3953, DOI 10.1016/0006-2952(89)90673-4; THAKKER DR, 1986, J BIOL CHEM, V261, P178; VIDGREN J, 1991, PROTEINS, V11, P233, DOI 10.1002/prot.340110309; WOODARD RW, 1980, J BIOL CHEM, V255, P9124; 1979, SERC4 DAR LAB COLL C	29	379	386	3	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					354	358		10.1038/368354a0	http://dx.doi.org/10.1038/368354a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127373				2022-12-28	WOS:A1994NB98500052
J	WILLIAMS, JA; PADDOCK, SW; VORWERK, K; CARROLL, SB				WILLIAMS, JA; PADDOCK, SW; VORWERK, K; CARROLL, SB			ORGANIZATION OF WING FORMATION AND INDUCTION OF A WING-PATTERNING GENE AT THE DORSAL/VENTRAL COMPARTMENT BOUNDARY	NATURE			English	Article							DROSOPHILA-MELANOGASTER; IMAGINAL DISKS; DIFFERENTIATION; TRANSCRIPTION; ENCODES; PRODUCT; ELEGANS; FIELDS	The appendages of arthropods and vertebrates possess a third, proximodistal patterning axis that is established after the primary anteroposterior and dorsoventral body axes by mechanisms that are largely unknown. The vestigial gene is required for formation of the entire Drosophila wing, and the dorsal/ventral boundary is shown to organize wing formation and vestigial gene expression. Interactions between dorsal and ventral cells in the growing imaginal disc induce vestigial gene expression through a discrete, extraordinarily conserved imaginal disc-specific enhancer. The link between dorsal/ventral compartmentalization and wing formation distinguishes the development of this sheet-like appendage from that of legs and antennae.	UNIV WISCONSIN, HOWARD HUGHES MED INST, MOLEC BIOL LAB, MADISON, WI 53706 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison								ANDERSON DT, 1963, J EMBRYOL EXP MORPH, V11, P339; BAKER NE, 1988, DEVELOPMENT, V102, P489; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BOWNES M, 1981, DIFFERENTIATION, V18, P89, DOI 10.1111/j.1432-0436.1981.tb01108.x; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COHEN SM, IN PRESS DEV DROSOPH; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; KUKALOVAPECK J, 1978, J MORPHOL, V156, P53, DOI 10.1002/jmor.1051560104; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1993, NATURE, V366, P305, DOI 10.1038/366305a0; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; Meinhardt H., 1991, Seminars in Developmental Biology, V2, P129; NELSON HB, 1993, W ROUX ARCH DEV BIOL, V202, P341; PADDOCK SW, 1993, BIOTECHNIQUES, V14, P42; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STEINER E, 1976, ROUX ARCH DEV BIOL, V180, P9, DOI 10.1007/BF00848882; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WIESCHAUS E, 1976, DEV BIOL, V50, P249, DOI 10.1016/0012-1606(76)90150-0; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; WILLIAMS JA, 1988, EMBO J, V7, P1355, DOI 10.1002/j.1460-2075.1988.tb02951.x; WILLIAMS JA, 1990, MOL GEN GENET, V221, P8, DOI 10.1007/BF00280361; WILLIAMS JA, 1993, BIOESSAYS, V15, P567, DOI 10.1002/bies.950150902; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; XU T, 1993, DEVELOPMENT, V117, P1223	34	222	223	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	1994	368	6469					299	305		10.1038/368299a0	http://dx.doi.org/10.1038/368299a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127364				2022-12-28	WOS:A1994NB98500036
J	KEEGAN, AD; NELMS, K; WHITE, M; WANG, LM; PIERCE, JH; PAUL, WE				KEEGAN, AD; NELMS, K; WHITE, M; WANG, LM; PIERCE, JH; PAUL, WE			AN IL-4 RECEPTOR REGION CONTAINING AN INSULIN-RECEPTOR MOTIF IS IMPORTANT FOR IL4-MEDIATED IRS-1 PHOSPHORYLATION AND CELL-GROWTH	CELL			English	Article							STIMULATORY FACTOR-I; HUMAN INTERLEUKIN-4 RECEPTOR; SIGNAL TRANSDUCTION; FC-EPSILON; EXPRESSION CLONING; MOLECULAR-CLONING; B-CELLS; IDENTIFICATION; TRANSMISSION; SUPERFAMILY	Interleukin-4 (IL-4) treatment of 32D cells overexpressing insulin receptor substrate 1 (IRS-1) causes prompt tyrosine phosphorylation of IRS-l. Transfection of truncation mutants of the human IL-4 (huIL-4) receptor into 32D-IRS-1 cells demonstrated that the region from amino acid 437-557 is important for IL-4 signaling. This region of the IL-4 receptor (IL-4R) contains the motif (488)PL-X4-NPXYXSXSD(502) (insulin/IL-4R [I4R]) found in the insulin and insulin-like growth factor 1 receptors. Mutation of Y497 to F yielded receptors that caused little or no IRS-1 phosphorylation in response to huIL-4 when expressed in 32D-IRS-1 cells. Most cell lines expressing Y497F also failed to proliferate in response to huIL-4. Furthermore, a glutathione-S-transferase fusion protein containing the I4R motif-bound IRS-1,tyrosine kinase(s), and other unidentified phosphoproteins with molecular sizes of 140, 80, and 55 kd. Thus, the central tyrosine of the I4R motif has a major role in IL-4-mediated signal transduction in 32D cells.	HARVARD UNIV,DEPT MED,JOSLIN DIABET CTR,BOSTON,MA 02215; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	Harvard University; Joslin Diabetes Center, Inc.; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	KEEGAN, AD (corresponding author), NIAID,IMMUNOL LAB,BETHESDA,MD 20892, USA.							BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; CONRAD DH, 1987, J IMMUNOL, V139, P2290; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; GALIZZI JP, 1990, INT IMMUNOL, V2, P669, DOI 10.1093/intimm/2.7.669; HARADA N, 1992, J BIOL CHEM, V267, P22752; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; KOETTNITZ K, 1993, EUR J IMMUNOL, V23, P988, DOI 10.1002/eji.1830230437; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LOWENTHAL JW, 1988, J IMMUNOL, V140, P456; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; OHARA J, 1988, P NATL ACAD SCI USA, V85, P8221, DOI 10.1073/pnas.85.21.8221; OHARA J, 1987, NATURE, V325, P537, DOI 10.1038/325537a0; PARK LS, 1987, P NATL ACAD SCI USA, V84, P1669, DOI 10.1073/pnas.84.6.1669; PAUL WE, 1991, BLOOD, V77, P1859; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SEDER RA, 1991, P NATL ACAD SCI USA, V88, P2835, DOI 10.1073/pnas.88.7.2835; SELDIN DC, 1994, IN PRESS P NATL ACAD, V91; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; VITETTA ES, 1985, J EXP MED, V162, P1726, DOI 10.1084/jem.162.5.1726; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4	43	297	303	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 11	1994	76	5					811	820		10.1016/0092-8674(94)90356-5	http://dx.doi.org/10.1016/0092-8674(94)90356-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124718				2022-12-28	WOS:A1994NA89000007
J	DOLL, R; EVANS, HJ; DARBY, SC				DOLL, R; EVANS, HJ; DARBY, SC			PATERNAL EXPOSURE NOT TO BLAME	NATURE			English	Editorial Material							WEST CUMBRIA; CHILDREN BORN; SURVIVORS; LEUKEMIA; SEASCALE; FOLLOW; COHORT		WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	DOLL, R (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC UNITS,WOODSTOCK RD,OXFORD OX2 6HE,ENGLAND.							CRAFT AW, 1993, EPIDEMIOL COMM HLTH, V47, P109; DRAPER GJ, 1993, BRIT MED J, V306, P89, DOI 10.1136/bmj.306.6870.89; FORD AM, 1993, NATURE, V363, P358, DOI 10.1038/363358a0; GARDNER MJ, 1987, BRIT MED J, V295, P819, DOI 10.1136/bmj.295.6602.819; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1987, BRIT MED J, V295, P822, DOI 10.1136/bmj.295.6602.822; GRAHAM SAXON, 1966, NAT CANCER INST MONOGR, V19, P347; HAWKINS MM, 1989, INT J CANCER, V43, P975, DOI 10.1002/ijc.2910430604; HEASMAN MA, 1986, LANCET, V1, P266; KINLEN LJ, 1993, BRIT MED J, V306, P1153, DOI 10.1136/bmj.306.6886.1153; KINLEN LJ, 1993, BRIT MED J, V306, P1718, DOI 10.1136/bmj.306.6894.1718; KNEALE GW, 1980, BRIT J CANCER, V41, P222, DOI 10.1038/bjc.1980.33; MCLAUGHLIN JR, 1993, BRIT MED J, V307, P959, DOI 10.1136/bmj.307.6910.959; NEEL JV, 1990, AM J HUM GENET, V46, P1053; PARKER L, 1993, BRIT MED J, V307, P966, DOI 10.1136/bmj.307.6910.966; ROMAN E, 1993, BMJ-BRIT MED J, V306, P615, DOI 10.1136/bmj.306.6878.615; YOSHIMOTO Y, 1990, AM J HUM GENET, V46, P1041; 1993, HSE INVESTIGATION LE	18	126	127	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					678	680		10.1038/367678a0	http://dx.doi.org/10.1038/367678a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	8107860				2022-12-28	WOS:A1994MX63100025
J	SMITH, GW; COHEN, SB				SMITH, GW; COHEN, SB			HYPERKALEMIA AND NON-OLIGURIC RENAL-FAILURE ASSOCIATED WITH TRIMETHOPRIM	BRITISH MEDICAL JOURNAL			English	Note							SERUM CREATININE				SMITH, GW (corresponding author), FAZAKERLEY DIST GEN HOSP,LIVERPOOL L9 7AL,MERSEYSIDE,ENGLAND.							BERGLUND F, 1975, J UROLOGY, V114, P802, DOI 10.1016/S0022-5347(17)67149-0; DIJKMANS BAC, 1981, BRIT J CLIN PHARMACO, V12, P701, DOI 10.1111/j.1365-2125.1981.tb01293.x; MYRE SA, 1987, THER DRUG MONIT, V9, P161, DOI 10.1097/00007691-198706000-00006; SANDBERG T, 1986, J ANTIMICROB CHEMOTH, V17, P123, DOI 10.1093/jac/17.1.123-a	4	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	1994	308	6926					454	454		10.1136/bmj.308.6926.454b	http://dx.doi.org/10.1136/bmj.308.6926.454b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW976	8124180	Green Published			2022-12-28	WOS:A1994MW97600027
J	RUGARLI, EI; BALLABIO, A				RUGARLI, EI; BALLABIO, A			KALLMANN SYNDROME - FROM GENETICS TO NEUROBIOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ISOLATED HYPOGONADOTROPIC HYPOGONADISM; DISTAL SHORT ARM; HUMAN X-CHROMOSOME; EXTRACELLULAR-MATRIX; STEROID SULFATASE; NEURITE OUTGROWTH; CANDIDATE GENE; MOLECULES; ANOSMIA; CELLS				RUGARLI, EI (corresponding author), BAYLOR COLL MED,INST MOLEC GENET,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.			Rugarli, Elena/0000-0002-5782-1067; BALLABIO, Andrea/0000-0003-1381-4604	NIGMS NIH HHS [GM46970] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046970] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLABIO A, 1986, HUM GENET, V72, P237, DOI 10.1007/BF00291885; BALLABIO A, 1989, P NATL ACAD SCI USA, V86, P10001, DOI 10.1073/pnas.86.24.10001; Ballabio Andrea, 1992, Human Molecular Genetics, V1, P221, DOI 10.1093/hmg/1.4.221; Ballabio A, 1992, CURR OPIN GENET DEV, V2, P417, DOI 10.1016/S0959-437X(05)80152-2; BICK D, 1992, NEW ENGL J MED, V326, P1752, DOI 10.1056/NEJM199206253262606; BURRIS AS, 1988, FERTIL STERIL, V50, P343; CHIQUET M, 1991, SEMIN NEUROSCI, V3, P341; DANEK A, 1992, ANN NEUROL, V31, P299, DOI 10.1002/ana.410310312; De Morster G, 1954, SCHWEIZ ARCH NEUROL, V74, P309; DELCASTILLO I, 1992, NAT GENET, V2, P305, DOI 10.1038/ng1292-305; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; DRENTH J, 1980, J BIOL CHEM, V255, P2652; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; GRIFFIN JE, 1992, WILLIAMS TXB ENDOCRI, P822; HARDELIN JP, 1992, P NATL ACAD SCI USA, V89, P8190, DOI 10.1073/pnas.89.17.8190; HARDELIN JP, 1993, HUM MOL GENET, V2, P373, DOI 10.1093/hmg/2.4.373; HENKIN RI, 1966, J CLIN INVEST, V45, P1631, DOI 10.1172/JCI105470; HERMANUSSEN M, 1985, CLIN GENET, V28, P106; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; INCERTI B, 1992, NAT GENET, V2, P311, DOI 10.1038/ng1292-311; Jones J R, 1976, Obstet Gynecol Annu, V5, P443; Kallmann FJ, 1944, AM J MENT DEF, V48, P203; KERTZMAN C, 1990, NEUROLOGY, V40, P1057, DOI 10.1212/WNL.40.7.1057; KLINGMULLER D, 1987, J CLIN ENDOCR METAB, V65, P581, DOI 10.1210/jcem-65-3-581; KNORR JR, 1993, AM J NEURORADIOL, V14, P845; LANDER AD, 1989, TRENDS NEUROSCI, V12, P189, DOI 10.1016/0166-2236(89)90070-2; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LEGOUIS R, 1993, P NATL ACAD SCI USA, V90, P2461, DOI 10.1073/pnas.90.6.2461; Letourneau PC, 1992, CURR OPIN GENET DEV, V2, P625, DOI 10.1016/S0959-437X(05)80183-2; LUTZ B, 1993, FEBS LETT, V325, P128, DOI 10.1016/0014-5793(93)81428-3; MCGUIRE PG, 1990, NEURON, V4, P633, DOI 10.1016/0896-6273(90)90121-U; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; NAFTOLIN F, 1971, NATURE, V232, P496, DOI 10.1038/232496a0; NASS R, 1985, NEUROLOGY, V35, P1059, DOI 10.1212/WNL.35.7.1059; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; ROGERS SL, 1987, J CELL BIOL, V105, P1435, DOI 10.1083/jcb.105.3.1435; RUGARLI EI, 1993, NAT GENET, V4, P19, DOI 10.1038/ng0593-19; SANTEN RJ, 1991, REPRODUCTIVE ENDOCRI, P749; SCHWANKHAUS JD, 1989, NEUROLOGY, V39, P223, DOI 10.1212/WNL.39.2.223; SCHWANZELFUKUDA M, 1989, MOL BRAIN RES, V6, P311, DOI 10.1016/0169-328X(89)90076-4; SCHWANZELFUKUDA M, 1989, NATURE, V338, P161, DOI 10.1038/338161a0; SUNOHARA N, 1986, ANN NEUROL, V19, P174, DOI 10.1002/ana.410190211; TRUWIT CL, 1993, AM J NEURORADIOL, V14, P827; TUCK RR, 1983, J NEUROL NEUROSUR PS, V46, P671, DOI 10.1136/jnnp.46.7.671; TURNER RC, 1974, P ROY SOC MED, V67, P33, DOI 10.1177/003591577406700120; WEGENKE JD, 1975, CLIN GENET, V7, P368; WHITE BJ, 1983, AM J MED GENET, V15, P417, DOI 10.1002/ajmg.1320150307; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; YOUSEM DM, 1993, AM J NEURORADIOL, V14, P839; 1983, SMELL IDENTIFICATION	51	62	67	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2713	2716		10.1001/jama.270.22.2713	http://dx.doi.org/10.1001/jama.270.22.2713			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	8133589				2022-12-28	WOS:A1993MJ82100031
J	NEUMANN, HPH; BERGER, DP; SIGMUND, G; BLUM, U; SCHMIDT, D; PARMER, RJ; VOLK, B; KIRSTE, G				NEUMANN, HPH; BERGER, DP; SIGMUND, G; BLUM, U; SCHMIDT, D; PARMER, RJ; VOLK, B; KIRSTE, G			PHEOCHROMOCYTOMAS, MULTIPLE ENDOCRINE NEOPLASIA TYPE-2, AND VONHIPPEL-LINDAU DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHROMOGRANIN-A; FAMILIAL PHEOCHROMOCYTOMA; MR; NEUROFIBROMATOSIS; FEATURES; MEMBERS; LESIONS; COMPLEX; TUMOR; CT	Background. Pheochromocytoma is a feature of two disorders with an autosomal dominant pattern of inheritance - multiple endocrine neoplasia type 2 (MEN-2) (with medullary thyroid carcinoma and hyperparathyroidism) and von Hippel-Lindau disease (with angioma of the retina, hemangioblastoma of the central nervous system, renal-cell carcinoma, pancreatic cysts, and epididymal cystadenoma). The frequency of these syndromes in patients with pheochromocytoma is not known. Methods. In an unselected group of patients with pheochromocytoma, we performed pentagastrin tests, parathyroid hormone assays, computed tomography (CT) or magnetic resonance imaging (MRI) of the brain, ophthalmoscopy, CT imaging of the abdomen, and ultrasonography of the testes. We also screened members of families with MEN-2 or von Hippel-Lindau disease for pheochromocytoma by measuring plasma and urine catecholamines and plasma chromogranin A and by performing abdominal ultrasonography, CT and MRI, and metaiodobenzylguanidine scintigraphy. Results. Nineteen of 82 unselected patients with pheochromocytomas (23 percent) were carriers of familial disorders; 19 percent had von Hippel-Lindau disease and 4 percent had MEN-2. Prospectively, in 36 of 79 subjects at risk for pheochromocytoma (46 percent), 42 unsuspected pheochromocytomas were found. Overall, there were 130 patients with 185 pheochromocytomas; 43 had von Hippel-Lindau disease, 24 had MEN-2, and 63 had sporadic tumors. The patients with familial and those with sporadic pheochromocytomas differed in mean age at diagnosis (32 vs. 46 years, P<0.001), multifocal localization (55 vs. 8 percent, P<0.001), and cancer (0 vs. 11 percent, P = 0.005); but not in the frequency of extraadrenal tumors (24 vs. 16 percent). Thirty-eight percent of carriers of von Hippel-Lindau disease and 24 percent of carriers of MEN-2 had pheochromocytoma as the only manifestation of their syndrome. Conclusions. All patients with pheochromocytomas should be screened for MEN-2 and von Hippel-Lindau disease to avert further morbidity and mortality in the patients and their families. All patients in families with MEN-2 or von Hippel-Lindau disease should be screened for pheochromocytoma, even if they are asymptomatic.	UNIV FREIBURG,DEPT RADIOL,W-7800 FREIBURG,GERMANY; UNIV FREIBURG,DEPT OPHTHALMOL,W-7800 FREIBURG,GERMANY; UNIV FREIBURG,DEPT SURG,W-7800 FREIBURG,GERMANY; UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103	University of Freiburg; University of Freiburg; University of Freiburg; University of California System; University of California San Diego	NEUMANN, HPH (corresponding author), UNIV FREIBURG,DEPT MED,DIV NEPHROL & HYPERTENS,HUGSTETTERSTR 55,D-79106 FREIBURG,GERMANY.							ATUK NO, 1979, MEDICINE, V58, P209, DOI 10.1097/00005792-197905000-00001; BRAVO EL, 1991, KIDNEY INT, V40, P544, DOI 10.1038/ki.1991.244; CARMAN CT, 1960, NEW ENGL J MED, V263, P419, DOI 10.1056/NEJM196009012630901; CHATAL JF, 1985, J CLIN ENDOCR METAB, V61, P769, DOI 10.1210/jcem-61-4-769; EASTON DF, 1989, AM J HUM GENET, V44, P208; GLOWNIAK JV, 1985, ARCH INTERN MED, V145, P257, DOI 10.1001/archinte.145.2.257; GREEN JS, 1986, CAN MED ASSOC J, V134, P133; GRIFFITHS DFR, 1987, Q J MED, V64, P769; HORTON WA, 1976, ARCH INTERN MED, V136, P769, DOI 10.1001/archinte.136.7.769; HSIAO RJ, 1990, AM J MED, V88, P607, DOI 10.1016/0002-9343(90)90526-J; LAMIELL JM, 1989, MEDICINE, V68, P1; Landsberg L., 1992, WILLIAMS TXB ENDOCRI, P621; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEVINE E, 1982, AM J ROENTGENOL, V139, P505, DOI 10.2214/ajr.139.3.505; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NEUMANN HPH, 1987, VASA-J VASCULAR DIS, V16, P220; NEUMANN HPH, 1992, J NEUROL NEUROSUR PS, V55, P898, DOI 10.1136/jnnp.55.10.898; NEUMANN HPH, 1991, LANCET, V337, P1052, DOI 10.1016/0140-6736(91)91705-Y; NEUMANN HPH, 1991, GASTROENTEROLOGY, V101, P465, DOI 10.1016/0016-5085(91)90026-H; OCONNOR DT, 1986, NEW ENGL J MED, V314, P1145, DOI 10.1056/NEJM198605013141803; OCONNOR DT, 1989, CLIN CHEM, V35, P1631; QUINT LE, 1987, RADIOLOGY, V165, P89, DOI 10.1148/radiology.165.1.3628794; REINIG JW, 1986, RADIOLOGY, V158, P81, DOI 10.1148/radiology.158.1.3940403; RICCARDI VM, 1981, NEW ENGL J MED, V305, P1617, DOI 10.1056/NEJM198112313052704; SATO Y, 1988, RADIOLOGY, V166, P241, DOI 10.1148/radiology.166.1.3336687; SCHIMKE RN, 1990, AM J MED GENET, V37, P375, DOI 10.1002/ajmg.1320370317; STEIN PP, 1990, MEDICINE, V70, P46; VASEN HFA, 1987, AM J MED, V83, P847, DOI 10.1016/0002-9343(87)90641-3; WILSON RA, 1978, HUM PATHOL, V9, P181, DOI 10.1016/S0046-8177(78)80109-9; YEH HC, 1980, AM J ROENTGENOL, V135, P1167, DOI 10.2214/ajr.135.6.1167	32	356	364	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1993	329	21					1531	1538		10.1056/NEJM199311183292103	http://dx.doi.org/10.1056/NEJM199311183292103			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG188	8105382				2022-12-28	WOS:A1993MG18800003
J	JANKOWSKI, RF; MANDALIA, S				JANKOWSKI, RF; MANDALIA, S			COMPARISON OF ATTENDANCE AND EMERGENCY ADMISSION PATTERNS AT ACCIDENT AND EMERGENCY DEPARTMENTS IN AND OUT OF LONDON	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare the sociodemographic characteristics, diagnoses, and mode of referral of people and emergency admissions between an accident and emergency department in inner London and one in a town outside London. Design-Standardised questionnaire completed prospectively over two weeks by fieldworkers in each accident and emergency department. Setting-Accident and emergency departments in an inner London teaching hospital and an associated teaching hospital outside London. Subjects-3039 adults newly attending the departments, 1476 in inner London and 1563 outside London. Main outcome measures-Sociodemographic characteristics, diagnosis, mode of referral, and whether the patient was admitted. Results-General practitioner referrals accounted for similar proportions of the adult attendances (12% in inner London, 15% outside London). People attending at the inner London department were more likely to be tourists or long distance commuters (12% (179/1476) v 6% (95/1563)), single (43% (643) v 32% (505)), to live alone (24% (360) v 14% (225)), to have moved recently (13% (194) v 7% (107)), or to be homeless (3.3% (48) v 0.6% (10)). Broad clinical groupings of patients were similar in both departments. 291 people were admitted in inner London and 284 outside London. The proportions admitted from each sociodemographic group were similar in the two hospitals. Conclusion-Differences in sociodemographic characteristics were more important than general practice referral patterns in determining the differences in people attending at accident and emergency departments inside and outside London. Many of these characteristics are likely to be found in other inner city populations. A strategy to improve acute care in inner London should take account of the needs of these sociodemographically different groups.			JANKOWSKI, RF (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DIV COMMUNITY HLTH,ST THOMAS CAMPUS,LONDON SE1 7EH,ENGLAND.							FARMER DT, 1982, RELATIONSHIP ACCIDEN; Inwald A C, 1980, J R Coll Gen Pract, V30, P220; LAMBERTS H, 1987, ICPC INT CLASSFICATI; MILNER PC, 1988, J EPIDEMIOL COMMUN H, V42, P274, DOI 10.1136/jech.42.3.274; Tomlinson B., 1992, REPORT INQUIRY LONDO; 1992, USER PERSPECTIVE VIE; 1992, NHS ACCIDENT EMERGEN	7	18	18	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1993	306	6887					1241	1243		10.1136/bmj.306.6887.1241	http://dx.doi.org/10.1136/bmj.306.6887.1241			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	8123074	Green Published, Bronze			2022-12-28	WOS:A1993LB80400018
J	SAUVE, JS; THORPE, KE; SACKETT, DL; TAYLOR, W; BARNETT, HJM; HAYNES, RB; FOX, AJ				SAUVE, JS; THORPE, KE; SACKETT, DL; TAYLOR, W; BARNETT, HJM; HAYNES, RB; FOX, AJ			CAN BRUITS DISTINGUISH HIGH-GRADE FROM MODERATE SYMPTOMATIC CAROTID STENOSIS	ANNALS OF INTERNAL MEDICINE			English	Article						HEART SOUNDS; CAROTID STENOSIS; CEREBROVASCULAR DISORDERS; ENDARTERECTOMY, CAROTID; CEREBRAL ISCHEMIA, TRANSIENT	STROKE; RISK	Objective: To determine whether cervical bruits, alone or combined with other clinical characteristics, can distinguish high-grade (70% to 99%) carotid artery stenoses from less severe stenoses in patients with symptoms of cerebrovascular disease. Design: Cross-sectional comparison of clinical observations with contemporaneous angiography. Setting: The North American Symptomatic Carotid Endarterectomy Trial (NASCET), a multicenter randomized controlled trial of carotid endarterectomy. Patients: All patients enrolled in the NASCET from its inception in 1988 to November 1991. Results: A focal ipsilateral carotid bruit had a sensitivity of 63% and a specificity of 61% for high-grade stenosis and, when absent, only lowered the probability for high-grade stenosis from a pretest value of 52% to a post-test probability of 40%. When combined with four other clinical characteristics (an infarction on computed tomography of the head, a carotid ultrasound scan suggesting more than 90% stenosis, a transient ischemic attack rather than a minor stroke as a qualifying event, and a retinal rather than a hemispheric qualifying event), the predicted probabilities of high-grade stenosis ranged from a low of 18% (when none of the features was present) to a high of 94% (when all the features were present). Conclusions: Cervical bruits alone were not sufficiently predictive of high-grade symptomatic carotid stenosis to be useful in selecting patients for angiography; they were absent in over one third of patients with high-grade stenosis. When combined with other clinical variables, patients with high or low probabilities of 70% to 99% stenoses could be identified, but this prediction model still missed many individuals with high-grade stenosis, even in this training set of selected patients.	UNIV WESTERN ONTARIO HOSP, LONDON N6A 5A5, ON, CANADA; UNIV WESTERN ONTARIO, JOHN P ROBARTS RES INST, LONDON N6A 5K8, ON, CANADA; MCMASTER UNIV, CHEDOKE MCMASTER HOSP, HAMILTON L8N 3Z5, ON, CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); McMaster University				Haynes, Robert Brian/0000-0002-1453-3196; Thorpe, Kevin/0000-0002-7586-3893				CHAMBERS BR, 1985, NEUROLOGY, V35, P742, DOI 10.1212/WNL.35.5.742; GAUTIER JC, 1975, REV NEUROL, V131, P175; HANKEY GJ, 1990, BMJ-BRIT MED J, V300, P1485, DOI 10.1136/bmj.300.6738.1485; HAYNES RB, 1992, CLIN RES, V40, pA184; HEYMAN A, 1980, NEW ENGL J MED, V302, P838, DOI 10.1056/NEJM198004103021504; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; INGALL TJ, 1989, ARCH NEUROL-CHICAGO, V46, P418, DOI 10.1001/archneur.1989.00520400078023; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SAUVE S, 1992, CLIN RES, V40, pA304; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WOLF PA, 1981, JAMA-J AM MED ASSOC, V245, P1442, DOI 10.1001/jama.245.14.1442; ZIEGLER DK, 1971, NEUROLOGY, V21, P860, DOI 10.1212/WNL.21.8.860	14	48	50	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1994	120	8					633	637		10.7326/0003-4819-120-8-199404150-00002	http://dx.doi.org/10.7326/0003-4819-120-8-199404150-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE850	8135446				2022-12-28	WOS:A1994NE85000002
J	BELCHETZ, PE				BELCHETZ, PE			DRUG-THERAPY - HORMONAL TREATMENT OF POSTMENOPAUSAL WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ESTROGEN REPLACEMENT THERAPY; POST-MENOPAUSAL WOMEN; NON-CONTRACEPTIVE ESTROGENS; CORONARY HEART-DISEASE; BREAST-CANCER RISK; ACUTE MYOCARDIAL-INFARCTION; LONG-TERM ESTROGEN; ENDOMETRIAL CANCER; BONE LOSS; EXOGENOUS ESTROGENS				BELCHETZ, PE (corresponding author), GEN INFIRM, DEPT ENDOCRINOL, GREAT GEORGE ST, LEEDS LS1 3EX, ENGLAND.							ADAM S, 1981, BRIT MED J, V282, P1277, DOI 10.1136/bmj.282.6272.1277; ADAMI S, 1989, BONE MINER, V7, P79, DOI 10.1016/0169-6009(89)90064-0; AITKEN JM, 1973, BRIT MED J, V2, P325, DOI 10.1136/bmj.2.5862.325; AITKEN JM, 1973, BMJ-BRIT MED J, V3, P515, DOI 10.1136/bmj.3.5879.515; ALAZZAWI F, 1987, BRIT MED J, V294, P1261, DOI 10.1136/bmj.294.6582.1261-a; [Anonymous], 1974, N Engl J Med, V290, P15; ARAFAT ES, 1988, AM J OBSTET GYNECOL, V159, P1203, DOI 10.1016/0002-9378(88)90448-6; ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; ASTEDT B, 1977, ACTA OBSTET GYN SCAN, P45; BAIN C, 1981, CIRCULATION, V64, P42, DOI 10.1161/01.CIR.64.1.42; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BEAGLEHOLE R, 1988, BRIT MED J, V297, P571, DOI 10.1136/bmj.297.6648.571; BELCHETZ P, 1990, PRACTITIONER, V234, P491; BELCHETZ P, 1989, BMJ-BRIT MED J, V298, P1467, DOI 10.1136/bmj.298.6686.1467; BERGKVIST L, 1990, NEW ENGL J MED, V322, P204; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; BHAVNANI BR, 1983, J CLIN ENDOCR METAB, V56, P1048, DOI 10.1210/jcem-56-5-1048; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; BRINTON LA, 1981, CANCER-AM CANCER SOC, V47, P2517, DOI 10.1002/1097-0142(19810515)47:10<2517::AID-CNCR2820471035>3.0.CO;2-L; BUNGAY GT, 1980, BRIT MED J, V281, P181, DOI 10.1136/bmj.281.6234.181; BURCH JC, 1974, AM J OBSTET GYNECOL, V118, P778, DOI 10.1016/0002-9378(74)90487-6; BURING JE, 1987, AM J EPIDEMIOL, V125, P939, DOI 10.1093/oxfordjournals.aje.a114632; BUSH TL, 1983, JAMA-J AM MED ASSOC, V249, P903, DOI 10.1001/jama.249.7.903; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; CASAGRANDE J, 1976, J NATL CANCER I, V56, P839, DOI 10.1093/jnci/56.4.839; CHRISTIANSEN C, 1982, J CLIN ENDOCR METAB, V55, P1124, DOI 10.1210/jcem-55-6-1124; CHRISTIANSEN C, 1981, LANCET, V1, P459; CHU J, 1982, AM J OBSTET GYNECOL, V143, P569, DOI 10.1016/0002-9378(82)90549-X; CLAYDEN JR, 1974, BRIT MED J, V1, P409, DOI 10.1136/bmj.1.5905.409; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; COLDITZ GA, 1992, HORMONE REPLACEMENT THERAPY AND BREAST CANCER RISK, P63; COOPE J, 1975, BRIT MED J, V4, P139, DOI 10.1136/bmj.4.5989.139; CRAIG TJ, 1974, J NATL CANCER I, V53, P1577; CREASMAN WT, 1986, OBSTET GYNECOL, V67, P326; CREASMAN WT, 1991, OBSTET GYNECOL, V77, P308, DOI 10.1097/00006250-199102000-00031; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; CROFT P, 1989, BRIT MED J, V298, P165, DOI 10.1136/bmj.298.6667.165; DENNERSTEIN L, 1979, MATURITAS, V1, P247, DOI 10.1016/0378-5122(79)90015-X; DRAPER J, 1990, BRIT MED J, V300, P786, DOI 10.1136/bmj.300.6727.786; DRIFE JO, 1990, HRT OSTEOPOROSIS, P241; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; DUPONT WD, 1989, CANCER-AM CANCER SOC, V63, P948, DOI 10.1002/1097-0142(19890301)63:5<948::AID-CNCR2820630527>3.0.CO;2-U; EAKER ED, 1987, CORONARY HEART DISEA, P122; EDELSON RN, 1985, HEADACHE, V25, P376, DOI 10.1111/j.1526-4610.1985.hed2507376.x; ELWOOD JM, 1980, GYNECOL ONCOL, V10, P173, DOI 10.1016/0090-8258(80)90079-7; ERNSTER VL, 1988, PREV MED, V17, P201, DOI 10.1016/0091-7435(88)90064-3; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; GAMBRELL RD, 1986, MATURITAS, V8, P159, DOI 10.1016/0378-5122(86)90022-8; GANGAR K, 1989, BRIT MED J, V299, P601, DOI 10.1136/bmj.299.6699.601-a; GANGAR KF, 1991, LANCET, V338, P839; GENANT HK, 1982, ANN INTERN MED, V97, P699, DOI 10.7326/0003-4819-97-5-699; GOLDMAN L, 1991, NEW ENGL J MED, V325, P800, DOI 10.1056/NEJM199109123251108; GOODMAN HM, 1989, J REPROD MED, V34, P231; Gordan G S, 1973, Trans Assoc Am Physicians, V86, P326; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 1992, ANN INTERN MED, V117, P1038; Hallstrom T, 1973, MENTAL DISORDER SEXU; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P525, DOI 10.1016/0002-9378(79)90288-6; HART DM, 1987, OSTEOPOROSIS; HENDERSON, 1988, AM J OBSTET GYNECOL, V159, P1574; HENDERSON BE, 1988, AM J OBSTET GYNECOL, V159, P312, DOI 10.1016/S0002-9378(88)80074-7; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HIATT RA, 1984, CANCER, V54, P139, DOI 10.1002/1097-0142(19840701)54:1<139::AID-CNCR2820540128>3.0.CO;2-X; HILLNER BE, 1986, AM J MED, V80, P1115, DOI 10.1016/0002-9343(86)90674-1; HOOVER R, 1976, NEW ENGL J MED, V295, P401, DOI 10.1056/NEJM197608192950801; HOOVER R, 1981, J NATL CANCER I, V67, P815; HORWITZ RI, 1978, NEW ENGL J MED, V299, P1089, DOI 10.1056/NEJM197811162992001; HULKA BS, 1982, AM J OBSTET GYNECOL, V143, P638, DOI 10.1016/0002-9378(82)90108-9; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; HUTCHINSON TA, 1979, LANCET, V2, P705; HUTTON JD, 1979, J ROY SOC MED, V72, P835; JICK H, 1980, AM J EPIDEMIOL, V112, P586, DOI 10.1093/oxfordjournals.aje.a113031; JICK H, 1978, JAMA-J AM MED ASSOC, V239, P1407, DOI 10.1001/jama.239.14.1407; JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105; KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447; KAUFMAN DW, 1984, JAMA-J AM MED ASSOC, V252, P63, DOI 10.1001/jama.252.1.63; KELSEY JL, 1981, JNCI-J NATL CANCER I, V67, P327; Kicovic P M, 1989, Minerva Endocrinol, V14, P63; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KUHL H, 1990, MATURITAS, V12, P171, DOI 10.1016/0378-5122(90)90003-O; Lang W R, 1967, Clin Obstet Gynecol, V10, P454, DOI 10.1097/00003081-196709000-00003; LAVECCHIA C, 1986, INT J CANCER, V38, P853, DOI 10.1002/ijc.2910380612; LEIBLUM S, 1983, JAMA-J AM MED ASSOC, V249, P2195, DOI 10.1001/jama.249.16.2195; LHERMITE M, 1990, MATURITAS, V12, P215, DOI 10.1016/0378-5122(90)90005-Q; Lind T, 1979, Br J Obstet Gynaecol, V86 Suppl 3, P1, DOI 10.1111/j.1471-0528.1979.tb16232.x; LINDSAY R, 1978, CLIN SCI MOL MED, V54, P193, DOI 10.1042/cs0540193; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; LINDSAY R, 1988, MENOPAUSE, P156; LOBO RA, 1991, J CLIN ENDOCR METAB, V73, P925, DOI 10.1210/jcem-73-5-925; LOVE RR, 1988, BREAST CANCER RES TR, V12, P297, DOI 10.1007/BF01811242; MARKIEWICZ L, 1990, J STEROID BIOCHEM, V35, P535, DOI 10.1016/0022-4731(90)90196-Y; MCDONALD JA, 1986, BREAST CANCER RES TR, V7, P193, DOI 10.1007/BF01806250; MCKINLAY SM, 1974, BRIT J PREV SOC MED, V28, P108; MEADE TW, 1990, HRT AND OSTEOPOROSIS, P223; MILLS PK, 1989, CANCER, V64, P591, DOI 10.1002/1097-0142(19890801)64:3<591::AID-CNCR2820640305>3.0.CO;2-U; MOON TE, 1991, ARCH INTERN MED, V151, P17, DOI 10.1001/archinte.151.1.17; MUNKJENSEN N, 1988, BRIT MED J, V296, P1150, DOI 10.1136/bmj.296.6630.1150; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; NACHTIGALL LE, 1979, OBSTET GYNECOL, V53, P277; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; PATERSON MEL, 1982, BRIT J OBSTET GYNAEC, V89, P464, DOI 10.1111/j.1471-0528.1982.tb03638.x; PERSSON I, 1983, ACTA OBSTET GYN SCAN, V62, P289, DOI 10.3109/00016348309156224; PERSSON I, 1989, BRIT MED J, V298, P147, DOI 10.1136/bmj.298.6667.147; PERSSON I, 1990, J CLIN EPIDEMIOL, V43, P677; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; PETITTI DB, 1987, OBSTET GYNECOL, V70, P289; PETITTI DB, 1986, NEW ENGL J MED, V315, P131; PFEFFER RI, 1978, AM J EPIDEMIOL, V107, P479, DOI 10.1093/oxfordjournals.aje.a112567; POWERS MS, 1985, AM J OBSTET GYNECOL, V152, P1099, DOI 10.1016/0002-9378(85)90569-1; PURDIE DW, 1990, OSTEOPOROSIS, P251; RAVNIHAR B, 1979, EUR J CANCER, V15, P395, DOI 10.1016/0014-2964(79)90074-4; RAVNIKAR VA, 1987, AM J OBSTET GYNECOL, V156, P1332, DOI 10.1016/0002-9378(87)90173-6; RIIS BJ, 1987, AM J OBSTET GYNECOL, V156, P61, DOI 10.1016/0002-9378(87)90203-1; RIJPKEMA AHM, 1990, MATURITAS, V12, P259, DOI 10.1016/0378-5122(90)90007-S; ROBBOY SJ, 1979, OBSTET GYNECOL, V54, P269; ROCHE M, 1990, HRT OSTEOPOROSIS, P362; ROSENBERG L, 1976, NEW ENGL J MED, V294, P1256, DOI 10.1056/NEJM197606032942302; ROSENBERG L, 1980, JAMA-J AM MED ASSOC, V244, P339, DOI 10.1001/jama.244.4.339; ROSS RK, 1980, JAMA-J AM MED ASSOC, V243, P1635, DOI 10.1001/jama.243.16.1635; ROSS RK, 1981, LANCET, V1, P858; SARREL PM, 1990, MATURITAS, V12, P287, DOI 10.1016/0378-5122(90)90008-T; SARTWELL PE, 1977, JNCI-J NATL CANCER I, V59, P1589, DOI 10.1093/jnci/59.6.1589; SAVVAS M, 1988, BRIT MED J, V297, P331, DOI 10.1136/bmj.297.6644.331; SEMMENS JP, 1982, JAMA-J AM MED ASSOC, V248, P445; SHAPIRO S, 1980, NEW ENGL J MED, V303, P485, DOI 10.1056/NEJM198008283030903; SHERWIN BB, 1989, OBSTET GYNECOL, V73, P759; SHOUPE D, 1991, NEW ENGL J MED, V325, P1811; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; SMITH PJB, 1976, MANAGEMENT MENOPAUSE, P291; SPECTOR TD, 1989, BRIT MED J, V299, P1434, DOI 10.1136/bmj.299.6713.1434; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STANWELLSMITH R, 1984, ADVERSE DRUG REACT T, V3, P187; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V266, P1362; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STEVENSON JC, 1989, BRIT MED J, V298, P924, DOI 10.1136/bmj.298.6678.924; STOLL BA, 1988, LANCET, V1, P1278; SZKLO M, 1984, PREV MED, V13, P510, DOI 10.1016/0091-7435(84)90019-7; TALAMINI R, 1985, INT J EPIDEMIOL, V14, P70, DOI 10.1093/ije/14.1.70; THOMAS DB, 1982, JNCI-J NATL CANCER I, V69, P1017; THOMPSON SG, 1989, J EPIDEMIOL COMMUN H, V43, P173, DOI 10.1136/jech.43.2.173; TURKEN S, 1989, J NATL CANCER I, V81, P1086, DOI 10.1093/jnci/81.14.1086; UTIAN WH, 1988, MENOPAUSE, P262; VANDENBROUCKE JP, 1991, LANCET, V337, P1482, DOI 10.1016/0140-6736(91)93173-7; VARNER RE, 1990, POSTREPRODUCTIVE GYN, P143; VOIGT LF, 1991, LANCET, V338, P274, DOI 10.1016/0140-6736(91)90417-N; VONSCHOULTZ B, 1988, MENOPAUSE, P130; WALLACE WA, 1990, J ROY SOC MED, V83, P699, DOI 10.1177/014107689008301109; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WALTER S, 1978, UROL INT, V33, P135, DOI 10.1159/000280190; Weinstein M C, 1983, Obstet Gynecol Surv, V38, P445, DOI 10.1097/00006254-198308000-00001; WEINSTEIN MC, 1980, NEW ENGL J MED, V303, P308, DOI 10.1056/NEJM198008073030604; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WHITEHEAD MI, 1981, NEW ENGL J MED, V305, P1599, DOI 10.1056/NEJM198112313052701; WILSON PD, 1987, BRIT J OBSTET GYNAEC, V94, P568, DOI 10.1111/j.1471-0528.1987.tb03152.x; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P2438; Wren BG, 1988, MENOPAUSE, P181; WUEST JH, 1953, CIRCULATION, V7, P801, DOI 10.1161/01.CIR.7.6.801; ZIEL HK, 1975, NEW ENGL J MED, V293, P1167, DOI 10.1056/NEJM197512042932303	170	320	323	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 14	1994	330	15					1062	1071						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF022	8127335				2022-12-28	WOS:A1994NF02200008
J	PAGE, TL				PAGE, TL			TIME IS THE ESSENCE - MOLECULAR ANALYSIS OF THE BIOLOGICAL CLOCK	SCIENCE			English	Editorial Material							MESSENGER-RNA LEVELS; PERIOD GENE-PRODUCT; DROSOPHILA-MELANOGASTER; VISUAL-SYSTEM; ADULT				PAGE, TL (corresponding author), VANDERBILT UNIV,DEPT BIOL,NASHVILLE,TN 37235, USA.				NINDS NIH HHS [NS15264] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015264] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; EDERY I, IN PRESS P NATL ACAD; Edmunds LN, 1988, CELLULAR MOL BASES B; EWER J, 1988, NATURE, V333, P82, DOI 10.1038/333082a0; EWER J, 1990, J NEUROGENET, V7, P31, DOI 10.3109/01677069009084151; FELDMAN J F, 1973, Genetics, V75, P605; FRISCH B, IN PRESS NEURON; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LUI X, 1992, J NEUROSCI, V12, P2735; NORRIS JL, 1992, GENE DEV, V6, P1654, DOI 10.1101/gad.6.9.1654; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; TAKAHASHI JS, 1993, ANNU REV PHYSIOL, V55, P729, DOI 10.1146/annurev.physiol.55.1.729; TAKAHASHI JS, 1992, SCIENCE, V258, P238, DOI 10.1126/science.1384127; VITATERNA MH, IN PRESS SCIENCE; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; ZERR DM, 1990, J NEUROSCI, V10, P2749; [No title captured]	24	16	16	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 18	1994	263	5153					1570	1572		10.1126/science.8128243	http://dx.doi.org/10.1126/science.8128243			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	8128243				2022-12-28	WOS:A1994NB67300019
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW SEAFOOD SAFETY INITIATIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					812	812						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ498	8114223				2022-12-28	WOS:A1994MZ49800040
J	BALCH, WE; MCCAFFERY, JM; PLUTNER, H; FARQUHAR, MG				BALCH, WE; MCCAFFERY, JM; PLUTNER, H; FARQUHAR, MG			VESICULAR STOMATITIS-VIRUS GLYCOPROTEIN IS SORTED AND CONCENTRATED DURING EXPORT FROM THE ENDOPLASMIC-RETICULUM	CELL			English	Article							PLASMA-MEMBRANE PROTEINS; GOLGI-COMPLEX; INTERMEDIATE COMPARTMENT; INTRACELLULAR MEMBRANES; CELL-SURFACE; TRANSPORT; ER; CLATHRIN; DENSITY	Newly synthesized proteins are believed to move from the endoplasmic reticulum (ER) to the Golgi by bulk flow, and sorting is assumed to occur exclusively in the trans-Golgi network (TGN). Using quantitative immunoelectron microscopy, we demonstrate that vesicular stomatitis virus glycoprotein (VSV-G) is sorted from resident ER proteins and concentrated 5- to 10-fold in 40-80 nm vesicles during vesicle budding from the ER. Accumulation of VSV-G in pre-Golgi vesicular carriers is the only detectable concentration step in its transport to the TGN. From these results, it is apparent that export from the ER is not exclusively mediated by bulk flow. The ER exerts an unanticipated level of control to insure selective and efficient entry of mature protein into the secretory pathway.	UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	BALCH, WE (corresponding author), SCRIPPS RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA.				NCI NIH HHS [CA 58689, CA46128] Funding Source: Medline; NIGMS NIH HHS [GM42336] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689, P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH W E, 1992, Current Biology, V2, P157, DOI 10.1016/0960-9822(92)90276-G; BERGMANN JE, 1981, P NATL ACAD SCI-BIOL, V78, P1746, DOI 10.1073/pnas.78.3.1746; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FITTING T, 1982, J BIOL CHEM, V257, P4011; GRIFFITHS G, 1984, J CELL BIOL, V98, P2133, DOI 10.1083/jcb.98.6.2133; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; HOBMAN TC, 1992, J CELL BIOL, V118, P795, DOI 10.1083/jcb.118.4.795; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JAMIESON JD, 1967, J CELL BIOL, V34, P577, DOI 10.1083/jcb.34.2.577; KUGE O, 1994, IN PRESS J CELL BIOL; LAFAY F, 1974, J VIROL, V14, P1220, DOI 10.1128/JVI.14.5.1220-1228.1974; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; Nguyen Van PPF, 1989, J BIOL CHEM, V264, P17494; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PETER F, 1992, J BIOL CHEM, V267, P10631; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PIND S, 1994, IN PRESS J CELL BIOL, V125; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; ROMISCH K, 1992, P NATL ACAD SCI USA, V89, P7227, DOI 10.1073/pnas.89.15.7227; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SARASTE J, 1991, J CELL SCI, V100, P415; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	40	342	346	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 11	1994	76	5					841	852		10.1016/0092-8674(94)90359-X	http://dx.doi.org/10.1016/0092-8674(94)90359-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124720				2022-12-28	WOS:A1994NA89000010
J	BOTHERAS, L				BOTHERAS, L			CAREER MANAGEMENT FOR SCIENTISTS	NATURE			English	Editorial Material											BOTHERAS, L (corresponding author), MACMILLAN DAVIES,PHARMACEUT & HEALTHCARE,SALISBURY HOUSE,HERTFORD,HERTS,ENGLAND.								0	1	1	1	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					764	764		10.1038/367764a0	http://dx.doi.org/10.1038/367764a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	8107874	Bronze			2022-12-28	WOS:A1994MX63100065
J	WESTRIN, CG; NILSTUN, T				WESTRIN, CG; NILSTUN, T			THE ETHICS OF DATA UTILIZATION - A COMPARISON BETWEEN EPIDEMIOLOGY AND JOURNALISM	BRITISH MEDICAL JOURNAL			English	Article								Legal controls over data collection in European countries have badly affected the work of epidemiologists. By contrast, journalists have been allowed far greater freedoms. The aims and tasks of both professions are in line with accepted values in our society-especially those of inquiry and the benefits of an open society. Society seems willing to accept that, in the interests of wider public good, journalism may sometimes invade individuals' privacy and do them harm, but it is not prepared to offer epidemiology an equal measure of tolerance.	LUND UNIV,DEPT MED ETH,S-22362 LUND,SWEDEN; AKAD SJUKHUSET,DEPT SOCIAL MED,S-75185 UPPSALA,SWEDEN	Lund University; Uppsala University; Uppsala University Hospital								ALLEBECK P, 1989, LAKARTIDNINGEN, V37, P3050; [Anonymous], 1991, LAW MED HLTH CARE, V19, P247; DAHL AA, 1988, NORD PSYKIATR TIDSSK, V42, P257; FISKESJO B, 1989, MOTION PARLIAMENT CH, pC877; HAFNER H, 1986, PSYCHIATRIC CASE REG, P366; KNOX EG, 1992, BRIT MED J, V304, P727, DOI 10.1136/bmj.304.6829.727; LAST JM, 1990, INT J EPIDEMIOL, V19, P226, DOI 10.1093/ije/19.1.226; LAST JM, ETHICS MED INDIVIDUA, P125; RUSSEL E, 1992, P WORKSHOP ISSUES HA; SJOLENIUS B, 1989, LEGISLATION HLTH C 2, P321; 1987, JOURNALISTEN, P37	11	21	21	0	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	1994	308	6927					522	523		10.1136/bmj.308.6927.522	http://dx.doi.org/10.1136/bmj.308.6927.522			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MX814	8136673	Green Published			2022-12-28	WOS:A1994MX81400029
J	BARRETTCONNOR, E; PALINKAS, LA				BARRETTCONNOR, E; PALINKAS, LA			LOW BLOOD-PRESSURE AND DEPRESSION IN OLDER MEN - A POPULATION-BASED STUDY	BRITISH MEDICAL JOURNAL			English	Article							SYMPTOMS; MOOD	Objective-To determine if an association exists between low blood pressure and depressive symptoms in older men living in the community. Design-Cross sectional, population based study. Setting-Town of Rancho Bernardo, California, United States. Subjects-846 men aged 60-89 years. Comparisons between hypotensive, normotensive, and hypertensive groups were limited to 594 men not taking drugs for hypertension. Main outcome measures-Mean scores on Beck depression inventory and prevalence of scores greater than or equal to 13. n Results-Men with diastolic blood pressure <75 mm Hg had significantly higher depression scores (mean scores 6.35 v 4.96; P < 0.001) and more categorical depression (7.6% v 1.8% with scores greater than or equal to 13; P < 0.01) than men with diastolic blood pressure levels between 75 and 85 mm Hg. Men with diastolic blood pressure levels > 85 mm Hg had higher depression scores than men with intermediate blood pressure levels (mean scores 5.85 v 4.96; P < 0.05). Men with diastolic hypotension scored significantly higher on both affective and somatic item subscales of the Beck depression inventory and on individual measures of fatigue, pessimism, sadness, loss of appetite, weight loss, and preoccupation with health. Low diastolic blood pressure was a significant predictor of both mean depression score and prevalence of categorical depression, independent of age and change in weight since the baseline visit. The presence of several chronic diseases was associated with depressed mood and higher blood pressure but not with low blood pressure. Conclusion-The association of relatively low diastolic blood pressure with higher depressive symptom scores and rates of categorical depression was independent of age or weight loss. Since fatigue is a prominent symptom of depression, any association of low blood pressure with fatigue could reflect depressive disorders or clinically important depression.			BARRETTCONNOR, E (corresponding author), UNIV CALIF SAN DIEGO,DEPT FAMILY & PREVENT MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.				NIA NIH HHS [R37 AG07181-05] Funding Source: Medline; NIDDK NIH HHS [R01-DK31801] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG007181] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1976, Prev Med, V5, P207; Beck A. T., 1960, ARCH GEN PSYCHIAT, V4, P53, DOI DOI 10.1001/ARCHPSYC.1961.01710120031004; Bengtsson C, 1987, Scand J Prim Health Care, V5, P155, DOI 10.3109/02813438709013997; DIMSDALE JE, 1992, ARCH INTERN MED, V152, P35, DOI 10.1001/archinte.152.1.35; Fleiss JL, 1981, STAT METHODS RATES P; GOLDBERG EL, 1980, PSYCHOL MED, V10, P243, DOI 10.1017/S0033291700044007; KLEINBAUM DJ, 1978, APPLIED REGRESSION A; MANTEL N, 1959, J NATL CANCER I, V22, P719; NAKAGAWARA M, 1987, PSYCHIAT RES, V21, P85, DOI 10.1016/0165-1781(87)90065-5; NIELSEN AC, 1980, ARCH GEN PSYCHIAT, V37, P999; PEMBERTON J, 1989, BRIT MED J, V298, P660, DOI 10.1136/bmj.298.6674.660; PILGRIM JA, 1993, BRIT MED J, V306, P655, DOI 10.1136/bmj.306.6878.655-a; PILGRIM JA, 1992, BRIT MED J, V304, P75, DOI 10.1136/bmj.304.6819.75; PLUMB MM, 1977, PSYCHOSOM MED, V39, P264, DOI 10.1097/00006842-197707000-00007; ROBBINS JM, 1982, SOC SCI MED, V16, P27, DOI 10.1016/0277-9536(82)90420-8; SHROUT PE, 1989, J CLIN EPIDEMIOL, V42, P69, DOI 10.1016/0895-4356(89)90027-9; WESSELY S, 1990, BRIT MED J, V301, P362, DOI 10.1136/bmj.301.6748.362	17	103	105	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	1994	308	6926					446	449		10.1136/bmj.308.6926.446	http://dx.doi.org/10.1136/bmj.308.6926.446			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MW976	8124175	Green Published			2022-12-28	WOS:A1994MW97600022
J	MORGAN, JM; CARMICHAEL, AJ				MORGAN, JM; CARMICHAEL, AJ			FIXED DRUG ERUPTION WITH FLUCONAZOLE	BRITISH MEDICAL JOURNAL			English	Note											MORGAN, JM (corresponding author), S CLEVELAND HOSP,MIDDLESBROUGH TS4 3BW,ENGLAND.							BREATHNACH SM, 1992, ADVERSE DRUG REACT, P72; TUCKER RM, 1990, J ANTIMICROB CHEMOTH, V26, P561, DOI 10.1093/jac/26.4.561	2	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	1994	308	6926					454	454		10.1136/bmj.308.6926.454a	http://dx.doi.org/10.1136/bmj.308.6926.454a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW976	8124179	Green Published			2022-12-28	WOS:A1994MW97600026
J	BURNS, K; DUGGAN, B; ATKINSON, EA; FAMULSKI, KS; NEMER, M; BLEACKLEY, RC; MICHALAK, M				BURNS, K; DUGGAN, B; ATKINSON, EA; FAMULSKI, KS; NEMER, M; BLEACKLEY, RC; MICHALAK, M			MODULATION OF GENE-EXPRESSION BY CALRETICULIN BINDING TO THE GLUCOCORTICOID RECEPTOR	NATURE			English	Article							MESSENGER-RNA; PROTEIN; CELLS; DNA	CALRETICULIN is a multifunctional protein that acts as a major Ca2+-binding (storage) protein in the lumen of the endoplasmic reticulum1. It is also found in the nucleus2, suggesting that it may have a role in transcription regulation. Calreticulin has been reported to bind to the synthetic peptide KLGFFKR3, which is almost identical to an amino-acid sequence in the DNA-binding domain of the superfamily of nuclear receptors4-6. Could calreticulin interact with the DNA-binding domain of these receptors and affect their function? Here we report that the amino terminus of calreticulin interacts with the DNA-binding domain of the glucocorticoid receptor and prevents the receptor from binding to its specific glucocorticoid response element. Overexpression of calreticulin in mouse L fibroblasts inhibits glucocorticoid-response-mediated transcriptional activation of a glucocorticoid-sensitive reporter gene and of the endogenous, glucocorticoid-sensitive gene encoding cytochrome P450. Together these results indicate that calreticulin may be important in gene transcription, regulating the glucocorticoid receptor and perhaps other members of the superfamily of nuclear receptors.	UNIV ALBERTA, CARDIOVASC DIS RES GRP, EDMONTON T6G 2S2, AB, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2S2, AB, CANADA; CLIN RES INST MONTREAL, MONTREAL H2W 1R7, QUEBEC, CANADA	University of Alberta; University of Alberta; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Famulski, Konrad/J-8685-2012					ARGENTIN S, 1991, J BIOL CHEM, V266, P23315; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BURNS K, 1992, J BIOL CHEM, V267, P19039; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DROUIN J, 1992, MOL ENDOCRINOL, V6, P1299, DOI 10.1210/me.6.8.1299; EDWARDS RJ, 1991, METHOD ENZYMOL, V206, P220; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; HARDWICK JP, 1983, J BIOL CHEM, V258, P182; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1991, J BIOL CHEM, V266, P7155; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008	19	343	354	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	1994	367	6462					476	480		10.1038/367476a0	http://dx.doi.org/10.1038/367476a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	8107808				2022-12-28	WOS:A1994MU67900059
J	CLARK, EA; LEDBETTER, JA				CLARK, EA; LEDBETTER, JA			HOW B-CELLS AND T-CELLS TALK TO EACH OTHER	NATURE			English	Article							DEPENDENT ANTIBODY-RESPONSES; ACTIVATION ANTIGEN-B7; LYMPHOCYTES-T; SOLUBLE FORM; RECEPTOR; CD40; LIGAND; EXPRESSION; ADHESION; SIGNAL	The B cells of the immune system, which secrete antibodies against foreign antigens, are fully specific and effective only after maturation in lymph nodes and other lymphoid tissues. Immunocompetent T cells play a crucial part in this process, but the molecular details of the way in which the two cell types interact have only recently become apparent.	UNIV WASHINGTON,REG PRIMATE RES CTR,SEATTLE,WA 98195; BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,SEATTLE,WA 98121	University of Washington; University of Washington Seattle; Bristol-Myers Squibb	CLARK, EA (corresponding author), UNIV WASHINGTON,MED CTR,DEPT MICROBIOL,SC-42,SEATTLE,WA 98195, USA.			Clark, Edward A/0000-0001-8061-5475				ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; BARRETT TB, 1991, J IMMUNOL, V146, P1722; CHALUPNY NJ, 1993, EMBO J, V12, P2691, DOI 10.1002/j.1460-2075.1993.tb05930.x; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; CLARK EA, 1993, J IMMUNOL, V150, P4715; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; DAMLE NK, 1991, EUR J IMMUNOL, V21, P1277, DOI 10.1002/eji.1830210527; DURIE FH, 1993, SCIENCE, V261, P1328, DOI 10.1126/science.7689748; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FOY TM, 1993, J EXP MED, V178, P1567, DOI 10.1084/jem.178.5.1567; FREEMAN GJ, 1989, J IMMUNOL, V143, P2714; FREEMAN GJ, 1993, SCIENCE, V262, P907, DOI 10.1126/science.7694362; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HILL A, 1993, NATURE, V361, P494, DOI 10.1038/361494a0; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; Kawabe T., 1993, Tissue Antigens, V42, P309; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LANE PJL, 1991, J IMMUNOL, V147, P4103; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; MACLENNAN ICM, 1992, IMMUNOL REV, V126, P143, DOI 10.1111/j.1600-065X.1992.tb00635.x; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MCHEYZERWILLIAMS MG, 1993, J EXP MED, V178, P295, DOI 10.1084/jem.178.1.295; MOLLER G, 1992, IMMUNOL REV, V126, P5; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; OCHS HD, 1993, CLIN IMMUNOL IMMUNOP, V67, pS33, DOI 10.1006/clin.1993.1081; OSMOND DG, 1993, IMMUNOL TODAY, V14, P34, DOI 10.1016/0167-5699(93)90322-C; PARKER DC, 1993, ANNU REV IMMUNOL, V11, P331, DOI 10.1146/annurev.iy.11.040193.001555; PESANDO JM, 1989, J EXP MED, V170, P2159, DOI 10.1084/jem.170.6.2159; RANHEIM EA, 1993, J EXP MED, V177, P925, DOI 10.1084/jem.177.4.925; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; RONCHESE F, 1993, J EXP MED, V177, P679, DOI 10.1084/jem.177.3.679; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; VANDENEERTWEGH AJM, 1993, J EXP MED, V178, P1555, DOI 10.1084/jem.178.5.1555; WEISS U, 1992, EUR J IMMUNOL, V22, P511, DOI 10.1002/eji.1830220233; YELLIN MJ, 1994, J IMMUNOL, V152, P598; YOKOCHI T, 1982, J IMMUNOL, V128, P823; YOUNG JW, 1992, J CLIN INVEST, V90, P229, DOI 10.1172/JCI115840	60	614	640	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					425	428		10.1038/367425a0	http://dx.doi.org/10.1038/367425a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	8107800				2022-12-28	WOS:A1994MU67900044
J	FEACHEM, R				FEACHEM, R			HEALTH DECLINE IN EASTERN-EUROPE	NATURE			English	Editorial Material											FEACHEM, R (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.							ANDA R, 1993, EPIDEMIOLOGY, V4, P285, DOI 10.1097/00001648-199307000-00003; BOBAK M, 1992, HEALTH POLICY PLANN, V7, P234, DOI 10.1093/heapol/7.3.234; Eberstadt N, 1990, Communist Econ, V2, P347; EBERSTADT N, IN PRESS COMMUNIST E; Feachem RGA, 1992, HLTH ADULTS DEV WORL; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; 1993, 1993 WORLD BANK WORL	8	53	53	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					313	314		10.1038/367313a0	http://dx.doi.org/10.1038/367313a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	8114931				2022-12-28	WOS:A1994MT54000030
J	MANSELL, PI; RECKLESS, JPD; LOVELL, CR				MANSELL, PI; RECKLESS, JPD; LOVELL, CR			SEVERE ANAPHYLACTIC REACTION TO LATEX RUBBER SURGICAL GLOVES	BRITISH MEDICAL JOURNAL			English	Article							CONTACT URTICARIA		ROYAL UNITED HOSP,BATH BA1 3NG,ENGLAND									GELFAND DW, 1991, AM J ROENTGENOL, V156, P1; MAMANN CP, 1993, AM J CONTACT DERMATI, V4, P4; PECQUET C, 1990, J AM ACAD DERMATOL, V22, P631, DOI 10.1016/0190-9622(90)70086-W; TURJANMAA K, 1988, DERMATOL CLIN, V6, P47, DOI 10.1016/S0733-8635(18)30688-0; TURJANMAA K, 1988, BRIT MED J, V297, P1029, DOI 10.1136/bmj.297.6655.1029	5	19	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 22	1994	308	6923					246	247		10.1136/bmj.308.6923.246	http://dx.doi.org/10.1136/bmj.308.6923.246			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT539	8111259	Green Published			2022-12-28	WOS:A1994MT53900021
J	LIU, L; STEVENSON, SB; SCHOR, CM				LIU, L; STEVENSON, SB; SCHOR, CM			QUANTITATIVE STEREOSCOPIC DEPTH WITHOUT BINOCULAR CORRESPONDENCE	NATURE			English	Article							OCCLUDING CONTOURS; ILLUSORY CONTOURS; STEREOPSIS; RIVALRY; CAPTURE	WHAT features in a stereogram define the disparities that lead to stereoscopic depth? The usual answer is that luminance-defined edges from the two eyes are matched and produce depth perception1,2. But parts of an object may be occluded by other objects and absent from one eye's view. It was suggested that unpaired monocular elements might signal occlusion in depth, and the qualitative perception of depth associated with unmatched elements has, been shown to be consistent with the geometry of occlusion3-5. We designed a stereogram that simulates a particular occlusion situation: an opaque white rectangle is stereoscopically in front of a large black rectangle pasted on a white background. The position of the occluder is adjusted so that its left edge obscures the left-hand edge of the black rectangle in the right eye view and its right edge obscures the right-hand edge of the black rectangle in the left eye view. We report here that quantitative stereopsis can be seen from this stereogram, even though there are no binocular corresponding luminance edges to match.			LIU, L (corresponding author), UNIV CALIF BERKELEY,SCH OPTOMETRY,BERKELEY,CA 94720, USA.			Liu, Lei/0000-0002-1332-9724				BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; HARRIS JP, 1973, PERCEPTION, V2, P235, DOI 10.1068/p020235; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; KELLMAN PJ, 1991, COGNITIVE PSYCHOL, V23, P141, DOI 10.1016/0010-0285(91)90009-D; MARR D, 1979, PROC R SOC SER B-BIO, V204, P301, DOI 10.1098/rspb.1979.0029; NAKAYAMA K, 1990, VISION RES, V30, P1811, DOI 10.1016/0042-6989(90)90161-D; NAKAYAMA K, 1990, COLD SPRING HARB SYM, V55, P911; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; RAMACHANDRAN VS, 1973, NATURE, V242, P412, DOI 10.1038/242412a0; RAMACHANDRAN VS, 1986, PERCEPT PSYCHOPHYS, V39, P361, DOI 10.3758/BF03203005; RAMACHANDRAN VS, 1985, NATURE, V317, P527, DOI 10.1038/317527a0; SHIMOJO S, 1990, VISION RES, V30, P69, DOI 10.1016/0042-6989(90)90128-8; TAKEICHI H, 1992, PERCEPTION, V21, P177, DOI 10.1068/p210177; TREISMAN A, 1962, Q J EXP PSYCHOL, V14, P23, DOI 10.1080/17470216208416507	14	47	48	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 6	1994	367	6458					66	69		10.1038/367066a0	http://dx.doi.org/10.1038/367066a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MP865	8107776				2022-12-28	WOS:A1994MP86500060
J	MANSER, E; LEUNG, T; SALIHUDDIN, H; ZHAO, ZS; LIM, L				MANSER, E; LEUNG, T; SALIHUDDIN, H; ZHAO, ZS; LIM, L			A BRAIN SERINE THREONINE PROTEIN-KINASE ACTIVATED BY CDC42 AND RAC1	NATURE			English	Article							GTP-BINDING-PROTEIN; GDP DISSOCIATION INHIBITOR; FOCAL ADHESIONS; RAS PROTEINS; R-RAS; RHO; IDENTIFICATION; EXPRESSION; HOMOLOG; PHOSPHORYLATION	A new brain serine/threonine protein kinase may be a target for the p21ras-related proteins Cdc42 and Rac1. The kinase sequence is related to that of the yeast protein STE20, implicated in pheromone-response pathways. The kinase complexes specifically with activated (GTP-bound) p21, inhibiting p21 GTPase activity and leading to kinase autophosphorylation and activation. Autophosphorylated kinase has a decreased affinity for Cdc42/Rac, freeing the p21 for further stimulatory activities or downregulation by GTPase-activating proteins. This bimolecular interaction provides a model for studying p21 regulation of mammalian phosphorylation signalling pathways.	INST NEUROL,LONDON WC1N 1PJ,ENGLAND	University of London; University College London	MANSER, E (corresponding author), NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,GLAXO IMCB GRP,KENT RIDGE,SINGAPORE 0511,SINGAPORE.		Manser, Edward/ABD-2301-2020					Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; Barbacid M., 1987, REV BIOCH, V56, P779; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOUCET JP, 1992, J BIOL CHEM, V267, P16503; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEUNG T, 1993, J BIOL CHEM, V268, P3813; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MARSH L, 1991, REV CELL BIOL, V7, P699; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MENARD L, 1992, EUR J BIOCHEM, V206, P537, DOI 10.1111/j.1432-1033.1992.tb16957.x; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SELF AJ, 1993, ONCOGENE, V8, P655; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SLUIJS P, 1992, CELL, V70, P729; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG J, 1992, MOL CELL BIOL, V12, P4937, DOI 10.1128/MCB.12.11.4937; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	49	1320	1362	2	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 6	1994	367	6458					40	46		10.1038/367040a0	http://dx.doi.org/10.1038/367040a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	8107774				2022-12-28	WOS:A1994MP86500051
J	SMIT, JJM; SCHINKEL, AH; ELFERINK, RPJO; GROEN, AK; WAGENAAR, E; VANDEEMTER, L; MOL, CAAM; OTTENHOFF, R; VANDERLUGT, NMT; VANROON, MA; VANDERVALK, MA; OFFERHAUS, GJA; BERNS, AJM; BORST, P				SMIT, JJM; SCHINKEL, AH; ELFERINK, RPJO; GROEN, AK; WAGENAAR, E; VANDEEMTER, L; MOL, CAAM; OTTENHOFF, R; VANDERLUGT, NMT; VANROON, MA; VANDERVALK, MA; OFFERHAUS, GJA; BERNS, AJM; BORST, P			HOMOZYGOUS DISRUPTION OF THE MURINE MDR2 P-GLYCOPROTEIN GENE LEADS TO A COMPLETE ABSENCE OF PHOSPHOLIPID FROM BILE AND TO LIVER-DISEASE	CELL			English	Article							MULTIDRUG-RESISTANCE GENE; BETA-INTERFERON GENE; EMBRYONIC STEM-CELLS; MOUSE PGK-1 GENE; HEPATOBILIARY TRANSPORT; MONOCLONAL-ANTIBODIES; COMPLEMENTARY-DNA; BILIARY-EXCRETION; LIPID ASYMMETRY; RAT-LIVER	Two types of P-glycoprotein have been found in mammals: the drug-transporting P-glycoproteins and a second type, unable to transport hydrophobic anticancer drugs. The latter is encoded by the human MDR3 (also called MDR2) and the mouse mdr2 genes, and its tissue distribution (bile canalicular membrane of hepatocytes, B cells, heart, and muscle) suggests a specialized metabolic function. We have generated mice homozygous for a disruption of the mdr2 gene. These mice develop a liver disease that appears to be caused by the complete inability of the liver to secrete phospholipid into the bile. Mice heterozygous for the disrupted allele had no detectable liver pathology, but half the level of phospholipid in bile. We conclude that the mdr2 P-glycoprotein has an essential role in the secretion of phosphatidylcholine into bile and hypothesize that it may be a phospholipid transport protein or phospholipid flippase.	NETHERLANDS CANC INST, DIV MOLEC GENET, 1066 CX AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, ACAD MED CTR, DEPT PATHOL, 1105 AZ AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	SMIT, JJM (corresponding author), NETHERLANDS CANC INST, DIV MOLEC BIOL, PLESMANLAAN 121, 1066 CX AMSTERDAM, NETHERLANDS.							ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ALLAIN CC, 1974, CLIN CHEM, V20, P470; ALPINI G, 1988, J CLIN INVEST, V81, P569, DOI 10.1172/JCI113355; BAAS F, 1990, CANCER RES, V50, P5392; BARINAGA M, 1992, SCIENCE, V256, P444, DOI 10.1126/science.1373905; BERR F, 1993, J BIOL CHEM, V268, P3976; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRADLEY G, 1992, CANCER RES, V52, P5154; BUSCHMAN E, 1991, MOL CELL BIOL, V11, P595, DOI 10.1128/MCB.11.2.595; BUSCHMAN E, 1992, J BIOL CHEM, V267, P18093; CHIN JE, 1989, MOL CELL BIOL, V9, P3808, DOI 10.1128/MCB.9.9.3808; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DE, 1990, J LIPID RES, V31, P55; COLEMAN R, 1992, BIOCHIM BIOPHYS ACTA, V1125, P113, DOI 10.1016/0005-2760(92)90036-U; COLEMAN R, 1987, BIOCHEM J, V244, P249, DOI 10.1042/bj2440249; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DENG CX, 1992, MOL CELL BIOL, V12, P3365, DOI 10.1128/MCB.12.8.3365; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DEVAUX PF, 1992, ANNU REV BIOPH BIOM, V21, P417, DOI 10.1146/annurev.bb.21.060192.002221; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; ELFERINK RPJ, 1989, J CLIN INVEST, V84, P476, DOI 10.1172/JCI114189; Endicott J A, 1991, DNA Seq, V2, P89, DOI 10.3109/10425179109039677; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; FERRELL JE, 1985, BIOCHEMISTRY-US, V24, P2849, DOI 10.1021/bi00333a006; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Fromm H, 1992, Gastroenterology, V103, P343; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1993, CANCER RES, V53, P747; GROS P, 1991, CANCER INVEST, V9, P563, DOI 10.3109/07357909109018954; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; GURANTZ D, 1981, J LIPID RES, V22, P373; HARRISON PTC, 1984, LAB ANIM, V18, P325, DOI 10.1258/002367784780865324; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JANSEN PLM, 1987, HEPATOLOGY, V7, P71, DOI 10.1002/hep.1840070116; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KAPLAN MM, 1993, GASTROENTEROLOGY, V104, P651, DOI 10.1016/0016-5085(93)90440-N; KATAGIRI K, 1992, GASTROENTEROLOGY, V102, P1660, DOI 10.1016/0016-5085(92)91727-L; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; KUO MT, 1992, CELL GROWTH DIFFER, V3, P531; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LINCKE CR, 1990, CANCER RES, V50, P1779; LOWE PJ, 1984, BIOCHEM J, V222, P631, DOI 10.1042/bj2220631; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARZOLO MP, 1990, HEPATOLOGY, V12, pS134; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MORI N, 1986, GENE, V45, P275; NOOTER K, 1991, BRIT J CANCER, V63, P663, DOI 10.1038/bjc.1991.152; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.med.42.1.277; PHILLIPS MJ, 1986, LAB INVEST, V54, P593; RATHJEN PD, 1990, GENE DEV, V4, P2308, DOI 10.1101/gad.4.12b.2308; RAYMOND M, 1990, MOL CELL BIOL, V10, P1642, DOI 10.1128/MCB.10.4.1642; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; RONINSON IB, 1992, MUTAT RES, V276, P151, DOI 10.1016/0165-1110(92)90005-T; Sambrook J, 1989, MOL CLONING LABORATO; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SCHINKELAH, 1991, SEMIN CANCER BIOL, V2, P213; SCHRIER SL, 1992, BLOOD, V79, P782; SONNEVELD P, 1992, BLOOD, V79, P1496, DOI 10.1182/blood.V79.6.1496.bloodjournal7961496; SPIVAK W, 1985, BIOCHEM J, V225, P787, DOI 10.1042/bj2250787; STEIN AF, 1988, TOXICOL APPL PHARM, V93, P351, DOI 10.1016/0041-008X(88)90037-3; STRICKER BHC, 1992, DRUG INDUCED DISORDE, V5, P71; SUCHY FJ, 1986, AM J PHYSIOL, V251, pG655, DOI 10.1152/ajpgi.1986.251.5.G665; Szasz G., 1974, METHOD ENZYMAT AN, P715; TEETER LD, 1990, MOL CELL BIOL, V10, P5728, DOI 10.1128/MCB.10.11.5728; TEETER LD, 1991, MOL CARCINOGEN, V4, P358, DOI 10.1002/mc.2940040506; TENASBROEK ALM, 1993, IN PRESS MOL BIOCH P; THORGEIRSSON SS, 1991, PHARMACOL THERAPEUT, V49, P283, DOI 10.1016/0163-7258(91)90059-U; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TURLEY SD, 1978, J LIPID RES, V19, P924; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANDERBLIEK AM, 1987, EMBO J, V6, P3325, DOI 10.1002/j.1460-2075.1987.tb02653.x; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VANDERBLIEK AM, 1988, CANCER RES, V48, P5927; VANDERBLIEK AM, 1986, MOL CELL BIOL, V6, P1671, DOI 10.1128/MCB.6.5.1671; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; VANDERVALK P, 1990, ANN ONCOL, V1, P56; WHEELER HO, 1972, J CLIN INVEST, V51, P1337, DOI 10.1172/JCI106930; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	88	1258	1284	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 5	1993	75	3					451	462		10.1016/0092-8674(93)90380-9	http://dx.doi.org/10.1016/0092-8674(93)90380-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MF830	8106172				2022-12-28	WOS:A1993MF83000008
J	WETSTEYN, JCFM; DEGEUS, A				WETSTEYN, JCFM; DEGEUS, A			COMPARISON OF 3 REGIMENS FOR MALARIA PROPHYLAXIS IN TRAVELERS TO EAST, CENTRAL, AND SOUTHERN AFRICA	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AMERICAN TRAVELERS; CHEMOPROPHYLAXIS; CHLOROQUINE; PREVENTION; RESIDENTS	Objective-Confirmation of breakthroughs in three different malaria chemoprophylactic regimens (chloroquine 300 mg weekly and proguanil 100 mg daily; chloroquine 300 mg weekly and proguanil 200 mg daily; proguanil 200 mg daily) and assessment of compliance. Design-Prospective, randomised multicentre trial. Setting-Five vaccination centres in the Netherlands. Subjects-Dutch travellers to east, central, and southern Africa. Main outcome measures-Plasmodium falciparum seen on blood film; concentrations of drugs measured in blood spots. Results-P falciparum infection was confirmed in 12 (21%) of 58 travellers with fever suspected to be due to malaria. No difference in prophylaxis failures between the regimens was found. Breakthroughs were difficult to confirm, as compliance could be determined in only 30% of the participants with fever and chloroquine in their regimen. One breakthrough was proved. The risk per 1000 people per month for travellers was 5.4 (95% confidence interval 2.4 to 12.6) for chloroquine 300 mg weekly and proguanil 100 mg daily, 2.8 (0.9 to 10.1) for chloroquine 300 mg weekly and proguanil 200 mg daily, and 6.0 (2.6 to 14.0) for proguanil 200 mg daily. Conclusion-Prophylaxis failures occurred in less than 1% of the participants, and only 21% of those with a fever were suffering from falciparum malaria. Compliance was moderate. The chloroquine-proguanil combination can still be recommended for visitors to east, central, and southern Africa.	UNIV ABERDEEN, ABERDEEN AB9 1FX, SCOTLAND	University of Aberdeen	WETSTEYN, JCFM (corresponding author), UNIV AMSTERDAM, ACAD MED CTR, INFECT DIS & TROP MED UNIT, MEIBERGDREEF 9, 1105 AZ AMSTERDAM, NETHERLANDS.							BASCO LK, 1992, LANCET, V339, P63; FOGH S, 1988, BMJ-BRIT MED J, V296, P820, DOI 10.1136/bmj.296.6625.820; LACKRITZ EM, 1991, JAMA-J AM MED ASSOC, V265, P383, DOI 10.1001/jama.265.3.383; LOBEL HO, 1990, B WORLD HEALTH ORGAN, V68, P209; MCLARTY DG, 1984, LANCET, V2, P656; PHILLIPSHOWARD PA, 1990, BMJ-BRIT MED J, V300, P499, DOI 10.1136/bmj.300.6723.499; PHILLIPSHOWARD PA, 1988, BMJ-BRIT MED J, V296, P245, DOI 10.1136/bmj.296.6617.245; ROMBO L, 1987, B WORLD HEALTH ORGAN, V65, P879; STEFFEN R, 1990, B WORLD HEALTH ORGAN, V68, P313; WETSTEYN JCFM, 1985, B WORLD HEALTH ORGAN, V63, P101; 1988, B WORLD HEALTH ORGAN, V66, P177; 1989, BMJ, V299, P1087; 1991, INT TRAVEL HLTH; 1993, BMJ, V306, P1247	14	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 23	1993	307	6911					1041	1043		10.1136/bmj.307.6911.1041	http://dx.doi.org/10.1136/bmj.307.6911.1041			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD556	8123120	Bronze, Green Published			2022-12-28	WOS:A1993MD55600018
J	ANNAS, GJ				ANNAS, GJ			DETENTION OF HIV-POSITIVE HAITIANS AT GUANTANAMO - HUMAN-RIGHTS AND MEDICAL-CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							AIDS							Annas, George/0000-0001-5836-7831				ANNAS GJ, 1993, NEW ENGL J MED, V328, P585, DOI 10.1056/NEJM199302253280825; BAYER R, 1989, NEW ENGL J MED, V320, P1022, DOI 10.1056/NEJM198904133201529; BAYER R, 1993, WASHINGTON POST 0112, pA17; DUBLER NN, 1989, MILBANK Q, V67, P171, DOI 10.2307/3350137; Eide AsbjOrn, 1992, UNIVERSAL DECLARATIO; Friedman Thomas L., 1993, NY TIMES        0610, pA12; GOSTIN LO, 1990, NEW ENGL J MED, V322, P1743, DOI 10.1056/NEJM199006143222411; GRODIN MA, 1993, HASTINGS CTR REP, V23, P4; Rohter L., 1993, NY TIMES, pA20; SCIOLINO E, 1993, NY TIMES        1016, P1; Strossen Nadine, 1992, U TOL L REV, V24, P203	11	17	17	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1993	329	8					589	592		10.1056/NEJM199308193290826	http://dx.doi.org/10.1056/NEJM199308193290826			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LR892	8123086				2022-12-28	WOS:A1993LR89200028
J	PARIS, JJ; SCHREIBER, MD; STATTER, M; ARENSMAN, R; SIEGLER, M				PARIS, JJ; SCHREIBER, MD; STATTER, M; ARENSMAN, R; SIEGLER, M			BEYOND AUTONOMY - PHYSICIANS REFUSAL TO USE LIFE-PROLONGING EXTRACORPOREAL MEMBRANE-OXYGENATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PRACTICE GUIDELINES; FUTILITY		UNIV CHICAGO, CHICAGO, IL 60637 USA	University of Chicago	PARIS, JJ (corresponding author), BOSTON COLL, CHESTNUT HILL, MA 02167 USA.							ANGELL M, 1991, NEW ENGL J MED, V325, P511, DOI 10.1056/NEJM199108153250712; [Anonymous], 1991, ANN INTERN MED, V115, P478; [Anonymous], 1990, CRIT CARE MED, V18, P1435; AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FIEL SB, 1991, ARCH INTERN MED, V151, P870, DOI 10.1001/archinte.151.5.870; LANTOS J D, 1989, American Journal of Medicine, V87, P81, DOI 10.1016/S0002-9343(89)80487-5; LEVY FH, 1992, ANESTH ANALG, V75, P1053; MAPPES TA, 1986, BIOMEDICAL ETHICS, P54; MILES SH, 1991, NEW ENGL J MED, V325, P512, DOI 10.1056/NEJM199108153250713; PARIS JJ, 1990, NEW ENGL J MED, V322, P1012, DOI 10.1056/NEJM199004053221420; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; RAFFIN TA, 1992, PRINCIPLES CRITICAL, P2185; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; TRUOG RD, 1992, NEW ENGL J MED, V326, P1560, DOI 10.1056/NEJM199206043262310; Truog Robert D, 1992, J Clin Ethics, V3, P143; VEATCH RM, 1992, AM J LAW MED, V18, P15; WEBER TR, 1992, J PEDIATR SURG, V27, P1100, DOI 10.1016/0022-3468(92)90568-R; WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946; YOUNGER SJ, 1988, JAMA-J AM MED ASSOC, V260, P2094, DOI 10.1001/jama.260.14.2094; Zussman Robert, 1992, INTENSIVE CARE MED E; 1990, CHEST, V97, P949; 1992, JAMA-J AM MED ASSOC, V268, P2282	24	49	49	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1993	329	5					354	357		10.1056/NEJM199307293290512	http://dx.doi.org/10.1056/NEJM199307293290512			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN621	8110219				2022-12-28	WOS:A1993LN62100012
J	MOERTEL, CG				MOERTEL, CG			DRUG-THERAPY - CHEMOTHERAPY FOR COLORECTAL-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PROSPECTIVE RANDOMIZED TRIAL; POSTOPERATIVE ADJUVANT CHEMOTHERAPY; BIOCHEMICAL MODULATION; LIVER METASTASES; COLON CANCER; FOLINIC ACID; LARGE-BOWEL; COMBINED 5-FLUOROURACIL; LEUKEMIC CELLS; RECTAL-CANCER				MOERTEL, CG (corresponding author), MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA.							[Anonymous], 1985, NEW ENGL J MED, V312, P1465; ANSFIELD FJ, 1960, CANCER CHEMOTH REP, P21; ARNAUD JP, 1989, BRIT J SURG, V76, P284, DOI 10.1002/bjs.1800760322; BEART RW, 1990, ARCH SURG-CHICAGO, V125, P897; BOICE JD, 1983, NEW ENGL J MED, V309, P1079, DOI 10.1056/NEJM198311033091802; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BUROKER TR, 1985, J CLIN ONCOL, V3, P1624, DOI 10.1200/JCO.1985.3.12.1624; BUYSE M, 1988, JAMA-J AM MED ASSOC, V259, P3571; BYFIELD JE, 1982, INT J RADIAT ONCOL, V8, P1923, DOI 10.1016/0360-3016(82)90451-5; CHANG AE, 1987, ANN SURG, V206, P685, DOI 10.1097/00000658-198712000-00001; CURRERI AR, 1958, CANCER RES, V18, P478; DOROSHOW JH, 1991, J CLIN ONCOL, V9, P365, DOI 10.1200/JCO.1991.9.3.365; DOUGLASS HO, 1986, NEW ENGL J MED, V315, P1294; ERLICHMAN C, 1988, J CLIN ONCOL, V6, P469, DOI 10.1200/JCO.1988.6.3.469; ERLICHMAN C, 1991, J CLIN ONCOL, V9, P2076; FIELDING LP, 1992, LANCET, V340, P502, DOI 10.1016/0140-6736(92)91708-G; FISHER B, 1988, JNCI-J NATL CANCER I, V80, P21, DOI 10.1093/jnci/80.1.21; GERSTNER J, 1991, P AN M AM SOC CLIN, V10, P134; GLIMELIUS B, 1989, J CLIN ONCOL, V7, P1437; GRAGE TB, 1981, SURG CLIN N AM, V61, P1321; GREM JL, 1989, J NATL CANCER I, V81, P1413, DOI 10.1093/jnci/81.18.1413; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; HANSEN R, 1991, P AN M AM SOC CLIN, V10, P154; HEIDELBERGER C, 1958, CANCER RES, V18, P305; HIGGINS GA, 1984, CANCER, V53, P1, DOI 10.1002/1097-0142(19840101)53:1<1::AID-CNCR2820530102>3.0.CO;2-L; HIGGINS GA, 1976, CANCER-AM CANCER SOC, V38, P1461, DOI 10.1002/1097-0142(197610)38:4<1461::AID-CNCR2820380402>3.0.CO;2-7; HINES JD, 1989, CANCER, V63, P1022, DOI 10.1002/1097-0142(19890315)63:6+<1022::AID-CNCR2820631306>3.0.CO;2-5; HOHN DC, 1989, J CLIN ONCOL, V7, P1646, DOI 10.1200/JCO.1989.7.11.1646; HOOK CC, 1992, ANN NEUROL, V31, P262, DOI 10.1002/ana.410310306; JANIK J, 1993, J CLIN ONCOL, V11, P125, DOI 10.1200/JCO.1993.11.1.125; KEMENY N, 1987, ANN INTERN MED, V107, P459, DOI 10.7326/0003-4819-107-4-459; KEYOMARSI K, 1986, CANCER RES, V46, P5229; KOVACH JS, 1992, J NATL CANCER I, V84, P515, DOI 10.1093/jnci/84.7.515; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; LAURIE JA, 1989, J CLIN ONCOL, V7, P1447, DOI 10.1200/JCO.1989.7.10.1447; LOEHRER PJ, 1988, J CLIN ONCOL, V6, P642, DOI 10.1200/JCO.1988.6.4.642; LOKICH JJ, 1989, J CLIN ONCOL, V7, P425, DOI 10.1200/JCO.1989.7.4.425; MACHOVER D, 1992, J NATL CANCER I, V84, P321, DOI 10.1093/jnci/84.5.321; MAHOOD DJ, 1991, J CLIN ONCOL, V9, P449, DOI 10.1200/JCO.1991.9.3.449; MARTIN JK, 1990, ARCH SURG-CHICAGO, V125, P1022; MOERTEL C, 1992, P AN M AM SOC CLIN, V11, P161; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MOERTEL CG, 1969, LANCET, V2, P865; MOERTEL CG, 1993, J CLIN ONCOL, V11, P2386, DOI 10.1200/JCO.1993.11.12.2386; OCONNELL M, 1993, P AN M AM SOC CLIN, V12, P190; OCONNELL M, 1991, P AN M AM SOC CLIN, V10, P134; OCONNELL M, 1993, P AN M AM SOC CLIN, V12, P193; PARK JG, 1988, J NATL CANCER I, V80, P1560, DOI 10.1093/jnci/80.19.1560; PETRELLI N, 1987, J CLIN ONCOL, V5, P1559, DOI 10.1200/JCO.1987.5.10.1559; PETRELLI N, 1989, J CLIN ONCOL, V7, P1419, DOI 10.1200/JCO.1989.7.10.1419; POON MA, 1989, J CLIN ONCOL, V7, P1407, DOI 10.1200/JCO.1989.7.10.1407; POON MA, 1991, J CLIN ONCOL, V9, P1967, DOI 10.1200/JCO.1991.9.11.1967; ROUGIER P, 1992, J CLIN ONCOL, V10, P1112, DOI 10.1200/JCO.1992.10.7.1112; Rustum Y M, 1987, NCI Monogr, P165; STEVENSON HC, 1991, J CLIN ONCOL, V9, P2052, DOI 10.1200/JCO.1991.9.11.2052; STRAW JA, 1984, CANCER RES, V44, P3114; TAYLOR I, 1985, BRIT J SURG, V72, P359, DOI 10.1002/bjs.1800720509; VIETTI T, 1971, JNCI-J NATL CANCER I, V47, P865; WEINERMAN B, 1990, P AN M AM SOC CLIN, V9, P103; WINDLE R, 1987, BRIT J SURG, V74, P569, DOI 10.1002/bjs.1800740707; WOLMARK N, 1988, JNCI-J NATL CANCER I, V80, P30, DOI 10.1093/jnci/80.1.30; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879; WOLMARK N, 1990, J CLIN ONCOL, V8, P1466, DOI 10.1200/JCO.1990.8.9.1466; WOOLLEY PV, 1992, J CLIN ONCOL, V10, P549; YORK M, 1993, P AN M AM SOC CLIN, V12, P200; ZANIBONI A, 1993, P AN M AM SOC CLIN, V12, P191; 1969, ADV GASTROINTESTINAL, P73; 1990, J CLIN ONCOL, V8, P185; 1984, NEW ENGL J MED, V310, P737	69	380	403	2	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 21	1994	330	16					1136	1142						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF699	8133857				2022-12-28	WOS:A1994NF69900008
J	SAXMAN, S; PORTMAN, RA				SAXMAN, S; PORTMAN, RA			ACID-FAST ORGANISMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									UNIV OKLAHOMA,OKLAHOMA CITY,OK 73104	University of Oklahoma System; University of Oklahoma Health Sciences Center	SAXMAN, S (corresponding author), INDIANA UNIV,SCH MED,INDIANAPOLIS,IN 46202, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 14	1994	330	15					1055	1055						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF022	8127334				2022-12-28	WOS:A1994NF02200006
J	WADDLE, DM				WADDLE, DM			MATRIX CORRELATION TESTS SUPPORT A SINGLE ORIGIN FOR MODERN HUMANS	NATURE			English	Article							HOMINID BURIAL SITE; ESR DATES; ISRAEL; EVOLUTION	THE debate over human origins has focused on two competing theories. The single African origin model holds that anatomically modern Homo sapiens evolved in Africa 100,000-200,000 years ago. Members of this population migrated out of Africa, replacing archaic human groups through Asia and Europe, with racial differentiation occurring within the past 100,000 years1-3. The alternative regional continuity model proposes continuous evolution over the past million years, with racial variation developing early, and similar modern human traits developing in all regions as the result of worldwide gene flow4-6. The persistence of specific morphological features within regions over the past million years supports regional continuity, whereas the identification of anatomically modern fossil specimens from Africa and the Levant 50-60,000 years before they are found elsewhere, provides support for a single origin. I give here the first quantitative test of the fossil evidence for each of these models. Results support a single African and/or Levantine origin for modern humans.	SUNY STONY BROOK,DOCTORAL PROGRAM ANTHROPOL SCI,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								Clarke R.J., 1985, P301; Cooke HBS, 1945, MAN, V45, P6, DOI 10.2307/2793006; DELSON E, 1988, NATURE, V332, P206, DOI 10.1038/332206a0; GRUN R, 1991, ARCHAEOMETRY, V33, P153, DOI 10.1111/j.1475-4754.1991.tb00696.x; GRUN R, 1990, NATURE, V344, P537, DOI 10.1038/344537a0; HAY RL, 1987, RESULTS LAETOLI EXPE, P23; Howells W. W., 1973, PAPERS PEABODY MUSEU, V67; Leakey M. D., 1982, HOMO ERECTUS PLACE H, P753; MANTEL N, 1967, CANCER RES, V27, P209; MERCIER N, 1993, J ARCHAEOL SCI, V20, P169, DOI 10.1006/jasc.1993.1012; SCHWARCZ HP, 1988, J HUM EVOL, V17, P733, DOI 10.1016/0047-2484(88)90063-2; SMOUSE PE, 1992, YEARB PHYS ANTHROPOL, V35, P187; Sneath P.H.A., 1973, NUMERICAL TAXONOMY; SOKAL RR, 1991, NATURE, V351, P143, DOI 10.1038/351143a0; STRINGER C, 1988, SCIENCE, V241, P773, DOI 10.1126/science.241.4867.773; Stringer C.B., 1985, P289; STRINGER CB, 1989, NATURE, V338, P756, DOI 10.1038/338756a0; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; THORNE AG, 1992, SCI AM, V266, P76, DOI 10.1038/scientificamerican0492-76; VALLADAS H, 1988, NATURE, V331, P614, DOI 10.1038/331614a0; Vandermeersch B., 1985, P306; Vandermeersch B., 1981, HOMMES FOSSILES QAFZ; WADDLE DM, 1993, THESIS STATE U NEW Y; WOLPOFF MH, 1988, SCIENCE, V241, P772, DOI 10.1126/science.3136545; WOLPOFF MH, 1989, HUMAN REVOLUTION, P62	25	75	76	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 31	1994	368	6470					452	454		10.1038/368452a0	http://dx.doi.org/10.1038/368452a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ND120	8133890				2022-12-28	WOS:A1994ND12000062
J	SEBZDA, E; WALLACE, VA; MAYER, J; YEUNG, RSM; MAK, TW; OHASHI, PS				SEBZDA, E; WALLACE, VA; MAYER, J; YEUNG, RSM; MAK, TW; OHASHI, PS			POSITIVE AND NEGATIVE THYMOCYTE SELECTION INDUCED BY DIFFERENT CONCENTRATIONS OF A SINGLE PEPTIDE	SCIENCE			English	Article							CYTOTOXIC LYMPHOCYTES-T; CELL ANTIGEN RECEPTOR; CLONAL DELETION; THYMIC SELECTION; TRANSGENIC MICE; TOLERANCE INDUCTION; MHC; CD8; COMPLEX; MOLECULES	T lymphocyte maturation is dependent on interactions between the T cell receptor (TCR) expressed on the developing thymocyte and intrathymic major histocompatibility complex (MHC)-peptide ligands. The relation between the peptide-MHC complex that results in negative or positive selection has not been identified. Here, the requirements for the maturation of thymocytes expressing a defined transgenic TCR specific for a viral peptide are studied in fetal thymic organ culture. Low concentrations of the viral peptide antigen recognized by this transgenic TCR can mediate positive selection, whereas high concentrations result in thymocyte tolerance. These findings support the affinity-avidity model of thymocyte selection.	ONTARIO CANC INST, DEPT MED BIOPHYS, TORONTO M4X 1K9, ON, CANADA; ONTARIO CANC INST, DEPT IMMUNOL, TORONTO M4X 1K9, ON, CANADA; AMGEN INST, TORONTO M4X 1K9, ON, CANADA; AMGEN INC, BOULDER, CO 80301 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Amgen				Ohashi, Pamela S./0000-0003-2915-9317				ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; APASOV S, 1993, P NATL ACAD SCI USA, V90, P2837, DOI 10.1073/pnas.90.7.2837; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DAVIS MM, 1990, ANNU REV BIOCHEM, V59, P475, DOI 10.1146/annurev.biochem.59.1.475; FINK PJ, 1978, J EXP MED, V148, P766, DOI 10.1084/jem.148.3.766; FUNGLEUNG WP, 1993, EUR J IMMUNOL, V23, P212, DOI 10.1002/eji.1830230133; GLAS R, 1992, P NATL ACAD SCI USA, V89, P11381, DOI 10.1073/pnas.89.23.11381; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; HUGO P, 1993, IMMUNOL REV, V135, P133, DOI 10.1111/j.1600-065X.1993.tb00647.x; KAYE J, 1992, J IMMUNOL, V148, P3342; KILEEN N, 1992, J EXP MED, V176, P89; KNOBLOCH M, 1992, INT IMMUNOL, V4, P1169, DOI 10.1093/intimm/4.10.1169; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; MARRACK P, 1993, J EXP MED, V178, P2173, DOI 10.1084/jem.178.6.2173; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; OHASHI PS, 1993, INT IMMUNOL, V5, P131, DOI 10.1093/intimm/5.2.131; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PIRCHER H, 1993, EUR J IMMUNOL, V23, P669, DOI 10.1002/eji.1830230315; PIRCHER H, 1992, EUR J IMMUNOL, V22, P399, DOI 10.1002/eji.1830220217; PIRCHER H, 1992, INT IMMUNOL, V4, P1065, DOI 10.1093/intimm/4.9.1065; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; ROBEY EA, 1992, CELL, V69, P1089, DOI 10.1016/0092-8674(92)90631-L; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SHA WC, 1989, NATURE, V341, P746; SHERMAN LA, 1992, SCIENCE, V258, P815, DOI 10.1126/science.1439792; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; Singer A., 1986, PROG IMMUNOL, V6, P60; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; VASQUEZ NJ, 1992, J EXP MED, V175, P1307, DOI 10.1084/jem.175.5.1307; YAGI J, 1990, INT IMMUNOL, V2, P83, DOI 10.1093/intimm/2.1.83; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882; ZUNIGAPFLUCKER JC, 1989, J EXP MED, V169, P2085, DOI 10.1084/jem.169.6.2085	48	471	482	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 18	1994	263	5153					1615	1618		10.1126/science.8128249	http://dx.doi.org/10.1126/science.8128249			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	8128249				2022-12-28	WOS:A1994NB67300033
J	PHILLIPS, KA; LOWE, RA; KAHN, JG; LURIE, P; AVINS, AL; CICCARONE, D				PHILLIPS, KA; LOWE, RA; KAHN, JG; LURIE, P; AVINS, AL; CICCARONE, D			THE COST-EFFECTIVENESS OF HIV TESTING OF PHYSICIANS AND DENTISTS IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE WORKERS; PERFORMING INVASIVE PROCEDURES; DENTAL PROFESSIONALS; SURGICAL-PROCEDURES; OPERATING-ROOM; BLOOD CONTACT; INFECTION; RISK; AIDS	Objective.-To evaluate the cost-effectiveness of alternative policies for human immunodeficiency testing (HIV) testing of physicians and dentists. Methods.-Decision analysis and cost-effectiveness analysis from a societal perspective were used. Data were derived from extensive literature review and consultation with experts. We conducted sensitivity analyses and also performed a cost-benefit analysis. Analyses.-We analyzed policies for mandatory or voluntary testing of all physicians, surgeons, and dentists; for those testing positive, we analyzed mandatory or voluntary exclusion from practice, restriction from performance of invasive procedures, or requirements to inform patients of serostatus. Main Outcome Measure.-Cost per patient infection averted. Results.-Although one-time mandatory testing of surgeons and dentists with mandatory restriction of those found to be HIV-positive is more cost-effective than other policies, the cost-effectiveness varies tremendously under different scenarios. Results were highly sensitive to several data inputs, especially HIV seroprevalence of surgeons and dentists and transmission risk. For example, under a medium seroprevalence and transmission risk scenario, mandatory testing of all surgeons might avert 25 infections at a total cost of $27.9 million or $1 115 000 per infection averted and an incremental cost of $291 000 compared with current testing; however, the incremental cost-effectiveness per patient infection averted ranges from $29 807 000 under a low-risk scenario to a savings of $81 000 under a high-risk scenario. Conclusion.-Our analysis neither justifies nor precludes a mandatory testing policy. Further research on the key data inputs is needed. Given the ethical, social, and public health implications, mandatory testing policies should not be implemented without greater certainty as to their cost-effectiveness.	UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DIV GEN INTERNAL MED,SAN FRANCISCO,CA; UNIV CALIF BERKELEY,CTR STUDENT HLTH,BERKELEY,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California Berkeley	PHILLIPS, KA (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,CTR AIDS PREVENT STUDIES,PREVENT SCI GRP,SAN FRANCISCO,CA 94143, USA.		Lowe, Robert A/A-4926-2008; Ciccarone, Daniel/I-5404-2013	Lowe, Robert A/0000-0002-4732-9634; Ciccarone, Daniel/0000-0002-2355-5477	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U01HS007373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019105, P50MH042459] Funding Source: NIH RePORTER; AHRQ HHS [HSO7373-01] Funding Source: Medline; NIMH NIH HHS [MH19105-02, P50 MH42459] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		[Anonymous], 1990, MMWR MORB MORTAL WKL, V39, P380; [Anonymous], 1989, GUIDE CLIN PREVENTIV; ARMSTRONG FP, 1987, MIL MED, V152, P414; ARNO PS, 1991, SEP IMP REG GUID LEG; BARTLETT JG, 1992, INFECT DIS CLIN PRAC, V1, P11; BELL DM, 1992, INFECT AGENTS DIS, V1, P253; BIDDLECOM AE, 1992, J ACQ IMMUN DEF SYND, V5, P1131; BOWLEG L, 1992, INTERGOVERNMENTA JUN, P1; CHAMBERLAND ME, 1991, JAMA-J AM MED ASSOC, V266, P3459, DOI 10.1001/jama.266.24.3459; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; CLEARY PD, 1987, JAMA-J AM MED ASSOC, V258, P1757, DOI 10.1001/jama.258.13.1757; COLOMBOTOS J, 1991, PHYSICIANS NURSES AI; COWAN DN, 1991, JAMA-J AM MED ASSOC, V265, P2826, DOI 10.1001/jama.265.21.2826; DANILA RN, 1991, NEW ENGL J MED, V325, P1406, DOI 10.1056/NEJM199111143252003; DICKINSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1802, DOI 10.1001/jama.269.14.1802; FLYNN NM, 1987, WESTERN J MED, V146, P439; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GERBERDING JL, 1991, INFECT CONT HOSP EP, V12, P443, DOI 10.1086/646376; GERBERT B, 1993, ARCH INTERN MED, V153, P313, DOI 10.1001/archinte.153.3.313; GRUNINGER SE, 1992, J AM DENT ASSOC, V123, P57, DOI 10.14219/jada.archive.1992.0075; HARDY AM, 1991, ADV DATA VITAL HLTH, V204; HEDLUND K, 1990, 6TH INT C AIDS SAN F; HELLINGER FJ, 1992, INQUIRY-J HEALTH CAR, V29, P356; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HENDERSON DK, 1990, PRINCIPLES PRACTICE, P2221; HOLLENBERG J, 1989, SMLTREE 2 90 VERSION; HOLTGRAVE DR, 1993, ARCH INTERN MED, V153, P1225, DOI 10.1001/archinte.153.10.1225; HUSSAIN SA, 1988, BRIT J SURG, V75, P324; KAHN JG, 1992, UPDATED ESTIMATES IM; KELLEY PW, 1990, AM J PUBLIC HEALTH, V80, P405, DOI 10.2105/AJPH.80.4.405; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; KRAHN M, 1993, MED CARE, V31, P403, DOI 10.1097/00005650-199305000-00003; LETTAU LA, 1992, INFECT CONT HOSP EP, V13, P336, DOI 10.1086/646541; MARGOLIS TE, 1992, J LEGAL MED, V13, P357, DOI 10.1080/01947649209510888; MCKAY NL, 1991, INQUIRY-J HEALTH CAR, V28, P236; MIIKE L, 1991, HIV HLTH CARE WORKPL; MISHU B, 1993, JAMA-J AM MED ASSOC, V269, P1843, DOI 10.1001/jama.269.14.1843; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; PANLILIO AL, 1990, 6TH INT C AIDS SAN F; PETERSEN LR, 1990, AM J PUBLIC HEALTH, V80, P1087, DOI 10.2105/AJPH.80.9.1087; POPEJOY SL, 1991, SURG GYNECOL OBSTET, V172, P480; QUEBBEMAN EJ, 1991, ANN SURG, V214, P614, DOI 10.1097/00000658-199111000-00012; RAYHAWK P, 1991, INTERGOVERNMENTA DEC, P4; REYNOLDS RA, 1985, SOCIOECONOMIC CHARAC; ROBERT L, 1993, PROGRAM ABSTRACTS SO; ROGERS AS, 1993, JAMA-J AM MED ASSOC, V269, P1795, DOI 10.1001/jama.269.14.1795; RUSSO G, 1992, INFECT CONT HOSP EP, V13, P107, DOI 10.1086/646482; SCHATZ B, 1991, AIDS PUBLIC POLICY J, V7, P71; SCHOCHETMAN G, 1989, ANNU REV MICROBIOL, V43, P629; SCHOCHETMAN G, 1992, AIDS TESTING METHODO; SCHWARTZ JS, 1988, JAMA-J AM MED ASSOC, V259, P2574, DOI 10.1001/jama.259.17.2574; SCHWARTZ JS, 1990, JAMA-J AM MED ASSOC, V264, P1704, DOI 10.1001/jama.264.13.1704; SIEW C, 1992, Journal of the American Dental Association, V123, P37; SLOAND EM, 1991, JAMA-J AM MED ASSOC, V266, P2861, DOI 10.1001/jama.266.20.2861; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V268, P489, DOI 10.1001/jama.268.4.489; TURNOCK BJ, 1989, JAMA-J AM MED ASSOC, V261, P3415, DOI 10.1001/jama.261.23.3415; VERRUSIO AC, 1989, J AM DENT ASSOC, V118, P553, DOI 10.14219/jada.archive.1989.0082; VONREYN CF, 1993, JAMA-J AM MED ASSOC, V269, P1807, DOI 10.1001/jama.269.14.1807; 1991, MMWR MORB MORTAL WKL, V40, P1; 1991, REVISED RECOMENDATIO; 1991, ESTIMATES RISK ENDEM; 1990, MMWR MORB MORTAL WKL, V39, P117; 1989, GUIDELINES PREVENTIO; 1991, HIV SCREENING PREGNA; 1992, PHYSICIAN CHARACTERI; 1993, MMWR MORB MORTAL WKL, V42, P329; 1992, STATISTICAL ABSTRACT; 1990, MMWR MORB MORTAL WKL, V39, P110; 1992, PREVENTING HIV TRANS; 1987, DISTRIBUTION DENTIST; 1990, SURVEY DENTAL PRACTI; 1991, MMWR MORB MORTAL WKL, V40, P377	74	28	29	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					851	858		10.1001/jama.271.11.851	http://dx.doi.org/10.1001/jama.271.11.851			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MZ498	8114240				2022-12-28	WOS:A1994MZ49800032
J	CARPENTER, WT; BUCHANAN, RW				CARPENTER, WT; BUCHANAN, RW			SCHIZOPHRENIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POSTERIOR PARIETAL CORTEX; CEREBRAL BLOOD-FLOW; FIRST-RANK SYMPTOMS; TERM FOLLOW-UP; BASAL GANGLIA; PRENATAL EXPOSURE; NEGATIVE SYMPTOMS; MONOZYGOTIC TWINS; PARAHIPPOCAMPAL GYRUS; ADULT SCHIZOPHRENIA				CARPENTER, WT (corresponding author), UNIV MARYLAND, MARYLAND PSYCHIAT RES CTR, SCH MED, POB 21247, BALTIMORE, MD 21228 USA.				NIMH NIH HHS [MHCNS44211, MHCRC40279] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH040279, P50MH040279, P50MH044211] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; ALTSHULER LL, 1990, ARCH GEN PSYCHIAT, V47, P1029; ALTSHULER LL, 1991, ARCH GEN PSYCHIAT, V48, P482; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P943; ANGST J, 1988, SCHIZOPHRENIA BULL, V14, P501, DOI 10.1093/schbul/14.4.501; [Anonymous], 1988, NATURE, V336, P95, DOI 10.1038/336095a0; ANTHONY WA, 1986, SCHIZOPHRENIA BULL, V12, P542, DOI 10.1093/schbul/12.4.542; ARNDT S, 1991, BRIT J PSYCHIAT, V158, P317, DOI 10.1192/bjp.158.3.317; BACHRACH L, 1989, SURVIVAL STRATEGIES, P9; Bachrach L. L., 1992, TREATING HOMELESS ME, P13; BALDESSARINI RJ, 1991, NEW ENGL J MED, V324, P746; Barnes T R, 1990, Mod Probl Pharmacopsychiatry, V24, P43; BARR CE, 1990, ARCH GEN PSYCHIAT, V47, P869; BARTA PE, 1990, AM J PSYCHIAT, V147, P1457; BASSETT AS, 1988, LANCET, V1, P799; BENES FM, 1987, ARCH GEN PSYCHIAT, V44, P608; Bleuler E., 1950, DEMENTIA PRAECOX; BOGERTS B, 1993, SCHIZOPHRENIA BULL, V19, P431, DOI 10.1093/schbul/19.2.431; BOGERTS B, 1993, BIOL PSYCHIAT, V33, P236, DOI 10.1016/0006-3223(93)90289-P; BOGERTS B, 1990, PSYCHIAT RES-NEUROIM, V35, P1; BOGERTS B, 1985, ARCH GEN PSYCHIAT, V42, P784; BOYD JH, 1986, SCHIZOPHRENIA BULL, V12, P173, DOI 10.1093/schbul/12.2.173; BRACHA HS, 1992, AM J PSYCHIAT, V149, P1355; BRADY JP, 1984, AM J PSYCHIAT, V141, P491; BREIER A, 1992, ARCH GEN PSYCHIAT, V49, P921; BREIER A, 1991, ADV NEUROPSYCHIATRY, V1, P141; BROWN R, 1986, ARCH GEN PSYCHIAT, V43, P36; BUCHANAN RW, 1993, AM J PSYCHIAT, V150, P59; BUCHANAN RW, 1990, AM J PSYCHIAT, V147, P290; BUCHSBAUM MS, 1992, ARCH GEN PSYCHIAT, V49, P935; CARLSSON A, 1988, NEUROPSYCHOPHARMACOL, V1, P179, DOI 10.1016/0893-133X(88)90012-7; CARLSSON A, 1963, ACTA PHARMACOL TOX, V20, P140; CARLSSON M, 1990, TRENDS NEUROSCI, V13, P272, DOI 10.1016/0166-2236(90)90108-M; Carpenter W, 1989, SCHIZOPHRENIA SCI FO, P13; CARPENTER WT, 1979, SCHIZOPHRENIA BULL, V5, P490, DOI 10.1093/schbul/5.3.490; CARPENTER WT, 1988, SCHIZOPHRENIA BULL, V14, P645, DOI 10.1093/schbul/14.4.645; CARPENTER WT, 1993, ARCH GEN PSYCHIAT, V50, P825; CARPENTER WT, 1990, AM J PSYCHIAT, V147, P1138; CARPENTER WT, 1991, ARCH GEN PSYCHIAT, V48, P69; CARPENTER WT, 1991, AM J PSYCHIAT, V148, P819; CARPENTER WT, 1973, ARCH GEN PSYCHIAT, V28, P847; CARPENTER WT, 1974, AM J PSYCHIAT, V131, P682; CAVADA C, 1989, J COMP NEUROL, V287, P393, DOI 10.1002/cne.902870402; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; CHRISTISON GW, 1991, SCHIZOPHRENIA BULL, V17, P217, DOI 10.1093/schbul/17.2.217; COLTER N, 1987, ARCH GEN PSYCHIAT, V44, P1023; CROW TJ, 1988, BRIT J PSYCHIAT, V153, P675, DOI 10.1192/bjp.153.5.675; CROW TJ, 1992, BRIT J PSYCHIAT, V161, P390, DOI 10.1192/bjp.161.3.390; DAVIS JM, 1975, AM J PSYCHIAT, V132, P1237; DAVIS KL, 1991, AM J PSYCHIAT, V148, P1474; DELISI LE, 1991, BIOL PSYCHIAT, V29, P159, DOI 10.1016/0006-3223(91)90044-M; DELISI LE, 1991, BIOL PSYCHIAT, V29, P519; DONALDSON SR, 1983, SCHIZOPHRENIA BULL, V9, P504, DOI 10.1093/schbul/9.4.504; DWORKIN RH, 1988, AM J PSYCHIAT, V145, P1077; ERLENMEYERKIMLING L, 1987, J PSYCHIAT RES, V21, P401, DOI 10.1016/0022-3956(87)90087-2; FALLOON IRH, 1982, NEW ENGL J MED, V306, P1437, DOI 10.1056/NEJM198206173062401; GLAZER WM, 1992, J CLIN PSYCHIAT, V53, P426; GOLDSTEIN MJ, 1978, ARCH GEN PSYCHIAT, V35, P1169; GOMES UCR, 1980, BRIT J PSYCHIAT, V137, P346, DOI 10.1192/bjp.137.4.346; GRATZ SS, 1992, PROG NEURO-PSYCHOPH, V16, P425, DOI 10.1016/0278-5846(92)90051-F; HARDING CM, 1988, SCHIZOPHRENIA BULL, V14, P633, DOI 10.1093/schbul/14.4.633; HERZ MI, 1991, ARCH GEN PSYCHIAT, V48, P333; HOGARTY GE, 1986, ARCH GEN PSYCHIAT, V43, P633; Howells John G., 1991, CONCEPT SCHIZOPHRENI; JAKOB H, 1986, J NEURAL TRANSM, V65, P303, DOI 10.1007/BF01249090; JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301; JERNIGAN TL, 1991, ARCH GEN PSYCHIAT, V48, P881; JESTE DV, 1989, ARCH GEN PSYCHIAT, V46, P1019; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KANE JM, 1993, SCHIZOPHRENIA BULL, V19, P287, DOI 10.1093/schbul/19.2.287; KAUFMANN CA, 1988, RECEPTORS LIGANDS PS, P187; KAY SR, 1990, SCHIZOPHRENIA BULL, V16, P537, DOI 10.1093/schbul/16.3.537; KEMALI D, 1982, BIOL PSYCHIAT, V17, P711; KENDLER KS, 1986, AM J PSYCHIAT, V143, P1098; KENDLER KS, 1988, RELATIVES RISK MENTA, P247; KENNEDY JL, 1988, NATURE, V336, P167, DOI 10.1038/336167a0; KIRKPATRICK B, 1989, J NERV MENT DIS, V177, P52, DOI 10.1097/00005053-198901000-00009; KOVELMAN JA, 1984, BIOL PSYCHIAT, V19, P1601; Kraepelin E., 1919, CUTTING SHEPHERD; LEFF J, 1982, BRIT J PSYCHIAT, V141, P121, DOI 10.1192/bjp.141.2.121; Leff J., 1985, EXPRESSED EMOTION FA; LENZENWEGER MF, 1991, SCHIZOPHRENIA BULL, V17, P515, DOI 10.1093/schbul/17.3.515; LEWIS SW, 1987, J PSYCHIAT RES, V21, P413, DOI 10.1016/0022-3956(87)90088-4; LIDDLE PF, 1987, BRIT J PSYCHIAT, V151, P145, DOI 10.1192/bjp.151.2.145; LIDDLE PF, 1992, BRIT J PSYCHIAT, V160, P179, DOI 10.1192/bjp.160.2.179; LIN KM, 1988, SCHIZOPHRENIA BULL, V14, P555, DOI 10.1093/schbul/14.4.555; LINGJAERDE O, 1991, ACTA PSYCHIAT SCAND, V84, P453, DOI 10.1111/j.1600-0447.1991.tb03177.x; MAAS JW, 1993, NEUROPSYCHOPHARMACOL, V8, P97, DOI 10.1038/npp.1993.11; MARCUS J, 1985, ARCH GEN PSYCHIAT, V42, P753; MARCUS J, 1981, ARCH GEN PSYCHIAT, V38, P703; MCGLASHAN TH, 1988, SCHIZOPHRENIA BULL, V14, P515, DOI 10.1093/schbul/14.4.515; MEDNICK SA, 1988, ARCH GEN PSYCHIAT, V45, P189, DOI 10.1001/archpsyc.1988.01800260109013; Mueser K. T., 1990, RECENT ADV SCHIZOPHR, P213; NEMEROFF CB, 1987, PSYCHOPHARMACOLOGY 3, P727; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; PICKAR D, 1992, ARCH GEN PSYCHIAT, V49, P345; POPE HG, 1978, ARCH GEN PSYCHIAT, V35, P811; REYNOLDS GP, 1983, NATURE, V305, P527, DOI 10.1038/305527a0; REYNOLDS GP, 1987, DEV PSYCHIATRY, V8, P61; ROBERTSON HA, 1991, CAN J NEUROL SCI, V18, P380, DOI 10.1017/S0317167100032480; Rosenthal D., 1970, GENETIC THEORY ABNOR; Rotrosen J., 1987, PSYCHOPHARMACOLOGY 3, P759; RUPP A, 1993, PSYCHIAT CLIN N AM, V16, P413; SCHOOLER NR, 1990, HDB SCHIZOPHRENIA, V4, P45; SCOTT J, 1993, BRIT J PSYCHIAT, V162, P314, DOI 10.1192/bjp.162.3.314; SHAM PC, 1992, BRIT J PSYCHIAT, V160, P461, DOI 10.1192/bjp.160.4.461; SHELTON RC, 1987, PSYCHOPHARMACOLOGY 3, P773; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; SHERRINGTON R, 1988, NATURE, V336, P164, DOI 10.1038/336164a0; SIRIS SG, 1987, ARCH GEN PSYCHIAT, V44, P533; STERNBERG DE, 1982, ARCH GEN PSYCHIAT, V39, P285; STEVENS JR, 1973, ARCH GEN PSYCHIAT, V29, P177; STONE MH, 1991, CONCEPT SCHIZOPHRENI, P125; STRABE ER, 1992, SCHIZOPHRENIA EMPIRI, P385; STRAUBE ER, 1992, SCHIZOPHRENIA EMPIRI, P361; STRAUSS J S, 1974, Schizophrenia Bulletin, V11, P61; STRAUSS JS, 1977, SCHIZOPHRENIA BULL, V3, P182, DOI 10.1093/schbul/3.2.182; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; SUDDATH RL, 1989, AM J PSYCHIAT, V146, P464; SUDDATH RL, 1990, NEW ENGL J MED, V322, P1616; SUSSER ES, 1992, ARCH GEN PSYCHIAT, V49, P983; SWAYZE VW, 1992, BIOL PSYCHIAT, V31, P221, DOI 10.1016/0006-3223(92)90046-3; TAMMINGA CA, 1992, ARCH GEN PSYCHIAT, V49, P522; TARSY D, 1973, NATURE-NEW BIOL, V245, P262, DOI 10.1038/newbio245262a0; THAKER GK, 1987, ARCH GEN PSYCHIAT, V44, P522; TIENARI P, 1991, SCHIZOPHRENIA YOUTH, P42; TORREY EF, 1992, SCHIZOPHR RES, V6, P100, DOI 10.1016/0920-9964(92)90107-G; Van Kammen DP, 1987, PSYCHOPHARMACOLOGY 3, P745; VANKAMMEN DP, 1990, ARCH GEN PSYCHIAT, V47, P161; VANKAMMEN DP, 1987, PSYCHOPHARMACOLOGY 3, P753; VOLKOW ND, 1987, AM J PSYCHIAT, V144, P151; WALKER EF, IN PRESS AM J PSYCHI; WALTRIP RW, 1990, J NERV MENT DIS, V178, P729, DOI 10.1097/00005053-199012000-00001; WEINBERGER DR, 1992, AM J PSYCHIAT, V149, P890; WEINBERGER DR, 1987, ARCH GEN PSYCHIAT, V44, P660, DOI 10.1001/archpsyc.1987.01800190080012; WEINBERGER DR, 1982, SCHIZOPHRENIA BRAIN, P148; WOLKIN A, 1992, ARCH GEN PSYCHIAT, V49, P959; ZUBIN J, 1977, J ABNORM PSYCHOL, V86, P103, DOI 10.1037/0021-843X.86.2.103; 1987, DIAGNOSTIC STATISTIC	140	394	400	1	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 10	1994	330	10					681	690		10.1056/NEJM199403103301006	http://dx.doi.org/10.1056/NEJM199403103301006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY575	8107719				2022-12-28	WOS:A1994MY57500006
J	MUTA, T; KUROSAKI, T; MISULOVIN, Z; SANCHEZ, M; NUSSENZWEIG, MC; RAVETCH, JV				MUTA, T; KUROSAKI, T; MISULOVIN, Z; SANCHEZ, M; NUSSENZWEIG, MC; RAVETCH, JV			A 13-AMINO-ACID MOTIF IN THE CYTOPLASMIC DOMAIN OF FC-GAMMA-RIIB MODULATES B-CELL RECEPTOR SIGNALING	NATURE			English	Article							LYMPHOCYTES-B; TYROSINE PHOSPHORYLATION; ANTIGEN RECEPTORS; ZETA-CHAIN; ACTIVATION; HETEROGENEITY; IMMUNOGLOBULIN; COMPLEX; TAIL; BETA	THE FC receptor on B lymphocytes, Fc gamma RIIB (beta 1 isoform), helps to modulate B-cell activation triggered by the surface immuno-globulin complex(1,2). Crosslinking of membrane immunoglobulin by antigen or anti-IG F(ab')(2) antibody induces a transient increase in cytosolic free Ca2+, a rise in inositol-3-phosphate, activation of protein kinase C, and enhanced protein tyrosine phosphorylation(3-5). Crosslinking Fc gamma RIIB with the surface immunoglobulin complex confers a dominant signal that prevents or aborts lymphocyte activation triggered through the ARH-1 motifs of the signal transduction subunits Ig-alpha and Ig-beta. Here we show that Fc gamma RIIB modulates membrane immunoglobulin-induced Ca2+ mobilization by; inhibiting Ca2+ influx, without changing the pattern of tyrosine phosphorylation. A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB is both necessary and sufficient for this effect. Tyrosine at residue 309 in this motif is phosphorylated upon co-crosslinking with surface immunoglobulin; mutation of this residue aborts the inhibitory effect of Fc gamma RIIB. This inhibition is directly coupled to signalling mediated through Ig-alpha and Ig-beta as evidenced by chimaeric IgM/alpha and IgM/beta molecules. The 13-residue motif in Fc gamma RIIB controls lymphocyte activation by inhibiting a Ca2+ signalling pathway triggered through ARH-1 motifs as a result of recruitment of novel SH2-containing proteins that interact with this Fc gamma RIIB cytoplasmic motif.	ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	Rockefeller University	MUTA, T (corresponding author), SLOAN KETTERING INST, DEWITT WALLACE RES LAB, 1275 YORK AVE, NEW YORK, NY 10021 USA.		Kurosaki, Tomohiro/D-1306-2009; Nussenzweig, Michel/AAE-7292-2019; Ravetch, Jeffrey/Z-1596-2019	Kurosaki, Tomohiro/0000-0002-6352-304X; Ravetch, Jeffrey/0000-0003-2024-9041				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; DESIDERIO SV, 1992, CURR OPIN IMMUNOL, V4, P252, DOI 10.1016/0952-7915(92)90073-N; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; HUNZIKER W, 1990, NATURE, V345, P628, DOI 10.1038/345628a0; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JONES B, 1986, J IMMUNOL, V136, P348; KAMEYAMA M, 1985, PFLUG ARCH EUR J PHY, V405, P285, DOI 10.1007/BF00582573; KOLANUS W, 1992, EMBO J, V11, P4861, DOI 10.1002/j.1460-2075.1992.tb05592.x; LAI MZ, 1987, J IMMUNOL, V139, P3973; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MELLMAN I, 1988, CURR OPIN IMMUNOL, V1, P16, DOI 10.1016/0952-7915(88)90046-5; RANSOM JT, 1988, J IMMUNOL, V140, P3150; RANSOM JT, 1986, J IMMUNOL, V137, P708; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WILSON HA, 1987, J IMMUNOL, V138, P1712; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	26	426	449	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 3	1994	368	6466					70	73		10.1038/368070a0	http://dx.doi.org/10.1038/368070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	8107887				2022-12-28	WOS:A1994MY56900056
J	KAFFMAN, A; HERSKOWITZ, I; TJIAN, R; OSHEA, EK				KAFFMAN, A; HERSKOWITZ, I; TJIAN, R; OSHEA, EK			PHOSPHORYLATION OF THE TRANSCRIPTION FACTOR-PHO4 BY A CYCLIN-CDK COMPLEX, PHO80-PHO85	SCIENCE			English	Article							ACID-PHOSPHATASE SYNTHESIS; REGULATORY GENE PHO4; SACCHAROMYCES-CEREVISIAE; NEGATIVE REGULATORS; PROTEIN; YEAST; EXPRESSION; SYSTEM; SEQUENCE; ACTIVATION	Induction of the yeast gene PHO5 is mediated by the transcription factors PHO2 and PHO4. PHO5 transcription is not detectable in high phosphate; it is thought that the negative regulators PHO80 and PHO85 inactivate PHO2 and PHO4. Here it is reported that PHO80 has homology to yeast cyclins and interacts with PHO85, a p34cdc2/CDC28-related protein kinase. The PHO80-PHO85 complex phosphorylates PHO4; this phosphorylation is correlated with negative regulation of PHO5. These results demonstrate the existence of a cyclin-cdk complex that is used for a regulatory process other than cell-cycle control and identify a physiologically relevant substrate for this complex.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California Berkeley								BERBEN G, 1988, GENE, V66, P307, DOI 10.1016/0378-1119(88)90367-8; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURGLIN TR, 1988, CELL, V53, P339, DOI 10.1016/0092-8674(88)90153-5; CREASY CL, 1993, NUCLEIC ACIDS RES, V21, P1975, DOI 10.1093/nar/21.8.1975; ESPINOZA FH, COMMUNICATION; FISHER F, 1991, ONCOGENE, V6, P1099; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; GILLIQUET V, 1990, GENE, V96, P181, DOI 10.1016/0378-1119(90)90251-L; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; KOREN R, 1986, GENE, V41, P271, DOI 10.1016/0378-1119(86)90107-1; LEGRAIN M, 1986, NUCLEIC ACIDS RES, V14, P3059, DOI 10.1093/nar/14.7.3059; LEMIRE JM, 1985, MOL CELL BIOL, V5, P2131, DOI 10.1128/MCB.5.8.2131; MURRAY A, 1993, CELL CYCLE INTRO, P114; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; OFARRELL P, 1991, COLD SH Q B, V56, P83; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; OGAWA N, 1993, MOL GEN GENET, V238, P444, DOI 10.1007/BF00292004; OKADA H, 1992, CURR GENET, V21, P95, DOI 10.1007/BF00318466; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RUBIN GM, 1973, J BIOL CHEM, V248, P3860; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SENGSTAG C, 1987, NUCLEIC ACIDS RES, V15, P233, DOI 10.1093/nar/15.1.233; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; Toh-e A, 1986, Yeast, V2, P129, DOI 10.1002/yea.320020209; TOHE A, 1988, MOL GEN GENET, V214, P162, DOI 10.1007/BF00340196; TOHE A, 1974, J BACTERIOL, V120, P608, DOI 10.1128/JB.120.2.608-617.1974; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; UEDA Y, 1975, J BACTERIOL, V122, P911, DOI 10.1128/JB.122.3.911-922.1975; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299; UESONO Y, 1992, MOL GEN GENET, V231, P426, DOI 10.1007/BF00292712; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YOSHIDA K, 1989, MOL GEN GENET, V217, P40, DOI 10.1007/BF00330940; YOSHIDA K, 1989, MOL GEN GENET, V217, P31, DOI 10.1007/BF00330939	36	323	333	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 25	1994	263	5150					1153	1156		10.1126/science.8108735	http://dx.doi.org/10.1126/science.8108735			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	8108735				2022-12-28	WOS:A1994MX75900037
J	HOWARD, RS; LIVELY, CM				HOWARD, RS; LIVELY, CM			PARASITISM, MUTATION ACCUMULATION AND THE MAINTENANCE OF SEX	NATURE			English	Article							RECOMBINATION; REPRODUCTION	Two classes of models attempt to explain why obligate parthenogenesis only rarely replaces sexual reproduction in natural populations, in spite of the apparent reproductive advantage that parthenogens gain by producing only female offspring1. The mutation-accumulation models suggest that sex is adaptive because it purges the genome of harmful recurrent mutations2,3. The ecological genetic models postulate that sex is adaptive in variable environments, particularly when the relevant variation is generated by coevolutionary interactions with parasites4-7. Both of these models have considerable merit, but would seem to have limitations. The mutation-accumulation models require high rates of mutation3,8; the coevolutionary models require that parasites have severe fitness effects on their hosts9. In addition, parasites could select for clonal diversity and thereby erode any advantage that sex gains by producing variable progeny10. Here we consider the interaction between mutation accumulation and host-parasite cevolution. The results suggest that even moderate effects by parasites combined with reasonable rates of mutation could render sex evolutionarily stable against repeated invasion by clones.			HOWARD, RS (corresponding author), INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405, USA.		Howard, Robert/O-3137-2017; Lively, Curtis M/A-8057-2011					Bell G., 1982, MASTERPIECE NATURE; CLARKE B, 1976, GENETIC ASPECTS HOST, V14, P87; FELSENSTEIN J, 1974, GENETICS, V78, P737; HAIGH J, 1978, THEOR POPUL BIOL, V14, P251, DOI 10.1016/0040-5809(78)90027-8; HAMILTON WD, 1980, OIKOS, V35, P282, DOI 10.2307/3544435; HAMILTON WD, 1990, P NATL ACAD SCI USA, V87, P3566, DOI 10.1073/pnas.87.9.3566; HOWARD RS, IN PRESS THEOR POPUL; HUTSON V, 1981, PROC R SOC SER B-BIO, V213, P345, DOI 10.1098/rspb.1981.0070; JAENIKE J, 1978, Evolutionary Theory, V3, P191; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; LEVIN DA, 1975, AM NAT, V109, P437, DOI 10.1086/283012; LIVELY CM, 1992, EVOLUTION, V46, P907, DOI [10.2307/2409745, 10.1111/j.1558-5646.1992.tb00608.x]; LYNCH M, 1990, EVOLUTION, V44, P1725, DOI 10.1111/j.1558-5646.1990.tb05244.x; MAY RM, 1983, PROC R SOC SER B-BIO, V219, P281, DOI 10.1098/rspb.1983.0075; MAYNARD SMITH J., 1978, EVOLUTION SEX; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8	16	250	252	0	78	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					554	557		10.1038/367554a0	http://dx.doi.org/10.1038/367554a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	8107824				2022-12-28	WOS:A1994MV86300057
J	MUSK, AW; SHEAN, R; WALKER, N; SWANSON, M				MUSK, AW; SHEAN, R; WALKER, N; SWANSON, M			PROGRESS ON SMOKING CONTROL IN WESTERN-AUSTRALIA	BRITISH MEDICAL JOURNAL			English	Article								In 1990, 20 years of campaigning by the Western Australian branch of the Australian Council on Smoking and Health succeeded in getting tobacco advertising banned in Western Australia and a fund set up to replace the sponsorship of sport by tobacco companies. The council coordinated the activities of the mainly professional medical organisations that formed its members, ensuring that messages about the dangers of tobacco were consistently presented from different angles. The campaigners also ensured that medical data were reworked for presentation to decision makers and public, invaded the corporate world, and minimised opposition by enlisting the support of sportspeople opposed to tobacco sponsorship. The council hopes now that elimination of advertising will reduce the prevalence of smoking.	AUSTRALIAN COUNCIL SMOKING & HLTH,SUBIACO,WA 6008,AUSTRALIA									ARMSTRONG BK, 1988, MED J AUSTRALIA, V149, P1; MUSK AW, 1985, BRIT MED J, V290, P1562, DOI 10.1136/bmj.290.6481.1562; SHEAN RE, 1988, MED J AUSTRALIA, V148, P58, DOI 10.5694/j.1326-5377.1988.tb104505.x	3	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	1994	308	6925					395	398		10.1136/bmj.308.6925.395	http://dx.doi.org/10.1136/bmj.308.6925.395			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV862	8124149	Green Published			2022-12-28	WOS:A1994MV86200026
J	JOOSTEN, MHAJ; COZIJNSEN, TJ; DEWIT, PJGM				JOOSTEN, MHAJ; COZIJNSEN, TJ; DEWIT, PJGM			HOST-RESISTANCE TO A FUNGAL TOMATO PATHOGEN LOST BY A SINGLE BASE-PAIR CHANGE IN AN AVIRULENCE GENE	NATURE			English	Article							BACTERIAL SPOT DISEASE; SYRINGAE PV GLYCINEA; CLADOSPORIUM-FULVUM; RACE; PROTEINS; AVR9	HOST genotype specificity in interactions between biotrophic pathogens and plants in most cases complies with the gene-for-gene model1; success or failure of infection is determined by absence or presence of complementary genes, avirulence and resistance genes, in the pathogen and host plant, respectively. Resistance, expressed by the induction of a hypersensitive response in the host, is envisaged to be based on recognition of the pathogen, mediated through direct interaction between products of pathogen avirulence genes (the so-called race-specific elicitors) and receptors in the host plant, the putative products of resistance genes1. The interaction between the biotrophic fungus Cladosporium fulvum and its only host, tomato (Lycopersicon esculentum), is a well-established model system for studying fungus-plant gene-for-gene relationships1. Here we report the isolation of race-specific elicitor AVR4 of C. fulvum and the cloning of its encoding avirulence gene. We present evidence that, in nature, a single base-pair change in this avirulence gene leads to virulence of races previously avirulent on tomato genotypes carrying the complementary Cf4 resistance gene.	WAGENINGEN UNIV AGR,DEPT PHYTOPATHOL,POB 8025,6700 EE WAGENINGEN,NETHERLANDS	Wageningen University & Research			Joosten, Matthieu/AAB-5150-2022; de Wit, Pierre/A-1998-2013; de Wit, Pierre J. G.M./CAI-9966-2022; Joosten, Matthieu/AAB-5131-2022	de Wit, Pierre/0000-0002-4208-288X; Joosten, Matthieu/0000-0002-6243-4547				DEWIT PJGM, 1992, ANNU REV PHYTOPATHOL, V30, P391, DOI 10.1146/annurev.py.30.090192.002135; DEWIT PJGM, 1982, PHYSIOL PLANT PATHOL, V21, P1, DOI 10.1016/0048-4059(82)90002-9; HERBERS K, 1992, NATURE, V356, P172, DOI 10.1038/356172a0; JOOSTEN MHAJ, 1990, PLANT PHYSIOL, V94, P585, DOI 10.1104/pp.94.2.585; KEARNEY B, 1988, NATURE, V332, P541, DOI 10.1038/332541a0; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KOBAYASHI DY, 1990, MOL PLANT MICROBE IN, V3, P103, DOI 10.1094/MPMI-3-103; STASKAWICZ BJ, 1984, P NATL ACAD SCI-BIOL, V81, P6024, DOI 10.1073/pnas.81.19.6024; VANDENACKERVEKEN GFJM, 1993, PLANT PHYSIOL, V103, P91, DOI 10.1104/pp.103.1.91; VANDENACKERVEKEN GFJM, 1992, PLANT J, V2, P359, DOI 10.1111/j.1365-313X.1992.00359.x; VANKAN JAL, 1992, PLANT MOL BIOL, V20, P513, DOI 10.1007/BF00040610; VANKAN JAL, 1991, MOL PLANT MICROBE IN, V4, P52, DOI 10.1094/MPMI-4-052; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	13	303	319	1	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					384	386		10.1038/367384a0	http://dx.doi.org/10.1038/367384a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	8114941				2022-12-28	WOS:A1994MT54000073
J	MORLA, A; ZHANG, ZH; RUOSLAHTI, E				MORLA, A; ZHANG, ZH; RUOSLAHTI, E			SUPERFIBRONECTIN IS A FUNCTIONALLY DISTINCT FORM OF FIBRONECTIN	NATURE			English	Article							CELL-ADHESION; METASTATIC CELLS; RECEPTOR; MATRIX; VITRONECTIN; MIGRATION; INTEGRINS; PEPTIDE; SURFACE; LAMININ	FIBRONECTIN is an extracellular matrix protein that is important in development, wound healing and tumorigenesis1-5. In the blood it is dimeric, but in tissues forms disulphide crosslinked fibrils Here we show that a fragment from the first type-III repeat of fibronectin binds to fibronectin and induces spontaneous disulphide crosslinking of the molecule into multimers of high relative molecular mass which resemble matrix fibrils. Treatment of fibronectin with this inducing fragment also converts fibronectin into a form that has greatly enhanced adhesive properties (hence the term superfibronectin) and which suppresses cell migration. Whereas cells attach to fibronectin through integrins, cell attachment to superfibronectin is mediated both by integrins and by receptors with properties distinct from those of integrins. Superfibronectin may be closely related to the natural matrix form of fibronectin.	LA JOLLA CANC RES FDN,CTR CANC,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,SCH MED,MOLEC PATHOL PROGRAM,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego								ALI IU, 1978, BIOCHIM BIOPHYS ACTA, V510, P140, DOI 10.1016/0005-2736(78)90136-0; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; FURCHT LT, 1984, CIBA F SYMP, V108, P130; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOODMAN SL, 1985, CELL, V41, P1029, DOI 10.1016/S0092-8674(85)80083-0; HYNES RO, 1977, P NATL ACAD SCI USA, V74, P2855, DOI 10.1073/pnas.74.7.2855; Hynes RO, 1990, FIBRONECTINS; KESKIOJA J, 1977, BIOCHEM BIOPH RES CO, V74, P699, DOI 10.1016/0006-291X(77)90359-X; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LACOVARA J, 1984, CANCER RES, V44, P1657; MCCARTHY JB, 1985, CANCER METAST REV, V4, P125, DOI 10.1007/BF00050692; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; MOSHER DF, 1983, J BIOL CHEM, V258, P6595; PASQUALINI R, 1993, J CELL SCI, V105, P101; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SUZUKI S, 1986, P NATL ACAD SCI USA, V83, P8614, DOI 10.1073/pnas.83.22.8614; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	26	263	275	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 13	1994	367	6459					193	196		10.1038/367193a0	http://dx.doi.org/10.1038/367193a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ780	8114919				2022-12-28	WOS:A1994MQ78000067
J	OLIVE, DL; SCHWARTZ, LB				OLIVE, DL; SCHWARTZ, LB			MEDICAL PROGRESS - ENDOMETRIOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DOSE MEDROXYPROGESTERONE ACETATE; CELL-PROLIFERATION INVITRO; PELVIC ENDOMETRIOSIS; INFERTILE WOMEN; PERITONEAL ENDOMETRIOSIS; RETROGRADE MENSTRUATION; INTRAUTERINE INSEMINATION; OVARIAN ENDOMETRIOSIS; MINIMAL ENDOMETRIOSIS; SERUM CONCENTRATIONS		YALE UNIV, SCH MED,DEPT OBSTET & GYNECOL, REPROD ENDOCRINOL & INFERTIL SECT,333 CEDAR ST, NEW HAVEN, CT 06510 USA	Yale University								ACOSTA AA, 1973, OBSTET GYNECOL, V42, P19; ADAMSON GD, 1993, FERTIL STERIL, V59, P35; [Anonymous], 1992, Fertil Steril, V57, P514; [Anonymous], 1979, Fertil Steril, V32, P633; [Anonymous], 1985, Fertil Steril, V43, P351; ANSBACHER R, 1983, CLIN PERINATOL, V10, P295, DOI 10.1016/S0095-5108(18)30967-9; ARRIVE L, 1989, RADIOLOGY, V171, P687, DOI 10.1148/radiology.171.3.2717739; BADAWY SZA, 1990, FERTIL STERIL, V53, P930; BADAWY SZA, 1984, OBSTET GYNECOL, V63, P271; BARBIERI RL, 1982, FERTIL STERIL, V37, P737; BARBIERI RL, 1986, FERTIL STERIL, V45, P630; BARBIERI RL, 1977, FERTIL STERIL, V28, P809; BARTOSIK D, 1986, FERTIL STERIL, V46, P796; BAYER SR, 1988, J REPROD MED, V33, P179; BAYER SR, 1989, ENDOMETRIOSIS CONT C, P169; BEYTH Y, 1975, FERTIL STERIL, V26, P1094; BLUMENKRANTZ MJ, 1981, OBSTET GYNECOL, V57, P667; BUTTRAM VC, 1978, FERTIL STERIL, V30, P240; BUTTRAM VC, 1982, FERTIL STERIL, V37, P478; CANDIANI GB, 1991, FERTIL STERIL, V56, P230; CHAFFKIN LM, 1991, FERTIL STERIL, V55, P252; CHATMAN DL, 1982, J REPROD MED, V27, P156; CHAUHAN M, 1989, FERTIL STERIL, V51, P815; CHONG AP, 1990, FERTIL STERIL, V53, P407; CORNILLIE FJ, 1990, FERTIL STERIL, V53, P978; CUNHA GR, 1980, BIOL REPROD, V22, P19, DOI 10.1095/biolreprod22.1.19; DENTON R O, 1955, South Med J, V48, P1027; DJURSING H, 1981, ACTA OBSTET GYN SCAN, V60, P529, DOI 10.3109/00016348109155479; DLUGI AM, 1990, FERTIL STERIL, V54, P419; DMOWSKI WP, 1981, AM J OBSTET GYNECOL, V141, P377, DOI 10.1016/0002-9378(81)90598-6; DMOWSKI WP, 1975, OBSTET GYNECOL, V46, P147; DODSON WC, 1991, FERTIL STERIL, V55, P457; DUNPHY BC, 1989, HUM REPROD, V4, P527, DOI 10.1093/oxfordjournals.humrep.a136938; DUNSELMAN GAJ, 1991, FERTIL STERIL, V56, P340; FEDELE L, 1992, FERTIL STERIL, V58, P28; FEDELE L, 1989, AM J OBSTET GYNECOL, V161, P871, DOI 10.1016/0002-9378(89)90739-4; Filatow D, 1933, ROUX ARCH DEV BIOL, V127, P776; FLOYD WS, 1980, INT J FERTIL, V25, P75; FOSTER DC, 1981, OBSTET GYNECOL, V58, P552; FRASER IS, 1991, AUST NZ J OBSTET GYN, V31, P158, DOI 10.1111/j.1479-828X.1991.tb01807.x; FRIEDMAN H, 1985, RADIOLOGY, V157, P217, DOI 10.1148/radiology.157.1.2930866; GARZA D, 1991, J REPROD MED, V36, P177; Geist SH, 1933, AM J OBSTET GYNECOL, V25, P751; GOEBEL R, 1977, ACTA ENDOCRINOL-COP, V85, P134; GOLAN A, 1989, FERTIL STERIL, V51, P747; GOLDSTEIN DP, 1980, J REPROD MED, V24, P251; GORDTS S, 1984, FERTIL STERIL, V42, P520; GUZICK DS, 1983, FERTIL STERIL, V40, P580; HALME J, 1984, OBSTET GYNECOL, V64, P151; HARTZ SC, 1991, FERTIL STERIL, V55, P14; HEIM K, 1933, ARCH GYNAK, V152, P269; HENZL MR, 1990, AM J OBSTET GYNECOL, V162, P570, DOI 10.1016/0002-9378(90)90432-7; HENZL MR, 1988, NEW ENGL J MED, V318, P485, DOI 10.1056/NEJM198802253180805; Huffman J W, 1981, Pediatr Ann, V10, P44; HULL ME, 1987, FERTIL STERIL, V47, P40; Iwanoff N, 1898, MONATSSCHR GEBURTSH, V7, P295; JANSEN RPS, 1986, FERTIL STERIL, V46, P141; JAVERT CT, 1949, CANCER, V2, P399, DOI 10.1002/1097-0142(194905)2:3<399::AID-CNCR2820020304>3.0.CO;2-L; JENKINS S, 1986, OBSTET GYNECOL, V67, P335; KAPLAN CR, 1989, AM J OBSTET GYNECOL, V160, P40, DOI 10.1016/0002-9378(89)90083-5; KAUPPILA A, 1985, OBSTET GYNECOL, V65, P379; KAUPPILA A, 1988, FERTIL STERIL, V49, P37; KEETTEL WC, 1951, AM J OBSTET GYNECOL, V61, P440, DOI 10.1016/0002-9378(51)90266-9; KEMPERS RD, 1960, SURG GYNECOL OBSTET, V111, P348; KENNEDY SH, 1990, FERTIL STERIL, V53, P998; KISTNER RW, 1977, FERTIL STERIL, V28, P1008; KONINCKX PR, 1992, FERTIL STERIL, V57, P523; KONINCKX PR, 1980, J REPROD MED, V24, P257; KONINCKX PR, 1991, FERTIL STERIL, V55, P759; KRUITWAGEN RFPM, 1991, EUR J OBSTET GYN R B, V41, P215, DOI 10.1016/0028-2243(91)90027-I; LEMAY A, 1984, MED MANAGEMENT ENDOM, P263; LEVANDER G, 1955, Acta Obstet Gynecol Scand, V34, P366; LICHTEN EM, 1987, J REPROD MED, V32, P37; LIU DTY, 1986, BRIT J OBSTET GYNAEC, V93, P859, DOI 10.1111/j.1471-0528.1986.tb07995.x; LLOYD FP, 1964, AM J OBSTET GYNECOL, V89, P468; MAHMOOD TA, 1991, HUM REPROD, V6, P544, DOI 10.1093/oxfordjournals.humrep.a137377; MALKASIAN GD, 1986, AM J OBSTET GYNECOL, V155, P515, DOI 10.1016/0002-9378(86)90269-3; Markee JE, 1940, CONTRIB EMBRYOL, V28, P223; MATHUR S, 1982, CLIN EXP IMMUNOL, V50, P259; Maximow A, 1927, ARCH EXP ZELLFORSCH, V4, P1; MCGINLEY R, 1979, STEROIDS, V33, P127, DOI 10.1016/0039-128X(79)90021-7; MELEGA C, 1991, ANN NY ACAD SCI, V622, P256; MELICOW MM, 1967, CANCER, V20, P1715, DOI 10.1002/1097-0142(196710)20:10<1715::AID-CNCR2820201022>3.0.CO;2-E; MERRILL J A, 1963, Surg Forum, V14, P397; MERRILL JA, 1966, AM J OBSTET GYNECOL, V94, P780; MICHOWITZ M, 1983, DERMATOLOGICA, V167, P326, DOI 10.1159/000249810; MUNGYER G, 1987, IN VITRO CELL DEV B, V23, P111; MURPHY AA, 1986, FERTIL STERIL, V46, P522; NEZHAT C, 1987, BRIT J HOSP MED, V38, P219; NISOLLE M, 1990, FERTIL STERIL, V53, P984; NORWOOD GE, 1960, CLIN OBSTET GYNECOL, V3, P456, DOI 10.1097/00003081-196006000-00016; Novak E, 1926, AM J OBSTET GYNECOL, V12, P0484, DOI 10.1016/S0002-9378(15)30434-8; NOWROOZI K, 1987, INT J FERTIL, V32, P442; OLIKER AJ, 1971, J UROLOGY, V106, P858, DOI 10.1016/S0022-5347(17)61418-6; OLIVE DL, 1987, OBSTET GYNECOL, V69, P412; OLIVE DL, 1986, AM J OBSTET GYNECOL, V154, P613, DOI 10.1016/0002-9378(86)90611-3; OLIVE DL, 1991, AM J OBSTET GYNECOL, V164, P953; OLIVE DL, 1986, REPRODUCTIVE FAILURE, P153; OLIVE DL, 1989, ENDOMETRIOSIS CONT C, P189; OLIVE DL, 1989, ENDOMETRIOSIS CONT C, P213; OOSTERLYNCK DJ, 1991, FERTIL STERIL, V56, P45; PAUERSTEIN CJ, 1989, ENDOMETRIOSIS CONT C, P127; PINKERT TC, 1979, CANCER, V43, P1562, DOI 10.1002/1097-0142(197904)43:4<1562::AID-CNCR2820430451>3.0.CO;2-W; PUNNONEN R, 1980, EUR J OBSTET GYN R B, V11, P195, DOI 10.1016/0028-2243(80)90069-6; RANNEY B, 1971, OBSTET GYNECOL, V37, P734; REDWINE DB, 1987, FERTIL STERIL, V48, P1062; REDWINE DB, 1988, FERTIL STERIL, V50, P665; REDWINE DB, 1992, INFERTIL REPROD MED, V3, P697; Ridley JH., 1968, OBSTET GYNEC SURV, V23, P1, DOI [10.1097/00006254-196801000-00001, DOI 10.1097/00006254-196801000-00001]; RIVA HL, 1962, OBSTET GYNECOL, V19, P111; RODRIGUEZESCUDERO FJ, 1988, FERTIL STERIL, V50, P522; Sampson JA, 1927, AM J OBSTET GYNECOL, V14, P422, DOI 10.1016/S0002-9378(15)30003-X; Sampson JA, 1921, ARCH SURG-CHICAGO, V3, P245, DOI 10.1001/archsurg.1921.01110080003001; Sampson JA, 1925, AM J OBSTET GYNECOL, V10, P649, DOI 10.1016/S0002-9378(25)90629-1; SATALOFF DM, 1989, SURGERY, V105, P109; SCHENKEN RS, 1980, FERTIL STERIL, V34, P581; SCHENKEN RS, 1984, FERTIL STERIL, V41, P122; SCHENKEN RS, 1989, ENDOMETRIOSIS CONT C, P293; SCHRODT GR, 1980, J UROLOGY, V124, P722, DOI 10.1016/S0022-5347(17)55627-X; SCHWARTZ LB, 1992, J REPROD MED, V37, P63; SCOTT RB, 1950, ANN SURG, V131, P697, DOI 10.1097/00000658-195005000-00008; SIMMS JS, 1991, OBSTET GYNECOL, V78, P850; SIMPSON JL, 1980, AM J OBSTET GYNECOL, V137, P327, DOI 10.1016/0002-9378(80)90917-5; STEELE RW, 1984, AM J REPROD IMMUNOL, V6, P33, DOI 10.1111/j.1600-0897.1984.tb00106.x; STRATHY JH, 1982, FERTIL STERIL, V38, P667; STRIPLING MC, 1988, FERTIL STERIL, V49, P427; STROWITZKI T, 1991, ANN NY ACAD SCI, V626, P308; SURREY ES, 1991, FERTIL STERIL, V56, P672; SYROP CH, 1987, FERTIL STERIL, V48, P1; TELIMAA S, 1989, AM J OBSTET GYNECOL, V161, P866, DOI 10.1016/0002-9378(89)90738-2; Telimaa S, 1987, Gynecol Endocrinol, V1, P363, DOI 10.3109/09513598709082709; TELIMAA S, 1988, FERTIL STERIL, V50, P872; TELIMAA S, 1987, GYNECOL ENDOCRINOL, V1, P3; TELINDE RW, 1950, AM J OBSTET GYNECOL, V60, P1147, DOI 10.1016/0002-9378(50)90517-5; THIBODEAU LL, 1987, J NEUROSURG, V66, P609, DOI 10.3171/jns.1987.66.4.0609; TJADEN B, 1990, OBSTET GYNECOL, V76, P89; TOGASHI K, 1991, RADIOLOGY, V180, P73, DOI 10.1148/radiology.180.1.2052726; TULANDI T, 1991, FERTIL STERIL, V56, P790; VANCAILLIE T, 1989, ENDOMETRIOSIS CONT C, P249; VERNON MW, 1985, FERTIL STERIL, V44, P684; WALTERS MD, 1989, ENDOMETRIOSIS CONT C, P267; WHEELER JM, 1989, J REPROD MED, V34, P41; WICKS M J, 1949, Northwest Med, V48, P611; WILD RA, 1985, AM J REPROD IM MIC, V8, P84; WILLEMSEN WNP, 1985, FERTIL STERIL, V44, P92; YLIKORKALA O, 1983, ACTA OBSTET GYN SCAN, P105; ZAWIN M, 1989, RADIOLOGY, V171, P693, DOI 10.1148/radiology.171.3.2717740; ZAWIN M, 1990, RADIOLOGY, V175, P503, DOI 10.1148/radiology.175.2.2109336	148	658	690	2	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1993	328	24					1759	1769		10.1056/NEJM199306173282407	http://dx.doi.org/10.1056/NEJM199306173282407			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG038	8110213				2022-12-28	WOS:A1993LG03800007
J	EDWARDS, CQ; KUSHNER, JP				EDWARDS, CQ; KUSHNER, JP			CURRENT CONCEPTS - SCREENING FOR HEMOCHROMATOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HLA-LINKED HEMOCHROMATOSIS; IDIOPATHIC HEMOCHROMATOSIS; HEREDITARY HEMOCHROMATOSIS; IRON OVERLOAD; BIOCHEMICAL EXPRESSION; BLOOD-DONORS; PHENOTYPIC-EXPRESSION; SIDEROBLASTIC ANEMIA; COMPUTED-TOMOGRAPHY; SERUM FERRITIN		UNIV UTAH, COLL MED, DEPT MED, 4C-334, 50 N MED DR, SALT LAKE CITY, UT 84132 USA; LATTER DAY ST HOSP, DEPT MED, SALT LAKE CITY, UT 84143 USA	Utah System of Higher Education; University of Utah					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM020630] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00064] Funding Source: Medline; NIADDK NIH HHS [AM-20630] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS PC, 1991, GASTROENTEROLOGY, V101, P368, DOI 10.1016/0016-5085(91)90013-B; ANDERSEN PB, 1991, EUR J HAEMATOL, V47, P174; BARRON R, 1989, GASTROENTEROLOGY, V96, P1204, DOI 10.1016/0016-5085(89)91642-9; BASSETT ML, 1981, HEPATOLOGY, V1, P120, DOI 10.1002/hep.1840010206; BASSETT ML, 1982, HUM GENET, V60, P352, DOI 10.1007/BF00569217; BEZWODA WR, 1979, SCAND J HAEMATOL, V22, P113; BOMFORD A, 1976, Q J MED, V45, P611; BONKOVSKY HL, 1990, AM J GASTROENTEROL, V85, P554; BONKOVSKY HL, 1990, GASTROENTEROLOGY, V99, P1079, DOI 10.1016/0016-5085(90)90629-F; BORETTO J, 1992, HUM GENET, V89, P33, DOI 10.1007/BF00207038; BORWEIN ST, 1983, CLIN INVEST MED, V6, P171; Bothwell T.H., 1979, IRON METABOLISM MAN; BOTHWELL TH, 1982, SEMIN HEMATOL, V19, P54; BRITTENHAM GM, 1982, NEW ENGL J MED, V307, P1671, DOI 10.1056/NEJM198212303072703; CARTWRIGHT GE, 1980, J CLIN INVEST, V65, P989, DOI 10.1172/JCI109785; CHAPMAN RWG, 1980, BMJ-BRIT MED J, V280, P440, DOI 10.1136/bmj.280.6212.440; COOK JD, 1976, BLOOD, V48, P449; CROSBY WH, 1963, BLOOD, V22, P429, DOI 10.1182/blood.V22.4.429.429; DADONE MM, 1982, AM J CLIN PATHOL, V78, P196, DOI 10.1093/ajcp/78.2.196; EDWARDS CQ, 1989, GASTROENTEROLOGY, V97, P972, DOI 10.1016/0016-5085(89)91506-0; EDWARDS CQ, 1982, CLIN HAEMATOL, V11, P411; EDWARDS CQ, 1981, PROG HEMATOL, V12, P43; EDWARDS CQ, 1980, HUM IMMUNOL, V1, P19, DOI 10.1016/0198-8859(80)90005-1; EDWARDS CQ, 1982, AM J HEMATOL, V13, P101, DOI 10.1002/ajh.2830130202; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; EDWARDS CQ, 1981, BLOOD, V58, P844; EDWARDS CQ, 1980, ANN INTERN MED, V93, P519, DOI 10.7326/0003-4819-93-4-519; EDWARDS CQ, 1990, AM J MED SCI, V300, P245, DOI 10.1097/00000441-199010000-00009; ELLIOTT R, 1986, AUST NZ J MED, V16, P491, DOI 10.1111/j.1445-5994.1986.tb02018.x; FARGION S, 1986, AM J CLIN PATHOL, V86, P645, DOI 10.1093/ajcp/86.5.645; FINCH CA, 1982, NEW ENGL J MED, V306, P1520, DOI 10.1056/NEJM198206243062504; FINCH SC, 1955, MEDICINE, V34, P381, DOI 10.1097/00005792-195512000-00001; GAMBINO R, 1991, HOSP PRACT, V26, P41; GERAGHTY DE, 1992, P NATL ACAD SCI USA, V89, P2669, DOI 10.1073/pnas.89.7.2669; GUYADER D, 1989, GASTROENTEROLOGY, V97, P737, DOI 10.1016/0016-5085(89)90646-X; HADDY TB, 1988, AM J PEDIAT HEMATOL, V10, P23; HALLBERG L, 1989, J INTERN MED, V225, P249, DOI 10.1111/j.1365-2796.1989.tb00074.x; HOUSMAN JF, 1989, GASTROINTEST RADIOL, V14, P59, DOI 10.1007/BF01889156; KARLSSON M, 1988, ACTA MED SCAND, V224, P385; LALOUEL JM, 1988, ANN NY ACAD SCI, V526, P34; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; LINDMARK B, 1985, ACTA MED SCAND, V218, P299; LLOYD DA, 1978, CAN MED ASSOC J, V119, P1051; MACDONALD RA, 1965, AM J MED SCI, V249, P62; MACSWEEN RN, 1973, J CLIN PATHOL, V26, P936, DOI 10.1136/jcp.26.12.936; MEYER T, 1990, J INTERN MED, V227, P397, DOI 10.1111/j.1365-2796.1990.tb00178.x; MILMAN N, 1991, DAN MED BULL, V38, P385; MILMAN N, 1991, EUR J HAEMATOL, V47, P292; MOHLER DN, 1986, AM J MED SCI, V292, P320, DOI 10.1097/00000441-198611000-00014; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; OLSSON KS, 1983, ACTA MED SCAND, V213, P145; POWELL LW, 1990, GASTROENTEROLOGY, V98, P1625, DOI 10.1016/0016-5085(90)91100-K; Sheldon J. H., 1935, HAEMOCHROMATOSIS; SIMON M, 1980, GASTROENTEROLOGY, V78, P703; SIMON M, 1974, NOUV PRESSE MED, V4, P1432; Stewart MJ, 1931, LANCET, V2, P565; VALBERG LS, 1976, CAN MED ASSOC J, V114, P417; VALBERG LS, 1980, GASTROENTEROLOGY, V79, P884; VELATI C, 1990, HAEMATOLOGICA, V75, P309; von Recklinghausen FD, 1889, TAGEBL VERSAMML NATU, V62, P324; WIGGERS P, 1991, J INTERN MED, V230, P265, DOI 10.1111/j.1365-2796.1991.tb00441.x	61	213	226	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1993	328	22					1616	1620						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE289	8110209				2022-12-28	WOS:A1993LE28900008
J	LANDAU, C; LANGE, RA; HILLIS, LD				LANDAU, C; LANGE, RA; HILLIS, LD			MEDICAL PROGRESS - PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA-PECTORIS; ANGIOGRAPHIC FOLLOW-UP; TRANS-LUMINAL ANGIOPLASTY; CHRONIC TOTAL OCCLUSIONS; ARTERY BYPASS-SURGERY; FISH OIL SUPPLEMENTS; BALLOON ANGIOPLASTY; RANDOMIZED TRIAL; NATIONAL-HEART		UNIV TEXAS, SW MED CTR,DEPT INTERNAL MED,DIV CARDIOVASC, ROOM CS 7102, DALLAS, TX 75235 USA; PARKLAND MEM HOSP & AFFILIATED INST, CARDIAC CATHETERIZAT LAB, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Lange, Richard/AAM-9594-2021					ADELMAN AG, 1993, NEW ENGL J MED, V329, P228, DOI 10.1056/NEJM199307223290402; AMBROSE JA, 1992, J AM COLL CARDIOL, V20, P1197, DOI 10.1016/0735-1097(92)90378-Z; ARNOLD AER, 1992, CIRCULATION, V86, P111, DOI 10.1161/01.CIR.86.1.111; AUSTIN GE, 1987, ARCH PATHOL LAB MED, V111, P1158; BAIRATI I, 1992, CIRCULATION, V85, P950, DOI 10.1161/01.CIR.85.3.950; BARNATHAN ES, 1987, CIRCULATION, V76, P125, DOI 10.1161/01.CIR.76.1.125; BELL MR, 1992, CIRCULATION, V85, P1003, DOI 10.1161/01.CIR.85.3.1003; BERTRAND ME, 1990, CIRCULATION, V82, P190; BLACK AJR, 1988, AM J CARDIOL, V62, P809, DOI 10.1016/0002-9149(88)91228-3; BLACK AJR, 1988, J AM COLL CARDIOL, V11, P714, DOI 10.1016/0735-1097(88)90201-X; BOURASSA MG, 1992, AM J CARDIOL, V70, P174, DOI 10.1016/0002-9149(92)91271-5; BOURASSA MG, 1991, J AM COLL CARDIOL, V18, P368, DOI 10.1016/0735-1097(91)90588-Z; BREDLAU CE, 1985, CIRCULATION, V72, P1044, DOI 10.1161/01.CIR.72.5.1044; Chesebro JH, 1989, CIRCULATION S2, V80, pII; COHEN DJ, 1993, J AM COLL CARDIOL, V22, P1052, DOI 10.1016/0735-1097(93)90415-W; CORCOS T, 1985, AM HEART J, V109, P926, DOI 10.1016/0002-8703(85)90231-5; COWLEY MJ, 1984, AM J CARDIOL, V53, pC12, DOI 10.1016/0002-9149(84)90738-0; DEFEYTER PIMJ, 1993, J AM COLL CARDIOL, V21, P1539, DOI 10.1016/0735-1097(93)90366-9; DEFEYTER PJ, 1991, CIRCULATION, V83, P927, DOI 10.1161/01.CIR.83.3.927; DEFEYTER PJ, 1991, AM J CARDIOL, V68, pB125, DOI 10.1016/0002-9149(91)90395-2; DEFEYTER PJ, 1985, NEW ENGL J MED, V313, P342, DOI 10.1056/NEJM198508083130602; DEHMER GJ, 1988, NEW ENGL J MED, V319, P733, DOI 10.1056/NEJM198809223191201; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; DETRE KM, 1990, CIRCULATION, V82, P739, DOI 10.1161/01.CIR.82.3.739; DOTTER CT, 1964, CIRCULATION, V30, P654, DOI 10.1161/01.CIR.30.5.654; ELLIS SG, 1990, AM J CARDIOL, V66, P932, DOI 10.1016/0002-9149(90)90928-T; ELLIS SG, 1989, AM HEART J, V117, P777, DOI 10.1016/0002-8703(89)90612-1; ELLIS SG, 1988, CIRCULATION, V77, P372, DOI 10.1161/01.CIR.77.2.372; ELLIS SG, 1990, TXB INTERVENTIONAL C, P200; FARB A, 1990, J AM COLL CARDIOL, V16, P1421, DOI 10.1016/0735-1097(90)90386-4; FAXON DP, 1982, ARTERIOSCLEROSIS, V2, P125, DOI 10.1161/01.ATV.2.2.125; FAXON DP, 1990, CIRCULATION, V81, P9; FISCHELL TA, 1988, CIRCULATION, V78, P1323, DOI 10.1161/01.CIR.78.6.1323; Foley David P., 1993, Journal of the American College of Cardiology, V21, p322A; GABLIANI G, 1988, AM HEART J, V116, P696, DOI 10.1016/0002-8703(88)90326-2; GALAN KM, 1988, AM J CARDIOL, V61, P260, DOI 10.1016/0002-9149(88)90927-7; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRAMBOW DW, 1992, AM J CARDIOL, V70, P577, DOI 10.1016/0002-9149(92)90194-4; GRIGG LE, 1989, J AM COLL CARDIOL, V13, P665, DOI 10.1016/0735-1097(89)90609-8; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; GRUENTZIG AR, 1987, NEW ENGL J MED, V316, P1127, DOI 10.1056/NEJM198704303161805; GRUNTZIG A, 1978, LANCET, V1, P263, DOI 10.1016/s0140-6736(78)90500-7; HARTZ AJ, 1992, AM J CARDIOL, V70, P179, DOI 10.1016/0002-9149(92)91272-6; HAUDE M, 1993, J AM COLL CARDIOL, V21, P26, DOI 10.1016/0735-1097(93)90713-B; HAUDENSCHILD C, 1993, AM J MED S4A, V94, pA4; HERNANDEZ RA, 1992, J AM COLL CARDIOL, V19, P1402, DOI 10.1016/0735-1097(92)90594-D; HILLIS LD, 1990, CIRCULATION, V82, P305, DOI 10.1161/01.CIR.82.1.305; HIRSHFELD JW, 1991, J AM COLL CARDIOL, V18, P647, DOI 10.1016/0735-1097(91)90783-6; HOLLMAN J, 1992, AM HEART J, V124, P9, DOI 10.1016/0002-8703(92)90913-G; HOLLMAN J, 1989, CIRCULATION S2, V80, P65; HOLMES DR, 1988, J AM COLL CARDIOL, V12, P1149, DOI 10.1016/0735-1097(88)92593-4; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; IVANHOE RJ, 1992, CIRCULATION, V85, P106, DOI 10.1161/01.CIR.85.1.106; KAHN JK, 1990, AM HEART J, V119, P484, DOI 10.1016/S0002-8703(05)80268-6; KILLIP T, 1988, NEW ENGL J MED, V319, P366, DOI 10.1056/NEJM198808113190610; KIMURA T, 1993, J AM COLL CARDIOL, V21, P1557, DOI 10.1016/0735-1097(93)90368-B; KING SB, 1990, CIRCULATION, V82, P508; KLEIN W, 1990, CLIN PHYSIOL BIOCH, V8, P101; KNUDTSON ML, 1990, J AM COLL CARDIOL, V15, P691, DOI 10.1016/0735-1097(90)90648-9; KUNTZ RE, 1993, J AM COLL CARDIOL, V21, P15, DOI 10.1016/0735-1097(93)90712-A; LAMBERT M, 1988, J AM COLL CARDIOL, V12, P310, DOI 10.1016/0735-1097(88)90399-3; Landau C, 1992, J Interv Cardiol, V5, P29, DOI 10.1111/j.1540-8183.1992.tb00820.x; LANDAU C, 1994, AM J CARDIOL, V73, P95, DOI 10.1016/0002-9149(94)90735-8; LANDAU C, 1991, CIRCULATION S2, V84, P291; LANDAU C, IN PRESS AM J MED; LANGE RA, 1993, AM J MED SCI, V306, P265, DOI 10.1097/00000441-199310000-00010; LASKEY MAL, 1990, AM J CARDIOL, V65, P1425, DOI 10.1016/0002-9149(90)91348-A; LAZAR HL, 1992, ANN THORAC SURG, V53, P269, DOI 10.1016/0003-4975(92)91331-3; LEE TC, 1990, CATHETER CARDIO DIAG, V20, P185, DOI 10.1002/ccd.1810200307; LEEMAN DE, 1988, AM J CARDIOL, V61, pG38, DOI 10.1016/S0002-9149(88)80031-6; LEIMGRUBER PP, 1986, CIRCULATION, V73, P710, DOI 10.1161/01.CIR.73.4.710; LEISCH F, 1986, BRIT HEART J, V56, P341; LEITSCHUH ML, 1991, AM J CARDIOL, V67, P1056, DOI 10.1016/0002-9149(91)90865-I; LEMBO NJ, 1990, AM J CARDIOL, V65, P422, DOI 10.1016/0002-9149(90)90804-A; LIBBY P, 1992, CIRCULATION, V86, P47; LINCOFE AM, 1992, J AM COLL CARDIOL, V19, P926, DOI 10.1016/0735-1097(92)90272-O; LINCOFF AM, 1993, J AM COLL CARDIOL, V21, P866, DOI 10.1016/0735-1097(93)90341-W; MABIN TA, 1985, J AM COLL CARDIOL, V5, P198, DOI 10.1016/S0735-1097(85)80037-1; MCGARRY TF, 1992, AM HEART J, V123, P1445, DOI 10.1016/0002-8703(92)90793-U; MEIER B, 1991, J AM COLL CARDIOL, V17, pB50; MILNER MR, 1989, AM J CARDIOL, V64, P294, DOI 10.1016/0002-9149(89)90522-5; MULCAHY R, 1985, AM HEART J, V109, P753, DOI 10.1016/0002-8703(85)90634-9; MULLER DWM, 1992, AM J CARDIOL, V69, P63, DOI 10.1016/0002-9149(92)90677-Q; MYLER RK, 1990, CIRCULATION, V82, P88; MYLER RK, 1992, J AM COLL CARDIOL, V19, P1641, DOI 10.1016/0735-1097(92)90631-V; NEUHAUS KL, 1992, J AM COLL CARDIOL, V19, P885, DOI 10.1016/0735-1097(92)90265-O; NICHOLS AB, 1989, J AM COLL CARDIOL, V13, P1094, DOI 10.1016/0735-1097(89)90267-2; NOBUYOSHI M, 1988, J AM COLL CARDIOL, V12, P616, DOI 10.1016/S0735-1097(88)80046-9; OKAMOTO S, 1992, AM HEART J, V123, P1439, DOI 10.1016/0002-8703(92)90792-T; OKEEFE JH, 1992, J AM COLL CARDIOL, V19, P1597, DOI 10.1016/0735-1097(92)90624-V; OKEEFE JH, 1991, AM J CARDIOL, V67, P373, DOI 10.1016/0002-9149(91)90044-L; ONEILL WW, 1992, CIRCULATION, V86, P1710, DOI 10.1161/01.CIR.86.6.1710; OWEIDA SW, 1990, J VASC SURG, V12, P310, DOI 10.1067/mva.1990.22293; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PEPINE CJ, 1990, CIRCULATION, V81, P1753, DOI 10.1161/01.CIR.81.6.1753; PERRY RA, 1988, BRIT HEART J, V60, P367; PLATKO WP, 1989, J AM COLL CARDIOL, V14, P1645, DOI 10.1016/0735-1097(89)90010-7; POPMA JJ, 1989, ANN INTERN MED, V110, P547, DOI 10.7326/0003-4819-110-7-547; POPMA JJ, 1992, J AM COLL CARDIOL, V19, P1372, DOI 10.1016/0735-1097(92)90590-J; POTKIN BN, 1992, J AM COLL CARDIOL, V20, P942, DOI 10.1016/0735-1097(92)90197-U; QUIGLEY PJ, 1989, AM J CARDIOL, V63, P409, DOI 10.1016/0002-9149(89)90309-3; RAIZNER A, 1988, CIRCULATION S2, V78, P290; REIS GJ, 1989, LANCET, V2, P177; REIS GJ, 1991, AM J CARDIOL, V68, P1431, DOI 10.1016/0002-9149(91)90275-P; RODRIGUEZ A, 1993, J AM COLL CARDIOL, V22, P1060, DOI 10.1016/0735-1097(93)90416-X; ROUBIN GS, 1987, AM J CARDIOL, V60, pB39; ROUBIN GS, 1992, CIRCULATION, V85, P916, DOI 10.1161/01.CIR.85.3.916; ROUBIN GS, 1988, CIRCULATION, V78, P557, DOI 10.1161/01.CIR.78.3.557; RUOCCO NA, 1992, AM J CARDIOL, V69, P69, DOI 10.1016/0002-9149(92)90678-R; RYAN T J, 1988, Journal of the American College of Cardiology, V12, P529; SAFIAN RD, 1990, CIRCULATION, V82, P69, DOI 10.1161/01.CIR.82.1.69; SAHNI R, 1991, AM HEART J, V121, P1600, DOI 10.1016/0002-8703(91)90002-Y; SAVAGE MP, 1991, J AM COLL CARDIOL, V17, P22, DOI 10.1016/0735-1097(91)90700-J; SCHIEMAN G, 1990, CIRCULATION, V82, P2052, DOI 10.1161/01.CIR.82.6.2052; SCHWARTZ L, 1988, NEW ENGL J MED, V318, P1714, DOI 10.1056/NEJM198806303182603; Serruys P. W., 1993, Journal of the American College of Cardiology, V21, p322A; SERRUYS PW, 1991, CIRCULATION, V84, P1568, DOI 10.1161/01.CIR.84.4.1568; SERRUYS PW, 1991, NEW ENGL J MED, V324, P13, DOI 10.1056/NEJM199101033240103; SIMOONS M L, 1988, Lancet, V1, P197; SIMPFENDORFER C, 1987, AM J CARDIOL, V59, P267, DOI 10.1016/0002-9149(87)90797-1; SINCLAIR IN, 1988, AM J CARDIOL, V61, pG61, DOI 10.1016/S0002-9149(88)80034-1; SOWARD AL, 1985, AM J CARDIOL, V56, P794, DOI 10.1016/0002-9149(85)91141-5; STAMMEN F, 1992, AM J CARDIOL, V69, P1533, DOI 10.1016/0002-9149(92)90698-X; STEELE PM, 1985, CIRC RES, V57, P105, DOI 10.1161/01.RES.57.1.105; STONE GW, 1990, J AM COLL CARDIOL, V15, P849, DOI 10.1016/0735-1097(90)90285-W; TALLEY JD, 1990, CIRCULATION, V82, P1203, DOI 10.1161/01.CIR.82.4.1203; TENAGLIA AN, 1992, J AM COLL CARDIOL, V20, P685, DOI 10.1016/0735-1097(92)90025-I; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; THORNTON MA, 1984, CIRCULATION, V69, P721, DOI 10.1161/01.CIR.69.4.721; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; TOPOL EJ, 1993, CIRCULATION, V87, P1489, DOI 10.1161/01.CIR.87.5.1489; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; URBAN P, 1989, J AM COLL CARDIOL, V13, P1085, DOI 10.1016/0735-1097(89)90265-9; URBAN P, 1988, BRIT HEART J, V60, P485; VAL PG, 1987, AM J CARDIOL, V60, pB50; VANDORMAEL MG, 1987, J AM COLL CARDIOL, V10, P246, DOI 10.1016/S0735-1097(87)80003-7; VANLIERDE JM, 1992, BRIT HEART J, V68, P51; WALLER BF, 1983, CLIN CARDIOL, V6, P363, DOI 10.1002/clc.4960060802; WEBB JG, 1990, J AM COLL CARDIOL, V16, P812, DOI 10.1016/S0735-1097(10)80327-4; WEINTRAUB WS, 1993, J AM COLL CARDIOL, V21, P6, DOI 10.1016/0735-1097(93)90711-9; WHITWORTH HB, 1986, J AM COLL CARDIOL, V8, P1271, DOI 10.1016/S0735-1097(86)80296-0; WILLIAMS DO, 1992, CIRCULATION, V85, P533, DOI 10.1161/01.CIR.85.2.533; WOHLGELERNTER D, 1986, AM J CARDIOL, V58, P460, DOI 10.1016/0002-9149(86)90015-9; WYMAN RM, 1988, J AM COLL CARDIOL, V12, P1400, DOI 10.1016/S0735-1097(88)80002-0; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002; 1989, NEW ENGL J MED, V320, P618; 1993, LANCET, V341, P573; 1988, JAMA-J AM MED ASSOC, V260, P2849; 1991, BRIT MED J, V302, P555; 1992, CIRCULATION, V86, P100	150	291	308	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 7	1994	330	14					981	993		10.1056/NEJM199404073301407	http://dx.doi.org/10.1056/NEJM199404073301407			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND793	8121462				2022-12-28	WOS:A1994ND79300007
J	FOGELMAN, AM				FOGELMAN, AM			STRATEGIES FOR TRAINING GENERALISTS AND SUBSPECIALISTS	ANNALS OF INTERNAL MEDICINE			English	Article							INTERNAL-MEDICINE MANPOWER	A strategy is proposed for attracting trainees to careers in general internal medicine coupled with a program that attracts a smaller number of trainees to research careers without attracting trainees into careers in the practice of the subspecialties. A novel training track analogous to the Medical Scientist Training Program, the Specialty Training and Academic Research (STAR) Program has been established. It is anticipated that within the next 5 years, 80% of the trainees in the department of medicine at the University of California, Los Angeles, Medical Center will be training for practice in general internal medicine; the remaining 20% will be enrolled in the STAR Program.			FOGELMAN, AM (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA.							ANDERSEN RM, 1992, ANN INTERN MED, V117, P243, DOI 10.7326/0003-4819-117-3-243; BARONDESS JA, 1993, ANN INTERN MED, V119, P153, DOI 10.7326/0003-4819-119-2-199307150-00010; FITZGERALD FT, 1993, NEW ENGL J MED, V328, P654, DOI 10.1056/NEJM199303043280912; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; KASSIRER JP, 1993, NEW ENGL J MED, V328, P648, DOI 10.1056/NEJM199303043280910; KRONICK R, 1993, NEW ENGL J MED, V328, P148, DOI 10.1056/NEJM199301143280225; LACOMBE M, 1993, ANN INTERN MED, V118, P384, DOI 10.7326/0003-4819-118-5-199303010-00010; LACOMBE MA, 1991, AM J MED, V91, P276, DOI 10.1016/0002-9343(91)90128-K; LEVINSKY NG, 1993, NEW ENGL J MED, V328, P656, DOI 10.1056/NEJM199303043280913; LYTTLE CS, 1991, ANN INTERN MED, V114, P36, DOI 10.7326/0003-4819-114-1-36; PETERSDORF RG, 1993, NEW ENGL J MED, V328, P651, DOI 10.1056/NEJM199303043280911; WENNBERG JE, 1993, HEALTH AFFAIR, V12, P89, DOI 10.1377/hlthaff.12.2.89	12	43	43	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					579	583		10.7326/0003-4819-120-7-199404010-00009	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8116997				2022-12-28	WOS:A1994NC76400009
J	VANLEEUWEN, F; SAMOS, CH; NUSSE, R				VANLEEUWEN, F; SAMOS, CH; NUSSE, R			BIOLOGICAL-ACTIVITY OF SOLUBLE WINGLESS PROTEIN IN CULTURED DROSOPHILA IMAGINAL DISC CELLS	NATURE			English	Article							SEGMENT-POLARITY GENE; ENCODES; EXPRESSION; ARMADILLO; PRODUCT; HOMOLOG; INT-1; PLAKOGLOBIN; EPIDERMIS; EMBRYOS	THE phenotypes caused by mutations in Wnt genes suggest that their gene products are involved in cell-to-cell communication(1-6) Wnt genes indeed encode secreted molecules(7-10), but soluble active Wnt protein has not been found. We have developed a novel cell culture assay for the Drosophila Wnt gene wingless(11,12), using a Drosophila imaginal disc cell line (cl-8; ref. 13), and measured effects on the adherens junction protein armadillo(14,15), a known genetic target of wingless(16). Transfection of a temperature-sensitive wingless complementary DNA into cl-8 cells increases the levels of the armadillo protein. The wingless protein does not affect the rate of synthesis of armadillo, but leads to increased stability of an otherwise rapidly decaying armadillo protein. The wingless protein in the extracellular matrix and soluble medium from donor cells also increases the levels of armadillo protein. The protein in the medium acts fast and is inhibited by an antibody to wingless protein, demonstrating that Wnt products can act as soluble extracellular signalling molecules.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,BECKMAN CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University			van Leeuwen, Frank/AAQ-6799-2020	van Leeuwen, Frank/0000-0003-1107-6513				BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; CHULAGRAFF Q, 1993, SCIENCE, V261, P1594, DOI 10.1126/science.8372355; CMBERLEDGE S, 1993, NATURE, V363, P549; CURRIE DA, 1988, DEVELOPMENT, V102, P804; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PEEL DJ, 1992, ROUX ARCH DEV BIOL, V201, P120, DOI 10.1007/BF00420423; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, J CELL SCI, V105, P993; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2	27	181	193	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					342	344		10.1038/368342a0	http://dx.doi.org/10.1038/368342a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127369				2022-12-28	WOS:A1994NB98500048
J	ZELL, ER; DIETZ, V; STEVENSON, J; COCHI, S; BRUCE, RH				ZELL, ER; DIETZ, V; STEVENSON, J; COCHI, S; BRUCE, RH			LOW VACCINATION LEVELS OF US PRESCHOOL AND SCHOOL-AGE-CHILDREN - RETROSPECTIVE ASSESSMENTS OF VACCINATION COVERAGE, 1991-1992	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To obtain estimates on (1) the percentage of children who were up-to-date on the recommended childhood vaccination series, (2) the percentage of children who were age-appropriately immunized, and (3) coverage levels by individual vaccines. Design.-Vaccination levels were estimated by conducting retrospective immunization coverage surveys of the school health records of children entering kindergarten or first grade in the 1990-1991 or 1991-1992 school year. A multistage cluster survey design was used. Setting.-Survey sites were selected from among the 60 largest urban areas in the United States. One small city and one rural area were selected for comparison. Results.-By their second birthday, 11% to 58% (median, 44%) of the children were fully vaccinated. Stricter measurement criteria lowered coverage levels further. Completed series levels at school entry were 71% to 96% (median, 87%). Conclusions.-Vaccination levels at the second birthday were far below the goal for the year 2000. All health providers need to administer vaccines according to the recommended schedule.			ZELL, ER (corresponding author), CTR DIS CONTROL & PREVENT,NATL IMMUNIZAT PROGRAM,1600 CLIFTON RD NE,MAILSTOP E-62,ATLANTA,GA 30333, USA.							BOBO JK, 1993, PEDIATRICS, V91, P308; CHEN RT, 1989, AM J EPIDEMIOL, V129, P173, DOI 10.1093/oxfordjournals.aje.a115106; EDDINS DL, 1985, 20TH P NAT IMM C DAL; HADLER SC, 1991, 25TH P NAT IMM C WAS; HINMAN AR, 1991, AM J DIS CHILD, V145, P559, DOI 10.1001/archpedi.1991.02160050085023; HINMAN AR, 1990, PEDIATRICS, V86, P1064; HINMAN AR, 1990, 24TH P NAT IMM C ORL; Orenstein W A, 1990, J Health Care Poor Underserved, V1, P315; 1989, MMWR MORB MORTAL WKL, V38, P219; 1989, MMWR MORB MORTAL WKL, V38, P205; 1991, REPORT COMMITTE INFE; 1990, SAMPLING PROCEDURE C; 1991, DHHS PHS9150213 PUBL; 1992, MMWR MORBJ MORTAL WK, V40, P888	14	94	95	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					833	839		10.1001/jama.271.11.833	http://dx.doi.org/10.1001/jama.271.11.833			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MZ498	8114237				2022-12-28	WOS:A1994MZ49800029
J	LEE, KF; BACHMAN, K; LANDIS, S; JAENISCH, R				LEE, KF; BACHMAN, K; LANDIS, S; JAENISCH, R			DEPENDENCE ON P75 FOR INNERVATION OF SOME SYMPATHETIC TARGETS	SCIENCE			English	Article							NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; FACTOR FAMILY; SWEAT GLANDS; NEUROTRANSMITTER PLASTICITY; RECEPTORS; MEMBER; MATURATION; NEURONS; BRAIN	The low-affinity neurotrophin receptor p75 binds all neurotrophins with similar affinity. For elucidation of its function, mice bearing a null mutation in the p75 locus were generated. Examination of sympathetic innervation of target tissues revealed that pineal glands lacked innervation and sweat gland innervation was absent or reduced in particular footpads. The absence of adult innervation reflects the failure of axons to reach these targets during development rather than a target deficit. These results indicate that p75 facilitates development of specific populations of sympathetic neurons, for which it may support axon growth.	MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT NEUROSCI, CLEVELAND, OH 44106 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Case Western Reserve University					NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023678] Funding Source: NIH RePORTER; NCI NIH HHS [5 R35 CA44339] Funding Source: Medline; NINDS NIH HHS [NS 023678] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARBACID M, 1993, ONCOGENE, V8, P2033; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; de Champlain J, 1970, ACTA PHYSIOL SCAND, V80, P276, DOI 10.1111/j.1748-1716.1970.tb04791.x; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GRANT ME, UNPUB; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KENNEDY WR, 1984, NEUROSCIENCE, V11, P741, DOI 10.1016/0306-4522(84)90057-5; LANDIS SC, 1988, DEV BIOL, V126, P129, DOI 10.1016/0012-1606(88)90246-1; LANDIS SC, 1983, DEV BIOL, V98, P349, DOI 10.1016/0012-1606(83)90365-2; LEBLANC G, 1986, J NEUROSCI, V6, P260; Lee K. T., UNPUB; LEE KF, IN PRESS DEVELOPMENT; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LI K, 1991, CELL TISSUE RES, V264, P515, DOI 10.1007/BF00319041; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; RUBIN E, 1985, J NEUROSCI, V5, P673; SACHS C, 1970, European Journal of Pharmacology, V9, P67, DOI 10.1016/0014-2999(70)90322-5; SLOTKIN TA, 1987, J PHARMACOL EXP THER, V243, P101; STEVENS LM, 1988, DEV BIOL, V130, P703, DOI 10.1016/0012-1606(88)90362-4; TUCKER DC, 1990, ANN NY ACAD SCI, V588, P120, DOI 10.1111/j.1749-6632.1990.tb13202.x; YAN Q, 1988, J NEUROSCI, V8, P3481; ZHANG ET, 1991, CELL TISSUE RES, V265, P63, DOI 10.1007/BF00318140	33	173	173	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 11	1994	263	5152					1447	1449		10.1126/science.8128229	http://dx.doi.org/10.1126/science.8128229			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128229				2022-12-28	WOS:A1994MZ92700035
J	ESCOBAR, AL; MONCK, JR; FERNANDEZ, JM; VERGARA, JL				ESCOBAR, AL; MONCK, JR; FERNANDEZ, JM; VERGARA, JL			LOCALIZATION OF THE SITE OF CA2+ RELEASE AT THE LEVEL OF A SINGLE SARCOMERE IN SKELETAL-MUSCLE FIBERS	NATURE			English	Article							CALCIUM TRANSIENTS; ARSENAZO-III; SARCOPLASMIC-RETICULUM; CONTRACTION; FIBERS; RESOLUTION	THE development of mechanical force in skeletal muscle fibres is brought about by rapid increases in the intracellular calcium concentration (Ca2+ transients) which can be detected by optical methods1-7. Local stimulation experiments8 and ultrastructural evidence9,10 suggest that, at a microscopic level, these Ca2+ transients are generated by the release of Ca2+ ions from the terminal cisternae of the sarcoplasmic reticulum in response to the depolarization of the transverse tubules (t-tubules)11-14 . Nevertheless, to date, there is no functional information on the exact location at which Ca2+ release takes place. The present experiments were designed to obtain direct evidence about dynamic changes in localization and microscopic distribution of Ca2+ in a single sarcomere using two independent novel methodologies: confocal spot detection of Ca2+ transients15,16 and Ca2+ imaging with pulsed laser excitation17,18.	UNIV CALIF LOS ANGELES,DEPT PHYSIOL,LOS ANGELES,CA 90024; MAYO CLIN & MAYO FDN,DEPT PHYSIOL & BIOPHYS,ROCHESTER,MN 55905	University of California System; University of California Los Angeles; Mayo Clinic								BAYLOR SM, 1982, J PHYSIOL-LONDON, V331, P179, DOI 10.1113/jphysiol.1982.sp014369; DULHUNTY AF, 1992, P ROY SOC B-BIOL SCI, V247, P69, DOI 10.1098/rspb.1992.0010; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; ESCOBAR A, 1993, BIOPHYS J, V64, pA241; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801; GRINVALD A, 1988, PHYSIOL REV, V68, P1285, DOI 10.1152/physrev.1988.68.4.1285; HIBINO M, 1991, BIOPHYS J, V59, P209, DOI 10.1016/S0006-3495(91)82212-3; HUXLEY AF, 1958, J PHYSIOL-LONDON, V144, P426, DOI 10.1113/jphysiol.1958.sp006111; MILEDI R, 1977, PROC R SOC SER B-BIO, V198, P201, DOI 10.1098/rspb.1977.0094; MINTA A, 1989, J BIOL CHEM, V264, P8171; MONCK J, 1994, BIOPHYS J, V66, pA351; MONCK JR, 1992, J CELL BIOL, V116, P745, DOI 10.1083/jcb.116.3.745; NIGGLI E, 1990, CELL CALCIUM, V11, P121, DOI 10.1016/0143-4160(90)90065-3; PALADE P, 1982, J GEN PHYSIOL, V79, P679, DOI 10.1085/jgp.79.4.679; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PARKER I, 1993, J PHYSIOL-LONDON, V461, P133, DOI 10.1113/jphysiol.1993.sp019506; PEACHEY LD, 1965, J CELL BIOL, V25, P209, DOI 10.1083/jcb.25.3.209; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Sandow A, 1970, Annu Rev Physiol, V32, P87, DOI 10.1146/annurev.ph.32.030170.000511; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SHEPPARD JR, J MICROSC, V149, P73; SOMLYO AV, 1981, J CELL BIOL, V90, P577, DOI 10.1083/jcb.90.3.577; TAKAMATSU T, 1990, CELL CALCIUM, V11, P111, DOI 10.1016/0143-4160(90)90064-2; VERGARA J, 1992, ADV EXP MED BIOL, V311, P227; VERGARA J, 1991, BIOPHYS J, V59, P12, DOI 10.1016/S0006-3495(91)82193-2; VERGARA J, 1993, BIOPHYS J, V64, pA37; WILSON T, 1987, OPT LETT, V12, P227, DOI 10.1364/OL.12.000227; WINEGRAD S, 1970, J GEN PHYSIOL, V55, P77, DOI 10.1085/jgp.55.1.77	30	98	99	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					739	741		10.1038/367739a0	http://dx.doi.org/10.1038/367739a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	8107869				2022-12-28	WOS:A1994MX63100059
J	MOMBURG, F; ROELSE, J; HOWARD, JC; BUTCHER, GW; HAMMERLING, GJ; NEEFJES, JJ				MOMBURG, F; ROELSE, J; HOWARD, JC; BUTCHER, GW; HAMMERLING, GJ; NEEFJES, JJ			SELECTIVITY OF MHC-ENCODED PEPTIDE TRANSPORTERS FROM HUMAN, MOUSE AND RAT	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; ANTIGEN PRESENTATION; LINKED TRANSPORTER; RMA-S; EXPRESSION; INVITRO; HLA-B27; CELLS; GENES	MAJOR histocompatibility complex (MHC) class I molecules present peptides from degraded intracellular antigens to CD8(+) T cells(1). These peptides are translocated in an ATP-dependent fashion(2-4) into the lumen of the endoplasmic reticulum (ER) for binding to class I molecules(5,6) by means of the MHC-encoded transporters associated with antigen processing, TAP1 and TAP2. These are members of a family of proteins containing an ATP-binding cassette and form heterodimers in the ER membrane(7-10). Defects in the genes encoding TAP1 or TAP2 account for impaired class I assembly and antigen presentation in several human and rodent cell lines(7,11-13). Whereas MHC class I molecules select peptides according to binding motifs(14-17), it is not clear to what extent the TAP1-TAP2 transporters have peptide sequence and length specificity. Previous studies of the rat MHC class I molecule, RT1A(a), suggested a specific conveyance of peptides by rat TAP1-TAP2 (ref. 18). Here we substitute the amino- and carboxy-terminal and the penultimate amino-acid residues of model peptides to show that these residues influence the efficiency of transport. Human TAP and rat TAP(a) translocated peptides with hydrophobic and basic C termini, whereas mouse TAP and rat TAP(u) preferred peptides with hydrophobic C termini. This pattern correlates with the predominant peptide binding profiles of mouse and human class I molecules.	NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,1066 CX AMSTERDAM,NETHERLANDS; BABRAHAM INST,AGR & FOOD RES COUNCIL,DEPT IMMUNOL,CAMBRIDGE CB2 4AT,ENGLAND	Netherlands Cancer Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	MOMBURG, F (corresponding author), GERMAN CANC RES CTR,TUMOR IMMUNOL PROGRAM,NEUENHEIMER FELD 280,D-69120 HEIDELBERG,GERMANY.		Neefjes, Jacques J.C./H-8780-2017	Neefjes, Jacques J.C./0000-0001-6763-2211; Howard, Jonathan/0000-0003-2756-5143				ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; POWIS SJ, 1991, J EXP MED, V173, P913, DOI 10.1084/jem.173.4.913; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; RADA C, 1990, P NATL ACAD SCI USA, V87, P2167, DOI 10.1073/pnas.87.6.2167; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; YOUNG Y, 1992, J BIOL CHEM, V267, P11669; ZHANG QJ, 1993, P NATL ACAD SCI USA, V90, P2217, DOI 10.1073/pnas.90.6.2217	28	336	338	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 17	1994	367	6464					648	651		10.1038/367648a0	http://dx.doi.org/10.1038/367648a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	8107849				2022-12-28	WOS:A1994MW68800055
J	YEO, JP; ALDERUCCIO, F; TOH, BH				YEO, JP; ALDERUCCIO, F; TOH, BH			A NEW CHROMOSOMAL PROTEIN ESSENTIAL FOR MITOTIC SPINDLE ASSEMBLY	NATURE			English	Article							CELL-FREE-EXTRACTS; LARGE T-ANTIGEN; XENOPUS EGGS; MICROTUBULES; CENTROSOMES; COMPONENTS; LINES	ASSEMBLY of the mitotic spindle, the machinery responsible for chromosomal segregation, is regulated by Cdc2 kinase1-5, and requires mitotic chromatin5-8. However, the molecular identity of the kinase substrate and chromatin factor is unknown. Here we have cloned a human complementary DNA encoding an evolutionarily conserved chromosomal protein of relative molecular mass 47,000 (M(r) 47K) which has three consensus motifs for Cdc2 kinase-mediated phosphorylation9. The protein is phosphorylated only during mitosis and is associated with polypeptides having M(r)s of 31K, 67K and 200K. Mitotic arrest is induced by antisense messenger RNA or by affinity-purified autoantibody. In the arrested cells, the chromosomes remain unsegregated and the mitotic spindle is absent. We propose that the chromosomal protein is activated by phosphorylation at the interphase/mitosis transition by Cdc2 kinase, and that the protein, alone or as a complex, is a previously unidentified Cdc2 kinase substrate and chromatin factor necessary for spindle assembly.	MONASH UNIV,SCH MED,DEPT PATHOL & IMMUNOL,PRAHRAN,VIC 3181,AUSTRALIA	Monash University			Alderuccio, Frank/D-5808-2011	Alderuccio, Frank/0000-0003-4853-3394				ALDERUCCIO F, 1991, J EXP MED, V173, P941, DOI 10.1084/jem.173.4.941; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BOOTSMA D, 1964, EXP CELL RES, V33, P301, DOI 10.1016/S0014-4827(64)81035-1; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICUTTINI FM, 1992, BLOOD, V80, P102; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; Karsenti E, 1991, Semin Cell Biol, V2, P251; KARSENTI E, 1986, TRENDS BIOCHEM SCI, V11, P460, DOI 10.1016/0968-0004(86)90247-1; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KOOY J, 1992, J BIOL CHEM, V267, P20255; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MU FT, 1988, CLIN EXP IMMUNOL, V71, P100; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NICKLAS RB, 1985, J CELL BIOL, V100, P1, DOI 10.1083/jcb.100.1.1; Nigg E A, 1991, Semin Cell Biol, V2, P261; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PEDEN KWC, 1989, EXP CELL RES, V185, P60, DOI 10.1016/0014-4827(89)90037-2; PICARD A, 1988, DEV BIOL, V128, P121, DOI 10.1016/0012-1606(88)90273-4; SANDERS WS, 1992, CELL, V70, P451; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SCHICKEDANZ J, 1986, VIROLOGY, V148, P47, DOI 10.1016/0042-6822(86)90402-2; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	30	24	25	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 20	1994	367	6460					288	291		10.1038/367288a0	http://dx.doi.org/10.1038/367288a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	8121495				2022-12-28	WOS:A1994MR49400061
J	SIEGFRIED, E; WILDER, EL; PERRIMON, N				SIEGFRIED, E; WILDER, EL; PERRIMON, N			COMPONENTS OF WINGLESS SIGNALING IN DROSOPHILA	NATURE			English	Article							SEGMENT-POLARITY GENE; MOLECULAR-CLONING; HUMAN PLAKOGLOBIN; PROTEIN; ARMADILLO; EXPRESSION; PRODUCT; HOMOLOG; ENCODES; MELANOGASTER	THE determination of specific cell fates and polarity within each segmental unit of the Drosophila embryo involves the products of the segment polarity genes1. One of these, wingless (wg), encodes a secreted protein 2,3 that is homologous to the mammalian protooncogene Wnt-1 (refs 4, 5). In the embryonic epidermis, wg is expressed in a single row of cells within each segmental unit, although its activity is required for the correct patterning of most of the epidermis4,6. Initially Wg signals to adjacent posterior cells, maintaining engrailed (en) expression7,8. Later during embryogenesis, wg specifies the differentiation of naked cuticle9. Wg signalling functions by inactivating or antagonizing the activity of zeste-white 3 (zw3)10. We have investigated the requirement in the Wg signal transduction pathway for the three genes armadillo (arm)11,12, dishevelled (dsh) and porcupine (porc)13, all of which have embryonic mutant phenotypes similar to wg. Our results indicate that dsh and porc act upstream of zw3, and arm acts down-stream of zw3.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	SIEGFRIED, E (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,200 LONGWOOD AVE,BOSTON,MA 02115, USA.			Perrimon, Norbert/0000-0001-7542-472X				BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHOU TB, 1992, GENETICS, V131, P643; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KLINGENSMITH J, 1989, DEV BIOL, V134, P130, DOI 10.1016/0012-1606(89)90084-5; KLINGENSMITH J, IN PRESS GENES DEV; MARTINEZARIAS A, 1988, DEVELOPMENT, V103, P153; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; PEIFER M, IN PRESS DEVELOPMENT; PERRIMON N, 1984, GENETICS, V108, P927; PERRIMON N, 1989, DEV BIOL, V135, P287, DOI 10.1016/0012-1606(89)90180-2; PERRIMON N, 1989, GENETICS, V121, P333; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANDENHEUVEL M, IN PRESS EMBO J; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3	33	295	297	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 6	1994	367	6458					76	80		10.1038/367076a0	http://dx.doi.org/10.1038/367076a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	8107779				2022-12-28	WOS:A1994MP86500063
J	NIGHTINGALE, SL				NIGHTINGALE, SL			MEDWATCH CONFERENCE COSPONSORED BY THE FDA AND THE AMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2669	2669						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	8133573				2022-12-28	WOS:A1993MJ82100006
J	TOBIAS, JS; SOUHAMI, RL				TOBIAS, JS; SOUHAMI, RL			FULLY INFORMED CONSENT CAN BE NEEDLESSLY CRUEL	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CLINICAL-TRIAL; ETHICS		UCL, SCH MED, LONDON WC1, ENGLAND	University of London; University College London; UCL Medical School	TOBIAS, JS (corresponding author), MIDDLESEX HOSP, MEYERSTEIN INST CLIN ONCOL, CANC SERV, LONDON W1N 8AA, ENGLAND.							ABE O, 1992, LANCET, V339, P71; [Anonymous], 1986, Lancet, V1, P397; BAUM M, 1989, BRIT MED J, V299, P251, DOI 10.1136/bmj.299.6693.251; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; HELLMAN S, 1991, NEW ENGL J MED, V324, P1585, DOI 10.1056/NEJM199105303242208; INGELFINGER FJ, 1980, NEW ENGL J MED, V303, P1507, DOI 10.1056/NEJM198012253032604; RAPHAEL A, 1988, OBSERVER        1009; SEGELOV E, 1992, ANN ONCOL, V3, P103, DOI 10.1093/oxfordjournals.annonc.a058119; THORNTON HM, 1992, LANCET, V339, P44, DOI 10.1016/0140-6736(92)90157-X; Williams C, 1992, INTRO NEW TREATMENTS, P49; Williams C.J., 1992, INTRO NEW TREATMENTS; 1980, LANCET, V2, P245; 1990, GUIDELINES PRACTICE	13	117	117	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 6	1993	307	6913					1199	1201		10.1136/bmj.307.6913.1199	http://dx.doi.org/10.1136/bmj.307.6913.1199			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF824	8135933	Green Published, Bronze			2022-12-28	WOS:A1993MF82400030
J	BRYAN, CS				BRYAN, CS			WHAT IS THE OSLERIAN TRADITION	ANNALS OF INTERNAL MEDICINE			English	Article							INTERNAL-MEDICINE	Discussants of internal medicine often invoke but seldom define ''the Oslerian tradition,'' which has many meanings. No definition provides clear insight into the issues now relevant to American internal medicine, primarily because, as William Osler knew, the field itself shows definitional ambivalence. The tradition might be best understood as a virtuous approach to medicine and to life as taught and modeled by Osler. If we understand his philosophy and methods, we will be better prepared to use and pass on (tradere, ''to deliver'') something of greater value: the ability to make wise choices that are in society's best interest.			BRYAN, CS (corresponding author), UNIV S CAROLINA, SCH MED, DEPT MED, 2 RICHLAND MED PK, SUITE 502, COLUMBIA, SC 29203 USA.							ADLER MJ, 1984, VISION FUTURE 12 IDE, P115; BARONDESS JA, 1993, ANN INTERN MED, V119, P153, DOI 10.7326/0003-4819-119-2-199307150-00010; BARONDESS JA, 1991, ANN INTERN MED, V115, P962, DOI 10.7326/0003-4819-115-12-962; BLY R, 1990, IRON JOHN BOOK MEN, P1; BONDY PK, 1980, YALE J BIOL MED, V53, P213; BURNUM JF, 1977, ARCH INTERN MED, V137, P226, DOI 10.1001/archinte.137.2.226; CAMPBELL J, 1949, HERO 1000 FACES, P387; CHESNEY AM, 1963, J HOPKINS HOSPITAL J, V3, P175; CUSHING H, 1925, LIFE W OSLER, V2, P411; CUSHING H, 1925, LIFE W OSLER, V1, P94; CUSHING H, 1975, LIFE W OSLER, V2, P76; DAVISON WC, 1969, J AMER MED ASSOC, V210, P2219, DOI 10.1001/jama.210.12.2219; DUBOVSKY SL, 1983, JAMA-J AM MED ASSOC, V250, P3057, DOI 10.1001/jama.250.22.3057; FREESE AS, 1968, TODAYS HLTH, V46, P39; FULLER LE, 1993, JAMA-J AM MED ASSOC, V270, P1033, DOI 10.1001/jama.1993.03510090017004; FYE WB, 1989, NEW ENGL J MED, V320, P1425, DOI 10.1056/NEJM198905253202123; GOLDEN RL, 1992, ANN INTERN MED, V116, P255, DOI 10.7326/0003-4819-116-3-255; Harrell G T, 1973, Bull Hist Med, V47, P545; HINOHARA S, 1993, ANN INTERN MED, V118, P638, DOI 10.7326/0003-4819-118-8-199304150-00012; INLOW WD, 1964, B HIST MED, V38, P119; JOY M, 1985, AM J MED, V79, P5, DOI 10.1016/0002-9343(85)90538-8; KAMPMEIER RH, 1970, SOUTH MED J, V60, P345; KASSIRER JP, 1993, NEW ENGL J MED, V328, P648, DOI 10.1056/NEJM199303043280910; KEYNES G, 1968, BMJ-BRIT MED J, V4, P599, DOI 10.1136/bmj.4.5631.599; KING LS, 1991, TRANSFORMATIONS AM M, P4; KREISBERG RA, 1991, AM J MED, V91, P273, DOI 10.1016/0002-9343(91)90127-J; LEE PR, 1992, MAYO CLIN PROC, V67, P876, DOI 10.1016/S0025-6196(12)60827-1; LEPORE MJ, 1982, DEATH CLIN REQUIEM R; MACIEIRACOELHO A, 1988, INTERDISCIPLINARY TO, P1; MacIntyre A., 2007, AFTER VIRTUE, V3rd; MAUGHAM WS, 1945, SUMMING UP, P308; MCCARTY DJ, 1987, NEW ENGL J MED, V317, P567, DOI 10.1056/NEJM198708273170909; MCCRAE T, 1920, W OSLER BRIEF TRIBUT, P59; MCKECHNIE JL, 1983, WEBSTERS NEW 20TH CE, P1934; MOORE T, 1992, CARE SOUL GUIDE CULT, P3; NAISBITT J, 1982, MEGATRENDS, P39; NOBLE J, 1993, AM J MED, V95, P231, DOI 10.1016/0002-9343(93)90266-R; Osler O., 1932, AEQUANIMITAS OTHER A, P395; Osler W, 1909, Br Med J, V2, P925; Osler W, 1900, LANCET, V2, P73; Osler W, 1910, BMJ-BRIT MED J, V1910, P1470, DOI 10.1136/bmj.1.2581.1470; OSLER W, 1892, REMARKS SPECIALISM, P2; OSLER W, 1907, MODERN MED ITS THEOR, V1, pR15; OSLER W, 1905, AEQUANIMITAS OTHER A, P137; OSLER W, 1920, OLD HUMANITIES NEW S, P63; OSLER W, 1907, ST MARYS HOSP GAZETT, V13, P95; OSLER W, 1911, NORTHUMBERLAND DURHA, V18, P178; OSLER W, 1944, SCI IMMORTALITY, P42; OSLER W, 1932, AEQUANIMITAS OTHER A, P445; OSLER W, 1915, INT CLIN, V4, P1; PANUSH RS, 1993, AM J MED, V95, P1, DOI 10.1016/0002-9343(93)90225-E; PELLEGRINO ED, 1990, B NEW YORK ACAD MED, V66, P221; PEPPER W, 1891, T ASSOC AM PHYSICIAN, V6, pR15; REGELSON W, 1978, JAMA-J AM MED ASSOC, V239, P317, DOI 10.1001/jama.239.4.317; REITEMEIER RJ, 1991, ANN INTERN MED, V114, P69, DOI 10.7326/0003-4819-114-1-69; ROLAND CG, 1974, ANN INTERN MED, V81, P690, DOI 10.7326/0003-4819-81-5-690; SCHROEDER SA, 1992, ANN INTERN MED, V116, P583, DOI 10.7326/0003-4819-116-7-583; Shelp E. E., 1985, VIRTUE MED EXPLORATI; SIEGLER M, 1993, MAYO CLIN PROC, V68, P461, DOI 10.1016/S0025-6196(12)60195-5; SPIRO H, 1992, ANN INTERN MED, V116, P843, DOI 10.7326/0003-4819-116-10-843; STEVENS R, 1986, ANN INTERN MED, V105, P592, DOI 10.7326/0003-4819-105-4-592; STEVENS R, 1988, GRAND ROUNDS 100 YEA, P339; TIGERTT WD, 1983, J HIST MED ALL SCI, V38, P259, DOI 10.1093/jhmas/38.3.259; WHEELER HB, 1990, NEW ENGL J MED, V322, P1540, DOI 10.1056/NEJM199005243222129; Wilkinson A, 1956, LIONS WAY DISCURSIVE	65	12	12	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1994	120	8					682	687		10.7326/0003-4819-120-8-199404150-00010	http://dx.doi.org/10.7326/0003-4819-120-8-199404150-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE850	8135454				2022-12-28	WOS:A1994NE85000010
J	LE, DT; WEIBERT, RT; SEVILLA, BK; DONNELLY, KJ; RAPAPORT, SI				LE, DT; WEIBERT, RT; SEVILLA, BK; DONNELLY, KJ; RAPAPORT, SI			THE INTERNATIONAL NORMALIZED RATIO (INR) FOR MONITORING WARFARIN THERAPY - RELIABILITY AND RELATION TO OTHER MONITORING METHODS	ANNALS OF INTERNAL MEDICINE			English	Article						DRUG MONITORING; PROTHROMBIN TIME; WARFARIN; INTERNATIONAL NORMALIZED RATIO; THROMBOPLASTIN	NATIVE PROTHROMBIN ANTIGEN; ORAL ANTICOAGULANT-THERAPY; SENSITIVITY INDEX ISI; THROMBOPLASTIN REAGENTS; TIME; PRECISION	Objective: To enhance understanding of the reliability of the international normalized ratio (INR) for monitoring warfarin therapy and its relation to other monitoring techniques. Design: Prospective cohort study. Setting: A university hospital. Patients: 79 patients attending an anticoagulation clinic. Measurements: International normalized ratios obtained with a portable capillary monitor (Coumatrak) and the following from a simultaneous plasma sample: INRs from prothrombin times done with six thromboplastins, prothrombin-proconvertin (P&P) test activity, specific prothrombin activity, and native prothrombin antigen. Results: Converting to INRs failed to standardize prothrombin time results obtained with high- and low-sensitivity thromboplastins. Coumatrak INRs correlated best with INRs obtained with high-sensitivity thromboplastins. The INR range of 2.0 to 3.0 corresponded to a P&P range of 30% to 13%, a native plasma prothrombin antigen range of 56 to 24 mu g/mL, and a specific prothrombin activity range of 43% to 21%. Conclusions: Low-sensitivity thromboplastins may give erroneously high INRs in the upper therapeutic range. Plasma prothrombin times should be done with a high-sensitivity thromboplastin, particularly in patients maintained at the upper limit of the therapeutic range. An INR so obtained correlated well with an INR obtained with a portable capillary blood monitor.	UNIV CALIF SAN DIEGO, LA JOLLA, CA USA	University of California System; University of California San Diego					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL027234] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 27234] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKER DM, 1993, ARCH PATHOL LAB MED, V117, P602; BJERKLUND CJ, 1957, THESIS OSLO U OSLO; BLANCHARD RA, 1983, J LAB CLIN MED, V101, P242; BRAUN PJ, 1992, THROMB HAEMOSTASIS, V68, P160; BUSSEY HI, 1992, ARCH INTERN MED, V152, P278, DOI 10.1001/archinte.152.2.278; FURIE B, 1984, BLOOD, V64, P445; FURIE B, 1990, BLOOD, V75, P344; HIRSH J, 1992, ARCH INTERN MED, V152, P257, DOI 10.1001/archinte.152.2.257; HIRSH J, 1992, CHEST, V102, pS312, DOI 10.1378/chest.102.4.312S; HIRSH J, 1987, ARCH INTERN MED, V147, P769, DOI 10.1001/archinte.147.4.769; KAZAMA M, 1990, THROMB HAEMOSTASIS, V64, P535; LEWIS SM, 1985, J CLIN PATHOL, V38, P133; LOELIGER EA, 1992, ANN HEMATOL, V64, P60, DOI 10.1007/BF01715346; MCCURDY SA, 1992, ARCH INTERN MED, V152, P589, DOI 10.1001/archinte.152.3.589; NG VL, 1993, AM J CLIN PATHOL, V99, P689, DOI 10.1093/ajcp/99.6.689; OWREN PA, 1951, SCAND J CLIN LAB INV, V3, P201, DOI 10.3109/00365515109060600; OWREN PA, 1955, 1954 INT C THROMB EM, P1085; POGGIO M, 1989, THROMB HAEMOSTASIS, V62, P868; POLLER L, 1989, J CLIN PATHOL, V42, P97, DOI 10.1136/jcp.42.1.97; SISE HS, 1958, NEW ENGL J MED, V259, P266, DOI 10.1056/NEJM195808072590603; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; TABERNER DA, 1989, J CLIN PATHOL, V42, P92, DOI 10.1136/jcp.42.1.92; VANRIJN JLML, 1989, CLIN CHEM, V35, P840; XI M, 1989, THROMB HAEMOSTASIS, V62, P788; ZIVELIN A, 1993, J CLIN INVEST, V92, P2131, DOI 10.1172/JCI116814; 1983, TECHNICAL REPORT SER, V687, P81	26	64	66	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					552	558		10.7326/0003-4819-120-7-199404010-00004	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8116992				2022-12-28	WOS:A1994NC76400004
J	BARTECCHI, CE; MACKENZIE, TD; SCHRIER, RW				BARTECCHI, CE; MACKENZIE, TD; SCHRIER, RW			THE HUMAN COSTS OF TOBACCO USE .1.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CIGARETTE-SMOKING; PASSIVE SMOKING; HEART-DISEASE; UNITED-STATES; HEALTH CONSEQUENCES; LUNG-CANCER; RISK-FACTORS; WOMEN; MORTALITY; TRENDS		UNIV COLORADO, SCH MED, DEPT MED, DENVER, CO 80262 USA; DENVER HLTH & HOSP, DENVER, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Denver Health Medical Center								ARONOW WS, 1978, NEW ENGL J MED, V299, P21, DOI 10.1056/NEJM197807062990105; BARON JA, 1984, AM J EPIDEMIOL, V119, P9, DOI 10.1093/oxfordjournals.aje.a113730; BARRY J, 1989, JAMA-J AM MED ASSOC, V261, P398, DOI 10.1001/jama.261.3.398; BLOT WJ, 1988, CANCER RES, V48, P3282; BORING CC, 1993, MMWR-MORBID MORTAL W, V42, P857; BROWNSON RC, 1993, ARCH INTERN MED, V153, P469, DOI 10.1001/archinte.153.4.469; CHRISTEN WG, 1992, JAMA-J AM MED ASSOC, V268, P989; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; DEANFIELD JE, 1986, AM J CARDIOL, V57, P1005, DOI 10.1016/0002-9149(86)90665-X; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; English JP, 1940, J AMER MED ASSOC, V115, P1327, DOI 10.1001/jama.1940.02810420013004; ESCOBEDO LG, 1990, JAMA-J AM MED ASSOC, V264, P1550, DOI 10.1001/jama.264.12.1550; FAIRBANKS LL, 1985, NEW YORK STATE J MED, V85, P464; FIELDING JE, 1987, NEW ENGL J MED, V317, P1343, DOI 10.1056/NEJM198711193172108; FIORE MC, 1992, MED CLIN N AM, V76, P289, DOI 10.1016/S0025-7125(16)30354-6; FONTHAM ETH, 1991, CANCER EPIDEM BIOMAR, V1, P35; FRANK E, 1993, WESTERN J MED, V159, P83; GLANTZ SA, 1993, JAMA-J AM MED ASSOC, V269, P793, DOI 10.1001/jama.269.6.793; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; HAAPANEN A, 1989, CIRCULATION, V80, P10, DOI 10.1161/01.CIR.80.1.10; HALLSTROM AP, 1986, NEW ENGL J MED, V314, P271, DOI 10.1056/NEJM198601303140502; HOLLY EA, 1986, J NATL CANCER I, V76, P983; HUSSEY HH, 1976, JAMA-J AM MED ASSOC, V235, P1367, DOI 10.1001/jama.235.13.1367; JANERICH DT, 1990, NEW ENGL J MED, V323, P632, DOI 10.1056/NEJM199009063231003; KLEIN J, 1993, NEW ENGL J MED, V328, P66, DOI 10.1056/NEJM199301073280116; KNEKT P, 1991, J CLIN EPIDEMIOL, V44, P933, DOI 10.1016/0895-4356(91)90056-F; Krupski W C, 1991, Ann Vasc Surg, V5, P291, DOI 10.1007/BF02329389; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; LAYDE P M, 1981, Lancet, V1, P541; MARCUS AC, 1989, NCI MONOGRAPHS, V0008; MCBRIDE PE, 1992, MED CLIN N AM, V76, P333, DOI 10.1016/S0025-7125(16)30356-X; MCCUSKER K, 1992, AM J MED, V93, pS18, DOI 10.1016/0002-9343(92)90622-I; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MCINTOSH ID, 1984, CAN J PUBLIC HEALTH, V75, P141; MECKLENBURG RE, 1992, NCI NIH923330 PUBL; MENON P, 1992, J ALLERGY CLIN IMMUN, V89, P560, DOI 10.1016/0091-6749(92)90323-T; MUSCAT JE, 1991, AM HEART J, V121, P141, DOI 10.1016/0002-8703(91)90967-M; NEWCOMB PA, 1992, MED CLIN N AM, V76, P305, DOI 10.1016/S0025-7125(16)30355-8; OHKUBO C, 1982, PREV MED, V11, P173, DOI 10.1016/0091-7435(82)90016-0; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P61, DOI 10.1001/jama.261.1.61; PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P56, DOI 10.1001/jama.261.1.56; ROSENOW EC, 1993, MAYO CLIN PROC, V68, P168, DOI 10.1016/S0025-6196(12)60165-7; SHAH PK, 1988, CHEST, V94, P449, DOI 10.1378/chest.94.3.449; SHERMAN CB, 1992, MED CLIN N AM, V76, P355, DOI 10.1016/S0025-7125(16)30357-1; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; SLATTERY ML, 1989, JAMA-J AM MED ASSOC, V261, P1593, DOI 10.1001/jama.261.11.1593; STEENLAND K, 1992, JAMA-J AM MED ASSOC, V267, P94, DOI 10.1001/jama.267.1.94; SUGIISHI M, 1993, CIRCULATION, V87, P76, DOI 10.1161/01.CIR.87.1.76; TRICHOPOULOS D, 1992, JAMA-J AM MED ASSOC, V268, P1697, DOI 10.1001/jama.268.13.1697; WALLACE L, 1987, ARCH ENVIRON HEALTH, V42, P272, DOI 10.1080/00039896.1987.9935820; WEST S, 1992, JAMA-J AM MED ASSOC, V268, P1025, DOI 10.1001/jama.268.8.1025; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; 1993, SMOKING RELATED DEAT; 1979, HLTH CONSEQUENCES SM; 1992, NIH923461 DEP HLTH H; 1986, DHHS CDC878398 DEP H; 1989, DHHS CDC898411 DEP H; 1993, MMWR MORB MORTAL WKL, V42, P645; 1990, NIH903107 DEP HLTH H; 1975, HIST STATISTICS US C, V1, P55; 1993, MMWR MORB MORTAL WKL, V42, P230; 1990, DHHS CDC908416 PUBL; 1992, TOB CONTROL, V1, P231; 1987, DHHS CDC878396 DEP H; 1982, DHHS PHS8250179 DEP; 1992, RESPIRATORY HLTH EFF; 1993, CANCER FACTS FIGURES	68	350	359	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 31	1994	330	13					907	912		10.1056/NEJM199403313301307	http://dx.doi.org/10.1056/NEJM199403313301307			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC608	8114863				2022-12-28	WOS:A1994NC60800007
J	ROSENBERG, SA; YANG, JC; TOPALIAN, SL; SCHWARTZENTRUBER, DJ; WEBER, JS; PARKINSON, DR; SEIPP, CA; EINHORN, JH; WHITE, DE				ROSENBERG, SA; YANG, JC; TOPALIAN, SL; SCHWARTZENTRUBER, DJ; WEBER, JS; PARKINSON, DR; SEIPP, CA; EINHORN, JH; WHITE, DE			TREATMENT OF 283 CONSECUTIVE PATIENTS WITH METASTATIC MELANOMA OR RENAL-CELL CANCER USING HIGH-DOSE BOLUS INTERLEUKIN-2	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACTIVATED KILLER CELLS; ESTABLISHED PULMONARY METASTASES; TUMOR-INFILTRATING LYMPHOCYTES; RECOMBINANT INTERLEUKIN-2; AUTOLOGOUS TUMOR; INVITRO GROWTH; IMMUNOTHERAPY; REGRESSION; RESPONSES; LYSIS	Objective.-To determine the efficacy of treatment using high-dose bolus interleukin 2 (IL-2) in patients with metastatic melanoma or renal cell cancer. Design and Setting.-Consecutive series of all patients treated with high-dose IL-2 in the Surgery Branch of the National Cancer Institute from September 1985 through December 1992. Patients.-Two hundred eighty-three patients with metastatic melanoma or metastatic renal cell cancer who had failed standard treatment for their cancers. Interventions.-Patients received IL-2 at a dose of 720 000 IU/kg intravenously every 8 hours for a maximum of 15 doses per cycle. Two cycles constituted a treatment course, and patients with stable or responding disease received additional treatment courses. A total of 447 courses of treatment were administered. Main Outcome Measures.-Regression of measurable tumor, durability of response to treatment, and survival. Results.-Nine patients (7%) with metastatic melanoma achieved complete regression of all disease and 14 patients (10%) had partial regression. Ten patients (7%) with metastatic renal cell cancer experienced complete regression and 20 patients (13%) had partial regression. Of the 19 patients with complete regression, 15 have remained in complete remission from 7 to 91 months aftertreatment. Three treatment-related deaths (1.1%) occurred early in this series, but as experience with the administration of this IL-2 regimen increased, no treatment-related deaths occurred in 214 patients treated during the last 5 years of the study. Conclusion.-Biologic therapy with IL-2 can cause significant antitumor effects in patients with advanced metastatic melanoma or renal cell cancer. Because IL-2 does not have a direct effect on cancer cells but rather mediates its antitumor activity by altering host immune reactions, these data represent the best available evidence that immunologic therapy for cancer can be effective in selected patients.			ROSENBERG, SA (corresponding author), NCI,DIV CANC TREATMENT,SURG BRANCH,9000 ROCKVILLE PIKE,BLDG 10,ROOM 2B42,BETHESDA,MD 20892, USA.							ATKINS MB, 1988, NEW ENGL J MED, V318, P1557, DOI 10.1056/NEJM198806163182401; BALCH CM, 1993, CANC PRINCIPLES PRAC, P1612; BELLDEGRUN A, 1987, ANN INTERN MED, V106, P817, DOI 10.7326/0003-4819-106-6-817; BOCK SN, 1990, J CLIN ONCOL, V8, P161, DOI 10.1200/JCO.1990.8.1.161; DENICOFF KD, 1987, ANN INTERN MED, V107, P293, DOI 10.7326/0003-4819-107-2-293; DEVITA VT, 1993, CANCER PRINCIPLES PR; ELSON PJ, 1988, CANCER RES, V48, P7310; ETTINGHAUSEN SE, 1987, BLOOD, V69, P1654; ETTINGHAUSEN SE, 1986, CANCER RES, V46, P2784; FAIRLAMB DJ, 1981, CANCER, V47, P2102, DOI 10.1002/1097-0142(19810415)47:8<2102::AID-CNCR2820470833>3.0.CO;2-K; FISHER B, 1989, J CLIN ONCOL, V7, P1852, DOI 10.1200/JCO.1989.7.12.1852; GASPARI AA, 1987, JAMA-J AM MED ASSOC, V258, P1624, DOI 10.1001/jama.258.12.1624; GRIMM EA, 1982, J EXP MED, V155, P1823, DOI 10.1084/jem.155.6.1823; ITOH K, 1988, J EXP MED, V168, P1419, DOI 10.1084/jem.168.4.1419; KIRKWOOD JM, 1993, PRINCIPLES PRACTICE, P1; KLEMPNER MS, 1990, NEW ENGL J MED, V322, P959, DOI 10.1056/NEJM199004053221404; KURZROCK R, 1991, BIOL THERAPY CANCER, P247; LEE RE, 1989, J CLIN ONCOL, V7, P7, DOI 10.1200/JCO.1989.7.1.7; LOTZE MT, 1981, CANCER RES, V41, P4420; LOTZE MT, 1981, J IMMUNOL, V126, P2215; LOTZE MT, 1986, JAMA-J AM MED ASSOC, V256, P3117, DOI 10.1001/jama.256.22.3117; LOTZE MT, 1985, J IMMUNOL, V135, P2865; LOTZE MT, 1991, BIOL THERAPY CANCER, P159; MALKOVSKA V, 1993, THERAPEUTIC APPLICAT, V2, P143; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; MULE JJ, 1984, SCIENCE, V225, P1487, DOI 10.1126/science.6332379; MUUL LM, 1987, J IMMUNOL, V138, P989; OGNIBENE FP, 1988, CHEST, V94, P750, DOI 10.1378/chest.94.4.750; POCKAJ BA, 1993, J CLIN ONCOL, V22, P136; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1992, J CLIN ONCOL, V10, P180, DOI 10.1200/JCO.1992.10.2.180; ROSENBERG SA, 1984, SCIENCE, V223, P1412, DOI 10.1126/science.6367046; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; ROSENBERG SA, 1985, J EXP MED, V161, P1169, DOI 10.1084/jem.161.5.1169; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; ROSENBERG SA, 1991, BIOL THERAPY CANCER, P214; ROSENSTEIN M, 1986, J IMMUNOL, V137, P1735; SCHWARTZENTRUBER DJ, 1992, J IMMUNOTHER, V12, P1, DOI 10.1097/00002371-199207000-00001; SCHWARTZENTRUBER DJ, 1991, J IMMUNOL, V146, P3674; SCHWARTZENTRUBER DJ, 1991, CANCER, V68, P2384, DOI 10.1002/1097-0142(19911201)68:11<2384::AID-CNCR2820681109>3.0.CO;2-A; SPARANO JA, 1993, THERAPEUTIC APPLICAT, V2, P99; STRAUSSER JL, 1978, J IMMUNOL, V121, P1491; SUNDERLAND MC, 1993, THERAPEUTIC APPLICAT, V2, P119; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; TOPALIAN SL, 1989, J IMMUNOL, V142, P3714; WEBB DE, 1988, CLIN NEPHROL, V30, P141; YRON I, 1980, J IMMUNOL, V125, P238	47	959	993	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	1994	271	12					907	913		10.1001/jama.271.12.907	http://dx.doi.org/10.1001/jama.271.12.907			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA743	8120958				2022-12-28	WOS:A1994NA74300025
J	HANNAN, EL; KILBURN, H; RACZ, M; SHIELDS, E; CHASSIN, MR				HANNAN, EL; KILBURN, H; RACZ, M; SHIELDS, E; CHASSIN, MR			IMPROVING THE OUTCOMES OF CORONARY-ARTERY BYPASS-SURGERY IN NEW-YORK-STATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE; MORTALITY	Objective.-To assess changes in outcomes of coronary artery bypass graft (CABG) surgery in New York since 1989, when the State Department of Health began collecting, analyzing, and disseminating information regarding risk factors, mortality, and complications of CABG surgery. These new data stimulated specific quality improvement activities at hospitals throughout the state. Design.-A clinical database was used to identify significant independent risk factors and to assess risk-adjusted provider mortality rates. Setting.-All 30 hospitals performing CABG surgery in New York during the period 1989 through 1992. Patients.-All 57187 patients undergoing isolated CABG surgery who were discharged from New York State hospitals in 1989 through 1992. Main Outcome Measures.-Actual, expected (from a logistic regression model), and risk-adjusted in-hospital mortality. Results.-Actual mortality decreased from 3.52% in 1989 to 2.78% in 1992. Because average patient severity of illness increased, risk-adjusted mortality decreased even more-a decrease of 41% from 4.17% in 1989 to 2.45% in 1992. The risk-adjustment model performed well; there were no clinically or statistically significant differences between actual and predicted numbers of deaths at any of 10 levels of patient severity. Conclusions.-We believe that this quality improvement program, based on the collection and dissemination of risk-adjusted mortality data for CABG surgery, played a significant role in the observed decline in the death rate from this procedure. Quality improvement programs based on similar principles for other procedures and conditions should be undertaken.	NEW YORK STATE DEPT HLTH,ALBANY,NY 12237; SUNY ALBANY,DEPT HLTH POLICY & MANAGEMENT,ALBANY,NY	State University of New York (SUNY) System; State University of New York (SUNY) System; State University of New York (SUNY) Albany					AHRQ HHS [HS07086-01, HS06503] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BERWICK DM, 1991, CURING HLTH CARE; BYER MJ, 1992, NY TIMES        0321, pA23; CAMPEAU L, 1975, CIRCULATION, V54, P522; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HANNAN EL, 1992, MED CARE, V30, P892, DOI 10.1097/00005650-199210000-00002; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HANNAN EL, 1991, MED CARE, V29, P430, DOI 10.1097/00005650-199105000-00004; HANNAN EL, 1991, MED CARE, V29, P1091; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; 1992, CONSUMER GUIDE CORON	13	638	644	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					761	766		10.1001/jama.271.10.761	http://dx.doi.org/10.1001/jama.271.10.761			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY288	8114213				2022-12-28	WOS:A1994MY28800030
J	PFARR, CM; MECHTA, F; SPYROU, G; LALLEMAND, D; CARILLO, S; YANIV, M				PFARR, CM; MECHTA, F; SPYROU, G; LALLEMAND, D; CARILLO, S; YANIV, M			MOUSE JUND NEGATIVELY REGULATES FIBROBLAST GROWTH AND ANTAGONIZES TRANSFORMATION BY RAS	CELL			English	Article							C-JUN; DNA-BINDING; FOS PROTEINS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; GLUCOCORTICOID RECEPTOR; FUNCTIONAL ANTAGONISM; G0-TO-G1 TRANSITION; ACTIVATION DOMAIN; ESTROGEN-RECEPTOR	As NIH 3T3 fibroblasts become quiescent, the level of c-Jun protein decreases while JunD accumulates. When resting cells are stimulated with fresh serum, nuclear-localized JunD is rapidly degraded, followed by resynthesis of both c-Jun and JunD later in G1. Overexpression of JunD results in slower growth and an increase in the percentage of cells in G0/G1 while c-Jun overexpression produces larger S/G2 and M phase populations. In addition, JunD partially suppresses transformation by an activated ras gene whereas c-Jun cooperates with ras to transform cells. These data indicate that two closely related transcription factors can function in an opposing manner.	INST GENET MOLEC MONTPELLIER, UNITE MIXTE RECH 9942, F-34033 MONTPELLIER 01, FRANCE; INST PASTEUR, DEPT BIOTECHNOL, CNRS, UNITE VIRUS ONCOGENES 1644, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			MECHTA-GRIGORIOU, Fatima/C-5253-2017; lallemand, dominique/O-7445-2017; Pfarr, Curt/HHD-1410-2022	MECHTA-GRIGORIOU, Fatima/0000-0002-3751-6989; lallemand, dominique/0000-0002-0212-7342; 				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIRAI S-I, 1989, New Biologist, V1, P181; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, NEW BIOL, V3, P870; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARTY L, 1990, BIOCHIMIE, V72, P885, DOI 10.1016/0300-9084(90)90007-4; MCCOY MS, 1986, MOL CELL BIOL, V6, P1326, DOI 10.1128/MCB.6.4.1326; MECHTA F, 1989, New Biologist, V1, P297; MILLER AD, 1984, CELL, V36, P51; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	77	298	301	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	1994	76	4					747	760		10.1016/0092-8674(94)90513-4	http://dx.doi.org/10.1016/0092-8674(94)90513-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124713				2022-12-28	WOS:A1994MZ28500016
J	ARNASON, U; GULLBERG, A				ARNASON, U; GULLBERG, A			RELATIONSHIP OF BALEEN WHALES ESTABLISHED BY CYTOCHROME-B GENE SEQUENCE COMPARISON	NATURE			English	Article							FIN WHALE; BALAENOPTERA-MUSCULUS; MITOCHONDRIAL-DNA; PHYSALUS; MAMMALS	A RECENT revision1 of whale phylogeny suggested that the sperm whale was more closely related to rorquals than to other toothed whales. This made the suborder Odontoceti (toothed whales) paraphyletic, and implied that the latest common ancestor of rorquals and sperm whales may have lived only 10-13 million years ago. This is at variance with palaeontological evidence for the greater antiquity for both mysticetes (baleen whales) and sperm whales, so the Mysticeti, as well as the Odontoceti, must also be paraphyletic if the dates implied in ref. 1 were correct. Here we present a more comprehensive phylogenetic analysis that demonstrates the monophyly of mysticetes and identifies no particular affinity between the sperm whales and rorquals.			ARNASON, U (corresponding author), LUND UNIV, DEPT GENET, DIV EVOLUT MOLEC SYST, SOLVEGATAN 29, S-22362 LUND, SWEDEN.							ADEGOKE JA, 1993, CHROMOSOMA, V102, P382, DOI 10.1007/BF00360402; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; ARNASON U, 1992, MOL BIOL EVOL, V9, P1018; ARNASON U, 1993, J MOL EVOL, V37, P312; ARNASON U, 1981, HEREDITAS, V95, P277; ARNASON U, 1993, BIOCHEM SYST ECOL, V21, P115, DOI 10.1016/0305-1978(93)90016-K; ARNASON U, 1993, MOL BIOL EVOL, V10, P960; ARNASON U, 1991, J MOL EVOL, V33, P556, DOI 10.1007/BF02102808; ARNASON U, 1991, HEREDITAS, V114, P263, DOI 10.1111/j.1601-5223.1991.tb00333.x; ARNASON U, 1991, HEREDITAS, V115, P183, DOI 10.1111/j.1601-5223.1991.tb03554.x; ARNASON U, 1973, HEREDITAS, V75, P67; Barnes L.G., 1978, P582; BARNES LG, 1985, MAR MAMMAL SCI, V1, P15, DOI 10.1111/j.1748-7692.1985.tb00530.x; Barnes LG, 1984, GRAY WHALE ESCHRICHT, P3; Czelusniak J., 1990, Current Mammalogy, V2, P545; FELSENSTEIN J, 1991, PHYLIP VERSION 3 4 1; GOODMAN M, 1989, INT CONGR SER, V824, P43; Gray JE, 1874, T P NZ I, V6, P93; GRETARSDOTTIR S, 1993, MOL BIOL EVOL, V10, P306; HEYNING JE, 1990, NATO ADV SCI I A-LIF, V196, P67; HEYNING JE, 1989, CONTRIBUTIONS SCI NA, V405, P1; IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385; MED JG, 1993, MAMMAL SPECIES WORLD, P349; MILINKOVITCH MC, 1993, NATURE, V361, P346, DOI 10.1038/361346a0; Miller G. S., 1923, Smithsonian Miscellaneous Collections, V76, P1; NOVACEK M, 1993, NATURE, V361, P298, DOI 10.1038/361298a0; RICE DW, 1977, NOAA NMFS SSRF711 TE; SPILLIAERT R, 1991, J HERED, V82, P269, DOI 10.1093/oxfordjournals.jhered.a111085; Swofford D.L., 1993, PHYLOGENETIC ANAL US	29	103	120	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					726	728		10.1038/367726a0	http://dx.doi.org/10.1038/367726a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	8107866				2022-12-28	WOS:A1994MX63100055
J	THUNNISSEN, AMWH; DIJKSTRA, AJ; KALK, KH; ROZEBOOM, HJ; ENGEL, H; KECK, W; DIJKSTRA, BW				THUNNISSEN, AMWH; DIJKSTRA, AJ; KALK, KH; ROZEBOOM, HJ; ENGEL, H; KECK, W; DIJKSTRA, BW			DOUGHNUT-SHAPED STRUCTURE OF A BACTERIAL MURAMIDASE REVEALED BY X-RAY CRYSTALLOGRAPHY	NATURE			English	Article							SOLUBLE LYTIC TRANSGLYCOSYLASE; ESCHERICHIA-COLI; BACTERIOPHAGE-T4 LYSOZYME; PROTEINS; DETECTOR	THE integrity of the bacterial cell wall depends on the balanced action of several peptidoglycan (murein) synthesizing and degrading enzymes1,2. Penicillin inhibits the enzymes responsible for peptide crosslinks in the peptidoglycan polymer3. Enzymes that act solely on the glycosidic bonds are insensitive to this antibiotic, thus offering a target for the design of antibiotics distinct from the beta-lactams. Here we report the X-ray structure of the periplasmic soluble lytic transglycosylase (SLT; M(r) 70,000) from Escherichia coli. This unique bacterial exomuramidase cleaves the beta-1,4-glycosidic bonds of peptidoglycan to produce small 1,6-anhydromuropeptides4-6. The structure of SLT reveals a 'superhelical' ring of alpha-helices with a separate domain on top which resembles the fold of lysozyme. Site-directed mutagenesis and a crystallographic inhibitor-binding study confirmed that the lysozyme-like domain contains the active site of SLT.	UNIV GRONINGEN,DEPT CHEM,BIOSON RES INST,NIJENBORGH 4,9747 AG GRONINGEN,NETHERLANDS; F HOFFMANN LA ROCHE & CO LTD,PHARMA RES DEPT,CH-4002 BASEL,SWITZERLAND	University of Groningen; Roche Holding			Dijkstra, Bauke W./H-4308-2019; Thunnissen, Andy-Mark/A-1777-2010	Dijkstra, Bauke W./0000-0001-9731-6586; Thunnissen, Andy-Mark/0000-0002-1915-9850; Rozeboom, Henriette/0000-0002-1656-6477				BANASZAK L, 1991, ANNU REV BIOPHYS BIO, V20, P221, DOI 10.1146/annurev.biophys.20.1.221; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BEACHEY EH, 1981, EUR J BIOCHEM, V116, P355, DOI 10.1111/j.1432-1033.1981.tb05342.x; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BERSCHUEREN KHG, 1993, J MOL BIOL, V232, P856; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1992, XPLOR VERSION 3 0 MA; ENGEL H, 1991, J BACTERIOL, V173, P6773, DOI 10.1128/jb.173.21.6773-6782.1991; HARDY LW, 1991, BIOCHEMISTRY-US, V30, P9457, DOI 10.1021/bi00103a010; HOLTJE JV, 1975, J BACTERIOL, V124, P1067; HOLTJE JV, 1985, MOL CYTOLOGY ESCHERI, P77; IMOTO T, 1972, ENZYMES, P666; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KECK W, 1985, EUR J BIOCHEM, V148, P493, DOI 10.1111/j.1432-1033.1985.tb08866.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; Rogers H., 1980, MICROBIAL CELL WALLS, P437; ROZEBOOM HJ, 1990, J MOL BIOL, V212, P557, DOI 10.1016/0022-2836(90)90221-7; SHINAGAWA S, 1985, J ANTIBIOT, V38, P17, DOI 10.7164/antibiotics.38.17; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P440; TEMPLIN MF, 1992, J BIOL CHEM, V267, P20039; WAXMAN DJ, 1983, ANNU REV BIOCHEM, V52, P825, DOI 10.1146/annurev.bi.52.070183.004141; WEAVER LH, 1987, J MOL BIOL, V193, P189, DOI 10.1016/0022-2836(87)90636-X	27	145	146	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					750	754		10.1038/367750a0	http://dx.doi.org/10.1038/367750a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	8107871	Green Submitted			2022-12-28	WOS:A1994MX63100062
J	DEJONGE, JW; KNOTTNERUS, JA; VANZUTPHEN, WM; DEBRUIJNE, GA; BOUDIER, HAJS				DEJONGE, JW; KNOTTNERUS, JA; VANZUTPHEN, WM; DEBRUIJNE, GA; BOUDIER, HAJS			SHORT-TERM EFFECT OF WITHDRAWAL OF DIURETIC DRUGS PRESCRIBED FAR ANKLE EDEMA	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the effect of withdrawing diuretic drugs on oedema in patients prescribed them for only ankle oedema, excluding patients with cardiac, hepatic, or renal failure. Design-Randomised controlled trial. Setting-15 general practices in the Netherlands. Patients-1202 patients aged 65 years or older and taking diuretic drugs, 63 of whom were eligible for the trial. Main outcome measure-Change in volumetrically determined ankle oedema (oedema index) over six weeks. Results-34 patients were randomised to stop diuretics and 29 to the control group. In eight patients diuretics had to be restarted. Among patients who had diuretics withdrawn successfully, rebound oedema caused a temporary increase in mean oedema index. The peak level (3.5% (95% confidence interval 1.5% to 5.2%) was reached in the third week, after which the oedema seemed to be returning to the baseline level. Conclusion-Few patients who have been prescribed diuretics for only ankle oedema clearly have no contraindications to withdrawing diuretics. If patients are unlikely to have cardiac insufficiency and careful monitoring is provided, withdrawal of diuretics seems to be feasible, though moderate rebound oedema may occur for a short time.			DEJONGE, JW (corresponding author), UNIV LIMBURG, DEPT GEN PRACTICE, POB 616, 6200 MD MAASTRICHT, NETHERLANDS.		Knottnerus, Andre/F-4866-2013; Knottnerus, Johannes A/A-3829-2009					BURR M L, 1977, Age and Ageing, V6, P38; CARLSON KJ, 1985, J CHRON DIS, V38, P733, DOI 10.1016/0021-9681(85)90115-8; Dixon W. J., 1990, BMDP STATISTICAL SOF; MACGREGOR GA, 1975, LANCET, V1, P489; MACGREGOR GA, 1979, LANCET, V1, P397; MACLENNAN WJ, 1988, BMJ-BRIT MED J, V296, P1551, DOI 10.1136/bmj.296.6636.1551; Myers M G, 1982, Age Ageing, V11, P213, DOI 10.1093/ageing/11.4.213; Pocock SJ., 2013, CLIN TRIALS PRACTICA; Thulesius O, 1973, Vasa, V2, P325; WALMA EP, 1989, HUISSARTS WET, V32, P326; WILCOCK GK, 1982, GERIATRIC PROBLEMS G, P64; 1978, BRIT MED J, V1, P1092	12	27	27	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 19	1994	308	6927					511	513		10.1136/bmj.308.6927.511	http://dx.doi.org/10.1136/bmj.308.6927.511			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX814	8136670	Green Published			2022-12-28	WOS:A1994MX81400024
J	KUHLBRANDT, W; WANG, DN; FUJIYOSHI, Y				KUHLBRANDT, W; WANG, DN; FUJIYOSHI, Y			ATOMIC MODEL OF PLANT LIGHT-HARVESTING COMPLEX BY ELECTRON CRYSTALLOGRAPHY	NATURE			English	Article							PHOTOSYNTHETIC REACTION CENTER; A/B-PROTEIN COMPLEX; CHLOROPHYLL-A; RHODOPSEUDOMONAS-VIRIDIS; ENERGY-TRANSFER; 3A RESOLUTION; DENSITY MAPS; MEMBRANE; MICROSCOPY; PHOSPHORYLATION	The structure of the light-harvesting chlorophyll a/b-protein complex, an integral membrane protein, has been determined at 3.4 Angstrom resolution by electron crystallography of two-dimensional crystals. Two of the three membrane-spanning alpha-helices are held together by ion pairs formed by charged residues that also serve as chlorophyll ligands. In the centre of the complex, chlorophyll a is in close contact with chlorophyll b for rapid energy transfer, and with two carotenoids that prevent the formation of toxic singlet oxygen.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN		KUHLBRANDT, W (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.		Fujiyoshi, Yoshinori/E-5989-2012	Fujiyoshi, Yoshinori/0000-0002-8070-1493; Kuhlbrandt, Werner/0000-0002-2013-4810; Wang, Da-Neng/0000-0002-6496-4699				BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; BENNETT J, 1979, EUR J BIOCHEM, V99, P133, DOI 10.1111/j.1432-1033.1979.tb13239.x; BOOY FP, 1993, ULTRAMICROSCOPY, V48, P273, DOI 10.1016/0304-3991(93)90101-3; BORN M, 1975, PRINCIPLES OPTICS, P333; BOWERS PG, 1967, PROC R SOC LON SER-A, V296, P435, DOI 10.1098/rspa.1967.0036; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUTT HJ, 1991, ULTRAMICROSCOPY, V36, P307, DOI 10.1016/0304-3991(91)90123-N; CASHMORE AR, 1984, P NATL ACAD SCI-BIOL, V81, P2960, DOI 10.1073/pnas.81.10.2960; CESKA TA, 1994, J APPL CRYSTALLOGR, V27, P200, DOI 10.1107/S0021889893009537; COGDELL RJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P63, DOI 10.1016/S0304-4173(87)80008-3; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; DEMMIGADAMS B, 1992, REV PLANT PHYSL, V43, P599; DEXTER DL, 1953, J CHEM PHYS, V21, P836, DOI 10.1063/1.1699044; EADS DD, 1989, J PHYS CHEM-US, V93, P8271, DOI 10.1021/j100363a001; ECCLES J, 1983, P NATL ACAD SCI-BIOL, V80, P4959, DOI 10.1073/pnas.80.16.4959; EVANS PR, 1991, CRYSTALLOGRAPHIC COM, V5, P136; FUJIYOSHI Y, 1980, ULTRAMICROSCOPY, V5, P459, DOI 10.1016/S0304-3991(80)80004-0; FUJIYOSHI Y, 1991, ULTRAMICROSCOPY, V38, P241, DOI 10.1016/0304-3991(91)90159-4; GLAESER RM, 1989, ULTRAMICROSCOPY, V27, P307, DOI 10.1016/0304-3991(89)90021-1; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; HILLER RG, 1993, J PHOTOCHEM PHOTOBIO, V57, P125; HOFFMANN NE, 1986, P NATL ACAD SCI USA, V84, P8844; IDE JP, 1987, BIOCHIM BIOPHYS ACTA, V893, P349, DOI 10.1016/0005-2728(87)90056-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUHLER RK, 1993, PHOTOSYNTH RES, V35, P171, DOI 10.1007/BF00014747; KEARNS DR, 1971, CHEM REV, V71, P395, DOI 10.1021/cr60272a004; KRAMER H, 1980, BIOCHIM BIOPHYS ACTA, V593, P319, DOI 10.1016/0005-2728(80)90069-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; KUHLBRANDT W, 1989, J MOL BIOL, V207, P823, DOI 10.1016/0022-2836(89)90247-7; MATTHEWS BW, 1979, J MOL BIOL, V131, P259, DOI 10.1016/0022-2836(79)90076-7; MAURING K, 1987, SPECTROCHIM ACTA A, V43, P507, DOI 10.1016/0584-8539(87)80052-1; MICHEL H, 1991, J BIOL CHEM, V266, P17584; MULLET JE, 1983, J BIOL CHEM, V258, P9941; NUSSBERGER S, 1993, J MOL BIOL, V234, P347, DOI 10.1006/jmbi.1993.1591; PALSSON LO, IN PRESS FEBS LETT; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; PETER GF, 1991, J BIOL CHEM, V266, P16745; PICOREL R, 1992, PHOTOCHEM PHOTOBIOL, V56, P263, DOI 10.1111/j.1751-1097.1992.tb02156.x; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; SIEFERMANNHARMS D, 1985, BIOCHIM BIOPHYS ACTA, V811, P325, DOI 10.1016/0304-4173(85)90006-0; STERLING C, 1964, ACTA CRYSTALLOGR, V17, P1224, DOI 10.1107/S0365110X64003152; UNWIN PNT, 1975, J MOL BIOL, V94, P425, DOI 10.1016/0022-2836(75)90212-0; van der Vos R, 1991, APPL MAGN RESON, V2, P179, DOI 10.1007/BF03166035; WANG DN, 1991, J MOL BIOL, V217, P691, DOI 10.1016/0022-2836(91)90526-C; WANG DN, 1992, BIOPHYS J, V61, P287, DOI 10.1016/S0006-3495(92)81836-2; 1974, INT TABLES XRAY CRYS, V4, P71	53	1545	1609	4	202	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 17	1994	367	6464					614	621		10.1038/367614a0	http://dx.doi.org/10.1038/367614a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	8107845				2022-12-28	WOS:A1994MW68800044
J	BARRES, BA; RAFF, MC; GAESE, F; BARTKE, I; DECHANT, G; BARDE, YA				BARRES, BA; RAFF, MC; GAESE, F; BARTKE, I; DECHANT, G; BARDE, YA			A CRUCIAL ROLE FOR NEUROTROPHIN-3 IN OLIGODENDROCYTE DEVELOPMENT	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; GLIAL PROGENITOR-CELL; GROWTH-FACTOR; MONOCLONAL-ANTIBODY; NEURONAL DEATH; DIFFERENTIATION; ASTROCYTE; CULTURE; INVITRO; ANTIGEN	THE neurotrophins nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin4/5 promote the survival of subpopulations of vertebrate neurons in vitro, but so far only nerve growth factor has been demonstrated to be essential for normal neuronal development1-4; no neurotrophin has previously been shown to function in normal glial cell development. We found recently that neurotrophin-3 promotes the survival of pure oligodendrocyte precursor cells in vitro, and although by itself it induces only a small percentage of these cells to synthesize DNA, in combination with platelet-derived growth factor it induces the majority of them to do so5. Neither of these factors, however, has been shown to contribute to oligodendrocytes precursor cell proliferation in vivo or to stimulate pure populations of these cells to proliferate (as opposed to synthesize DNA) in vitro. Here we show that neurotrophin-3 and platelet-derived growth factor collaborate to promote clonal expansion of oligodendrocyte precursor cells in vitro and to drive the intrinsic clock that times oligodendrocyte development6. We also show that neurotrophin-3 helps stimulate the proliferation of oligodendrocyte precursor cells in vivo and is thus required for normal oligodendrocyte development.	UNIV LONDON UNIV COLL,DEPT BIOL,MRC,DEV NEUROBIOL PROGRAMME,LONDON WC1E 6BT,ENGLAND; MAX PLANCK INST PSYCHIAT,DEPT NEUROBIOCHEM,D-82152 PLANEGG,GERMANY; BOEHRINGER MANNHEIM,D-82377 PENZBERG,GERMANY	University of London; University College London; Max Planck Society			Messier, Claude/A-2322-2008; Barde, Yves/F-6019-2011	Messier, Claude/0000-0002-4791-1763; Barde, Yves/0000-0002-7627-461X				BARDE Y-A, 1990, Progress in Growth Factor Research, V2, P237, DOI 10.1016/0955-2235(90)90021-B; BARNSTABLE CJ, 1984, NEUROSCIENCE, V11, P847, DOI 10.1016/0306-4522(84)90195-7; BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1993, DEVELOPMENT, V118, P283; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN S, 1960, P NATL ACAD SCI USA, V46, P302, DOI 10.1073/pnas.46.3.302; EISENBARTH GS, 1979, P NATL ACAD SCI USA, V76, P4913, DOI 10.1073/pnas.76.10.4913; ELKABES S, 1993, ABSTR SOC NEUROSCI, V19, P251; GOBLET C, 1992, METHOD ENZYMOL, V216, P160; GONCHOROFF NJ, 1985, CYTOMETRY, V6, P506, DOI 10.1002/cyto.990060604; GOTZ R, 1992, EUR J BIOCHEM, V204, P745, DOI 10.1111/j.1432-1033.1992.tb16689.x; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; MAGAUD JP, 1988, J IMMUNOL METHODS, V106, P95, DOI 10.1016/0022-1759(88)90276-1; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; MILLER RH, 1985, DEV BIOL, V111, P35, DOI 10.1016/0012-1606(85)90432-4; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; RAFF MC, 1985, CELL, V42, P61, DOI 10.1016/S0092-8674(85)80101-X; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RANSCHT B, 1982, P NATL ACAD SCI-BIOL, V79, P2709, DOI 10.1073/pnas.79.8.2709; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; TEMPLE S, 1986, CELL, V44, P773, DOI 10.1016/0092-8674(86)90843-3; TEMPLE S, 1985, NATURE, V313, P223, DOI 10.1038/313223a0	29	318	325	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					371	375		10.1038/367371a0	http://dx.doi.org/10.1038/367371a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	8114937				2022-12-28	WOS:A1994MT54000068
J	CUNDY, T; CORNISH, J; EVANS, MC; ROBERTS, H; REID, IR				CUNDY, T; CORNISH, J; EVANS, MC; ROBERTS, H; REID, IR			RECOVERY OF BONE-DENSITY IN WOMEN WHO STOP USING MEDROXYPROGESTERONE ACETATE	BRITISH MEDICAL JOURNAL			English	Article									FAMILY PLANNING ASSOC NEW ZEALAND,AUCKLAND,NEW ZEALAND		CUNDY, T (corresponding author), UNIV AUCKLAND,DEPT MED,AUCKLAND 1,NEW ZEALAND.			Cundy, Timothy/0000-0003-4890-9400; Roberts, Helen/0000-0002-8107-5746				CUNDY T, 1991, BRIT MED J, V303, P13, DOI 10.1136/bmj.303.6793.13; JOHANSEN JS, 1988, J CLIN ENDOCR METAB, V67, P701, DOI 10.1210/jcem-67-4-701; SCHLECHTE J, 1989, J CLIN ENDOCR METAB, V68, P412, DOI 10.1210/jcem-68-2-412; WARREN MP, 1986, NEW ENGL J MED, V314, P1348, DOI 10.1056/NEJM198605223142104	4	118	121	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 22	1994	308	6923					247	248		10.1136/bmj.308.6923.247	http://dx.doi.org/10.1136/bmj.308.6923.247			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT539	8111260	Green Published			2022-12-28	WOS:A1994MT53900022
J	KATO, K; CLARK, GD; BAZAN, NG; ZORUMSKI, CF				KATO, K; CLARK, GD; BAZAN, NG; ZORUMSKI, CF			PLATELET-ACTIVATING-FACTOR AS A POTENTIAL RETROGRADE MESSENGER IN CA1 HIPPOCAMPAL LONG-TERM POTENTIATION	NATURE			English	Article							NITRIC-OXIDE; ARACHIDONIC-ACID; DENTATE GYRUS; RAT; RECEPTOR; INHIBITION; CURRENTS; RELEASE; NEURONS; BRAIN	LONG-term potentiation (LTP) refers to a persisting enhancement of neurotransmission that follows high-frequency activation of certain synapses1. Although both pre- and postsynaptic mechanisms contribute to LTP2,3, it is believed that the enhanced release of neurotransmitter that accompanies this process results from the production of a diffusible messenger in postsynaptic neurons which traverses the synaptic cleft and alters the function of presynaptic terminals4,5. One candidate for such a messenger is arachidonic acid, a metabolite produced by phospholipase A2 which augments synaptic transmission when coupled with presynaptic stimulations. However, the effects of arachidonic acid require activation of the postsynaptic receptor for N-methyl-D-aspartate6. Previously we found that platelet-activating factor (1 O-alkyl-2-acetyl-sn-glycero-3-phosphocholine), another phospholipase A2-derived messenger7, selectively enhances excitatory postsynaptic currents in hippocampal neurons by a presynaptic mechanism8. We now present evidence that platelet-activating factor, acting at a receptor localized to synaptic regions, participates in LTP in the CA1 region of rat hippocampal slices and may serve as part of a retrograde signalling cascade.	WASHINGTON UNIV, SCH MED, DEPT PSYCHIAT, 4940 CHILDRENS PL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT NEUROBIOL, ST LOUIS, MO 63110 USA; LOUISIANA STATE UNIV, MED CTR, SCH MED, CTR NEUROSCI, NEW ORLEANS, LA 70112 USA; LOUISIANA STATE UNIV, MED CTR, SCH MED, DEPT NEUROL, NEW ORLEANS, LA 70112 USA; LOUISIANA STATE UNIV, MED CTR, SCH MED, DEPT OPHTHALMOL, NEW ORLEANS, LA 70112 USA	Washington University (WUSTL); Washington University (WUSTL); Louisiana State University System; Louisiana State University System; Louisiana State University System			Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444				ARAI A, 1992, EUR J NEUROSCI, V4, P411, DOI 10.1111/j.1460-9568.1992.tb00890.x; BAZAN NG, 1989, ANN NY ACAD SCI, V559, P1; BAZAN NG, 1992, EMERGING STRATEGIES, P238; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; CLARK GD, 1992, NEURON, V9, P1211, DOI 10.1016/0896-6273(92)90078-R; DELCERRO S, 1990, BEHAV NEURAL BIOL, V54, P213, DOI 10.1016/0163-1047(90)90595-W; DOUCET JP, 1992, MOL NEUROBIOL, V6, P407, DOI 10.1007/BF02757944; GRIBKOFF VK, 1992, J NEUROPHYSIOL, V68, P639, DOI 10.1152/jn.1992.68.2.639; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; KANDEL ER, 1992, SCIENCE, V258, P243, DOI 10.1126/science.1411522; KATO K, 1993, NEUROSCIENCE, V53, P39, DOI 10.1016/0306-4522(93)90282-K; KATO K, 1991, BRAIN RES, V563, P94, DOI 10.1016/0006-8993(91)91519-7; KUBA K, 1990, PROG NEUROBIOL, V34, P197, DOI 10.1016/0301-0082(90)90012-6; LI YG, 1992, SOC NEUR ABSTR, V18, P343; LYNCH MA, 1991, J NEUROCHEM, V56, P113, DOI 10.1111/j.1471-4159.1991.tb02569.x; LYNCH MA, 1989, NEUROSCIENCE, V30, P693, DOI 10.1016/0306-4522(89)90162-0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MARCHESELLI VL, 1990, J BIOL CHEM, V265, P9140; MARCHESELLI VL, IN PRESS J NEUROSCI; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; WIERASZKO A, 1993, NEURON, V10, P553, DOI 10.1016/0896-6273(93)90342-O; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; YUE TL, 1990, J NEUROCHEM, V54, P1809, DOI 10.1111/j.1471-4159.1990.tb01239.x; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	30	225	230	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	1994	367	6459					175	179		10.1038/367175a0	http://dx.doi.org/10.1038/367175a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ780	8114914				2022-12-28	WOS:A1994MQ78000062
J	SCHNELL, L; SCHNEIDER, R; KOLBECK, R; BARDE, YA; SCHWAB, ME				SCHNELL, L; SCHNEIDER, R; KOLBECK, R; BARDE, YA; SCHWAB, ME			NEUROTROPHIN-3 ENHANCES SPROUTING OF CORTICOSPINAL TRACT DURING DEVELOPMENT AND AFTER ADULT SPINAL-CORD LESION	NATURE			English	Article							NEURITE GROWTH-INHIBITORS; NERVOUS-SYSTEM; MESSENGER-RNA; RAT; AXONS; BRAIN; MOTONEURONS; EXPRESSION; EXTENSION; SURVIVAL	THE number of neurotrophic factors found in the central nervous system is rapidly growing, but their functions in vivo are largely unknown. In the peripheral nervous system they promote the survival of developing and lesioned neurons and enhance nerve fibre growth and regeneration1-6. Here we study the effects of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) on the largest tract system leading from the brain to the spinal cord, the corticospinal tract (CST)7. The developing CST grows down the spinal cord during the first postnatal days and innervates its targets after a waiting period by collateral sprouting8-10. We find that NT-3 injected locally specifically enhances this sprouting, whereas BDNF has no effect. In adult rats, injection of NT-3 (but not BDNF) into the lesioned spinal cord increases the regenerative sprouting of the transected CST. The distance of growth of the sprouts is very restricted, but application of an antibody that neutralizes myelin-associated neurite growth inhibitory proteins'' results in long-distance regeneration of CST fibres.	MAX PLANCK INST PSYCHIAT,DEPT NEUROBIOCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society	SCHNELL, L (corresponding author), UNIV ZURICH,BRAIN RES INST,AUGUST FOREL STR 1,CH-8029 ZURICH,SWITZERLAND.		Barde, Yves/F-6019-2011; Schwab, Martin E/B-6818-2016	Barde, Yves/0000-0002-7627-461X				ALTAR CA, 1993, J NEUROSCI, V13, P733; [Anonymous], 1959, DEGENERATION REGENER; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BREGMAN BS, 1989, J COMP NEUROL, V282, P355, DOI 10.1002/cne.902820304; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CASALE EJ, 1988, J COMP NEUROL, V278, P275, DOI 10.1002/cne.902780210; DAVIES AM, 1990, ANNU REV NEUROSCI, V13, P61, DOI 10.1146/annurev.neuro.13.1.61; DCHANT G, 1993, DEVELOPMENT, V119, P545; DIAMOND J, 1992, J NEUROSCI, V12, P1454; ERNFORS P, 1991, EUR J NEUROSCI, V3, P953, DOI 10.1111/j.1460-9568.1991.tb00031.x; FRIEDMAN WJ, 1991, EUR J NEUROSCI, V3, P688, DOI 10.1111/j.1460-9568.1991.tb00854.x; GOTZ R, 1992, EUR J BIOCHEM, V204, P745, DOI 10.1111/j.1432-1033.1992.tb16689.x; HEFFNER CD, 1990, SCIENCE, V247, P217, DOI 10.1126/science.2294603; KUNKELBAGDEN E, 1993, NEUR ABSTR, V19, P681; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; NUDO RJ, 1988, J COMP NEUROL, V277, P53, DOI 10.1002/cne.902770105; OLEARY DDM, 1988, NEURON, V1, P901, DOI 10.1016/0896-6273(88)90147-X; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; RINGSTEDT T, 1993, DEV BRAIN RES, V72, P119, DOI 10.1016/0165-3806(93)90165-7; ROMANES G. J., 1964, PROGR BRAIN RES, V11, P93; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHNELL L, 1993, EUR J NEUROSCI, V5, P1156, DOI 10.1111/j.1460-9568.1993.tb00970.x; SCHREYER DJ, 1982, NEUROSCIENCE, V7, P1837, DOI 10.1016/0306-4522(82)90001-X; SCHWAB ME, 1991, J NEUROSCI, V11, P709; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0	28	774	813	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 13	1994	367	6459					170	173		10.1038/367170a0	http://dx.doi.org/10.1038/367170a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ780	8114912				2022-12-28	WOS:A1994MQ78000060
J	FRADKIN, JE; MILLS, JL; SCHONBERGER, LB; WYSOWSKI, DK; THOMSON, R; DURAKO, SJ; ROBISON, LL				FRADKIN, JE; MILLS, JL; SCHONBERGER, LB; WYSOWSKI, DK; THOMSON, R; DURAKO, SJ; ROBISON, LL			RISK OF LEUKEMIA AFTER TREATMENT WITH PITUITARY GROWTH-HORMONE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; MEDULLOBLASTOMA; EPIDEMIOLOGY; CHILDREN; HISTORY	Objective.-To determine whether pituitary-derived human growth hormone treatment increases the subsequent risk of developing leukemia and lymphoma. Design.-Cohort study. Setting.-United States. Participants.-A total of 6284 recipients of pituitary-derived human growth hormone distributed by the National Hormone and Pituitary Program between 1963 and 1985. Main Outcome Measures.-Leukemia and lymphoma. Results.-Three cases of leukemia occurred in 59736 patient-years of follow-up from the start of growth hormone therapy to case ascertainment at interview; this number was not significantly higher (P=.23) than the 1.66 cases expected in the US age-, race-, and gender-matched general population. Three additional cases, found in an extended follow-up that provided 83 917 person-years of risk, yielded a minimum rate of leukemia that was significantly increased (six cases found, 2.26 expected; P=.028). The relative risk of leukemia in pituitary growth hormone recipients compared with the general population was 1.8 (90% confidence interval [CI], 0.82 to 7.5) for the defined follow-up and 2.6 (90% CI, 1.2 to 5.2) for the extended follow-up. Five of the six subjects who developed leukemia had antecedent cranial tumors (four craniopharyngioma, one astrocytoma) as the cause of growth hormone deficiency, and four had received radiotherapy. There was no increase in leukemia in patients with idiopathic growth hormone deficiency. The association of leukemia and craniopharyngioma was significant (P<.001). There was no excess of lymphoma in the cohort. Conclusions.-This cohort of growth hormone recipients had a significantly increased rate of leukemia compared with the age-, race-, and gender-matched general population. However, the upper bound CI of the relative risk in our population (5.2) is well below the other estimates (7.6). Compared with the general population, our study population had more possible risk factors for leukemia (radiation, tumor) that may have contributed to the excess observed. The clustering of cases of leukemia in craniopharyngioma patients should be further evaluated.	NICHHD, BETHESDA, MD 20892 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA USA; US FDA, ROCKVILLE, MD 20857 USA; WESTAT CORP, ROCKVILLE, MD USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Centers for Disease Control & Prevention - USA; US Food & Drug Administration (FDA); Westat; University of Minnesota System; University of Minnesota Twin Cities	FRADKIN, JE (corresponding author), NIDDKD, DIV DIABET ENDOCRINOL & METAB DIS, WESTWOOD BLDG, ROOM 621, BETHESDA, MD 20892 USA.		Robison, Leslie/N-8122-2018	Mills, James/0000-0003-4496-332X				BLATT J, 1991, PEDIATR HEMAT ONCOL, V8, P77, DOI 10.3109/08880019109033430; BOICE JD, 1987, J NATL CANCER I, V79, P1295; COLTMAN CA, 1990, NEW ENGL J MED, V322, P52, DOI 10.1056/NEJM199001043220109; DANOFF BF, 1982, CANCER, V48, P1580, DOI 10.1002/1097-0142(19820415)49:8<1580::AID-CNCR2820490810>3.0.CO;2-7; DARBY S, 1989, NEW CANCERS MED TREA; DOLL R, 1989, J ROY STAT SOC A STA, V152, P341, DOI 10.2307/2983131; ENDO M, 1988, MED PEDIATR ONCOL, V16, P45, DOI 10.1002/mpo.2950160111; ESTROV Z, 1991, J CLIN ONCOL, V9, P394, DOI 10.1200/JCO.1991.9.3.394; Finlay J L, 1987, Hematol Oncol Clin North Am, V1, P753; FISHER DA, 1988, LANCET, V1, P1159; FORBES GM, 1992, MED J AUSTRALIA, V157, P27, DOI 10.5694/j.1326-5377.1992.tb121603.x; FRADKIN JE, 1991, JAMA-J AM MED ASSOC, V265, P880, DOI 10.1001/jama.265.7.880; KELLEY KW, 1989, BIOCHEM PHARMACOL, V38, P705, DOI 10.1016/0006-2952(89)90222-0; LAMPKIN BC, 1988, PEDIATR CLIN N AM, V35, P743; MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532; MEADOWS AT, 1991, PEDIATR HEMAT ONCOL, V8, pR7, DOI 10.3109/08880019109033419; MILLS JL, 1990, HORM RES, V33, P116, DOI 10.1159/000181494; MORI S, 1986, HORMONE CLIN, V34, P549; NEGLIA JP, 1988, PEDIATR CLIN N AM, V35, P675; OGAWA M, 1988, JPN J CLIN ONCOL, V18, P255; REDMOND G P, 1992, Pediatric Research, V31, p83A; RIES LAG, 1991, NIH912789 PUBL; RON E, 1988, AM J EPIDEMIOL, V127, P713, DOI 10.1093/oxfordjournals.aje.a114852; SASAKI U, 1988, JPN J CLIN ONCOL, V18, P81, DOI 10.1093/jjco/18.1.81; WADA E, 1989, JPN J CLIN ONCOL, V19, P36; WATANABE S, 1989, JPN J CANCER RES, V80, P822, DOI 10.1111/j.1349-7006.1989.tb01721.x; WATANABE S, 1993, J PEDIATR ENDOCRINOL, V6, P99; 1989, NCI892789 PUBL	28	104	104	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1993	270	23					2829	2832		10.1001/jama.270.23.2829	http://dx.doi.org/10.1001/jama.270.23.2829			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK941	8133622				2022-12-28	WOS:A1993MK94100032
J	SIMON, GE; DANIELL, W; STOCKBRIDGE, H; CLAYPOOLE, K; ROSENSTOCK, L				SIMON, GE; DANIELL, W; STOCKBRIDGE, H; CLAYPOOLE, K; ROSENSTOCK, L			IMMUNOLOGICAL, PSYCHOLOGICAL, AND NEUROPSYCHOLOGICAL FACTORS IN MULTIPLE CHEMICAL-SENSITIVITY - A CONTROLLED-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						ANXIETY; ENVIRONMENTAL EXPOSURE; HYPERSENSITIVITY; IMMUNOLOGICAL FACTORS; DEPRESSION	ENVIRONMENTAL ILLNESS; 20TH-CENTURY DISEASE; IMMUNE PROFILES; FORMALDEHYDE; ANTIBODIES; FOOD; EXPOSURE	Objective: To examine the role of immunologic, psychological, and neuropsychological factors in multiple chemical sensitivity. Design: Case-control comparison. Setting: Community allergy practice (cases), university-based clinics for musculoskeletal injuries (controls). Participants: Forty-one patients with chemical sensitivity and 34 control patients with chronic musculoskeletal injuries. Main Outcome Measures: Immunologic measures included autoantibody titers, lymphocyte surface markers, and interleukin-1 generation by monocytes. Psychological evaluation included standardized measures of anxiety, depression, and somatization. Results: Immunologic testing did not differentiate patients with chemical sensitivity from controls. The only difference noted (lower interleukin-1 generation among cases) appeared attributable to laboratory methods. Patients with chemical sensitivity reported greater prevalence of current anxiety or depressive disorder (44% versus 15%, P = 0.006). This difference, however, did not appear to precede the onset of chemical sensitivity, and 25% of chemically sensitive patients showed no significant current psychological disturbance. Cases reported significantly more ''medically unexplained'' physical symptoms before and after the onset of chemical sensitivity. When considering only symptoms that preceded chemical sensitivity, 25% of cases (and no controls) satisfied criteria for somatization disorder. Neuropsychological testing revealed no significant case-control differences. Conclusions: Immunologic testing failed to confirm findings from earlier uncontrolled studies, militating against proposed immunologic mechanisms. The decreased memory and concentration frequently described in multiple chemical sensitivity were not confirmed by brief neuropsychological testing. Psychological symptoms, although not necessarily etiologic, are a central component of chemical sensitivity.	UNIV WASHINGTON, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	SIMON, GE (corresponding author), GRP HLTH COOPERAT PUGET SOUND, CTR HLTH STUDIES, 1730 MINOR AVE, SEATTLE, WA 98101 USA.							ANESHENSEL CS, 1987, J HEALTH SOC BEHAV, V28, P232, DOI 10.2307/2136843; BLACK DW, 1990, JAMA-J AM MED ASSOC, V264, P3166, DOI 10.1001/jama.264.24.3166; BRODSKY CM, 1983, PSYCHOSOMATICS, V24, P731, DOI 10.1016/S0033-3182(83)73168-3; BROUGHTON A, 1988, AM J IND MED, V13, P463, DOI 10.1002/ajim.4700130406; CULLEN MR, 1987, OCCUP MED, V2, P655; DEROGATIS LR, 1977, SCL90R ADM SCORING P; FIEDLER N, 1992, J OCCUP ENVIRON MED, V34, P529; JEWETT DL, 1990, NEW ENGL J MED, V323, P429, DOI 10.1056/NEJM199008163230701; KATON W, 1990, Journal of Clinical Psychiatry, V51, P3; LEVIN AS, 1987, OCCUP MED, V2, P669; MCGOVERN JJ, 1983, ARCH OTOLARYNGOL, V109, P292; MEANS B, 1989, VITAL HLTH STATISTIC, V6; REA WJ, 1978, ANN ALLERGY, V41, P101; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; SCHOTTENFELD RS, 1985, AM J PSYCHIAT, V142, P198; SIMON GE, 1990, AM J PSYCHIAT, V147, P901; SIMON GE, 1991, AM J PSYCHIAT, V148, P1494; STEWART DE, 1985, CAN MED ASSOC J, V133, P1001; TERR AI, 1986, ARCH INTERN MED, V146, P145, DOI 10.1001/archinte.146.1.145; TERR AI, 1989, J OCCUP ENVIRON MED, V31, P257, DOI 10.1097/00043764-198903000-00012; THRASHER JD, 1988, AM J IND MED, V14, P479, DOI 10.1002/ajim.4700140411; THRASHER JD, 1987, ARCH ENVIRON HEALTH, V42, P347, DOI 10.1080/00039896.1987.9934357; THRASHER JD, 1990, ARCH ENVIRON HEALTH, V45, P217, DOI 10.1080/00039896.1990.9940805; THRASHER JD, 1989, AM J IND MED, V15, P187, DOI 10.1002/ajim.4700150207; VONKORFF M, 1988, PAIN, V32, P173, DOI 10.1016/0304-3959(88)90066-8; White LJ, 1989, ANN INTERN MED, V111, P168, DOI 10.7326/0003-4819-111-2-168; 1991, CLIN ECOLOGY CSA REP; 1987, DIAGNOSTIC STATISTIC; 1981, J ALLERGY CLIN IMMUN, V67, P333; 1986, W J MED, V144, P239	30	163	165	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1993	119	2					97	103		10.7326/0003-4819-119-2-199307150-00001	http://dx.doi.org/10.7326/0003-4819-119-2-199307150-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU902	8129805				2022-12-28	WOS:A1993LU90200001
